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OP001 LAPAROSCOPIC ILEOCECAL RESECTION VERSUS
INFLIXIMAB TREATMENT OF TERMINAL ILEITIS IN CROHN’S
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R.A.M. D’Haens3, P. Stokkers9, C.Y. Ponsioen3
1Surgery and Gastroenterology & Hepatology, AMC, Amsterdam/Netherlands
2Department of Surgery, Academic Medical Center, Amsterdam/Netherlands
3Gastroenterology & Hepatology, Academic Medical Center, Amsterdam/
Netherlands
4Surgery, Academic Medical Center, Amsterdam/Netherlands
5Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical
Centre, Amsterdam/Netherlands
6Surgery, OLVG West, Amsterdam/Netherlands
7Gastroenterology & Hepatology, Meander Medisch Centrum MDL, Amersfoort/
Netherlands
8Surgery, Meander Medisch Centrum, Amersfoort/Netherlands
9Gastroenterology & Hepatology, OLVG West, Amsterdam/Netherlands
Contact E-mail Address: e.j.degroof@amc.uva.nl
Introduction: The optimal therapeutic approach to ileocecal Crohn’s disease (CD)
remains unclear.
Aims & Methods: The objective of this study was to compare infliximab with
laparoscopic ileocecal resection in patients with thiopurine or steroid refractory
recurrent CD of the terminal ileum, with respect to quality of life (QoL) and
costs. A multicentre randomised controlled, open-label trial was performed in 33
centres in the Netherlands and the UK. Adult patients with CD of the terminal
ileum who failed4 3 months of thiopurine treatment or steroids without signs of
a critical stricture were randomised to infliximab or laparoscopic ileocecal resec-
tion. Patients with a prior ileocecal resection, a diseased length4 40 cm, abdom-
inal abscesses or fluid collections or an American Society of Anaesthesiologists
(ASA) score of III or IV were excluded. The primary endpoint was QoL mea-
sured by the Inflammatory Bowel Disease Questionnaire (IBDQ) at one year
follow-up. Furthermore, the mean direct costs per individual patient were pro-
spectively documented and analysed according to intention-to-treat until one
year after start of treatment. Dutch Trial Registry NTR1150.
Results: Between May 2008 and October 2015, 143 patients were randomised
(32.9% male) with a median age of 27.0 years (interquartile range (IQR) 22.0–
40.0). Eventually, 65 patients started with infliximab treatment and 70 patients
were operated. On April 28th 2016, 96.5% of the patients have completed follow-
up. At baseline, the mean difference (MD) in IBDQ score was 4.9 points in
favour of the resection group. After correction for the baseline difference, the
MD at one year follow-up was 5.8 points in favour of resection (95% confidence
interval (CI) 4.7 to 16.3, p¼ 0.28). The mean direct total costs per patient at
one year were E14,589 in the infliximab group and E10,318 in the resection
group (MD 04,270, 95% CI 01,325 – 07,126, p¼ 0.005). Infliximab was stopped
in 21 patients (30.0%) due to intolerance or insufficient response, 13 of whom
underwent an ileocecal resection after a median time of 27.0 weeks (IQR 11.0–
33.5) after start of infliximab treatment. CD related serious adverse events in
terms of Clavien Dindo IIIb complications occurred in three patients (4.1%) in
the laparoscopic ileocecal resection group and in one patient allocated to inflix-
imab eventually going for surgery. Three patients (4.1%) in the resection group
were started on infliximab within one year. Readmissions (for flares or additional
surgery or dilatation) during follow-up were comparable (21.4% of patients in
the infliximab versus 17.8% in the resection group).
Conclusion: QoL at one year was not significantly different between the laparo-
scopic ileocecal resection and infliximab group. Given the lower bound of the
95% CI, laparoscopic ileocecal resection can be considered a non-inferior alter-
native for infliximab treatment at significantly lower cost.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP002 CELL AUTONOMOUS AND NON-CELL AUTONOMOUS
RESCUE OF NNOS DEFICIENT MOUSE COLON FOLLOWING IN
VIVO ENTERIC NERVOUS SYSTEM STEM CELL
TRANSPLANTATION
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Introduction: Enteric neural stem cells (ENSC) have been identified as a possible
treatment for enteric neuropathies following successful colonization of recipient
gut after transplantation. However, the ability of ENSC to rescue pathophysio-
logical conditions remains unclear. Loss of neuronal subtypes, including neuro-
nal nitric oxide synthase (nNOS), has been implicated in many enteric
neuropathies. nNOS-/- mice display slow colonic transit providing a model to
test ENSC rescue in a pathological setting.
Aims & Methods: Our aim was to assess the functional integration of trans-
planted ENSC within recipient nNOS-/- colon. Initially, donor ENSC were
obtained from Wnt1-cre;YFP transgenic mice allowing specific fluorescent label-
ing, FACS selection and fate mapping of cells. YFPþ ENSC were transplanted
to nNOS-/-distal colon at post natal day (P)14. Subsequently, integration and
functionality were assessed using immunolabelling and organ bath physiology
after 4 weeks.
Results: After 1 month, YFPþ/nNOSþ neurons were identified and transcrip-
tional analysis showed specific expression of nNOS in recipient nNOS-/- colon. In
NANC (non-adrenergic non-cholinergic) conditions, organ bath physiology
revealed significant increases in electrical field stimulation (EFS)-induced relaxa-
tion (Area under curve;AUC) in transplanted nNOS-/- (1.13 0.16 g.s, n¼ 5)
compared with non-transplanted nNOS-/- (0.31 0.0.08 g.s, n¼ 5; P¼ 0.0016).
In transplanted colonic segments, addition of the nitric oxide synthase blocker L-
NAME resulted in significant reductions in the observed EFS-induced relaxation
(0.74 0.17 g.s vs 0.12 0.16 g.s, n¼ 4; P¼ 0.0389) demonstrating restora-
tion of nitrergic responses after transplantation. Interestingly, significant
increases in basal contractile amplitude were also observed in transplanted
nNOS-/- colonic segments (0.30 0.06 g, n¼ 5) compared with both C57BL/6J
(0.10 0.01 g, n¼ 5; P¼ 0.0093) and non-transplanted nNOS-/- mice
(0.05 0.008 g, n¼ 5; P¼ 0.0025). These high-amplitude contractions were unaf-
fected by application of tetrodotoxin, suggesting that transplantation of ENSC
can also lead to changes in underlying myogenic motility patterns. To assess the
mechanisms involved in these non-cell autonomous phenomena we sought to
investigate potential changes in gut morphology. No significant change was
observed in the diameter of the distal colon between transplanted nNOS-/-
mice (1.04 0.13mm; n¼ 3) compared to either non-transplanted nNOS-/-
(1.12 0.68mm; n¼ 3; P¼ 0.609) or sham-operated nNOS-/- (1.05 0.02mm;
n¼ 3; P¼ 0.947). In addition, no change in muscle thickness was observed
between transplanted nNOS-/- mice (55.33 8.67mm; n¼ 3) compared to either
non-transplanted nNOS-/- (54.0 8.0 mm; n¼ 3; P¼ 0.915) or sham-operated
nNOS-/- (54.33 2.96 mm; n¼ 3; P¼ 0.918). Ongoing work is targeting other
potential processes such as modification of cell types involved in neuromuscular
signaling, including interstitial cells of Cajal within the transplanted
microenvironment.
Conclusion: Here we demonstrate, for the first time, that transplanted ENSC
integrate and effect restoration of function, at the organ level, in a pathological
GI disease model potentially via both ENSC-specific and non ENSC-specific
processes.
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PREDICTS RESPONSIVENESS TO A DIET LOW IN FODMAPS
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Introduction: Dietary interventions may be recommended to IBS patients yet
effects on gut microbiota and factors predicting response are largely unknown.
Aims & Methods: We aimed to determine how two different diets affect gut
microbiota and if bacterial profiles and modelling thereof can be used to predict
patient intervention response in a secondary analysis of a previously published
intervention study (Bo¨hn et.al 2015). After a 10 day screening period 61 IBS
patients with at least moderately severe IBS symptoms according to IBS
Symptom Severity Score (IBS-SSS) followed either a traditional IBS (n¼ 30) or
low-FODMAP (n¼ 31) diet for 4 weeks. Faecal samples were collected and IBS-
SSS were completed before and after the intervention. Food intake was recorded
in 4-days food diaries before (baseline) and during the interventions. Responders
were defined as having a reduction of IBS-SSS 50 after the intervention. Faecal
bacterial composition was evaluated by GA-mapTM Dysbiosis Test which mea-
sures probe signal intensity (PSI) of 54 DNA probes targeting 300 bacteria on
different taxonomic levels. Bacterial profiles created for each patient were evalu-
ated by multivariate discrimination analysis and graded from 1–5, relative to a
healthy reference group. A dysbiosis index (DI) 2 signify normal microbiota
composition and 3 signify altered microbiota composition (dysbiosis). For all
models, both strong and moderate outliers were sequentially excluded.
Results: At baseline, 45 patients (25 randomized to traditional diet and 20 to low-
FODMAP) had a DI 3, i.e. dysbiosis; of these, 10 patients following the tradi-
tional IBS diet and 3 following the low-FODMAP diet experienced an improve-
ment in DI, while 6 following the traditional diet and 11 on the low-FODMAP diet
had worsening of their dysbiosis; the rest experienced no change. In the low-
FODMAP group, but not traditional diet group, non-responders (n¼ 19) had
more severe dysbioisis than responders (n¼ 12) ((3 (3–4) DI; 2 (2–3) DI;
p¼ 0.007) at baseline. Although patients on a traditional diet consumed signifi-
cantly less protein, fat and alcohol, they experienced no change in overall bacterial
composition after the intervention. Patients on a low-FODMAP diet ate signifi-
cantly less carbohydrates, fibre, monosaccharides, fructose and total FODMAPS,
and had significant reduction in potentially beneficial Bifidobacterium after the
intervention (33 (25.4–122.4) PSI) compared to before (152 (45.7–70) PSI,
p¼ 0.0005) which was even more prominent in non-responders. An OPLS-DA
model of before the low-FODMAP intervention demonstrated satisfactory mod-
elling and predictive abilities (R2Ycum 0.652, Q2 cum 0.541), showing that bac-
terial profiles differed between responders and non-responders. An OPLS-DA
model of the traditional diet group was inadequate, showing good model fit but
poor predictability (R2Ycum 0.742, Q2 cum 0.004), demonstrating that bacterial
profiles did not differ between responders and non-responders.
Conclusion: Faecal bacterial profiles predict patient responsiveness to a low-
FODMAP dietary intervention. Thus, before considering dietary interventions,
bacterial profiles could be determined in order to identify patients whom are
likely to respond favourably.
Disclosure of Interest: L. O¨hman: Unrestricted research grants from AstraZeneca;
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OP004 ENDOSCOPIC OR SURGICAL STEP-UP APPROACH FOR
NECROTIZING PANCREATITIS, A MULTI-CENTER
RANDOMIZED CONTROLLED TRIAL
S. Van Brunschot
Gastroenterology and Hepatology, Academic Medical Center, Amsterdam/
Netherlands
Contact E-mail Address: sandravanbrunschot@gmail.com
Introduction: Infected necrotizing pancreatitis is a potentially lethal disease that
almost always requires an invasive intervention. In recent years, the surgical step-
up approach has become standard of care replacing primary open necrosectomy.
A promising minimally invasive alternative is the endoscopic step-up approach. We
conducted amulticenter randomized trial (TENSION trial) comparing a endoscopic
and surgical step-up approach in patients with infected necrotizing pancreatitis.
Aims & Methods: Patients with infected necrotizing pancreatitis were randomly
assigned to the endoscopic or surgical step-up approach. The endoscopic step-up
approach consisted of endoscopic transluminal drainage followed, if necessary,
by endoscopic necrosectomy. The surgical step-up approach consisted of percu-
taneous catheter drainage followed, if necessary, by video-assisted retroperito-
neal debridement (VARD). The primary endpoint was a composite of major
complications (i.e. new onset organ failure, bleeding, perforation of a visceral
organ, enterocutaneous fistula and incisional hernia) or death during 6 months of
follow-up. Secondary endpoints included, among other, pancreatic fistula, length
of hospital stay and costs.
Results: A total of 98 patients were enrolled in 19 Dutch hospitals. The primary
endpoint occurred in 10 of 51 patients (20%) in the endoscopic group and in 13
of 49 patients (28%) in the surgical group (risk ratio 0.75; 95% CI 0.37 to 1.52,
P¼ 0.35). There were no significant differences in the individual components of
the primary endpoint (e.g. death 18% versus 13%; P¼ 0.50). In the endoscopic
group, 21 patients (41%) as compared with 23 patients (49%) in de surgical
group did not need necrosectomy after drainage as first step of treatment (risk
ratio 0.84; 95% CI 0.54 to 1.31, P¼ 0.43). There was a lower incidence of pan-
creatic fistula (5% versus 32%; P¼ 0.001) and length of hospital stay was shorter
(median 36 days versus 69 days; P¼ 0.03) in the endoscopic group. Furthermore,
the difference in total mean costs was 013655 (19%, BCa 95% CI -10836–35782)
in favour of the endoscopic group.
Conclusion: The TENSION trial did not show superiority of the endoscopic step-
up approach, as compared with a surgical step-up approach, in reducing major
complications or death in patients with infected necrotizing pancreatitis.
However, the rate of pancreatic fistula, length of hospital stay and costs were
significantly reduced in the endoscopic group.
Disclosure of Interest: All authors have declared no conflicts of interest.
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OP005 EFFICACY AND SAFETY OF DOSE ADJUSTMENT
AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–
SEVERE CROHN’S DISEASE PATIENTS: RESULTS FROM THE
IM-UNITI MAINTENANCE STUDY
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Introduction: Ustekinumab (UST) has been shown to induce and maintain clin-
ical response and remission in moderate to severe Crohn’s disease (CD) in 2
induction (UNITI-1 and 2) and 1 maintenance (IM-UNITI) randomized, pla-
cebo controlled Phase 3 trials. We evaluated the efficacy of UST in 2 additional
groups in IM-UNITI: patients who underwent dose adjustment following loss of
response (LOR) and patients who did not have a clinical response to IV UST
during induction and had an additional subcutaneous (SC) dose.
Aims & Methods: Patients achieving clinical response after single dose IV induc-
tion were randomized to SC placebo (PBO), UST 90 mg every 12 weeks (q12w)
or every 8 weeks (q8w). Patients who met LOR criteria, defined as a CDAI score
of  220 and a  100 point increase from the maintenance baseline CDAI score,
between weeks 8 and 32 of the maintenance trial could undergo a single dose
adjustment as follows: PBO!q8w, q12w!q8w, and q8w!q8w (no dose adjust-
ment) and were assessed for clinical response ( 100 point decrease in CDAI) and
clinical remission (CDAI5 150) 16 weeks later. Separately, UST patients not in
clinical response 8 weeks after the IV induction dose were given SC UST 90 mg
and if in clinical response 8 weeks later were continued on q8w dosing.
Results: 51 (39%), 29 (23%), and 28 (22%) patients in the PBO, q12w and q8w
groups, respectively, underwent dose adjustment after meeting LOR criteria.
Among these patients, clinical remission and clinical response were observed in
39% and 71% of patients adjusting PBO!q8w (a situation similar to a drug
holiday), 41% and 55% in the q12w!q8w group, and 32% and 46% in the
q8w!q8w group when assessed 16 weeks later (Table 1). Median change in
CDAI after adjustment was 121, 141 and 78.5 in the PBO!q8w,
q12w!q8w and q8w!q8w groups, respectively. Of 467 patients not in response
to UST following IV induction in UNITI1&2, 50.5% and 28.9% were in clinical
response and remission 8 weeks after one additional UST dose (90mg SC). Among
the 251 of these patients continuing dosing at week 8 of maintenance, 68.1% were
in response and 50.2% were in remission at Week 44. No increases or changes in
patterns of adverse events were seen among patients who dose adjusted.
Conclusion: In patients who met LOR criteria, dose adjustment from UST 90 mg
q12w to 90 mg q8w provided some additional clinical benefit compared to
patients who remained on UST 90 mg q8w. Additionally, patients who were
initial induction non-responders can benefit from continued treatment with at
least 1 SC UST dose 8 weeks after IV induction.
Table 1: Proportion of subjects achieving clinical response and remission 16
weeks after dose adjustment
Clinical Response Clinical Remission
PBO!UST q8w 71% 39%
UST q12w!UST q8w 55% 41%
UST q8w! UST q8w 46% 32%
A2 United European Gastroenterology Journal 4(5S)
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OP006 VEDOLIZUMAB EXPOSURE CORRELATES WITH CLINICAL,
BIOLOGICAL AND ENDOSCOPIC OUTCOME IN PATIENTS WITH
INFLAMMATORY BOWEL DISEASE
A. Gils1, E. Dreesen1, G. Compernolle1, M. Peeters1, E. Brouwers1, V. Ballet2,
M. Noman2, M. Ferrante2, G. Van Assche2, S. Vermeire2
1Department Of Pharmaceutical and Pharmacological Sciences, KU Leuven,
Leuven/Belgium
2Department Of Gastroenterology and Hepatology, University Hospitals Leuven,
Leuven/Belgium
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Introduction: Vedolizumab (VDZ) specifically targets the 4b7 integrin on gut-
homing lymphocytes and has been approved for the treatment of patients with
moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). We studied
the relation between serum VDZ trough concentrations (TC) and clinical, biolo-
gical and endoscopic outcomes in real-life practice.
Aims & Methods: The first 75 patients (49 CD, 26 UC) who initiated VDZ
therapy (300 mg IV administered) in our tertiary referral center were sampled
at trough during induction (w2 and w6) and early maintenance (w10, w14 and
w22) treatment. Clinical response (clinical symptoms and physician global assess-
ment) was correlated to VDZ TC. All patients with UC received sigmoidoscopy
at baseline and w10 and mucosal healing was defined as a Mayo endoscopic sub-
score of 0 or 1. Biological response (CRP decrease 50% from baseline) and
remission (CRP5 mg/L) were assessed at w6 and w22 in patients with CD. An
ELISA for measuring serum VDZ TC was developed in house. TC are shown as
median [IQR].
Results: A substantial interindividual variability in VDZ TC was observed at w2
(27.8 mg/mL [21.5–35.9]), w6 (25.5 mg/mL [16.4–36.3]), w10 (23.6 mg/mL [12.0–
37.7]) and w22 (11.3 mg/mL [4.4–17.5]). VDZ TC at w14 are about twice as high
in patients receiving an additional infusion at w10 (23.7 mg/mL [17.1–36.6],
n¼ 42) compared to patients who did not receive a w10 infusion (13.1 mg/mL
[6.6–19.3], n¼ 28) (p5 .0001). Biological response and remission were achieved
in 52% (14/27) and 30% (8/27) of patients with CD. Significantly higher VDZ
TC were observed at w6 in case of biological response (23.8 mg/mL [16.1–33.8]),
compared to non-response (11.8 mg/mL [7.2–18.2]) (p¼ .004) and when biological
remission was achieved (25.4 mg/mL [23.7–35.5]), compared to when no remission
was achieved (13.0 mg/mL [9.8–19.8]) (p¼ .0004). At w22, 59% (16/27) of
patients with CD were in biological remission. Patients who were in biological
remission at w22 had significantly higher VDZ TC throughout w2 to w22, com-
pared to patients who were not in biological remission at w22 (table 1).
Table 1: Vedolizumab trough concentrations, in mg/mL, median [IQR] (n),
during induction (w2 and w6) and early maintenance (w10, w14 and w22)
treatment correlate with biological remission (CRP 5 mg/L) at w22 in patients
with CD.
Biological remission at w22 No biological remission at w22
w2* 31.8 [23.9–38.9] (23) 23.6 [18.4–31.9] (17)
w6** 33.5 [22.1–38.5] (23) 16.6 [9.0–31.4] (17)
w10*** 37.9 [24.4–45.1] (15) 12.8 [7.5–19.3] (10)
w14** 25.8 [16.1–39.4] (22) 14.0 [9.7–18.6] (17)
w22*** 16.1 [9.5–25.2] (23) 6.3 [2.8–11.2] (17)
*p5 .05; ** p5 .01; *** p5 .001 Endoscopic healing was achieved in 65% (13/
20) of patients with UC. Patients with endoscopic healing had significantly higher
VDZ TC at w6 (30.5 mg/mL [18.6–38.0]), compared to patients who did not
achieve endoscopic healing (16.6 mg/mL [11.0–29.3]) (p¼ .02). Clinical response
was achieved in 69% (47/68) of the patients. Only in patients with UC, clinical
response was associated with higher VDZ TC at w2 (27.8 mg/mL [22.3–37.1],
n¼ 16) and w6 (32.0 mg/mL [17.8–37.7], n¼ 16) compared to absence of clinical
response (21.6 mg/mL [16.0–25.2] and 16.6 mg/mL [11.0–20.6], resp., n¼ 7)
(p¼ .03 and p¼ .02).
Conclusion: This is the first real-life experience with VDZ that shows substantial
variability in exposure to VDZ between patients. A clear exposure-response
correlation was observed as early as w2 and w6, with significant impact of
higher VDZ TC on meaningful outcomes as biological response, remission and
endoscopic healing. Our data support a potentially important role for early
therapeutic drug monitoring also with VDZ.
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SUCCESS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
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Introduction: Vedolizumab is an anti-4b7 monoclonal antibody effective in
ulcerative colitis (UC) and Crohn’s disease (CD). Data regarding pharmacoki-
netics/ pharmacodynamics of vedolizumab are still scarce.
Aims & Methods: Aim: To assess whether early vedolizumab trough levels (weeks
2, 6) correlate with response to vedolizumab induction therapy. Methods: A
novel ELISA-based assay was developed for measuring vedolizumab levels,
and employed in prospectively-followed IBD patients receiving vedolizumab
induction therapy. Drug levels were assessed for association with clinical remis-
sion, defined by HBI55 and SCCAI53 for CD and UC, respectively. The
primary outcome was the comparison of week 6 levels in patients with or without
clinical remission at the same time-point. Association of week 2 and week 6 levels
with week 14 clinical remission was also sought, as well as association of trough
levels with inflammatory markers (Albumin and C-reactive protein, CRP).
Results: Seventy-two patients were included (47 CD, 25 UC), of whom 14 (30%)
and 15 (32%) of CD patients and 6(25%) and 8 (32%) of UC patients reached
clinical remission by weeks 6 and 14, respectively. The median level of vedolizu-
mab at week 6 was not different between patients who achieved remission by
week 6 and those who did not (37.3 vs. 29.4 mg/ml respectively, p¼ 0.85). Clinical
remission rates at week 6 were also not associated with drug level quartiles at
week 6. Similarly, neither week 2 or 6 levels were predictive of clinical remission
at week 14 (35.4 vs. 44.8 mg/ml, p¼ 0.75, 33.9 vs. 25.5 mg/ml, p¼ 1, respectively).
Vedolizumab levels were also not associated with steroid free remission (p¼ 0.1,
p¼ 0.57) or with CRP normalization (p¼ 0.26, p¼ 0.73) at weeks 6 and 14,
respectively. Among UC patients separately analyzed, week 2 levels were asso-
ciated with clinical remission at week 14 (p¼ 0.04). However, statistical signifi-
cance for this difference was not retained after Bonferroni correction for multiple
testing. Finally, multivariable analysis for clinical remission at week 6 has been
performed including baseline albumin level and patient weight. When adjusting
for these co-variates, week 6 vedolizumab levels were not associated with clinical
remission at week 6 (p¼ 0.56).
Conclusion: In this real-life cohort of consecutive IBD patients receiving vedoli-
zumab, drug levels during induction were not associated with or predictive of
clinical response to induction therapy and were not associated with CRP normal-
ization or steroid-free clinical remission. Future studies are pertinent in order to
elucidate the role of therapeutic drug monitoring of vedolizumab during induc-
tion and maintenance.
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Introduction: Tumour necrosis factor antagonists (anti-TNFs) are effective at
inducing and maintenance disease remission in patients with moderate to
severe ulcerative colitis (UC) or Crohn’s disease (CD). However, considerable
proportions of patients do not respond to therapy or lose response over time.
Aims &Methods: This study uses real-world data to identify predictors of non- or
loss of response to anti-TNF therapy. The study recruited UC and CD patients
from 6 countries [Canada, France, Germany, Italy, Spain, and the United
Kingdom (UK)] aged 18 years who initiated anti-TNFs (infliximab/adalimu-
mab) during June 2009 to June 2011 (CD) or June 2009 to June 2013 (UC). Data
were collected on patient demographics, clinical characteristics and healthcare
resource use. Patients were classified as having non- or loss of response if they:
were hospitalized or required UC/CD surgery whilst on therapy, discontinued
due to UC or CD flare, required dose-escalation or augmentation with steroids/
immunosuppressants 4 months after therapy initiation, or disease severity
became worse after therapy initiation. Multilevel multivariate logistic regression
was used to identify predictors of non- or loss of response.
Results: The study included 1195 patients (45% UC, 55% CD; 9.6% Canada,
13% France, 22% Germany, 23% Italy, 19% Spain and 14% UK). Mean age:
40.3 (SD¼ 13.7); 51%: male. Most patients had a Charlson comorbidity index
(CCI) score of 0–1 (83%), 16% were current smokers, mean BMI was 24.8
(SD¼ 7.18) and mean disease duration was 8 years (SD¼ 8.07). Most patients
had a physician global assessment of moderate (45%) at study entry. Mean
follow up was 3.4 years (UC) and 4.4 years (CD). Overall, 22% of patients
had a primary non-response and 71% were classified as having non- or loss of
response to anti-TNF therapy in the maintenance period (4 months after initiat-
ing anti-TNF) over a mean follow up period of 32 months (SD¼ 20.4).
Significant predictors of non-/loss of response are shown in the Table 1.
Table 1: Predictors of non-response or loss of response among patients with
ulcerative colitis and Crohn’s disease
Baseline Variables
Odds Ratio
(95% Confidence Interval) P-value
Patients with
Ulcerative Colitis
Rectal Bleeding (Reference: None) - 0.04
- Passing blood alone 0.24 (0.06–0.97)
- Passing blood with stool 50% of time 0.35 (0.10–1.19)
- Passing blood with stool 550% of time 0.17 (0.05–0.62)
Endoscopic Findings
(Reference: Inactive/Mild)
- 0.02
- Moderate 3.19 (1.14–8.97)
- Severe 4.86 (1.61–14.7)
Patients with Crohn’s Disease
Number of Liquid or Soft Stools per Day1 1.12 (1.00–1.24) 0.04
C-reactive Protein (CRP)1,2 1.02 (1.00–1.03) 0.03
Note: Only the significant predictors are included in the table above. Other non-
significant variables included age, gender, body mass index, disease duration,
Charlson comorbidity index score, and use of corticosteroids or immunomodu-
lators. 1Both were analyzed as continuous variables. 2Highest CRP values during
the baseline period were used.
Conclusion: In this cohort the majority of patients did not respond or lost
response to anti-TNF therapy over time. Predictors for patients with UC
included the absence of rectal bleeding and moderate/severe endoscopic scores,
and for patients with CD included higher CRP and higher number of liquid or
soft stools per day. These predictors should be considered when evaluating treat-
ment options for patients.
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Introduction: Management of inflammatory bowel disease (IBD) has evolved in
the last decade. Clinical trials have shown that the combination of anti-TNFs and
thiopurines is more efficient than monotherapy with either of these. The impact
of these results in real-life practice is unknown. Moreover, the frequency of
treatment withdrawal has never been assessed in population-based cohort
studies.
Aims &Methods: Our aim was to assess IBD course and therapeutic management
including treatment withdrawal, surgery rates and hospital stays in the current
era of anti-TNFs. Every patient affiliated to the French national health insurance
with a diagnosis of IBD based on listed long-term diseases and/or hospital dis-
charge diagnosis was included from 2009 to 2013, and followed up until 31
December 2014. Cumulative incidence rates were used to estimate the cumulative
probabilities of medication use, surgery and hospitalization among prevalent and
incident patients. Treatment sequences including treatment withdrawal after
introduction of thiopurines, anti-TNFs and combotherapy were assessed for
incident patients included between 2009 and 2012.
Results: 195,834 individuals were diagnosed with IBD (Crohn’s disease (CD), 106
436 (31,353 incident patients); ulcerative colitis (UC), 89,398 (27,578 incident
patients)). Among incident patients treated with thiopurines or anti-TNFs (17
566 CD and 8035 UC patients), the first treatment was thiopurines, anti-TNFs
monotherapy, and combotherapy in 69.1%, 24.8% and 6.1% of CD patients and
78.2%, 17.7% and 4.1% of UC patients, respectively. Subsequently, 36.8% and
20% of CD patients were exposed to anti-TNFs monotherapy and combother-
apy, respectively, 5 years after diagnosis. More than 25% of CD and UC incident
patients included between 2009 and 2012 withdrew thiopurines or anti-TNFs,
during more than three months after a first treatment course. Drug withdrawal
was related to hospitalization or surgical procedures in less than 30% of these
patients. Nearly 50% of CD patients and 40% of UC patients went back to their
initial treatment after withdrawal. Around 5% of CD patients and 4% of UC
patients stopped all IBD therapy during follow-up. Five years after diagnosis, the
cumulative risks of first intestinal resection in CD, and colectomy in UC were
12.8% and 3.5%, respectively.
Conclusion: The step-up approach remains the dominant strategy in IBD,
whereas exposure to anti-TNFs is high and surgery rates are low. Treatment
withdrawal in IBD is more common than expected. This study emphasizes the
growing need of studying de-escalation strategy in IBD.
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Introduction: The identification of chidren at risk for failure to reach sustained
remission despite exposure to anti-TNF remains challenging in Crohn’s disease
(CD).
Aims &Methods:Data from BELCRO (Belgian observational prospective cohort
of paediatric CD) were analysed after 5 yrs follow-up. Disease severity was
scored at diagnosis and yearly thereafter as inactive, mild and moderate-to-
severe on a 3-point scale based on PCDAI/PGA scores. Sustained remission
was defined as inactive disease for  2 yrs follow-up. Univariate analyses were
performed between anti-TNF exposed patients with or without sustained remis-
sion and correlations assessed between variables and the outcomes average dis-
ease severity and sustained remission.
Results: Of 66 anti-TNF exposed patients (median (IQR) age 13.1 (11.5–15.2) yrs,
50% male), 17% failed to reach sustained remission. Disease location was similar
in both groups andmild disease at diagnosis (45% vs. 16%; p¼ .03) more frequent
in the group failing sustained remission. There were no differences between age,
gender, WBC or CRP at diagnosis and treatment between both groups.
Percentages of infliximab and adalimumab use were similar in both groups, includ-
ing drug switching and dose or interval adjustments. When stratified by follow-up
clinic, infliximab in paediatric follow-up was less frequently associated with failure
to reach sustained remission compared to sustained remission.
Univariate analyses of the type of follow-up clinic and anti-TNF treatment
between patients with or without sustained remission (more than one anti-
TNF possible).
Variable, number (%)
No sustained
remission
(n¼ 11)
Sustained
remission
(n¼ 55) P value
Paediatric follow-up and infliximab 3 (27) 37 (67) .01
Paediatric follow-up and adalimumab 1 (9) 8 (15) .63
Adult clinic follow-up and infliximab 6 (55) 14 (25) .05
Adult clinic follow-up and adalimumab 2 (18) 4 (7) .25
Paediatric follow-up and adjustments 1 (9) 8 (15) .63
Adult follow-up and adjustments 1 (9) 3 (11) .65
Higher average disease severity (2.1 (2.0–2.3) vs. 1.6 (1.3–1.8); p5 .001), adult
clinic follow-up (73% vs. 27%; p5 .01), surgery for CD (1 (0–3) vs. 0 (0–3);
p5 .01) and active disease after 5 yrs (91% vs. 24%; p5 .05) were associated
with failure to reach sustained remission. Both colonic disease and adult follow-
up (AUC¼ .66; both p¼ .04) correlated with average disease severity (no correc-
tion for multiple testing). No other correlations were found.
Conclusion: Patient phenotype at diagnosis does not predict failure to reach
sustained remission despite anti-TNF exposure. Mild disease may not trigger
appropriate treatment and lead to active and complicated disease course.
Sustained remission occurred most with infliximab in paediatric follow-up.
Information on serum levels is lacking.
Disclosure of Interest: F. Smets: None communicated
I. Hoffman: None communicated
P. Alliet: None communicated
W. Arts: None communicated
B. Hauser: None communicated
S. Van Biervliet: None communicated
E. Van de Vijver: None communicated
H. Peeters: None communicated
P. Bossuyt: Advisory baord: Mundipharma, Dr Falk Benelux, MSD, Janssens-
Cilag. Lecturing fee: Abbvie, Takeda, Vifor Pharma. Educational grant: Abbvie
J. Rahier: Advisory board and consultancy: abbvie, msd, GSK, hospira, jansens,
takeda. Speaker fee: abbvie, msd. Grant: abbvie, msd, takeda.
T. Moreels: None communicated
O. Dewit: None communicated
D. Franchimont: None communicated
V. Muls: None communicated
F. Fontaine: None communicated
E.J. Louis: Fees for: Educational Grant: MSD, Abbvie. Speaker Fees: Abbvie,
Ferring, MSD, Chiesi, Mitsubishi Pharma, Hospira, Janssen, Takeda. Advisory
Board: Abbvie, Ferring, MSD, Takeda, Mitsubishi Pharma, Celltrion,
Prometheus.
J. Coche: None communicated
M. De Vos: None communicated
F. Baert: None communicated
S. Vermeire: Grant/research support Takeda, MSD, Abbvie. Consultancy/speak-
er’s fees from Abbvie, MSD, Takeda, Pfizer, Galapagos, Genentech/Roche,
Mundipharma, Celgene, Hospira, Second Genome.
G. Veereman: Grant from MSD to Bespghan. Advisory board Janssen and
Boehringer Ingeleheim. Consulting Mead Johnson.
All other authors have declared no conflicts of interest.
MONDAY, OCTOBER 17, 2016 10:30–12:00
IS MASS ERADICATION OF H. PYLORI RATIONAL? – ROOM C_____________________
OP011 IS HELICOBACTER PYLORI ERADICATION ABLE TO
IMPROVE THE SCORES OF ATROPHIC GASTRITIS AND
INTESTINAL METAPLASIA? – LONG-TERM FOLLOW-UP STUDY
IN HIGH RISK POPULATION OF GASTRIC CANCER
Y.J. Hwang1, N. Kim2, Y.J. Choi1, H. Yoon2, C. M. Shin2, Y.S. Park2,
D.H. Lee2
1Internal Medicine, Seoul National University Bundang Hospital, Seongnam/
Korea, Republic of
2Department Of Internal Medicine, Seoul National University Bundang Hospital,
Seongnam/Korea, Republic of
Contact E-mail Address: justfighter@naver.com
Introduction: Helicobacter pylori (H. pylori) is a risk factor of atrophic gastritis
(AG) and intestinal metaplasia (IM) which can undergo to gastric cancer.
However, the reversibility of AG and IM by H. pylori eradication is controver-
sial, so far.
Aims & Methods: This study was performed to evaluate the reversibility of AG and
IM by anti-H. pylori therapy in large number of patients for a long period in South
Korea. A total of 810 patients with follow-up at least 1 year were enrolled from
January, 2006 to September, 2014. On the basis of H. pylori infection status and
eradication, the subjects were divided into three groups, as follows: Group A
(n¼ 214) included those patients who were H. pylori negative. Group B (n¼ 580)
had successful eradication result for H. pylori. Group C (n¼ 116) had not received
eradication therapy or showed eradication failure. The histological features of the
AG and IM in the antrum and body were measured, respectively, using Sydney
system scores. All of three groups were followed at 1, 2, 4 and 5 or more years.
Results: In patients with successful eradication (Group B), grades of AG and IM
in both antrum and body significantly decreased at 1, 2, 4 and 5 or more years
(p5 0.001) (Table). In contrast, in the H. pylori negative group (Group A), no
significant change was documented for grades of AG and IM in either antrum or
body except for grades of IM in body at 2 years and AG in body at 4 years
(Table). Similarly, in Group C, no significant change was documented for grades
of AG and IM in either antrum or body except for scores of AG in body at 5 or
more years (Table).
Table: Histological changes in atrophic gastritis and intestinal metaplasia at 1, 2,
4 and 5 or more years after eradication therapy.
group n baseline 1 year 2 years 4 years 45 years
AG in antrum A 110 1.46  0.66 1.35  1.04 1.19  1.06 1.03  1.01 1.45  0.89
AG in antrum B 282 1.49  0.62 0.87  0.86 a 0.86  0.90 a 0.76  0.88 a 0.56  0.89 a
AG in antrum C 52 1.46  0.70 1.24  0.95 0.80  1.10 1.17  1.17 0.43  0.79
AG in body A 66 1.71  0.72 1.38  1.07 1.12  1.12 1.04  0.91 a 1.82  1.01
AG in body B 195 1.62  0.65 0.77  0.92 a 0.78  0.95 a 0.75  0.98 a 0.25  0.68 a
AG in body C 34 1.85  0.74 1.08  1.14 1.50  1.05 0.67  1.03 0.14  0.38 a
IM in antrum A 117 1.81  0.68 1.61  0.86 1.56  0.87 1.63  0.96 1.54  0.89
IM in antrum B 369 1.65  0.66 1.37  0.83 a 1.28  0.94 a 1.11  0.92 a 0.66  0.88 a
IM in antrum C 69 1.67  0.66 1.68  0.98 1.71 0.85 1.06  0.99 1.33  1.00
IM in body A 85 1.78  0.70 1.52  1.04 1.25  1.15 a 1.41  1.06 1.54  1.07
IM in body B 247 1.64  0.67 1.24  0.84 a 1.00  0.94 a 0.92  0.94 a 0.73  0.94 a
IM in body C 48 1.71  0.62 1.57  0.95 1.20  0.63 1.00  1.00 1.00  1.10
: p5 0.001. Group A included those patients who were H. pylori negative.
Group B had successful eradication result for H. pylori. Group C had not
received eradication therapy or showed eradication failure. AG, atrophic gastri-
tis; IM, intestinal metaplasia.
Conclusion: This study shows improvement of AG and IM in both antrum and
body by H. pylori eradication, which could be underlying mechanism of the
prevention of gastric cancer by H. pylori eradication.
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Introduction: Although the association between risk of gastric cancer and
Helicobacter pylori (H. pylori) in case-control study have evaluated, the effect
of current H. pylori infection on the risk of gastric cancer has not been studied in
a large general population.
Aims & Methods: Their first Health check-up persons, who underwent compre-
hensive screening including endoscopy and H. pylori test from 2003 to 2013, were
enrolled. Current infection of H. pylori was defined as positive rapid urease test.
Negative current infection was defined as negative rapid urease test and absence
of previous H. pylori eradication. Adjusted regression analysis was performed
and estimated odds ratio (OR) and 95% confidence interval (CI).
Results: Among 35519 persons with 19396 men, 113 gastric cancers and 158
gastric adenomas were detected. In adjusted analysis, age (OR 1.06, 95% CI
1.04–1.08), current infection of H. pylori (OR 2.39, 95% CI 1.53–3.74), first
degree relatives with gastric cancer (OR 2.08, 95% CI 1.30–3.32), and high
glucose (OR 1.66, 95% CI 1.04–2.65) increased the risk of gastric cancer, whereas
high HDL (60mg/dL) reduced the risk of gastric cancer (OR 0.49, 95% CI
0.22–0.94). In sub-analysis by H. pylori, age was a common risk factor of gastric.
First degree relatives (OR 3.23, 95% CI 1.39–7.50) increased gastric cancer risk in
the absence of H. pylori, whereas high glucose (OR 1.98, 95% CI 1.16–3.39)
increased gastric cancer risk in the presence of H. pylori.
Conclusion: Current infection of H. pylori increased the risk of gastric cancer
about 2.4-fold in a large general population.
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Introduction: We have recently identified that Apelin (APLN) was highly
expressed in 18 paired hepatocellular carcinoma (HCC) tumor tissues compared
to adjacent normal liver specimen by transcriptome sequencing. APLN is an
endogenous ligand for the G-protein-coupled APJ receptor. In this study, we
aim to investigate its function, mechanism of action and clinical implication in
HCC.
Aims & Methods: APLN expression was examined in paired human HCC tissues,
HCC cell lines, and mouse models of liver cancer. Biological function of APLN
was determined using cell viability, colony formation, cell cycle, apoptosis and
murine xenograft assays. Downstream effectors and pathways were identified by
promoter luciferase reporter assay and western blot. Clinical implication of
APLN was assessed in two human HCC cohorts.
Results: Liver cancer was induced in genetically obese mice (db/db, deficient in
leptin receptor) and wild-type mice with diethylnitrosamine. mRNA analysis of
mice HCC tissues and adjacent non-HCC livers revealed that APLN was a top
candidate gene consistently up-regulated in HCC tumor tissues compared to
adjacent non-tumor tissues. APLN was also overexpressed in human HCC tis-
sues as compared with adjacent normal tissues at mRNA level (28 pairs of non-
alcoholic steatohepatitis (NASH) -HCC and 26 pairs of HBV-HCC patients) and
protein level (9 pairs of NASH-HCC patients). APLN was ubiquitously
expressed in eight HCC cell lines (7404, HepG2, Huh6, Huh7, PLC5, SKHEP1
and two NASH-HCC cell lines HKCI-2 and HKCI-10), whilst no or very low
expression was observed in a normal liver cell line (MIHA) and human normal
liver tissues. Ectopic expression of APLN (in Huh7, Miha, HKCI-2 and HKCI-
10) was found to promote cell proliferation, accelerate G1/S phase progression
by increasing cyclin D1 expression, and render cells more resistant to MG132 or
staurosporine induced apoptosis. Silencing of APLN by shAPLN transfection
(HepG2 and SK-Hep1) had the opposite effects in vitro and significantly inhib-
ited xenograft tumor growth in vivo. Promoter luciferase reporter assays revealed
that APLN promoted the PI3K/AKT pathway. Ectopic expression of APLN or
exogenous addition of APLN peptide induced the phosphorylation of AKT and
glycogen synthase kinase-3beta. Conversely, silencing of APLN or administra-
tion of ML221, an antagonist of APLN receptor, inactivated PI3K-AKT signal-
ing. APLN expression was significantly higher in late stage HCC (II-IV) than
early stage HCC (I) (P5 0.05 for our cohort, and P5 0.01 for TCGA cohort).
Kaplan–Meier curves showed that higher APLN expression was significantly
associated with shortened survival in patients with HCC (N¼ 43 for our
cohort, and N¼ 328 for TCGA cohort; both P5 0.05).
Conclusion: APLN is commonly up-regulated in HCC. APLN plays an important
ocogenic role in promoting liver tumor growth via activation of PI3K-AKT
pathway. Higher expression of APLN is correlated with a more advanced clinical
stage and worse prognosis in HCC patients.
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Introduction: Oncogene-induced senescence induces the immune-mediated clear-
ance of these precancerous senescent hepatocytes, preventing malignant transfor-
mation and tumor initiation; a process termed ‘senescence surveillance’ (1).
However, senescent hepatocytes can give rise to hepatocellular carcinomas
(HCC), if the senescence program is abrogated and/or senescent cells are not
cleared (1). We set out to identify the mechanism of recruitment of senescent cell-
clearing macrophages. Furthermore, we studied the effect of senescence-asso-
ciated immune responses on neighboring full-blown tumor cells in the liver.
Aims & Methods: To induce senescence in mouse livers, either oncogenic Nras
(NrasG12V) or an effector loop mutant (NrasG12V/D38A), which is incapable
of downstream signaling and senescence induction, were hydrodynamically deliv-
ered into C57BL/6, CCR2 KO and p19 KO mice. To achieve tumor development
in senescent livers, luciferase-expressing hepatocellular carcinoma cells were
intrasplenically injected into mice after hydrodynamic gene delivery. Tumor
growth was assessed using weight and bioluminescence measurements as well
as quantification of macroscopic tumors. Senescent livers with or without
tumors were analyzed using flow cytometry and immunohistochemistry.
Furthermore, peritumoral tissue of 226 HCC patients was hierarchical clustered
based on the expression of 35 senescence-associated genes (2). Senescence-asso-
ciated gene signature expression was then compared with chemokine expression
and survival. In addition, human peritumoral tissue was analyzed by immuno-
histochemistry for the presence of senescence and myeloid cell markers.
Results: In tumor-free livers, senescent hepatocytes induced CCR2þ immature
myeloid cell (iMC) accumulation, followed by iMC maturation into macro-
phages, which clear senescent hepatocytes. In CCR2 KO mice, iMC recruitment
and macrophage accumulation was impaired, causing persistence of oncogenic
Nras-expressing hepatocytes and ultimately HCC development. In contrast, how-
ever, tumor cells in senescent livers blocked the maturation of CCR2þ iMC into
macrophages, which lead to an accumulation of iMC. These iMC inhibited NK
cell cytotoxicity against tumor cells, as demonstrated by reduced NK cell degra-
nulation in vivo. NK cell inhibition through senescence-recruited iMC lead to
accelerated tumor growth. Accordingly, in CCR2 KO mice or C57BL/6 wild type
mice depleted of iMC, senescence-induced tumor growth promotion was abro-
gated. Finally, gene expression and immunohistochemistry analyses in peritu-
moral tissue of patients with hepatocellular carcinoma confirmed the
association of senescence-induced CCL2 expression, myeloid cell accumulation,
NK cell inhibition and poor prognosis.
Conclusion: Senescence-induced CCL2-CCR2 signaling and the ensuing myeloid
cell accumulation harbor context dependent functions in preventing HCC initia-
tion, but also promoting progression of established HCC. These findings hold
important translational significance for clinical practice: 1. CCR2 antagonists
may fuel liver cancer growth in patients with chronic liver disease, in which
senescent hepatocytes accumulate. 2. In patients with HCC, CCR2 antagonists
may reduce senescence-augmented immunosuppression induced by liver tumors.
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IMPROVEMENTS OF ENDOSCOPIC RESECTION TECHNIQUES IN THE COLON
– ROOM K_____________________
OP015 COLD FORCEPS AVULSION (CFA) WITH ADJUVANT SNARE
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Introduction: Non-lifting (NL) large laterally spreading and colorectal lesions
(NL-LSL) are challenging to resect endoscopically and often necessitate surgery.
Previously attempted endoscopic resection, pre-resection biopsy and sub-lesion
carbon particle suspension are common reasons for NL. Conventional endo-
scopic mucosal resection (EMR) techniques are often ineffective due to extensive
submucosal fibrosis. Simple methods for safe and effective endoscopic manage-
ment of NL-LSL have not been described.
Aims & Methods: The study aimed to evaluate the characteristics of NL-LSL and
the safety and efficacy of endoscopic treatment by Cold Forceps Avulsion (CFA)
followed by thermal ablation of the avulsion site by Snare Tip Soft Coagulation
(STSC). Amongst a prospective observational study of patients referred for wide
field EMR of LSL 420mm, LSLs which could not be completely resected by
snare due to NL were labelled NL-LSL. These were divided into previously
attempted non-lifting LSLs (PANL-LSL) and naı¨ve, non-lifting LSLs (NNL-
LSL). [MB1] Such lesions had completion of resection using a standardized
approach with CFA and STSC. The NL area was isolated by circumferential
snare excision of all adjacent tissue including adenoma and/or normal mucosa to
free the lateral margins. This then allowed effective CFA of NL adenoma.
Systematic CFA was then performed to remove all visible NL adenoma. The
exposed submucosa of the avulsion site and its margins were treated with con-
trolled thermal ablation using STSC (ERBE effect 4, 80W). Scheduled surveil-
lance colonoscopy was performed at 5 months (SC1) and 18 months (SC2) post
the index procedure. The primary outcome was endoscopic and histological
evidence of adenoma clearance. The secondary outcome was safety. Standard
statistical analyses were performed to compare standard LSL with NL-LSL.
Results: From January 2012 to April 2016, 677 patients (mean age 69 years,
50.6% male) with 780 lesions (median size 35 mm (IQR 25–45mm), 65.4%
proximal colon) were referred for WF-EMR. 33 lesions were excluded due to
suspicion for submucosal invasive cancer and the patients referred for surgery.
EMR was performed on 83 NL-LSL and 664 standard LSL. 14 lesions were
excluded at initial EMR as a two-stage procedure was required for their resec-
tion. Key comparisons between NL-LSL and standard LSL are presented in table
1. PANL-LSL (n¼ 33) were smaller and more likely to be non-granular (62.5
versus 33.9%, p¼ .003) than standard LSL. NNL (n¼ 50) were also more likely
to be non-granular (46 versus 33.9%, p¼ .12) and were associated with previous
biopsy (32 vs 13.8%, p ¼ .001) and carbon particle suspension injection within
10mm of the lesion (26 vs 3.8%, p5 .001). Neither intra-procedural bleeding nor
deep injury were more common in NL-LSL treated with CFA and STSC. The
technique was technically successful in all cases. One perforation was recognised
secondary to CFA in a previously attempted lesion and was successfully closed
with endoscopic clips with no sequelae. Endoscopic recurrence at SC1 was not
significantly different for PANL-LSL treated with CFA and STSC than LSLs
treated with complete snare excision, whereas NNL-LSL recurred more fre-
quently (16.0 vs 12.2%, p¼ .578 and 28.2 vs 12.2%, p¼ .005 respectively).
Conclusion: CFA and adjuvant STSC is a safe, effective and surgery-sparing
therapy for the majority of NL-LSL. It is easy to use, inexpensive and does
not require additional equipment. Early recurrence rates at SC1 are comparable
between PANL-LSL and standard LSL. NNL-LSL recur more frequently. Non-
granular LSLs were over-represented in both groups. They may be more suscep-
tible to developing fibrosis after biopsy and therefore care should be taken to
avoid significant tampering with these lesions prior to referral for definitive
endoscopic treatment.
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Introduction: Colorectal endoscopic submucosal dissection (ESD) is currently not
a common treatment for unskilled endoscopists because of technical difficulties.
Recently, the scissors-type knife, SB knife Jr type (SB Jr), was launched to reduce
the difficulty of colorectal ESD, although it can be a time-consuming procedure.
Aims & Methods: The aim of the present study was to evaluate the efficacy and
safety of the combined SB Jr and Flushknife for colorectal ESD compared with
using the Flushknife alone performed by supervised residents. This was a pro-
spective randomized controlled trial in a cancer referral center. Eighty-five
patients, with the same number of superficial colorectal neoplasms, were enrolled
and randomly assigned to undergo ESD using the Flushknife alone (Flush group)
or the SB Jr supported Flushknife (SB Jr group). The procedures were conducted
by two residents. Primary endpoint was self-completion rate by the residents.
Abstract No: OP015
Table 1: lesions where cold forceps avulsion and snare tip soft coagulation (CFA and STSC) was used in the resection of PANL or NNL; p values represent
comparison to LSL. Two stage procedures were excluded. SD – standard deviation, IQR – interquartile range, SC1 – surveillance colonoscopy 1, ICV – ileocaecal
valve, PANL – previously attempted non lifting lesion, NNL – naı¨ve non lifting lesion.
PANL n¼ 33 p NNL n¼ 50 p LSL n¼ 650
Patient
Age, mean (SD) 70.2 (8.6) .121 73.0 (9.5) 5.001 66.9 (12.1)
Male, (%) 18 (54.5) .598 29 (58.0) .266 324 (49.8)
Lesion
Median size (IQR) 25 (20–30) 5 .001 37.5 (25–50) .424 35 (25–45)
Morphology (%)
Granular 8 (25.0) .003 22 (44.0) .012 323 (52.4)
Non granular 20 (62.5) 23 (46.0) 209 (33.9)
Unclassified 4 (12.5) 5 (10.0) 85 (13.8%)
Location (%)
Rectum 11 (34.4) .121 6 (13.0) .091 121 (18.8)
Splenic to sigmoid 6 (18.8) 11 (23.9) 98 (15.2)
Transverse 5 (15.6) 14 (30.4) 132 (20.5)
Ascending and caecum (þICV) 10 (31.3) 15 (32.6) 294 (45.6)
Submucosal fibrosis 33 (100) 5 .001 50 (100) 5.001 179 (27.6)
Previous attempt at resection (%) 33 (100) 5 .001 0 (0) 5 .030 56 (8.7)
Previous biopsy (%) na 16 (32.0) .001 90 (13.8)
SPOT mark within 10mm of lesion (%) na 13 (26) 5 .001 25 (3.8)
Histopathology (%)
Conventional adenoma 25 (92.6) .324 44 (90.0) .147 482 (77.5)
Serrated adenoma 2 (7.4) 4 (10.0) 135 (21.7)
Cancer 0 (0) 0 (0) 4 (0.6)
Other 0 (0) 0 (0) 1 (0.2)
Procedure
Duration, minutes, median (IQ range) 35 (18–45) .004 25 (15–40) .003 20 (10–30)
Intraprocedural bleeding requiring endoscopic control (%) 2 (7.7) .078 11 (22.4) .966 144 (22.2)
Deep injury (%) 6 (18.2) .181 1 (2.0) .049 66 (10.7)
Outcomes
Endoscopic Recurrence at SC1 (%) 4 (16.0) .578 11 (28.2) .005 59 (12.2)
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Results: Self-completion rate was 66.7% in the SB Jr group, which was signifi-
cantly higher than that in the Flush group (39%, P¼ 0.01). Even after exclusion
of four patients in the SB Jr group in whom ESD was completed using the
Flushknife alone, the self-completion rate was significantly higher (62.8% vs.
39%; P¼ 0.03). The median procedure time among the self-completion cases
did not differ significantly between the two groups (58.5 vs. 50.5 min;
P¼ 0.14). No severe adverse events were observed in either group.
Conclusion: SB Jr supported Flushknife significantly improved residents’ self-
completion rate for colorectal ESD compared with the Flushknife alone, with
no increase in procedure time or adverse events. (University hospital Medical
Information Network Clinical Trials Registry number UMIN000009497).
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Introduction: Rectal polyps extending to the dentate line (RPDL) pose a technical
challenge to endoscopic resection due to the narrow lumen, rich venous/haemor-
rhoidal plexus and proximity to the skin. Conventional snare EMR is challenging
due to the restrcited space and lack of precision with the snare. This has led to the
use of surgical techniques like TEMS and TAR for resection of RPDLs. Knife
Assisted snare Resection (KAR) allows for precise mucosal incision at the dentate
line and the dissection of the polyp from the anorectal junction.
Aims & Methods:We aim to assess the feasibility, safety and efficacy of KAR for
RPDLs. This is a prospective observational study of patients who underwent
KAR with a mean follow-up of 32 months (range 1–83 months). All procedures
were done on a day case basis and were carried out under sedation by two
endoscopists using high-definition gastroscopes with a distal transparent cap.
The polyp margin on the anal side was injected with lifting solution consisting
of gelofusin, indigo carmine, 1% lignocaine and adrenaline. Haemostasis was
maintained using a combination of the endoscopic knife and coag-grasper
(Olympus Medical). A mucosal incision was extended around the margins of
the polyp, followed by submucosal dissection to facilitate snare deployment to
achieve complete polyp resection. Post-procedural antibiotics were not routinely
given.
Results: A total of forty patients (20 female, median age 69 years) underwent
KAR for RPDLs over the study period. The polyp characteristics and histology
are described in Table 1. The curative resection after a single KAR was achieved
in 33 (82.5%) patients. 7 of the 40 patients required further KARs, leading to a
total curative resection rate to 97%. The risk factors for multiple resections are
polyps measuring 4 60mm and encompassing 4 50% of the circumference
(p5 0.01). Overall, there was one complication where the patient had delayed
bleeding which was managed conservatively. None of the patients experienced
perforation, or post-procedural sepsis.
Table 1: Lesion characteristics and histology
Lesion size, median (range), mm 50 (12–150)
Morphology, n (%) LST – G,
nodular mixed LST – G,
homogenous LST – NG Is
29 (72.5) 2 (5) 2 (5) 7 (17.5)
Scarring, n (%) 13 (32.5)
Histology, n (%)
Adenoma with LGD Adenoma with HGD
Cancer Other – Condyloma acuminatum
30 (75) 6 (15) 3 (7.5) 1 (2.5)
Conclusion: This is the largest reported series of KAR for RPDLs. Our data
demonstrates that for Western endoscopists, KAR is a very safe and effective
technique in the treatment of RPDLs. As KAR is a viable alternative to full ESD,
TEMS and TAR, it will play an increasingly significant role in the management
of RPDLs.
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Introduction: Endoscopic mucosal resection (EMR) of large sessile and lateral
spreading colonic lesions 20 mm (LSLs) is safe and effective. The main limita-
tion is adenoma recurrence, which occurs in up to 20% at first surveillance
colonoscopy (SC1), mandating a structured surveillance program. Surveillance
procedures create compliance burdens, additional costs and potential patient
morbidity. Endoscopically invisible micro-adenoma present at the margin of
the resected LSL may account for adenoma recurrence. Adjuvant thermal abla-
tion of the EMR defect margin may reduce adenoma recurrence rates.
Aims & Methods: A prospective multi-center randomized control study was per-
formed (NCT01789749). The primary end-point was endoscopic and histological
recurrence at SC1. Standard inject and resect EMR technique was used for all
lesions. Exclusion criteria included previously attempted lesions, incomplete
snare excision or involvement of the ileocaecal valve. After successful complete
LSL excision by EMR and careful inspection of the defect to ensure no residual
adenoma, mucosal defects were randomized 1:1 to either thermal ablation of the
defect edges using snare tip soft coagulation (STSC) at 80w effect 4, or no
additional treatment. SC1 was performed at 5–6 months, with standardized
photo documentation and biopsies of the scar.
Results: Over 32 months to January 2015, 768 lesions  20 mm were referred for
EMR at 4 centers (407 were enrolled, 48 were later excluded, 359 were rando-
mized (null arm n¼ 178, active arm n¼ 181)). Patient, procedure and lesion
characteristics were similar between the two groups. 267 (74.3%) patients have
completed SC1. Endoscopic, and histologic recurrences at SC1 were significantly
lower in the active arm (8/138 (5.8%) versus 26/129 (20.2%), p5 .001, relative
risk (RR)¼ 0.29 (95% CI 0.14–0.61) and 6/104 (5.8%) versus 20/97 (20.6%),
p¼ 0.002, RR¼ 0.28 (95% CI 0.12–0.67) respectively) (Table 1). Endoscopic
assessment of the post EMR scar had a sensitivity of 100%, a specificity of
98% and a negative predictive value of 100% for correctly identifying recurrence
when compared to histology results. There was no difference in the rate
of delayed bleeding between the active and null groups (8/124 (6.5%) versus
9/136 (6.6%), p ¼ .957) and no difference in delayed perforation (0/124 (0%)
vs 1/136 (0.7%), p¼ .341).
Table 1: Endoscopic and histological recurrence in patients randomised to null
versus active arm of the SCAR study. Relative risk (RR); Confidence interval
(CI)
Null arm Active arm RR (95% CI) P value
Endoscopic
recurrence (95% CI)
26/129 20.2%
(14.1–27.9%)
8/138 5.8%
(2.9–11.0%)
0.29
(0.14–0.61)
5 .001
Histological
recurrence
(95% CI)
20/97 20.6%
(13.8–29.7%)
6/104 5.8
(2.7–12.0%)
0.28
(0.12–0.67)
0.002
Conclusion: Thermal ablation of the margin of the post EMRmucosal defect with
STSC, results in significantly lower adenoma recurrence rates at first surveillance
colonoscopy. Routine implementation of this simple and safe technique may
enhance EMR efficacy and reduce surveillance requirements with fewer proce-
dures and extended intervals.
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Introduction: Endoscopic submucosal dissection (ESD) is one of the most useful
methods for treating early colorectal neoplasms, and an insulation-tipped knife,
hook knife, or needle knife are conventionally used to perform ESD. However,
because these devices are used without fixation of target tissue, there is the
potential risk of complications due to an unexpected incision. To reduce the
risk of complications associated with using a conventional knife to perform
ESD, we used a scissors-type knife (stag beetle [SB] knife Jr, Akita Sumitomo
Bakelite Co.) that maintains an adequate dissection layer and prevents an unex-
pected muscular layer injury. We previously reported that performing colorectal
ESD with an SB knife Jr is an easy, safe, and technically efficient method.
However, the long-term outcomes of this method are unknown.
Aims & Methods:We aimed to evaluate the feasibility and long-term outcomes of
ESD performed with an SB knife Jr for treating early colorectal neoplasms. ESD
was performed for 227 lesions in 211 patients (male:female ratio ¼ 116:95; mean
age ¼ 69.1 years) between October 2010 and March 2016. We evaluated the
patients’ clinicopathological characteristics, en bloc resection rate, histological
complete resection rate, R0 resection rate, tumor size, procedure time, complica-
tions, and long-term outcomes, including local recurrence, and the survival rate.
Results: The sites of the neoplasms were as follows: right colon, 94 lesions
(41.4%); left colon, 58 (25.6%), and rectum, 75 (33.0%). Regarding the macro-
scopic type of lesions, there were 95 (41.9%) laterally spreading tumors (LSTs) of
the granular type, 79 (34.8%) LSTs of the nongranular type, and 48 (21.1%)
polypoid lesions. Histological examination findings showed that 102 lesions
(44.9%) were intramucosal carcinomas, 22 (9.7%) were shallow submucosal
invasive carcinomas (51,000 mm), 25 (11.0%) were deep submucosal invasive
carcinomas (41,000 mm), and 78 (34.4%) were tubular adenomas. The mean size
of the resected tumors was 32.0 14.9 mm, and the median procedure time was
76.5 minutes (range, 10–420 minutes). The rates of en bloc resection, histological
complete resection, and R0 resection were 98.2% (223/227 lesions), 93.8% (213/
227), and 85.0% (193/227), respectively. All lesions were treated easily and safely
without an unexpected incision, and no perforations occurred during the proce-
dure. Delayed bleeding, delayed perforation, and rectal stricture occurred in
3.8% (6/227), 0.4% (1/227), and 0.4% (1/227) of the lesions, respectively, and
all of these complications were cured conservatively. The median follow-up time
was 558 days (range, 18–1,976 days). Local recurrence was observed in only 0.8%
of the lesions (2/227). One patient (0.5%) died of colorectal cancer, and 5 patients
(2.3%) died of other diseases. The 5-year overall survival rate and disease-specific
survival rate were 94.8% and 98.7%, respectively.
Conclusion: ESD performed with an SB knife Jr is a technically efficient and safe
method that is associated with favorable long-term outcomes in cases of early
colorectal neoplasms.
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Introduction: The incidence of iatrogenic colonic perforation has been gradually
increasing. An effective method of treating iatrogenic perforations including
visual recognition followed by immediate closure during colonoscopy reduces
the incidence of sequelae and the morbidity and mortality. Perforations in the
sigmoid colon are more frequent and more difficult to close due to the narrow
lumen and considerable mobility.
Aims & Methods: This study was to evaluate the efficacy of combined use of
endoclip and a novel tissue grasper closure technique using double channel endo-
scope for large colon perforation in sigmoid colon model. This study was
designed as a prospective, randomized, experimental study using ex vivo porcine
colorectal specimens. Thirty-five standardized and variable artificial perforations
were closed in the hemoclip group (hemoclips) and twin-grasper group (hemo-
clips with a novel tissue grasper). We counted the number of hemoclips used per
case to assess the cost and efficacy of the procedure.
Results: In the hemoclip group (n¼ 20), among the 1.5, 2.0, 2.5, and 3.0 cm
defects, the mean number of clips (3.8 0.8, 4.8 0.8, 6.0 1.6, and 8.4 2.1,
respectively, p¼ 0.001) and closure time (5.3 1.8, 7.6 0.5, 9.9 3.3, and
13.9 4.1 min, respectively, p¼ 0.001) differed significantly. In the twin-grasper
group (n¼ 15), among the 2.0, 2.5, and 3.0 cm defects, the mean number of clips
(4.0 1.0, 5.0 0.7, and 5.4 1.1, respectively, p¼ 0.101) and closure time
(7.7 0.6, 8.3 1.9, and 9.1 2.7 min, respectively, p¼ 0.506) did not differ
significantly. In 3 cm defects, the mean number of hemoclips used per case and
total closure time were significantly lower in the twin-grasper group than the
hemoclip group.
The results between hemoclip group and twin-grasper group
Groups
Number of
endoclips
Procedure
time(min)
Complete closure
in water leak
Endoscopical
fail
2.0 cm hemoclip 4.8 0.8 7.6  0.5 60% 0%
2.0 cm twin-grasper 4.0 1.0 7.7 0.6 80% 0%
p-value 0.207 0.776 0.545
2.5 cm hemoclip 6.0 1.6 9.9 3.3 60% 0%
2.5 cm twin-grasper 5.0 0.7 8.3 1.9 60% 0%
p-value 0.233 0.384
3.0 cm hemoclip 8.4 2.1 13.9  4.1 40% 20%
3.0 cm twin-grasper 5.4 1.1 9.1 2.7 60% 0%
p-value 0.022 0.06 0.58
Conclusion: The twin grasper-clips technique seems to reduce the use of hemo-
clips and to result in more effective and rapid closure than does the conventional
technique in large perforations of the sigmoid colon.
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Introduction: Endoscopic technique is the first choice for the treatment of bile
duct stones, with success rates, ranging from 85% to 95%, and relatively low
complication rate. However, some stones can become a great challenge for endos-
copists. Complementary methods are available as mechanical lithotripsy and
papillary balloon dilation after sphincterotomy. Single operator cholangioscopy
combined with electrohydraulic lithotripsy (EHL) is emergent in this scenario.
Aims & Methods: We compare the success between two methods in the endo-
scopic removal of difficult bile duct stones: Spyglass associated with EHL X
Balloon dilation of the major duodenal papilla. 100 patients were randomized
into two groups. Group one was Spyglass þ EHL and group 2 balloon dilation.
From april of 2014 to present date (March 2016) we have enrolled 82 patients.
Include criteria were: Over 18 years, difficult biliary stones, signed term of con-
sent. All patients receive antibiotic prophylaxis with 400mg of Ciprofloxacin IV.
Failures in both groups were submitted to plastic stenting. To compare the
methods we use the student t-test and Mann-Whitney Rank Sum test.
Complications were analyzed by the Fisher test and Q squared.
Results: The average age was 55.1 þ/ 16.9 years. Women corresponded to
76.54% of the patients. Success rate reached 77.77% in group 1 and 72.22% in
group 2 (P¼ 0.568). Median procedure time was 71.08 minutes (17–150) in group
1 and 49.81 (17–180) in group 2 (P¼ 0.021). X-ray time was 10.89 minutes in
group 1 and 10.16 in group 2 (P¼ 0.052). Median number of stones per patient
was 2.31 (1–8) in group 1 and 2.22 (1–15) in group 2 (P¼ 0.605). Size of the
stones in group 1 was 1.88 (1–3.5) and 2.09 (1–3.5) in group 2 (P¼ 0.015). Minor
adverse event occurred in one patient of each group. There was one death not
related to procedure (cardiologic cause).
Conclusion: To our knowledge this is the largest randomized controlled trial
comparing this two techniques. We found so far an overall success rate of
77.77% in Spyglass þ EHL procedure and 72.22% in balloon dilation group.
United European Gastroenterology Journal 4(5S) A9
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
It is important highlight that only one session of Spyglass þ EHL was performed
in each patient of our protocol. Better success rates can be achieved with two or
more sessions and increase up to 90%. Cross-over of the failure cases in both
groups is bringing us a very interesting result and suggests that in some cases the
methods can be complementary. There was no statistical difference between the
groups, although spyglass group had numerically a little higher success rate. The
study provides us an evidence-based algorithm of difficult stones endoscopic
treatments. In addition, we observed potential advantages when we associate
the methods, providing one step more before declaring endoscopic failure in
treating a difficult biliary stone.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Antral vascular ectasia (GAVE) is a capillary-like vascular malfor-
mation usually located in gastric antrum. Liver cirrhosis, autoimmune, cardiac
and chronic renal disease are ussualy concomitant. Patients often require high
number of RBC transfusions because of anemia or melena. Treatment includes
argon plasma coagulation (APC), Band ligation (BL) and radiofrequency abla-
tion (RFA). Patients usually respond to 3 to 5 APC, or 2 to 3 band ligation (BL)
sessions, if not, refractory GAVE is considered and other treatments should be
offered. RFA is effective but expensive and requires at least two sessions. Hybrid-
APC is new technique that combines submucosal injection of saline solution to
create a ‘‘safety cushion’’ with the use of APC, this could have the advantage of a
deeper and safer treatment compared with other endoscopic modalities.
Aims & Methods: We aimed to evaluate the safety and efficacy of hybrid-APC in
naı¨ve or refractory GAVE patients. Methods: This is a prospective, longitudinal
and comparative (before and after) pilot study that includes symptomatic
patients with GAVE (endoscopic and histologic diagnosis). Naı¨ve or refractory
patients (defined as more than 5 previous APC or 3 BL without endoscopic,
clinical and laboratorial response) between 18 and 90 years old were included.
We excluded patients with GAVE without clinical manifestations or anemia of
other GI source. After a creation of a ‘‘saline cushion’’ with the APC catheter in
the GAVE zone, all received APC with forced coagulation at 80w effect 2 in a
single session and then they were followed at 1,3 and 6 months. New session was
applied if anemia and endoscopic picture of GAVE were documented.
Characteristics of the patients were described and expressed in means and SD
or median and IQR and percentages as appropriate. Comparisons between quan-
titative variables was done using paired T-test and considering p5 0.05 as sta-
tically significant.
Results. Between July 2015 and March 2016 9 patients were included, 8 women
and 1 men. Mean age was 64.7  12.5yo. 44.4% presented anemia and 55.6%
melena. Median number of transfusions was 9 (2–15). 3 had liver cirrhosis, 2
chronic renal failure, 1 cardiac disease and 3 without any association. GAVE
type was ‘‘watermelon’’ in 6 and ‘‘punctate’’ in 3. 44.4% were naı¨ve and 55.6%
refractories to previous treatment (3 in APC and 2 with BL). The median
previous treatments in refractory patients were 4 (3–9). All patients reached
normal Hb levels after 6months. The mean difference between prehybrid-APC
(5.98  1.49gr/dl) and 6m after hybrid-APC (13.7  0.76gr/dl) was þ7.74 gr/dl
(p5 0.000/CI 95% 6.84–8.64) student T-test. 8 patients received 1 session and 1
required 2. No major complications were observed (Table 1).
Conclusion: Based on these preliminary results, Hybrid-APC is safe and effective
for the treatment of GAVE (nave or refractory) with the advantage of needing
only 1 or maximum 2 applications and with excellent results at medium term.
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OP023 CD24 INDUCES THE ACTIVATION OF B-CATENIN IN
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Introduction: CD24 is a GPI-linked protein that functions as an adhesion mole-
cule and is overexpressed at an early stage of CRC.The Wnt/b-catenin signaling
pathway plays an important role in CRC carcinogenesis process. We had shown
that CD24 could affect the tumorigenesis process in Apc Min mice
Aims & Methods: Aim to study the cellular interactions between CD24 and b-
catenin, and their effects on intestinal tumorigenesis Methods CD24-inducible
293T-Rex cells previously developed in our lab and SW480 CRC cells stably
transfected with CD24were used to study this interaction in vitro. Apc Min
and CD24 knockout (KO) mice, both on a C57BL/6J genetic background,
were crossed to generate double KO transgenic mice. Genotypes were routinely
verified by analysis ofDNA extracted from tail biopsies. Small and large bowel
polyps were counted macroscopically following methylene blue staining and his-
tology was verified microscopically. Colonic polyps were measured and counted
Abstract No: OP022
Characteristics of procedures, patients and outcome
PATIENT
AGE/
GENDER
CLINICAL
PICTURE
NAIVE VS
REFRACTORY
NUMBER
OF
PACKED
RBC
TRANSFUSED
NUMBER
OF
HYBRID
APC
TREATMENTS/ TIME
GAVE
TYPE COMPLICATIONS
PRE HYBRIDKNIFE
HB
(GR/DL)
POST
HYDRIBKNIFE
HB AT 1M
(GR/DL)
POST
HYBRYDKNIFE
HB
AT 6M
(GR/DL)
1 58/F Anemia Naive 2 1 Watermelon None 8 13.6 14.2
2 60/F Melena Refractory
(4 APC)
10 1 Watermelon Mild
abdominal pain
3.5 6.6 13.3
3 61/F Melena Refractory
(9 APC)
15 1 Punctate None 6.1 9.2 12.9
4 79/F Melena Refractory
(3 BL)
9 1 Watermelon None 4.2 10.8 13.4
5 67/F Anemia Refractory
(4 APC/4 BL)
12 2 Watermelon None 6.3 8.4 13.1
6 55/F Anemia Naive 2 1 Punctate None 7.2 10.1 14.5
7 67/F Anemia Naive 8 1 Watermelon Mild abdominal pain 6.5 11.4 14.1
8 48/M Melena Naive 6 1 Watermelon None 7.2 10.2 15.1
9 89/F Melena Refractory
(5 APC)
14 1 Punctate None 4.9 9.3 13
Total Mean
64.7  12.5
8F/ 1M
44.4%
Anemia
55.6% Melena
44.4% Naive
55.6% Refractory
Median 9
(2–15)
88.8%
1 Treatment
21.2%
2 Treatments
66.6%
Watermelon
33.4%
Punctate
77.8%
No complications
22.2% Mild
abdominal pain
5.98  1.49 9.95  1.96 13.7  0.76
A10 United European Gastroenterology Journal 4(5S)
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
using mice colonoscopy. Histology confirmed by an experienced pathologist was
used to study this interaction in vitro.
Results: In vitro Western blotting analyses showed that expression of CD24 in
293T-Rex cells induced the activation of b-catenin and co-immunoprecipitation
studies of CD24 and b-catenin indicated that these two proteins might beinter-
acting, while down-regulation of CD24 in SW480 cells caused a decrease in the
levels of active b-catenin and cytoplasmic/nuclear fractionation showed that
more active b-catenin enters the nucleus in cells thatexpress CD24 (clone1) com-
pared to control cells (clone 4). In addition, in both cell lines, TOP/FOPluciferase
reporter assay showed a significant increase in Luciferase activity upon CD24
expression induction Depletion of CD24 alleles in Apc Min mice led to a sig-
nificant reduction in the number of polyps in the intestine.C57BL6/J mice carry-
ing the Apc Min mutation develop 24.3  3.7 adenomas and several
carcinomas in the smallintestine by the age of 16 weeks. The ApcMin/CD24
þ/- mice developed 8  1.4 polyps and ApcMin/CD24 -/- (doubleKO) mice
developed 7  1.7 polyps (p¼ 0.006). Colonoscopy showed a significant reduc-
tion in thenumber and size of polyps upon depletion of CD24 alleles. The
ApcMin displayed severe splenomegaly (355  68 mg)compared to (205  51
mg) in ApcMin/CD24 þ/- mice and (141  49 mg) in double KO mice similar
to WT mice (p¼ 0.006). Hb level was 3.8  2.5 in the ApcMin significantly lower
than in the double KO mice (8.2  0.9) and the WT (p¼ 0.0009)
Conclusion: 1. CD24 plays a major role in intestinal tumorigenesis 2. Knocking
down even one copy of CD24 almost completelyabolished formation in vivo, and
prevent anemia and splenomegaly the whole mark of intestinal blood loss seeing
inthe ApcMin 3. CD24 interacts with the Wnt pathway by activating b-catenin 4.
Down regulation of CD24 maybe animportant aim in the therapy of CRC
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Introduction: Variants in the gene locus encoding protein tyrosine phosphatase
non-receptor type 2 (PTPN2) are associated with Crohn’s disease (CD) and
ulcerative colitis (UC). We have previously shown that loss of PTPN2 in T
cells results in enhanced colitis and signs of autoimmunity. Inflammasomes
form upon cytosolic presence of danger molecules and induce the cleavage of
pro-IL-1b and pro-IL-18 into their active forms. Secretion of IL-1b is an impor-
tant activator of innate and adaptive immune functions, while IL-18 is involved
in epithelial cell protection.
Aims & Methods: In this study, we aimed to address whether loss of PTPN2 in
macrophages affects inflammasome activation and whether this affects colitis
severity and susceptibility for colorectal cancer. To specifically delete PTPN2
in macrophages, mice with a floxed PTPN2 gene were crossed with mice expres-
sing Cre-recombinase under the Lysozyme promoter (PTPN2-LysMCre mice).
Acute colitis was induced in 10–12 week old female mice by administration of 2%
DSS for 7 days, chronic colitis by administration of four cycles of 1.5% DSS for
7 days, followed by 10 days normal drinking water each. For tumour induction,
mice were injected with AOM at day 1 and day 10 of each DSS cycle during
chronic colitis induction.
Results: PTPN2-deficient macrophages show enhanced levels of cleaved caspase-
1 and IL-1b upon in vitro activation of the NOD-like receptor protein 3 (Nlrp3)
and absent in melanoma 2 (AIM2) inflammasomes, finally resulting in enhanced
secretion of active IL-1b and IL-18. This effect was mediated by increased phos-
phorylation of the inflammasome adaptor apoptosis associated speck-like pro-
tein containing a CARD (ASC), a mechanism recently shown to promote
inflammasome activation. In vivo, PTPN2-LysMCre mice suffered from pro-
nounced acute colitis, accompanied with enhanced secretion of mature IL-1b
and IL-18, but concomitant decreased IL-10 production. On the other hand,
no differences were observed in T cell subsets or other T helper cell associated
cytokine expression/secretion. In chronic colitis, PTPN2-LysMCre mice again
showed enhanced inflammasome activation in the intestine, and further devel-
oped metaplasia to squamous epithelium in the distal part of the colon epithe-
lium, but there was no overt effect on colitis severity. Of interest, however, and in
contrast to their WT littermates, PTPN2-LysMCre mice did not develop any
tumours upon AOM-DSS treatment. Interestingly, when IL-1b was inhibited,
acute colitis severity in PTPN2-LysMCre mice did not differ from that observed
in WT animals. Further, inhibition of IL-1b restored susceptibility to AOM-DSS
induced tumours in PTPN2-LysMCre mice.
Conclusion: PTPN2 is an important regulator of inflammasome activation, and
loss of PTPN2 in macrophages enhances acute colitis. Further, during chronic
intestinal inflammation, macrophage-specific loss of PTPN2 promotes metapla-
sia to squamous epithelium, but at the same time protects from tumour forma-
tion. This indicates an important, previously under-estimated macrophage-
specific role for PTPN2 during intestinal inflammation and tumour induction.
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Introduction: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is
the procedure of choice to obtain samples for reaching the definitive diagnosis of
lesions of the gastrointestinal (GI) tract and of adjacent organs (1). The proce-
dure is safe and very accurate, especially when rapid on-site evaluation (ROSE)
of the adequacy of the collected specimens is performed. However, in centers
where ROSE is not available, it has been suggested that the performance of EUS-
fine needle biopsy (EUS-FNB) can result in a greater chance to reach a diagnosis
than a typical EUS-FNA sample. Based on a previous study (2), which reported a
19-gauge flexible needle to be able to sample transduodenal lesions and be diag-
nostic in all 32 included patients, an algorithm for EUS-tissue acquisition (EUS-
TA) of solid lesions from the duodenum depending on the availability of ROSE
has been proposed. Thus, in institutions with no availability of ROSE, for lesions
accessed from the duodenum, which represent the most difficult sampling posi-
tion because of the stiffness induced by the needle assembly on the echoendo-
scope shaft, the authors recommended the use of a 19-gauge needle made of
nitinol with increased flexibility (3).
Aims & Methods: To test the validity of this recommendation we performed a
prospective multicenter study aimed at evaluating the technical feasibility, pro-
curement yield, and diagnostic accuracy of this newly developed 19-gauge nitinol
flexible needle in patients with solid lesions or enlarged lymph nodes that could
be punctured only from the duodenum. Consecutive patients with solid lesions
who needed to undergo EUS sampling from the duodenum were prospectively
enrolled in 6 tertiary care referral centers. Puncture of the lesion was performed
with the 19-gauge flexible needle (ExpectTM 19 Flex and Slimeline ExpectTM 19
Flex) and at least 3 needle passes were performed in each case. The feasibility,
procurement yield, and diagnostic accuracy were evaluated.
Results: 246 patients (144 males, mean age 65.1  12.7 years) with solid lesions
(203 cases, 82.5%) or enlarged lymph nodes (43 cases, 17.5%) were enrolled. The
mean size of the target lesion was 32.6  12.2 mm. The procedure was technically
feasible in 228 (92.7%) patients, with an overall procurement yield of 76.8%.
Two centers had suboptimal procurement yields of 66.7% and 64.2% (table).
Major complications occurred in six patients (2.4%): two cases of bleeding, two
of mild acute pancreatitis, one perforation that required surgery and one duo-
denal hematoma that resolved spontaneously. Considering malignant vs. non-
malignant diseases, the sensitivity, specificity, positive likelihood ratio, negative
likelihood ratio, and diagnostic accuracy were 70.7% (95% CI, 64.3–76.6), 100%
(95% CI, 79.6–100), 35.3 (95% CI. 2.3–549.8), 0.3 (95% CI, 0.2–0.4), and 73.6%
(95% CI, 67.6–79), respectively. On multivariate analysis, the only determinant
of successful EUS-FNB was the center in which the procedure was performed.
Study Center Technical success rates Procurement yield
A 64/67 (95.5) 43/67 (64.2)
B 44/45 (97.8) 38/45 (84.4)
C 39/40 (97.5) 34/40 (85)
D 37/39 (94.9) 32/39 (82.1)
E 20/30 (66.7) 20/30 (66.7)
F 24/25 (96) 22/25 (88)
Conclusion: The findings of our study, with a procurement yield and diagnostic
accuracy of only 76.8% and 73.6%, respectively, redefine the role of the 19-gauge
flexible needle for transduodenal EUS-FNB. Thus, the correct diagnosis was
missed in about 1 every 4 patients. Since the prevalence of malignant disease
in our population was 86%, this finding cannot be considered negligible. The
results of our study are of particular interest since we showed that the diagnostic
performance of the 19-gauge flexible needle has a wide intercenter variability, not
depending on the expertise of the endoscopist. In conclusion, our results suggest
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that the use of the 19-gauge flexible needle for transduodenal FNB cannot be
widely suggested and its implementation should receive a local validation, with
careful evaluation of both the local technical success rates and diagnostic yields.
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Introduction: Prior studies comparing the 22 and 25G needles and utility of
suction for EUS-FNA of pancreatic masses were indefinite due to patient hetero-
geneity and small sample size. Also, the optimal tissue acquisition technique for
onsite and offsite specimen assessment is unclear.
Aims & Methods:We aimed to compare the 22 and 25G needles and evaluate the
role of suction in EUS-FNA of pancreatic masses. Methods: Consecutive
patients with solid pancreatic masses were randomized to 1 of 4 cohorts: 22G
needle with suction, 22G needle without suction, 25G needle with suction and
25G needle without suction. After two dedicated passes were performed for cell
block (offsite) evaluation, an experienced pathologist rendered rapid onsite eva-
luation (ROSE) for specimen adequacy. Cross-over to alternate arms was per-
mitted if ROSE was indeterminate at 8 passes. Diagnostic accuracy of ROSE was
confirmed by final pathology interpreted by a second independent pathologist.
Final diagnosis was established by surgical histology or patient follow-up at 12
months. Main outcome measures were to compare diagnostic adequacy and
accuracy of ROSE, number of passes to establish onsite diagnostic adequacy,
specimen bloodiness, diagnostic accuracy of cell block and operating character-
istics between cohorts. To detect a 15% difference in diagnostic accuracy and cell
block yield between the type of needles and use of suction at 80% power and type
1 error of 0.05, the total sample size was estimated at 352 patients.
Results: The median age of 352 patients was 69 years, 54.3% male, median size of
mass was 3cm with vascular invasion in 55.4% and FNA passes were transduo-
denal in 68.5%. The final diagnosis was adenocarcinoma or other malignancy in
290 (82.4%) and benign or chronic pancreatitis in 62 (17.6%) patients. Interim
analysis pending completion of 12-month follow-up is shown in the Table.
Conclusion: While there was no overall difference in operating characteristics
between the 22 and 25G needles, the use of suction must be avoided in centers
utilizing ROSE as it increases specimen bloodiness and number of passes needed
to achieve diagnostic adequacy, particularly with 22G needles.
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Introduction: For 10 years, EUS-guided biliary drainage has been an option as
EUS guided choledoco-duodenostomy or hepatico-gastrostomy. Two small ran-
domized studies showed no difference between EUS guided BD vs Percutaneous
drainage. The aim of this work was to evaluate in a multicenter randomized study
the percutaneous biliary drainage (PBD) vs EUS-guided biliary drainage (EBD)
in patients with an obstructive jaundice when ERCP failed or impossible due do
duodenal involvement or previous Surgery as gastrectomy or Whipple resection.
Aims & Methods: Inclusion criteria were: benign or malignant obstructive jaun-
dice with failure of ERCP. Exclusion criteria were: ascites, blood coagulation
disorders, stenosis of the right bile duct. Randomization ratio was 1: 1, with a
stratification by indication (benign vs malignant) and by centers (4 centers were
included). The route of the biliary drainage was randomized as PTB (arm A) and
EGD (arm B). But the choice of the EGD technique was free for the operator as
(Anterograde transpapillary stenting, choledoco-duodenostomy, hepatico-gas-
trostomy). The main goal was to evaluate the specific morbidity and mortality
during the 30 days following the biliary drainage in each arm. To prove a
decrease of 50% of the morbidity rate in the EGD arm (A¼ 30%, B¼ 15%),
55 patients should be included in the EGD arm (B) as a Simon plan in 2 steps
with an intermediate analysis to exclude severe adverse events in the EGD arm.
Intermediate analysis was performed after inclusion of 47 patients and showed
significantly higher morbidity rate in the PTB arm. Then, PTB arm was stopped
and inclusions were made only in the EGD arm.
Results: Sixty-five patients from 4 centres were screened between 2011 to 2015.
Eight patients were excluded (ascites, ERCP finally feasible). Fifty-six patients
were randomized (Arm A ¼ 21/ Arm B¼ 35). The 2 groups were similar except
the sex ratio (Female: Arm A, n¼ 11; Arm B, n¼ 7; p¼ 0.012). The biliary
stenosis was malignant in 52 cases (Arm A¼ 19; Arm B¼ 33). Biliary access
was successful in 100% in the Arm A and in 94% in the Arm B. However,
technical success was respectively 17/21 (85%) in the Arm A and 33/56 (94%)
in the Arm B. No difference was showed regarding the decrease of the bilirubin
level after the drainage in the two arms. Median hospitalization duration was
shorter in the Arm B (6 days range 3–30 days) than the Arm A (12 days range 2–
32 days). Ten patients died 30 days following the biliary drainage, 7 deaths were
reliable to biliary drainage procedure (Arm A¼ 3, Arm B¼ 4) p¼ 1. Specific
complication occurred in twelve patients (62%) in the Arm A vs 7 (31%) in
the Arm B p¼ 0,0276: Bleeding (A¼ 5[24%], B¼ 3[9%]; ns), Cholangitis
(A¼ 3 [14%], B ¼ 1[3%]), Sepsis not related to cholangitis (A¼ 7 [35%], B¼ 5
[25%]), Peritonitis (A ¼ 1[5%], B¼1[3%], ns), external biliary fistula (A¼ 1[5%],
B¼ 0[0%], ns).
Abstract No: OP026
Comparison of procedure outcomes according to needle size and use of suction
22G No Suction
(n¼ 88)
22G Suction
(n¼ 88)
25G No Suction
(n¼ 85)
25G Suction
(n¼ 91) p-value
ROSE-Diagnostic adequacy: n (%) 88 (100) 86 (97.7) 85 (100) 91 (100) 0.182
Total no. of passes for onsite diganostic adequacy Mean (SD) 1.8 (1.9) 2.8 (2.7) 1.7 (1.5) 2.0 (2.2) 50.001
Median (IQR) 1 (1–2) 2 (1–3) 1 (1–1) 1 (1–2)
Specimen bloodiness: n (%) Mild 52 (59.1) 32 (36.4) 55 (64.7) 43 (47.3) 0.008
Moderate 20 (22.7) 34 (38.6) 20 (23.5) 30 (33.0)
Severe 16 (18.2) 22 (25.0) 10 (11.8) 18 (19.8)
ROSE-Diagnostic performance: % (95% CI) Accuracy 98.9 (93.8–100) 93.2 (85.7–97.5) 97.6 (91.8–99.7) 97.8 (92.3–99.7) 0.230
Sensitivity 100 (95.1–100) 92.6 (83.7–97.6) 97.1 (89.9–99.6) 98.8 (93.2–100) -
Specificity 93.3 (68.1–99.8) 95.0 (75.1–99.9) 100 (79.4–100) 90.9 (58.7–99.8) -
PPV 98.6 (92.7–100) 98.4 (91.6–100) 100 (94.6–100) 98.8 (93.2–100) -
NPV 100 (76.8–100) 79.2 (57.8–92.9) 88.9 (65.3–98.6) 90.9 (58.7–99.8) -
Diagnostic cell block: n (%) 71 (80.7) 63 (71.6) 56 (65.9) 67 (73.6) 0.177
EUS-FNA-Diagnostic performance: % (95% CI) Accuracy 98.9 (93.8–100) 93.2 (85.7–97.5) 98.8 (93.6–100) 98.9 (94.0–100) 0.060
Sensitivity 98.6 (92.6–100) 92.6 (83.7–97.6) 98.6 (92.2–100) 98.8 (93.2–100) -
Specificity 100 (78.2–100) 95.0 (75.1–99.9) 100 (79.4–100) 100 (71.5–100) -
PPV 100 (95.0–100) 98.4 (91.6–100) 100 (94.7–100) 100 (95.4–100) -
NPV 93.8 (69.8–99.8) 79.2 (57.8–92.9) 94.1 (71.3–99.9) 91.7 (61.5–99.8) -
Technical failure: n (%) 0 5 (5.7) 1 (1.2) 7 (7.7) 0.011
Adverse events: n (%) 4 (4.5) 3 (3.4) 7 (8.2) 10 (11.0) 0.179
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Conclusion: This randomized prospective study showed similar high technical and
clinical success rates in PTB and EUS-guided biliary approach. Specific compli-
cation rate was higher in the PTB arm than in the EUS-guided biliary drainage.
EUS guided biliary drainage should be the first therapeutic approach after failure
of ERCP, in selected patients.
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Introduction: Endoscopic enteral stenting (ES) in malignant gastric outlet
obstruction (GOO) is limited by high rates of stent obstruction. EUS-guided
gastroenterostomy (EUS-GE) is a novel procedure that potentially offers sus-
tained patency without tumor ingrowth/overgrowth.
Aims & Methods: The aim of this study is to compare EUS-GE with ES in terms
of 1) need for re-intervention, 2) technical success (proper stent positioning as
determined via endoscopy and fluoroscopy), 3) clinical success (ability to tolerate
oral intake without vomiting), and 4) procedure-related adverse events (AEs).
This is a multicenter retrospective study of all consecutive patients who under-
went either EUS-GE at 4 centers between 2013 and 2015 or ES at one center
between 2008 and 2010.
Results: A total of 82 patients (mean age 66-years 13.5 and 40.2% female) were
identified: 30 in EUS-GE and 52 in ES. Technical and clinical success were not
significantly different 86.7% EUS-GE vs. 94.2% ES (p¼ 0.2) and 83.3% EUS-
GE vs. 69.2% ES (p¼ 0.2) respectively. Need for re-intervention, however, was
significantly lower in EUS-GE 3.3% vs. 46.2% ES (p5 0.001). Post-procedure
mean length of hospitalization was comparable at 11.3 days 6.6 for EUS-GE
vs. 9.5 days 8.3 for ES (p¼ 0.3). Rates and severity of AEs (as per the ASGE
lexicon) were also similar occurring in 16.7% EUS-GE vs. 11.5% ES (p¼ 0.5).
On multivariable analysis, EUS-GE was independently associated with fewer
needs for re-intervention (OR 0.03, p¼ 0.002).
Conclusion: EUS-GE may be ideal for malignant GOO with comparable effec-
tiveness and safety to ES while being associated with fewer requirements for re-
intervention.
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Introduction: EUS-guided trans-mural drainage using plastic stents may be inade-
quate for pancreatic fluid collections (PFC) having solid debris, i.e. ‘‘Walled Off
Necrosis (WON)’’. Recent publications have reported variable outcome using
covered metal stents for PFC drainage, using either conventional or dedicated
metal stents. There are few reports on dedicated metal stent for EUS guided
drainage of only WON. Treatment strategy using a ‘‘step-up approach’’ by endo-
scopic methods has not been systematically addressed.
Aims & Methods: To evaluate the efficacy of a dedicated covered bi-flanged metal
stent (BFMS) using a ‘‘step-up approach’’ in drainage of symptomatic WON.
Consecutive patients with symptomatic WON undergoing EUS-guided drainage
using BFMS were included from January 2013 to December 2015. Patients were
reassessed at 48–72 hours for symptom improvement and reduction in size of
collection. The endoscopic interventions were approached in a step-up manner to
manage patients who did not have expected clinical improvement after index
drainage of WON with BFMS. Declogging of blocked lumen of BFMS was
the first step. Second step involved a naso-cystic catheter (NCT) placement
through BFMS followed by intermittent irrigation with saline and hydrogen
peroxide. Third step involved direct endoscopic necrosectomy (DEN), which
was performed through BFMS in patients with persistent symptoms. Patients
were reassessed between 4 to 8 weeks and BFMS were removed after document-
ing radiological resolution of collection. The main outcome measures studied
were technical success, clinical success, adverse events and the need for various
endoscopic reinterventions, using step-up approach.
Results: A total of 205 patients (mean age 34.8 12.5 years, 181 males) under-
went EUS-guided drainage with BFMS. Technical success was achieved in 203
patients (99%). Peri-procedure adverse events occured in 8 (3.9%) patients
(bleeding in 6 and perforation in 2). WON resolved with BFMS in 158
(74.6%). Endoscopic re-intervention, required in 49 (23.9%) patients, for persis-
tent or new onset symptoms, was approached in step-up manner. At first, de-
clogging of BFMS alone succeeded in 10 out of 21. Second step of naso-cystic
placement through BFMS followed by irrigation with saline and hydrogen per-
oxide improved 16 out of 39. At final step, DEN improved outcome in 19 out of
23. BFMS migrated in 5 (2.9%) patients (2 internal, 3 external). Four patients
failed to achieve clinical success, requiring surgery (n¼ 2) or additional percuta-
neous drainage (n¼ 2). Overall, clinical success was achieved in 198 (96.5%)
patients.
Conclusion: EUS-guided drainage with BFMS is safe and effective in WON.
BFMS substantially reduces the requirement of DEN. Success rate incrementally
improves with endoscopic step-up approach.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Biliary obstruction secondary to colorectal cancer liver metastases is
associated with a poor prognosis without drainage especially when chemotherapy
cannot be re started. However, little information is known about clinical benefits
of such endoscopical and radiological interventions, as well as the impact of
chemotherapy achievement. The aim of this study was to determine survival
after biliary drainage and look for prognostic factors.
Aims & Methods: This retrospective study analyzed patients from two expert
French centers between 2005 and 2014. Patients were included after first biliary
endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous
transhepatic cholangiography (PTC) drainage for biliary obstruction secondary
to liver metastases of colorectal cancer occurring during chemotherapy.
Demographical, biochemical, and outcome data were registered. We used
Kaplan-Meyer analysis to assess survival after first biliary stenting and cox
models for univariate and multivariate analysis.
Results: The final analysis included 69 patients. Sixty patients underwent ERCP,
2 underwent PTC drainage, and 7 underwent both techniques. Overall median
survival was 115 days (5–1876). In univariate analysis, a previous liver surgery, a
technical and a functional success of drainage and restarted chemotherapy were
significantly associated with an improved survival. Chemotherapy was restarted
after a median of 27 days. When drainage was efficient survival improved from
33 days to 262 days (p5 0.001). In multivariate analysis, protective factors for
survival included a previous hepatectomy (hazard ratio (HR) 0.41, 95% CI [0.22–
0.75], p¼ 0.004), functional success drainage (HR 0.29, 95% CI [0.15–0.56],
p¼ 0.0002). Predictive factors for death included increased lines of chemotherapy
(HR 1.68, 95% CI [1.36–2.06], p5 0.001), and fever before drainage (HR 2.97,
95% CI [1.39–6.36], p¼ 0.005).
Conclusion: This the first study concerning benefits of biliary drainage during the
course of chemotherapy of colorectal cancer with malignant biliary obstruction.
A successful biliary drainage leads to improved survival and allows achievement
of chemotherapy for 50% of patients.
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Introduction: Primary sclerosing cholangitis (PSC) is a chronic inflammatory
disease of biliary epithelium leading to strictures intra- and extrahepatic bile
ducts and finally to cholestasis and secondary biliary cirrhosis (1). The chronic
inflammation is associated with increased proliferation of biliary epithelial cells
and a markedly increased risk of biliary dysplasia and cholangiocarcinoma (2),
SIR ranging from 55 to 973 (3–4). The lifetime risk of CCA is around 10% (5).
CCA is the most common reason for death among PSC patients (6–7). CCA is
thought to develop through metaplasia, low-grade dysplasia, and high-grade-
dysplasia (8). Chronic inflammation has been regarded as risk factor for dyspla-
sia and malignancy. Because CCA is generally a contraindication for liver trans-
plantation (LT) and the prognosis of CCA is dismal, it would be feasible to
screen the dysplastic changes of the biliary epithelium to treat patients with LT
before development of advanced malignancy, detected based on imaging methods
or symptoms.
Aims & Methods: We aimed to evaluate the grade of bile duct inflammation as a
risk factor for dysplasia and cholangiocarcinoma in PSC patients. In total, 210
patients with confirmed PSC referred for ERC for disease surveillance were
included (121 females, 179 males). After cannulation of the common bile duct
bile sample was aspirated using balloon catheter and immersed immediately in
liquid nitrogen (196oC) and then stored in 20oC. Brush cytology (BC) was
collected both from extra- and intrahepatic bile ducts for Papanicolau staining
for grading dysplasia and inflammation. Neutrophilic inflammation in BC was
evaluated semiquantitatively (0¼neutrophils/epithelial cells 50.05,
1¼neutrophils/epithelial cells 0.05–0.4, 2¼neutrophils/epithelial cells 40.4).
Bile concentrations of calprotectin were analyzed using ELISA method. Liver
function tests were taken at the time of ERC. ERC findings were scored accord-
ing to modified Amsterdam score, [Helsinki score] (9).
Results: Bile duct inflammation assessed by biliary calprotectin correlated sig-
nificantly with neurophils in BC, with S-CA19–9, S-ALP and S-AST levels and
interestingly with S-IgG. Patients with dysplasia or CCA had markedly elevated
B-calprotectin, as compared to those without dysplasia (34.7 vs 4.0 mg/l, respec-
tively), see table. The risk of dysplasia was associated with advanced bile duct
disease, (mERC score48 vs54, OR 15.2 [95% 1.8–127.9], p¼ 0.012), increased
bile duct inflammation based on BC-neutrophils (BC-Neurophil 1–2 vs 0, OR 8.2
[95%1.1–64.0], p¼ 0.044), B-calprotectin higher than 45 mg/l (OR 3.3 [95%1.1–
9.9], p¼ 0.0032) and S-Ca19–9 426 kU/l vs526 kU/l (OR 7.4[95% 2.0–27.6],
P¼ 0.003).
Bile calprotectin in relation to variables of PSC activity
Variable N B-calpro, mg/l, median [25%–75%] p-value
ERC-score4 94 0.4 [0.1–3.9] 50.0001
ERC score44 116 13.8 [1.6–96.3]
Bil-Neutrophils
- 0 74 0.2 [0–1.1] 50.0001
- 1 100 5.3 [0.9–22.9]
- 2 36 172.8 [59.1–286.8]
Dysplasia
- No 203 4.0 [0.2–41.0] 0.023
- Yes 14 34.7 [4.8–99.5]
S-CA19–9 kU/l
- 526 (UNL) 198 2.7 [0.2–28.5] 0.003
- 26 (UNL) 12 57.4 [19.4–179.3]
S-ALP, U/l
- 105 (UNL) 101 1.2 [0.2–9.6] 50.0001
- 4105 (UNL) 109 6.1 [0.5–81.9]
S-AST, U/L
- 40 (UNL) 141 1.4 [0.1–21.0] 50.0001
- 440 (UNL) 69 8.3 [1.0–89.6]
S-IgG, g/l
- 15 (UNL) 177 2.8 [0.2–27.0] 0.008
- 415 (UNL) 33 19.5 [1.3–112.1]
Conclusion: S-ALP, AST and IgG seem to be good surrogate markers for bile
duct inflammation compared to biliary calprotectin levels. Risk of dysplasia is
associated with bile duct inflammation assessed by brush cytology neutrophils,
B-calprotectin and S-Ca19–9 levels426 kU/l. These variables seem be useful for
individual risk stratification for PSC patients for disease progression and
dysplasia.
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Introduction: Glycoprotein 2 [GP2] and CUB zona pellucida-like domain 1
[CUZD1] belong to protein families involved in gut innate immunity processes
and have recently been identified as specific targets of anti-pancreatic autoanti-
bodies [PAbs] in Crohn’s disease [CD]. We aimed to determine the prevalence
and prognostic potential of novel target-specific PAbs regarding long-term dis-
ease course in a cohort of a primary sclerosing cholangitis [PSC] patients.
Aims & Methods: Sera of 69 PSC patients (median age[range]: 32[5–79] years,
concomitant IBD:67% and cirrhosis:20%) were tested by indirect immunofluor-
escence test [IIFT] system with GP2 and CUZD1 expressing transfected HEK
293 cells [anti-rPAg2 and rPAg1 IgA/IgG]. Classical serologic markers of IBD
were also assessed (pANCA and aLFS IgA/IgG by IIFT, while ASCA IgG/IgA
and anti-OMP PlusTM IgA by ELISA). A previously reported inflammatory
bowel disease [IBD] patient cohort (CD:264 and UC:179) were the controls.
Poor disease outcome was defined as orthotopic liver transplantation [OLTx]
and/or liver-related death during the follow-up (median: 94 months].
Results: A total of 43.5% of PSC patients were positive for either of the two
target-specific anti-PABs, with a significant difference compared to patients with
CD [26.8%, p5 0.01] or UC [7.6%, p5 0.001]. Distribution of the two types of
PAbs was equal and one-third of the positive cases showed double positivity.
Anti-GP2 antibody positivity was exclusively IgA type, while anti-CUZD1 anti-
bodies were of both IgA and IgG isotypes. No difference was found in the
frequency of PAbs according to the baseline disease characteristics. Positivity
for the IgA subtype of anti-GP2, but not for the classical serologic markers,
predicted a faster progression of the disease. In Kaplan-Meier analysis, anti-
GP2 IgA positivity was associated with shorter time to OLTx and/or liver-related
death [pLogRank50.01], and remained an independent predictor after adjusting
for the presence of cirrhosis in Cox-regression analysis (HR: 4.31 [1.05–17.61]).
Conclusion: Our small-scale study has shown that occurrence of target-specific
PAbs is common in PSC. Association of IgA type anti-GP2 antibody with faster
disease progression serves as an additional hint towards the significance of gut-
liver interaction in the disease course of PSC.
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Introduction: Gut-liver interaction is a pathogenic feature of primary sclerosing
cholangitis (PSC), however the effect of this cross-talk on the disease course has
not been fully elucidated. A panel of serological markers that reflect either
mechanical or immunological gut barrier dysfunction were assessed in a cohort
of patients with PSC. Association of these markers with disease specific charac-
teristics and the long-term disease course was evaluated.
Aims & Methods: Sera of 69 PSC patients (median age[range]:32[5–79] years,
concomitant IBD: 67% and cirrhosis: 20%) were assayed for intestinal fatty
acid-binding protein(I-FABP) and various immunoglobulin A (IgA) molecules
(IgA1, IgA2 and secretory[s]IgA, anti-F-actin[AAA IgA] and anti-gliadin[AGA
IgA/IgG]) by ELISA. Poor disease outcome was defined as orthotopic liver
transplantation [OLTx] and/or liver-related death during the follow-up
(median: 94 months]. 155 healthy subjects (HCONT) and 179 ulcerative colitis
(UC) patients were the controls.
Results: In PSC, median I-FABP level was similar to that in HCONT (216 vs. 244
pg/mL) but higher than in UC (176 pg/mL, p5 0.05). sIgA level (95.7 mg/ml) was
two- and three-fold higher compared to either the HCONT or the UC
(p5 0.001, for both). 28.4%, 9% and 20.9% of PSC patients were positive for
AAA IgA, AGA IgA and AGA IgG, respectively. Frequencies of AAA IgA
(p5 0.001, for both) and AGA IgG (p¼ 0.01, for both) but not AGA IgA
were significantly higher compared to HCONT and UC. Regarding disease-spe-
cific characteristics, sIgA level was significantly lower in PSC patients with con-
comitant IBD (80.7 vs. 160.4 mg/ml). In Kaplan-Meier analysis only target-
specific IgAs and sIgA (4175 mg/ml) were associated with a shorter time to
OLTx and/or liver-related death, whereas total IgA or IgA2/IgA1 ratio and I-
FABP were not. All markers remained significant after adjusting for the presence
of cirrhosis in Cox-regression analysis (HR[95%CI]: 3.67[1.05–12.82] for sIgA,
5.15[1.27–20.86] for AAA IgA and 5.07[1.25–20.54] for AGA IgA). Combining
these markers further enhanced their predicative potential (HR[95%CI]:
11.30[2.84–44.93] for 2 marker positivity).
Conclusion: In our small-scale study, gut-related IgA type antibodies identified
PSC patients with progressive disease, further highlighting the importance of the
gut-liver interaction in PSC.
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Introduction: IgG4-related sclerosing cholangitis (IgG4-SC) often presents similar
medical images to extrahepatic cholangiocarcinoma (ECC). However, the differ-
entiation is crucial for further treatment.
Aims & Methods: To elucidate characteristics of medical images of IgG4-SC and
ECC, we retrospectively analyzed images of multi-detector computed tomogra-
phy (MDCT) and intraductal ultrasonography (IDUS). Biopsy-based diagnoses
from stenotic bile ducts were also compared. From April 2005 to March 2013, 48
IgG4-SC patients and 50 ECC patients who underwent an initial ERCP at our
institution were analyzed. Diagnosis of IgG4-SC was made based on the
Japanese clinical diagnostic criteria (2012), and autoimmune pancreatitis (AIP)
based on International Consensus Diagnostic Criteria (ICDC). The pathological
criteria consist of four items: (1) marked lymphocytic and plasmacyte infiltration
and fibrosis, (2) infiltration of IgG4-positive plasma cells: 410 IgG4-positive
plasma cell/HPF, (3) storiform fibrosis, and (4) obliterative phlebitis. In all
cases of ECC, pathological evidence of carcinoma was obtained from biliary
biopsy, cytology or surgical material. On MDCT, we defined the long thickened
bile duct when the enhanced, biliary wall thickness was recognized at more than
10 mm upstream of the stenosis.
Results: Autoimmune pancreatitis (AIP) was accompanied in 88% (42/48) of
IgG4-SC patients at the initial diagnosis. On MDCT imaging, the long thickened
bile duct rate was higher in IgG4-SC cases than in ECC cases (76% of IgG4-SC
and 32% of ECC, respectively). By IDUS, a continuous circular-symmetric wall
thickness more than 10 mm upstream from stenosis was recognized in 84% of
IgG4-SC cases and in 36% of ECC cases. In IgG4-SC cases, biliary biopsy
revealed one or more positive pathological diagnostic items in only 13% of
cases. In ECC cases, the sensitivity of biopsy was 92%, and brush cytology
increased this by 6%. Among three out of six IgG4-SC patients without AIP,
pancreatoduodenectomy was performed without careful examination. The
remaining three underwent steroid trial after negative work up for malignancy.
Conclusion: A longitudinal biliary wall-thickness, upstream of the stenosis, was
characteristic for imaging of IgG4-SC. Endobiliary forceps biopsy is effective for
discriminating IgG4-SC from ECC.
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Introduction: Farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear
receptor, plays a critical role in maintaining lipid, glucose and BA homeostasis.
FXR expression is significantly decreased in livers of non-alcoholic fatty liver
disease (NAFLD) patients and genetic ablation leads to hepatic steatosis and
hyperlipidaemia. The FXR gene expresses four biologically active variants
(FXR1–4), which regulate hepatic and lipid metabolism in an isoform-depen-
dent manner.
Aims & Methods: Our aim was to screen potential BA-derived FXR agonists for
their ability to selectively activate different FXR isoforms and protect liver cells
against free fatty acid (FFA)-induced steatosis and cytotoxicity. Nineteen novel
BA derivatives, synthesized based on the cholic (CA), deoxycholic (DCA), che-
nodeoxycholic (CDCA) and ursodeoxycolic (UDCA) acid scaffolds were incu-
bated in HepG2 cells transfected with a dual-luciferase reporter construct and
overexpression vector plasmids for FXR1–4 isoforms. Selected BA-derivatives
were then co-incubated in HepG2 cells treated with 200 and 500 mM oleic and
palmitic acid (2:1 ratio), for assessment of cellular cytotoxicity using the MTS,
LDH and ToxilightTM assays, as well as intracellular lipid accumulation, by oil
red O (ORO) staining. Additionally, mRNA levels of both direct and indirect key
FXR-targets, namely SHP, SREBP1-c, PPAR-, CYP7a1 and VLDLR, were
assessed after incubation of primary mouse hepatocytes with the select BA-
derivatives.
Results: As a result of the diverse structural modifications, BA derivatives
showed differential activation of the FXR1–4 isoforms, when compared to
their precursor BAs. From the precursor BAs, only CDCA, a natural FXR
ligand, significantly activated FXR1 and 2 isoforms, with CA and UDCA
displaying a modest activation of FXR1 isoform only. Interestingly, 2 novel
CA-, 1 DCA- and 4 UDCA-derivatives were stronger activators of both FXR1
and 2, comparing with their corresponding precursors. Further, 3 novel CA-, 2
DCA-, 3 CDCA- and 4 UDCA-derivatives specifically and significantly activated
FXR3 and 4. Incubation of HepG2 cells with the FFAs mixture led to a 5–
25% reduction in cell viability and a 10–35% increase in cell death, concomi-
tantly with a dose-dependent accumulation of lipid droplets. Pre-incubation of
cells with CA-derivatives preferentially activating FXR2 over 1 isoform
reverted most of the FFA-induced cell death and lipid accumulation. Of note,
these derivatives were among the stronger inducers of SHP, VLDLR and PPAR-
 mRNA expression in primary mouse hepatocytes.
Conclusion: Altogether, we describe a novel strategy to screen for selective ago-
nists of FXR1–4 isoforms and have identified new selective BA-derived FXR1
through 4 agonists. In particular, derivatives with a higher FXR2 over 1
binding ratios appear to be more effective in affording cytoprotection against
lipotoxicity in liver cells. The differential functional effect of these new molecules
will undoubtedly contribute for a better understanding of pharmacological tar-
geting and therapeutic efficacy of FXR agonists in liver diseases such as
NAFLD. (Supported by HMSP-ICT/0018/2011,SFRH/BD/110672/2015 and
SFRH/BD/80975/2011 FCT, Portugal).
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Introduction: PNPLA3 (patatin-like phospholipase domain containing 3) encodes
carbohydrate-regulated lipogenic and/or lipolytic enzymes in liver. The mutation
of isoleucine to methionine at position 148 (I148M) causes a loss of function
effect leading to increased triglyceride synthesis and accumulation in liver (1).
The PNPLA3 rs738409 C4G p.I148M has been associated with steatosis and
fibrosis in various liver disease and increased risk for development of liver cir-
rhosis and hepatocellular cancer (2). The impact of PNPLA3 rs738409 [G] on
liver damage has a strong environmental interaction and is usually associated
concomitant liver insult. PSC is a chronic inflammatory disease of bile duct
epithelium leading to strictures and may secondarily cause liver cirrhosis. PSC
is also associated with inflammatory bowel disease and markedly increased risk
of cholangiocarcinoma (3,4). PLPN3 variant has been associated with elevations
of liver enzymes in IBD (5) and in increased risk of bile duct stenosis in male PSC
patients (6). Survival free of liver transplantation is reduced in male PSC patients
with development of dominant strictures in carriers of PNPLA3 I148M variant
(5).
Aims & Methods: To evaluate the allele dose effect of PNPLA3 variant on the
clinical manifestations, disease severity, progression and prognosis of PSC in a
large patient population from single center.
Results: Of the 563 patients 334 (59.3%) had the wild type (CC), 197 (35%) were
heterozygous (CG) and 32 (5.7%) were homozygous for the mutation (GG). A
concomitant IBD was diagnosed in 80% of the males and 60% the females.
Summary of the results are presented in the table.
PNPLA3 rs738409 in PSC
Variable, mean(SD)
CC,
n¼ 334
CG,
n¼ 197
GG,
n¼ 32
p for
linearity
Males, n (%) 195(58) 124(63) 17(53) 0.75
Age at diagnosis of PSC,y 38(14) 36(13) 35(13) 0.10
Weight, kg, males 82(14) 80(15) 81(14) 0.37
Weight, kg, females 69(7) 70(17) 71(13) 0.62
IBD, n (%) 263(71) 152(77) 21(65) 0.49
Age at dg of IBD 26(11) 26(11) 29(12) 0.74
ERC-score (0–16) 5.8(3.5) 5.4(3.3) 5.7(3.7) 0.88
Dominant strictures, n (%) 128(38) 61(31) 9(28) 0.061
Progression of ERC score/month* 0.014 0.002 0.004 0.44
Advanced fibrosis F3/4, (%)* 8.8 15.1 12.5 0.25
S-ALP, U/l 5105 183(148) 194(170) 182(135) 0.60
S-GT, U/l, 560 191(249) 236(269) 189(154) 0.94
S-ALT, U/l, 550 74(125) 78(96) 61(50) 0.35
S-AST, U/l, 545 55(73) 54(63) 59(41) 0.68
*Adjusted for sex, age and IBD Cholangiocarcinoma was diagnosed in 12 (3.6%)
patients with CC, in 6 (3.1%) of CG an in none of GG, (p for linearity¼0.42;
adjusted for sex, age and IBD). 49 patients underwent liver transplantation
during 5 years mean follow up: 2.5% (95% CI: 1.2 to 5.1) in CC, 3.1% (95%
CI: 1.3 to 7.3) in CG and 7.1% (95% CI: 1.8 to 24.4) in GG, (p for linear-
ity¼ 0.12; adjusted for sex, age and IBD).
Conclusion: The PNPLA3 I148M variant did not have any significant impact on
clinical manifestation, disease progression, development of dominant strictures,
on risk of cholangiocarcinoma or liver transplantation in PSC.
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Introduction: Colorectal cancer (CRC) develops through a series of genetic mod-
ifications that transform normal colonic epithelium to an adenoma and the
adenocarcinoma. In addition to the genetic instability, the activation of growth
factor pathways (eg. The activation of Cox-2, EGF, and VEGF) is common in
the pathogenesis of CRC cells. Lysophosphatidic acid (LPA) acts on LPA2
receptor to mediate multiple pathological effects that are associated with tumor-
igenesis. LPA2 expression is increased in CRC patients and proportionally
increases with the size of adenomas in rodent models. The absence of LPA2
attenuates tumor progression in rodent models of colorectal cancer, but whether
overexpression of LPA2 alone can lead to malignant transformation in the intest-
inal tract has not been studied.
Aims & Methods: The aim of this study is to determine whether increased LPA2
expression in intestinal epithelial cells (IECs) alone is sufficient to induce spon-
taneous transformation in the intestinal tract. In this study, we expressed human
LPA2 in IECs under control of the villin promoter. The transgene DNA was
injected into the pronuclei of fertilized eggs of C57BL/6J mice. The transgenic
mice were identified by PCR analysis of tail genomic DNA.
Results: Less than 4% of F1-generation mice had germline transmission of trans-
genic (TG) human LPA2 as such only 3 F1 mice out of 72 genotyped had TG
expression. These TG mice appeared anemic with hematochezia and died shortly
after birth. TG mice were smaller in size compared with the wild type mouse of
the same age and sex. Morphological analysis showed that TG LPA2 colon had
hyper-proliferation of IECs resulting in increased colonic crypt depth.
Surprisingly, TG small intestine had villus blunting and decreased IEC prolifera-
tion and dysplasia. In both intestine and colon, TG immunohistochemical ana-
lysis revealed that expression of LPA2 compromised the terminal epithelial
differentiation, consistent with epithelial dysplasia. Furthermore, we showed
that epithelial dysplasia was observed in founder mouse intestine, correlating
LPA2 overexpression with epithelial dysplasia.
Conclusion: We demonstrated that overexpression of LPA2 induces dysplasia in
mouse intestine that alter IEC proliferation and differentiation. Our results rein-
force the importance of the LPA-LPA2 axis in homeostatic regulation of IECs
and its potential contribution to carcinogenesis in the intestinal tract.
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Introduction: Colorectal cancer (CRC) development is characterized by the
sequential accumulation of somatic mutations, which promotes epithelial prolif-
eration and subsequently tumor invasion. Calcineurin is a phosphatase, which
contributes to innate and adaptive immunity through the activation of transcrip-
tion factors of the family of nuclear factor of activated T cells (NFAT). Systemic
inhibition of calcineurin as applied in human immunosuppression is associated
with an increased incidence of CRC. However, calcineurin and NFAT are also
expressed in CRC cell lines and rather promote than inhibit epithelial prolifera-
tion in vitro. These findings raise the question of whether calcineurin plays cell-
specific roles in CRC and, in particular, whether intestinal epithelial calcineurin
promotes tumor development in a cell-intrinsic manner.
Aims & Methods: To investigate the role of calcineurin and NFAT in intestinal
tumor development, we generated mice with intestinal epithelial cell (IEC)-spe-
cific deletion of the regulatory B1 subunit of calcineurin and analyzed these mice
in the Apcfl/wt and ApcMin/þ models of genetically induced intestinal tumor
development as well as in the AOM/DSS model of colitis-associated cancer.
For mechanistic studies, organoid cultures, immortalized IECs and CRC cell
lines as well as samples of more than 700 CRC patients were studied.
Results:We demonstrate that systemic inhibition of calcineurin with cyclosporine
leads to increased intestinal tumor growth in ApcMin/þ mice, which is consistent
with an increased CRC incidence observed in patients receiving calcineurin inhi-
bitors. In contrast, intestinal epithelial cell-specific deletion of calcineurin is
associated with reduced intestinal tumor formation and growth in the Apcfl/wt
and ApcMin/þ model. Antibiotic treatment of mice as well as backcrossing to a
Myd88-deficient background revealed that the activation of oncogenic epithelial
calcineurin is dependent on the intestinal microbiota and results from tumor-
associated alterations in microbial composition and stratification as well as from
increased tumor-associated toll-like receptor expression. Tumor-promoting
effects of epithelial calcineurin are elicited through NFAT-dependent transcrip-
tional regulation of Lgr5-positive tumor stem cells as shown by chromatin immu-
noprecipitation (ChIP), gene expression analysis and functional studies together
leading to control of tumor stem cell apoptosis and proliferation as shown by
FACS and immunofluorescence staining. Moreover, somatic mutations identi-
fied in human CRC are associated with constitutive activation of calcineurin,
while nuclear translocation of NFAT correlates with reduced survival in a large
cohort of CRC patients.
Conclusion: These results support the concept of cell-specific roles of calcineurin
in the regulation of colorectal carcinogenesis and reveal novel potential targets
for the prevention and treatment of CRC.
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Introduction: During colorectal carcinoma (CRC) formation exosomes play
important roles as intercellular regulators in conveying complex signals between
epithelial/carcinoma cells and their abnormal microenvironment.
Aims & Methods: Our aim was to characterize changes in exosome-based com-
munication in the colorectal adenoma-carcinoma sequence by determining ALG
2-interacting protein X (ALIX) exosome marker production on mRNA and
protein level. mRNA expression was analyzed using Affymetrix HGU133
Plus2.0 whole transcriptome data of healthy (n¼ 49), adenoma (n¼ 49) and
CRC (n¼ 49) samples. Immunohistochemistry was performed on healthy
(n¼ 27), adenoma (n¼ 42), CRC (n¼ 37) patients and stained for ALIX exo-
some, cytokeratin (CK) epithelial, podoplanin (PDPN) lymphatic vessel, Ki-67
proliferative and Musashi-1 (MSI1) stem cell markers. Slides were digitalized and
analyzed with digital microscopy.
Results: We found significantly decreased (p5 0.05) ALIX mRNA expression
both in adenoma and CRC samples compared to normal samples. Similarly,
significantly reduced (p5 0.05) ALIX protein levels were detectable in adenoma
and CRC samples compared to normal ones. The reduced protein expression was
accompanied by gradual transition from diffuse cytoplasmic (in normal epithe-
lium) expression to granular signals (in adenoma and CRC samples) with 0.6–
2 mm diameter size range of multivesicular bodies. The granular ALIX expression
was not limited to the proliferative and stem cells, but was also observed in
budding CKþ and MSI1þ stromal cells, as well as in the lumen of PDPNþ
lymphatic vessels in invasive CRCs.
Conclusion: The altered ALIX expression pattern in pre-neoplastic lesions sug-
gests that abnormal exosome transport may play an important role in the ade-
noma to carcinoma transformation. Furthermore, the increased frequency of
exosome marker expression in stromal and budding cancer cells, and also in
the lumen of lymphatic vessels suggests that the exosome based information
flow may be fundamental in the development of local and distant pre-metastatic
microenvironments in CRC patients. This study was funded by the Research and
Technology Innovation Fund, Hungary, KMR_12–1-2012–0216 and Hungarian
Scientific Research Fund (OTKA-K111743 grant).
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Introduction: Scaffold proteins mediate protein-protein interaction to bring
together key members of signaling pathways that drive cell division and
growth. The Naþ/Hþ exchanger regulatory factor (NHERF) family of proteins
is scaffolds that orchestrate interaction of receptors and cellular proteins. Among
the NHERF proteins, NHERF1 and NHERF2 share most similarities with
tandem PDZ domains and an ERM interacting motif in the carboxyl domain
that enables anchoring to the actin cytoskeleton. One major function of
NHERF1/2 is to recruit and spatially organize signaling proteins that either
alters protein functions or downstream signaling pathways originating from
receptor. NHERF1 is reported to be a tumor suppressor. However, the role of
NHERF2 in cancer progress has not been reported.
Aims & Methods: We investigated the role of NHERF2 in colon tumor progres-
sion. We first determined NHERF2 expression in human colorectal cancer
(CRC) using a tissue microarray. Next, the role of NHERF2 on colon cancer
growth and invasion was assessed by a loss-of-function approach (shRNA) and a
small peptide which blocked the PDZ domain of NHERF2 to bind using colon
cancer cell lines (HCT116, SW480, and HT-29). We validated tumor growth
change by xenograft model. Moreover, we used ApcMin/þ mouse model to
investigate the tumorigenesis in intestine with NHERF2 homozygous deletion
mice. To investigate the molecular mechanism of NHERF2 in tumor growth, we
performed the transcriptom analysis.
Results: We found that NHERF2 expression is elevated in advanced-stage CRC.
Knockdown of NHERF2 decreased cancer cell proliferation and invasion
in vitro, and tumor growth in a mouse xenograft tumor model. Histologic ana-
lysis confirmed the reduction of cell proliferation by Ki67 immunostaining. In
addition, deletion of NHERF2 in ApcMin/þ (ApcMin/þ;Nherf2-/-) mice
resulted in decreased tumor growth in ApcMin/þ mice and increased lifespan.
Blocking NHERF2 interaction with a small peptide designed to bind the second
PDZ domain of NHERF2 attenuated cancer cell proliferation. Although
NHERF2 is known to facilitate the effects of lysophosphatidic acid receptor 2
(LPA2), transcriptome analysis of xenograft tumors revealed that NHERF2-
dependent genes largely differ from LPA2-regulated genes. b-catenin and
ERK1/2 activation was mitigated in ApcMin/þ;Nherf2-/- adenomas.
Moreover, Stat3 phosphorylation and CD24 expression levels were suppressed
in ApcMin/þ;Nherf2-/- adenomas. Consistently, NHERF2 knockdown attenu-
ated Stat3 activation and CD24 expression in colon cancer cells. Interestingly,
NHERF2-dependent increase in CD24 expression was blocked by inhibition of
Stat3, suggesting that NHERF2 regulates Stat3 phosphorylation followed by the
increase in CD24.
Conclusion: This study demonstrated NHERF2 stimulates colon cancer growth
by intersecting at multiple signaling nodes. NHERF2 potentiates the oncogenic
effects in part by regulation of Stat3 and CD24. This study provides NHERF2 as
a new potential target for cancer treatment.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Pan Y, Wang L and Dai JL. Suppression of breast cancer cell growth by
Naþ/Hþ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res 2006;
8: R63.
2. Hayashi Y, Molina JR, Hamilton SR, et al. NHERF1/EBP50 is a new
marker in colorectal cancer. Neoplasia 2010; 12: 1013–1022.
3. Lin S, Wang D, Iyer S, et al. The absence of LPA2 attenuates tumor forma-
tion in an experimental model of colitis-associated cancer. Gastroenterology
2009; 136: 1711–1720.
4. Lin S, Lee SJ, Shim H, Chun J and Yun CC. The Absence of LPA receptor 2
Reduces the Tumorigenesis by ApcMin Mutation in the Intestine. Am J
Physiol Gastrointest Liver Physiol 2010; 299: G1128–G1138.
OP041 THE EXTRACELLULAR MATRIX PROTEIN EMILIN2 AS A
REGULATOR OF THE MYELOID RESPONSE IN A MODEL OF
INFLAMMATION-INDUCED COLON CARCINOGENESIS
E. Andreuzzi1, A. Paulitti1, G. Tarticchio1, E. Di Carlo2, R. Pellicani1,
A. Colombatti1, R. Cannizzaro3, M. Mongiat1
1Translational Research, Experimental Oncology Ii, CRO-IRCCS, Aviano/Italy
2Department Of Oncology and Experimental Medicine, University of Chieti-
Pescara, Chieti/Italy
3Oncological Gastroenterology, Centro di Riferimento Oncologico di Aviano
S.O.C. di Gastroenterologia, Aviano/Italy
Contact E-mail Address: eandreuzzi@cro.it
Introduction: EMILIN2 is an extracellular matrix molecule belonging to the EMI
Domain ENdowed (EDEN) protein family that exerts pleiotropic effects in the
tumor microenvironment overall functioning as a tumor suppressive molecule (1–
3). EMILIN2 affects tumor cell viability and proliferation by activating apopto-
sis and functioning as a negative regulator of the Wnt/b-catenin axis.
Interestingly EMILIN2 expression is down-modulated by methylation in a
number of tumors including breast and colorectal cancer (4). Our preliminary
results highlight a possible new function for E2 in the control of CRC incidence.
In particular these findings indicate that E2 seems to modulate the myeloid
response and to profoundly affect the inflammatory microenvironment asso-
ciated with CRC.
Aims & Methods: Given its involvement in the regulation of Wnt signaling, a
crucial pathway in colon carcinogenesis, and its altered expression in colorectal
cancer, we took advantage of the EMILIN2 null mouse model to assess its role in
colorectal cancer (CRC) development, subjecting the mice to the inflammation-
related AOM/DSS protocol. Colorectal tumors were induced subjecting the mice
to a AOM/DSS treatment. Tumor development was assessed by colonoscopy.
Histopathological and IHC analyses were performed on colon samples from
treated mice. b-catenin activation was assessed by Western blot and qPCR.
Multiplex serum cytokine analyses from the two mouse models were performed
through Luminex Screening and peripheral blood cells were counted. The inflam-
matory infiltrate was analysed by flow cytometry.
Results: The EMILIN2 KO mice developed a significantly higher number of
tumors compared to wt mice. Tumors from EMILIN2 KO mice were more
undifferentiated and at an advanced stage compared to the tumors from control
mice. Surprisingly, and contrary to our expectations, tumors from EMILIN2 KO
mice did not display any changes in the activation of the Wnt/b-catenin pathway
compared to the controls. Accordingly, the b-catenin target genes cyclin D1 and
c-Myc were not altered in the tumors and in the normal mucosa of the two mouse
models. Histopathological and IHC analysis indicated that the tumors from
EMILIN2 KO mice where characterized by a higher number of macrophages
and granulocytes than those from WT mice. Similar alterations in the KO model
were found during the acute fase of inflammation: mice subjected to DSS treat-
ment alone developed a more severe colitis than WT mice. Accordingly, the
infiltration of myeloid cells within the intestinal mucosa was altered and the
serum level of a number of cytokines, including IL-1b, INF-gamma, TNF-
and IL-10, was affected.
Conclusion: Our results let us suggest that EMILIN2 may affect colon carcinog-
esis impinging on the recruitment and/or the activation of myeloid cells. By
altering the inflammatory microenvironment, EMILIN2 may significantly influ-
ence colon cancer development.
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Introduction: Cancer stem cells (CSCs) are thought to be responsible for tumour
initiation, metastasis and relapse through their unlimited self-renewal and differ-
entiation potential. miRNAs have recently emerged as promising candidates to
target CSCs. miR-145 is a tumour suppressor miRNA, downregulated in colon
cancer adenomas and carcinomas. It has been shown to be involved in tumour
growth, metastasis and resistance to chemo/targeted agents, as well as in mod-
ulation of CSC-like properties in prostate cancer and lung adenocarcinoma. In
this context, we hypothesise that miR-145 may play a role in the ability of colon
CSCs (CCSCs) to self-renew and differentiate.
Aims & Methods: We aimed to evaluate the effect of miR-145 overexpression in
maintaining CCSCs-like properties. We produced miR-145 overexpressing and
empty vector control cells using HCT116, HT29, SW480 and SW620 colon
cancer cell lines, and examined their ability to form colon spheres in ultralow-
attachment plates and specific CCSC media. Colon spheres were dissociated to
single cells and reseeded to yield the second and third generation of colon
spheres. The number of spheres and cells per sphere were counted over 3 gen-
erations. mRNA expression levels of stemness markers were evaluated by SYBR
Real-Time PCR. CD44 and CD133 expression levels and aldehyde dehydrogen-
ase 1 (ALDH1) activity were evaluated by flow cytometry.
Results: Our results showed that forced miR-145 expression reduced colon sphere
diameter and number of cells per sphere in HCT116, HT29, SW480 and SW620
cells. Moreover, miR-145 overexpression had an impact on HT29 and SW620
sphere formation, reducing the number of colon spheres. Similar results were
observed with the second and third generation of cell line-derived colon spheres.
mRNA expression levels of the stemness markers KLF4 and BMI1, were sig-
nificantly reduced in colon spheres overexpressing miR-145 (p5 0.01). In addi-
tion, HT29 and SW480 cell line-derived colon spheres overexpressing miR-145
displayed reduced OCT4 mRNA levels. Furthermore, miR-145 overexpression
significantly decreased the proportion of CD44/CD133þ cells and ALDH1 activ-
ity (p5 0.05). The mature colonocyte marker, CK20, was increased in HCT116
spheres overexpressing miR-145 (p5 0.01).
Conclusion: miR-145 appears to be involved in colon sphere formation, self-
renewal of colon spheres and differentiation ability of HCT116 colon spheres.
miR-145 may contribute to the induction of CCSC differentiation to cells that are
sensitive to chemotherapy and targeted agents.
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Introduction: H. pylori rescue therapy is still a major concern for clinicians treat-
ing this infection. Although several rescue treatments have been proposed and
tested, the selection of resilient strains or acquisition of resistance after failed
eradication hinders the success rate of most proposed regimens. Traditionally
rescue treatments in Europe have been divided in bismuth quadruple therapy or
levofloxacin triple. Some authors have recently proposed a combination of both
strategies by adding bismuth to the traditional levofloxacin triple therapy.
Aims & Methods: To evaluate the use and outcomes of a quadruple therapy
containing a proton pump inhibitor, bismuth, levofloxacin and amoxicillin in
the European Registry on H. pylori Management (Hp-EuReg). Methods:
Systematic prospective registry of the clinical practice of European gastroenter-
ologists regarding H. pylori infection and treatment (31 countries and 280
recruiting investigators). A local coordinator was selected from each country.
Each coordinator selected a representative group of recruiting investigators
from his/her country. An electronic clinical research file (e-CRF) was created
on AEG-REDCap to systematically register all adult patients infected with H.
pylori. Variables included: Patient’s demographics, previous eradication
attempts, prescribed eradication treatments, adverse events, and outcomes
(cure rates, compliance, follow up, etc.). Patients with both eradication confir-
matory test and with less than one year follow-up have been considered ongoing
and were excluded from the analysis.
Results: Up to now, 16,025 patients have been included, and 12,921 have finished
follow up (59% females, 87% Caucasian). Mean age was 55 years. The bismuth-
levofloxacin quadruple treatment was prescribed to 327 patients (2% of all treat-
ments registered): 7% in first-line, 76% in second, 12% in third, and 5% in
following rescues. Overall efficacy was 84% (95%C.I.¼ 75–93%) by ITT and
92% (89–95%) by PP. First-line data is insufficient for analysis. Second-line
efficacy was 85% (80–91%) by ITT and 92% (89–94%) by PP. Treatment was
generally prescribed with esomeprazole (95%) and as a 14 day regimen (98%).
Compliance with treatment was 95%. Adverse events were reported in 38% of
cases and caused treatment discontinuation in 7 (2.1%) patients.
Conclusion: A 14-day regimen combining bismuth salts with levofloxacin triple
therapy as second-line treatment for H. pylori eradication achieves near 90%
eradication rates.
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Introduction: A proton pump inhibitor (PPI)-based triple regimen containing two
antibiotics (amoxicillin, APMC; and clarithromycin, CAM) was considered the
gold standard for the eradication of Helicobacter pylori for more than a decade.
However, low eradication rates have been reported worldwide because of
increased prevalence of clarithromycin-resistantH. pylori. Insufficient acid inhibi-
tion during treatment also causes eradication failure. This is because the antimi-
crobial agents are unstable and degraded in the stomach.Esomeprazole (EPZ) is a
relatively new PPI available in Japan since September 2011. EPZ has an improved
pharmacokinetic profile as regards CYP2C19 genotype; therefore, it shows less
individual variability. Vonoprazan (VPZ) is a potassium-competitive acid blocker
(P-CAB). P-CABs are a new class of gastric acid suppressants available since
February 2015 in Japan. VPZ has a potent and long-lasting anti-secretory effect
on Hþ,Kþ-ATPase due to its high accumulation in, and slow clearance from
gastric tissue. Therefore, VPZ is expected to have high eradication rates compared
with conventional PPIs. The aim of this study was to compare H. pylori eradica-
tion rates with EPZ-based and VPZ-based triple therapies with CAM and AMPC.
Aims & Methods: A total of 807 patients who had undergone upper gastrointest-
inal endoscopy and diagnosis with H. pylori infection from November 2013 to
March 2016 were enrolled. From December 2013 to September 2014, 431 patients
were treated with EPZ-based triple therapy, while 376 patients were treated with
VPZ-based triple therapy from April 2015 to March 2016. At baseline, demo-
graphical and clinical characteristics including gender, age, body mass index
(BMI), smoking status, and consumption of alcohol were checked. The first-
line eradication regimen was CAM 200 mg, AMPC 750 mg, and either EPZ 20
mg or VPZ 20 mg, each twice daily for 7 days. The second-line eradication
regimen was metronidazole 250 mg, AMPC 750 mg, and either EPZ 20 mg or
VPZ 20 mg, each twice daily for 7 days. The eradication of H. pylori infection
was diagnosed using 13C-urea breath tests at 4–8 weeks after each of therapy.
Results: The overall first-line eradication rate was 79.1% (341/431) for the EPZ
regimen and 84.6% (318/376) for the VPZ regimen based on Intension to treat
(ITT) analysis. The eradication rate by Par protocol (PP) analysis for the EPZ
and VPZ regimens were 79.9% (341/427) and 85.3% (318/373) respectively.
Significant differences were found both in ITT analysis (p ¼ 0.045) and in PP
analysis (p ¼ 0.046). The overall second-line eradication rate was 72.6% (45/62)
for the EPZ regimen and 85.3% (29/34) for the VPZ regimen based on ITT
analysis. Using PP analysis, the eradication rate was 88.2% (45/51) for the
EPZ regimen and 87.9% (29/33) for the VPZ regimen. There were no statistically
significant differences found between the eradication rates in both groups, from
both the ITT and PP analyses.
Conclusion: In conclusion, VPZ has a rapid, sustained, and possibly more potent
acid-inhibitory effect than EPZ, irrespective of CYP2C19 genotype. The rate of
H. pylori eradication obtained using the first-line VPZ regimen was significantly
higher than that for the first-line EPZ regimen. However, for the second-line
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treatment, there were no significant differences between the eradication rates
from EPZ and VPZ regimens.
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Introduction: The gastric epithelium is characterized by constant, rapid self-
renewal, which in the antrum is driven by long-lıved stem cells situated at the
base of the glands. Infection with the gastric pathogen Helicobacter pylori is the
main risk factor for gastric cancer and increases stem cell and the turnover
kinetics of the glands. Wnt signaling is known to be crucial for stem cell home-
ostasis in several tissues and for long-term organoid culture of stomach epithe-
lium, but it is not clear how Wnt signaling is spatially organized in the stomach
in vivo and whether it modulates stem cell kinetics and glandular turnover.
Aims & Methods: The aim of the present study was to characterize the cellular and
molecular Wnt-network in the stomach and to explore its function in physiological
epithelial turnover, as well as upon infection withH. pylori. Using in single molecule
situ hybridization, different stem cell- and WNT-signaling reporter mice and the
murine and as well as human 3D-organoid system we addressed these questions.
Results: We found that Wnt-responsive cells are limited to the base of the antral
glands where stem cells reside. However, in addition to previousy descibed Lgr5-
positive cells, we found another Wnt-dependent population of highly prolifera-
tive Lgr5-negative stem cells in the gland base. We show that the positional
identity of these Axin2-positive stem cells relies on R-spondin 3, which is pro-
duced by stromal myofibroblasts. Wnt signaling stimulated by exogenous R-
spondin induces an expansion and increased proliferation of Axin2-positive
stem cells in the stomach antrum while the Lgr5-positive cells remain silenced.
Infection of mice with H. pylori increases expression of R-spondin 3, which also
induces the expansion of Axin2-positive cells and results in gland hyperplasia. By
increasing gland turnover following infection, R-spondin counterbalances bac-
terial gland colonization through increased shedding of cell-attached bacteria.
Conclusion: Thus, stromal R-spondin hierarchically organizes the stem cell com-
partment producing two Wnt–responsive populations that differ in position
within the gland, proliferation kinetics, and sensitivity to R-spondin. In addition
to its role in physiological gland homeostasis R-spondin driven regeneration is
increased by infection with H. pylori, limiting glandular colonization. This estab-
lishes a new link between infection, stem cell signaling and epithelial homeostasis.
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Introduction: Gastrin is important for normal function and maturation of the
gastric oxyntic mucosa. Hypergastrinemia is associated with several premalig-
nant conditions in the stomach and might be involved in gastric carcinogenesis.
Previously, we have shown that gastrin regulates expression of the pro-survival
factor clusterin (CLU). Expression of CLU is often dysregulated during tumor-
igenesis and in the stomach, upregulation of CLU marks emergence of spasmo-
lytic polypeptide-expressing metaplasia (SPEM). Here, we study the expression
of CLU in gastric oxyntic mucosa of animal models with elevated levels of gastrin
and elucidate its role in gastric cells during prolonged stress.
Aims & Methods: Using gastric tissue from humans, rats treated with proton
pump inhibitors and/or a cholecystokinin type B receptor (CCK-BR) antagonist,
Hþ/Kþ-ATPase b-subunit knockout (H/K-b KO) mice and Mongolian gerbils
infected with Helicobacter pylori and treated with a CCKBR antagonist, we
examined the expression pattern and gastrin-mediated regulation of CLU using
parallel reaction monitoring mass spectrometry, in situ hybridization and immu-
nohistochemistry. Human gastric cancer cell lines were used to study the gastrin-
mediated regulation and biological function of secretory CLU in vitro.
Results: CLU was highly expressed in neuroendocrine cells in normal oxyntic
mucosa of humans, rats and mice. In response to hypergastrinemia, expression of
CLU was significantly increased and localization shifted from neuroendocrine
cells to basal groups of proliferative cells in the mucous neck cell-chief cell lineage
in three different animal models. This shift was partly inhibited by antagonizing
the CCKBR in rats and Mongolian gerbils. The oxyntic mucosa of H/K-b KO
mice contained distinct areas with CLU-positive mucous cell hyperplasia, possi-
bly representing SPEM. In vitro, gastrin increased the secretion of CLU, and
both gastrin and secretory CLU promoted survival of gastric cells following
starvation- and chemotherapy-induced stress.
Conclusion: Our findings suggest that gastrin and CLU participate in premalig-
nant remodeling of the oxyntic mucosa by influencing the balance between sur-
vival and apoptosis in gastric epithelial cells.
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Introduction: A negative association exists between H. pylori infection and both
gastroesophageal reflux disease1 and oesophageal adenocarcinoma2 and this may
be due to the infection reducing intragastric acidity. To exert such a protective
effect the reduced acidity would need to be evident in the majority of H. pylori-
infected subjects. To investigate this we have examined the acid secretory capa-
city of H. pylori-positive and negative volunteers in a Western population.
Aims & Methods: We studied 31H. pylori-positive and 28H. pylori-negative volun-
teers, matched for age, gender and BMI. Jumbo biopsies were taken at eleven
pre-determined locations from the gastroesophageal junction and stomach. High-
resolution pHmetry (12 sensors at 11mm intervals) and manometry (36 sensors at
7.5mm intervals) was performed for 20 minutes fasted and then for 90 minutes
following a standardised meal. The position of the squamocolumnar junction
(SCJ), marked with two endoscopically placed radio-opaque clips, was visualised
radiologically relative to the probes. The biopsy specimenswere scored quantitatively
for inflammation and stained with monoclonal antibody to Hþ/KþATPase and
pepsinogen I for calculating parietal cell and chief cell densities respectively.
Results: The mean age of the H. pylori-positive group was 55 years (38y–78y)
compared to 56 years (24y–74y) for the H. pylori-negative group.
Under fasting conditions, the H. pylori-positive subjects had less intragastric
acidity compared to the H. pylori-negatives at all sensors more than 1.1cm
distal to the peak lower oesophageal sphincter (LOS) pressure (all p5 0.01).
Throughout the three 30-minute postprandial periods, intragastric acidity was
significantly less in H. pylori positives at the sensors 2.2, 3.3 and 4.4cm distal to
the peak LOS pressure (all p5 0.05), but there was no significant difference in
the sensors 5.5 and 6.6cm distal to peak LOS pressure (Table 1). The postpran-
dial acid pocket was thus attenuated in H. pylori positives compared to negatives.
The H. pylori positives had a significant reduction in density of both parietal and
chief cells compared to H. pylori negatives, and this was seen in 10 of the 11
gastric locations (p5 0.01 for 9 locations). The degree of reduction was similar
for the two cell types. The cardia mucosal length was longer in H. pylori positives
(1.5mm vs 0.7mm; p ¼ 0.013).
17/31 (54.8%) of the H. pylori positives were also CagA seropositive and they
showed more a more marked reduction in intragastric acidity and increased
mucosal inflammation compared to the CagA negative subjects.
Table 1: Median pH (IQR) detected by sensors relative to the peak LOS pres-
sure during the 30–60 minute postprandial period. NOTE: *p5 0.05, **p5 0.01
H. pylori negative H. pylori positive
Sensor location Median pH (IQR) Median pH (IQR)
1.1cm proximal 7.06 (1.42) 7.00 (0.75)
Peak LOS pressure 6.76 (1.02) 6.88 (0.48)
1.1cm distal 5.25 (4.19) 6.40 (1.72)
2.2cm distal 1.95 (1.00) 3.21 (4.46)**
3.3cm distal 1.59 (2.29) 2.07 (2.29)**
4.4cm distal 1.81 (2.09) 2.93 (3.25)*
5.5 cm distal 2.13 (2.02) 3.48 (2.89)
6.6cm distal 3.39 (2.19) 4.10 (2.23)
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Conclusion: The majority of H. pylori-infected subjects have reduced intragastric
acidity compared to the uninfected population and this is most marked close to
the gastroesophageal junction. The density of parietal cells and chief cells is
reduced in H. pylori infected subjects throughout the gastric mucosa. These
findings may explain the negative association between H. pylori infection and
both gastroesophageal reflux disease and oesophageal adenocarcinoma.
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Introduction: Functional dyspepsia (FD) is a functional gastrointestinal disorder
with a prevalence of up to 15–20% in the general population. Recently, impaired
duodenal mucosal integrity was reported as a potential pathophysiological
mechanism in FD (Vanheel H, Gut 2014). However, the factors controlling duo-
denal mucosal integrity remain unknown. In this pilot study, we evaluated
whether luminal bile salt content is associated with duodenal permeability in
healthy volunteers.
Aims & Methods: This study was carried out in 21 healthy volunteers (11 men,
25  6years). Duodenal biopsies were obtained by gastroduodenoscopy and used
to measure the in vitro transepithelial resistance (TEER) using Ussing chambers.
Meantime, fluorescein isothiocyanate dextran (FITC-dx4, MW 4kDa) was
applied to assess paracellular permeability. After the gastroduodenoscopy, an
aspiration catheter was placed in the second part of the duodenum under fluoro-
scopic control. Duodenal fluid aspirates were collected at fixed time points
during 1 hour in fasted state and 1.5 hour after a liquid meal (Nutridrink,
200ml). Concentration and composition of the bile salt pool (including glyco-
cholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxy-
cholic acid, glycodeoxycholic acid, taurodeoxycholic acid,
glycoursodeoxycholic acid and tauroursodeoxycholic acid) in these aspirates
was evaluated. Correlation analysis was used to look for an association between
luminal bile salt content and duodenal mucosal integrity.
Results: Duodenal biopsies of healthy volunteers displayed a paracellular passage
of 27.23  7.93 pmol and a TEER of 19.85 2.63 V.cm2. A negative correlation
was found between the concentration of tauroursodeoxycholic acid and the duo-
denal TEER in fasted state as well as at the first bile salt peak after liquid meal
and in fed state (r¼0.6268, p¼ 0.0292; r¼0.5154, p¼ 0.0286; r¼0.4957,
p¼ 0.0364 respectively). The concentration of glycodeoxycholic acid showed a
positive correlation with TEER in fed state (r¼ 0.5747, p¼ 0.0126). The total BA
pool showed no correlation with paracellular permeability and TEER in healthy
volunteers.
Conclusion: These results imply that the composition of the duodenal bile salt
pool may contribute to variations in duodenal mucosal permeability in healthy
volunteers. Whether the bile salt concentrations explored in the present study are
altered in patients with FD is addressed in ongoing studies.
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Introduction: Patients with gastro-oesophageal reflux disease are more sensitive
to painful acid perception than healthy volunteers. This is true even when there is
no macroscopic mucosal inflammation. Impaired integrity of the oesophageal
mucosa has been heavily implicated in this sensitivity, displaying the presence
of dilated intercellular spaces and an impaired barrier integrity in patients with
non-erosive reflux disease. Afferent nerves can be found within the oesophageal
mucosa, and it is highly likely that these play a role in reflux perception.
We have recently demonstrated that, in healthy volunteers, there is a differential
location of afferent nerve fibres within the distal and proximal oesophageal
mucosa. In the proximal oesophagus these nerves lie superficially and close to
the lumen. In the distal oesophageal mucosa they lie much deeper and closer to
the basal epithelium.
Aims & Methods: We aimed to investigate the location of distal and proximal
oesophageal mucosal afferent nerves in well-phenotyped patients with non-ero-
sive reflux disease. We investigated mucosa from 10 patients with typical heart-
burn symptoms, normal macroscopic oesophageal appearances, and all had
pathological oesophageal acid exposure on reflux testing (oesophageal pH expo-
sure 44.2%).
In each patient, endoscopic mucosal biopsies were taken from 3 cm above the
gastro-oesophageal junction (distal), and at 20 cm from the incisors (proximal).
Biopsies were fixed in 4% paraformadehyde, cryoprotected, and 10 mm sections
were cut on a cryostat and prepared on slides. Slides were examined immunohis-
tochemically for presence and location of calcitonin gene-related peptide
(CGRP)- and protein gene product (PGP) 9.5 - immunoreactive nerve fibres.
Where fibres were identified their location in the mucosa was recorded in
terms of cell layers from luminal surface.
Results: In the proximal oesophagus of patients with NERD, afferent nerves were
found a mean of 7.7 1.3 cell layers from the surface. In the distal oesophagus
nerves were found a mean of 8.9 2 cell layers from the surface.
In contrast, in healthy volunteers proximal nerves were found 12.3 0.9 cell
layers from the lumen in the proximal oesophagus, and 22.2 2.7 cell layers
from the lumen in the distal oesophagus. On ANOVA, the more superficial
location of distal oesophageal nerves in patients versus healthy controls was
statistically significant (p5 0.001). There was a non-significant trend to more
superficial proximal nerves in NERD patients versus healthy volunteers.
Conclusion: Distal oesophageal afferent mucosal nerves are significantly closer to
the lumen in patients with NERD versus healthy controls, and the usual differ-
ential location between proximal and distal fibre location is lost. This may be
relevant for symptomatic acid perception in patients with reflux disease, and may
be a target for topical treatment of these patients.
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Introduction: Reflux episodes that extend to the proximal esophagus are more
likely to be perceived. Our hypothesis is that the enhanced sensitivity of the
proximal esophagus is related to more pronounced impairment of mucosal integ-
rity in this part of the esophagus.
Aims & Methods:We aimed to assess acid sensitivity and mucosal integrity of the
proximal and distal esophageal segments separately in patients with gastroeso-
phageal reflux disease (GERD) and to investigate the relationship between these
parameters. We included patients with heartburn and evidence of GERD on
ambulatory pH-impedance measurement. After PPI washout, an esophageal
hydrochloric acid perfusion test measuring segmental acid sensitivity proximally
and distally in the esophagus (3 and 18 cm above the Z-line) and an upper
endoscopy with biopsies at both levels were performed. During endoscopy, elec-
trical tissue impedance spectroscopy was performed at the two levels and biopsies
were taken from macroscopically unaffected mucosa. Biopsies were used to mea-
sure dilation of intercellular spaces with transmission electron microscopy as a
morphological measure of impaired integrity and to investigate transepithelial
electrical resistance and transepithelial fluorescein permeability in Ussing
Chambers as a functional measure of mucosal integrity.
Results: We included 12 GERD patients (mean age 48 years, range 28–65, M:F
4:8). Lag time to heartburn perception was shorter after proximal acid perfusion
(mean (95% CI) 0.8 minutes (0.1–1.5)) than after distal acid perfusion (3.9 min-
utes (2.4–5.4)); log rank p¼ 0.02. In vivo extracellular tissue impedance was
lower in the distal esophagus (median (95% CI) 4563 .m (3640–5429)) com-
pared to the proximal esophagus (8170 .m (7353–10110)); p¼ 0.02.
Transepithelial fluorescein permeability was higher in the distal than the prox-
imal segment (median 2051 nmolcm-2h-1 (IQR 1201–3708) and 368 nmolcm-2h-1
(IQR 0–1389); p¼ 0.033). Intercellular space ratio and transepithelial electrical
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resistance were not statistically significant between the proximal and distal
esophagus.
Conclusion: The proximal segment of the esophagus in GERD patients off PPI is
more rapidly sensitive to acid perfusion, while the distal esophagus shows a more
pronounced impairment of mucosal integrity. These findings show that the
enhanced sensitivity to acid in the proximal esophagus is not explained by
increased mucosal permeability.
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Introduction: Incidence of chronic laryngeal symptoms in primary care is about
2%/year and, gastroesophageal reflux disease (GERD) is considered by far the
main disorder associated to them, leading to a specific syndrome called
Laryngopharyngeal Reflux (LPR). Several studies demonstrated that pepsin
measurement in saliva can be adopted as surrogate marker of GERD in LPR
patients. Recently, a low-cost, non-invasive salivary pepsin test (PeptestTM, RD
Biomed Limited, UK) was found able to measure pepsin in the saliva/sputum
and to discriminate with good sensitivity and specificity between patients with
typical GERD (i.e. with heartburn and regurgitation), confirmed at impedance-
pH monitoring, from those without reflux disease (i.e. functional heartburn).
Thus, it has been hypothesized about the utility of using this novel device to
diagnose LPR in primary care setting.
Aims & Methods: We aimed to investigate the usefulness of PeptestTM in pri-
mary care patients presenting with chronic laryngeal symptoms suggestive of
LPR. In a prospective multicenter, controlled, pilot study, consecutive patients
presenting with chronic laryngeal symptoms were enrolled by primary care phy-
sicians. Uninvestigated individuals with no gastrointestinal symptoms or disease
(including GERD or dyspepsia) or history of surgery served as healthy controls
(HCs). All subjects completed the validated reflux symptom index (RSI) ques-
tionnaire and in case of a score 413, a symptom-based diagnosis of LPR was
made. Also the gastrointestinal symptom scale (GIS) questionnaire was com-
pleted to investigate reflux symptoms and Quality of Life. All individuals were
asked to provide 2 samples of sputum collected one hour after lunch and dinner.
A positive PeptestTM was considered in case of a concentration of pepsin higher
than 25mg/mL.
Results: Between February and April 2014 and during August 2015, 86 patients
with LPR (37 Male/49 Female, age 54  14; RSI13, mean RSI 22  6, mean
GSI 22  6.4) and 59 healthy controls (30M/29F, mean age 41  15; RSI55,
mean RSI 0.5 1, mean GSI 33 5.6) were tested. In total 256 samples were
examined, whereas 34 samples were discarded because of technical problems (i.e.
unclear storage, poor/excessive quantity). At least one positive result was found
in 64/86 (74%) LPR patients and in 54/59 (92%) HCs (p5 0.0095), whereas two
positive results were observed in 34/70 (49%) LPR patients and 26/46 (57%) HCs
(p¼ 0.4505). One (in case of a single test) or two negative tests were registered in
22/86 (26%) LPR patients vs 4/59 (7%) of HCs (p5 0.0039). PeptestTM had an
accuracy of 47% (IC95 39%–55%) a sensitivity of 74% (IC95 65%–84%), a
specificity of 7% (IC95 0%–13%), a positive predictive value of 54% (IC95
45%–63%) and a negative predictive value of 2% (IC95 0%–8%) in identifying
LPR as diagnosed by RSI.
Conclusion: In this pilot study, PeptestTM was not able to discriminate among
primary care patients with LPR from those without and therefore cannot be
suggested as preliminary tool to select patients requiring pH monitoring.
Further studies including investigated healthy controls are mandatory to eluci-
date the diagnostic utility of salivary pepsin measurement in primary care setting
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Introduction: Randomized controlled trials report about 30% of GERD patients
complain of bothersome remaining symptoms (heartburn, regurgitation) despite
PPI. The LOPA (Lost Patients) I Study of 333 GERD patients seen in general
practice revealed 46% of patients experienced heartburn or regurgitation symp-
toms at least twice per week despite PPI. A total of 20% were dissatisfied with
their treatment. Few patients had received specific GERD diagnostics or recom-
mended other options (510%).
Aims & Methods: The LOPA II study is a prospective, multicenter, observational
study conducted in 7 general practice clinics. Patients with chronic GERD,
taking PPI therapy for at least 1 year, and not satisfied with their treatment
were asked to complete a questionnaire. Patients were asked the duration of
their PPI therapy, satisfaction with their current condition, frequency of symp-
toms in the last week, whether they had previously received diagnostic evaluation
or surgical consult related to GERD, whether they plan to consult a reflux
specialist for further diagnostics, and reasons for dissatisfaction with their cur-
rent medication treatment. ‘‘Lost Patients’’ were defined as those with a satisfac-
tion score of 1 or 2 on a 5-point Likert scale (1: very dissatisfied; 2: dissatisfied),
GerdQ score at least 8, and have not previously received specialized GERD
diagnostics.
Results: 200 consecutive patient responses were collected within one year.
Patients suffered from GERD an average of 9.7 years and prescribed PPI therapy
for an average duration of 8.2 years. 74% were dissatisfied or very dissatisfied on
their current PPI therapy (score of 1 or 2). 89% reported heartburn or regurgita-
tion at least 2 days in the prior week (57% 4–7 days). 53% reported using
additional medication other than their prescribed PPI at least 2 days per week
(32% 4–7 days). In patients dissatisfied on PPI, most cited insufficient symptom
control (91%) as a reason for dissatisfaction. In addition, 26% cited concern with
long-term use of drugs and 23% the need for daily medication. 92% of patients
had received an upper endoscopy, 8% had a prior pH-metry, 5% manometry,
and 7% received prior surgical consult for GERD. The rate of ‘‘Lost Patients’’ in
this study was 63%.
Conclusion: Chronic GERD patients who are dissatisfied with their PPI therapy
are rarely offered specialized GERD diagnostic procedures or treatment alter-
natives. Half of the patients took medication in addition to PPI to control their
reflux. In addition to persistent symptoms, concerns of long-term PPI use and
burden of daily medication play a role in patient dissatisfaction with PPI therapy.
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Introduction: Acid suppression is the mainstay of gastroesophageal reflux disease
(GERD) therapy, and proton pump inhibitors (PPIs) are the first choice of drug
treatment. Patients with GERD experience persistent heartburn or regurgitation
up to 20–30% for PPI therapy. Reflux events are almost always accompanied by
transient lower oesophageal sphincter relaxations (TLESRs). Several studies
showed that gastric dysmotility such as delayed gastric emptying or impaired
gastric accommodation increased TLESRs 1). Acotiamide is a new prokinetic
drug that improves gastric motility. We previously reported that acotiamide
significantly reduced TLESRs in healthy subjects 2). Our aim was to assess the
effect of acotiamide in patients with GERD, who are unresponsive to PPI
therapy.
Aims & Methods: This study design was a randomized, placebo-controlled,
double-blind, parallel-group study. Patients who had reflux symptoms despite
being on PPIs for at least 8 weeks were randomized to receive either acotiamide
(10 mg thrice daily) or a matching dose of placebo for 2 weeks. The medicine was
administered 30 min before every meal. In addition, patients continued their PPI
treatment regimen (maintaining the same dose and type during the study).
Symptoms were assessed at baseline and weeks 1 and 2 using questionnaires,
and graded as 1 (much improved) to 7 (severely worsened). Grade 1 or 2
(improved) was indicative of treatment efficacy. If possible, 24-h multichannel
intraluminal impedance-pH (24-h MII-pH) monitoring was performed at base-
line and week 2.
Results: In total, 22 patients were enrolled in this study. The acotiamide and
placebo groups consisted of 12 and 10 patients (6 and 7 women; mean age, 56
and 68 years, mean body mass index [BMI], 21 and 23, respectively). There were
no significant differences in patient characteristics between both groups. The
effective rate was 25 and 10% for acotiamide and the placebo after 2 weeks,
respectively, and no statistical significance was observed (p¼ 0.368). Fifteen
patients consented to the 24-h MII-pH monitoring at baseline and after 2
weeks. The acotiamide group showed a significant decrease in the number of
total reflux events, acid and liquid reflux events (39.6 vs. 25.5, p¼ 0.028; 14.7 vs.
5.4, p¼ 0.034; and 17.6 vs. 8.3, p¼ 0.009, respectively). The placebo group
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showed no significant change. In patients with a symptom index4 50% or total
reflux events 4 40, the effective rate was significantly different (p¼ 0.038) at 60
and 33% for the acotiamide and placebo groups, respectively. These results
suggest that acotiamide may be effective in patients with associated reflux events.
Conclusion: Acotiamide significantly reduced the reflux events and improved
reflux symptoms in patients whose symptoms were associated with reflux
events. Co-administration of acotiamide and PPIs may be a new strategy for
PPI-refractory GERD patients.
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Introduction: The potassium competitive acid blocker (P-CAB) Vonoprazan
(VPZ) has potent acid inhibitory efficacy. We assessed clinical efficacy for
Gastro-oesophageal reflux disease (GORD) symptom.
Aims & Methods: This study was a single-center, prospective, randomized con-
trolled, open-label, parallel-group trial conducted to assess the clinical efficacy of
Esomeprazole (EPZ) 20 mg once daily vs. VPZ 20 mg once daily for the resolu-
tion of GORD symptoms in newly diagnosed patients.
Patients 20 years of age with upper gastrointestinal symptoms of at least mod-
erate severity (Global Overall Symptom score [GOS]  4 on a 7-point Likert
scale) were randomized to treatment with EPZ or VPZ.
The primary endpoint was the proportion of patients with sufficient relief of
upper gastrointestinal symptoms (GOS  2) after 4 weeks of treatment.
Secondary endpoints were the proportion of patients with complete overall
symptom relief (GOS¼ 1), Frequency Scale for the Symptoms of
Gastroesophageal Reflux Disease (FSSG) score, and tolerance for both treat-
ment. All patients provided informed consent before enrolment in the trial.
Results: 88 patients were entered and randomly assigned to the EPZ group and
the VPZ group.
After 4 weeks, proportion of patients with sufficient relief was achieved by 88.6%
in the EPZ group, compared to 58.1% in the VPZ group (p5 0.01).
The worsened provability in FSSG Functional Dyspepsia (FD) score were sig-
nificantly lower in the EPZ group (6.8% / 4.5%) than in the VPZ group (27.9% /
18.6%) after 2 weeks and 4 weeks treatment (p5 0.05, p5 0.01).
Both treatment were generally well tolerated, but a patient in the VPZ group
withdrew because of the adverse events.
Discussion: Despite VPZ has potent acid inhibitory efficacy, EPZ 20 mg once
daily provides significant clinical efficacy for the resolution of GORD symptoms
beyond that afforded by treatment with VPZ 20 mg once daily. In addition, the
probability of worsen FD symptoms were significantly lower in the EPZ group
than the VPZ group. The result observed in this study was considered to be
caused by the multifactorial pathophysiology of GERD. Various mechanisms
may contribute to dyspeptic symptoms, for example, finding that patients with
gastric achlorhydria or hypergastrinemia showed impaired gastric motility may
be supportive of this point (2).
These findings can suggest that increasing the degree of acid inhibition beyond
that already achieved by EPZ 20 mg does not translate into increased clinical
efficacy for the resolution of GORD symptoms in newly diagnosed patients.
Conclusion: EPZ 20 mg once daily was more effective than VPZ 20 mg once daily
for the resolution of GORD symptoms in newly diagnosed patients.
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Introduction: Gastroesophageal reflux disease is characterized by reflux of the
gastric contents causing troublesome esophageal and extraesophageal symptoms
that could affect adversely the quality of life. About 10–40% of patients with
GERD fail to show adequate symptomatic response to the standard dose of PPI.
several mechanisms could explain refractory GERD as improper PPI dosing,
patient non-compliance, esophageal hypersensitivity, residual acid reflux,alkaline
or bile reflux, nocturnal acid breakthrough. Alternative therapeutic options
included laparoscopic fundoplication, lower esophageal magnetic beads which
are expensive, and about 10% of patients experience persistanse of heart burn, or
develop dysphagia
Aims & Methods: We aimed to evaluate the safety and efficacy of endoluminal
rubber band ligation in the management of refractory GERD. 20 patients were
enrolled in the study after informed consent was taken. They were treated with
rubber band ligation and the cap used for ligation had a diameter of 11mm and
loaded with 6 rings. The main outcome is reduction of reflux symptoms measured
by GERD health related quality of life Questionnaire. Patients were included if
they were 18 years of age or older with typical symptoms of heartburn or regur-
gitation refractory or less responsive to maximally optimized dose of PPI therapy
(given twice, 30 min before food) and even after adding H2 receptor blocker
before bedtime and baclofen 10 mg twice daily to the unresponsive patients.
Patients excluded if they had lower esophageal ulcers, pregnancy, red flag signs
as loss of weight, fever, dysphagia, odynophagia, bleeding. Large hiatal hernia
more than 2 cm, paraesopgageal hernia, active Helicobacter pylori infection,
eosinophilic esophagitis were also excluded. Band ligation was performed in
the four quadrants 5 mm distal to the Z-line which is measured before and
after the sessions were completed.
Results: 13 males and 7 females were enrolled in the study. Their mean age
39.5 6.2 with a range (31–49 years). The pre-endoscopic intervention character-
istics were mean hemoglobin 10.6 0.9 gm/dl, mean GERD related quality of life
questionnaire (GERD-QLQ) value was 35.4 6.9, depth of Z- line 34 1.1cm,
frequency of the sessions needed 1.6 0.6 times over 4 months. After 6 months of
follow up, GERD-QLQ score had dramatically improved 15.4 4.6 (t¼ 11.85,
p¼ 0.000), depth of Z line became 35 0.9 cm (t¼3.2, p¼ 0.005), hemoglobin
level showed non-significant increase (10.9 0.8 gm/dl, p¼ 0.06). 5 patients
experienced mild dysphagia (25%) improved after 6.5 2.2 days, 8 patients
(40%) experienced transient epigastric pain which disappeared within 5.4 1.5
days. 13 patients stopped PPI use (65%), 6 patients were on demand therapy
(30%), and only one patient needed continuous low dose PPI which was signifi-
cantly reduced when compared to pre-endoscopic PPI intake.
Conclusion: Endoluminal band ligation is a safe, well tolerated and cost-effective
therapeutic option for refractory GERD.
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Introduction: LSG is the most commonly performed bariatric procedure in the
US /Canada and the Asia-Pacific region. However, LSG can result in new
GERD and may worsen preexisting GERD.i LSG patients with GERD not
well controlled with PPI do not have good treatment options except for more
invasive, anatomy-altering gastric bypass surgery. LES electrical stimulation
therapy has shown to improve outcomes in GERD patients.ii-iii
Aims & Methods: To evaluate the safety and efficacy of LES stimulation in LSG
patients with GERD not controlled with maximum dose PPI therapy. Patients
with LSG-associated GERD with bothersome symptoms on maximum PPI dose
underwent LES stimulator implant procedure and were enrolled in an interna-
tional patient registry prospectively tracking outcomes in GERD patients treated
with LES electrical stimulation. Electrical stimulation was delivered at 5mA,
220uSec pulse in 12, 30 minute sessions daily. GERD outcomes pre and post-
stimulation were evaluated.
Results: 12 patients, 66% (8/12) women at 8 centers have been treated. Median
age was 46 (IQR¼ 34–55) years. All (12/12) were on at least daily double-dose
PPIs. At their last follow-up (median¼ 12 months), 75% (6/8) were off-PPIs and
one each was using PPIs on 5 50% of days and standard dose once a day. The
later was on daily PPI for GI prophylaxis for chronic steroid therapy for kidney
transplants and not GERD symptoms. Median esophageal pH at baseline was
16.4% (IQR 8.5–22.4), which improved to 1.3% (IQR 0.4–2.2) at last follow-up
at least 6 month post-implant (n¼ 6; p¼ 0.01). All patients improved esophageal
acid exposure, 83% (5/6) patients had normalized acid exposure and 1/6 patient
had 440% improvement in distal esophageal acid exposure. Median GERD-
HRQL scores at baseline was 25 (IQR 18–31) which improved to 4 (IQR 3–10) at
last follow-up (n¼ 6; p¼ 0.015). No SAEs related to the device or procedure were
reported. No dysphagia or other GI side effects were reported.
Conclusion: Preliminary results on patients with LSG and GERD with bother-
some symptoms despite maximal medical therapy, treated with LES electrical
stimulation, revealed that LES stimulation is safe and results in a significant
improvement in GERD symptoms and esophageal acid exposure. Most patients
were off their PPI therapy with remaining taking PPI at a reduced dose. Data
from a larger patient experience for this indication is being collected using the
international registry trial.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Antireflux surgery for GERD associated with failed peristalsis,
either primary or in patient with prior lung transplant can be a challenge.
Traditional antireflux surgery i.e. fundoplication has high rates of dysphagia
and Roux-en-y reconstruction is very invasive. Partial fundoplication is tradi-
tionally employed but is not as effective in controlling reflux. Electrical stimula-
tion of the LES (LES-EST) has emerged as a new alternative for the treatment of
GERD. High-res manometry (HRM) studies reveal no negative effect on eso-
phageal peristalsis or LES relaxation, making it an attractive treatment option
for GERD patients with failed peristalsis. We report the outcome of LES-EST in
this subgroup patients.
Aims & Methods: Seven patients (6 men; mean age¼ 58) diagnosed with severe
GERD and failed peristalsis (n¼ 5), failed peristalsis and lung transplant (n¼ 1)
or lung transplant (n¼ 1) were found eligible for LES-EST and agreed to
undergo the procedure. Esophageal body function was assessed with HRM
and reflux was diagnosed with Multichannel Intraluminal Impedance-pH testing
(MII-pH). The LES Stimulation system (EndoStim, BV, The Hague, The
Netherlands) was implanted using standard technique (Surg Endosc.
2013;27:1083–92) and stimulation was delivered in 12, 30 minute sessions of
5mA, 215usec, at 20Hz. Postop follow-up endpoints included clinical symptoms,
MII-pH and PPI intake. Mean follow-up was 6 months (2–24).
Results: Surgical implant was completed successfully and electrical stimulation
was initiated in all cases. Short and mid-term data was available for 5 patients
while 2 patients were recently implanted and data will be included prior to the
meeting. At their last follow-up, there was no dysphagia associated with LES-
EST reported. Median GERD-HQRL score had improved from 12.5(8.3,20.5) to
6.0(3.0, 8.0). There was an improvement4 50% in pH-exposure showing median
esophageal ph at baseline of 25.75(10.2, 54.5) that improved to 9.1(8.4, 25.1). 4/5
patients (80%) were either free of PPI or with a reduced those compared to pre-
op and all with good response, 2 of these patients were taking PPI due to chronic
immunosuppressant drugs for their lung transplant and not for reflux symptoms.
Interestingly, one of the lung transplanted patients improved his FEV1 from 49
to 77 after the procedure while the second one remained stable at 47 under
chronic rejection.
Conclusion: Our preliminary case-series represents the first report of successful
use of LES-EST in patients with GERD associated with severe esophageal dys-
motility or lung transplant. Our early results suggest that LES-EST maybe a safe
and effective treatment in these patients without the risk of new-onset dysphagia.
A longer follow-up in a larger group of patients is required to fully establish the
role of LES-EST in this difficult group of patients.
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Introduction: Endocuff (ARC Medical Design, Leeds, UK) is a device that
mounted on the tip of the scope promises inspection of greater surface of the
colonic mucosa as the endoscope is gradually withdrawn by pulling backwards,
flattening and stretching the colonic folds. We aimed to compare adenoma miss-
rates of Endocuff-assisted colonoscopy (EC) with that of the conventional one
(CC).
Aims & Methods: Our study population underwent same-day, back-to-back, (EC
as index procedure followed by CC or vice versa, randomly assigned 1:1) colo-
noscopies by six endoscopists with documented adenoma detection rates435%,
in four tertiary endoscopy facilities. Missed-adenoma detection rate (overall and
in the proximal colon) for the two procedures was the study’s primary end-point.
Secondary endpoints included among others, measurement of missed-advanced
adenoma rate, modification of the surveillance schedule according to the second
exam, true negative index colonoscopies and early adverse events rate.
ClinicalTrials.gov Identifier: NCT02340065.
Results:We randomized 200 patients (aged 61 10 years; 86.4% CRC screening-
surveillance cases). There were 7 EC and 1 CC incomplete exams. Scope insertion
times were similar for EC and CC (5:44 3:13min vs. 5:37 0.2:37 min, p¼ 0.6);
however, there was a trend for longer EC withdrawal times (7:15 2:52 min vs.
6:50 1:52 min, p¼ 0.06). Overall, we detected one cancer and 194 (EC¼ 109;
CC¼ 85) adenomas; 84 in the proximal colon. By per-lesion analysis (table), EC
showed significant lower overall and proximal colon adenoma miss-rates com-
pared with CC (14.7 [8–21]% vs. 37.6 [27–48]%; p¼ 0.0004 and 10.4 [1.8–19]%
vs. 39 [23–55]%; p¼ 0.004, respectively). A similar superiority for EC was not
revealed regarding advanced adenomas either overall or in the proximal colon.
Index colonoscopy did not miss the cancer. By per-patient analysis, the second
exam indicated modification of the surveillance schedule, according to the ASGE
guidelines, in 17 and 5 patients who underwent CC and EC index exams
(OR¼ 3.8 [95%CI: 1.4–10.9]; p¼ 0.01), respectively; however no difference in
the modification of the surveillance schedule was detected when European guide-
lines were taken into account. The CC index arm had significantly more false
negative (no adenoma) first examinations compared to EC (14 of 100 vs. 3 of 94;
p¼ 0.01). There were no adverse events related to EC or CC.
Conclusion: In comparison with conventional colonoscopy, Endocuff-assisted
colonoscopy reduces adenoma miss-rate by more than three times, even when
highly efficient endoscopists perform the procedures.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endocytoscopy (EC) can be used to evaluate not only cell nuclei but
also microvessels in vivo. We reported the efficacy of observing the endocyto-
scopic vascular (ECV) pattern by using EC with narrow-band imaging for diag-
nosing colorectal lesions (Kudo S, et al. GIE 2015.1). As the interpretation of the
ECV pattern is difficult for novice endoscopists and requires substantial training,
we have developed a tentative model of a computer-aided diagnosis (CAD)
system for the ECV pattern (ECV-CAD) (Misawa M, et al. Gastroenterology,
in press.2). However, in our previous study, we did not compare the performance
of ECV-CAD with that of human endoscopists. Therefore, it is uncertain
whether ECV-CAD can achieve a diagnostic ability as high as that of expert
endoscopists.
Aims & Methods: The aim of this study was to compare the diagnostic ability of
ECV-CAD with that of human endoscopists in characterization of colorectal
lesion. The algorithm of ECV-CAD is based on texture analysis, which can
quantify the pattern of endoscopic images, and vessel features. ECV-CAD pro-
vides a 2-class diagnosis (neoplastic or non-neoplastic) including its probability
value. To validate the diagnostic ability of ECV-CAD, 173 randomly selected EC
images (non-neoplasm, 49; neoplasm, 124) that were not used for machine-learn-
ing processes were evaluated with ECV-CAD. To compare diagnostic ability
between ECV-CAD and manual endoscopy, we selected 4 expert endoscopists
(with an experience of 4200 cases of EC) and 3 novices (with an experience of
520 cases of EC). The EC images used for the evaluation with ECV-CAD were
randomly allocated to the assessors. The assessors recorded their diagnosis (non-
neoplasm or neoplasm) with its confidence level (high or low). For ECV-CAD, a
probability of 490% was considered as a high-confidence computed diagnosis.
The sensitivity, specificity, accuracy, positive predictive value (PPV), and nega-
tive predictive value (NPV) of distinguishing neoplasms from non-neoplasms, as
well as the ratio of high-confidence diagnosis were calculated. Furthermore, the
diagnostic ability when the diagnosis was made in high confidence was also
calculated.
Results: The overall accuracy of ECV-CAD was 87.8%, whereas the accuracy for
high-confidence cases was 93.5%. These values were higher than those for trai-
nees (P¼ 0.01, McNemar test) and comparable to those of experts (P¼ 0.85,
McNemar test). The high-confidence diagnosis ratio of ECV-CAD was 72.0%
(124 of 172). The NPV for neoplasms with a high confidence was 94.4%, 84.6%,
and 46.3% for ECV-CAD, experts, and novices, respectively. The details of the
diagnostic abilities are shown in the Table.
Table: Diagnostic Abilities
ECV-CAD(%)Experts(%)Novices(%)
Overall accuracy (total / high confidence)87.8 / 93.5 84.2 / 90.8 63.4 / 71.7
Sensitivity (total / high confidence) 94.3 / 99.0 85.6 / 92.9 61.5 / 71.2
Specificity (total / high confidence) 71.4 / 70.8 80.6 / 84.0 68.0 / 73.1
PPV (total / high confidence) 89.2 / 93.3 91.7 / 94.8 82.8 / 88.6
NPV (total / high confidence) 83.3/ 94.4 69.0 / 79.0 41.3 / 46.3
High confidence rate 72.0 70.9 39.7
Conclusion: The overall accuracy of ECV-CAD was comparable to that of
experts and significantly better than that of novices. Thus, ECV-CAD could be
a powerful decision-making tool for less experienced endoscopists.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Thiopurines are associated with an increased risk of lymphoma.
The risk of lymphoma associated with anti-TNFs is uncertain.
Aims & Methods: The aim of this study was to assess the risk of lymphoma in
patients with inflammatory bowel disease (IBD) treated with thiopurines, anti-
TNFs or the combination of both treatments (combotherapy). Every patient
affiliated to the French national health insurance with a diagnosis of IBD,
based on listed long-term diseases and/or hospital discharge diagnosis, was
included from 1st July 2009 through 31st December 2013, and followed up
until December 31st, 2014. A propensity score was built, using a multinomial
logistic regression conditional of multiple covariates, to predict the probability to
receive thiopurines, anti-TNFs or combotherapy at baseline. Hazard ratios for
lymphoma were estimated using Cox proportional hazards regression in which
each treatment was introduced as a time dependent covariate.
Results: The cohort included 173 190 patients with IBD, followed for a median
time of 4.9 years, accounting for 522 487 persons-years (PY) unexposed to thio-
purines or anti-TNFs, 111 113 PY exposed to thiopurines, 60 736 PY exposed to
anti-TNFs and 11 514 PY exposed to combotherapy. Among them, 166, 56, 31
and 13 patients developed lymphoma, respectively. In multivariate analysis,
patients exposed to thiopurines or anti-TNFs monotherapy had an increased
risk of lymphoma as compared to unexposed patients (Hazard ratio and 95%
confidence interval (HR95%) 1.64 (1.08–2.26) and HR95%: 1.87 (1.15–3.03),
respectively). Patients exposed to combotherapy had a more than four-fold
increased risk of lymphoma as compared to unexposed patients (HR95%: 4.83
(2.51–9.16)).
Conclusion: The risk of lymphoma associated with combotherapy is more than
two-fold higher than that associated with thiopurines and anti-TNFs monother-
apy. This risk should be taken into consideration and weighed against potential
benefits of combotherapy.
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CC Index 53 32 - 3.5 (1.8–7) 22 14 - 5.5 (1.7–17)
EC Index 93 - 16 43 - 5
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Introduction: Risk factors for cancer in inflammatory bowel disease [IBD] are
debated (1). In a prospective, multicentre, nested case-control study at 3 years
(2012–2014), we reported IBD phenotype as a risk factor for cancer (2). The
analysis included 44,619 IBD patients (21,953 Crohn’s disease (CD), 22,666
ulcerative colitis (UC). Cancer occurred in 174 patients (99 CD [CD-K], 75
UC [UC-K]) (2). A larger study is required to identify risk factors for cancer,
including cancer subtypes
Aims & Methods: In a prospective multicenter nested case-control-study, we
aimed to assess, in a large IBD population followed up in the long term, risk
factors for incident cases of cancer, including cancer subtypes. The role of clinical
characteristics of IBD vs immunomodulators (IMM) use as risk factors was also
assessed. At this purpose, all IBD patients with incident cancer and their matched
controls referring to the same 16 Units involved in the study at 3 years (Jan 2012-
Dec 2014) (2) were followed up for additional 15 months (Jan 2015-Mar. 2016:
follow up 44 years; 51 months). The study population also included all the
additional IBD patients referring to the same Units, with incident cancer from
Jan. 2015 to Mar. 2016. Each IBD patient with cancer (IBD-K) was matched
with 2 IBD patients without cancer (IBD-C) for: IBD type, gender, age. Risk
factors considered: age (at last visit, at diagnosis of IBD, of cancer), IBD extent,
CD phenotype [B1-B3], perianal CD, smoking, family history of IBD, IBD-
related surgery, current/past use of thiopurines [IS], TNF antagonists (1),
any IMM. Data were expressed as median (range),Wilcoxon, Chi-squared test,-
multivariate logistic regression analysis as appropriate.
Results: Incident cancer occurred in 208 IBD patients: 117 CD [CD-K], 91 UC
[UC-K]. IBD-C included 416 patients: 234 CD [CD-C], 182 UC [UC-C]. IBD-K
and IBD-C included 624 patients (351 CD [165 F;47%]; 273 UC [117F;43%]).
Cases and controls did not differ in terms of age (CD-K vs CD-C:p¼ 0.92; UC-K
vs UC-C:p¼ 0.32) and IBD duration (CD-K vs CD-C: p¼ 0.63;UC-K vs UC-C:
p¼ 0.53). In IBD, cancers (n¼ 208) involved (n [%]): digestive system (76
[36.5%]: 53 [25.5%] colorectal cancer (CRC), 8 [10.5%] small bowel adenocarci-
noma, SBA), skin (28 [13.5%]), urinary tract (23 [11.1%]), breast (17 [8.1%]),
lung 14 [6.7%], genital tract (11 [5.2%]), thyroid (8 [3.8%]), lymphoma (7
[3.4%]), others (24 [11.5%]). CRC (n¼ 53) was more frequent in UC vs CD (n
[%]: 31/91 [34%] vs 22/117 [19%]; p¼ 0.01), while extracolonic cancers (n¼ 155)
in CD vs UC (95/117 [81%] vs 60/91 [66%]; p¼ 0.01). Lymphoma (n¼ 7) and
SBA (n¼ 8) occurred only in CD. In CD, risk factors included perianal disease
for CRC (3.61 [1.23–10.63]), penetrating (B3) vs non-penetrating non stricturing
CD (B1) for extracolonic cancers (OR 2.21 [1–4.99]). IS and anti-TNF use was
at limit of the statistical significance as risk factor for overall cancer in CD (OR
1.59 [0.96–2.66]). In UC, risk factors were: pancolitis and UC-related surgery for
cancer overall (OR 1.95 [1.07–3.59] and 3.99 [1.55–11.14]); UC duration (OR 3.74
[1.37–13.17]) for CRC; pancolitis and left-sided vs distal UC (OR 2.11 [1.04–4.4]
and 2.47 [1.06–5.73]) and UC-related surgery (OR 3.07 [1.15–8.02] for extraco-
lonic cancers. The same risk factors (extensive UC, penetrating CD, IS and anti-
TNF use) were at limit of the statistical significance for urinary tract and skin
cancers.
Conclusion: In a long-term multicentre study, clinical characteristics of IBD (UC
extent, penetrating CD, perianal CD). were risk factors for incident cancer. CRC
was more frequent in UC and extracolonic cancers in CD.
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Table: Hazard ratio for lymphoma in thiopurines, anti-TNFs monotherapy and combotherapy exposed patients compared to unexposed patients
Treatment
Never exposed to
thiopurines
or anti-TNFs
Thiopurines
monotherapy Anti-TNFs monotherapy Combotherapy
Persons-years 522 487 PY 111 113 PY 60 736 PY 11 514 PY
Cases Cases Hazard Ratio (95% CI) Cases Hazard Ratio (95% CI) Cases Hazard Ratio (95% CI)
Crude Adjusted Crude Adjusted Crude Adjusted
Total 166 56 1.39 (1.02–1.90) 1.64 (1.08–2.26) 31 1.30 (0.88–1.93) 1.87 (1.15–3.03) 13 2.99 (1.69–5.29) 4.83 (2.51–9.16)
Non-Hodgkin lymphoma 150 45 1.19 (0.85–1.68) 1.56 (0.98–248) 25 1.10 (0.71–1.70) 1.94 (1.05–3.05) 9 2.19 (1.11–4.31) 4.09 (1.93–8.64)
Hodgkin lymphoma 16 11 3.32 (1.54–7.18) 2.41 (0.86–6.72) 6 3.31 (1.28–8.54) 2.52 (0.78–8.20) 4 11.50 (3.82–35.59) 9.09 (2.46–33.66)
Adjusted for age and propensity score
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Introduction: Conventional immunosuppressants (thiopurines or methotrexate)
and anti-TNF agents (IMMs) can influence the immunologic control of cancer
and they might ease cancer spread and recurrence. Therefore, a past history of
cancer is a relative contraindication for their use in inflammatory bowel disease
(IBD).
Aims & Methods: We aimed to describe the risk of incident cancers (recurrent or
new) in patients with IBD and a past history of malignancy treated with IMMs,
and to identify risk factors. IBD patients included in ENEIDA Project from
GETECCU with a past history of cancer were identified and compared between
those who were further treated with IMMs and those who never were treated
with these drugs (controls).
Results: We identified 947 patients with previous cancer of whom 526 did not
received IMMs before the diagnosis of cancer. Of these, 385 were controls and
141 were subsequently treated with IMMs after a median of 60 (23–130) months
from cancer diagnosis. After a median follow-up of 68 months (27–126), 52
patients(10%) developed incident cancers (50% recurrent and 50% new). The
most frequent recurrent ones were breast (35%) and prostate (20%) cancers.
Incident cancers occurred similarly in patients further treated with IMMs and
controls (9% vs. 12%p¼ 0.33), as did regarding the type of the index cancer.
However, cancer-related deaths were more frequent among controls (4% vs.
0%;p¼ 0.013). Cancer-free survival was 99%, 98% and 97% at 1, 2, and 5
years in patients further treated with IMMs and 97%, 96% and 92% at 1, 2
and 5 years in controls, respectively (p¼ 0.003).
Conclusion: In this large, retrospective cohort, treatment with conventional immuno-
suppressants or anti-TNFagents in patients with IBDanda past history of cancerwas
not associated with an increased risk of new or recurrent cancers.
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Introduction: Serious and opportunistic infections are a major concern in patients
with inflammatory bowel disease (IBD) treated with immunosuppressive agents
and biologics.
Aims & Methods: The aim of this study was to assess the risk of serious and
opportunistic infections associated with thiopurines monotherapy, anti-TNFs
monotherapy and the combination of both treatments (combotherapy). Every
patient affiliated to the French national health insurance with a diagnosis of IBD
based on listed long-term diseases and/or hospital discharge diagnosis was
included from 2009 to 2013, and followed up until 31 December 2014. A pro-
pensity score was built to predict the probability to receive a monotherapy with
thiopurines, anti-TNFs or combotherapy at baseline. Hazard ratios of infections
were estimated based on Cox regression models, stratified on age at cohort entry
(aged 18–64 years and  65 years) and with treatments considered as time-
dependent variables. Serious and opportunistic infections were classified accord-
ing to infection sites and pathogens, respectively.
Results: 173 077 IBD patients were included and followed during 4.9 years in
median, accounting for 512 805 persons-years (PY) unexposed to anti-TNFs or
thiopurines, 108 315 PY exposed to thiopurines monotherapy, 57 464 PY
exposed to anti-TNFs monotherapy and 11 089 PY exposed to combotherapy.
Among them, a total of 4926, 1144, 1096 and 252 serious infections and 245, 183,
120 and 47 opportunistic infections occurred, respectively. After adjustment
(based on propensity score, age, time-varying exposure to corticosteroids and
past history of serious infections), exposures to thiopurines monotherapy, anti-
TNFs monotherapy and combotherapy were associated with an increased risk of
serious and opportunistic infections, compared to unexposed patients.
Combotherapy was associated with an increased risk of serious and opportunistic
infections compared to anti-TNFs exposure in patients aged 18–64 years (hazard
ratio and confidence interval 95% (HR95%) 1.31 (1.14–1.51), HR95%: 2.12 (1.49–
3.00), respectively), while exposure to anti-TNFs was associated with an
increased risk of serious infections compared to thiopurines in patients aged
18–64 years and  65 years: HR95%: 1.82 (1.67–1.99) and HR95%: 1.83 (1.43–
2.35), respectively. Exposure to thiopurines was associated with an increased risk
of viral infections compared to anti-TNFs monotherapy in patients aged 18–64
years (HR95%: 1.74 (1.20–2.52)). Similar results were observed in a sensitivity
analysis conducted in incident patients.
Conclusion: Thiopurines, anti-TNFs monotherapy and combotherapy are all
associated with an increased risk of serious infections in IBD patients compared
to unexposed patients. However, the risk of serious infections is higher with anti-
TNFs than with thiopurines and the risk of serious and opportunistic infections
is higher with combotherapy than with anti-TNFs. The risk of serious and
opportunistic infections should be taken into consideration and weighed against
potential benefits of anti-TNFs.
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Introduction: Previous population-based cross-sectional studies have shown that
health-related quality of life (HRQoL) in patients with the inflammatory bowel
diseases (IBD) ulcerative colitis (UC) and Crohn’s disease (CD) is reduced, espe-
cially in association with disease activity. Data describing the course of HRQoL
in IBD are scarce.
Aims & Methods: The aim of the present study was to assess the course of
HRQoL at three prescheduled time-points during 20 years of follow-up in an
inception cohort with IBD patients. IBD patients included in a population-based
inception cohort from 1990–93 (Inflammatory Bowel Disease in South-East
Norway – IBSEN) were invited to follow-up visits five, ten and 20 years after
diagnosis. In addition to structured interviews and clinical examinations at inclu-
sion and follow-up visits, the Short Form 36 (SF-36) and the Norwegian version
of the Inflammatory Bowel Disease Questionnaire (N-IBDQ) were completed by
the patients at all follow-up visits. The mean N-IBDQ total scores and the mean
SF-36 dimensional scores were calculated. In this abstract, we present the total
N-IBDQ scores and the dimensional SF-36 scores for general health (GH), stra-
tified by diagnose and sex. Norman et al. (1) defined the difference between
HRQoL scores exceeding ½ standard deviation (SD) as clinically relevant.
Consequently, we defined patients with changes in scores less than 1/2 SD
during follow-up as to have stable HRQoL scores.
Results: Of the initially 756 included patients with confirmed IBD, 599 (79%)
were still alive after 20 years. HRQoL questionnaires were answered by 522, 327
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and 438 patients at the five, ten and 20 years follow up, respectively. Of these
patients, 199 (139 UC, 60 CD) and 191 (133 UC, 58 CD) answered the N-IBDQ
and the SF-36 at every follow-up visit, respectively. We could not register clini-
cally relevant changes between the mean N-IBDQ total scores and the mean GH
dimensional scores during the different follow-up visits (Table 1). Of 139 UC
patients and 60 CD patients, who answered the N-IBDQ at all follow-up visits,
54 (38.9%) and 17 (28.3%) had stable scores. Of 133 UC patients and 58 CD
patients, who answered the SF-36 at all follow-up visits, 31 (23.3%) and 13
(22.4%) had stable scores.
Table 1: N-IBDQ total scores and General Health dimensional scores
UC UC CD CD
Men Women Men Women
Follow-up year 5 10 20 5 10 20 5 10 20 5 10 20
All patients
IBDQ N 180 108 140 168 113 154 88 61 72 86 45 72
Mean scores 190 191 187 181 180 179 187 186 184 174 180 172
SD 25 29 23 29 33 28 31 26 26 30 28 26
SF-36 N 178 104 142 165 110 153 86 61 73 86 45 69
GH Mean scores 68 68 70 64 62 65 66 63 69 57 60 58
SD 22 24 21 24 23 24 27 25 22 24 22 21
Patients participating
in every follow-up
IBDQ N 62 77 39 21
Mean scores 191 195 191 182 183 181 182 188 181 175 178 180
SD 23 26 20 29 36 29 30 25 28 28 29 19
SF-36 N 61 76 39 21
GH Mean scores 72 73 72 65 64 64 64 69 66 58 62 64
SD 20 21 21 25 22 24 29 23 22 20 23 16
N-IBDQ: Inflammatory Bowel Disease Questionnaire (Norwegian version). SF-
36: Short Form 36. GH: General Health dimension. SD: standard deviation, N:
Number of participants
Conclusion: Mean HRQoL scores in our IBD cohort did not vary during follow-
up visits five, ten and 20 years after diagnosis. However, only a minority of CD
and UC patients had stable HRQoL scores during the 20 years of follow-up.
Therefore, a more detailed reporting on changes in subgroups might help to
identify factors associated with an unstable course of HRQoL in IBD.
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Introduction: The long-term efficacy of infliximab (IFX) in Crohn’s disease (CD)
patients is suboptimal and prognostic factors for real-life long-term efficacy are
insufficiently studied.
Aims & Methods: The aim of this study was to identify patient- and disease-
related factors influencing the real-life long-term response of infliximab in CD.
All consecutive CD patients treated with IFX between December 1994 and
January 2016 at a tertiary centre, were retrospectively analysed. Only patients
who responded to an induction dose (5mg/ kg on week 0, 2 and 6), followed by
scheduled IFX maintenance treatment were included. Exclusion criteria were:
prior infliximab use, ever episodic treatment, drug interval (414 weeks), CD-
related surgery during induction therapy and extra-intestinal manifestations as
main indication. IFX failure was the primary endpoint, defined as stopping IFX
due to one of the following reasons: 1) loss of response (LOR) despite treatment
optimization, 2) presence of persistent antibodies towards infliximab (ATI), and
3) the need for IBD related surgery. Since 2010–2011, IFX and ATI serum
concentrations at trough were measured in the majority of patients with an in-
house-developed and clinically validated drug sensitive bridging enzyme-linked
immunosorbent assay (ELISA). Therapeutic drug monitoring (TDM) was
defined as the use of serum IFX & ATI concentration measurements to guide
treatment decisions and optimization. Patient- and disease-related factors were
used to identify independent predictors of IFX failure-free survival using Cox
proportional hazards model and Kaplan-Meier analysis. Internal validation of
the Cox regression analysis was performed with bootstrapping with 1000 replica-
tions. The c-statistic was used to assess the predictive accuracy of the regression
model.
Results: A total of 261 CD patients were included in the final analysis. Median
time on IFX was 2.4 [IQR 1.4–4.7] years, and 65 (24.9%) patients experienced
IFX failure. Median age at start of IFX was 32.8 [22.6–44] years, after a median
disease duration of 3.4 [0.7–13.6] years. In total, 39 (14.9%) patients received
anti-TNF prior to IFX start (adalimumab or certolizumab pegol). TDM was
used in 202 (77.4%) patients. Estimated 1, 5, and 10 year IFX failure-free survi-
val was 93.7% (95% CI 90.7–9i6.7), 65.9% (58.3–73.5) and 58.2% (45.6–70.9),
respectively. When combining all available IFX measurements during the follow-
up of the study, median IFX concentrations were lower in patients who experi-
enced IFX failure (3.1 [0.3–7.5] mg/mL) compared to patients who did not fail
IFX (5.3 [3.1–8.4] mg/mL), p5 0.0001). Multivariate Cox regression identified
disease duration 5 1 year (hazard ratio (HR) 2.5 (95% CI 1.2–5.2), p¼ 0.02),
isolated L1 disease location (HR 2.0 (1.1–3.5), p¼ 0.02), prior anti-TNF use (HR
2.3 (1.1–4.8), p¼ 0.03), hemoglobin 5 13.5 g/dL (HR 2.3 (1.2–4.4), p¼ 0.02),
absence of TDM use (HR 8.0 (4.1–15.6), p¼ 1x109), and first IFX dose opti-
mization within first year (HR 3.7 (2.1–6.6), p¼ 5x106) as independent predic-
tors of IFX failure-free survival. All these factors remained significant after
internal validation with bootstrapping. This final model had a c-statistic of
0.80 which is considered as a well discriminating model. Stratifying patients
into risk groups resulted in estimated 3 year IFX failure-free survival rates of
95.3% (95% CI 94.2–96.4) for the low risk group (0 or 1 risk factor), 79.3%
(78.4–80.2) for the medium risk group (2–3 risk factors), and 26.3% (8.6–44.0)
for the high risk group ( 4 risk factors) (p¼ 8x1013). IFX concentrations at
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Table: Hazard ratios for any serious or opportunistic infections according to medication exposure
Exposed to
thiopurines versus
unexposed to
thiopurines or anti-TNFs
Exposed to
anti-TNFs monotherapy
versus unexposed to
thiopurines or anti-TNFs
Exposed to
Combotherapy
versus unexposed to
thiopurines or anti-TNFs
Exposed to
anti-TNFs monotherapy
versus thiopurines
monotherapy
Exposed to
Combotherapy versus
exposed to anti-TNFs
monotherapy
Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Crude Adjusted Crude Adjusted Crude Adjusted Crude Adjusted Crude Adjusted
Serious infections, all
18–64 years 1.29 (1.20–1.39) 1.27 (1.15–1.39) 2.40 (2.23–2.58) 2.31 (2.10–2.53) 3.02 (2.65–3.45) 3.03 (2.62–3.50) 1.86 (1.70–2.03) 1.82 (1.67–1.99) 1.26 (1.09–1.45) 1.31 (1.14–1.51)
 65 years 0.94 (0.81–1.10) 1.19 (0.97–1.47) 1.76 (1.43–2.16) 2.18 (1.73–2.76) 1.82 (1.03–3.22) 2.46 (1.37–4.39) 1.86 (1.45–2.38) 1.83 (1.43–2.35) 1.04 (0.57–1.89) 1.13 (0.62–2.05)
Serious infections,
excluding GI infections
18–64 years 1.31 (1.20–1.42) 1.31 (1.17–1.45) 2.60 (2.39–2.83) 2.54 (2.29–2.83) 3.21 (2.77–3.73) 3.29 (2.79–3.88) 1.99 (1.80–2.20) 1.95 (1.76–2.16) 1.24 (1.05–1.45) 1.29 (1.10–1.52)
65 years 0.89 (0.74–1.06) 1.09 (0.87–1.38) 1.86 (1.50–2.32) 2.28 (1.77–2.94) 1.84 (0.99–3.43) 2.45 (1.30–4.63) 2.10 (1.60–2.75) 2.09 (1.59–2.74) 0.99 (0.51–1.90) 1.07 (0.56–2.07)
Opportunistic infections, all
18–64 years 4.31 (3.48–5.36) 5.04 (3.88–6.55) 5.37 (4.20–6.87) 6.10 (4.56–8.16) 11.3 (8.13–15.8) 12.9 (8.95–18.6) 1.25 (0.98–1.59) 1.21 (0.95–1.54) 2.11 (1.49–2.98) 2.12 (1.49–3.00)
65 years 2.38 (1.41–3.99) 1.84 (0.87–3.91) 4.88 (2.55–9.31) 3.92 (1.75–8.78) 7.23 (1.77–29.5) 6.40 (1.45–28.2) 2.05 (0.97–4.36) 2.13 (1.00–4.54) 1.48 (0.33–6.70) 1.63 (0.36–7.38)
Opportunistic infections,
excluding
mycobacterial infections
18–64 years 5.30 (4.13–6.81) 6.07 (4.50–8.19) 5.31 (3.95–7.14) 5.91 (4.19–8.34) 10.4 (6.92–15.7) 11.6 (7.44–18.2) 1.00 (0.76–1.33) 0.97 (0.73–1.29) 1.96 (1.28–3.01) 1.97 (1.28–3.02)
 65 years 1.87 (1.00–3.47) 1.17 (0.46–2.97) 4.18 (1.98–8.84) 2.82 (1.07–7.44) 8.59 (2.10–35.1) 6.42 (1.37–30.0) 2.24 (0.91–5.50) 2.40 (0.97–5.91) 2.06 (0.44–9.71) 2.28 (0.48–10.8)
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week 14 were available in 199 (76.2%) patients, and in this subgroup of patients,
IFX concentration at week 14 was also a significant predictor of IFX failure-free
survival (HR 0.87 (0.80–0.94), p¼ 0.001).
Conclusion: This study identified several predictors of clinically relevant IFX
failure in CD patients. Stratifying patients according to the amount of risk
factors can identify patients at high risk for IFX failure. Initiating IFX sooner
rather than later and using TDM in this group to proactively strive for adequate
drug concentrations may ensure optimal disease outcome.
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Introduction: Enteral nutrition (EN) is a well-established treatment in pediatric
Crohn’s disease (CD) for induction of remission as well as disease flares with
similar efficacy compared to steroid therapy and no side effects. Some reports
indicate a role for EN as maintenance therapy, but usually on top of other
treatment or after surgically induced remission. The aim of our study was to
test feasibility and efficacy of cyclic EEN as sole maintenance therapy.
Aims & Methods: Nine patients with active luminal paediatric Crohn’s disease,
L1 (n¼ 2) or L3 (n¼ 7), followed at Necker Hospital between 2012 and 2014
were included in this prospective pilot study. After 8 weeks of exclusive enteral
nutrition with Modulen IBD, patients who came into complete CRP-negative
remission were proposed to continue on cyclic EEN therapy as sole treatment in
an open manner. Cyclic EEN consists of a 6 weeks phase of normal feeding
followed by a 2 weeks phase of exclusive enteral nutrition, without any conco-
mitant CD-related medication. Patients were followed on a fixed scheme (3
months visits) with collection of anthropometric, clinical and biological data.
Results: At inclusion, all patients were in deep remission (CRP-negative). At
month 6 and 12 follow-up visit, 8 of the 9 patients (89%) (wPCDAI 8.4 9.2)
and 5 of 6 patients (wPCDAI 5.7 3.2), respectively were in clinical remission.
Concomitant to the clinical response, biological scores markedly improved with
mean CRP 21.8 14.2 mg/L at M0, 9.8 11.7 mg/L at M6 (p5 0.05) and
5.4  2.7 at M12 (n¼ 6) (p5 0.05) and albumin normalization with 33.8 3.8
g/l at M0, 39.9 5.1 g/l at M6 (p5 0.05) and 42.8 2.9 at M12 (n¼ 6)
(p5 0.05). 3 patients relapsed before M12. Patients presented catch up growth
with net improvement of their anthropometric measurements at M2 and stabili-
zation thereafter (Table 1).
M0 (n¼ 9) M2 (n¼ 9) M6 (n¼ 9) M12 (n¼ 6)
Z score weight -0.96  1.13 -0.37  0.97 0.07  0.81 0.30  1.18
Z score height -0.18  0.84 -0.11  0.80 0.09  1.14 0.35  0.76
Z score BMI -1.37  1.07 -0.38  0.89 -0.82  1.15 -0.66  1.20
Conclusion: This study demonstrates for the first time prolonged clinical, biolo-
gical remission and improved growth in pediatric CD patients treated only with
cyclic enteral nutrition. Cyclic EN can be an efficacious non pharmacological
treatment of Crohn’s disease patients potentially acting ahead of the inflamma-
tory cascade in the intestinal mucosa. A sufficiently power randomized controlled
trials is currently conducted by the GETAID pe´diatrique to confirm these pilot
data.
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Introduction: The existing literature on intestinal microbiota in inflammatory
bowel diseases (IBD) reveals conflicting changes in microbiota composition in
all patients, having most of studies been conducted only on fecal microbiota.
Microbiota adhering to the gut mucosa might affect epithelial and mucosal
function to a greater degree than fecal bacteria.
Aims & Methods: The aim of the present study was to evaluate the mucosal and
fecal microbiota composition in healthy controls (CTRLs) and IBD patients, in a
case-control study exploited by 16S rRNA targeted metagenomics-based
approach (phylotyping, PH). Fecal specimens were collected from 14 IBD
patients [10 Crohn’s disease (CD), 4 ulcerative colitis (UC)], and from 11 healthy
subjects, undergone colonoscopy for screening. Mucosal specimens were
obtained during colonoscopy from the terminal ileum, and descending colon.
PH was assessed by pyrosequencing as follows. All patients were in wash-out
from antibiotics, probiotics and corticosteroids. Genomic DNA was isolated
from the entire set of samples. The V1-V3 region of 16S rRNA locus was ampli-
fied on a 454-Junior Genome Sequencer. Reads were analyzed by Quantitative
Insights into Microbial Ecology (QIIME, v.1.8.0), grouped into operational
taxonomic units (OTUs) at a sequence similarity level of 97% by PyNAST for
taxonomic assignment, and aligned by UCLUST for OTUs matching against
Greengenes database (v. 13.8).
Results: In adult IBD patients colonic biopsies showed a statistically significant
increase of Proteobacteria and decrease of Firmicutes and Actinobacteria, com-
pared to CTRLs. The microbiota analysis of stool samples from IBD patient
showed an increment of Proteobacteria and decrease of Bacteroidetes, although
the difference was not significant compared to CTRLs. Particularly, a predomi-
nant presence of Enterobacteriaceae in IBD and a predominant presence of
Ruminococcaceae, Rikenellaceae and Prevotella in CTRLs were prevalent
(P5 0.05). Stratifying patient findings, according to intestinal sampling site,
the analysis revealed that only Ruminococcaceae resulted statistically increased
in the colon. Tacking in account only colon biopsy samples, a significant reduc-
tion of Coprococcus, Faecalibacterium prausnitzii, Lachnospiraceae,
Rikenellaceae, Roseburia, Ruminococcaceae was observed in patients and an
increment of Enterobacteriaceae was observed in CTRLs. Finally, stratifying
samples on the bases of disease activity a decrease of Ruminococcus,
Peptostreptococcus and Paraprevotella and an increase in Enterococcus was asso-
ciated to active disease status (P5 0.05).
Conclusion: The present study shows that in the mucosal microbiota of IBD
patients, irrespective of disease localization and activity, phylum Proteobacteria
was significantly more represented, while phylum Firmicutes and Actinobacteria
were reduced. The profiles of fecal microbiota partially replicate those of the
mucosal microbiota being not statistically different from controls. It appears
that microbiota adhering to the gut mucosa better discriminates patients from
controls especially when considering family species. Our data suggest the high
diagnostic potential of microbiota profiling with special reference to mucosal
biosystem
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Introduction: Adherent-invasive Escherichia coli (AIEC) are abnormally predo-
minant on Crohn’s disease (CD) ileal mucosa. AIEC are pathobiont bacteria able
to induce inflammatory responses that could initiate or perpetuate the chronic
gut inflammation. Antibacterial treatments, such as bacteriophages (viruses
infecting bacteria) represent a way to eliminate these bacteria from the GI
tract without disturbing the microbiota homeostasis. Here, we evaluated the
potential of bacteriophages to reduce AIEC colonization associated to intestinal
mucosa.
Aims & Methods: Three bacteriophages were selected to efficiently target AIEC
bacteria isolated from CD patient. Efficacy of this bacteriophage cocktail was
investigated using two in vivo experimental models: transgenic mice expressing
CEACAM6 colonized by AIEC strain LF82 and the DSS chemically-induced
colitis model infected with AIEC strain LF82.
Results: In LF82-colonized CEACAM6-expressing mice, 24h after the oral
administration of the selected cocktail of three bacteriophages, the fecal
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concentration of LF82 bacteria has significantly dropped by two log in the
bacteriophage group and stays significantly lower than in control group four
days post-treatment, without any additional bacteriophage administration
demonstrating the benefit of self-amplification of bacteriophages over time.
Furthermore, we found that administration of the cocktail during the first day
reduces progressively over a period of five days the colonization level of LF82
bacteria through the entire gut. In addition, bacteriophage treatment reduced
colitis symptoms in the DSS-induced model, with a reduction of LF82 bacteria
levels in feces, compared to the control group. Then, we showed that bacterio-
phages were driving a long-term digestive tract decolonization of AIEC LF82
bacteria which in turns reduces colitis symptoms.
Conclusion: Bacteriophages targeting AIEC bacteria with high efficacy in murine
models suggest that such a treatment could reduce AIEC-associated symptoms in
CD patients, providing an incentive to initiate clinical studies. The use of bacter-
iophages provides therefore, a new ‘‘microbiota friendly’’ way to efficiently target
gut pathogens.
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Introduction: Ciprofloxacin is one of the most frequently used antibiotics in
hospitalized inflammatory bowel disease (IBD) patients. In the last few years
an emerging resistance to ciprofloxacin, ranging from 43% to 82%, has been
described in extended-spectrum beta-lactamase (ESBL)-producing bacteria colo-
nizing the gut [1; 2]. The objective of this study was to evaluate the gut coloniza-
tion with ESBL-producing Enterobacteriaceae in IBD patients, resistance to
ciprofloxacin and bacterial plasmid genes associated with that.
Aims & Methods: Rectal swabs from all consecutive patients with confirmed
ulcerative colitis (UC) and Crohn’s disease (CD) hospitalized in Riga East
Clinical University Hospital 2012–2015 were collected, Enterobacteriaceae were
cultured and analyzed for ESBL presence according to EUCAST guidelines,
resistance to ciprofloxacin and bacterial plasmid genes CTX-M, TEM and
SHV were detected.
Results: A total of 86 patients with confirmed IBD diagnosis were included in the
study – 65 (75%) with UC, 21 (24%) with CD. We found that 7 (11%) of the UC
patients and 2 (10%) of the CD patients were colonized with ESBL producing
Enterobacteriaceae. The isolated ESBL producing strains from UC patients
included Escherichia coli (n¼ 5), Klebsiella oxytoca (n¼ 1) and Escherichia her-
manii (n¼ 1). The isolated ESBL-producing Enterobacteriaceae from CD
patients included Escherichia coli (n¼ 2). The isolated bacterial plasmid genes
associated with ESBL-production in UC included CTX-M (n¼ 7; 100%),
TEM (n¼ 2; 29%), SHV (n¼ 1; 14%), in CD – TEM (n¼ 2; 100%) and
CTX-M (n¼ 1; 50%). In UC 4 (57%) of the isolated ESBL-producing
Enterobacteriaceae were resistent to ciprofloxacin. In CD all of the ESBL-
producing Enterobacteriaceae were sensitive to ciprofloxacin. In 1 case of
ESBL resistance CTX-M, TEM and SHV gene combination was observed, in
1 case CTX-M and TEM gene combination was observed and in 2 cases only
CTX-M gene was present.
Conclusion: 1. High gut colonization rate (11%) with ESBL-producing bacteria in
UC patients, mostly E. coli, expressing CTX-M gene. 2. High resistance to cipro-
floxacin (57%) in UC patients. 3. CTX-M gene associated with resistance to
ciprofloxacin.
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Introduction: Inflammatory bowel diseases (IBD) develop as a result of a combi-
nation of genetic predisposition, dysbiosis of the gut microbiota, and environ-
mental influences. Caspase recruitment domain 9 (CARD9), one of the numerous
IBD susceptibility genes, encodes an adaptor protein for innate immunity toward
a wide range of microorganisms. Card9–/– mice are more susceptible to colitis as a
result of impaired of the IL-22 pathway1. Our aim was to explore the role of the
gut microbiota in the susceptibility of Card9–/– mice to colitis.
Aims & Methods: Germ-free (GF) C57BL/6 wild-type (WT) mice were inoculated
by oral gavage with fresh stools from conventional WT (WT—4GF) or Card9–/–
(Card9–/–—4GF) mice. Colitis was induced by DSS. AHR activity in intestinal
content was determined using a reporter cell line. Immune response was assessed
at transcripts level, at the protein level and at the cellular level using flow cyto-
metry. Patients with IBD were genotyped for the major IBD-associated SNPs
including CARD9. Statistical analysis was performed using parametric or non-
parametric tests as appropriate.
Results: Bacterial and fungal gut microbiota of Card9–/– mice (assessed by 16s
and ITS2 sequencing) were altered compared to WT mice. Card9–/–—4GF mice
were more susceptible to colitis than WT—4GF with impaired recovery.
Moreover, IL-22 defect was observed in Card9–/–—4GF mice at the gene expres-
sion and protein levels in the colon and in MLNs. IL-22 production by T helper
22 cells, NKp46þ innate lymphoid cells, lymphoid tissue inducer cells, and
CD3–CD4–NKp46– cells was decreased in the colon of Card9–/–—4GF mice.
AHR ligands are known to promote gut IL-22 production2. Indeed, the levels of
Indole-3-acetic acid (IAA), an AHR ligands, were decreased in stools of
Card9–/–—4GF and Card9–/– mice. Moreover, feces from Card9–/– and
Card9–/–—4GF mice were defective in their ability to activate AHR. In
Card9–/–—4GF mice, susceptibility of colitis, and IL-22 defect were rescued
after treatment with AHR agonist (6-formylindolo(3,2-b)carbazole), or inocula-
tion with three Lactobacillus strains with strong AHR activity. These effects were
abrogated in the presence of AHR antagonist (CH223191). Reduced production
of AHR ligands was also observed in the microbiota from patients with IBD,
particularly in those with CARD9 risk alleles.
Conclusion: Card9 deletion has an effect on the gut microbiota in mice and its
transfer to WT GF recipient is sufficient to recapitulate the defective IL-22
activation and increased sensitivity to colitis observed in Card9–/– mice. These
alterations were due to an impaired ability of the microbiota of Card9–/– mice to
catabolize tryptophan into AHR ligands. Our results are relevant to humans, as
impaired microbial production of AHR ligands was observed in patients with
IBD. Thus, defects in expression of factors involved in innate immunity, such as
CARD9, can shape an altered microbiota, which can then modify the host
immune response. Correcting impaired microbiota functions, such as ability to
produce AhR ligands, is an attractive strategy in IBD.
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Introduction: In a randomised placebo-controlled trial, intensive FMT therapy
for active ulcerative colitis (UC) was significantly superior to placebo, producing
a clinical response in450% and clinical remission with endoscopic remission or
response in 27% of patients (ECCO 2016 & DDW 2016)1. This part of the
FOCUS study aimed to characterise the microbial changes underlying FMT in
UC, and identify those predictive of, and associated with, response and lack of
response.
Aims & Methods: Active UC patients were randomised to intensive FMT or
placebo enemas 5 days/week for 8 weeks, with placebo-treated patients subse-
quently offered 8 weeks of open label FMT. Each FMT enema was derived from
3–7 unrelated donors. Faecal samples were collected from patients at week 0, 4
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and 8, open label mid and end of treatment (if applicable), and 8 weeks after
FMT; colonic biopsies were collected at week 0 and 8, and end of open label
treatment (if applicable). Faecal samples were also collected from individual
donors and donor batches. DNA was extracted from faecal samples and 16S
ribosomal RNA gene sequencing performed using 2x300 bp Illumina Miseq
chemistry (F27 & 519R). Raw sequences were analysed using MOTHUR, and
statistical tests performed on counts and relative abundances.
Results: Faecal and colonic samples were collected from 70 study patients. 14
donors contributed to 21 donor batches. 314 patient and 113 donor (individual þ
batch) faecal samples along with 160 patient colonic samples were analysed.
26976  540 clean sequences per faecal sample and 28093 881 per colonic
biopsy were obtained with rarefaction curves suggesting sampling had reached
saturation. In both faecal and colonic samples -diversity significantly increased
at all FMT treatment time points relative to baseline (p5 0.005); this persisted 8
weeks after FMT in the faecal samples. On PCA, Cluster, and PERMANOVA
analyses FMT significantly influenced patient microbial profiles, with the shift
towards healthy donor microbiota most notable at the genus and OTU levels.
LEfSe analysis of both faecal and colonic samples showed a decrease in patient
Bacteroides and an increase in donor Prevotella with FMT, independent of clin-
ical outcome. A range of other microbial taxa were identified as transplanted or
displaced with FMT across all taxanomic levels. Patients receiving FMT who
achieved remission had greater baseline faecal and colonic mucosal -diversity
than those who did not achieve remission, and also had greater resultant diversity
with and after FMT treatment. Specific taxa were consistently significantly asso-
ciated with FMT remission across both faecal and colonic samples: taxa within
Barnesiella were associated with remission, while OTUs within Fusobacterium
and Sutterella were associated with lack of remission.
Conclusion: Baseline patient microbial diversity in UC appears to be predictive of
therapeutic response to FMT. Intensive FMT is associated with increased micro-
bial diversity, with the greatest diversity noted in patients achieving remission.
Increased diversity persists 8 weeks after cessation of therapy. Specific bacterial
taxa are transplanted or displaced by FMT, some of which are associated with
treatment outcome. A high level of concordance was observed between the faecal
and colonic mucosal microbiota. These findings may be important in both under-
standing the pathophysiology of the microbiota in UC and shaping future bac-
terial therapy.
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Introduction: Hepatic fibrosis is a growing health problem with no effective and
clinically approved therapy. Hepatic stellate cells (HSCs) are the key cells
involved in the pathogenesis of liver fibrosis. Upon activation, HSCs undergo
morphological and functional changes, and are transformed into contractile
ECM-producing myofibroblasts leading to scar tissue formation. HSCs contrac-
tion contributes significantly to the portal hypertension thereby further impairing
the liver function. Relaxin (RLN) has been shown to inhibit HSC activation and
contraction thereby ameliorate liver fibrosis and portal hypertension. However,
RLN has very poor pharmacokinetics and administration of high or frequent
doses can lead to detrimental side effects due to vasodilation.
Aims & Methods: In this study, we aimed to develop a nanoparticle-based deliv-
ery system to improve pharmacokinetics and therapeutic efficacy of RLN for the
diagnosis and treatment of liver fibrosis. We conjugated human RLN-2 to
PEGylated magnetic nanoparticles (RLN-MNP) and characterized the size,
charge and stability. We examined RLN-MNP for RLN conjugation and
HSCs-specific binding/uptake. We analysed RLN receptor (RXFP1) expression
on activated HSCs and CCl4-induced liver fibrosis mouse model. Finally, we
assessed the effects of RLN-MNP on human HSCs and CCl4-induced advanced
8-weeks liver fibrosis mouse model.
Results: RLN-MNP was successfully synthesized and remained stable at 4C.
RLN-MNP showed specific binding and uptake to TGFb-activated human
HSCs while MNP alone showed no binding/uptake. In vitro, RLN-MNP and
unconjugated RLN significantly inhibited TGFb-induced 3D-collagen gel con-
traction and HSCs migration. Significant up-regulation of RXFP1 in TGFb-
activated HSCs and CCl4-induced liver fibrosis mouse model was observed.
In vivo in established 8 weeks CCl4-induced liver fibrosis mouse model, both
RLN and RLN-MNP strongly attenuated fibrosis by inhibiting HSC activation,
ECM production and angiogenesis. Importantly, RLN-MNP, but not unconju-
gated RLN, increased Nitric oxide release by significant up-regulation of iNOS.
On the other hand, unconjugated RLN induced systemic side effects by inducing
systemic NO release (in serum) while RLN-MNP did not. In vivo studies for
MRI and portal hypertension using relaxin and relaxin magnetic nanoparticles
are currently ongoing.
Conclusion: This study presents a novel strategy to deliver RLN specifically to
HSCs, key pathogenic cells involved in liver fibrogenesis, for the diagnosis and
treatment of liver fibrosis.
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Introduction: Reactive oxygen species (ROS) are chemically reactive molecules
containing oxygen, including hydrogen peroxide (H2O2), hypochlorous acid
(HOCl), singlet oxygen (1O2), and superoxide (O
2-). ROS have been reported
to play an important role in the development of liver diseases.1 For example,
H2O2 can activate hepatic stellate cells in liver fibrogenesis. During hepatic
ischemia-reperfusion injury, HOCl is generated by neutrophils and diffuses
into hepatocytes, causing oxidant stress-mediated injury. O2- can react with
nitric oxide to form peroxynitrite to modify the cell structure and function of
proteins in diseased liver. Various methods have been developed to monitor ROS
generation in the liver, but the presence of different cellular sources for ROS as
well as the distinct chemical properties of specific ROS may lead to conflicting
results.2 Most developed ROS-detection probes were difficult to be distinguished
from endogenous fluorophores and only can be employed under one-photon
microscopy. Thus, an optimal strategy for precise real-time ROS detection is
highly required to rapidly and accurately reveal the cellular microenvironment
in liver diseases in clinic.
Aims & Methods: Four different two-photon fluorescent probes were designed
and synthesized for selective detection of chemically reactive molecules of thiols
and ROS including glutathione (GSH), H2O2, HOCl, and O
2-. Mouse models of
hepatic steatosis, fibrosis and ischemia-reperfusion injury were developed to
mimic human liver diseases.3 After sacrificing the animals, unfixed live liver
tissues were collected and incubated with each probe at the final concentration
of 50 to 100 mmol for 10min, and then imaged using multiphoton microscopy
(JenLab GmbH, Jena, Germany).4
Results: Each probe exhibited a strong positive fluorescent response only in the
presence of its specific chemically reactive molecule, whereas negligible fluores-
cent signals were observed upon the additions of other reactive oxygen/nitrogen
species and metal ions. There was a good linear relationship between the probe
responsive fluorescent intensity and the concentration of specific ROS. In the
liver with ischemia-reperfusion injury, reduced autofluorescence was detected,
indicating the hepatocyte necrosis. Remarkable enhancement of red fluorescence
was observed in hepatocytes with decreased autofluorescence, indicating the
reaction of with endogenous HOCl. The cellular concentration of GSH decreased
and H2O2 increased in the liver with fibrosis and steatosis compared to the
control. The concentration of each specific ROS was first calculated based on
the intensity of images at the cellular level.
Conclusion: We developed a quantitative imaging platform to real-time measure
specific ROS changes in liver diseases at the cellular level. This technique can be
used to investigate ROS-mediated liver injury and predict treatment response in
human liver biopsy, and can be readily extended to examination of diseases and
injury of other organs. We anticipate that in the near future this quantitative
imaging platform will be evaluated from bench to bedside, leading to real-time
monitoring of cellular microenvironment in human diseases.
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Introduction: For decades, stigmata of recent hemorrhage (SRH) in ulcers &
NVUGIH have been used to guide endoscopic hemostasis. Arterial blood flow
underlying SRH is rarely monitored, yet determines rebleed risk after treatments.
Aims & Methods: In a RCT, our primary aim was to compare 30-day rebleed
rates of index lesions for patients treated with Standard vs. DEP guided endo-
scopic hemostasis. In a 2-center study, patients were resuscitated & consented.
They & managing medical-surgical teams were blinded to endoscopic treatments.
Patients with severe inpatient or outpatient start of UGIH (clinical signs, hemo-
globin – Hgb - drop of 4 2 gms from baseline, & RBC transfusions) were
randomized at urgent endoscopy if they had benign appearing ulcers & some
SRH (active arterial bleed, non-bleeding visible vessel - NBVV, or adherent clot,
oozing without other SRH, or flat spot) or Dieulafoy’s lesions or Mallory Weiss
tears- MWT (with active bleeding or NBVV). For Standard treatment, hemoclip-
ping &/or multipolar probe electrocoagulation (MPEC-large probe) with or
without dilute epinephrine injection was used without DEP & visual end points
were control of bleeding, flattening VVs, & a foot-print at the SRH. For the DEP
group, SRH & lesion base were interrogated for underlying blood flow at 5 4
mm deep settings with an FDA approved control unit & disposable DEP probe
(Vascular Technology, Nashua, NH). Then Standard RX was applied on & out
from the SRH, where the artery was traced. DEP was used to recheck & if
residual blood flow was detected, further hemostasis was performed until no
blood flow was detected. Standard group patients with flat spots were not treated
endoscopically, but DEP patients were if they had blood flow detected. All
patients with ulcers & Dieulafoy’s lesions received high dose PPI infusion X 72
hours & then BID for 30 days. MWT patients were treated with anti-emetics &
BID PPI. Rebleeding was determined by a4 2 gm decrease of Hgb, with clinical
signs of rebleeding, & repeat endoscopy with more hemostasis as needed. Patients
were followed prospectively by research coordinators who recorded routine 30
day outcomes.
Results: All blood flow detected by DEP was reproducible & arterial. For 148
patients randomized, see the Table for 30 day rebleed rates by SRH. There was a
significant difference in rebleed rates (15.2% higher) in Standard group vs. DEP
group (p¼ 0.02138) & surgery (4/76 vs. 0/72 – p¼ 0.0484). 1 perforation occurred
in the Standard group & none in the DEP group.
Non-Variceal UGIB Doppler Probe RCT - Primary Outcome of 30 day Rebleeds
from the Same Lesion
Stigmata Standard DEP
Active Arterial bleed 5/10 (50.0%) 4/14 (28.6%)
NBVV 7/27 (25.9%) 4/26 (15.4%)
Adherent Clot 4/16 (25%) 0/13 (0%)
Flat Spots 3/16 (18.8%) 0/15 (0%)
Oozing bleeding 1/7 (14.3%) 0/4 (0%)
TOTALS 20/76 (26.3%) 8/72 (11.1%)*
*p¼ 0.02138 by Fisher Exact test
Conclusion: In a RCT of patients with severe NVUGIH, use of Doppler probe as
a guide to endoscopic hemostasis significantly reduced 30 day rebleed & surgery
rates compared to Standard, visually guided hemostasis. We now recommend
DEP (along with SRH) as a new guide for risk stratification & definitive endo-
scopic hemostasis in patients with severe NVUGIH. RCT was supported by a
VA Clinical Merit Review Research Grant & in part by NIH-NIDDK AM 41301
CURE DDRC-Human Studies Core. Registered with ClinicalTrials.gov as
Project CLIN-013–07F.
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Introduction: The Chicago Classification (CC) of esophageal motility disorders
for high resolution manometry (HRM) is based on ten 5mLs water swallows
(WS). We have previously reported the use of a solid test meal (STM) in patients
undergoing HRM to improve diagnostic sensitivity(1). We further validate the
use of a STM in a multiracial Asian cohort.
Aims & Methods: We aimed to determine if the use of a STM during routine
esophageal manometry improves diagnostic yield and symptom reproducibility.
Methods: Prospective series of patients referred for esophageal HRM between
November 2014-April 2016. All patients had undergone prior endoscopy with
findings of normal or mild (LA grade A esophagitis). WS and STM studies were
performed in the upright seated position. Diagnosis of major and minor esopha-
geal motility disorders were based on CC version 3.0 for water swallows (2) and
modified for solid swallows as appropriate (3). All medications known to inter-
fere with GI motility were stopped for at least one week prior to the study.
Symptoms reported by the patients during HRM study were analyzed for any
corresponding manometric abnormalities. Symptom associated dysfunction
(SAD) was defined as a symptom event reported during or up to 10 seconds
after concurrent esophageal dysmotility during STM.
Results: 119 (56 Male [47.1%]; mean age 50.9 16.2) consecutive patients (84
Chinese: 17 Malay:9 Indian:9 others) underwent HRMwith WS for evaluation of
(i) dysphagia (n¼ 56 [47.4%]), (ii) reflux symptoms (n¼ 45 [38.1%]) and (iii)
atypical chest pain (n¼ 17 [14.4%]). HRM with STM was performed in 114
(96%) patients. Compared to WS alone (n¼ 2/119 [1.7%]), more patients were
diagnosed with esophago-gastric junction (EGJ) outflow obstruction during a
STM (n¼ 8/114 [7.0%]); p¼ 0.05). (Table) Similarly, more patients were diag-
nosed with esophageal spasm with a STM (n¼ 5/114 [4.4%]) compared to WS (2/
119 [1.7%], p¼ 0.27) alone. Upper esophageal dysfunction (UES) was seen only
during STM in 3/114 [2.6%] patients. Conversely, more patients were diagnosed
with ineffective esophageal motility (IEM) during SWS (16/119 [13.4%]) com-
pared to during STM (6/114 [5.3%], p¼ 0.04) consistent with earlier reports of
improved peristaltic contractions in controls and patients with non-erosive reflux
disease (4) Symptom associated dysfunction during HRM occurred in signifi-
cantly more patients during the STM study (n¼ 26/114 [22.8%] compared to
SWS alone 1/119 [0.8%], p5 0.0001). The study was well tolerated in all
patients.
Conclusion: The use of additional physiological stimuli during routine esophageal
HRM improves the detection of clinically relevant esophageal dysfunction,
including disorders of the upper esophageal sphincter (UES) and the eso-
phago-gastric junction (EGJ). In addition, symptom associated dysfunction
occurred more frequently during the solid test meal. The improved diagnostic
yield can guide effective treatment.
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Introduction: A value of the combination of magnifying endoscopy of and image
enhancement endoscopy (IEE) technology (e.g. NBI, BLI) is reported in a diag-
nosis for the early gastric neoplasm. This combination is effective, but it is
necessary to speculate in real histology from the pattern of a two-dimensional
monotone. Therefore, this diagnostic method is still more difficult for general
endoscopists. Linked Color Imaging (LCI) was recently developed using a laser
endoscopic system (Fujifilm Co., Tokyo, Japan). LCI acquires images by simul-
taneously using narrow-band short wavelength light and white light in an appro-
priate balance. This combination of light provides more information about the
vasculature and architecture on the mucosal surface than that obtained with
typical white-light imaging. When we use acetic acid indigocarmine mixture
(AIM) with LCI mode, we discovered that the magnifying images of early gastric
cancer are very clear, three-dimensional and near to real histology. So, we exam-
ined the examined the utility of this method.
Aims & Methods: This was a prospective observational study performed at a
single tertiary referral center. The subjects are 72 lesions of 67 patients with
gastric neoplasm. We are indicated of the endoscopic submucosal dissection
(ESD), and were given pre-ESD endoscopy in our hospital from September
2014 to February 2016. Firstly we observed the lesions by magnifying endoscopy
with the BLI mode and diagnosed using VS classification system1). Secondly we
observed the lesions by magnifying endoscopy with LCIþAIM method and
diagnosed using VS classification system. Furthermore, we classified the visuali-
zation ability of the surface fine structure in Clear, Visible, and Invisible and
evaluated it. Finally, we carried out ESD and compared the image with the
histopathology.
Results: By the pathology results, 60 lesions were gastric cancer and 12 lesions were
gastric adenoma. The differentiation ability of a cancer and the non-cancer (ade-
noma) did not have the significant difference between the BLI mode and the
LCIþAIM methods. In the classification of visualization ability, 12 lesions were
Clear, 22 lesions were Visible, 38 lesions were Invisible by BLI mode. On the other
hand, 33 lesions were Clear, 34 lesions were Visible, 5 lesions were Invisible by
LCIþAIM method. In the visualization ability of the surface fine structure,
LCIþAIM method is significantly clearer than BLI mode (p5 0.05).
Conclusion:When we use AIM, indigocarmine accumulates in pit of the duct, and
duct structures become clear by the acetic acid, By LCI mode, we can observe the
vascular pattern of the lesion clearly. So by the combination of AIM and LCI, we
can observe the lesion three-dimensionally. By this method, we can compare
histopathology with an endoscopic image intuitively, so we believe that a mag-
nifying endoscopy diagnosis of the gastric cancer is enabled even if we do not use
various confusing classifications.
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Introduction: Gastric cancer (GC) remains a global challenge due to high mor-
bidity and mortality rates and poor response to chemotherapy treatment.
Increasing evidence suggests that exosomal microRNAs (miRNAs) possess
diverse cellular regulatory roles in cancer progression nowadays. The tumor
microenvironment is abundant with exosomes that are secreted by the cancer
cells themselves. Exosomes are nanosized, organelle-like membranous structures
that are increasingly being recognized as major contributors in the progression of
malignant neoplasms. For now, little is known about how cancer cell-derived
exosomes and miRNAs in exosomes modulate the microenvironment to optimize
conditions for tumor progression and metastasis.
Aims & Methods: We aimed to investigate whether cancer cell-derived exosomal
miRNA could modulate cancer progression and metastasis and can be used as a
diagnostic marker. In this study, we used miRNA microarray technology to
identify exosomal miRNAs that were differentially expressed in GC patients
and controls. We further examined the biological function of exosomal miR-21
on cell viability, apoptotic death and metastasis in human GC cells and explored
the possible downstream mechanism. We also included another 100 GC patients
and 100 controls to study whether exosomal miR-21 could be used as a potential
biomarker.
Results: We found that exosomes derived from GC patients exhibited significant
different miRNA expression patterns compared with those from controls. Of the
233 miRNAs that were differentially expressed, miR-21 stood out as one of the
most significantly upregulated miRNAs in cancer patients. miR-21 depletion in
GC cells led to decreased miR-21 levels in exosomes and significantly reduced cell
proliferation, migration, invasion and increased apoptosis, and the same phe-
nomenon was seen when transfect miR-21 inhibitor into the exosomes from GC
cells and co-culture the transfected exosomes with GC cells. Moreover, exosomal
miR-21 markedly enhanced snail and vimentin expression in GC cells, while
significantly decreasing E-cadherin levels, suggesting that exosomal miRNA
might play a role in epithelial-to-mesenchymal transition (EMT) process.
Finally, circulating exosomal miR-21 levels were closely associated with TNM
stage, and lymph node metastasis in GC patients and could be used as a useful
diagnostic biomarker with a sensitivity of 89.2% and specificity of 91.1%.
Conclusion: In conclusion, our findings suggest that GC cells could generate miR-
21-rich exosomes that are delivered to surrounding normal cells to promote
prometastatic behaviors and prompt further investigation into the therapeutic
value of exosome inhibition for cancer treatment and diagnostic marker for
cancer diagnosis.
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Abstract No: OP075
Summary of Manometry Findings with Single Water Swallows (SWS) and Solid Test Meal (STM)
Diagnosis on High-Resolution Manometry
Dysphagia
(N¼ 56) SWS
Dysphagia
(N¼ 51) STM
Reflux
(N¼ 46) SWS
Reflux
(N¼ 46) STM
Chest Pain
(N¼ 17) SWS Chest Pain (N¼ 17) STM
Achalasia Types I/II/III 15 10
Esophago-gastric junction (EGJ) outflow obstruction 3 6 1 1
Spasm 1 2 1 2 1
Jackhammer 1 1 1 1 3 4
Aperistalsis 4 0 3 2
Ineffective esophageal motility 9 5 6 1 1
Upper esophageal dysfunction 1 2
Normal 23 26 35 37 13 11
United European Gastroenterology Journal 4(5S) A33
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
OP078 URINARY KALLIKREIN-10 PREDICTS INCURABILITY FOR
GASTRIC CANCER
T. Shimura1, M. Ebi2, T. Yamada3, T. Yamada4, T. Katano5, S. Nomura1,
Y. Mori1, H. Kataoka1, T. Joh1
1Department Of Gastroenterology and Metabolism, Nagoya City University
Graduate School of Medical Sciences, Nagoya/Japan
2Aichi Medical University, Nagakute/Japan
3Japanese Red Cross Nagoya Daini Hospital, Nagoya/Japan
4Okazaki Public Health Center, Okazaki/Japan
5Nagoya City University Graduate School of Medical Sciences Gastroenterology
and Metabolism, Nagoya/Japan
Contact E-mail Address: tshimura@med.nagoya-cu.ac.jp
Introduction: Recent material and technical development enables us to get many
therapeutic choices for gastric cancer (GC). Accurate diagnosis is thus needed to
choose an optimal treatment for GC, however, the current imaging diagnosis is
not enough to identify incurable factors including peritoneal metastasis and local
invasion. We have previously reported the usefulness of urinary biomarkers for
diagnosis of GC. With the goal of discovering non-invasive biomarkers for pro-
gression and incurability of GC, we conducted this study using urine samples
from GC patients and healthy control.
Aims & Methods:Urine samples from 189 patients composed of 111 patients with
GC and 78 healthy controls were analyzed in this study. According to tumor
stage and operability, GC cohort was analyzed.
Results: We conducted a protease protein array analysis to identify potential
candidate biomarkers, and three proteins were found to be elevated in the
urine of advanced GC patients compared to early GC patients. Among them,
urinary kallikrein-10 (KLK10) and proteinase 3 were positively associated with
tumor stage progression. Moreover, urinary level of KLK10 (uKLK10) was
significantly elevated in the urine of inoperable GC patients compared to oper-
able GC patients (uKLK10: median, 33.5 ng/ml vs. 10.8 ng/ml; P¼ 0.006), and
disease-free survival (DFS) was significantly lower in GC patients with high
uKLK10 compared to low uKLK10 (HR: 2.53 (95%CI, 1.23–5.21), P¼ 0.007).
Urinary KLK10 distinguished operability of GC with an area under the curve
(AUC) of 0.710 and the combination of uKLK10 with tumor size showed an
AUC of 0.835. Immunohistochemical analyses also demonstrated a positive cor-
relation between tumor stage and KLK10 expression in GC tissues. In addition,
GC patients with high expression of pathological KLK10 (pKLK10) significantly
showed a shorter DFS than those with low pKLK10
Conclusion: uKLK10 is a promising non-invasive biomarker for incurable GC.
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Introduction: The new Rome IV criteria make several adjustments in diagnostic
requirements for IBS compared to Rome III. It is unknown how this will affect
the prevalence and demographic distribution of IBS
Aims & Methods: We used data from a large internet survey of the general
population in 3 countries to measure and compare Rome IV vs. Rome III IBS
rates and the demographics of the disorder. A community sample of 6,300 indi-
viduals age 18 and older in the US, UK and Canada (2,100 in each country)
completed the secure online survey. Quota-based sampling was used to ensure
equal proportion of sex (50%/50%) and age groups (40% aged 18–39, 40% aged
40–64, 20% aged 65þ) across countries, and to control education distributions
(30% maximum with college degree or equivalent). The survey included the
Rome IV Diagnostic Questionnaire for Adults, Rome III diagnostic modules
for IBS, and demographic questions. Latest national census figures were used
to calculate correction weights for age (in 5-year bins) and gender proportions
and obtain census-adjusted IBS prevalence estimates for each country.
Results: Of the 6,300 survey completers, 5,931 were retained for analysis (49.2%
female; mean age¼ 47.4, range 18–92; 1,949 US, 1,994 UK, 1,988 Canada) after
369 inconsistent responders were eliminated. Due to the quota-based sampling,
sex or age group proportions did not differ between countries. Rome IV vs.
Rome III IBS prevalence rates (census-corrected estimates in parentheses) were
6.1% (6.1%) vs. 10.8% (11.1%) in the US, 5.7 (5.8%) vs. 11.3% (11.7%) in
Canada, and 5.5% (5.5%) vs. 10.1% (10.6%) in the UK. There were no IBS
prevalence differences between countries, but Rome IV IBS prevalence was sig-
nificantly lower than Rome III IBS in all countries (p5 0.0001 for all compar-
isons). Women were more likely (p5 0.0001) to have IBS than men by both
Rome IV (7.1% vs. 4.1%; OR 1.87) and Rome III (14.4 vs. 7.2; OR 2.17) criteria
in the combined 3-country sample, and people age 65þ were significantly less
likely (p5 0.0001) than younger respondents to have IBS according to either
criteria. Similar age group and gender difference patterns were seen in the 3
countries (Table). The Rome IV IBS subtype distribution for the combined 3-
country sample (27.9% IBS-C, 34.3% IBS-D, 33.3% IBS-M, 4.7% IBS-U) was
significantly different (p5 0.0001) than with Rome III (16.6% IBS-C, 20.6%
IBS-D, 60.1% IBS-M and 2.1% IBS-U).
Table: Population Rome III and Rome IV IBS rates (%) by sex and age groups
in the US, UK and Canada survey samples (without census weighting).
ROME III IBS: Age 18–34 Age 35–49 Age 50–64 Age 65þ All age groups
US Females (n¼ 962) 15.6 16.6 13.7 9.9 14.2
US Males (n¼ 987) 7.2 9.3 8.4 5.6 7.6
UK Females (n¼ 976) 14.2 15.4 15.1 8.9 13.9
UK Males (n¼ 1018) 4.9 7.2 9.5 3.6 6.5
Canada Females (n¼ 980) 14.6 16.8 15.4 12.9 15.1
Canada Males (n¼ 1008) 6.3 10.3 8.2 5.9 7.6
ROME IV IBS: Age 18–34 Age 35–49 Age 50–64 65þ All age groups
US Females (n¼ 962) 6.6 10.6 6.9 3.7 7.1
US Males (n¼ 987) 8.8 3.6 4.2 1.9 5.1
UK Females (n¼ 976) 6.7 10.2 8.6 3.2 7.5
UK Males (n¼ 1018) 1.8 5.1 5.5 1.6 3.6
Canada Females (n¼ 980) 7.1 9.8 8.1 5.3 7.8
Canada Males (n¼ 1008) 2.5 5.4 5.0 2.1 3.7
Conclusion: These first-ever national population prevalence estimates for Rome
IV IBS show that IBS prevalence and demographic distribution is equivalent in
the US, UK and Canada, and confirm that the disorder is female-predominant
and less common in older individuals. IBS prevalence is significantly lower when
Rome IV criteria are used than with Rome III, and the new criteria also change
IBS subtype distribution, markedly reducing the IBS-M proportion. [Support:
The Rome Foundation]
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Introduction: Gastroesophageal reflux disease (GERD) and irritable bowel syn-
drome (IBS) are gastrointestinal (GI) disorders affecting a large part of the
general population, with relevant impact on quality of life and health care
costs. To date, population- and clinical-based studies have reported a certain
degree of overlap between GERD and IBS, which cannot be explained solely
by chance. By means of multichannel intraluminal impedance and pH (MII-pH)
monitoring, patients with proton pump inhibitor (PPI)-refractory heartburn can
be distinguished into PPI-refractory GERD and functional heartburn (FH), the
latter to be considered a functional GI disorder separate from GERD. Symptoms
of IBS have not yet been assessed in patients with reflux symptoms as distin-
guished into GERD and FH. Recently, it has been reported that patients with
GERD as well as patients with IBS have increased levels of anxiety, in turn
associated with increased perception of symptoms and reduced quality of life.
Again, the prevalence of anxiety in patients with reflux symptoms as clearly
distinguished into GERD and FH has not yet been assessed.
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Aims & Methods: Our aim was to assess the prevalence of IBS as well as anxiety
and depression in patients with typical reflux symptoms subdivided into GERD
and FH by means of upper GI endoscopy and MII-pH monitoring. We also
aimed to assess the prevalence of various clinical and endoscopic characteristics
in GERD and FH patients in order to develop a predictive model for distinguish-
ing FH from GERD in patients presenting with typical reflux symptoms, poten-
tially useful in clinical practice. Patients underwent a structured interview based
on questionnaires for GERD (GERDQ), IBS (RIIIAQ), anxiety and depression
(HADS). Upper GI endoscopy and 24h MII-pH off-therapy monitoring were
performed in all cases. In patients with IBS, fecal calprotectin was measured and
colonoscopy was scheduled for values 4100 mg/kg to exclude organic disease.
Multivariate logistic regression analysis was performed to identify independent
risk factors for FH. A predictive model for FH diagnosis based on clinical and
endoscopic findings was developed by applying the purposeful selection of cov-
ariates. The coefficients estimated in the multivariate logistic regression analysis
were used to predict FH diagnosis. The performance of the predictive model was
then assessed by examining measures of discrimination and calibration.
Discrimination was considered as the ability of the predictive model to differ-
entiate between patients with FH diagnosis and patients with GERD diagnosis
and was quantified by calculating the area under the ROC curve (AUC). A
calculator to help clinicians in automatically computing the predicted probability
of FH versus GERD in patients presenting with heartburn was built.
Results: Of the 701 consecutive heartburn patients who entered the study, 458
(65%) had GERD whereas 243 (35%) had FH. IBS was found in 143/458 (31%)
GERD but in 187/243 (77%) FH patients (P5 0.001). At multivariate analysis
IBS, anxiety, and smoking resulted independent risk factors for FH whereas
hiatal hernia resulted protective. We developed a predictive model based on
clinical and endoscopic characteristics (IBS. Smoking, Anxiety, Age  45,
Hiatal hernia, i.e. ISAAH). The area under ROC curve in an external validation
cohort of 51 patients was 0.920. Considering the previously established cut-off,
sensitivity and specificity of the predictive model in diagnosing FH against
GERD were 84.3% and 78.9%, respectively. A calculator to help clinicians in
automatically computing the predicted probability of FH versus GERD in
patients presenting with heartburn was built (URL: http://app.calculoid.com/#/
calculator/7012).
Conclusion: IBS overlaps more frequently with FH than with GERD, suggesting
common pathways and treatment. The score derived from ISAAH predictive
model allows a high level of suspicion for FH and can be useful in clinical
practice.
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Introduction: Irritable bowel syndrome (IBS) is characterised by many comorbid
symptoms as well as core symptoms, all of which are relevant for the clinical
management of this group of patients. However, the evolution of these symptoms
over time is poorly understood.
Aims & Methods: The aim of this study was to determine the probability of IBS-
related symptoms to persist or subside over time. The study consisted of three
parts. First, we addressed the question which factors can determine the prob-
ability of a symptom to persist or subside over time. A simulation showed there
were five: length of follow-up period, autocorrelation, the interaction between the
autocorrelation and symptom severity, the cut-off for symptom severity, and
skewness. Second, we used the five factors in a Monte Carlo simulation, gener-
ating a reference-table of probabilities for symptoms to persist or subside. Third,
our theoretical reference-table was matched with real data from a cohort of 276
IBS patients (70% female; age range 19 to 76 years, median age 39 years). These
subjects were thoroughly characterised at baseline, and completed questionnaires
annually over a five-year period, covering the following IBS-related symptoms /
aspects: gastrointestinal (GI) symptom severity (GSRS), GI-specific anxiety
(VSI), quality of life (IBS-QOL), coping resources (CRI), sense of coherence
(KASAM), and anxiety/depression (HADS). The cohort was used to retrieve
the five factor properties mentioned above (e.g. autocorrelations).
Results: A summary of the main results is shown in table 1. In IBS patients,
depression was the most persistent symptom over time, i.e. a 22% chance for
depression to persist, versus 23% to subside over a five-year period. Poor coping
resources and sense of coherence yielded similar percentages. Values were differ-
ent for anxiety (12% to persist and 44% to subside) and GI symptom severity (8
and 47%), with no major differences between the different GI symptoms (i.e.
diarrhoea, constipation, abdominal pain, satiety, indigestion, and reflux). For
IBS-QOL, there were differences between the domains: sexual relations (20%
chance to persist, 18% chance to subside) and sleep (20 and 25%), in contrast
to the domains mental health (7 and 56%), physical functioning (5 and 64%),
and emotional (5 and 57%). The QOL domains physical role, social role, and
food were intermediate.
Table 1: Probabilities for IBS-related symptoms to persist or subside over a five-
year period.
Symptom persists Symptom subsides
Probability 95% CI Probability 95% CI
Depression 22% 18–26% 23% 16–28%
Sense of coherence 21% 18–24% 17% 13–22%
Coping resources 19% 18–21% 20% 17–23%
GI-specific anxiety 16% 14–18% 27% 23–31%
Quality of life 16% 14–18% 27% 23–31%
Anxiety 12% 10–14% 44% 40–50%
GI symptom severity 8% 7–9% 47% 41–50%
Conclusion: For the first time, we show that IBS-related symptoms develop dif-
ferentially over time. GI symptoms had a high likelihood of subsiding over time,
in contrast to depression, sense of coherence, and coping resources. We suggest
more attention needs to be paid to the management of depression, and to provid-
ing tools for better coping resources in IBS patients.
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Introduction: Several studies have reported high prevalence of symptoms compa-
tible with irritable bowel syndrome (IBS) in patients with ulcerative colitis (UC)
in remission. However, previous studies have not excluded mild inflammatory
changes as a cause of these symptoms, and nothing is known about the preva-
lence of symptoms compatible with other functional bowel disorders (FBD) than
IBS in this group of patients and the burden of these symptoms.
Aims & Methods: In a cross-sectional study, patients with UC (n¼ 291) were
divided into active disease or deep remission (a total Mayo score 2, physician´s
global assessment¼ 0, rectal bleeding¼ 0 and an endoscopic subscore¼ 0, with
no relapse during the 3-month period prior to visit). The patients completed the
Rome III FBD module to define presence of symptoms compatible with FBD,
and questionnaires to measure psychological distress (Hospital Anxiety and
Depression Scale; HADS), stress (Perceived stress scale; PSS), GI symptom sever-
ity (GI Symptom Rating Scale; GSRS), somatic symptoms (Patient Health
Questionnaire-15; PHQ-15), disease-specific quality of life (Inflammatory
Bowel Disease Questionnaire; IBDQ), and general fatigue (Multidimensional
Fatigue Inventory; MFI).
Results: Active UC was present in 159 patients (55%). The 132 patients (45%) in
deep remission were assessed by the Rome III diagnostic criteria and 37% ful-
filled criteria for a FBD: 18% IBS (11% IBS-M, 4% IBS-C, 3% IBS-D), 12%
functional bloating, 4% functional diarrhea, and 3% functional constipation.
Additionally, among the UC patients in deep remission who did not meet diag-
nostic criteria for FBD, a substantial proportion reported some subthreshold
symptoms compatible with a functional bowel disorder, and only 18% of patients
with UC in deep remission reported no symptoms compatible with FBD (5one
day/month). Compared with UC patients in deep remission with symptoms meet-
ing diagnostic criteria for other FBDs (functional bloating, functional diarrhea,
functional constipation), or who did not meet diagnostic criteria for a FBD,
patients who fulfilled diagnostic criteria for IBS reported more severe psycholo-
gical distress (p5 0.0001), somatic symptoms (p5 0.0001), and general fatigue
(p¼ 0.004), as well as reduced quality of life (p5 0.0001), and they tended to
have higher levels of perceived stress (p¼ 0.06). None of these factors differed
between patients who met diagnostic criteria for a FBD other than IBS and
patients who did not meet diagnostic criteria for FBD. Age, disease duration,
fecal calprotectin levels or high-sensitive CRP did not differ between the groups.
Overall GI symptom severity (GSRS total score) was highest in patients with
symptoms compatible with IBS (p5 0.0001 vs no FBD and other FBD groups)
and intermediate in patients who fulfilled one of the other FBDs (p5 0.05 vs no
FBD group).
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Conclusion: Symptoms compatible with functional bowel disorders in general,
and not only IBS, are common in patients with UC in deep remission.
However, the overall disease burden seems to be greater in patients with symp-
toms compatible with IBS than with the other FBDs. These observations are of
great importance when managing patients with IBD to avoid escalating anti-
inflammatory treatment, and instead focus on other treatment options to help
these patients to manage their symptoms.
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Introduction: Symptom-based criteria to diagnose irritable bowel syndrome (IBS)
positively perform only modestly. Our aim was to assess whether including other
items from the clinical history and diagnostic workup improves their
performance.
Aims & Methods: We collected complete symptom, colonoscopy, and histology
data from 318 consecutive, unselected adult patients with lower gastrointestinal
(GI) symptoms in secondary care. The reference standard used to define presence
of true IBS was patient-reported lower abdominal pain or discomfort associated
with a change in bowel habit, in the absence of organic GI disease. Sensitivity,
specificity, and positive and negative likelihood ratios (LRs), with 95% confi-
dence intervals, were calculated for Rome III criteria, as well as for modifica-
tions, incorporating nocturnal symptoms, results of simple blood tests
(haemoglobin (Hb) and C-reactive protein (CRP)), measures of somatisation,
and/or affect (hospital anxiety or depression scale (HADS) score).
Results: Sensitivity and specificity of Rome III criteria for identifying IBS was
69.6%, and 82.0% respectively, with positive and negative LRs of 3.87 and 0.37.
Clinically useful enhancements in positive LRs when combining Rome III criteria
with items from the clinical history, and blood tests, are shown in the table.
Conclusion: Incorporating nocturnal symptoms, somatisation, and affect from
the clinical history, and haemoglobin and CRP measurements, enhances perfor-
mance of symptom-based criteria for IBS. Our findings suggest a different
approach to the development of future diagnostic criteria should be used.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP084 HEALTHCARE RESOURCE UTILISATION AMONG PATIENTS
WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA IN
THE EU5
C. Tucker1, J. L. Abel2, R. T. Carson2, N. M. Flores3, R. Liebert3
1Health Economics & Outcomes Research, Allergan plc, Buckinghamshire/United
Kingdom
2Allergan plc, Jersey City/United States of America/NJ
3Kantar Health, New York/United States of America/NY
Contact E-mail Address: Catherine.Tucker@allergan.com
Introduction: Irritable bowel syndrome (IBS) affects an estimated 10–15% of
adults, with the diarrhoea subtype (IBS-D) estimated to account for 30–40%
of cases. IBS is a chronic, unpredictable disorder associated with increased
healthcare-seeking behaviour and significant resource utilisation and costs.
However, information on the economic burden of IBS-D in Europe is limited.
Aims & Methods: The objective of this study was to assess healthcare resource
utilisation associated with IBS-D among a sample of adults in the EU5 (Spain,
France, Italy, Germany, United Kingdom). Respondents were identified from
the 2013 National Health and Wellness Survey, a self-administered, internet-
based survey. Diagnosed IBS-D patients were defined as those respondents
who reported a physician diagnosis of IBS-D; undiagnosed IBS-D patients
included respondents who reported experiencing IBS-D symptoms but did not
self-report a physician diagnosis. Controls included all respondents without IBS
(diagnosed or undiagnosed) or inflammatory bowel disease. IBS-D severity was
evaluated based on a single item assessing disease severity (mild, moderate, or
severe). Healthcare resource utilisation was evaluated based on the number of
patient-reported healthcare provider visits (any healthcare provider, gastroenter-
ologist, or general practitioner [GP]), emergency room (ER) visits, and hospita-
lisations in the past 6 months. Descriptive statistics were conducted to examine
sample characteristics. Bivariate analyses were used to compare resource use by
IBS-D severity. To further assess the burden of IBS-D specifically, multivariable
generalised linear models compared resource use across groups, controlling for
demographic and health characteristics, including age, gender, and
comorbidities.
Results: A total of 58,161 respondents were included (859 diagnosed IBS-D; 370
undiagnosed IBS-D; 56,932 controls). Overall, the mean age was 47 years, and
52.6% of respondents were female. Unadjusted analyses revealed that patients
(diagnosed and undiagnosed) with moderate (n¼ 499) or severe (n¼ 110) IBS-D
had significantly greater healthcare resource utilisation compared with patients
with mild IBS-D (n¼ 620), including more visits to any provider (8.65 and 10.10
vs. 6.22; both p5 0.05), a gastroenterologist (0.22 and 0.35 vs. 0.08; both
p5 0.05), the ER (0.37 and 0.46 vs. 0.19; both p5 0.05), and a greater
number of hospitalisations (0.21 and 0.36 vs. 0.11; both p5 0.05). After control-
ling for demographic and health characteristics, diagnosed IBS-D patients had a
significantly greater mean number of visits to any provider, a gastroenterologist,
a GP, and the ER, compared with both controls and undiagnosed IBS-D patients
(Table).
Conclusion: IBS-D patients utilised significantly greater outpatient healthcare
resources compared with controls, with diagnosed patients using more resources
than those who are undiagnosed. In addition, patients with moderate or severe
IBS-D have the greatest healthcare resource utilisation. The substantial burden
imposed by IBS-D patients on healthcare systems highlights the need for treat-
ments to more effectively treat and manage IBS-D symptoms.
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Sensitivity (95% CI) Specificity (95% CI) Positive LR (95% CI) Negative LR (95% CI)
Rome III Criteria and normal Hb and CRP 49.0% (34.8%–63.4%) 89.2% (83.2%–93.6%) 4.53 (2.67–7.64) 0.57 (0.42–0.73)
Rome III criteria and HADS score 8 47.2% (35.3%–59.4%) 89.1% (84.2%–92.9%) 4.33 (2.76–6.76) 0.59 (0.46–0.72)
Rome III criteria and high somatisation 37.9% (26.2%–50.7%) 94.8% (90.6%–97.5%) 7.27 (3.74–14.2) 0.66 (0.53–0.77)
Rome III criteria, normal Hb and CRP, and HADS score 8 34.0% (20.9%–49.3%) 93.2% (87.9%–96.7%) 5.04 (2.48–10.2) 0.71 (0.55–0.84)
Rome III criteria, normal Hb and CRP, and high somatisation 24.4% (12.4%–40.3%) 96.8% (92.0%–99.1%) 7.56 (2.63–21.7) 0.78 (0.63–0.90)
Rome III criteria, no nocturnal passage of stool, and HADS score 8 22.2% (13.3% –33.6%) 95.4% (91.7%–97.8%) 4.84 (2.33–10.0) 0.82 (0.70–0.91)
Rome III criteria, no nocturnal passage of stool, and high somatisation 18.2% (9.8%–29.6%) 99.0% (96.3%–99.9%) 17.3 (4.45–67.6) 0.83 (0.72–0.90)
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Introduction: Endoscopic submucosal dissection (ESD) has been established as a
standard treatment modality of early gastric cancer (EGC), however, long term
outcomes between ESD and gastrectomy were rarely reported, especially in terms
of ESD criteria.
Aims &Methods: This study aimed to compare long term outcomes between ESD
and gastrectomy, and according to the histopathologic ESD criteria; absolute
criteria (AC), expanded criteria (EC) and beyond expanded criteria (BEC).
Between 2006 and 2012, 925 EGC patients were enrolled; ESD was performed
in 468 patients, and gastrectomy in 457 patients.
Results: Recurrence rate was 1.9% in ESD patients, 0.7% in gastrectomy patients
(p¼ 0.08); 1.0%, 3.1% and 1.4% in AC, EC and BEC groups in ESD patients,
(p¼ 0.062) and 2.0% and 1.4% in the ACþEC and BEC groups in ESD patients
(p¼ 0.069), which were not significantly different between criteria groups. In
concrete, recurrence rate was 1.1% and 0% in AC group of ESD and gastrect-
omy patients, respectively, 3.1% and 1.9% in EC group, and 1.4% and 0% in
BEC group. 394 of 468 (84.2%) ESD patients were within criteria. (ACþEC
group), and 273 of 457 (59.7%) gastrectomy patients were out of ESD criteria
(BEC group).
Conclusion: The recurrence rate was neither significantly different between ESD
and gastrectomy patients, nor was significantly different between three criteria
groups among total patients. Thus, ESD with EC or even BEC might be an
alternative option in EGC patients who refuse gastrectomy or with high opera-
tion risk.
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Introduction: In patients with gastric superficial neoplasms, the probabilities of
success and of adverse events influence the decision process regarding treatment
allocation. These probabilities may be predicted using a priori patients’ and
lesions’ factors. However, the knowledge of risk factors alone is not readily
and completely usable by patients and clinicians in the decision process since it
is difficult to predict the addictive effect of risk factors in the outcome, in a given
patient. Bayesian networks are increasingly used for clinical decision support
since Bayesian statistical methods allow taking into account prior knowledge
when analyzing data and can aid in capturing and reasoning with uncertainty
in medicine[1].
Aims & Methods: The aim of this study was to develop a Bayesian model and a
computerized tool that can be used in clinical practice to predict outcomes after
ESD and aid in the decision-making process. Methods: Data from 245 ESDs
performed in our institution was collected, including pre-resection patient factors
(age, sex, ASA, antithrombotics) and lesion factors (size, localization,
morphology, pre-resection biopsies). The two main endpoints were curative
resection and post-procedural bleeding. We defined curative resection as a resec-
tion meeting the standard or expanded criteria of the Japanese Gastric Cancer
Treatment guidelines. For the analysis and model construction, morphology was
recoded into polypoid (0-Is, 0-Isp, 0-Ip), depressed (0-IIaþc, 0-IIcþa, 0-IIc and
0-III) and non-polypoid non-depressed (0-IIa, 0-IIb, 0-IIaþb). Univariate ana-
lysis was conducted with chi-squared test to identify associations between pre-
treatment factors and the two endpoints, for a significance level of 5%. Logistic
regression and Bayesian networks were then built for each outcome. Stratified
10-fold cross-validation was performed to assess the predictive accuracy and
discriminative power (ROC curves) of the models. Clinical decision support
was then enabled by the definition of risk matrices, direct use of Bayesian infer-
ence software and through the use of an online platform.
Results: In our sample, 85% were curative resections and PPB occurred in 8%. In
the univariate analysis, age 463 (p¼ 0.039), male sex (p¼ 0.027), ASA status
(p¼ 0.008), carcinoma histology (p5 0.001), polypoid or depressed morphology
(p¼ 0.015) and lesion size greater than 20mm (p¼ 0.006) were associated with
non-curative resection, while age470 (p¼ 0.041), ASA status (p¼ 0.017), antith-
rombotic medication (p5 0.001) and lesion size greater than 420mm
(p¼ 0.026) were associated with PPB. Logistic regression and Bayesian models
presented AUCs above 80% (in-sample) and 75% (cross-validation) on both
outcomes. Lesions with cancer at biopsies, 420mm, proximal and polypoid
are more prone to non-curative resection (table 1). Risk matrices for PPB were
also defined yielding a posteriori probabilities of PPB 55% in lesions 520mm
in the absence of antithrombotic medications while the risk of PPB increased in
greater lesions and in the presence of antithrombotic medications. The Bayesian
network can be interactively used in clinical practice to estimate individual prob-
ability of outcomes after ESD. Table 1 - Risk (a posteriori probabilities) matrix
for curative resection based on morphology, localization, size and pre-resection
histology, using a Bayesian model (cross-validation AUC¼ 78%,
95%CI¼ [75%,81%]).
Size
520mm
Size
520mm
Size
520mm
Size
20mm
Size
20mm
Size
20mm
Morphology Local LGD HGD IMC LGD HGD IMC
Polypoid
(0-Is, 0-Ip, 0-Isp)
Middle 85 74 42 66 49 20
Upper 91 83 56 77 62 30
Lower 93 86 61 81 67 35
Depressed
(0-IIc, 0-IIaþc, 0-IIcþa, III)
Middle 93 87 64 83 70 38
Upper 96 92 75 89 80 51
Lower 97 94 79 91 83 57
Non-polypoid, non-depressed
(0-IIa, 0-IIaþb, 0-IIb)
Middle 97 94 79 91 83 57
Upper 98 96 87 95 90 69
Lower 98 97 89 96 91 74
LGD - Low-grade dysplasia; HGD - High-grade dysplasia; IMC - intramucosal
carcinoma
Conclusion: The derived models presented good discriminative power in the pre-
diction of outcomes. Bayesian models and risk matrices can be used to predict
individualized probabilities, which can improve the information transmitted to
patient regarding a posteriori probabilities and can aid in the decision process
regarding allocation for endoscopic or surgical treatment. Additionally, a poster-
iori probabilities of adverse events can guide management after gastric ESD,
namely regarding the timing of discharge from hospital.
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Table
Adjusted mean,
number in past 6 months (SE)
Diagnosed IBS-D
(n¼ 859)
Undiagnosed
IBS-D (n¼ 370)
Controls
(n¼ 56,932)
p-value: Diagnosed
vs. controls
p-value: Diagnosed
vs. undiagnosed
p-value:
Undiagnosed vs. controls
Any provider visits 7.23 (0.31) 5.17 (0.35) 4.14 (0.02) 50.001 50.001 0.001
Gastroenterologist visits 0.19 (0.02) 0.01 (0.01) 0.03 (0) 50.001 50.001 0.146
General practitioner visits 2.69 (0.12) 2.06 (0.15) 1.70 (0.01) 50.001 0.001 0.007
Emergency room visits 0.27 (0.04) 0.12 (0.03) 0.17 (0) 0.002 0.012 0.264
Hospitalisations 0.14 (0.03) 0.08 (0.03) 0.11 (0) 0.099 0.148 0.430
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Introduction: Endoscopic submucosal dissection (ESD) is an effective treatment
for gastric superficial neoplasms, being curative in 80–85%. Identification of risk
factors for a non-curative resection is of paramount importance to improve
patient selection. Furthermore, it is important to evaluate the management
after an unsuccessful treatment in order to assess the clinical outcomes of each
option (careful surveillance or surgical treatment). Moreover, patients with an
early neoplastic lesion are at risk of developing metachronous lesions and endo-
scopic surveillance will still be needed after endoscopic resection. The identifica-
tion of risk factors for metachronous development is also important to adequate
surveillance.
Aims & Methods: The aims of this study were to identify risk factors for non-
curative resection and metachronous development and to evaluate management
and outcomes after non-curative resection. Methods: Single centre assessment of
a cohort of consecutive patients submitted to gastric ESD, with a minimum
follow-up of 18 months. The Japanese Gastric Cancer Treatment Guidelines
criteria were used in clinical practice; resections were also classified according
with the recently published European Society of Gastrointestinal Endoscopy
guidelines. Univariate analysis (independent samples t-test, Mann-Whitney U
test or chi-square test as appropriate) and multivariate logistic regression were
performed to identify risk factors. Odds ratio (OR) were computed along with
95% confidence intervals (CI). Survival was analyzed with Kaplan-Meyer curves
and log-rank test. Significance level was defined as p5 0.05.
Results: ESD was performed in 194 lesions (164 patients) between 2005–2014.
The median follow-up time was 40 months. En-bloc and complete resection rates
were 95.3% and 93.8%, respectively. Overall adverse events occurred in 13%.
Male sex, tumor size 20mm, longer procedural time and more advanced histol-
ogy in pre-resection biopsies were associated with non-curative resection
(p5 0.05) but only intramucosal carcinoma on pre-resection biopsies was iden-
tified as a significant risk factor on multivariate analysis (adjusted OR 3.04, 95%
CI 1.02–9.06). Histological upgrade (from low-grade dysplasia to high-grade
dysplasia or from high-grade dysplasia to carcinoma) occurred in 49.5% of the
cases. Metachronous lesions occurred in 18.4% and the incidence rate was 4.7
lesions/100 person-years. The median time for metachronous detection was 24
months (interquartile range 9–50.25 months). Older age at diagnosis was identi-
fied as the only predictor of metachronous development in logistic regression
(OR10 years 1.68, 95% CI 1.03–2.74). Overall survival was 94.5% and 89.5% at
1 and 3 years, respectively; disease-specific survival was 99.4%, with only one
patient dying of gastric cancer. Survival was significantly higher in patients with
curative resections (log-rank 4.538, p¼ 0.033). In the non-curative resection
group, patients submitted to surgery were significantly younger (mean age
66.7 9.4 versus 73.6 7.5 in the follow-up group, p¼ 0.037) and were less fre-
quently classified as ASA III/IV (23.1% versus 31.3%, p¼ 0.62). However, sur-
vival was not significantly different in the two groups (log-rank 0.009, p¼ 0.929).
In gastrectomy specimens, there was no residual neoplasia in 75%. Comparing
survival according to ESGE criteria, survival in patients with high-risk resection
was significantly worse than in patients with low-risk resection (log rank 7.539,
p¼ 0.006), while no significant differences were found in the survival of patients
with low and local-risk resection (log rank 0.133, p¼ 0.715).
Conclusion: The identified risk factors for non-curative resection help to improve
patient selection for endoscopic resection and also patient information regarding
probability of success. Metachronous incidence is significant, being older patients
at increased risk for its development. In the non-curative resection group, survi-
val did not differ between patients allocated to surveillance and those submitted
to gastrectomy. An individualized decision is adequate after a non-curative resec-
tion and surveillance seems to be an adequate option in selected cases.
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Introduction: In Japan, endoscopic submucosal dissection (ESD) has been a
standard option as minimum invasive treatment for early gastric cancer
(EGC). According to the current Japanese guideline, radical surgery is recom-
mended in patients who do not meet the curative criteria for ESD. Although the
concept of ‘‘No-touch isolation techniques’’ might prevent the spread of cancer
cells in colorectal and pancreatic cancer, in the influence of submucosal operation
during ESD for gastric cancer is unclear.
Aims & Methods: We aimed to reveal whether metastatic potential increases in
patients who underwent radical surgery after having failed to meet the curative
criteria. Among 15,838 patients undergoing ESD for EGC at 19 institutions in
Japan between 2000 and 2011, we enrolled consecutive patients who did not meet
the current curative criteria for ESD and additionally underwent radical surgery.
The exclusion criteria were patients merely positive for horizontal margin and
those with a follow-up period of53 years. The overall survival (OS) and disease-
specific survival (DSS) were calculated according to the Kaplan-Meier method
and analyzed by the log-rank test. In addition, the risk factors for recurrence
were calculated using Cox proportional hazards model. The estimated factors
were location (lower third or the other), tumor size (430 or 30 mm), tumor
depth (submucosal invasion 500 mm (SM2) or shallower than SM2), histo-
pathological type (undifferentiated or differentiated), lymphatic invasion, vascu-
lar invasion, ulceration (scar), positive vertical margin and lymph node
metastasis (LNM). In this study, recurrence was defined as the metastatic one.
Results: A total of 1,064 patients were analyzed with a median follow-up period
of 67 months. LNM was found in 89 patients (8.4%) and 14 patients (1.3%)
developed recurrence. All recurrent sites at the time of initial diagnosis were
distant lymph node or other organs, no regional lymph node. Multivariate ana-
lysis showed that the independent risk factors for recurrence were LNM (hazard
ratio [95% confidence interval]¼ 28.2 [7.12–112], p5 0.001) and vascular inva-
sion (4.37 [1.25–15.3], p¼ 0.021). The 3-year and 5-year OSs were 96.8% and
92.6%, respectively, and the 3-year and 5-year DSSs were 99.4% and 98.8%,
respectively.
Conclusion: This multicenter study with the largest cohort revealed that addi-
tional radical surgery for patients who do not meet the current curative criteria
for ESD of EGC has a low recurrence rate and excellent prognosis. Submucosal
operation during ESD for EGC does not make risk of LNM and prognosis
worse.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP089 ENDOSCOPIC FULL-THICKNESS RESECTION WITH DEFECT
CLOSURE IN THE STOMACH BY USING A NOVEL GRASP-AND-
LOOP (GAL) CLOSURE METHOD (WITH VIDEOS)
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Introduction: Endoscopic full-thickness resection (EFTR) is a minimally invasive
method for en bloc resection of GI lesions originating from the muscularis pro-
pria layer. Successful closure of the wall defect is a critical step.
Aims &Methods: The aim of this study was to evaluate the feasibility and efficacy
of a novel and simplified endoscopic Grasp-and-Loop (GAL) closure method
using an endoloop assistant with a grasping forceps for defect closure. From
January 2015 to March 2016, 13 patients with SMTs originating from the mus-
cularis propria layer who underwent EFTR were enrolled in this study. After
successful tumor resection, an endoloop was anchored onto the circumferential
margin of the gastric defect with a grasping forceps assistant and tightened gently
(with videos). Patient characteristics, tumor size, en bloc resection, and post-
operative complications were evaluated.
Results: Of the 13 lesions in the stomach, 2 were located in the greater curvature
of mid-upper body, 11 were located in the fundus. The endoscopic GAL closure
method was successfully performed after EFTR in all 13 patients without laparo-
scopic assistance. The mean procedure time was 43.5 min (range 20–80 min),
while the GAL closure procedure took a mean of 9.4 min (range 3–18 min). The
mean resected lesion size was 1.5 cm (range 0.5–3.5 cm). Pathological diagnosis
of these lesions were 11 gastrointestinal stromal tumors (GISTs) and 2 leiomyo-
mas. No major adverse events occurred during or after the procedure. All
patients were discharged after a mean time of 2.4 days (range 1–4 days). No
residual lesion or tumor recurrence was found during the follow-up period
(median, 5 months; range, 1–15 months).
Conclusion: The endoscopic Grasp-and-Loop closure method is feasible, effective
and safe for closing the gastric defect after EFTR in patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopic full-thickness resection (EFTR) and laparoscopic and
endoscopic cooperative surgery (LECS) are useful procedures to avoid excessive
resection of the gastric wall and postoperative complications, such as stenosis or
deformity, because the location of tumor can be confirmed endoscopically to
determine an appropriate resection line. However, these methods have some
disadvantages, such as loss of endoscopic view caused by collapse of the stomach
and peritoneal infection or tumor dissemination by outflow of gastric juice. Thus,
we developed new technique of EFTR, we called sealed EFTR, for sealing the
serosa of stomach with silicon sheet to prevent collapse of the stomach and
outflow of gastric juice.
Aims & Methods: We introduce our sealed EFTR technique and describe a
clinical study of EFTR in patients with submucosal invasive gastric cancer
who were diagnosed as negative for lymph node metastasis by laparoscopic
sentinel lymph node biopsy. Patients: Between December 2012 and April 2016,
9 patients with clinical T1 gastric cancer, who were outside of indication of ESD,
were enrolled in this study. Before surgery, written informed consent was
obtained from each patient. All procedures were conducted in accordance with
the ethical standards of the institution’s Committee on Human Experimentation.
Laparoscopic sentinel node biopsy. On the day before surgery, indocyanine green
solution (5mg/ml) is injected at a volume of 0.2ml into each of 4 points in the
submucosal layer around the lesion. Using an infrared fluorescence laparoscope,
sentinel nodes emitting fluorescence are identified. The lymphatic basins contain-
ing the bright nodes are dissected laparoscopically and subjected to rapid intrao-
perative pathological examination. When the sentinel lymph nodes are negative
for malignancy, EFTR is performed. On the other hand, when they are positive
for tumor cells, standard gastrectomy with D2 lymphadenectomy is performed.
Sealed EFTR At first, circumferential mucosal incision is performed in the same
manner as ESD. Continuously, silicon sheet and polyglycolic acid (PGA) sheet
are put on the serosa of the lesion and pasted with fibrinogen, thrombin solution.
Then, full-thickness incision is performed by Hook knife and/or IT knife. The
tumor, silicon sheet and PGA sheet are removed through oral cavity. Finally, the
defect of gastric wall is closed laparoscopically using hand-sewn sutures.
Results: Seven patients (78%) were negative for sentinel node metastasis, and
were performed EFTR. Four patients who were enrolled after 2014 were per-
formed EFTR using serosa sealing method (sealed EFTR). In sealed EFTR, it
was possible to incise all-layer of the stomach with keeping good endoscopic view
without collapse of the stomach by covering the serosa using silicon sheet and
PGA sheet. Postoperative diet intake was almost the same as before surgery. All
patients were preserved QOL without postoperative complications such as small
stomach syndrome or early satiety. During follow-up of 1 to 4 years, all patients
except one, who died of other cancer, are alive without recurrence or metastasis.
Conclusion: Serosa sealing method (Sealed EFTR) was considered to be useful
technique as one of the minimally invasive surgeries for lymph node negative
gastric cancer, because it was possible to incise all-layer of the stomach while
confirming the incision line from the inside of the stomach without exposure the
tumor to the abdominal cavity.
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OP091 CALORIC AND NON-CALORIC ARTIFICIAL SWEETENERS
HAVE DISSOCIABLE EFFECTS ON ANTRAL MOTILITY AND
PLASMA MOTILIN LEVELS IN HEALTHY VOLUNTEERS
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Introduction: Activation of gastrointestinal (GI) sweet taste receptors by caloric
sweeteners such as glucose or fructose induces the secretion of GI peptides to
regulate food intake. The effect of non-caloric sweeteners on GI peptide secretion
and satiation is controversial. We have recently shown that motilin-induced
gastric phase III contractions of the migrating motor complex (MMC) signal
hunger feelings. The mechanism underlying interruption of the MMC by specific
sweet tastants has not yet been studied. It is conceivable that this requires sweet
taste receptor activation and accompanying changes in the release of GI peptides.
Aims & Methods: The aim was to determine the effect of caloric and non-caloric
sweeteners on GI motility and GI peptide secretion as well as on hunger feelings
in healthy volunteers. The study was a randomized, double-blind, cross-over
trial. 12 healthy volunteers were included. Participants underwent gastroduode-
nal manometry recording for the occurrence of one phase III contraction fol-
lowed by the intragastric administration of 250mL tap water (control), or
equisweet caloric (50g glucose, 25g fructose) and non-caloric sweeteners
(220mg acesulfame-K (ace-K)) dissolved in 250mL tap water. Measurement
was continued until at least one subsequent phase III occurred. Recording of
antroduodenal pressures was performed using a Manoscan high resolution
manometry catheter. Blood samples were collected for determination of plasma
glucose and motilin concentrations. Visual analogue scales were used to rate
hunger and satiety feelings. Data were analyzed using mixed model analysis.
Post-hoc analyses were corrected using Bonferroni.
Results: Antral motility was significantly reduced in response to the caloric sweet-
eners (glucose: p¼ 0.004 and fructose: p¼ 0.010, respectively); antral motility
after ace-K administration did not differ significantly from placebo. Glucose
induced a significant reduction in antral motility compared to ace-K
(p¼ 0.010). In contrast, duodenal motility was significantly reduced by both
the caloric as well as non-caloric sweeteners compared to placebo (glucose:
p¼ 0.043, fructose: p¼ 0.006 and ace-K: p¼ 0.032, respectively). The change
over time of plasma glucose concentrations was significantly increased after
glucose and fructose compared to placebo administration (p¼ 0.026 and
p¼ 0.002, respectively); ace-K had no effect on plasma glucose concentrations.
The change over time of plasma motilin concentrations was significantly
decreased after fructose (p¼ 0.001) administration; ace-K administration
induced no difference compared to placebo. Plasma motilin levels were signifi-
cantly decreased after the caloric sweeteners compared to the non-caloric sweet-
ener ace-K (glucose: p¼ 0.005 and fructose: p¼ 0.008, respectively). The time
course of satiation scores differed significantly between glucose and ace-K
(p¼ 0.041) with a slower decrease in satiation scores after glucose compared to
ace-K administration.
Conclusion: Caloric and non-caloric sweeteners have dissociable effects on antral
but not duodenal motility; the reduction in antral motility after glucose and
fructose administration parallels changes in motilin secretion. These findings
provide an important contribution to the current discussion about possible phy-
siological effects of non-caloric sweeteners on appetite metabolism.
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Introduction: With the increasing prevalence of obesity and its possible associa-
tion with increasing sucrose consumption, non-nutritive sweeteners are gaining
popularity. Artificial sweeteners might have adverse effects and alternative solu-
tions are sought. Polyols such as xylitol and erythritol have been known for a
long time and their beneficial effects on caries prevention and potential health
benefits in diabetic patients have been demonstrated in several studies. Incretins
such as glucagon-like peptide-1 (GLP-1) and gastrointestinal peptides such as
cholecystokinin (CCK) are released from the gut in response to food intake,
promote satiation, reduce gastric emptying (GE) and modulate glucose home-
ostasis. While glucose ingestion stimulates sweet taste receptors in the gut, and
leads to incretin and gastrointestinal peptide release, the effect of xylitol and
erythritol has not been studied.
Aims & Methods: The aim was to study gastrointestinal peptide and incretin
release as well as effects on gastric emptying in response to xylitol and erythritol
intake. The study was conducted as a randomized, double-blind, parallel-group
trial. A total of 10 healthy lean and 10 non-diabetic obese (BMI 4 30) partici-
pants were included. Subjects received intragastric equisweet loads of 50 g xylitol
or 75 g erythritol dissolved in 300 mL tap water; 75 g glucose solution and 300
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mL tap water were control treatments. Solutions were enriched with 13C-sodium
acetate (for determination of gastric emptying). We measured plasma GLP-1 and
CCK, as well as plasma insulin and glucose levels. GE was measured by a 13C-
sodium acetate breath test.
Results: i) xylitol and erythritol lead to a marked increase in CCK (p5 0.001,
respectively) and GLP-1 (p¼ 0.001 and p5 0.001, respectively); ii) plasma insu-
lin and glucose are not (erythritol) or minimally (xylitol) affected; iii) xylitol and
erythritol induce a significant retardation in gastric emptying rates (p5 0.001,
respectively).
Conclusion: There is emerging evidence to indicate a beneficial role for dietary
polyols: erythritol and xylitol are low in calories, have no or only a small effect on
plasma glucose and insulin release, yet stimulate gastrointestinal satiation pep-
tides. A potential therapeutic application requires further studies.
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1 ANALOG, ON HUNGER AND SATIETY, INTERDIGESTIVE
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EMPTYING IN HEALTHY VOLUNTEERS
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Introduction: Liraglutide (LG) was recently approved for the treatment of obe-
sity. However, the mechanism by which it induces weight loss is incompletely
understood and involvement of altered gastrointestinal motility has been impli-
cated. Recent studies have implicated gastric phase III of the interdigestive
migrating motor complex (MMC), gastric accommodation (GA) and gastric
emptying (GE) in the control of hunger and food intake.
Aims & Methods: The aim of this study was to investigate the effect of LG on
MMC, GA, GE and hunger or satiation in healthy volunteers (HVs). The study
was an open-label, crossover trial conducted in 10 lean HVs. Liraglutide
(Victoza, Novo Nordisk, Belgium, 0.6 mg) was administered subcutaneously
14 hours before the start of the study protocol. No administration was done in
the placebo arm. The study consisted of protocol 1 (MMC) and protocol 2 (GA/
GE); in both protocols a high-resolution manometry probe was advanced via the
nose to the duodenum. Protocol 1: Gastroduodenal motility was registered for
the duration of 1 MMC cycle. Antral and duodenal motility index (MI) were
calculated as (number of contractions*average amplitude contractions*average
duration contractions)/5min. Average MI was calculated by averaging 6 conse-
cutive antral or duodenal channels. Occurrence of antral or duodenal phase III
contractions was evaluated. Protocol 2: After a stabilization period, HVs ingested
a liquid test meal (200 ml, 300 kcal; 89% carbohydrate, 11% protein) labeled
with 100 mg 13C-sodium octanoate. GA was measured as the intragastric pres-
sure (IGP) drop in the first 30 min after the drink and was calculated as the
average pressure over 5 channels in the fundus compared to baseline 5 minutes
before the drink. GE rates were determined from breath test samples collected
before the meal and at 15-min intervals for 4 hours. Occurrence of antral or
duodenal phases III within the 4 hours was evaluated. In both protocols feelings
of hunger, satiation and epigastric symptoms were measured using 100 mm visual
analogue scales (VAS). All data are expressed as meanSEM. Outcomes were
analyzed using mix-model analysis (MI, IGP, symptoms), paired t-test (half GE
time (t1/2) or chi square test (phase III occurrence and origin). p5 0.05 was
considered significant
Results: LG was well tolerated by all HVs[AR1]. Protocol 1: LG significantly
reduced the number of phase III contractions with a gastric origin from 65%
(placebo) to 5% (LG) (p¼ 0.0001). The antral MI of both first and second phase
III contractions was significantly lower after LG (p¼ 0.01 and 0.002 respec-
tively). Similarly, the duodenal MI was also lower after LG for both phases III
(p¼ 0.007 and 0.005 respectively). Protocol 2: LG administration did not affect
the IGP drop but it significantly delayed the GEt1/2 (p¼ 0.005) (Table). In the
control condition all volunteers had a phase III within 4 hours after the meal.
After LG this number decreased to 70 [AR2]% (ns). LG administration comple-
tely switched the origin of phase III contractions with a gastric origin from 90%
(control) to 0% (LG) (p¼ 0.0004). Antral and duodenal motility were signifi-
cantly lower in the LG arm compared to control (p¼ 0.002 and p¼ 0.05, respec-
tively). Hunger or satiation ratings [JT3] were not affected by LG treatment in
both protocols.
Parameter placebo LG p value
Average IGP drop 30 min
from the drink (mmHg)
7.7 1 6.6 0.6 0.6
GE t1/2 (min) 69.6 5.1 119.4 18.4 0.005
Conclusion: Acutely administered LG decreases both antral and duodenal moti-
lity during the interdigestive state and delays gastric emptying after a standard
liquid meal. However, at this dose it does not seem to influence gastric accom-
modation or hunger and satiation feelings.
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OP094 INFLAMMATORY AND ANTIOXIDANT RESPONSE
FOLLOWING STANDARD MEAL CONSUMPTION IN PATIENTS
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Introduction: The Rome III criteria recognize two distinct subgroups of func-
tional dyspepsia (FD): the postprandial distress syndrome (PDS) and the epigas-
tric pain syndrome (EPS). The underlying pathophysiological mechanisms of
these syndromes are partially known. Recently, the worsening of hypersensitivity
in the postprandial period was shown in PDS (1–2) and an impairment of gastric
compliance was detected in EPD (2). Moreover, in FD patients an altered per-
meability of intestinal mucosa, an altered expression of cell adhesion proteins and
the presence of mucosal infiltration of mast cells and eosinophils were shown (1),
suggesting a role for inflammation and permeability alterations in the pathogen-
esis of this condition.
Aims & Methods: Our aim was the evaluation of postprandial modification of
both inflammatory and antioxidant markers in a group of PDS patients in com-
parison with healthy volunteers (HV). 14 consecutive, non-smoking patients (9
females, mean age 42.8 11.2 yrs) affected by FD, subtype PDS, according to
Rome III criteria and a group of 13 HV comparable for age and gender were
enrolled. Chronic inflammatory and autoimmune diseases were excluded. Serum
levels of inflammatory cytokines (IL-1, IL-6 and TNF), insulin, glucose, uric
acid (UA) and lipopolysaccharide (LPS) were evaluated at fast and every 30
minutes after the ingestion of a standard meal (proteins 15.7%, lipids 28.3%,
carbohydrates 56%) for a 4-hour period. The presence and severity of symptoms
(abdominal pain, abdominal distension, bloating, flatulence, nausea, vomiting,
belching, heartburn, regurgitation, diarrhea, headache) were evaluated while
fasting and in the postprandial period by VAL.
Results: Mean fasting values of TNF, IL-1 and insulin were significantly higher
in PDS patients (1.62 1.21, 0.37 0.24, 15.4 10.24, respectively) in compar-
ison with HV (0.26 0.15, 0.13 0.11 and 7.45 6.08, respectively; p5 0.05 for
all). Similarly, postprandial values of TNF, IL-1 and insulin were significantly
higher in PDS (2.65 1.76, 0.64 0.59, 30.39 12.60, respectively) than in HV
(0.23 0.17, 0.19 0.11, 21.04 7.02 respectively) (p5 0.05 for all). In FD but
not in HV, mean postprandial levels of TNF were significantly higher than
fasting values (p5 0.05). As far as the antioxidant system is concerned, mean
postprandial values of UA were significantly higher in PDS (52.94 19.16) than
in HV (34.46 5.61) (p5 0.05). Serum levels of LPS and IL-6 did not show
significant differences between PDS and HV. As expected, only in PDS and
not in HV was there a significant increase of postprandial symptoms. Finally,
the severity of symptoms was significantly correlated with the postprandial serum
levels of both inflammatory and antioxidant markers.
Conclusion: Our results show that in PDS the ingestion of a standard meal
induces an inflammatory response and a secondary activation of the endogenous
antioxidant system, strictly correlated with symptom occurrence. Further studies
are needed to confirm the pathogenetic role of postprandial inflammatory
response in a condition characterized by low-grade inflammatory alterations.
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Introduction: Rumination syndrome and supra-gastric belching are two condi-
tions with limited treatment options. Baclofen, a -aminobutyric acid agonist,
increases lower oesophageal sphincter (LOS) pressure. We previously demon-
strated, in an open-label study, that baclofen reduces pressure flow events in
patients with clinically suspected rumination and/or supra-gastric belching.
Aims & Methods: To study the effect of baclofen in a placebo-controlled, double-
blind, cross-over study in patients with clinically suspected rumination and/or
supra-gastric belching. Consecutive patients with clinically suspected rumination
and/or supra-gastric belching were randomized in a double-blind fashion to
receive baclofen (10mg, 3 t.i.d) or placebo for 2 weeks with cross-over to the
alternative intervention after 1 week wash-out. At the end of each treatment
period, patients underwent a solid state high resolution impedance manometry
(HRiM) measurement. After positioning of the probe, 10 wet swallows were
performed to assess oesophageal function. After 30 min recording, patients
received a 1000 kcal solid meal and recordings continued for 1 hour. Patients
filled out daily diaries, questionnaires at the end of each treatment period (i.e.
overall treatment evaluation (OTE) on -3 to þ3 scale) and registered symptoms
during the HRiM using an event marker. The number of symptoms registered
and number and type of flow events during the HRiM were compared between
placebo and baclofen.
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Results: We enrolled 20 patients (mean age 42y (range 18–61), 13f). Lower oeso-
phageal sphincter (LOS) pressure was significantly higher in the baclofen treat-
ment arm compared to the placebo arm (17.81.4 vs. 12.8 1.4mmHg,
p¼ 0.001). The number of transient LOS relaxations was lower (6 1 vs. 8 2,
p¼ 0.05) and the integrated relaxation pressure was higher (11.8 1.0 vs.
8.1 1.2mmHg, p¼ 0.003) after baclofen compared to placebo. The number
of reflux events did not differ between both arms (4 1 vs. 3 1, NS). The
number of rumination episodes was significantly lower in the baclofen treatment
arm (15 3 vs. 9 2, p¼ 0.018), but the number of supra-gastric belching epi-
sodes was similar in both treatment groups (43 18 vs. 65 32, NS). In the
placebo arm 60% of rumination episodes were classified as primary rumination,
20% as secondary rumination and 20% as supra-gastric belch associated rumi-
nation. In the baclofen arm, distribution was similar, with 66% being primary
rumination, 11% secondary rumination and 22% supra-gastric belch associated
rumination. There was no difference in straining episodes between placebo and
baclofen arm, but the percentage of straining episodes associated with rumina-
tion was significantly lower in the baclofen arm (14.64 3.84 vs. 31.29 5.96,
p¼ 0.0005). The number of postprandial regurgitation symptoms marked by the
patients tended to be lower in the baclofen treatment arm (p¼ 0.09). OTE was
superior after baclofen compared to placebo (1 (0–2) vs. 0 (1–0), p¼ 0.04).
Conclusion: This study confirms that baclofen is an effective treatment option for
patients with rumination syndrome, probably through its effect on LOS pressure.
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Introduction: Open trials have suggested that GES could be effective for the relief
of refractory vomiting, associated or not with delayed gastric emptying (GE).
But, short randomized trials carried out in gastroparetic patients led to negative
results. Our aim was to perform a large multicenter randomized double-blind
controlled trial in patients with refractory vomiting associated or not with gas-
troparesis, to confirm or not the efficacy of GES.
Aims & Methods: Any patient, aged 18 to 70, with chronic (412 months) refrac-
tory vomiting, either idiopathic or associated with a type 1 or 2 diabetes mellitus
or possurgical, was eligible. After a screening period of 4 months to assess symp-
toms prospectively, patients were implanted with an ENTERRA (R) device with
2 electrodes sewn in the antrum. During the first month post surgery, the device
was not activated. Then each subject was randomized in a masked fashion to one
of 2 treatment arms: 4 months ‘‘ON’’ then 4 months ‘‘OFF’’ or 4 months ‘‘OFF’’
then 4 months ‘‘OFF’’. During the cross-over phase, both patients and physicians
were blinded to the stimulation status. When the device was ‘‘ON’’, stimulation
parameters were 14 Hz, 5mA, pulses of 330 msec. Two follow-up visits were
scheduled at 5 and 9 months after implantation. The primary end-points were
the vomiting score ranging from 0 (daily vomiting) to 4 (no vomiting) and the
QoL assessed by the GIQLI score.
Results: In 19 centers, 172 patients (women:66%), 45þ/12 years old, with
symptoms lasting from 5.1þ/5.9 years, associated with gastroparesis in 133,
were implanted. Among the 172 patients, 149 patients were evaluated at 9
months. Vomiting score was significantly better during the ‘‘ON’’ than during
the ‘‘OFF’’ period (median score: 2 vs 1, p5 0.001), without any carry-over
effect. The greater symptomatic benefit during the ‘‘ON’’ period was observed
both in diabetic and non diabetic patients and was more important in case of
gastroparesis (p5 0.009) than when GE was normal (p:0.05). GE was not sig-
nificantly faster during the ‘‘ON’’ period. The greater symptomatic effect with an
effective GES, was not associated with a better QoL.
Conclusion: An effective GES reduced significantly the frequency of refractory
vomiting both in diabetic and non diabetic patients.
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Introduction: Despite numerous efforts to develop novel therapies, pancreatic
ductal adenocarcinoma (PDAC) has remained one of the most devastating and
lethal malignancies worldwide. B-cell chronic lymphatic leukemia protein 3 (Bcl-
3) is an atypical member of the ankyrin repeat-containing IB family of NF-B
inhibitors that was first identified as a candidate proto-oncogene in chronic
lymphocytic leukemia. Accumulating evidence reveals that elevated Bcl-3 expres-
sion results in increased cell proliferation, cell survival and malignant potential.
However, the functional role of Bcl-3 in pancreatic cancer has not been eluci-
dated so far. In this study, we aim to identify whether Bcl-3 impacts pancreatic
cancer development and progression in humans and mice.
Aims & Methods: PDAC tissues and cell lines obtained from humans and a
KrasG12D mouse model (KC) of pancreatic cancer were investigated for Bcl-3
expression. The overall survival of human PDACs expressing high and low levels
of Bcl-3 was compared. Further, Bcl-3 was deleted in a KrasG12D mouse model
(KCB) and tumor incidence, metastases as well as proliferation, and apoptosis in
tumor tissues and primary tumor cells of KC and KCB mice were investigated.
Pancreatic Intraepithelial Neoplasia (PanIN) in KC and KCB mice at 13 and 24
weeks was analyzed.
Results: We show that Bcl-3 is highly expressed in human PDACs and in a KC
mouse model of pancreatic cancer, correlating with prognosis and overall survi-
val. Bcl-3 promotes cell growth and cell survival in vivo and in vitro. Further,
Bcl-3 leads to acceleration in PanIN progression, tumor development and metas-
tases in a KC mouse model of pancreatic cancer.
Conclusion: In summary, our data provide the first insights into the function of
Bcl-3 in pancreatic cancer, and indicate that Bcl-3 has an important pro-tumori-
genic role in pancreatic cancer development and progression.
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Introduction: Pancreatic cancer is the deadliest tumor type with less than 5%
survival rate, characterized by the presence of abundant stroma. Pancreatic stel-
late cells (PSCs) are the main precursor of myofibroblasts (cancer-associated
fibroblasts; CAFs) in tumor stroma and therefore become key target in pancrea-
tic tumor stroma (1). CAFs secrete growth factors, exosomes and extracellular
matrix (ECM) and thereby aggravate tumor growth and metastasis (2). This is of
paramount importance to find out new targets in stromal myofibroblasts which
could be used for developing novel prognostic, diagnostic and therapeutic
strategies.
Aims & Methods: In this study, we investigated integrin 5 (ITGA5), a receptor
for the ECM protein fibronectin, for its prognostic and therapeutic significance
in pancreatic tumor stroma. The ITGA5 expression was investigated using
immunohistochemical staining on tissue microarray consist of 137 patient sam-
ples of pancreatic tumors. In vivo, Panc-1 and PSCs were co-injected subcuta-
neously into the flank of SCID mice and investigated the expression of ITGA5
versus Panc-1 tumor alone. To elucidate the role of ITGA5, we knocked down
the expression of ITGA5 in PSCs using shRNA-ITGA5. We investigated the
phenotypic changes in ITGA5-KD PSCs after TGFb activation, using immunos-
tainings, quantitative PCR and RT2 profiler human fibrosis array. We also
examined the paracrine effect of TGF-b activated ITGA5-KD PSCs on the pro-
liferation of pancreatic tumor cells (Panc-1).
Results: In human patient tumor samples, a total of 85% and 66% of patients
were positive for stromal -SMA and ITGA5, respectively and well co-localized,
shown with double immunostaining. The ITGA5 expression was positively cor-
related with -SMA in 72% patients. Overall, clinical data analysis reveals that
the overexpression of ITGA5 (log-rank p¼ 0.022) and -SMA (log-rank
p¼ 0.006) are linked to significant decreased overall survival. In vivo, in mice
co-injected with Panc-1 and PSCs showed a significant increase of tumor growth
and a higher ITGA5 expression compared to Panc-1 tumors. Next, we studied
the effect of ITGA5 knockdown in PSCs on their phenotypic characteristics.
Knockdown (60%) of ITGA5 led to a dramatic reduction of several ECM mole-
cules and integrin receptors, shown with RT2 human profiler array. ITGA5-KD
PSCs had morphological changes, as they became flattened and lost FAK, Rac,
Cdc4 signaling, indicating the loss of lamelopodia and filopodia formation.
Furthermore, functional assays showed that ITGA5-KD PSCs had a substantial
decrease in cell adhesion, migration (wound healing assay), proliferation and 3D
spheroid formation compared to control shRNA-PSCs. Also, knockdown of
ITGA5 abolished the tumor cell proliferation induced by TGF-b activated
PSCs. These data indicated that ITGA5 induces differentiation and phenotypic
behavior of PSCs as well as PSC-induced paracrine effects on tumor cells.
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Conclusion: In conclusion, the present study reveals ITGA5 as a novel prognostic
and therapeutic target in pancreatic tumor stroma. These data make a strong
base to utilize this target for developing novel diagnostic and therapeutic state-
gies against pancreatic tumor.
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Introduction: Transforming growth factor (TGF)-b-induced epithelial-mesenchy-
mal transition (EMT) is a trigger of invasion and metastasis in pancreatic cancer.
Although long non-coding RNAs (lncRNAs), which are defined as non-coding
RNAs (ncRNAs) more than 200 nucleotides in length, have been implicated in
disease pathogenesis, their contributions to pancreatic cancer are not well under-
stood. Recently, the inter-relationship between two classes of ncRNA,
microRNAs (miRNAs) and lncRNAs, has been reported to contribute to the
epigenetic regulation of gene expression in several cancers.
Aims & Methods: Our aims were to investigate the involvement and functional
roles of TGF-b induced lncRNA during EMT and reveal contributions of the
inter-relationship between the TGF-b induced lncRNA and miRNA to the reg-
ulatory mechanisms of EMT in human pancreatic cancer. We used human pan-
creatic cancer (Panc-1, BxPC-3, MiaPaCa-2, QGP-1 and KP-3) and non-
malignant pancreatic ductal epithelial (hTERT-HPNE) cells. Expression profil-
ing of 90 lncRNAs and 2565 miRNAs were performed using qPCR and miRNA
microarray. miRNA targets were predicted by miRanda. Cells were treated with
10 ng/ml of TGF-b for 72 hours to induce EMT. siRNA or miRNA mimic were
used to modulate RNA expression. Cell viability was assessed by MTS assay and
trypan blue. Cell invasion and migration were examined by transwell and wound
healing assay. Expression of RNA was assessed by qPCR and of protein by
Western blot.
Results: LncRNA expression profiling identified 22 lncRNAs that were induced
by TGF-b in Panc-1 cells by 41.4-fold. Of these, HULC was amongst the top
most significantly up-regulated. HULC expression was induced by TGF-b by 1.5
to 2.7-fold in a panel of pancreatic cancer cells and up-regulated by 2.4 to 8.9-
fold in pancreatic cancer cells compared to hTERT-HPNE cells. In Panc-1 cells,
knockdown of HULC by siRNA significantly increased expression of E-cadherin
and decreased expression of N-cadherin, Snail and Vimentin (p5 0.05).
Moreover, siRNA to HULC decreased cell viability, invasion and migration.
Furthermore, to identify miRNAs that can target HULC and suppress EMT,
miRNA microarray and bioinformatics analysis were performed. Microarray
identified 187 miRNAs that were decreased by5 0.87 fold in Panc-1 cells treated
with TGF-b compared to control. Of these, miR-622 was predicted to target
HULC by miRanda. miR-622 expression was reduced by TGF-b by 0.5 to 0.9-
fold in a panel of pancreatic cancer cells. Overexpression of miR-622 using
miRNA mimic significantly decreased expression of HULC, increased expression
of E-cadherin and decreased expression of Snail, N-cadherin and Vimentin
(p5 0.05). In addition, miR-622 overexpression significantly reduced cell inva-
sion and migration.
Conclusion: These findings provide mechanistic insights into EMT in pancreatic
cancer by (a) identifying HULC as a highly induced lncRNA by TGF-b, (b)
demonstrating that HULC promotes EMT, (c) identifying that miR-622, as a
down regulated miRNA by TGF-b, can target HULC, and (d) showing a func-
tional role for miR-622 in EMT via targeting HULC. These observations impli-
cate miR-622 would suppress invasion and metastasis by inhibiting EMT
signaling through targeting HULC and suggest potential strategies to inhibit
invasion and metastasis in human pancreatic cancer.
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Introduction: The Src-homology-2 (SH2) domain containing protein tyrosine
phosphatase SHP-2 is expressed ubiquitously and is involved in an array of
intracellular signal transduction processes (Ras-Raf-MAPK, JAK-STAT,
Pi3K-Akt-mTOR, NFB,...). Thus, for instance, SHP-2 plays a role in cellular
responses to growth factors (PDGF, EGF, FGF, IGF-1,...), cytokines (IL6, IL3,
IL5, GM-CSF,...) and extracellular matrix (via integrins, focal adhesion com-
plex). Via these pathways SHP2 mediates transcriptional regulation of mitogenic
activation, cell proliferation, survival, differentiation, migration and metabolism.
The role of SHP-2 in organ development and homeostasis of the pancreas has so
far not been explored.
Aims & Methods:Mouse models with pancreas specific deletion of SHP-2 (Ptf1a-
Creex1/Ptpn11fl/fl) with or without mutated Kras (LSL-KrasG12D) and/or lineage
tracing allele (ACTB-TdTomato;-EGFP) were used for analysis.
Results: Early embryologic Deletion of SHP-2 in the pancreas via Ptf1a-Cre
preserves organ architecture and endocrine function. However, adequate expan-
sion of the exocrine compartment in the growing pancreas is impaired. In adult
mice, organ weight is reduced by about 50%, compared to unrecombined litter-
mate-controls. In the organ growth phase, (centro-)acinar cells display enhanced
cell death (necrosis and apoptosis) which is accompanied by markedly reduced
proliferation. In aged SHP-2panc mice acinar lobuli are consecutively replaced
by adipocytes. Lineage-tracing experiments provide insight into the origin of this
cell population (invasion vs. transdifferentiation) and will be presented.
Interestingly, introduction of mutated Kras (LSL-KrasG12D) into the model
fully compensates for the deletion of SHP-2. Finally, in the pancreas, we not
only observe an essential role of SHP2 in adequate activation of the RTK-Ras-
Raf-MEK-ERK-signaling axis but also in positive regulation of RTK-expression
levels.
Conclusion: The central role of the non-receptor tyrosine phosphatase SHP-2 in
organ development and homeostasis of the murine pancreas is linked to the
RTK-Ras-Raf-MEK-ERK-signaling axis. SHP-2 is essential for adequate trans-
mission of growth factor signals and thereby influences proliferation and survival
of the acinar cell.
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Introduction: The IKK/NF-B pathway has been shown to be a crucial mediator
of tumour growth and progression, exhibiting both tumour-promoting and
tumour-suppressive properties. How IKK/NF-B possesses these opposite activ-
ities during tumor development remains elusive.
Aims & Methods: In this study, we aimed to elucidate mechanisms by which
IKK/NF-B mediates its tumorigenic functions in pancreatic carcinogenesis.
To determine the role of RelA/p65, the functional subunit, which is responsible
for the transcriptional activity of NF-B, we used a mouse model of pancreatic
ductal adenocarcinoma (PDAC). We generated compound mutants KrasG12D
mice with specific deletion of the p65 gene in the pancreas. Pancreata were
investigated histologically and biochemically.
Results: Our data clearly demonstrate a dual role of NF-B/RelA activation in
pancreatic carcinogenesis. In early stages of tumorigenesis, the tumor-suppressive
function of NF-B is beneficial because it controls oncogene-induced senescence
(OIS) by regulating the CXCL1/KC-CXCR2 axis. However, as soon as OIS is
bypassed during late stages of tumorigenesis, NF-B supports tumor progression
by enhancing proliferation of the transformed pancreatic cancer cells.
Conclusion: Examining these context-dependent activities of RelA will be impor-
tant for effective clinical use of NF-kB inhibitors. Furthermore, these findings
underscore that caution should be exercised, when exploring the use of pharma-
ceuticals targeting the CXCR2 receptor as a therapeutic option for the treatment
of various solid tumors.
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Introduction: Neural invasion (NI) has emerged as a key pathologic feature of
pancreatic ductal adenocarcinoma (PDAC) and represents a distinct route of
tumour cell spread independent from lymphatic and haematogenous tumour
cell dissemination. NI is associated with an unfavourable course of the disease
and also constitutes a major cause of neuropathic pain, thus limiting the quality
of life. NI is considered as a mutual interaction between tumour cells and nerves
and involves both, the unidirectional tracking and invasion of tumour cells along
neural routes but also implicates tumour mediated changes in neural plasticity
resulting in nerve hypertrophy and increased nerve density in PDAC.
Aims & Methods: Here we describe several applicable tools, using live cell and
time-lapse microscopy, co-cultures of tumour cells or ex vivo PDAC xenograft
tissues with freshly isolated dorsal root ganglia (DRG), primary DRG neurons
and F11 hybridoma neurons to investigate the reciprocal interaction at the
tumour cell-nerve interface.
Results: To study the invasion of tumour cells along neurites we have combined
3D co-culture assays of dorsal root ganglia (DRG) and tumour cells with time-
lapse microscopy and specifically track the unidirectional movement of indivi-
dual tumour cells along neurites extending from DRGs. Quantification of the
dynamic process revealed that neuronal scaffolds provide the infrastructure for
an accelerated and consistent migration of tumour cells towards the DRG as the
source of chemotactic gradients. In another approach, using explanted PDAC
xenograft tissues instead of tumour cell colonies, it occurred that neurite out-
growth from DRGs is skewed towards the tumour tissue. Thus, neurites facing
the tumour were more elongated than neurites at the opposite site of the DRG,
suggesting that tumour gradients stimulate and/or attract neurite outgrowth and
elongation. In support of a tumour-derived chemotactic effect, supernatants
from different tumour cell lines displayed varying neurotrophic effects on the
outgrowth of freshly isolated primary neurons in transwell assays. In order to
gain a more dynamic representation on how neurites explore a chemoattractant
gradient, F11 hybridoma neurons were co-cultured with PDAC cell lines in
separate patches divided by a 500 mm gap. These assays use time-lapse imaging
and endpoint analysis in order to track the locomotion of individual neurite
extensions, monitor their outgrowth from neurons and elongation towards the
tumour cell front, and allow to quantitate length, velocity, forward migration
index, and directness of each protruding trajectory in response to different
PDAC cell lines. Moreover, the extent of growth cone formation and collapse
can be scored by determining dynamic changes in circumferential size and area of
growth cones.
Conclusion: These in vitro and ex vivo models emulate several important aspects
of nerve-tumour interactions and allow pharmacological or gain and loss-of-
function manipulations. In addition, semi- to fully-automated quantification
for high-throughput screening may offer investigators reliable tools to test
their candidate target genes or drugs.
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Introduction: IL-23 contributes to the activation, maintenance and proliferation
of Th17 cells, and the IL-23 pathway has been implicated in the pathogenesis of
Crohn’s disease (CD). Risankizumab is a humanized IgG1 monoclonal antibody
that binds the p19 subunit of IL-23 and inhibits binding of IL-23 to its receptor.
In a Phase II trial (NCT02031276), risankizumab was more effective than pla-
cebo for inducing clinical and endoscopic remission in patients with active CD
through 12 weeks.
Aims & Methods: We investigated the underlying mechanism of risankizumab in
this Phase II trial by characterising the molecular profile in the colon and/or
ileum tissue in a subset of patients with CD, who received either 200 mg (n¼ 26),
600 mg (n¼ 27) risankizumab or placebo (n¼ 26). From each patient, 6–9 biopsy
samples were obtained from inflamed lesions in the colon or ileum at baseline and
at 12 weeks post-treatment. Biopsy samples from ileum and from colon were
separately analysed by transcriptome-wide RNA-Seq profiling. Univariate asso-
ciations were assessed using linear regression. Effect size, p-values and FDR were
calculated for significant genes. CDEIS response (450% reduction from base-
line) and CDEIS remission (4; for patients with isolated ileitis of 2) were
evaluated at Week 12 by an independent blinded reviewer.
Results: Risankizumab treatment significantly decreased the expression of 1146
genes from baseline to Week 12 in the colon tissue of CD patients vs placebo
(p5 0.05). Of note, risankizumab treatment was associated with a significant
reduction in the expression of genes associated with the IL-23 pathway (IL-
23A, IL-26, IL-21R, IL-17A, STAT3), innate immunity (IL6, IL7, IL7R, IL8,
ICAM1, IL1, IL11, IL13RA2, IL15RA, IL18R1, TNF), tissue turnover (S-
100A8, A9, A12, MMP1, MMP3, MMP9, MMP12, ADAM8, ADAM12,
ADAM33) and solute carrier family (SLC11A1, SLC1A3, SLC2A3, SLC2A6,
SLC6A14, SLC7A11, SLC7A5). These overall changes in gene expression in the
risankizumab-treated cohort reflected the molecular changes observed in patients
achieving CDEIS response and remission at Week 12. A comparison of gene
expression changes in the colon significantly modulated by risankizumab at
Week 12 vs anti-TNF treatment at Week 14 in a published patient cohort high-
lighted larger decreases in suppression of pathways associated with epithelial
biology (cell–cell adhesion, morphogenesis, intracellular signal transduction,
second messenger signalling) following risankizumab treatment. In contrast, no
significant changes were observed in the molecular profile in the ileum from
patients treated with risankizumab vs placebo from baseline to Week 12.
Conclusion: The superior efficacy observed with risankizumab in active CD
patients at Week 12 was associated with significant molecular changes in the
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colon of CDEIS responding patients. The molecular profile appears to be differ-
entiated from anti-TNF treatment.
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Introduction: Ustekinumab (UST) has been shown to induce & maintain clinical
response & remission in 2 induction (UNITI-1&2) & 1 maintenance (IM-UNITI)
trials in moderate-severe Crohn’s disease (CD). A substudy evaluated the efficacy
of UST in the induction & maintenance of endoscopic healing.
Aims & Methods: Patients in the substudy had up to 3 colonoscopy evaluations
(i.e. at UNITI-1 or 2 baseline [BL] and Wk8, and IM-UNITI Wk44) in 5 ileo-
colonic segments (i.e. ileum, right colon, transverse colon, left colon, rectum)
within the 52-Wk study period. A single central reader blindly scored all video
endoscopies for ulcerations and simplified endoscopic activity score for CD
(SES-CD). At induction Wk0, patients received a single IV dose (UST 130 mg,
UST 6mg/ kg, or PBO). At maintenance Wk0 (i.e. induction Wk8), UST induc-
tion responders [Primary randomized maintenance population] were re-rando-
mized to subcutaneous (SC) PBO, UST 90mg every 12 wks (q12w), or UST
90mg every 8 wks (q8w). For the 3 non-randomized maintenance groups:
(1)UST induction non-responders received SC UST 90mg, then continued SC
UST 90mg q8w if CDAI decreased 100 after 8wks; (2)PBO induction nonre-
sponders received UST IV 130mg, then continued SC UST 90mg q12w if CDAI
decreased 100 after 8wks; and (3)PBO induction responders received PBO
throughout. Patients with SES-CD 3 (i.e. ulceration in any segment) at induc-
tion BL were eligible for analysis. The primary endpoint was change in SES-CD
from BL at induction Wk8 in the integrated UST group (data across induction
studies & dose groups) vs PBO. Efficacy at IM-UNITI Wk44 was evaluated in
the primary randomized maintenance population and the post-hoc pooled main-
tenance population (i.e. randomized & nonrandomized IM-UNITI populations
combined). Additional induction & maintenance endpoints included clinically
meaningful endoscopic improvement, endoscopic response, endoscopic remission
& mucosal healing; in both combined and individual treatment groups.
Results: The substudy primary endpoint was met, as UST induced significantly
greater reduction in SES-CD from BL at Wk8 vs PBO. Results were similar by
induction study & UST dose. Other induction endoscopic endpoints also con-
sistently favored UST vs PBO (Table 1a). At IM-UNITI Wk44, trends for
greater efficacy with UST vs. PBO maintenance, especially UST 90mg q8w,
was observed in the primary randomized maintenance population, but small
sample sizes (UST n¼ 46; PBO n¼ 24) precluded definitive conclusions. In the
larger post-hoc pooled maintenance population (Table 1b), consistent trends in
support of UST maintenance, especially UST 90mg q8w, were observed across
endoscopic endpoints at Wk44.
Conclusion: The endoscopy substudy primary endpoint was met; a single IV dose
of UST induced significantly greater reduction in endoscopic disease activity vs
PBO, despite a relatively early evaluation at Wk8. Results in the small primary
randomized maintenance population were supported by the larger post-hoc
pooled maintenance population; greater proportions of subjects receiving UST
maintenance, especially UST 90mg q8w, achieved maintenance endoscopic end-
points vs PBO. Together, these data support the efficacy of UST in inducing &
maintaining endoscopic healing of the mucosa in CD.
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Introduction: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor,
which has demonstrated high efficacy in patients with rheumatoid arthritis.
This 20-week Phase 2 study was designed to evaluate the efficacy and safety of
filgotinib in patients with active Crohn’s disease (CD).
Aims & Methods: 174 patients with moderate-to-severe CD (CDAI: 220 to 450,
endoscopic evidence of active disease) were randomized 3:1 to receive 200mg
filgotinib (FIL) or placebo (PBO) QD for 10 weeks. Based on Week 10 clinical
response, patients continued to receive filgotinib (200mg or 100mg QD) or
placebo for an additional 10 weeks. Patients who demonstrated clinical response
(CDAI-100) underwent corticosteroid tapering after Week 10. Anti-TNF-naı¨ve
as well as anti-TNF non-responders were included. Immunosuppressants were to
be discontinued prior to treatment initiation. Final data for the primary endpoint
of clinical remission (CDAI5 150) at Week 10 are presented.
Results: Baseline characteristics were comparable in both groups, including mean
disease duration (8.3 y), mean CDAI score (293), mean CRP (15.6 mg/L, 41%4
10mg/L), oral corticosteroids (51%, mean daily dose 21.6 mg/day). Primary
endpoint of the study was met: Filgotinib induced clinical remission in 47% of
the patients, compared to 23% in placebo recipients (p¼ 0.0077), and led to
improvement in PRO2 score, and quality of life (IBDQ changes from baseline)
compared to placebo (table 1). Numerically more patients on filgotinib normal-
ized CRP (FIL:27%, PBO:14%) and showed an improvement of at least 50% in
SES-CD endoscopy score (FIL:25%, PBO:13.6%), Histopathology overall total
score was decreased more significantly in the filgotinib group compared to pla-
cebo (p5 0.05).
Table 1: Key efficacy parameters
Variable/unit/population
Placebo
n¼ 44
filgotinib
n¼ 128 p-value
Clinical remission
(CDAI5 150), %, ITT-NRI
23 47 0.0077
PRO2, mean change from
baseline, ITT-LOCF
15.6 21.9 0.0321
17.6 33.8 0.0045
(continued)
Table 1a: Induction Week 8 (UNITI-1&2)
PBO (N¼ 97) UST (N¼ 155)
SES-CD Change from BL, mean (SD)x 0.7 (4.97) 2.8 (8.10)*
Clinically meaningful endoscopic improvement1 29.9% 47.7%*
Endoscopic Response2 13.4% 20.6%
Endoscopic Remission3 4.1% 7.7%
Mucosal Healing4 4.1% 9.0%
(Table 1b) Maintenance Week 44 (IM-MUNITI)
PBO
(N¼ 51)
90mg q12w
(N¼ 47)
90mg q8w
(N¼ 74)
SES-CD Change from BL, mean (SD) 2.0 (5.35) 1.5 (4.22) 3.8 (6.02)
Clinically meaningful endoscopic improvement1 27.5% 29.8% 48.6%*
Endoscopic Response2 4.2% 5.9% 24.1%*
Endoscopic Remission3 9.8% 12.8% 20.3%
Mucosal Healing4 9.8% 12.8% 21.6%
*P 50.05 xPrimary endpoint 1SES-CD reduction 3 from induction BL 2SES-
CD reduction 50% from induction BL 3SES-CD total score 2 4Complete
absence of ulcers
A44 United European Gastroenterology Journal 4(5S)
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
Table 1 Continued
Variable/unit/population
Placebo
n¼ 44
filgotinib
n¼ 128 p-value
Total IBDQ score, mean change
from baseline, ITT-LOCF
SES-CD improvement by at
least 50%, %, ITT-LOCF
13.6 25 NS
overall total histopathology
score, mean change from
baseline, ITT-LOCF
–0.6 –3.5 0.0359
CDAI: Crohn’s Disease Activity Index; ITT: Intent-to-treat; NRI: Non-respon-
der imputation; LOCF: Last observation carried forward; PRO2: Patient
Reported Outcome ¼ 7x (mean daily number of liquid or very soft stools) þ
7x (mean daily abdominal pain score); IBDQ: Inflammatory Bowel Disease
Questionnaire; SES-CD: Simple Endoscopic Score for Crohn’s Disease;
Histopathology score¼Adaptation from histopathology score D’haens
Overall, filgotinib was safe and well tolerated. Similar incidences in early dis-
continuations, SAEs and AEs including infections were observed, with the major-
ity of the SAEs related to worsening of CD. An increase in mean haemoglobin
concentration was observed, without difference between filgotinib and placebo.
No clinically significant changes from baseline in mean neutrophil counts or liver
function tests were observed. Filgotinib showed a favourable lipid profile with an
increase in HDL and no change in LDL, resulting in an improved atherogenic
index.
Conclusion: Inhibition of JAK1 with filgotinib induces clinical remission, sup-
ported by CRP, endoscopy and histopathology results, and improves quality of
life in patients with moderate to severe CD. The efficacy and safety data of
filgotinib suggest a favourable risk/benefit profile, showing its potential as an
oral treatment with a novel mechanism of action for the treatment of CD.
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Introduction: Tofacitinib is an oral, small molecule JAK inhibitor that is being
investigated for ulcerative colitis (UC). Two Phase 3 randomised placebo (PBO)-
controlled studies (OCTAVE Induction 1, NCT01465763; OCTAVE Induction
2, NCT01458951) demonstrated efficacy of tofacitinib 10 mg twice daily (BID) vs
PBO as induction therapy for patients (pts) with moderate to severe UC.1
Aims & Methods: We investigated the effect of prior tumour necrosis factor
inhibitor (TNFi) therapies or disease activity (baseline Mayo score) on clinical
efficacy endpoints and patient-reported outcomes (PROs) in pooled data from
OCTAVE Induction 1 and 2. Adults with moderately to severely active UC
(baseline Mayo score 6, rectal bleeding subscore 1 and endoscopic subscore
2) and prior failure/intolerance to 1 of corticosteroids, thiopurines or TNFi
were randomised (4:1) to receive tofacitinib 10 mg or PBO BID for up to 9 weeks
(wks). Efficacy endpoints at Wk 8 included: remission (primary endpoint; Mayo
score 2, no subscore41 and rectal bleeding subscore of 0), mucosal healing at
Wk 8 (Mayo endoscopic subscore 1), clinical response (decrease from baseline
Mayo score of 3 points and 30%, plus decrease in rectal bleeding subscore 1
or absolute subscore 1). All endoscopic scores were read centrally. PROs at Wk
8 included Inflammatory Bowel Disease Questionnaire (IBDQ) remission (total
score 170) and IBDQ response (16-point increase from baseline). For binary
endpoints, the comparison of tofacitinib 10 mg BID vs PBO was assessed using
the Cochran-Mantel-Haenszel (CMH) chi-square test stratified by study, prior
TNFi treatment, corticosteroid use at baseline and geographic region. Within
each subgroup, the CMH chi-square test stratified by study was used.
Results: At Wk 8, significantly more pts achieved remission, mucosal healing and
clinical response with tofacitinib 10 mg BID vs PBO (all p5 0.0001, Table). The
difference generally remained significant regardless of prior TNFi exposure, prior
TNFi failure, reason for TNFi failure (primary or secondary) or disease severity
(based on baseline Mayo score 9 or59; Table). For all three endpoints, greater
effects were observed when comparing secondary vs primary TNFi failure sub-
populations and baseline Mayo score 59 vs baseline Mayo score 9. IBDQ
remission and response were significantly greater with tofacitinib 10 mg BID
vs PBO at Wk 8 regardless of prior TNFi exposure/prior TNFi failure.
Conclusion: Tofacitinib demonstrated efficacy vs PBO, regardless of prior TNFi
therapy in pts with moderately to severely active UC. PRO results were similar in
pts with/without prior TNFi exposure or failure.
Table: Summary of efficacy endpoints in OCTAVE Induction 1 and OCTAVE
Induction 2 at Wk 8
Tofacitinib
10 mg BID N¼ 905
Placebo
N¼ 234
Difference
(95% CI)
Remission, n (%)i 159 (17.6) 14 (6.0) 11.6 (7.7, 15.5)***
Prior TNFi exposurea 60 (12.3) 1 (0.8) 11.5 (8.2, 14.8)***
No prior TNFi exposureb 99 (23.7) 13 (12.5) 11.2 (3.7, 18.8)*
Prior TNFi failurec 53 (11.4) 1 (0.8) 10.6 (7.3, 13.9)**
No prior TNFi failured 106 (24.1) 13 (11.8) 12.3 (5.0, 19.5)*
Prior TNFi failure (primary
non-responder)e
19 (7.5) 1 (1.4) 6.2 (2.0, 10.3)*
Prior TNFi failure (secondary
non-responder)f
31 (16.6) 0 (0.0) 16.6 (11.2, 21.9)*
Baseline Mayo score 59g 91 (28.3) 6 (7.3) 21.0 (13.5, 28.5)***
Baseline Mayo score 9h 68 (11.7) 8 (5.3) 6.4 (2.0, 10.8)*
Mucosal healing, n (%)i 271 (29.9) 32 (13.7) 16.3 (11.0, 21.6)***
Prior TNFi exposurea 112 (23.0) 8 (6.2) 16.8 (11.2, 22.4)***
No prior TNFi exposureb 159 (38.1) 24 (23.1) 15.1 (5.7, 24.4)*
Prior TNFi failurec 103 (22.2) 8 (6.5) 15.7 (10.0, 21.4)***
No prior TNFi failured 168 (38.2) 24 (21.8) 16.4 (7.4, 25.3)*
Prior TNFi failure (primary
non-responder)e
38 (15.0) 5 (6.8) 8.3 (1.0, 15.5)NS
Prior TNFi failure (secondary
non-responder)f
57 (30.5) 2 (4.7) 25.8 (16.7, 34.9)**
Baseline Mayo score 59g 145 (45.2) 17 (20.7) 24.4 (14.1, 34.8)***
Baseline Mayo score 9h 126 (21.6) 15 (9.9) 11.7 (5.9, 17.5)*
Clinical response, n (%)i 521 (57.6) 72 (30.8) 26.8 (20.1, 33.5)***
Prior TNFi exposurea 254 (52.0) 29 (22.3) 29.7 (21.3, 38.2)***
No prior TNFi exposureb 267 (64.0) 43 (41.3) 22.7 (12.2, 33.2)***
Prior TNFi failurec 237 (51.0) 29 (23.4) 27.6 (18.9, 36.3)***
No prior TNFi failured 284 (64.5) 43 (39.1) 25.5 (15.3, 35.6)***
Prior TNFi failure (primary
non-responder)e
116 (45.8) 19 (25.7) 20.2 (8.5, 31.9)*
Prior TNFi failure (secondary
non-responder)f
102 (54.5) 9 (20.9) 33.6 (19.5, 47.7)**
Baseline Mayo score 59g 205 (63.9) 30 (36.6) 27.3 (15.6, 39.0)***
Baseline Mayo score 9h 316 (54.3) 42 (27.8) 26.5 (18.3, 34.7)***
Full analysis set, non-responder imputation NSNot significant; *p5 0.05;
**p5 0.001; ***p5 0.0001 vs placebo 95% confidence interval was based on
normal approximation for the difference in binomial proportions aN¼ 488 for
tofacitinib 10 mg BID and N¼ 130 for placebo; bN¼ 417 for tofacitinib 10 mg
BID and N¼ 104 for placebo;cN¼ 465 for tofacitinib 10 mg BID and N¼ 124
for placebo; dN¼ 440 for tofacitinib 10 mg BID and N¼ 110 for placebo;
eN¼ 253 for tofacitinib 10 mg BID and N¼ 74 for placebo; fN¼ 187 for tofaci-
tinib 10 mg BID and N¼ 43 for placebo; gN¼ 321 for tofacitinib 10 mg BID and
N¼ 82 for placebo; hN¼ 582 for tofacitinib 10 mg BID and N¼ 151 for placebo;
istatistical significance based on the Cochran-Mantel-Haenszel chi-squared test
stratified by study, prior treatment with tumour necrosis factor inhibitors, corti-
costeroid use at baseline and geographic region BID, twice daily; CI, confidence
interval; TNFi, tumour necrosis factor inhibitor; Wk, week
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Introduction: In the COLLECT study the Toll like receptor (TLR-) 9 agonist
cobitolimod (formerly known as DIMS0150, Kappaproct) was evaluated for its
therapeutic efficacy in ulcerative colitis (UC) patients refractory to conventional
therapy.
Aims & Methods: In this post hoc analysis the therapeutic effects were analysed
with respect to disease activity of the patients at baseline. Cobitolimod was
studied in a randomized, double blind, placebo-controlled, multicentre, pan-
European trial named COLLECT in 131 patients with moderate to severe
active ulcerative colitis. Patients were on mandatory steroid therapy and could
be taking sulphasalazine, aminosalicylates, or thiopurines at stable doses.
Patients were randomly assigned to receive two single doses of cobitolimod (30
mg) or placebo (in a 2:1 ratio) topically through the endoscope to the inflamed
mucosa at baseline (week 0) and after 4 weeks (week 4). For this post-hoc
analysis efficacy was studied using the secondary endpoint symptomatic remis-
sion (SR) (absence of blood in stool and mean weekly stools 5 35) at week 4, 8
and 12. As endoscopic examination was performed at week 4 and 12 sympto-
matic remission in combination with mucosal healing (MH) defined as endo-
scopic Mayo score of  1 were assessed at week 4 and 12. Disease activity was
measured using the CAI score, which ranges from 0–23. In the FAS (full analysis
set) population 28% of the patients had moderate disease (CAI¼ 9), 46% had
moderate to severe disease setting (CAI¼ 10–11), while 26% had severe disease
(CAI  12) at baseline.
Results: In the moderate UC patient population (CAI¼ 9) symptomatic remis-
sion was achieved in 50/64/59% of the cobitolimod vs. 15/23/23% of placebo-
treated patients at week 4/8/12, respectively. In the moderate to severe UC
patient population (CAI¼ 10–11) symptomatic remission was evident in 32/40/
46% of the cobitolimod vs. 15/35/40% in placebo-treated patients at week 4/8/
12, respectively. In the severe UC patient population (CAI¼ 12 and more) 14/31/
22% of the cobitolimod vs. 10/20/30% of the placebo-treated patients showed
symptomatic remission at week 4/8/12. With respect to the endpoint sympto-
matic remission plus mucosal healing the patients with moderate disease
showed remission rates of 32/40% for cobitolimod vs. 8/8% for placebo-treated
patients at week 4/12, respectively. In patients with moderate to severe disease
rates for SR plus MH were 22/35% in the cobitolimod vs. 0/35% in placebo-
treated patients at week 4/12, respectively. In patients with severe disease these
rates were 9/18% in the cobitolimod vs. 0/20% in placebo-treated patients for
week 4/12, respectively.
Conclusion: The results of the COLLECT study demonstrate that the TLR-9
agonist cobitolimod is able to induce clinical remission in UC patients both
with moderate and severe disease activity. The concept of TLR-9 activation
represents a promising and well-tolerated novel therapeutic option for ulcerative
colitis patients with active disease and warrants further trials.
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Introduction: Ozanimod (RPC1063) is an oral, selective sphingosine 1-phosphate
(S1P) 1 and 5 receptor modulator in clinical development for the treatment of
Inflammatory Bowel Disease (ulcerative colitis [UC] and Crohn’s disease) and
relapsing multiple sclerosis. The objective of the open-label extension (OLE) of
the TOUCHSTONE trial is to evaluate the long-term efficacy and safety of daily
1 mg ozanimod in patients with moderate to severe UC who had initially parti-
cipated in the TOUCHSTONE trial.
Aims & Methods: A total of 197 patients were randomized (1:1:1) and treated
with daily ozanimod at 0.5 mg, 1mg (n¼ 67), or placebo in the TOUCHSTONE
trial. Of the initial 197 patients randomized 170 (86%) entered the OLE and
received daily 1 mg ozanimod with 109 (64%) remaining in the OLE as of the
data cut-off (March 2016). At the data cut-off, all remaining patients had
received treatment in the OLE for  1 year.
Results: At entry into the OLE, the partial Mayo Score (pMS) for patients on
placebo, ozanimod 0.5 mg, and 1.0 mg was 4.6, 4.5, and 3.3 respectively. At the
time of the data-cut in the OLE, the pMS had improved in all groups (1.7, 1.7,
and 1.9) at Week 44. The greatest improvement was reported in patients who
received placebo or ozanimod 0.5 mg in the TOUCHSTONE trial with a change
in pMS at Week 44 of –2.6, –2.7 and –1.3 in the placebo, 0.5 mg and 1 mg groups.
Improvement occurred rapidly, in the first 4 to 8 weeks of the OLE. The greatest
improvement was reported for patients who received placebo or ozanimod 0.5
mg in the TOUCHSTONE trial with a change in pMS at Week 4 of –1.8, –1.5
and –0.8 and a change in pMS at Week 8 of –2.4, –1.9 and –1.1 in the placebo, 0.5
mg and 1 mg groups. At the Week 44 visit in the OLE, 119/131 (90.9%) had little
or no active disease based on the physician global assessment (PGA 0 or 1), 129/
131 (98.4%) had little or no blood in their stools (rectal bleeding subscore [RBS]
0 or 1), 111/131 (84.7%) had no blood in the stools (RBS 0), and 105/131 (80.2%)
had little or no increase in their number of stools (Stool Frequency subscore of 0
or 1). The most common adverse events (AEs) (42.0%) during OLE were UC
flare, anemia, upper respiratory tract infection, nasal pharyngitis, back pain,
arthralgia, headache, alanine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) elevation. The only serious AEs in 2 patients were anemia, and
ulcerative colitis flare. ALT and AST 4 3x upper limit of normal occurred in 4
(2.4%) of the 170 patients in the OLE. All elevations were asymptomatic,
55xULN, transient, and resolving while receiving continued treatment.
Conclusion: Long-term treatment with ozanimod continues to be safe and well
tolerated with good compliance and evidence of durable efficacy.
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Introduction: Esophageal stricture formation after extensive endoscopic resection
remains a major limitation of endoscopic therapy for early esophageal neoplasia.
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We assessed a recently developed self-assembling peptide matrix as a wound
dressing after endoscopic resection for the prevention of esophageal stricture.
Aims & Methods: Ten pigs were randomly assigned to the self-assembling peptide
RADA-16 (4 [Arg-Ala-Asp-Ala]) or the control group after undergoing a 5 cm
long circumferential endoscopic submucosal dissection of the lower esophagus.
Esophageal diameter on endoscopy and esophagogram, weight variation, and
histological measurements of fibrosis, granulation tissue, and neoepithelium
were assessed in each animal.
Results: The rate of esophageal stricture at day 14 was 40% in the group treated
with self-assembling peptide vs. 100% in the control group (p¼ 0.04). Median
(IQR) esophageal diameter at day 14 was 8 mm (2.5–9) in the self-assembling
peptide group vs. 4 mm (3–4) in the control group (p¼ 0.13). The median (IQR)
stricture indexes on esophagograms at day 14 were 0.32 (0.14–0.48) and 0.26
(0.14–0.33) in treated and control groups, respectively (p¼ 0.42). Median
(IQR) weight variation during the study was þ0.2 (7.4; þ1.8) and 3.8
(5.4; þ0.6) in the treated and control groups, respectively (p¼ 0.9). No differ-
ences were observed between the groups in terms of histological outcomes. All
animals eventually developed esophageal strictures at day 28.
Conclusion: The application of a self assembling peptide matrix on esophageal
wounds after circumferential endoscopic submucosal dissection is safe and fea-
sible, and prevents early esophageal stricture occurence in our model.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP110 INTRALESIONAL STEROID INJECTION COMBINED WITH
ORAL STEROID ADMINISTRATION TO PREVENT ESOPHAGEAL
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Introduction: Endoscopic submucosal dissection (ESD) is becoming an important
and main therapy for early esophagus carcinoma or precancerous lesion.
However, stricture ofter occurs when the mucosal defects created by ESD are
larger than a half of circumference. It’s an urgent task to find out a safe and
effecient method to prevent stenosis.
Aims & Methods: To investigate the safety and efficiency of local steroid injection
combined with oral steroid administration in preventing esophageal stricture
after ESD of esophagus carcinoma or precancerous lesion which are no less
than a half of circumference. A single-center randomized controlled trial was
designed to examine the effects and safety of intralesional steroid injection com-
bined with oral steroid administration in preventing stricture after esophageal
ESD. 43 patients with mucosal defects no less than a half of circumference
following esophageal ESD were randomized to receive intralesional triamcino-
lone injection immediately after ESD and oral prednisone administration for
consecutive 12 weeks, which starting at a dose of 30 mg daily, tapered gradually
at a speed of 5 mg in every two weeks (n¼ 20, treatment group) or to be treated
conventionally (n¼ 23, control group). The primary endpoint was the frequency
of stricture. Secondary endpoints were the number of balloon dilatation, rate of
other complications and hospital stays.
Results: The frequency of stricture (20% vs. 69.6%) and the number of balloon
dilatation (mean 0.5 vs. 1.3) were less in treatment group, and the former one had
a significant difference. The hospital stays and rate of complications were similar
between two groups. One patient suffered perforation of stomach in the treat-
ment group, which was not a direct result of steroid injection or ESD.
Frequency of stricture formation, number of endoscopic balloon dilations
(EBDs) performed, hospital stays after ESD and other complications in two
groups.
Treatment
group
(n¼ 20)
Control
group
(n¼ 23) p-value
Frequency of stricture, n (%) 5(20) 16(69.6) 0.004*
Number of EBDs, n meanSD
(range)
0.5 1.1 (0–3) 1.3 2.0 (0–8) 0.241
Perforation by procedure, n per
session (%)
1/30 (3.7) 0/53(0) 0.361
Bleeding by procedure, n per
session (%)
0/30(0) 1/53(1.9) 1.0
Hospital stays after ESD, days
meanSD (range)
4.1 4.4 (1–22) 3.3 2.0 (1–8) 0.469
*Significant difference
Conclusion: Intralesional steroid injection combined with oral steroid adminis-
tration appears to be safe and effective in preventing esophageal stricture follow-
ing ESD of lesions no less than a half of circumference.
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Introduction: Addition of single operator cholangioscopy (SOC) to endoscopic
retrograde cholangiography (ERC) may improve diagnostic accuracy and
increase therapeutic efficiency in bile duct diseases. Indications for SOC, proce-
dural success and impact on subject management are investigated in a multi-
national prospective registry.
Aims & Methods: SOC registry using the SpyGlassTM Legacy (Spy Legacy) or
new SpyGlass DSTM (Spy DS) system and SpyBiteTM biopsy forceps (Boston
Scientific Corp, Marlboro, MA, USA) at 20 centers in 10 countries. The registry
was not designed as a comparative study. Procedural success defined as: Group
A: Indeterminate strictures/filling defects: ability to visualize lesions, provide
visual impression of malignancy, and, when applicable, obtain biopsies adequate
for histology. Group B: Biliary stones: ability to achieve stone clearance in one or
more SOC procedures. Group C: Other indications: ability to establish diagnosis
and/or complete therapy as intended.
Results: Total of 504 patients (pts) have completed primary endpoint informa-
tion, 207 (41%) pts using Spy DS. Average age 61 years, 54% male. Indications
for SOC were Group A in 278 (55%) pts, Group B in 190 (38%) pts and Group C
in 62 (12%) pts, principally including pre-operative assessment of tumor margins
(20), confirmation of stone clearance (15), selective guidewire placement (8),
extraction of migrated stent (5) assessment of cause of occluded self-expanding
metal stent (3), unexplained hemobilia (3), dilated left hepatic duct (2), and
presence of residual IPNB after photodynamic therapy (1). Investigators rated
image quality as ‘‘Excellent or Good’’ in 98% Spy DS cases and 78% of Spy
Legacy cases (P5 0.0001). Procedural success was reached in 504 (84%) proce-
dures overall, namely in 279 (85%) procedures in Group A, 190 (82%) in Group
B, and 56 (89%) in Group C. Thirteen (7%) pts in Group B required 2 or more
SOC procedures to reach stone clearance. Failures were inability to provide
impression of malignancy (31 Group A), intraductal biopsies not yielding deter-
minate histopathology (8 Group A), inability to reach stone clearance (33 Group
B), inability to assess ductal tumor (3 Group C) and failed guidewire placement
(3 Group C). Overall procedural success trended to be higher in Spy DS than in
Spy Legacy group namely 86% (178/207) versus 82% (244/297) (p¼ 0.262). SOC
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altered diagnosis/therapy and/or influenced management in 417 (85%) pts.
Malignant visual impression as a predictor for malignant pathology of SpyBite
biopsies is better for Spy DS than Spy Legacy (p¼ 0.014). Adverse events in 7
(1%) pts: 2 mild pancreatitis, 2 mild and 1 moderate cholangitis, 1 moderate
bleeding and 1 micro perforation.
Conclusion: SOC, especially using Spy DS, has high procedural success and
provides important impact on diagnosis, therapy and/or management in a wide
range of indications, with excellent safety profile.
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OP113 PROPOSAL OF A MACROSCOPIC CLASSIFICATION FOR
TISSULAR LESIONS OF THE BILE DUCT DETECTED DURING
PER ORAL CHOLANGIOSCOPY (POCS)
C. Robles-Medranda1, M. Soria2, M. Valero1, M. Puga1, H. Alvarado1,
J. Ospina1, H. Pitanga Lukashok1
1Endoscopy, Instituto Ecuatoriano de Enfermedades Digestivas-IECED-University
Hospital Omni, Guayaquil/Ecuador
2Endoscopy, Instituto Ecuatoriano de Enfermedades Digestivas - IECED,
Guayaquil/Ecuador
Contact E-mail Address: carlosoakm@yahoo.es
Introduction: The macroscopic aspects to determine malignancy of the bile duct
during per oral cholangioscopy (POCS) are: presence of irregular surface with
bleeding and drooling or tortuous vessels. For benign lesions the typical aspects
are lesions with smooth surface ‘‘without vessels or mass’’. However, many mis-
diagnosis are made due to a lack of correlation between the macroscopic aspects
and histology. Moreover, masses are many times benign, and reported data
shows 78% of sensitivity for visual impression diagnosing malignancy.
Aims &Methods: Propose a macroscopic classification of bile duct tissular lesions
for differentiation between benign and malignant lesions.
A retrospective study from Sept-2013 to Sept-2015 was made at our institution in
patients evaluated by POCS (using SpyGlass legacy and DS). Inclusion criteria:
tissular lesions detected by POCS. Exclusion criteria: absence of histology con-
firmation (either biopsy or surgical resection for malignancy) and/or absence of
POCS at 6 months follow-up (for benign lesions). To determine the macroscopic
classification all patients’ records were evaluated. 315 images were analyzed and
classified as benign or malignant by an expert with more than 140 POCS cases,
and compared to histology. Based on the morphological and vascular pattern the
lesions were classified as follows:
Benign lesions: Type 1 ‘‘Villous pattern’’ (micronodular or villous pattern with-
out vascularity), Type 2 ‘‘Polypoid pattern’’ (adenoma or granuloma pattern
without vascularity) and Type 3 ‘‘Inflammatory pattern’’ (regular or irregular
fibrous and congestive pattern with regular vascularity). Malignant lesions: Type
1 ‘‘Flat pattern’’ (flat and smooth or irregular surface with irregular or spider
vascularity); Type 2 ‘‘Polypoid’’ (polypoid or mass with fibrosis and irregular or
spider vascularity), Type 3 ‘‘ulcerated" (irregular pattern ulcerated and infiltra-
tive with or without fibrosis with irregular or spider vascularity) and type 4
‘‘honey-comb pattern’’ (fibrous honey-comb pattern with or without irregular
or spider vascularity). Inter-observer and intra-observer agreement was calcu-
lated using 40 random images of lesions for 1 expert and 2 non-expert in
POCS. Finally a prospective, non randomized, double blind evaluation of diag-
nostic accuracy, sensitivity, specificity, PPV, NPV using the new classification
was performed for consecutive tissular lesions detected from Oct-2015 to April-
2016 correlated with histology.
Results: 130 patients were studied, (retrospective: 87 / prospective: 43); 30 female,
mean age 61 (50–74). Absence of statistical difference in genre (p value ¼ 0.606)
or age (p¼ 0.107) between groups. For retrospective evaluation 46/87 patients
were evaluated, 21 female, mean age 61 (52–73). 18/46 cases were malignant and
28/46 benign. The overall interobserver agreement was substantial when lesions
were classified as benign or malignant (K¼ 0.75 – CI 0.46–0.89) and when lesions
were classified by sub-types (K¼ 0.71 – CI 0.39–0.88).The intraobserver agree-
ment was almost perfect when lesions were classified as benign and malignant
(K¼ 0.88 – CI 0.66–1.0) and when lesions were classified by sub-types (K¼ 0.90
– CI 0.71–1.0). For the prospective evaluation 23/43 patients were evaluated, 9
female, mean age 61 (48–72) years old. 13/23 cases were malignant and 10/23
benign. The accuracy was 86.9%, sensitivity 100%, specificity 70%, PPV 81.3%,
NPV 100%.
Conclusion: The proposed macroscopic classification could help physicians to
distinguish benign from malignant lesions with a good inter and intra-observer
concordance.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Data on the efficacy of prophylactic rectal indomethacin to prevent
post-ERCP pancreatitis in consecutive patients is inconsistent. We therefore con-
ducted a meta-analysis of high-quality randomized clinical trials specifically
studying rectal indomethacin in prevention of post-ERCP pancreatitis in conse-
cutive patients.
Aims & Methods: Relevant studies for the meta-analysis were identified through
search of MEDLINE, EMBASE and Cochrane Central Register of Controlled
Trials databases. Randomized controlled clinical trials employing rectal indo-
methacin for the prevention of post-ERCP pancreatitis were included. The pri-
mary outcome was the overall rates of post-ERCP pancreatitis.
Results: A total of 2473 patients from 6 studies were included. The incidence of
post-ERCP pancreatitis across all 2473 patients was 7% (95% CI, 6%–9%). We
found that there was no significant difference in overall rates of post-ERCP
pancreatitis in consecutive patients between rectal indomethacin and placebo
(OR, 0.67; 95% CI, 0.46–1.00, p¼ 0.050). There was also no difference in rates
of moderate to severe (OR, 0.66; 95% CI, 0.28–1.56, p¼ 0.345) or mild (OR,
0.71; 95% CI, 0.45–1.10, p¼ 0.127) post-ERCP pancreatitis between indometha-
cin and placebo.
Conclusion: In a contemporary meta-analysis of available randomized controlled
trials of consecutive patients undergoing ERCP, rectal indomethacin did not
show significant prevention effect of post-ERCP pancreatitis.
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Introduction: Bleeding after endoscopic sphincterotomy (EST) is one of the most
frequent complications of therapeutic ERCP. Although the use of proton pump
inhibitor (PPI) has been shown to reduce the risk of rebleeding in patients with
peptic ulcer bleeding after endoscopic hemostasis, the role of acid suppression in
preventing EST bleeding has not been evaluated. We hypothesized that preemp-
tive high dose PPI could reduce the risk of post-EST bleeding.
Aims & Methods: The aim of this study was to study the role of high-dose PPI in
patients undergoing EST. It was a prospective randomized open-label study
performed in the endoscopy centre of a university teaching hospital.
Consecutive patients who were scheduled to have ERCP and EST were enrolled.
We excluded patients who had previous EST, prior gastric surgery, or were
taking PPIs. Antiplatelet therapies were continued as usual. Anti-coagulants
(warfarin or heparin) were stopped with coagulopathy corrected prior to
ERCP. Eligible patients were randomized to receive either PPI or standard
care (SC). PPI group would receive esomeprazole given intravenously at 80mg
every 12h for Day 1, starting 4 hours prior to ERCP, and followed by oral
esomeprazole 40mg bid from Day 2 to 10. Standard care arm would receive
usual care without any acid suppressive therapy. Endoscopists were unaware
of the treatment allocation of the patients. Primary outcome was the proportion
of patients with immediate or delayed post-EST bleeding. Immediate bleeding
was defined as bleeding that occurred during the procedure and required endo-
scopic hemostasis. Delayed bleeding was defined as bleeding after the completion
of ERCP which manifested as overt GIB with melena or hematemesis. All
patients were followed up for 30 days. Secondary outcomes included drop in
hemoglobin 42 g without overt bleeding, transfusion requirement and all-
cause mortality at 30 days. Analysis was based on modified intention-to-treat,
which included only randomized patients who had undergone EST.
Results: 196 patients were enrolled and 71 patients did not have EST. The ana-
lysis included 125 patients who had undergone EST with 60 in the PPI group and
65 in SC group. The mean age was 70.9 (SD¼ 14.8) years with 62 (49%) men.
The baseline characteristics of the two groups including indications for ERCP,
use of anti-platelet agents or anti-coagulants, and comorbidity were comparable.
Immediate bleeding was noted in 9 (15%) patients in the PPI group and 4 (6.2%)
in the SC groups (P¼ 0.14). Overt delayed ES bleeding was respectively seen in 2
(3.3%) and 5 (7.7%) patients in PPI and SC arms (P¼ 0.44). There was also no
significant difference in the proportions of patients with hemoglobin drop of42
g without overt bleeding (Day 10: 13.3% in PPI group and 9.2% in SC group;
P¼ 0.57). Other outcomes including hospital stay (13.1 vs 11.8 days; P¼ 0.69),
transfusion requirement (5% vs 7.7%; P¼ 0.72) and 30-day mortality (3.3% vs
1.5%; P¼ 0.61) were also comparable between the PPI and SC groups.
Conclusion: The use of high-dose PPI did not appear to significantly reduce the
risk of both immediate and delayed bleeding in patients undergoing EST.
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OP116 IMPACT OF INTENSIVE HYDRATION ON THE INCIDENCE OF
POST-ERCP PANCREATITIS: DOUBLE-BLINDED RANDOMIZED
CONTROLLED TRIAL
P. Boal Carvalho1, F. Dias De Castro1, M. Barbosa1, J. Magalha˜es1, B. Rosa1,
J. Cotter2
1Gastroenterology Department, Hospital Senhora da Oliveira, Guimaraes/Portugal
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Introduction: Pancreatitis is the most frequent complication following endoscopic
retrograde cholangiopancreatography (ERCP), with an estimated incidence of
1.6% to 15.7%, depending on patient and procedure-related factors. Intensive
hydration with lactated Ringer’s solution has been shown in small studies to
reduce post-ERCP pancreatitis (PEP) incidence and severity.
Aims & Methods:We aimed to assess whether intensive hydration impacts on the
incidence and severity of PEP. We performed a prospective, double-blinded
randomized controlled trial, including consecutive patients submitted to ERCP
in our institution. Patients with previous sphincterotomy, chronic pancreatitis,
heart failure (NYHA 3), chronic kidney disease (stage3) and shock were
excluded. Patients were randomized (1:1) to either intensive hydration with lac-
tated Ringer’s solution (3 mL/kg/h during the procedure, 20mL/ kg bolus after
the procedure, and 3 mL/kg/h for 8 hours after the procedure), or standard
hydration (1.5 mL/kg/h of lactated Ringer’s solution during and for 8 hours
after the procedure). A blood panel including serum levels of amylase and
lipase was obtained at 4 and 24 hours after ERCP. Primary outcome was the
incidence of PEP (defined as epigastric pain plus either amylase or lipase levels
43 times the upper limit of normal at 24h). Secondary outcomes were severity of
PEP, incidence of volume overload, patient and procedure-related factors asso-
ciated with PEP, and the predictive values of serum amylase/lipase at 4 hours
after ERCP for PEP development.
Results: Included were 75 patients, 38 in the intensive hydration arm, and 37 in
the standard hydration arm. Both groups were homogeneous for patient and
procedure-related factors. PEP incidence was 9.3% (n¼ 7), and was lower in
the intensive hydration arm (5.3% versus 13.5%, p¼ 0.204). Additionally, both
PEP in the intensive hydration arm were mild, while out of the 5 PEP in the
normal hydration arm, two patients presented with moderate and severe PEP,
respectively. Contrast injection of the Wirsung was significantly associated with
PEP (28.6% versus 7.1%, p¼ 0.016), while no other patient or procedure-related
factors associated with PEP incidence. Finally, both amylase levels52 times and
lipase levels 5 3 times the upper limit of normal at 4 hours demonstrated a
Table (OP114)
Characteristics of Included Trials
Montano Loza, 2007 Sotoudehmanesh, 2007 Dobronte, 2012 Dobronte, 2014 Patai, 2015 Levenick, 2016
Methodology
Intervention 100mg PR before
ERCP
100mg PR before ERCP 100mg PR before
ERCP
100mg PR before
ERCP
100mg PR before
ERCP
100mg PR during
ERCP
Location Mexico-multicenter Iran-single center Hungary-single center Hungary-multicenter Hungary-single center US-single center
Definition of post-
ERCP pancreatitis
Clinical, amylase Clinical, amylase Pain, amylase, pro-
longed admission
Clinical, amylase, pro-
longed admission
Pain, amylase, pro-
longed admission
Pain, amylase, pro-
longed admission
Pancreatic stent used? Yes (10 cases in indo-
methacin group; 9
cases in placebo
group)
No N/A No No Yes (36 cases in indo-
methacin group; 35
cases in placebo
group)
Randomization
Total randomized 150 490 228 686 539 449
Total analysed 150 442 228 665 539 449
Indomethacin 75 221 130 347 270 223
Placebo 75 221 98 318 269 226
Baseline demographics
Mean age (y)
Indomethacin 55 58 66 66 66 65
Placebo 51 58 67 68 65 64
% Female
Indomethacin 65 56 63 62 67 53
Placebo 68 53 70 67 67 52
Procedure
demographics
% Difficult cannulation
Indomethacin N/A N/A N/A 18 29 21
Placebo N/A N/A N/A 16 30 19
% Pancreatic duct
injection
Indomethacin 7 20 63 71 23 22
Placebo 8 19 68 68 30 22
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negative predictive value of 100% for the development of PEP. No complication
was observed as a consequence of intensive hydration.
Conclusion: In our series, the incidence of PEP was 9.3%, and a non-significant
risk reduction trend was observed in patients undergoing intensive hydration,
with no severe pancreatitis being observed in this group. Wirsung contrast injec-
tion significantly increased the risk of PEP. Lower serum amylase and lipase
levels at 4 hours after ERCP were excellent predictors for absence of PEP at
24 hours, displaying a negative predictive value of 100%.
Disclosure of Interest: All authors have declared no conflicts of interest.
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OP117 INTRAGASTRIC BITTER TASTANT ALTERS BRAIN ACTIVITY
IN HOMEOSTATIC AND HEDONIC REGIONS AND DECREASES
OCTANOYLATED GHRELIN LEVELS AND HEDONIC FOOD
INTAKE
J. Iven, J. Biesiekierski, D. Zhao, I. Depoortere, L. Van Oudenhove, J. Tack
Targid, University of Leuven, Leuven/Belgium
Contact E-mail Address: julie.iven@kuleuven.be
Introduction: Intragastric administration of bitter tastants decreases hunger rat-
ings in the fasted state. Activation of bitter taste receptors can alter ghrelin levels,
a gut hormone which increases hunger in between meals and becomes active after
octanoylation. This indicates a potential role for bitter agonists in the regulation
of appetite and food intake, putatively via interference with gut-brain signals to
regions involved in homeostatic (brainstem, hypothalamus) and hedonic (meso-
limbic reward system) control of feeding.
Aims & Methods: The aim of this project was to study the effect of intragastric
administration of the bitter tastant Quinine Hydrochloride (QHCl) on brain
activity in homeostatic and hedonic regions and on circulating ghrelin plasma
levels. Furthermore, to test the hypothesis of lower hunger and prospective food
consumption ratings, and lower hedonic food intake after QHCl administration
compared to placebo. Fifteen healthy women were studied after an overnight
fast. Brain activity before and up to 50 minutes after infusion of QHCl (10mmol/
kg) or distilled water (placebo) was recorded using functional magnetic reso-
nance imaging (MRI). Hunger and prospective food consumption scores were
assessed every 10 min using Visual Analogue Scales. Blood samples were taken at
the same time points. Hedonic food intake was measured immediately after
scanning using an ad libitum chocolate milkshake drink test. MRI preprocessing
and analysis was conducted using SPM12. Brain responses over time to QHCl
versus placebo infusion were compared in a priori defined regions of interest
(ROI) at both voxel- and cluster-level threshold of pFWEcorrected 5 0.05. The
infusion-by-time interaction effect was tested on hunger and prospective food
consumption scores with mixed models. Hedonic food intake was compared
between infusions using a one-tailed paired T-test. Blood plasma was analysed
for circulating ghrelin levels using radioimmunoassays.
Results: Compared to placebo, intragastric QHCl infusion significantly increased
neural activity in 5 different clusters within the ROIs, with local maxima in the
putamen, insula, caudate, amygdala, anterior cingulate cortex, medial prefrontal
cortex, medial orbitofrontal cortex and hippocampus. A decrease of neural activ-
ity was observed in the brainstem. Significantly lower prospective food consump-
tion scores were observed after QHCl administration compared to placebo
(p¼ 0.02), but no significant differences were observed for hunger scores.
Milkshake intake was significantly lower after QHCl administration, compared
to placebo (p¼ 0.04; Cohen’s d¼ 0.50). A significant decrease of octanoylated
ghrelin plasma levels was observed post-infusion after bitter administration com-
pared to placebo (p¼ 0.05).
Conclusion: Intragastric administration of the bitter tastant QHCl significantly
altered activity in homeostatic and hedonic brain regions. Prospective food con-
sumption ratings, circulating octanoylated ghrelin levels and hedonic food intake
were decreased after QHCl. These observations indicate a potential role for bitter
agonists in the treatment of obesity.
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OP118 TRANSDIAGNOSTIC COGNITIVE BEHAVIOUR THERAPY
SHOW PROMISE FOR BOTH MOOD AND GASTROINTESTINAL
SYMPTOMS IN PATIENTS WITH FUNCTIONAL
GASTROINTESTINAL DISORDERS
M.P. Jones1, B. Dear1, N. Titov1, V. J. Fogliati1, N.J. Talley2
1Psychology, Macquarie University, North Ryde/Australia/NSW
2University of Newcastle Faculty of Health PVC Office, Callaghan/Australia
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Introduction: Irritable Bowel Syndrome (IBS) is a heterogenous disorder charac-
teristised by recurrent abdominal pain combined with alteration in bowel habit.
It is associated with reduced quality-of-life and significant economic cost to
society. IBS sufferers also have elevated scores for anxiety and depression
which have been speculated to be part of the disease etiology [1]. Indirect evi-
dence for the role of mood in IBS prevalence comes from studies showing that a
proportion of patients show improvement in abdominal symptoms with antide-
pressants [2] but also in response to psychological therapies including cognitive
behaviour therapy (CBT) [3]. Newer forms of CBT including internet-delivered
CBT (iCBT) have shown similar effect sizes to conventional CBT in patients with
mood disorder [4]. iCBT provides access to therapy for patients who are geogra-
phically or culturally isolated from qualified psychologists and has been shown to
be cost-effective [5]. The eCentreClinic at Macquarie University (Australia) has
developed a transdiagnostic model of CBT which is applied via distance mode,
primarily via internet but also by telephone.
Aims & Methods: This study sought to pilot a new form of iCBT designed for
chronic health conditions, including functional gastrointestinal disorders, with
respect to: 1. Reduction in abdominal symptom burden, anxiety and depression
2. Identify changes in psychological factors that correlate with improvements in
abdominal symptom burden. These aims were addressed using a single arm
design with measurements of psychological factors and symptoms pre, mid and
post-therapy. n¼ 27 individuals from across Australia were recruited at the
eCentreClinic at Macquarie University (Australia) which specialises in online
psychological threapies. Abdominal symptoms were assessed using the
Gastrointestinal Symptom Rating Scale (GSRS) while anxiety was measured
via the GAD-7 and depression via the PHQ-9. Aim 1 was addressed via
change from pre- to post-treatment in scores while aim 2 was addressed by
correlating change in GSRS scores with change in anxiety, depression and pain
catastrophising scores.
Results: Of 27 patients who commenced therapy 22 completed the entire course
and provided post-therapy measures. There was no difference in baseline scores
for any measure between completers and non-completers. Scores for both
abdominal symptom and psychological traits were substantially and statistically
significantly improved at the end of therapy (Table 1).
Table 1: Baseline and change in scores for abdominal symptoms and psycho-
logical factors
Score Baseline Change Cohen’s d
GSRS 44.2 (11.0) 7.6 (10.5) 0.72
Anxiety 10.0 (5.2) 5.1 (4.4) 1.16
Depression 9.7 (4.8) 4.1 (5.3) 0.78
Catastrophising 19.8 (11.3) 11.5 (11.9) 0.97
At end of therapy 77% of patients had reduced GSRS scores and 95% reported
the program was worth the effort expended. The percentage change in GSRS
score was positively correlated with percentage change in pain catastrophising
(¼ 0.53, p¼ 0.01) and depression (¼ 0.53, p¼ 0.01) and to a lesser extent with
change in anxiety (¼ 0.36, p¼ 0.1).
Conclusion: Based on this pilot trial, a transdiagnostic iCBT program developed
specifically for functional gastrointestinal disorders shows considerable promise
with improvements in both gastrointestinal symptoms as well as psychological
functioning. The correlation between change in both mood scores and catastro-
phizing with change in abdominal symptoms opens avenues for further under-
standing of the mechanisms by which iCBT improves the gastrointestinal
sufferings of these patients. The low cost of iCBT compared with conventional
face-to-face therapy is attractive given challenges to public health budgets and its
modality makes therapy accessible to potential patients who are not able to travel
to a psychologist. Further, the transdiagnostic model on which this particular
iCBT treatment is based is readily adaptable to other functional somatic syn-
dromes so offers hope to a wide range of disorders.
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OP119 DYSBIOSIS INDUCES GUT INFLAMMATION AND
DEPRESSIVE-LIKE BEHAVIOR ASSOCIATED WITH BRAIN
BIOCHEMICAL AND FUNCTIONAL ALTERATIONS WHICH ARE
RESTORED BY PROBIOTIC TREATMENT
F. Turco1, F. Guida2, I. Palumbo1, M. Iannotta2, A. Furiano2, L. Luongo2,
R. Cuomo1, S. Maione2, V. De Novellis2
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Introduction: The gut-brain axis has been indicated as major substrate of patho-
physiological mechanisms in psychiatric comorbidities associated with chronic
inflammatory bowel disorders. In particular, intestinal microbiota alterations
may play a role in communication between these two systems1. However, such
communication is not fully understood and probably involves multiple
mechanisms.
Aims & Methods: In the present study we examined the presence of gut inflam-
mation, the behavior, as well as, the brain biochemical and functional alterations
in an antibiotic-induced dysbiosis animal model. Young male mice received a
mixture of nonabsorbable antimicrobials (ampicilline, streptomicin and clynda-
micin), which has been associated to the microflora composition alteration2, for 2
weeks. Afterwards, animals were treated with probiotic (Lactobacillus Casei DG,
109 cells) or vehicle up to 7 days. Whereupon, various behavioral testing were
performed. After sacrifice, mice intestine was cut in segments (duodenum, jeju-
num, ileum and colon) and expression of pro-inflammatory markers (IL-1b,
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TNF and iNOS) was evaluated by Western Blot analysis. Extracellular record-
ing from CA3 region of dorsal hippocampus was performed. Astrocytes and
microglial cells markers (GFAP and Iba-1, respectively) expression was evaluated
by immunohistochemistry.
Results: Biochemical evaluations indicated that dysbiosis induced an overall gut
inflammatory condition (significant increase in IL-1b, TNF and iNOS expres-
sion), associated with a depressive-like behavior and a reduced social interaction.
Altered behavior was accompanied by significant changes CA3 pyramidal neu-
rons firing activity. Moreover, the number of GFAP and Iba-1 positive cells was
significantly increased by dysbiosis. Very intriguingly, probiotic treatment sig-
nificantly decreased IL-1b, TNF and iNOS expression, normalized mice beha-
vior, restored the spontaneous ongoing activity of CA3 pyramidal neurons and
reduced the GFAP and Iba-1 positive cells number.
Conclusion: We found that, in mice, dysbiosis induced gut inflammation and
sickness behaviours associated with biochemical and electrophysiological altera-
tions in hippocampus. Probiotic treatment counteracted the gut inflammation
and restored the behavioural phenotype as well as the biochemical and functional
changes occurring in the brain of dysbiotic mice. These data suggest that intest-
inal dysbiosis, via the gut-brain axis, might contribute to the psychiatric co-
morbidity in patients with bowel disorders associated with an altered microflora
and that probiotic treatment may improve this condition.
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OP120 QUORUM SENSING MOLECULES OF GUT MICROBIOTA
AFFECT INTESTINAL TASTE RECEPTORS AND ANOREXIGENIC
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Introduction: Accumulating evidence suggests that the gut microbiota controls
host satiety and hungry (1). Even if quantitative modifications of the gut micro-
biota have been described in obesity, bacterial derived soluble factors are likely
involved in host dietary habits.
Aims & Methods: In this study we investigated the role of quorum sensing mole-
cules (the autoinducers, AI) used for communication within gut microbial com-
munities (2), in modifying food intake in the host. Adults CD1 male mice were
fed a high-fat diet (HFD, 35% energy by fat) or a normal diet (4% energy by fat)
and then daily rectally dosed with vehicle or 30 ng/g body weight of purified AI
namely N-(3-oxododecanoyl)-L-homoserine lactone (AHL-12) or 2-Heptyl-3-
hydroxy-4(1H)-quinolone (PQS). Two weeks later we determined: a) gut micro-
biota composition by quantitative PCR (qPCR) on fecal DNA; b) enteroendo-
crine cells (EECs) density in colonic mucosa by immunohistochemistry (IHC) for
synaptophysin; c) mRNA levels specific for taste receptors and for anorectic or
orexigenic peptides by qRT-PCR on colon and hypothalamus; d) food intake,
body weight gain, oral glucose tolerance test.
Results: In HFD-fed mice rectally administration of AHL-12 or PQS restored the
gut microbiota composition and normalized EECs density in colonic mucosa,
altered by fat diet. AI administration increased the mRNA levels of Tas2r5,
Tas2r38 and Tas2r105 whereas did not affect Tas2r131 and Tas1r3 allelic var-
iants of bitter taste receptors. Moreover, AHL-12 and PQS significantly
increased mRNA levels of anorectic peptides namely Cholecystokinin, Leptin
and Neurotensin in the gut and Brain-Derived Neurotrophic Factor in the
hypothalamus. Intraperitoneal administration of AHL-12 or PQS had no effects,
supporting an intestinal direct action. Accordingly, the rectal but not the perito-
neal administration of PQS and to a lesser extent AHL-12 significantly reduced
food intake, decreased fat-diet induced body weight gain and improved oral
glucose tolerance test.
Conclusion: We speculate that gut microbial AI mediate satiety through activa-
tion of taste receptors expressed by EECs and the release of gut peptides involved
in food intake.
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OP121 OXIDATIVE STRESS ACTIVATES NLRP3 INFLAMMASOME
AND IMPAIRS GASTRIC ANTRUM SMOOTH MUSCLE ACTIVITY
IN OBESE PATIENTS
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Introduction: Obesity is associated to oxidative stress and chronic inflammation.
Oxidative stress activates NLRP3 inFammasome with recruitment of ASC and
pro caspase-1, leading to caspase-1 (CASP) activation and subsequent interleu-
kin-1b (IL-1b) secretion. Motor disorders of the gastric antrum are observed in
obese patients (OB) with in vitro impairment of VIP-induced relaxation both of
smooth muscle cells (SMC) and strips
Aims & Methods: Our aim was to evaluate in vivo obese antral smooth muscle
impairment and to study in vitro the roles for oxidative stress and inflammation
on SMC motor alterations. Antral scans were obtained by Magnetic Resonance
Imaging (MRI) before and after a liquid meal in OB and normal weight (NW)
patients. SMC were isolated from human gastric antrum from 19 OB
(40.95BMI552.0 kg/m2) submitted to sleeve gastrectomy and 9 NW patients
submitted to gastrectomy for gastric cancer (19.05BMI525.0 kg/m2).
Antioxidant capacity was evaluated by ELISA; qPCR analysis was performed
for mRNA for NLRP3, ASC, CASP, IL-1b, TNF and COX-2 and the data
were normalized to b-actin mRNA levels. The effect of NADPH inhibitor
Apocynin (APO:1mg/ml) in reverting OB SMC alterations was tested both on
mRNA expression and on VIP (1mM) induced antral relaxation. Data are
expressed as mean SE, p5 0.05 considered significant.
Results: In respect to NW, RMI scans showed a reduced antral motility, both
during fasting and post-prandial periods, in OB consisting in a significant reduc-
tion of the width of antral contraction waves and magnitude of antral diameters
variations. OB SMC presented a statistically significant decrease in antioxidant
capacity (%59.02 0.13) associated to a stronger increase of mRNA encoding
for the inflammatory proteins TNF (%46.60 0.80), COX 2 (%348.18 0.63)
and NLRP3 inFammasome-related molecules. Pretreatment of OB gastric SMC
with APO restored by 84.71 0.2 antioxidant capacity and completely inhibited
the expressions in OB NLRP3 (26.25 0.35), ASC (34.52 2.18), CASP-1
(31.80 1.50) and IL-1b transcripts (3.58 0.86), all undetermined after APO
treatment. Associated to inhibition of the inflammasome components expression,
APO completely restored VIP-induced relaxations in obese SMC (OB:
%79.60 11.84 vs NW: %79.96 5.78).
Conclusion: Our study indicates a role for ROS in activation of NLRP3 inflam-
masome in obese gastric smooth muscle leading to a significant dysmotility that
could be restored by the use of antioxidants
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Introduction: The pathogenesis and treatment of esophagogastric junction out-
flow obstruction (EGJOO) are not fully understood. The lower esophageal
sphincter (LES) reportedly exhibits accommodation responses, and LES pressure
is suppressed by swallowing and pharyngeal water stimulation (PWS) (Mittal,
RK et. al. Gastroenterology. 1996;111:378–384); PWS-induced LES relaxation
appears to be analogous to gastric receptive relaxation. We have previously
reported that acotiamide was effective for patients with EGJOO.
Aims & Methods: This study aimed to evaluate the physiologic characteristics of
acotiamide-sensitive LES relaxation in patients with EGJOO. High-resolution
manometry was performed according to a standard protocol with the participant
in the supine position, while swallowing ten 5-mL liquid boluses. 13 patients with
EGJOO (mean age 65.5  standard deviation 4.1 years, eight of whom were
women) and 19 participants with normal esophageal pressures (mean age
50.0 3.0 years, 11 of whom were women) were enrolled. Basal LES pressure
(BLESP) and the integrated relaxation pressure (IRP) were measured. The extent
of PWS-induced LES relaxation (mmHg) was calculated as the difference
between BLESP and the mean LES pressure in the 5-s period before PWS.
Results: There was no difference in BLESP between normal subjects (34.6 2.1
mmHg) and patients with EGJOO (32.7 1.8 mmHg), but IRP was significantly
higher in patients with EGJOO (20.3 1.4 mmHg) than normal subjects
(10.8 0.6 mmHg). In normal subjects, LES pressure immediately declined
from 34.6 2.1 mmHg to 25.6 1.4 mmHg when the fluid bolus stimulated
the mouth and pharynx on the first swallow. Mean PWS-induced LES relaxation
was 9.0 1.7 mmHg in normal subjects, but was absent in patients with EGJOO.
United European Gastroenterology Journal 4(5S) A51
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
The mean LES pressure induced by PWS was 33.0 1.6 mmHg, and did not
differ significantly from the BLESP 32.7 1.8 mmHg). Acotiamide was adminis-
tered to address severe symptoms in six out of 13 patients with EGJOO.
Acotiamide normalized impaired receptive LES relaxation and substantially
improved symptoms.
Conclusion: Normal subjects have receptive LES relaxation, but this is impaired
in EGJOO. Acotiamide normalizes IRP in EGJOO, mainly by restoring LES
receptive relaxation.
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Introduction: It is a difficult to observe a lesion in the cervical esophagus because
of the difficulty in spreading the lumen. It is a challenge not only to find eso-
phageal cancers at an early stage, but also to successfully treat them by ESD
compared with lesions located at the thoracic esophagus.
Aims & Methods: The aim of this study was to clarify the safety and efficacy of
ESD for superficial cancer located at the cervical esophagus. Patients who met
the following criteria (case group) were enrolled in this retrospective study: 1)
ESD was performed from January 2006 to December 2015; 2) the lesion was
located at the cervical esophagus; and 3) squamous cell carcinoma (SCC) was
proven histologically. Forty-five patients met those criteria. As a control group,
379 patients with 405 lesions of SCC which were located at the middle thoracic
esophagus were enrolled. The lesions with entire circumferential mucosal defect,
recurrent lesions after radiotherapy, and the lesions located near the scar were
excluded in both groups. We evaluated adverse events including stricture and
pneumonia, procedure time, en bloc resection rate, and frequency of local
recurrence.
Results: In the case group, the average age was 67.3 years old, and the male-to-
female ratio was 38:7. The average maximum size of lesions was 20.7 mm, and
the histological depth of invasion was EP/LPM, MM, and SM2 in 39, 5, and 1
cases, respectively. The en bloc resection rate and R0 resection rate was 100%
and 91.1%, respectively, and the mean procedure time was 57 min. ESD was
performed under general anesthesia in 32 patients (71.1%). Damage of the
muscle layer during treatment was observed in 5 patients, for which clipping
was performed in 2 patients. Esophageal stricture was observed in 9 patients
(41%), for which local injection of steroid was administered in 6 patients. No
post-ESD bleeding was observed. Although perforation was identified in one
patient, he recovered with conservative treatment. Chemoradiotherapy as addi-
tional treatments were conducted in 1patient. No local recurrence was observed
during an average duration of follow-up of 34.1 months. In the control group,
the average age was 67.3 years old, and the male-to-female ratio was 334:45. The
average maximum size of lesions was 24.2 mm, and the histological depth of
invasion was EP/LPM, MM/SM1, and SM2 in 306, 67, and 32 cases, respec-
tively. The en bloc resection rate and R0 resection rate was 100% and 96%,
respectively, and the mean procedure time was 54 min. ESD was performed
under general anesthesia in 45 patients (11.1%). Damage of the muscle layer
during treatment was observed in 91 patients (22.5%), for which clipping was
performed in 38 patients. Esophageal stricture was observed in 14 patients (6.6%)
of 213 patients with more than half of mucosal defect, for which local injection of
steroid or PGA sheet were administered in 38 patients. No post-ESD bleeding
was observed. Although perforation was identified in three patients, they recov-
ered with conservative treatment.Surgery or chemoradiotherapy as additional
treatments were conducted in 19 or 49 patients respectively. Local recurrence
was observed in one patient during an average duration of follow-up of 41.8
months.
Conclusion: Safe ESD for superficial esophageal cancer in the cervical esophagus
could be achieved under an appropriate management and successful local control
was also confirmed. The stricture after ESD in the cervical esophagus developed
significantly higher than those in the middle esophagus.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP124 SUBMUCOSAL TUNNELING ENDOSCOPIC RESECTION VS.
THORACOSCOPIC SURGERY FOR LARGE SYMPTOMATIC
SUBMUCOSAL TUMORS IN THE ESOPHAGUS AND
ESOPHAGOGASTRIC JUNCTION
T. Chen, M. Xu
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Fudan University, Shanghai/China
Contact E-mail Address: xumeidong@aliyun.com
Introduction: Small gastrointestinal submucosal tumors (SMTs) are asympto-
matic and undetectable, while patients with larger tumors have symptoms, and
require intervention. Previously, thoracoscopic surgery (TS) is the gold standard
for these large SMTs in esophagus and esophagogastric junction (EGJ). We
described a new technique, submucosal tunneling endoscopic resection (STER),
for the resection of upper gastrointestinal SMTs. Recently, reports about STER
are increasing. However, it is unclear whether STER is feasible for large SMTs.
Moreover, studies about comparasion of STER and surgery for upper gastro-
intestinal SMTs are still little known.
Aims & Methods: The aim of this study is to compare the clinical outcomes of
STER and thoracoscopic surgery for large symptomatic SMTs in esophagus and
esophagogastric junction, as well as to analyze the clinicopathological factors
that effect the feasiblilty of STER. Patients with large SMTs originating from
the MP layer in esophagus and EGJ were enrolled in this retrospective study
between May 2011 and December 2013. The clinicopathological data of a total of
145 patients were collected and analyzed.
Results: Among the 145 patients, 39 patients (26.9%) complained specific symp-
toms, while 106 patients (73.1%) had non-specific complaints. In the STER
group, the mean tumor long and transverse diameters were 5.8 cm and 2.2 cm.
Meanwhile, in the TS group, the mean tumor long and transverse diameters were
6.5 cm and 3.1 cm, respectively. Among all SMTs, 64 had regular shapes (44.1%)
and 81 had irregular shapes (55.9%). All of the tumors were located in esophagus
(84, 57.9%), and EGJ (61, 42.1%). There was no significant difference between
the two groups in age, gender, symptom, tumor size, tumor location, tumor
shape, and tumor histopathology. No recurrence was found in both groups
during the follow up period. In this study, en bloc resection was achieved in
84.1% of the cases in the STER group and 85.7% of the cases in the TS
group, and there was no significance (p¼ 0.794). In addition, the incidence of
complications in this study was 8.5% in STER group and 4.8% in TS group.
There was no significant difference in complications rates of the 2 groups.
However, the procedure time and the hospital stay in the STER group were
significantly shorter than those of the TS group. Based on statistical analysis,
tumors with long diameter larger than 7.0 cm, transverse diameter lager than 3.5
cm and irregular shape were 3 significant risk factors for STER-related piecemeal
resection, while tumor with transverse diameter lager than 3.5 cm was the risk
factor for STER-related complications.
Conclusion: STER is feasible and safe for large symptomatic SMTs in esophagus
and EGJ. It is associated with a shorter procedure time and hospital stay com-
pared with TS. Besides long diameter and irregular shape, transverse diameter of
SMTs is the critical factor for en bloc resection. STER for tumors with large
transverse diameter and irregular shape is feasible, but associated with a rela-
tively high risk of difficulty in retrieval of tumors.
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OP125 CHARACTERISTICS OF METACHRONOUS GASTRIC
NEOPLASMS OCCURRING AFTER ENDOSCOPIC SUBMUCOSAL
DISSECTION FOR GASTRIC ADENOMAS AND CANCERS
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Introduction: With the progress of endoscopic diagnosis and treatment, endo-
scopic treatment has come to be used for gastric adenomas and early gastric
cancers (EGCs). Endoscopic submucosal dissection (ESD) has become accepted
as a minimally invasive treatment for superficial gastric neoplasms. However, the
development of metachronous gastric neoplasms has been occasionally detected
during follow-up after ESD. The clinicopathologic characteristics of these lesions
occurring after ESD were investigated.
Aims & Methods: From August 2006 to December 2015, stomach ESD was
performed for 375 patients with 426 lesions of gastric adenoma and differen-
tiated-type EGC at Aichi Cancer Center Aichi Hospital. Periodic upper gastro-
intestinal endoscopy, blood tests, and chest and abdominal computed
tomography were performed every 6 to 12 months after treatment. During the
follow-up period, 31 metachronous lesions (27 patients) were discovered at endo-
scopy more than 1 year after initial ESD. The characteristics of these lesions were
examined retrospectively.
Results: The median age at initial ESD was 72 (range, 56–82) years. The male to
female ratio was 23:4. On endoscopy, all patients were found to have atrophic
gastritis of the open-type according to the Kimura-Takemoto classification.
Helicobacter pylori testing was positive in 18 patients (66.7%), negative in 8
patients (29.6%), and unknown in 1 patient (3.7%). Of these 18H. pylori-positive
patients, 17 underwent H. pylori eradication therapy after initial ESD, and it was
successful in 16(94.1%). The median duration from initial ESD to the detection
of a metachronous lesion was 25.9 (range, 12.4–83.8) months. The locations of
the lesions were classified as follows: upper third (U), middle third (M), and
lower third (L). Of 29 primary lesions (27 patients), 1 lesion (3.4%) was U, 11
lesions (37.9%) were M, and 17 lesions (58.6%) were L. The gross type was 0-I in
one lesion (3.4%), 0-IIa in 15 lesions (51.7%), 0-IIc in 12 lesions (41.4%), and 0-
IIaþIIc in one lesion (3.4%). The median tumor size was 10 (range, 2–50) mm.
En bloc resection was performed for 28 lesions (96.6%). Aspiration pneumonia
occurred in one patient after ESD, but the patient was successfully treated by
intravenous antibiotics. There were no treatment-related deaths. On pathological
examination, 21 were tubular adenocarcinoma, and 8 were tubular adenoma.
Histologically, curative resection was obtained in 27 lesions (93.1%). In contrast,
the location of 31 metachronous lesions was U in 9 lesions (29%), M in 8 lesions
(25.8%), and L in 14 lesions (45.2%). The gross type was 0-IIa in 16 lesions
(51.6%), 0-IIb in 1 lesion (3.2%), 0-IIc in 13 lesions (41.9%), and 0-IIaþIIb in 1
lesion (3.2%). The median tumor size was 9 (range, 1.5–38) mm. En bloc resec-
tion was performed for 28 lesions (90.3%). Aspiration pneumonia occurred in
one patient after ESD, but the patient was successfully treated by intravenous
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antibiotics. There were no treatment-related deaths. On pathological examina-
tion, 20 were tubular adenocarcinoma, and 11 were tubular adenoma.
Histologically, curative resection was obtained in 26 of the 31 lesions (83.9%).
There were no differences in gross type (elevated type/flat and depressed type),
tumor size, or histology between primary and metachronous lesions. However,
location (U/M/L) was significantly different (P¼ 0.029). Furthermore, there were
significant differences in U/M (P¼ 0.016) and U/L (P¼ 0.014). Therefore, there
was a slightly higher frequency of metachronous lesions in the U area.
Conclusion: Metachronous lesions tended to develop in the U area. These results
suggest that it is necessary to carefully observe the U area by surveillance endo-
scopy after ESD for gastric neoplasms.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP126 A SIMPLE SCORING SYSTEM TO STRATIFY CURABILITY
AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY
GASTRIC CANCER WHICH HAS PATHOLOGICAL FACTORS
HIGHLY RELATED WITH LYMPH NODE METASTASIS:
DEVELOPMENT AND VALIDATION OF ‘‘ECURA SYSTEM’’
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Introduction: According to the European and Japanese guidelines for endoscopic
submucosal dissection (ESD) of early gastric cancer (EGC), radical surgery is
recommended for patients after ESD that does not meet the curative criteria
because of the potential risk of lymph node metastasis (LNM). However, as
LNM occurs in only 5–10% of patients who undergo radical surgery, this recom-
mendation for all such patients may be overestimated.
Aims & Methods: This multicenter study aimed to establish a scoring system
(eCura system) for deciding the potential risk of LNM after ESD with patholo-
gical factors related with LNM. Of the 15,785 consecutive patients who under-
went ESD for EGC from January 2000 to August 2011, we retrospectively
reviewed 2,006 patients who did not meet the curative criteria for ESD of
EGC. This study consisted of two stages. First, the risk-scoring system for
LNM was developed using multivariate logistic regression analysis in 1,101
patients who underwent radical surgery after having failed to meet the curative
criteria. The estimated factors were tumor size (430 mm), tumor depth (sub-
mucosal invasion 500 mm: SM2), histopathological type (undifferentiated-type),
lymphatic invasion, venous invasion, ulceration (scar), and positive vertical
margin (VM). We assigned weighted points proportional to b regression coeffi-
cient values for the factors determined in the multivariate analysis. Second, for
validating the risk-scoring system, the validity by survival analysis was evaluated
in 905 patients without additional treatment.
Results: In the development stage, based on accordant regression coefficients, five
risk factors for LNM were weighted with point values: 3 points for lymphatic
invasion and 1 point each for tumor size430 mm, positive VM, venous invasion,
and SM2. Then, the patients were categorized into three LNM risk groups: low
(0–1 point: 2.5% risk), intermediate (2–4 points: 6.7%), and high (5–7 points:
22.7%). The C statistic (95% confidence interval (CI)) of the system for LNM
was 0.74 (0.62–0.87) and the bootstrapping analysis showed similar results (95%
CI, 0.62–0.86). In the validation stage, cancer-specific survival differed signifi-
cantly among these groups (99.6%, 95.5%, and 90.1%, respectively, at 5 years;
p5 0.001). Cox proportional hazards regression analysis showed that the high-
risk [hazard ratio (95% CI)¼ 15.5 (4.03–59.4), p5 0.001] and intermediate-risk
[6.63 (1.75–25.1), p¼ 0.005] groups had significantly higher cancer-specific mor-
tality compared with the low-risk group. Moreover, the C statistic of the system
for cancer-specific mortality was 0.78.
Conclusion: This scoring system predicted cancer-specific survival, which may be
helpful to value the risk of LNM in patients after ESD that does not meet the
curative criteria.
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OP127 COMPARISON OF EMR AND ENDOSCOPIC SUBMUCOSAL
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Introduction: Endoscopic mucosal resection (EMR) and endoscopic submucosal
dissection (ESD) are now being increasingly used for the treatment of gastro-
intestinal neoplasia. However, their efficacies (en-bloc and curative resection)
have not been compared. EMR is associated with local recurrences, especially
when lesions larger than 20 mm are resected in a piecemeal manner (1). In
piecemeal-resected specimens, histologic assessment becomes difficult, because
of the effects of burning on the lesion. ESD permits a larger resection of the
tissue over the muscularis propria, including large lesions and positive non-lifting
sign lesions, with its major advantage being the ability to achieve a higher en-bloc
resection rate due to submucosal dissection with a direct view. This results in
enhanced curability and more accurate histopathological assessment. However,
this procedure is known to have several disadvantages such as greater technical
difficulty, longer procedure time and increased risk of related complications.
Aims & Methods: The aim of this study is to find the best method for treating
early gastrointestinal neoplasia. Fifty-one patients (mean patient age 71, range
32–92 years, male: female ratio 25/26) including 19 involved adenoma with low-
grade dysplasia, 21 intraepithelial cancers with high-grade dysplasia, 3 minute
submucosal cancers, 6 submucosal deep cancers and 2 carcinoid tumors sub-
mitted to ESD, were compared to 98 patients (mean patient age 62.7, range
20–88 years, male: female ratio 52/46) who underwent EMR (20 involved ade-
noma with low grade dysplasia, 42 intraepithelial cancers with high-grade dys-
plasia, 24 minute submucosal cancers, 3 submucosal deep cancers, 4 carcinoid
tumors, 3 granular cell tumors and 2 Brunner’s adenoma). In ESD group, the
mean operation time was 1.6 hrs and the mean size of resected specimen was 25.5
mm (range 10–80 mm); in EMR group, the mean operation time was 0.5 hrs and
the mean size of resected specimen was 26.2 mm (range 10–100 mm). En-bloc
resection rate, curative resection rate, piecemeal resection, recurrence rate, post-
operative bleeding and perforation rate were compared with the use of the chi-
square test.
Results: En-bloc resection rate (ESD: 82.4%, 42/51 vs EMR: 51%, 50/98;
p5 0.01) and curative resection rate (ESD: 88.2%, 45/51 vs EMR: 72.9%, 71/
98; p5 0.05) were significantly higher in ESD group in comparison with EMR
group. Piecemeal resection was significantly lower in ESD (17.7%, 9/51) when
compared to EMR group (49.9%, 48/98) (p5 0.01). In the EMR group, 6
patients developed local recurrences (6.1%): five were successfully treated by
additional EMR and one by surgical resection; in contrast, there was no recur-
rence in the ESD group (p¼NS). The post-operative bleeding rate was 3.92% (2/
51) in ESD and 3.1% (3/98) in EMR group (p¼NS). Perforation rate for ESD
was 3.9% (2/51) when compared to conventional EMR (2%, 2/98) (p¼NS).
Conclusion: In the present study, we evaluated the efficacy of 2 endoscopic resec-
tion methods from the perspectives of the en-bloc and curative resection rates.
Based on these aspects, an ESD was found to be the best method for early
gastrointestinal cancers; EMR would be a good alternative to an ESD, especially
in poor-risk patients or when performed by less experienced endoscopists.
Disclosure of Interest: All authors have declared no conflicts of interest.
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OP128 LONG-TERM OUTCOME OF THE INCIDENCE RATE OF
METACHRONOUS GASTRIC CANCERS AFTER HELICOBACTER
PYLORI ERADICATION – A FOLLOW-UP AND ANALYSES OF
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Introduction: The author and Japan Gast Study Group (JGSG) reported that the
eradication of Helicobacter pylori reduced the incidence of metachronous gastric
cancers (GC) after endoscopic mucosal resection significantly in the Lancet
20081).
Aims & Methods: We analyse long-term outcomes of the incidence rate of meta-
chronous GC for JGSG enrolled patients at Yamagata Prefectural Central
Hospital. Out of 89 enrolled patients, 6 patients died by other diseases and 43
patients were introduced to other clinics and hospitals, therefore 40 patients (the
eradication group 21, the non-eradication group 19) were followed-up at
Yamagata Prefectural Central Hospital. After this Lancet study, non-eradication
patients were recommended to receive an eradication therapy. Patients have been
followed-up once a year endoscopically. Among 40 patients the longest follow-up
case is in 15th observation year. A long-term incidence rate of metachronous GC
was analysed and compared between the two groups.
Results: Out of the eradication group, 1 metachronous GC was detected (9 years
7 months after the enrollment). Out of the non-eradication group, 4 metachro-
nous GC were detected (5 years 3 months, 6 years 7 months, 10 years 2 months,
13 years 10 months after the enrollment). When these 4 lesions were detected, 3
cases were not yet eradicated and 1 case was eradicated unsuccessfully. The
incidence rate of metachronous GC of the eradication group was 4.8% but
that of the non-eradication group was 21.1%.
Conclusion: The incidence rate of metachronous GC of the non-eradication
group was about four times higher than that of the eradication group even in
15th observation year. All 4 cases of metachronous GC of the non-eradication
group were persistent infected cases. The earlier eradication of Helicobacter
pylori is recommended.
Disclosure of Interest: All authors have declared no conflicts of interest.
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OP129 THE EFFECT OF PASIREOTIDE IN CYST REDUCTION OF
ASPIRATION SCLEROTHERAPY IN PATIENTS WITH LARGE
SYMPTOMATIC HEPATIC CYSTS, A RANDOMIZED CONTROLLED
TRIAL
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Introduction: Aspiration sclerotherapy is a therapeutical option for large sympto-
matic hepatic cysts. However, inadequate cyst reduction is frequently reported.
Somatostatin analogues are able to curtail cyst volume. We hypothesized that
combining the long-acting somatostatin analogue pasireotide (SOM230) with
aspiration sclerotherapy would enhance hepatic cyst reduction.
Aims & Methods: Our aim was to test whether pasireotide could improve the
efficacy of aspiration sclerotherapy of large symptomatic hepatic cysts. We con-
ducted a single-center, randomized (1:1 ratio), double-blind, placebo-controlled
trial in patients with a large (4 5 cm) symptomatic hepatic cyst. All patients
underwent aspiration sclerotherapy. In addition, we randomized patients
between two arms: (1) pasireotide 60 mg long-acting release (LAR) injection or
(2) placebo (saline) injection. Injections were administrated two weeks prior and
two weeks after aspiration sclerotherapy. Primary endpoint was proportional
cyst diameter reduction after six weeks, as measured by ultrasonography.
Secondary outcomes included long-term diameter reduction at 26 weeks, symp-
tomatic change at 26 weeks, and safety during the study. Symptomatic change
was evaluated using the polycystic liver disease-questionnaire (PLD-Q) that
assesses frequency and severity of 14 disease-specific symptoms leading to a
total PLD-Q sum score.
Results: Thirty-four patients (32 females (94%); mean age 53.6 7.8 years) were
randomized between pasireotide (n¼ 17) and placebo (n¼ 17). Pasireotide did
not improve efficacy of aspiration sclerotherapy at six weeks compared to con-
trols (23.6% [IQR 9.6–31.8%] versus 21.8% [IQR 9.6–31.8%], respectively;
p¼ 0.96). Long-term cyst diameter reduction was similar in both groups
(49.1% [IQR 27.0–73.6%] and 45.5% [IQR 29.2–59.6%]; p¼ 0.90). Mean
PLD-Q scores improved significantly in both groups (p5 0.01) indicating symp-
tomatic relief, but there were no differences between groups (p¼ 0.92). Transient
hyperglycaemia was seen in all patients allocated to pasireotide.
Conclusion: Aspiration sclerotherapy is a highly effective treatment option of
large symptomatic hepatic cysts, spiking with pasireotide does not further
improve efficacy.
Disclosure of Interest: J.P.H. Drenth: Novartis provided the study drug and
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Introduction: Knowledge of pathogenic spectrum for cholangitis is important for
adequate empiric therapy. Enterococcus species, which come well equipped with a
variety of intrinsic antibiotic resistances, are sometimes isolated. However, little
is known of risk factors for this organism’s isolation in patients with cholangitis.
We conducted a study to investigate them on the basis of single-center experience
in Japan.
Aims & Methods: Consecutive 191 hospitalized patients with cholangitis with
positive bile and /or blood culture between January 2009 and October 2015
were enrolled. Diagnosis of cholangitis was based on clinical symptoms, blood
chemistry and radiological imaging. Potential risk factors for Enterococcus spe-
cies isolation such as patient attributes (Age, sex, underlying conditions, and past
history) were retrospectively investigated. Univariate and multivariate analyses
to identify risk factors were performed using a proportional hazards model.
Results: 127 patients were men (67%). The average age was 74.2(34–97) years.
Enterococcus species were isolated in 128 episodes from bile and /or blood cul-
ture. Age over 75 years old(Odds Ratio [OR]¼1.984; 95% Confidence Interval
[CI] 1.109–3.548; P¼ 0.028), prior endoscopic sphinterotomy(OR¼ 5.676; CI
2.713–11.87; P50.0001), presence of device in biliary tract(OR¼ 3.141; CI
1.595–6.183; P¼ 0.0009), biliary reconstruction(OR¼ 5.895; CI 1.301–26.71;
P¼ 0.015), stayed in Intensive Care Unit in past admission(OR¼ 2.588; CI
1.342–4.992; P¼ 0.005), administration of penicillins(OR¼ 7.29; CI 0.905–
58.74; P¼ 0.045) were identified as risk factors for Enterococcus species isolation
by the univariate analysis. Multivariate analysis revealed that prior endoscopic
sphinterotomy (OR¼ 4.480; 95%CI 1.907–11.26; P¼ 0.0005) and biliary
reconstruction(OR¼ 8.945; CI 2.247–60.12; P¼ 0.001) were independent signifi-
cant risk factors.
Conclusion:We found prior endoscopic sphinterotomy and biliary reconstruction
were independent risk factors for Enterococcus species isolation in cholangitis.
We should consider empirial therapy with anti-enterococcal antibiotics when
managing patients with these attributes.
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Introduction: The risk of developing biliary tract cancer, including cancers of the
gallbladder and the extra-hepatic bile ducts, may be influenced by estrogen
Table (OP130)
Risk factors for enterococcal cholangitis
Enterococcus spp.
isolation
Non-enrerococcus
spp. isolation Univariate analysis Mutivariate analysis
(N¼ 109) (N¼ 82) Odds ratio (95% CI) P value
Adjusted odds ratio
(95% CI) P value
Age(years) 76.4(42–97) 71.4(34–97)
age=75 65(60%) 35(43%) 1.984(1.109–3.548) 0.028 1.637(0.844–3.191) 0.144
Male gender 72(66%) 55(67%) 0.955(0.520–1.754) 1
Onset after 48 h admission 21(19%) 19(23%) 0.791(0.393–1.593) 0.591
Biliary tract malignancies 54(50%) 38(46%) 1.137(0.640–2.018) 0.77
Diabetes mellitus 22(20%) 19(23%) 0.838(0.419–1.679) 0.722
Prior cholecystitis 12(11%) 4(4.9%) 2.412(0.749–7.774) 0.187
CBD stone 48(44%) 38(46%) 0.911(0.512–1.620) 0.77
Gallstone or biliary sludge 63(58%) 52(63%) 0.790(0.439–1.423) 0.458
Prior PTCD 12(11%) 9(11%) 1.003(0.401–2.508) 1
Prior EST 51(47%) 11(13%) 5.676(2.713–11.87) 50.0001 4.480(1.907–11.26) 0.0005
Presence of device in biliary tract 45(41%) 15(18%) 3.141(1.595–6.183) 0.0009 1.442(0.600–3.419) 0.408
Biliary tract reconstruction 14(13%) 2(2.4%) 5.895(1.301–26.71) 0.015 8.945(2.247–60.12) 0.001
Prior cholecystectomy 24(22%) 10(12&) 2.033(0.912–4.532) 0.088
Stay in ICU in present admission 53(49%) 35(43%) 1.244(0.698–2.218) 0.467
Stay in ICU in past admission 44(40%) 17(21%) 2.588(1.342–4.992) 0.005 1.731(0.826–3.675) 0.146
Any antibiotic treatment within previous 14 days 25(23%) 11(13%) 1.921(0.884–4.175) 0.134
Cephalosporins 17(16%) 10(12%) 1.330(0.574–3.081) 0.537
Penicillins 9(8.1%) 1(1.2%) 7.29(0.905–58.74) 0.045 3.157(0.461–64.83) 0.269
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exposure.1 Exogenous estrogens are used extensively to alleviate symptoms of
menopause, but the effect on biliary tract cancer risk is not known.2
Aims &Methods: This was a population-based cohort study conducted in Sweden
between July 2005 and December 2011 aiming to investigate the risk of biliary
tract cancer after menopausal hormonal therapy (MHT). The National
Prescribed Drug Register was used to identify MHT exposed women during
the study period. For each exposed woman, three unexposed women were ran-
domly selected from the same study base. Unexposed individuals were exactly
matched for history of delivery, thrombotic events and hysterectomy, creating 8
strata. Furthermore, additional matching (nearest neighbor) was performed for
age, smoking status, alcohol use, obesity and diabetes within each stratum.
Record linkage to the Swedish Patient Register allowed collection of potential
confounding factors and status of the matching variables. The cohort was fol-
lowed-up for biliary tract cancer and death by linkage to The Swedish Cancer
Register and the Cause of Death Register. Logistic regression models were esti-
mated to calculate odds ratios and matching 95% confidence intervals for the
association between MHT exposure and biliary tract cancer. All analyses were
stratified according to MHT regimen (estrogen or estrogen/progestogen combi-
nations). All matching variables were included in the logistic models.
Additionally, the risk of developing symptomatic gallstone disease was evaluated
using a similar logistic regression model.
Results: The final cohort included 290,186 MHT exposed, and 870,165 unex-
posed, women. The resulting total cohort consisted of more than 1.1 million
women and follow-up was performed over 7 years. The odds of gallbladder
cancer was decreased in MHT-exposed women (OR 0.6, 95% CI 0.4–0.8),
whereas no clear association between MHT-exposure and cancers of the extra-
hepatic bile ducts was seen (OR 0.8, 95% CI 0.6–1.2). There were no clear
differences when the analyses were stratified for estrogen or estrogen/progester-
one-combinations. Adjusting for clinically manifest gallstone disease attenuated
the odds of gallbladder cancer in MHT-exposed women (OR 0.8, 95% CI 0.6–
1.2). Additionally, MHT exposure significantly increased the risk of gallstone
disease (OR 7.0, 95% CI 6.6 – 7.3).
Conclusion: In conclusion, this large cohort study did not support a clear asso-
ciation between MHT and BTC. Furthermore, the reduced risk of GBC after
MHT exposure is likely to be explained by increased risk of symptomatic gall-
stone disease resulting in cholecystectomy. Thus, this study supports the role of
gallstones as an intermediate step in the development of GBC.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Moerman CJ, Berns MP, Bueno de Mesquita HB and Runia S. Reproductive
history and cancer of the biliary tract in women. Int J Can 1994; 57(2):
146–53.
2. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and
combined oestrogen/progestogen therapy versus placebo for hot flushes.
The Cochrane database of systematic reviews. 2004(4):CD002978.
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Introduction: The prognosis of extrahepatic cholangiocarcinoma (ECC) was poor
for the difficulty of early diagnosis due to their anatomical location and insidious
onset, and little effective tumor markers. Our previous study showed Mucin3A
(MUC3A) was the main differential protein in bile with proteomics technology
using isobaric tags for relative and absolute quantitation (iTRAQ) in 20 patients
with ECC and 20 patients with sphincter of oddi dysfunction (SOD).
Aims & Methods: Aim: To validate the histologic expression of MUC3A in ECC
and explore diagnosis value of serum MUC3A as the potential tumor marker for
diagnosis of ECC. Methods: (1) The expression of MUC3A was detected in 15
specimens of ECC and 20 normal bile duct tissues specimens by immunohisto-
chemistry method. The relationship between MUC3A and the clinicopathologic
features of ECC were investigated. (2) Serum MUC3A were detected in 16 pre-
operative patients with ECC and 15 preoperative patients with SOD, Serum
MUC3A in 16 patients with ECC were compared preoperative with postopera-
tive one month. (3) The clinical diagnosis application of serum MUC3A was
compared with CEA, CA19–9 in 20 patients with ECC and 20 patients with
SOD.
Results: (1) The positive cells rates of MUC3A in ECC specimens were significant
higher than in normal bile duct tissues specimens (83.3% vs. 35.0%, P5 0.01).
The expression of MUC3A was significant correlated with metastasis of lymph
node, infiltration and UICC stage of carcinoma, differentiation grade of carci-
noma (P5 0.05). (2) The preoperative serum values of MUC3A in patients with
ECC were significant higher than patients with SOD (57.8 19.6 vs.
25.1 9.2ng/ml, P5 0.01). Compared with the preoperative results, postopera-
tive one month serum MUC3A in patients with ECC were significant decreased
(26.8 4.6 vs. 57.8 19.6ng/ml, P5 0.01). ROC curve analysis showed serum
MUC3A could distinguish ECC with SOD while 40.7 ng/ml as the cut-off value
(AUC¼ 0.907, 84.6% sensitivity, 90% specificity). (3) The serum MUC3A has
much higher sensitivity (84.6%, 38.5%, 76.9%), specificity (90%, 95%, 85%),
diagnostic accuracies (86.6%, 63%, 80.4%) and less false positive rates (10%,
5%, 15%) than serum CA19–9, CEA in diagnosing ECC.
Conclusion: MUC3A is high expression in tumor tissue of ECC, and related to
the differentiation grade and stage of tumor. The MUC3A in peripheral blood is
valuable to preoperative diagnosis of ECC. MUC3A is expected to become one
of diagnosis and detection indicator of ECC.
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Introduction: Hepatopulmonary syndrome (HPS) is a severe pulmonary compli-
cation of liver disease for which no medical treatment is available. In rats,
common bile duct ligation (CBDL) has been documented as a model for
human HPS, which is characterized by pathological pulmonary angiogenesis.
Studies in genetically modified mice could offer opportunities for further
research, however, in this species the development of pulmonary angiogenesis
in biliary cirrhosis has not been outlined yet.
Aims & Methods: We aimed to elucidate the temporal changes in proangiogenic
signature of hepatic and pulmonary vasculature after CBDL in mice and in
addition identify potential proangiogenic factors contributing to the pathogenesis
of HPS. Male Swiss mice underwent CBDL or sham surgery and were sacrificed
at a weekly basis for 6 consecutive weeks. Pulmonary inflammation was studied
by cytology on broncho-alveolar lavage fluid, myeloperoxidase assay and lumi-
nex bead based assay on lung tissue. Liver and lungs were collected for protein
analysis and histology to assess liver fibrosis and hepatic and pulmonary angio-
genesis. Scanning electron microscopy was performed on vascular corrosion casts
to visualize pulmonary vasculature during cirrhosis ex vivo.
Results: CBDL progressively induced liver fibrosis from week 1 (F0–1) to week 6
(F4). This was accompanied by a gradual increase in hepatic immunopositivity
for Endoglin and von Willebrand Factor, two markers of endothelial cell activa-
tion (P5 0.0001). Hepatic levels of vascular endothelial growth factor (VEGF),
VEGF receptor 1 and 2 were significantly increased at week 6, whereas placental
growth factor (PlGF), which is exclusively involved in pathological angiogenesis,
was already upregulated at week 2 (P5 0.0001). In the pulmonary compartment,
CBDL resulted in neutrophil infiltration and increased pro-inflammatory med-
iators from week 2 to 6 (all P5 0.001). Pulmonary immunoreactivity for
Endoglin and von Willebrand Factor progressively increased from week 4 to 6,
while PlGF was already increased from week 2 onwards (all P5 0.0001).
Scanning electron microscopy revealed regions of abnormal vascular architec-
ture, mainly located at the pleural side, decreased intercapillary distance
(P5 0.001) and increased capillary density (P5 0.05) in lungs of cirrhotic mice.
Conclusion: CBDL in mice is associated with pathological pulmonary angiogen-
esis and may represent a model for human HPS. In addition, we point to PlGF as
an early indicator of pathological hepatic and pulmonary angiogenesis.
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Introduction: Gallbladder polyps can be divided in neoplastic polyps (adenoma,
dysplastic polyp, and carcinoma) and nonneoplastic polyps (eg. cholesterol
polyp, inflammatory polyp or adenomyoma).1 Cholecystectomy is only indicated
for neoplastic polyps, as they are (pre)malignant.2 Annually, over 23,000 chole-
cystectomies are performed in the Netherlands.3 However, there is scarce pathol-
ogy data on the prevalence of gallbladder polyps and attribution of neoplastic
and nonneoplastic polyps.
Aims & Methods: We aimed to assess nationwide pathology data on gallbladder
polyps over a 10-year period. Methods: The PALGA database, the Dutch
Pathology Registry,4 was used to identify all histopathologically proven gallblad-
der polyps over the period 2003–2013. The search was restricted to histological
samples of patients  18 years of age. Biopsies, and cholecystectomies performed
as part of primary non-gallbladder surgery (e.g. whipple or hepatectomy), were
excluded. All excerpts concerning primary gallbladder surgery containing a polyp
or (focal) wall thickening 4 5 mm were included. These excerpts were rated as
neoplastic (adenoma, dysplasia, carcinoma or other malignancies) or nonneo-
plastic (all other types of polyp). If both neoplastic and nonneoplastic lesions
were present, the excerpt was classified as neoplastic. Prevalence of gallbladder
United European Gastroenterology Journal 4(5S) A55
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
polyps and the attribution of neoplastic polyps and nonneoplastic polyps was
calculated. To determine prevalence of gallbladder polyps, we obtained the total
number of cholecystectomies between 2003–2013 from PALGA.
Results: In total 220,612 cholecystectomies were performed over the period 2003–
2013. The PALGA search identified 4532 excerpts, representing 4349 patients. A
total of 337 patients were excluded due to primary non-gallbladder surgery,
leaving 4012 unique cholecystectomies. In 2083 cholecystectomies (0.9%), a poly-
poid leasion was present. Which results in a calculated prevalence of polyps in
944/100,000 patients who undergone cholecystectomy. Of the polyps, 1172
(56.3%) were neoplastic; 278 (13.3%) adenomas (incl. cystadenoma), 190
(9.1%) dysplastic polyps, 647 (31.1%) adenocarcinomas, and 57 (2.7%) other
malignancies. Nine hundred and ten (43.7%) polyp were nonneoplastic; 375
(18%) cholesterol polyps, 334 (16%) adenomyoma’s, 70 (3.7%) hyperplastic
polyps, 54 (2.6%) mucosal polyps, 42 (2.0%) inflammatory polyps, 18 (0.9%)
papiloma’s and 17 (0.8%) other types of polyps.
Conclusion: Approximately one percent of gallbladders contain a polyp on his-
topathological assessment after cholecystectomy. Fifty-six percent of the polyps
after cholecystectomy are neoplastic.
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OP135 CHANGES IN CIRCULATINGMICRORNA AFTER TREATMENT:
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Introduction: Hepatocellular carcinoma (HCC) is the second leading cause of
cancer-related death worldwide. Although treatment options have improved in
the past 30 years, prognosis remains unfavorable in many patients. The lack of
effective models for outcome prediction prevents the opportunity for individua-
lized treatment protocols. The potential role of microRNAs (miRNA) as prog-
nostic biomarker has witnessed an increasing interest, owing to the non-invasive
nature of miRNA-based screening assays. While many studies have suggested
several miRNAs as biomarker candidates, dynamic variations over extended time
period have not been assessed until now.
Aims & Methods: To identify potential circulating miRNA signatures for the
prediction oftherapy response and patient follow-up. Methods: 15 consecutive
patients with early/intermediated stage HCC were enrolled and treated according
to the ESSL/AASLD practice guidelines. Patients were staged (CT scan and/or
MRI) at time 0 (T0, before treatment), 1 month (T1) and 6 months (T6) from
therapy. Pax-gene Blood RNA tubes and Vacuette tubes where used to collect
total blood and serum at T0,T1,T6. Small RNAs were isolated and hybridized on
Affymetrix GeneChip miRNA arrays 3.0. qRT-PCR was used for miRNA vali-
dation in an independent cohort of 15 matched patients. The Kaplan-Meier
model was used to estimate disease-free survival (DFS).
Results: 80 single miRNA profiles have been analyzed using a microarray
approach. We analyzed 1733 miRNas over the 6 months period. The analysis
yielded different profile in serum and blood identifying the two biofluids as two
distinctive sources of miRNA carrying the same message. Only a small portion of
the circulating mirnome remained significant in all time points indicating a
dynamic variation in the miRNA expression. Blood mir-3179, 373, 4773 signifi-
cantly increased from T0 to T6 while mir-2277–5p, 106b, 202 decrease. In serum,
mir-4649–3p, 3148, 371 increase while mir-103b decrease. The hierarchical clus-
tering of the most 150 variable miRNAs on log scale clearly differentiated T0
profiles from T1 and T6 both in blood and serum. Interestingly at T1 two main
clusters distinguished patient with a complete response from whose having only a
partial response to therapy. Further validation of miR-106b showed a correlation
between mir-106b levels and treatment response (P5 0.001), and the longer DFS
(P5 0.0038). MiRNA-106b was also significantly correlated with the with BCLC
staging A1 and A2 (P5 0.001).
Conclusion: This study underlines the importance of the different information
provided by miRNA profiles during the follow-up of a single patient. Circulating
mir-106b detection offers a promising non-invasive analysis tool to identifyg
patients with the longest disease-free survival in response to anticancer therapies.
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Introduction: Zinc ribbon domain-containing 1 antisense RNA 1 (ZNRD1-AS1)
genetic polymorphisms have been associated with hepatocellular carcinoma
(HCC) development. We aimed to determine impacts of ZNRD1-AS1 poly-
morphisms and their interactions with HBV genotypes on the risk of HCC.
Aims & Methods: We conducted a large multi-center case-control study with a
total of 1,507 HBV-related HCC cases and 1,560 HBV persistent carriers. Three
single nucleotide polymorphisms (SNPs) in ZNRD1-AS1 (rs3757328, rs6940552
and rs9261204) were genotyped using TaqMan allelic discrimination assay, and
HBV genotypes were identified by multiplex PCR.
Results: We found consistently significant associations between ZNRD1-AS1
rs6940552/rs9261204 and increasing risks of HCC (dominant genetic model:
adjusted OR¼ 1.16, 95% CI¼ 1.03–1.32 for rs6940552; adjusted OR¼ 1.20,
95% CI¼ 1.06–1.35 for rs9261204), and a borderline significant association of
rs3757328 with HCC risk. Besides, a dose-dependent manner was observed
between the increasing number of variant alleles of the three SNPs and the
risk for HCC (P for trend 50.001). Moreover, a strong combined effect of
three SNPs was observed among the subjects infected with non-B groups
(adjusted OR¼ 1.26, 95% CI¼ 1.05–1.50) on HCC risk, compared with those
in HBV B-related genotype groups (adjusted OR¼ 0.89, 95% CI¼ 0.69–1.15)
(P¼ 0.029 for heterogeneity test). We also detected a significant multiplicative
interaction between the variant alleles and HBV genotype on HCC susceptibility
(P¼ 0.030).
Conclusion: ZNRD1-AS1 SNPs (rs3757328, rs6940552 and rs9261204) and their
interaction with HBV genotypes may serve as susceptibility biomarkers for risk
of HBV-related HCC.
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Introduction: Recent studies suggest autophagy is highly active in regulatory T
(Treg) cells. High-mobility group box-1 protein (HMGB1), enriched in the
microenvironment of damaged and injured livers, is critical for T cell autophagy.
Aims & Methods: This study is designed to determine whether and how HMGB1-
dependent autophagy maintains the immunesuppressive features of Treg cells
during chronic hepatitis B virus (HBV) infection. Blood samples from patients
with chronic hepatitis B (CHB, n¼ 36), at immune-tolerant stages (IT, n¼ 25)
and healthy controls (n¼ 50) were collected. By flow cytometry,
CD4þCD25þCD127- (Treg) cells were purified from peripheral blood mononuc-
lear cells (PBMCs) for further analysis. Serum samples were prepared to deter-
mine HMGB1 levels. The autophagy in Treg cells were in vitro determined with
Lysotracker Green probes in the presence or absence of HMGB1, rapamycin and
3-methyladenine. HMGB1-dependent autophagy pathway and its effects on Treg
functions were determined by both western blot and quantitive real-time PCR.
The microtubule-associated protein 1 light chain 3 (LC3)-GFP mice were injected
with AAV-1.3HBV to further determine HMGB1-dependent autophagy in Treg
cells in the microenvironment of livers during chronic HBV infection.
Results: Treg cells from patients in IT group had significantly up-regulated base-
line autophagy levels compared to both CHB and HC groups, reflected by
increased intracellular mass of lysosomes. The mean fluorescence intensity
(MFI) of lysosomes in Treg cells significantly and positively correlated with
serum HMGB1 levels. In vitro, HMGB1 mainly acted through the receptor for
advanced glycation end-products (RAGEs) of Treg cells to up-regulate the
autophagy levels, with significantly decreased phosphorylation of mTOR and
increased Beclin-1/Vps34 proteins. Besides, HMGB1-RAGEs induced autophagy
was indispensible to maintain Foxp3, CTLA-4, IL-10 and TGF-beita mRNA
levels of Treg cells. In HBV-infected mouse models, the intra-hepatic HMGB1,
RAGEs and LC3 expressions were significantly increased. Moreover, down-regu-
lated p-mTOR and up-regulated Beclin-1/Vps34 proteins were detected in the
intra-hepatic Treg cells.
Conclusion: HMGB1-dependent autophagy is a new mechanism to maintain the
immunosuppressive features of Treg cells during chronic HBV infection.
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Introduction: Intrahepatic nitric oxide (NO) signaling including activation of its
receptor guanylyl cyclase (GC) is impaired in cirrhosis. The GC stimulator rio-
ciguat (RIO) is approved for treatment of pulmonary hypertension.
Experimental studies suggest antifibrotic effects of RIO. We investigated the
effects of RIO in cirrhotic rats with portal hypertension (PHT).
Aims & Methods: Two early and advanced cirrhotic rat models were used to
assess changes in hemodynamics and fibrosis after RIO treatment. Cirrhosis
was induced by i.p. carbontetrachloride (‘‘early’’: 1mL/ kg - ‘‘advanced’’:
2mL/ kg 50%CCl4, 8 weeks) or by bile duct ligation (BDL, ‘‘early’’: 3 weeks -
or ‘‘advanced’’: 5 weeks) in 100 male Sprague Dawley rats. Controls received
olive-oil (OO) or underwent sham operation (SO), respectively. RIO (1mg/ kg/d)
or vehicle was gavaged from weeks 5–8 in CCl4/OO and from weeks 2–3 [or 4–5]
in BDL/SO animals. Systemic hemodynamics, portal pressure (PP), superior
mesenteric blood flow (SMABF) and porto-systemic shunting (PSS) were mea-
sured. Hepatic fibrosis was quantified by hydroxyproline content (HP) and
chrome aniline blue (CAB) staining. Expression of TNF, endothelial nitric
oxide synthase (eNOS) and inducible NOS (iNOS) were quantified in liver
tissue by western blotting.
Results: BDL and CCl4 rats presented with cirrhosis, elevated PP, SMABF and
PSS, which was more pronounced in the advanced setting. In early BDL cirrho-
sis, preventive RIO treatment (W2–3) reduced PP (13.2 2.5 vs. 10.1 2.4
mmHg; p¼ 0.048), HP content (286 147 vs. 144 74 mg/g; p¼ 0.039) and
CAB area (24.7 4.6 vs. 13.3 2.1%; p5 0.001) without affecting systemic
hemodynamics, SMABF or PSS. When RIO was given to BDL rats with
advanced disease, PP (15.5 1.6 vs. 11.9 2.1mmHg; p¼ 0.002), HP content
(354 169 vs. 233 45mg/g; p¼ 0.044) and CAB area (29.9 2.2 vs. 19.3 5.7%;
p5 0.001) all significantly improved. Further, in BDL-RIO animals, hepatic
eNOS and iNOS content increased, while TNF expression was significantly
reduced. In early CCl4-rats, RIO treatment reduced CAB area (33.5 4.9 vs.
25.8 2.8%; p¼ 0.028) while the reduction in HP was not significant. The
increase in PP (8.13 1.31 vs. 6.43 0.40mmHg; p¼ 0.042) and SMABF
(52 5 vs. 42 4 mL/min; p¼ 0.010) observed in early CCl4 cirrhosis was sig-
nificantly blunted in RIO treated animals. In advanced CCl4 rats only a SMABF
reduction (75 11 vs. 43 6 mL/min; p¼ 0.036) and a trend towards lower CAB
area (43.8 6.1 vs. 28.9 7.5%; p¼ 0.056) was notable. RIO had no effects in
control animals (SO and OO rats).
Conclusion: RIO treatment significantly reduced liver fibrosis and portal pressure
in early biliary and toxic cirrhosis. Even in advanced biliary cirrhosis, RIO
treatment ameliorated liver fibrosis and portal hypertension.
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Introduction: The mechanism of liver atrophy due to portal vein embolization
was still unclear. With regard to the liver, autophagy has been reported to be
caused by starvation and related to hepatocellular atrophy1. Using pig models of
percutaneous transhepatic portal vein embolization (PTPE) with absolute etha-
nol, we have previously observed temporary elevation of serum levels of liver
enzymes immediately after ethanol injection and macroscopic liver atrophy
accompanied by an increased future liver remnant /total estimated liver volume
ratio 2 weeks after PTPE2. The other literature have reported that the relative
lobule size in the embolized lobe of the pig had gradually decreased to 23% of the
normal pig liver at 12 days after PTPE with a combination of coils and polyvinyl
alcohol particles; thereafter, the size did not change3. Therefore, in order to
clarify the mechanisms responsible for liver atrophy, pathological analysis
should be carried out within this time period. However, to the best of our knowl-
edge, these time-course studies have not yet been carried out4–5.
Aims & Methods:We attempted to investigate the mechanism of liver atrophy by
portal vein obstruction and clarify the role of autophagy and apoptosis. As pig
lobule structures were well-defined as compared with human specimen, we per-
formed percutaneous transhepatic portal embolization (PTPE) in 5 pigs. And
then sacrificed them at day 0, week 2, 4 or 6 (d0, w2, w4 and w6, respectively).
In specimens of embolized lobe (E) and non-embolized lobe (control, Cont), we
measured the distance between portal vein and central vein (PV-CV), area and
hepatocyte number per lobule and apoptotic activity. Immunohistochemical
reactivates of microtubule-associated protein-light chain 3 beta (LC3) as autop-
hagy and glutamine synthetase (GS) and cytochrome 2E1 (CYP2E1) as zonation
were evaluated.
Results: PV-CV and lobule area showed no significant difference between E and
Cont at d0, but were lower in E than in Cont at w2, w4 or w6 (P  0.001).
Hepatocyte number was not significantly reduced in E at d0 and w2 but was
reduced at w4 and w6 (P  0.01). Apoptotic activity was higher in E than in Cont
at d0 and w4. LC3 staining peaked in E at w2, with no significant difference
between E and Cont at w4 and w6. GS and CYP2E1 areas in E at w2, w4 and w6
were narrower than those in Cont.
Conclusion: Our morphological study focused on changes in the lobules over
time, and we observed two distinct phases of liver atrophy following portal
blood flow disruption. The first (the autophagic phase) was characterized by
lobular shrinkage without hepatocytes loss and high LC3 expression, and
lasted for the first two weeks following PTPE. The second phase, termed the
apoptotic phase, was characterized by reduced hepatocyte number without
reduced lobular size but with reduced LC3 expression and increased TUNEL
staining, and lasted 2–4 weeks.
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Introduction: For the investigation of hepatic hemodynamics in animal models
invasive methods are conventionally used. This study seeks to evaluate a non-
invasive Magnetic Resonance Imaging (MRI) method as a reliable diagnostic
tool in the widely used model of Thioacetamide (TAA)-induced liver injury.
Aims & Methods: (1) To quantitatively assess hepatic hemodynamic parameters
(portal vein area, portal blood flow velocity and portal blood flow volume) and
aortal blood flow volume using MRI technique in rats; (2) To investigate the
influence of the hepatotoxic agent TAA on these hemodynamic parameters. 54
male Wistar rats were studied. 15 of which were left untreated and 39 received
TAA in their drinking water (0.03g TAA / 100ml H2O). The TAA dosage was
adjusted weekly based on the body weight changes. From the 39 treated rats 15
received TAA for 12 weeks and 24 for 16 weeks. The following parameters were
measured by a 9.4 Tesla preclinical MR scanner: portal vein area, portal blood
flow velocity, portal blood flow volume and aortal blood flow volume.
Specifically gradient-echo fast phase contrast sequences were used with both
cardiac and respiratory gating. All MRI measurements were performed under
continuous Isoflurane anesthesia. The degree of liver injury was estimated by
standard histological criteria. Histological evaluation was performed in all 54 rats
while hemodynamic measurements could be evaluated in 50 rats. For statistical
analysis Kruskal-Wallis test was used.
Results: From the rats which received TAA for 12 weeks 100% (15/15) developed
liver fibrosis with a Desmet score of 1–3 (group 12w/fib). From the rats which
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received TAA for 16 weeks, 46% (11/24) developed liver fibrosis with a Desmet
score of 1–3 (group 16w/fib) and 54% (13/24) had liver cirrhosis with a Desmet
score of 4 (group 16w/cir). The untreated rats (15/54) served as control group
(group con). Mean portal vein area showed no significant differences among all
groups. However mean portal flow velocity was reduced by 15% in group 12w/
fib, 19% in group 16w/fib and 12% in group 16w/cir compared to group con. In
group 16w/cir mean weight was significantly lower than that of group con. Thus
flow volumes were adjusted according to the body weight in order to eliminate
weight-induced changes in hemodynamics. Mean aortal flow volume per body
weight showed no significant differences among all groups. In contrast mean
portal flow volume per body weight was significantly reduced in group 12w/fib
by 23% compared to group con. On the other hand, in group 16w/fib and group
16w/cir there was no further reduction of mean portal flow volume per body
weight. These results indicate that in the model of TAA-induced liver injury the
development of fibrosis is sufficient to cause a significant decrease in portal flow
volume. There were no significant differences between group 12w/fib and 16w/fib
in terms of all parameters, in particular portal flow volume.
Conclusion: In conclusion the non-invasive MRI technique can be a reliable
diagnostic tool to investigate the hepatic hemodynamics in different experimental
models of liver injury. In this particular animal model even the TAA-induced
liver fibrosis led to a significantly reduced portal liver perfusion. The molecular
mechanisms of this finding need to be further investigated.
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OP141 CORRELATION OF ENDOSCOPIC FINDINGS WITH SERUM
DRUG CONCENTRATIONS AND NEED FOR RESCUE THERAPY:
SUBANALYSIS OF THE TROUGH CONCENTRATION ADAPTED
INFLIXIMAB TREATMENT (TAXIT) TRIAL
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Introduction: The Trough Concentration Adapted Infliximab Treatment
(TAXIT) randomized controlled trial [1] showed that targeting patients’ inflix-
imab trough concentrations to a 3–7 mg/mL window resulted in a more efficient
use of the drug in patients with inflammatory bowel disease. Following dose
optimization, continued concentration-based dosing was not superior to clini-
cally-based dosing for achieving clinical and biochemical remission (primary
endpoint) after 1 year maintenance treatment. This subanalysis of TAXIT
aimed to explore the correlation between drug level-based dosing and endoscopic
healing.
Aims & Methods: This was a retrospective analysis of all endoscopies performed
at the end of TAXIT. For Crohn’s disease (CD), mucosal healing was defined as
absence of ulcerations (complete mucosal healing) or clear improvement in
ulcerations (partial mucosal healing) when compared to baseline. For ulcerative
colitis (UC), healing was defined as a Mayo endoscopic subscore of 0 or 1. Rates
of mucosal healing were compared for both arms in TAXIT (clinically-based arm
1 and concentration-based dosing arm 2) and infliximab trough concentrations
were correlated to the degree of healing.
Results: Of the 226 patients completing the TAXIT maintenance phase, 125
(55%) underwent endoscopy after one year (n¼ 55 in arm 1 and n¼ 70 in arm
2). In the clinically-based dosing arm 1, 50/55 (91%) patients had mucosal heal-
ing at the end of the study, as compared to 63/70 (90%) patients in the concen-
tration-based dosing arm 2 (p¼ 1). The rates of mucosal healing were also
comparable between both arms in CD patients (35/38 in arm 1 vs. 49/52 in
arm 2; p¼ 0.69) and in UC patients separately (15/17 in arm 1 vs. 14/18 patients
in arm 2; p¼ 0.66). Patients who reached the primary endpoint of TAXIT more
frequently had complete mucosal healing (73/84 or 87%) compared to patients
who did not reach the primary endpoint (28/41 or 68%) (p¼ 0.02). Numerically
more patients who needed rescue therapy during maintenance phase of TAXIT
had not achieved mucosal healing (3/12 or 25%) compared to patients who did
not need rescue therapy (9/113 or 8%) (p¼ 0.09). The mean serum trough con-
centrations during the maintenance phase of TAXIT were 5.31 mg/mL in patients
with mucosal healing and 4.26 mg/mL in patients without mucosal healing
(p¼ 0.07).
Conclusion: The primary endpoint of TAXIT, clinical and biochemical remission,
correlated with endoscopic mucosal healing. Similar rates of mucosal healing
were observed in patients after clinically-based dosing compared to concentra-
tion-based dosing. A trend towards less mucosal healing was seen if rescue ther-
apy was needed during TAXIT. Mean serum trough concentrations during the
maintenance phase of TAXIT were higher in patients with mucosal healing.
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Introduction: Safety data of the immunogenicity coming from the ‘real life’ use of
CT-P13, the first biosimilar to infliximab, in inflammatory bowel disease (IBD)
are still lacking.
Aims & Methods: Our aim was to assess the frequency and characteristics of
infusion reactions during CT-P13 therapy in 13 Hungarian and 1 Czech IBD
centres. Demographic data were collected and a harmonized monitoring strategy
was applied. Trough level (TL) and anti-drug antibody (ADA) concentration
were regularly measured by ELISA at baseline and before every subsequent
CT-P13 therapy in the Hungarian cohort. Predictors, characteristics, therapy
and outcomes of infusion reactions were prospectively evaluated.
Results: 384 consecutive IBD patients were included in the present cohort.
Twenty-eight Hungarian IBD patients (9.6%) developed infusion reaction
during the treatment. Infusion reaction did not occur in the Czech population
thus predictors were assessed only in the Hungarian patients. Infusion reaction
occurred most frequently during the 2nd and 3rd infusion. The most frequent
symptoms of infusion reactions were flushing, dyspnoea and chest pain. CT-
P13 therapy had to be stopped in 78.6% of the cases and was switched to
adalimumab in 42.8% of the patients. However in 21.4% CT-P13 therapy was
continued with the use of supplementary intervention. Previous anti-TNF expo-
sure and ADA positivity during the induction therapy were predictive factor for
infusion reaction. Concomitant azathioprine therapy showed borderline protec-
tive effect on infusion reaction.
Conclusion: Patients with previous exposure to anti-TNFs and ADA positivity
during the induction therapy were more likely to develop infusion reactions. CT-
P13 biosimilar is safe with low rate of infusion reaction.
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Introduction: Combination therapy with infliximab (IFX) and azathioprine (A) is
the most effective strategy in patients with Crohn’s disease (CD) and ulcerative
colitis (UC) naive to both therapies. However the optimal dose of AZA which is
needed is still controversial. We assessed the impact of AZA dose reduction on
the risk of clinical relapse and pharmacokinetics of IFX in inflammatory bowel
disease (IBD) patients on combination therapy.
Aims & Methods: This prospective study included three cohorts of IBD patients
treated for at least one year with IFX-AZA and being in deep remission (clinical
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and endoscopic and/or biomarkers remission) for at least 6 months. All patients
had an IFX trough level over 2 mg/mL and were on stable doses of AZA (2 to 2.5
mg/ kg/d) and IFX (5mg/ kg every 8 weeks). In cohort A, AZA and IFX were
continued unchanged; In cohort B, the dose of AZA was halved, with a minimum
dose of 50mg/d; in cohort C, AZA was stopped and IFX continued as mono-
therapy. Primary endpoint was failure defined as a clinical relapse (CDAI4 220
with fecal calprotectin 4 450 mg/g stools) and/or need to change the original
therapeutic regimen because of adverse events. Trough levels of IFX (TRI) and
antibodies (ATI) were measured before each infusion.
Results: 81 patients (45 CD and 36 CD, mean age: 29.7 years, mean disease
duration: 24 months)were included (28 in Cohort A; 27 in Cohort B; 26 in
Cohort C). The clinical characteristics, duration of combination therapy, bio-
markers levels and TRI were similar in the three cohorts at the time of inclusion.
Five patients (17.8%) in Cohort A, three in Cohort B (11.5%), and 8 in Cohort C
(30.7%) experienced failure at one year (p¼ 0.1 across group). Three patients in
Cohort A had to stop AZA or to reduce the dose due to myelotoxicity or
digestive intolerance. In cohort A, The mean TRI concentrations were similar
at the time of inclusion (3.65 vs 3.45 mg/ml, respectively). In Cohort B, the mean
TRI remained stable after the reduction of AZA dose (3.95 vs 3.6 mg/mL, respec-
tively) while there was a significant reduction in the mean 6-TGN levels (310
pmoles vs 128 pmoles, respectively; p¼ 0 .03) at one year whereas in cohort C,
there was a significant reduction in TRI (4.2 vs 2.1 mg/mL; p¼ 0.02). Four
patients (14.2%) in Cohort A, four patients in Cohort B (14.8%), and 11 in
Cohort C (42.3%) experienced an unfavourable evolution of IFX pharmacoki-
netic defined by a decrease of TRI5 1 mg/mL or undetectable TRI with positive
ATI (p¼ 0.022 between A and C, p¼ 0.039 between B and C, p¼ 0.87 between A
and B). By ROC analysis (AUROC: O.93), a threshold of 6-TGN5 105 pmoles
was associated with an unfavourable evolution of IFX pharmacokinetic (sensi-
tivity: 67%; specificity: 92%; Likelihood ratio: 7.67).
Conclusion: AZA dose reduction in IBD patients on combination therapy is as
effective as the maintenance of AZA at the same dose and may improve AZA
safety profile. A threshold of 6-TGN5 105pmoles was associated with an unfa-
vourable evolution of IFX pharmacokinetics.
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Introduction: Although dose escalation is widely used to optimize biological ther-
apy in case of clinical relapse, less is known about possibilities to de-escalate
therapy in patients with inflammatory bowel disease (IBD) who are in clinical
remission. Dose de-escalation may not only have beneficial economic repercus-
sions, it may possibly also decrease the occurrence of adverse events.
Aims & Methods: In this retrospective cohort analysis, the outcome of dose de-
escalation to adalimumab (ADM) 40 mg every three weeks (ETW) in patients
with IBD was studied. Out of 898 patients treated with ADM for Crohn’s disease
(CD) or ulcerative colitis (UC) in a tertiary referral center, we selected all patients
who had received maintenance therapy with ADM 40 mg ETW with serum levels
available before and after dose de-escalation. Serum was collected 4 months prior
to dose de-escalation (T-1, n¼ 33), at dose de-escalation (T0, n¼ 43), 4 months
after dose de-escalation (T1, n¼ 43) and 8 months after dose de-escalation (T2,
n¼ 26). ADM serum levels were measured using RIDASCREEN monitoring
kit (R-biopharm AG). In addition, patient reported outcome (PRO2), C-reactive
protein (CRP) and serum albumin were collected for each time-point. Other
baseline variables included disease behavior, disease location, smoking behavior,
concomitant therapy, body weight, and body mass index. Mann-Whitney U,
Wilcoxon Signed Rank test, and Cox regression were performed using SPSS 23.0.
Results: We identified 43 patients with dose de-escalation to ADM 40 mg ETW
(32 male, 39 CD, 4 UC, median age 37 years). All patients received monotherapy
with ADM every other week, which was initiated a median of 28 months prior to
dose de-escalation. Median PRO2 was 0, and median CRP level 1.4 mg/L.
Reasons for dose de-escalation were ADM associated adverse events (AE,
n¼ 1), serum levels above 7 mg/mL (n¼ 9), or a combination of both (n¼ 33).
Most frequently reported AE were skin manifestations (52%), arthralgia (24%)
and recurrent infections (21%). While ADM serum level dropped significantly 4
and 8 months after dose de-escalation, CRP levels remained stable (Table). In
patients with CD a significant increase in PRO2 was observed.
Conclusion: In this retrospective cohort analysis, 61% of patients were able to
continue ADM therapy at a dose of 40 mg ETW. Furthermore, in half of the
patients who experienced ADM related AE at baseline, the AE disappeared
completely. Regardless of ADM serum levels, disease remission should be objec-
tively assessed prior to dose de-escalation, since an elevated baseline CRP pre-
dicted the relapse following de-escalation with subsequent need for increase of
ADM dose.
Disclosure of Interest: S. Vermeire: Grants from MSD, Takeda and Abbvie,
lecture fees from Abbvie, MSD, Falk, Tillotts, Ferring, Centocor, Takeda,
Hospira; consultancy for Ferring, Abbvie, Shire, Genentech/Roche, Celgene,
Janssen, MSD, Takeda, Galapagos, Hospira, Mundipharma, Pfizer.
G. Van Assche: Gert Van Assche receives financial support for research from
Abbvie and MSD, lecture fees from Janssen, Takeda, Ferring, MSD, and Abbvie
and does consultancy for Abbvie, MSD, and Takeda.
A. Gils: Ann Gils has been a consultant for Merck, Janssen Biologics, and
Abbvie
M. Ferrante: Research grant from Janssen Takeda, lecture fees from Tillotts,
Ferring, Boehringer-Ingelheim, Janssen, Chiesi, Falk, Zeria, Mitsubishi Tanabe,
MSD, Takeda, and Abbvie and does consultancy for Abbvie, Ferring, MSD,
Boehringer-Ingelheim and Janssen.
All other authors have declared no conflicts of interest.
OP145 EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB AFTER
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Table (OP144): Clinical and serological evolution after dose de-escalation
T-1 (n¼ 33) T0 (n¼ 43) T1 (n¼ 43) T2 (n¼ 26)
Median (IQR) time from T0 18.0 weeks (13.5–26.1) 14.0 weeks (12.3–19.0) 30.5 weeks (26.8–34.5)
Median (IQR) ADA serum level 11.6 mg/mL (9.1–15.1) 11.5 mg/mL (9.3–14.3) 7.5 mg/mL (5.8–9.8) p5 0.001 7.2 mg/mL (5.4–8.6) p5 0.001
Median (IQR) C-reactive protein 1.6 mg/L (0.4–4.9) 1.4 mg/L (0.6–3.3) 1.3 mg/L (0.6–5.1) p¼ 0.217 1.7 mg/L (0.6–4.1) p¼ 0.139
Median (IQR) serum albumin 44.5 g/L (42.6–47.0) 44.1 g/L (42.2–47.0) 43.7 g/L (41.6–47.2) p¼ 0.893 42.4 g/L (40.9–45.0) p¼ 0.330
Median (IQR) PRO2 UC 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) p¼ 1.000
Median (IQR) PRO2 CD 0.0 (0.0–7.0) 0.0 (0.0–6.0) 2.0 (0.0–9.0) p¼ 0.048 4.5 (0.0–9.8) p¼ 0.021
p-values: relative to T0, Wilcoxon Signed Rank test; IQR: interquartile range During a median follow-up of 24 months, 39% of patients needed dose escalation to ADM
40 mg every other week due to clinical relapse (23%), ADM serum levels53 mg/mL (7%) or both (9%). The only independent factor associated with dose escalation
free survival was a baseline CRP5 3 mg/L [Odds ratio 3.76 (1.41–10.05), p¼ 0.008]. We were not able to define a minimal ADM serum level at T0 or T1 to consider or
maintain dose de-escalation. In 52% of patients dose de-escalation was associated with a complete disappearance of AE and this after a median of 4 months (8/17 skin
manifestation, 3/7 arthralgia, 2/7 recurrent infections).
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Introduction: Biosimilar infliximab CT-P13 received positive CHMP recommen-
dation in June 2013 for all indications of the originator product. It has been
previously shown that CT-P13 is effective and safe in inducing remission in
inflammatory bowel diseases (IBD). However, prospective, long-term data on
the efficacy and safety of the biosimilar infliximab in IBD are lacking.
Aims & Methods: A prospective, nationwide, multicentre, observational cohort
was designed to examine the efficacy and safety of CT-P13 infliximab biosimilar
in the induction and maintenance treatment of Crohn’s disease (CD) and ulcera-
tive colitis (UC). Demographic data were collected and a harmonized monitoring
strategy was applied. Clinical remission, response and biochemical response was
evaluated at week 14, 30 and 54. None of the patients had received infliximab
within 12 months prior to initiation of the biosimilar infliximab. Safety data was
registered.
Results: 291 consecutive IBD (184 CD and 107 UC) patients were included in the
present cohort, of which 100 patients reached the week 54 endpoint. The age at
disease onset was 23/28 years (median, IQR: 19–34 and 22–39) in CD and UC
patients, respectively. 32/49% of CD patients had colonic/ileocolonic disease
location, 41% had complicated disease behaviour, 35% had perianal disease
and 23% had gone through previous surgery. 8/33/59% of UC patients had
proctitis/left-sided colitis/extensive colitis. 25/14% of patients had received pre-
vious anti-TNF therapy in CD and UC, respectively. 60/52% of CD/UC patients
received concomitant immunosuppressives at baseline. 55, 57 and 47% of CD
patients reached clinical remission by week 14, 30 and 54. Clinical response was
83, 77 and 58%, respectively. 59, 46 and 53% of UC patients reached clinical
remission by week 14, 30 and 54. Clinical response was 78, 69 and 64%, respec-
tively. Previous anti-TNF exposure was associated with lower response and
remission rates in both CD (p5 0.001/0.01, p¼ 0.014/0.05 and p¼ 0.002/0.04)
and UC (p¼NS/0.06, p¼ 0.1/0.1 and p¼ 0.048/0.03) at weeks 14, 30 and 54.
Mean CRP decreased significantly both in CD and UC patients by week 14,
which was maintained throughout the 1-year follow-up. (CRP level decreased
from 20.5 to W14: 8, W30: 8.7 and W54: 12.1mg/L in CD and from 29.5 to W14:
8.5, W30: 13 and W54: 12.3 mg/L in UC). 21 (6.6%) patients had infusion
reactions, 23 (7.9%) patients had infections and 1 death occurred.
Conclusion: This prospective nationwide cohort shows that CT-P13 is effective
and safe in inducing and maintaining remission in both CD and UC. Efficacy was
influenced by previous anti-TNF exposure.
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Introduction: Biosimilar infliximab (Inflectra) has been approved by the
European Medicines Agency for the treatment of luminal Crohn’s disease
(CD) since 2013. Currently biosimilars offer a massive price reduction in most
European countries. Nevertheless, no study has yet compared the cost-effective-
ness of originator and biosimilar agents in luminal CD patients. (Furthermore,
there are no published studies reporting between-biologicals cost-effectiveness for
luminal CD in European countries.)
Aims & Methods: We aim to compare cost-effectiveness of adalimumab, inflix-
imab, vedolizumab and biosimilar infliximab for the treatment of luminal CD in
nine European countries (Belgium, France, Germany, Hungary, Italy, the
Netherlands, Spain, Sweden and the UK). A probabilistic Markov model was
developed to analyse the cost-effectiveness of selected biological treatment
sequences compared to the standard care or to other biological sequences in
patients with moderate to severely active luminal CD unresponsive to conven-
tional treatment. Transition probabilities of moving between health states were
estimated based on randomised controlled trials and cohorts. Country-specific
unit costs, including drugs, monitoring, administration, hospitalization and sur-
gical costs were considered. The model applied a third-party payer perspective
and a five-year time horizon. Discount rates for both costs and benefits complied
with the national pharmacoeconomic guidelines.
Results: The incremental cost-utility ratio (ICUR) of the biosimilar infliximab-
standard care treatment sequence vs. standard care varied between E35,170/
QALY (Hungary) and E71,624/QALY (Sweden). Over the five years, the average
undiscounted health gain was 0.3 QALY per patient. In all countries, biosimilar
infliximab was dominant relative to originator infliximab-standard care strategy.
The inclusion of additional biologicals to the treatment sequence resulted in a
higher cost-utility ratio. ICURs of biosimilar infliximab-adalimumab-vedolizu-
mab sequences ranged from E77,305/QALY to E125,643/QALY compared to
the standard care. The biosimilar infliximab-adalimumab-vedolizumab sequence
dominated the originator infliximab-adalimumab-vedolizumab sequence. The
results were most sensitive to changes in the perspective of the analysis, utility
values and time horizon (10-year).
Conclusion: Biosimilar infliximab is a cost-effective alternative to the originator
product for the treatment of adults with luminal CD, and it may contribute to
increasing the affordability of biological treatments throughout Europe.
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Introduction: Gastrointestinal bleeding (GIB) is a feared complication of antic-
oagulation therapy. Idarucizumab (IDA) is a rapid-onset specific reversal agent
for the direct thrombin inhibitor dabigatran. IDA should benefit management of
dabigatran users experiencing severe GIB.
Aims & Methods: The on-going REVERSE-ADTM study evaluates the safety and
efficacy of IDA 5 grams intravenously in dabigatran users with (A) life-threaten-
ing haemorrhage or (B) requirement for emergency surgery. Here, we analyze the
clinical characteristics and outcomes of REVERSE-ADTM enrolees presenting
with severe GIB. Our study is performed on an interim analysis cohort of 123
patients; centralized laboratory coagulation data are available for 90/123 (20/27
patients with major GIB).
Results: Of the 66 patients enrolled in REVERSE-ADTM due to severe bleeding,
27 (41%) bled in the GI tract. The mean age of GIB patients was 77.5 years
(range, 60–93), 15 (56%) were male, and renal impairment was present in 22 of
the 23 patients with creatinine clearance measurements (96%). Atrial fibrillation
was the indication for anticoagulation in 93%; 74% took their most recent
dabigatran dose 524 hours before presentation. Ten patients (37%) bled from
the upper GI tract, 8 (30%) from the lower GI tract, and 9 (33%) from an
unknown level of the GI tract. IDA achieved immediate reversal of dabiga-
tran-related anticoagulation, and its effect lasted for up to 24 hours in the major-
ity of patients. Hospital admission was required for 25 patients (93%, median
length of stay¼ 6.0 nights); 8 patients required 1 day in intensive care unit
(ICU) (30%, median length of ICU stay¼ 3.5 days). Patients with lower GI
bleeding had shorter time to cessation of bleeding (median 1.5 hours vs. 7.3
hours). No adverse events attributable to IDA were reported. A total of 24
patients received 1 unit packed red cells (mean 4.5 units); 9 received fresh
frozen plasma (mean 2.6 units); 2 received platelets (mean 1.5 units); and 1
received prothrombin complex concentrate prior to IDA treatment. There were
3 deaths by 90 days, but none directly attributable to GIB. Antithrombotic
therapy was resumed in 20 patients (74%) prior to study termination, within a
median of 6.1 days (range 0–41 days) after IDA administration. Dabigatran was
resumed in 6 patients (22%).
Conclusion: The GI tract is the most common site of anticoagulant-associated
haemorrhage meeting clinical criteria for emergent reversal. IDA achieves
immediate reversal of dabigatran-induced anticoagulation, an effect that is sus-
tained for up to 1 day in the majority of patients. Overall, GIB outcomes in this
setting are favourable; antithrombotic therapy can be resumed promptly in most
patients.
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Introduction: Melatonin is a major pineal gland hormone involved in the control
of sleep and circadian rhythm but present also in large quantities in the gut.
This indoleamine is a potent free radical scavenger and exerts protective action
against mucosal injury induced by gastric corrosive substances (ethanol, bile) and
stress but the possibility that melatonin directly protects in vitro gastric epithelial
cells (cytoprotection) against injury under conditions independent of systemic
(e.g. neural, vascular) factors has not been explored before. Likewise, the expres-
sion of melatonin receptors (MT1 & MT2) in gastric epithelial cells; and, their
spatial relation to factors promoting cell survival such as survivin, insulin like
growth factor (IGF-1) and its receptor 1 b (IGFR-1b) has not been so far
elucidated.
Aims & Methods: We studied whether the pretreatment with melatonin results in
protection of cultured rat gastric epithelial cells against indomethacin-induced
gastric mucosal injury and whether it affects the expression of MT1 and -2,
survivin, IGF-1 and IGFR-1b in these cells. In in vitro study, the cultured
normal rat gastric mucosal epithelial cells (RGM1) were pretreated with vehicle
or melatonin (10 mM) for 24 hrs and then exposed to either: medium alone
(controls), or indomethacin (IND–0.25 mM) for 4 hrs. In these cells the following
were assessed: 1) cell injury under confocal microscopy, 2) survival and apoptosis
using Calcein AM live cell tracking dye and MTT assay; 3) cell proliferation
using BrdU assay; 4) quantitatively expression of MT1 & 2, and survivin,
IGF-1 and IGFR-1b by Western blotting and immunostaining. For comparison,
the quantitative expression of MT1 and MT2 in gastric epithelial and submucosal
structures from full thickness wall specimens of a normal rat stomach was
evaluated.
Results: Rat gastric mucosa expressed both MT1 and MT2 (1.8-fold more MT1
than MT2; p5 0.01) in gastric epithelial progenitor cells, endothelial cells of
blood vessels, and in enteric neural elements. RGM1 cells expressed both MT1
and MT2, which were co-localized with survivin, IGF-1 and IGFR-1b. IND
treatment produced extensive cell injury and reduced RGM1 cell viability by
3.8-fold (p5 0.001 vs. control). In cells pretreated with melatonin, IND-induced
cell injury and death was dramatically reduced by 82 4% (p5 0.001) reflecting
a direct protective action of melatonin.
Conclusion: 1) Melatonin directly protects the gastric mucosal epithelial cells
against IND- induced injury and this effect is independent of systemic and
neural factors, 2) rat gastric epithelial RGM1 cells express melatonin receptors
MT1 and MT2 that are co-localized with survivin, IGF-1 and IGFR-1b indicat-
ing local autocrine interactions, and 3) besides the systemic hormonal action of
melatonin derived from pineal gland, this indoleamine can protect the gastric
epithelial cells possibly due to its local autocrine and paracrine actions and
interactions with survivin, IGF-1 and its receptor.
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Introduction: Patients who develop gastrointestinal (GI) bleeding during antic-
oagulant (AC) and/or antiplatelet (AP) therapy represent a clinical challenge.
Clinical decisio´n of either long-term interruption or short-term resumption of
these treatments will have important clinical implications concerning the risk of
vascular, GI bleeding and death events. Differences on the risks between AP or
AC users after drug resumption are not well established.
Aims & Methods: We aimed to determine the rate of rebleeding, vascular events
and death in a cohort of patients treated with AP or AC agents who developed a
major GIB (upper or lower) event. To compare these risks depending on the
treatment adopted after the GIB event. Methods: Retrospective long-term obser-
vational cohort study of patients who developed GIB while on AP and/or AC
treatment from March 2008 to August 2013. Drug use information was prospec-
tively collected during the GIB event. Data concerning the follow-up period,
which ended on December 31st 2013 were obtained from databases from 2 dif-
ferent Spanish Health care areas. Primary outcomes were vascular event, GI
rebleeding and death from any cause. Statistical analyses were performed using
SPSS software version 22.0.
Results: 774 patients were included (mean age 78.7 8.9; 56.6% males); 52.8%
(409/774), 38.5% (298/774), 8.7% (67/774) were on AP, AC or APþAC therapy
respectively. 22.6% of patients presented rebleeding, 17.1% ischemic event and
26.0% death during the follow up (median 23 months). Following the index GIB,
therapy was interrupted in 92.2% (714/774) of patients, although 80.1% (572/
714) resumed afterwards (median time 6 days (1–370). Resumption of therapy
was associated with higher risk of rebleeding (3.5% vs 24%;p5 0.001) but lower
risk of death (43.7% vs 19.9%;p5 0.001). Early resumption of therapy (7 days)
vs delayed (47) was associated with a higher rate of ischemic events (13% vs
20.4%;p¼ 0.020), with no statistical differences in GI events. AC users had
higher death risk (OR 1.5; 95%CI: 1.1–2.2) compared to AP users. Dual AP
users had higher risk of ischemic events (OR 2.1; 95%CI: 1.1–3.7). Rebleeding
event rates were 85 and 120 events per 1000 pt-year with AP and AC users
respectively. The corresponding event rates were 71 and 82 per 1000 pt-year
for vascular events, and 93 and 144 respectively for deaths.
Conclusion: Nearly 40% of patients presented a new adverse event related with
AP/AC treatment during the follow-up. The risk of death is higher in patients on
AC therapy compared with AP users. Resumption of AC/AP therapy is asso-
ciated with higher risk of rebleeding and lower risk of death without any influ-
ence on ischemic events. Resumption of AP or AC agents later than 7 days is
associated with significant higher risk of ischemic events.
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Introduction: Hydrogen sulfide (H2S) and prostaglandins are an important med-
iator of mucosal defense and suppression of its synthesis by NSAIDs leads to
increased susceptibility to enteropathy. H2S also exerts a number of anti-inflam-
matory effects. Thus, the ability of H2S to promote the healing of the damage
tissue and to resolution of inflammatory response has been exploited in the
development of novel therapeutic agents.
Aims & Methods: The purpose of our study was to investigate the role of
4-thiazolidinone derivatives (compounds Les-5054 [5-(3,5-Di-tert-butyl-4-
hydroxy-benzylidene)-2-thioxo-thiazolidin-4-one] and Les-5055 [3-(3,5-Di-tert-
butyl-4-hydroxy-phenyl)-2-mercapto-acrylic acid]) as a novel H2S donors in
promoting the resolution of inflammation and injury in small intestine. The
studies were conducted on 40 white rats weighing 180–250 g according to the
ethical requirements concerning the work with the laboratory animals. Animals
were divided into 4 groups: I – control; II – small intestinal injury produced by
indomethacin (IM) in the ulcerogenic dose (35 mg/ kg, subcutaneously) per 72 h;
III, IV – compounds Les-5054 and Les-5055 were administered three times per 72
h intragastrically at a single dose 10 mgkg-1 on the background of NSAID-
induced injury. Then the rats were sacrificed and in small intestinal mucosa
were measured the NOS and arginase activity, concentration of nitrite anion
and MDA, activity of enzymes of the antioxidant protection system (SOD and
catalase) and MPO activity; the concentration of L-arginine and H2S in blood
plasma.
Results: IM injection manifested by erosions and hemorrhages and leads to the
following changes: the activity of iNOS increased more than threefold (P5 0.01)
as well as the content of nitrite enhanced in two times while arginase activity
decrease more than 4 fold (P5 0.01); enhanced activity of lipid peroxidation
processes manifested by a steep rise of MDA concentration – by 56%
(P5 0.01), MPO activity enhanced more than 4 fold (P5 0.01) and catalase
activity – by 32% (P5 0.01). Compound Les-5054 displayed significant cytopro-
tective effect and decreased the total area of hemorrhagic lesions for 63%
(p5 0.05). The administration of Les-5054 on the background of IM decrease
the activity of iNOS for 35% (P5 0.01), and activity of eNOS increased for 52%
(P5 0.01), MDA concentration declined for 32% (P5 0.01), H2S concentration
increased for 24% (P5 0.05) as compared with indices of the second group.
Compound Les-5055 decreased the total area of hemorrhagic lesions for 37%
(p5 0.05) as compared with independent action of indomethacin. Parameters of
NO-synthase system in Les-5055-treated group showed the same tendency as
under the effect of Les-5054.
Conclusion: Administration of 4-thiazolidinone derivatives on the background of
indomethacin induced injury reduce the activity of iNOS, myeloperoxidase,
intensity of lipid peroxidation and increase generation of H2S, that may be
linked with the structure of this compounds. However compound Les-5054
showed more efficacious effect and antioxidant properties than compound
Les-5055. Thus, the novel 4-thiazolidinone derivatives, particularly compound
United European Gastroenterology Journal 4(5S) A61
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
Les-5054 demonstrated a remarkable anti-inflammatory and cytoprotective abil-
ity against experimentally NSAID-induced damage in small intestine.
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Introduction: There was considerable individual variability in NSAID-induced
small intestinal injury in previous studies on healthy subjects. Several studies
reported that several single nucleotide polymorphisms (SNPs) were associated
with gastrointestinal bleeding and/or ulceration. However, the studies investi-
gated only a few candidate SNPs in the enzymes of metabolizing NSAIDs and
arachidonic acid cascade. Therefore, a comprehensive analysis was necessary to
identify other unknown SNPs having a stronger effect on NSAID-induced small
intestinal injury than the reported SNPs.
Aims & Methods: The aim of the study was to identify the SNP most signifi-
cantly involved with NSAID-induced small intestinal mucosal injury. One-
hundred fifty healthy subjects were enrolled from an RCT which compared
small intestinal mucosal breaks after 14-day treatment between celecoxib mono-
therapy and concomitant treatment with loxoprofen and lansoprazole. Details
of the RCT were reported by Fujimori S et al (1). After the RCT, subjects were
divided into three groups on the basis of numbers of increasing small intestinal
mucosal breaks after NSAIDs treatment with zero (No injury group), one to
four (Mild injury group), and five and more mucosal breaks (Severe injury
group). A genome-wide association study (GWAS) was conducted among the
three groups to detect the SNP which was the most associated with NSAID
enteropathy.
Results: After RCT and GWAS analysis, 70 subjects receiving the loxoprofen
treatment and 69 subjects receiving the celecoxib treatment were determined to
eligible for analysis. The minimum p-value was detected in the analysis between
16 cases with five or more mucosal breaks (severe injury group) and 123 controls
with zero to four mucosal breaks (no injury group combined with mild injury
group). In the GWAS, five SNPs in bactericidal/permeability-increasing fold-
containing family B member 4 (BPIFB4) gene showed the lowest p-value
(p ¼ 2.69 x 107 with an odds ratio of 40.91). Among the five SNPs, four
were nonsynonymous SNPs (rs2070325: V268I, rs2889732: T320N, rs11699009:
F527L, rs11696307: T533I, rs11696310: intronic).
Conclusion: Although SNPs that surpassed the genome-wide significance level
(p 5 5 x 108) could not be identified through GWAS, results seemed to indicate
that the SNPs of BPIFB4 were associated with NSAID-induced small intestinal
mucosal injury. (UMIN: 000007936: The GWAS was financially supported by
grants from the Project for Development of Innovative Research on Cancer
Therapeutics and from the Tailor-made Medical Treatment Program (BioBank
Japan) funded by Ministry of Education, Culture, Sports, Science and
Technology of Japan.)
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Introduction: Aspirin is a potent anti-platelet agent used for the prevention of
cardiovascular and cerebro-vascular diseases. It has also been proven to be
effective in reducing the incidence of colorectal cancers (CRC) in many previous
studies. However, gastrointestinal (GI) bleeding is the most frequently reported
serious adverse events for the long term use of aspirin.
Aims & Methods: The objective of this study is to investigate whether the risk of
aspirin usage on increasing ulcer bleeding would outweigh its benefit on the
prevention of CRC. The present study investigated the electronic medical records
from 42 publically funded hospitals, which serves a 7 million population in Hong
Kong. All hospital admissions from 2000 to 2004 and their outcome in the
follow-up period were extracted until 2014. Aspirin users were matched with
age and gender in a ratio of 1:2 to non-aspirin users in the study period.
Incidences of CRC and GI bleeding were the primary outcomes. Logistic regres-
sion was used to compare incidence rates and Cox-proportional hazard regres-
sion model was used to compare the mortality rates. Subgroup analyses were
performed for those with ulcer bleeding, or for those with regular aspirin
prescribed.
Results: A total of 4,564,100 subjects were identified in the system between year
2000 and 2004, and 254,887 of them (5.6%) were prescribed aspirin for at least
one month. Among the subjects who were never prescribed aspirin, 491,852
subjects (10.8%) were identified in the system. The total sample size of this
study was 746,739. The baseline characteristics of aspirin and non-aspirin users
are described in Table 1. The mean ages of aspirin users and non-aspirin users
were 68.4 (SD¼ 13.1) and 66.4 (SD¼ 13.2) respectively. In the aspirin group,
78,316 patients (30.7%) had aspirin prescribed for 10 years or more, and 54,011
of them (69.0%) were routinely prescription during the years of clinic visits.
Median dose of aspirin used among the patients were 80 mg with interquartile
range from 80 mg to 100 mg. Average duration of aspirin prescribed was 6.3
years. Patients in aspirin group showed significantly lower incidence of CRC
(OR¼ 0.82; 95% CI¼ 0.80 to 0.85), and showed significant reduction in overall
mortality (HR¼ 0.89; 95% CI¼ 0.86 to 0.92). Whereas, patients in aspirin group
showed significantly higher incidence of GI bleeding (OR¼ 1.77; 95% CI¼ 1.74
to 1.80), and showed marginally significant higher mortality among those diag-
nosed with GI bleeding (HR¼ 1.03; 95% CI¼ 1.02 to 1.05). The results remained
consistent in the subgroup analyses.
Conclusion: This is a population-based study to concurrently compare the risk
and benefit of long-term use of aspirin. We concluded that long-term use of low-
dose aspirin will increase the incidence of GI bleeding, and moderate increase the
overall mortality among the patients with GI bleeding. On the other hand, the
long-term use of aspirin showed benefit to reduce CRC on both incidence and
overall mortality.
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Introduction: POEM was introduced as a minimally invasive and effective ther-
apeutic modality for the treatment of achalasia and spastic esophageal disorders
(SEDs). Data largely from single-center studies and small case series suggest
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POEM as a safe alternative to Heller Myotomy. However, the safety of POEM is
still debated since comprehensive analysis of adverse events (AEs) associated with
POEM in large cohort studies has not been performed.
Aims & Methods: We aimed to study (1) the rate of AEs and (2) factors asso-
ciated with occurrence of AEs in patients undergoing POEM. Methods: Patients
who underwent POEM performed for the treatment of achalasia and SEDs at 12
tertiary-care centers (5 US, 4 Europe, 2 Asia and 1 Australia) between 2011 and
2015 were used in a case-control study. Cases were defined by the occurrence of
any AEs related to POEM procedure. Control patients were selected for each AE
case by matching for age, gender, disease classification (type I&II vs. type III/
SEDs). All pertinent data including AEs were collected and their severity was
graded according to the ASGE lexicon’s severity grading system.
Results: A total of 1826 patients underwent POEM during the study period.
Overall, 153 AEs occurred in 137 patients (7.5%). A total of 48 inadvertent
mucosotomies occurred and represented the most common AE of POEM
(31% of all AEs, overall incidence 2.8%). Mild, moderate and severe AEs
occurred in 102 (74.5%), 26 (19%) and 9 (6.5%) patients, respectively. Among
the 9 severe AEs, 2 were esophageal leaks, 1 perforation, 1 aspiration pneumonia,
1 empyema, 1 pneumomediastinum, 1 cardiac arrhythmia and 2 delayed bleed-
ing). There were no deaths related to POEM. When patients with AEs were
compared with a control group (case-control analysis), there was no difference
between the 2 groups in terms of Charlson comorbidity index/ASA class, prior
therapy, sigmoid esophagus, operator specialty, direction of myotomy (anterior
vs. posterior), type of knife used, extent and length of myotomy, and operator
experience. However, time of procedure was significantly longer in cases as com-
pared to controls (123min  49 vs. 103min 38, p¼ 0.002). Length of stay was
significantly higher in patients who experienced AEs (4.9d vs. 2.7d, p5 0.001).
Conclusion: This is the largest study that comprehensively assessed safety of
POEM. It highly suggests POEM as a safe therapeutic modality with an overall
7.5% incidence of AEs. Severe AEs are rare. AEs result in prolongation of
hospital stay. Longer procedural times (indicative of technically complex proce-
dures) are associated with increases occurrence of AEs.
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Introduction: Peroral endoscopic myotomy (POEM) aims to palliate symptoms of
achalasia by reducing pressure at the lower esophageal sphincter (LES). Current
data demonstrates high short-term clinical response in 82–100% of patients.
However, long term data is very limited.
Aims & Methods: We aimed to study (1) clinical outcome of patients with a
minimum post-POEM follow-up of 2 years and (2) factors associated with
long term clinical failure after POEM. Methods: We conducted a retrospective
review of consecutive patients with achalasia who underwent POEM with a
minimum follow-up of 2 years at 10 tertiary-care centers (3 US, 4 Europe, 3
Asia). Clinical response was defined by decrease in Eckardt score to 3.
Results: A total of 179 patients (82 males (45.8%); mean age 49 yr) underwent
POEM for the treatment of achalasia (type I 11, type II 51, type III 6, unspecified
type 111). Of these, 16 patients (8.9%) had prior Heller myotomy, 65 (36%) had
prior pneumatic dilatation (PD) and 6 (3%) had prior botulinum injection.
POEM was successfully completed in all patients. A total of 18 adverse events
occurred in 8 (4.4%) patients (8 mucosotomies, 1 delayed bleeding, 1 esophageal
leak, 2 DVT/PE, 1 pneumothorax, 2 symptomatic pleural effusion, 2 aspiration
pneumonia, and 1 mediastinitis). The median follow-up was 30 months (IQR 26–
37). Clinical success was achieved in 97.5% (159/163), 99.8% (124/125), 90%
(161/179) in patients with follow-up within 6 months, at 12 months, and 24
months, respectively. Of 159 patients with clinical response at 6 months, 11 (7%)
experienced recurrent symptoms at 2 years. Mean Eckardt score decreased from
6.7 2.2 before POEM to 1.5 1.4 at the time of last follow-up (p5 0.001) and
4sIRP pressure improved, 23.3 8.7 to 7.1 4.4 mmHg (p5 0.001). As com-
pared to patients with clinical response, the non responders were more likely to
be younger (44 8 vs 49 16 yr, p 0.03) and had history of prior PD (11 (61%)
vs 54 (33%), p 0.03). In a multivariate analysis, history of prior PD was inde-
pendently associated with long-term treatment failure (OR 2.99; 95%CI 1.09–
8.22, p 0.03). Three patients with clinical failure underwent treatment with repeat
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POEM (n¼ 1) and Heller myotomy (n¼ 2) and clinical response was noted in 2
of them. Of 171 patients with available data, 24% patients reported reflux symp-
toms after POEM. Reflux esophagitis was noted in 26 patients of 144 (18%) who
had EGD after POEM. 15% of asymptomatic patients had reflux esophagitis.
Conclusion: POEM is safe and provides high initial clinical success and excellent
long-term outcomes. Less than 10% of patients who had clinical response at 6
months had recurrent symptoms at 2 years. History of prior pneumatic dilatation
is associated with clinical failure. Post-POEM symptomatic reflux occurs in
quarter of patients and esophagitis is found in 15% of asymptomatic patients.
Disclosure of Interest: S. Roman: Sabine Roman is a consultant for Medtronic
and Sandhill Scientific
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Introduction: Peroral Endoscopic Myotomy (POEM) has been recently developed
for the treatment of achalasia and other esophageal motility disorders. Despite
being widely used in many centers, data on the long-term efficacy of POEM are
still lacking. We report on a large consecutive series of patients treated with
POEM, with mid- and long-term follow-up.
Aims & Methods: All the patients who underwent POEM between May 2011 and
April 2016 at our endoscopy unit were retrospectively identified on a prospec-
tively collected database. Analyzed data included demographics, clinical history,
previous treatments, manometry and procedure data, complications and clinical
outcomes. Follow-up visits were scheduled at 3, 6, 12, 24, 36, 48 and 60 months
after POEM. EGD, manometry and barium swallow were regularly performed
during follow-up. pH-monitoring study was performed once, usually between the
6- and 12-month follow-up visit. Clinical success was defined by an Eckardt score
 3.
Results: A total of 347 patients underwent POEM (mean age 47 years, 48%
males). Seventy-eight patients (22.5%) had type I achalasia, 174 type II
(50.1%), 40 type III (11.5%), 2 Jackhammer esophagus (0.6%), 4 distal esopha-
geal spasm (1.1%), 1 nutcracker esophagus (0.3%); in 48 patients (13.8%) acha-
lasia type was not classified (ie: standard manometry or incomplete examination).
Before POEM, 52 patients had undergo pneumatic dilation (PD), 8 surgical
myotomy, 8 botulinum toxin injection. The procedure was effectively completed
in 338 cases (97%). Mild complications occurred in 3 patients (0.8%): a delayed
bleeding, a covered esophageal perforation, and a esophageal stricture following
a large ulceration. All the above mentioned complications were treated conser-
vatively. Four patients were lost at follow-up. A minimum 6-month follow-up
was available for 274 patients (mean follow-up 19 months). Clinical success was
achieved in 95% of patients. Thirteen patients had symptoms recurrence: 7
underwent successful PD, 3 surgery, 3 received no treatment because of mild
symptoms. Clinical success slightly decreased with time, being 97%, 97%,
93%, 85%, 72% and 67% after 6, 12, 24, 36, 48 and 60 months, respectively.
However, almost 50% of recurrences (6/13) occurred during the first 25 cases
(learning curve). No associations were found between preoperative manometric
pattern and clinical outcomes: the success rate of POEM was similar in patients
with type I, type II and type III achalasia (94%, 96% and 91%, respectively.
p40.05). A total reflux time 4 5% was diagnosed in 50% of the patients (111/
223) who underwent pH-study. Esophagitis was seen in 28% of patients, 22% of
patients receive PPI because of heartburn. Esophagitis healed completely with
proton pump inhibitors (PPI) in all the patients. GERD symptoms were effec-
tively controlled with PPI in all the patients but 2 who complained with heart-
burn and regurgitations.
Conclusion: Our mid-term and long-term follow-up analysis confirms the safety
and efficacy of POEM for the management of achalasia and other motility dis-
orders. The vast majority of initial clinical failure can be solved with endoscopic
re-treatment. Iatrogenic GERD-rate remains the only possible drawback of the
procedure.
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Introduction: Peroral endoscopic myotomy (POEM) is now a widely used treat-
ment for esophageal achalasia, supported by several large cohort studies.
Although major perioperative adverse events (mAE) are rare, in-depth investiga-
tions of related risks and preventive measures are lacking.
Aims & Methods: Hence, mAE during POEM were systematically assessed in
terms of incidence, risks, prevention, and management. This retrospective
single-center analysis included all patients (N¼ 1680) undergoing POEM
between August, 2010 and July, 2015 at our facility. Major adverse events
were defined as follows: vital-sign instability, required ICU stay, hospital read-
mission, conversion to open surgery, invasive postoperative procedure, blood
transfusion, or hospitalization 45 days due to functional impairment.
Results: A total of 55 patients (3.3%, 95% confidence interval [CI] 2.5–4.2%)
suffered mAE, distributed as follows: delayed mucosal barrier failure, 13 (0.8%,
95% CI 0.4–1.3%); delayed bleeding, 3 (0.2%, 95% CI 0.04–0.5%); hydrothorax,
8 (0.5%, 95% CI 0.2–0.9%); pneumothorax, 25 (1.5%, 95% CI 1.0–2.2%); and
miscellaneous, 6 (0.4%, 95% CI 0.1–0.8%). Four patients (0.2%) required ICU
admissions. No surgical conversions occurred, and 30-day mortality was zero. In
stepwise multivariate regression, experience 51 year (OR¼ 3.85, 95% CI 1.49–
9.95), air insufflation (OR¼ 3.41, 95% CI 1.37–8.50), and mucosal edema
(OR¼ 2.01, 95% CI 1.14–3.53) were identified as related risk factors. After
introducing CO2 insufflation, mAE rate declined to 1.9% (95% CI 1.2–2.7%)
and seemed to plateau after 3.5 years at 1%.
Conclusion: In general, POEM is a safe procedure. Major adverse events are rare
and usually may be prevented or anticipated and conservatively managed.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Table (OP154)
Aspirin Group (n¼ 254,887) Non-Aspirin Group (n¼ 491,852)
Age5 50 50–64 65–79 4¼ 80 24,067 (9.4%) 59,289 (23.3%) 121,671
(47.7%) 49,860 (19.6%)
57,690 (11.7%) 129,196 (26.3%) 232,319
(47.2%) 72,647 (14.8%)
Sex – Male 136,534 (53.8%) 260,933 (53.1%)
Duration of Aspirin Prescribed 1 month
to 5 6 months 6 months to 5 3
years 3 years to5 5 years 5 years to
5 10 years 10 years or more
48,591 (19.1%) 44,516 (17.5%) 34,013
(13.3%) 49,451 (19.4%) 78,316
(30.7%)
NA*
*Not Applicable for the Patients in Non-Aspirin Group.
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Introduction: In patients with persistent symptoms after Heller myotomy (HM),
treatment options include repeat HM, pneumatic dilation (PD) or peroral endo-
scopic myotomy (POEM). The data on efficacy and safety of POEM for patients
who failed prior HM are limited to small series.
Aims & Methods: We aimed to compare technical success, clinical response and
safety of POEM in achalasia patients with and without prior HM. Methods: We
conducted a retrospective review of achalasia patients who underwent POEM at
11 tertiary centers (4 US, 4 Europe, 3 Asia). Patients were divided into two
groups: (1) patients who had prior HM (HM group) and (2) those without
prior HM (control group). Control patients were selected for each HM case by
matching for age, achalasia subtypes (type I&II vs type III), and baseline Eckardt
scores (ES) [Stage II (ES 4–6) or Stage III (ES 4 6)]. Clinical response was
defined by decrease in ES to 3. Adverse events (AEs) were graded according
to the ASGE lexicon. Technical success, clinical success and AEs were compared
between the two groups.
Results: A total of 181 patients (91 HM, 90 controls) were included. There was no
difference between the groups in baseline demographics, ES and 4sIRP. The HM
group had higher proportion of patients with prior PD (44% vs 26%; p 0.01).
The length of myotomy was similar between the two groups. Technical success
rates were comparable between HM group (89/91; 98%; 2 failures due to exten-
sive submucosal fibrosis) and control group (100%) in control group (p 0.49).
Procedure time was similar between the two groups. The mean follow-up was 8.5
months (IQR 3.2–14.7) and was similar in both groups. 20 AEs occurred in 19
patients [7 (8%) in HM group and 12 (13%) in control group, p 0.23]. For HM
and control respectively, the rate of mild (5% vs 10%, p¼ 0.28) and moderate
(1% vs 3%, p¼ 0.34) AEs were similar. One severe AE (mediastinitis) occurred in
the HM group. Follow-up data were available in 153 patients. Clinical response
was significantly lower in the HM group as compared to the control (80% vs
94%, p 0.02). Mean post-POEM ES was also higher in the HM group (2.09 2.5
vs 1.08 1.2, p 0.002). On univariate analysis, prior HM (OR 3.54, p 0.02) and
prior PD (OR 3.36, p 0.01) were significantly associated with clinical failure.
Multivariate analysis demonstrated prior HM (adjusted OR 2.91, p 0.05) was
marginally associated with clinical failure after POEM. Post-POEM sympto-
matic reflux, presence of reflux esophagitis and abnormal pH acid exposure
were similar between the two groups.
Conclusion: In this large multicenter study, POEM was safe and effective for
achalasia patients who failed prior HM. Although rate of clinical success in
patients with prior HM is lower than those without prior HM, the safety profile
of POEM is comparable to that of patients with no prior HM.
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OP158 GASTRIC PERORAL ENDOSCOPIC ANTRO-PYLORO-
MYOTOMY (G-POEM) FOR THE TREATMENT OF REFRACTORY
GASTROPARESIS: LARGEST SERIES WITH CLINICAL AND
SCINTIGRAPHHIC FOLLOW-UP
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Introduction: Gastroparesis is an invalidating motility disorder and the available
treatments remain disappointing. Recently, a novel approach has been described
by performing a myotomy of the pylorus after creating a tunnel, with promising
results [1–3]. We report the largest retrospective clinical experience in 23 conse-
cutive patients treated by gastric peroral endoscopic myotomy (G-POEM). The
aim was to evaluate the results of this new technique.
Aims & Methods: This is a case consecutive report on 23 patients operated for
severe refractory gastroparesis, between January 2014 and April 2016, with a
rigorous prospectively designed follow-up. The inclusion criteria were patients
with a disturbed gastric emptying scintigraphy (GES) and elevated GCSI score4
2. The procedures were performed under general anesthesia in an intubated
patient, with large channel gastroscope using CO2 and the Triangle knife
(Olympus, Japan) as dissection device. The steps were: sub-mucosal injection
and mucosal incision 5 cm upstream the pylorus; submucosal tunnel by dissection
(Swift Coag, 35W, Effect 2) until reaching the pyloric arch, which had a consis-
tent aspect; retrograde antro-pyloro-myotomy of 3cm length; closure of the
mucosal flap with clips. The primary objective was to document, at 5 days,
one month and 3 months, the efficacy based on GCSI score and gastroparesis
symptoms (vomiting, nausea, abdominal pain and gastric fullness), and the
improvement of quality of life (visual analogic scale /5), The secondary objectives
were to document the GES evolution at 2 months and the procedure
complications.
Results: The procedure was completed on all the patients. We observed a sig-
nificant improvement of GCSI score at POD 5, 1 month and 3 months (3.5 0.8
vs. 0.8 0.8; 0.9 0.9; 1.1 1.5; p5 0.001). Regarding the severity of symptoms
analyzed separately, it was observed a significant improvement of each of them,
except anorexia. The overall clinical efficacy was 80%, with a mean overall
quality of life improvement 4 65%. The GES normalized in 75% of cases,
showing a significant improvement of the mean half emptying time (222 90
min vs. 133 90; p¼ 0.03) and of retention at 2 hours (76 20% vs.
44 26%; p¼ 0.009). Two patients underwent complications related to the pro-
cedure: one was a bleeding due to an ulceration along the tunnel path (coagula-
tion necrosis) treated by endoscopy, who then worsened a renal insufficiency and
was transferred to intensive care unit; the second had a secondary perforation of
an unseen fundic ulcer, which was managed endoscopically by a naso-cystic drain
and fasting, with excellent outcomes. All the other patients could be reefed at
POD2–3, and discharged at POD5–6, with PPI treatment.
Conclusion: Per-oral endoscopic pyloromyotomy seems to be an effective
approach for treating patients with documented severe refractory gastroparesis.
This procedure is also highly reproducible, when applying some tips to increase
the technical success rate, and safe with complication that could be managed
endoscopically. It could be a new hope for a many patients whom have a poor
quality of life. More data, especially in prospective studies are needed to confirm
these very promising results.
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1.62_____________________
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Introduction: Liver carcinoma is of particular importance, since it is a leading
cause of cancer-related deaths worldwide. Most frequently liver tumors are aris-
ing in an inflammatory milieu as a consequence of liver fibrosis and cirrhosis,
which primarily develop subsequently due to chronic liver diseases. Another
circumstance contributing to liver cancer formation is the disruption of the
p53 signaling pathway. In human liver tumors, p53 mutations are associated
with a poor prognosis. In this study, we analyze the cooperation between loss
of p53 and inflammatory response in the liver.
Aims & Methods: To investigate the sequence of inflammation and Trp53 dele-
tion, we combined two transgenic mouse models. For modulation of an inflam-
matory response, we used an inducible mouse model (Tet-Off system) with a
permanent expression of a constitutively active IKK2 isoform (CAIKK2). The
expression of CAIKK2, starting from birth, leads to a continuous activation of
the NF-kB pathway, simulating chronic inflammation. For the modulation of a
p53 loss, the inducible Cre-recombinase expressing transgenic mouse line
AlfpCre-ERT2 was crossed with a conditional Trp53 knockout mouse.
Tamoxifen treatment at the age of four weeks induces liver-specific deletion of
Trp53.
Results: Expression of the constitutively active IKK2 isoform leads to liver fibro-
sis development, increased proliferation in the liver and elevated expression of
inflammatory markers independent of the p53 status. During ageing, the
CAIKK2 expression and the inflammatory response decreased, the liver fibrosis
was reversible. The tumor incidence at the age of 9–12 month in CAIKK2
Trp53/ mice is significantly higher (67%) compared to CAIKK2 mice with
wild-type Trp53 (25%). Mice with induced liver-specific Trp53 deletion did not
exhibit liver tumor formation at the same age. The majority of liver tumors in
CAIKK2 Trp53/ mice show intrahepatic cholangiocarcinoma (ICC) (81%)
next to hepatocellular carcinoma (2%) and combined HCC/ICC (17%). In con-
trast, CAIKK2 mice with wild-type Trp53 developed mainly HCC (50%), but
also ICC (25%) and HCC/ICC (25%) at lower level.
Conclusion: The study shows that liver-specific Trp53 deletion in combination
with an inflammatory background results in elevated tumor incidence and leads
to an increased occurrence of ICCs in the liver.
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OP160 EXPRESSION OF CD161 ON CD4þ T CELLS PROMOTES
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Introduction: Hepatitis B virus (HBV)-related liver fibrosis always progresses
from inflammation to fibrosis. CD4þ T cell immune responses play a pivotal
role in the process. Recently, CD161 is considered to be a costimulatory molecule
on T cells and an important phenotypic marker of human Th17 cells.
Aims &Methods: This study was designed to investigate the roles of CD161 in the
pathogenesis of HBV-related liver fibrosis. Methods: A total of 54 CHB patients
who underwent liver biopsy and 20 healthy controls (HC) were enrolled. CHB
patients were further categorized according to the disease phase: immune-toler-
ant (IT, n¼ 12), immune-active (IA, n¼ 30), or inactive CHB (n¼ 12). Peripheral
blood mononuclear cells (PBMCs) and flow cytometry sorted CD4þCD161þ and
CD4þCD161- T cells were prepared for further flow cytometric and real-time
PCR analyses. Flow cytometry sorted CD4þCD161þ and CD4þCD161- T cells
were also cultured alone or co-culture with primary hepatic stellate cells (HSCs)
in in vitro experiments.
Results: Compared to HC, the percentage of CD4þCD161þ T cells significantly
increased among IA patients while dramatically decreased among IT patients,
but there was no significant difference between inactive CHB patients and HC.
Besides, CD161 showed a positive correlation with histological inflammation
grades and advanced histological fibrosis stages. In the PBMCs of CHB patients,
CD4þCD161þ T cells exhibited a CD45ROþ memory phenotype and secreted
more IFN-gamma, TNF-alpha, IL-17, IL-21 and IL-4 whereas produced less IL-
10 and IL-22 than CD4þCD161- T cells. In comparison with CD4þCD161- T
cells, in vitro culture of CD4þCD161þ T cells revealed that CD161 expression
increased the activity of acid Sphingomyelinase (aSM) and subsequent PI3K/
Akt, MAPK and mTOR pathways of CD4þ T cells. Both knocking down of
CD161 and using imipramine to inhibit aSM could down-regulate CD4þ T cell-
proliferation and production of IFN-gamma and IL-17, especially for IL-17.
HSCs express lectin-like transcript-1 (LLT1), the only ligand of human
CD161. HBcAg-stimulated HSCs upregulated LLT1 expression. In the co-cul-
ture system of HSCs and CD4þCD161þ T cells, CD161-LLT1 interaction not
only promoted the proliferation and activation of HSCs, but increased IL-17 and
IFN-gamma production of CD4þCD161þ T cells as well. Knocking down of
CD161 on CD4þ T cells or LLT1 on HSCs could partly reverse the aforemen-
tioned effects. In HSCs-CD4þCD161- T cells co-culture system, expression of
pro-fibrotic genes in HSCs were inhibited. However, when CD161 was overex-
pressed on CD4þCD161- T cells, we detected a reactivated HSCs phenotype.
Conclusion: Our data revealed that the expression of CD161 on CD4þ T cells
might promote HBV-related liver fibrosis through CD161-LLT1 interaction to
activate HSCs and through raising aSM to enhance the proinflammatory func-
tions of CD4þ T cells.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Takahashi T, Dejbakhsh-Jones S and Strober S. Expression of CD161
(NKR-P1A) defines subsets of human CD4 and CD8 T cells with different
functional activities. J Immunol 2006; 1: 211–216.
2. Li J, Qiu SJ, She WM, Wang FP, Gao H, Li L, Tu CT, Wang JY, Shen XZ
and Jiang W. Significance of the balance between regulatory T (Treg) and T
helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS One
2012; 6: e39307.
TUESDAY, OCTOBER 18, 2016 08:30–10:00
FREE PAPER SESSION: NOVEL DIAGNOSTIC TOOLS: GOING DEEPER AND DEEPER
INTO THE BOWEL – ROOM N1_____________________
OP161 FULL SPECTRUM ENDOSCOPY (FUSE) IN THE DETECTION
OF INFLAMMATORY BOWEL DISEASE NEOPLASIA (FUSION): A
RANDOMIZED CROSSOVER TANDEM STUDY VERSUS
CONVENTIONAL COLONOSCOPY
R. W. Leong, M. Ooi, C. Corte, Y. Yau, M. Kermeen, A. Alswaifi, P. Katelaris,
C. Mcdonald, M. Ngu
Gastroenterology and Liver Services, Concord Hospital, Sydney/Australia/NSW
Contact E-mail Address: rupert.leong@sswahs.nsw.gov.au
Introduction: Inflammatory bowel diseases (IBD) are the most significant
acquired risk factors of colorectal cancer and therefore surveillance colonoscopy
is widely endorsed. Conventional forward-viewing colonoscopy (FVC), however,
lacks acceptable sensitivity in IBD dysplasia identification and the addition of
dye-based chromoendoscopy is recommended. Full Spectrum Endoscopy
(FUSE) is a novel colonoscope that incorporates 2 additional cameras to the
forward camera and provides 330- degree panoramic view of the colonic mucosa.
Whether FUSE can decrease dysplasia miss rate in IBD surveillance has never
been tested previously.
Aims & Methods: This study aims to assess FUSE versus FVC in dysplasia
surveillance in an IBD population. The dysplasia yield of targetted versus
random colonic biopsies will also be assessed. Methods: A prospective, single-
center, randomized-order, back-to-back crossover tandem colonoscopy study
was conducted comparing FVC versus FUSE in an IBD- surveillance population.
Crohn’s disease (CD) and ulcerative colitis (UC) subjects were recruited from the
IBD Sydney Cohort population-based database, all of whom met the inclusion
criteria of published IBD surveillance guidelines. Subjects not due their surveil-
lance colonoscopy were excluded. The primary outcome was the per-lesion dys-
plasia miss rate of the first colonoscopy identified by the second colonoscopy
with chromoendoscopy. Secondary outcomes were per-subject dysplasia miss
rate, mean dysplasia lesions found, procedural times, and dysplasia yield of
targeted- versus random colonic biopsies. The trial was registered with the
Australia New Zealand Clinical Trials Registry (ACTRN12616000047493).
Results: In total 104 tandem (52-paired) colonoscopies were conducted with 27
subjects randomized to FVC first and 25 to FUSE first. Both arms were not
statistically significantly different for age, IBD duration, CD versus UC, and
additional dysplasia risk factors. The dysplasia prevalence rate of the cohort
was 30.8%. The dysplasia miss rates for FVC and FUSE were 71.4% versus
25.0% respectively (P¼ 0.0001). On per-subject analysis, the dysplasia miss
rate was 75.0% using FVC and 25.0% using FUSE (P¼ 0.046). FUSE identified
a mean of 0.37 dysplastic lesions versus 0.12 for FVC (P¼ 0.007). Targeted
biopsies increased dysplasia identification (26/163, 16.0%) versus random biop-
sies (2/687, 0.3%, P5 0.0001). Chromoendoscopy identified 10/28 (35.7%) of
dysplastic lesions. The total colonoscopy times were similar (21.2 minutes versus
19.1 minutes, P¼ 0.32) but colonoscope withdrawal time was significantly longer
(15.8 minutes versus 12.0 minutes, P¼ 0.03) for FUSE and FVC respectively.
Conclusion: Full Spectrum Endoscopy outperformed conventional forward view-
ing colonoscopy in inflammatory bowel disease subjects undergoing dysplasia
surveillance. A high dysplasia prevalence was identified most likely due to multi-
ple colonoscopy passes and the use of multiple advanced imaging modalities
comprising of high-definition white-light colonoscopy, FUSE and chromoendo-
scopy. Improved dysplasia identification rates may reduce colorectal cancer mor-
tality and increase interval colonoscopies. Improved dysplasia yield of targetted
biopsies versus random colonic biopsies was confirmed.
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Introduction: Optical biopsies of colonic polyps 5 10 mm in size could poten-
tially replace standard histological assessment. WavSTAT version 4 is a novel
optical biopsy system designed by Spectrascience Inc, San Diego, California,
USA. for prediction of histology based on laser induced autofluorescence
spectroscopy.
Aims & Methods: The primary aim of this study was to demonstrate the accuracy
of WavSTAT version 4 in characterizing colorectal polyps 510 mm that can be
resected and discarded (or left in-situ) without adverse clinical impact. The sec-
ondary aim was to compare the real time diagnostic performance of WavSTAT
version 4 with NBI and a combination of endoscopic and WavSTAT assess-
ments. Patients attending the endoscopy unit for lower gastrointestinal endo-
scopy as requested by their responsible physician were approached to
participate in the study. Adult patients aged above 18 years were included.
Table (OP162): Diagnostic performance of Wavstat4, Endosocpic assessment and combined alogithmic assessment for characterization fo colorectal poylps less than
10 mm in size and prediction of surveillance intervals
WavSTAT alone
WLEþNBI
assessment
Combination of WavSTAT þ endoscopic
assessment (algorithmic approach)
Sensitivity 97.6% (95% CI 0.88–0.95) 85.0% (95% CI 0.77–0.89) 95.8% (95%CI 0.89–0.96)
Specificity 46.9% (95%CI 0.44–0.98) 77.2% (95%CI 0.61–0.82) 78% (95%CI 0.66–0.79)
NPV 96.8% (95%CI 0.85–0.91 91% (95%CI 0.73–0.84) 98.5% (95% CI 0.89–0.95)
PPV 54.7% (95%CI 0.28–0.77) 66% (95%CI 0.44–0.79) 89.3% (95%CI 0.76–0.92)
Surveillance interval (% of patients
coded correctly)
81.2% 97% 100%
Surveillance interval (% of patients
called earlier)
18.8% 3% 0%
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Patients known to have inflammatory bowel disease or colorectal cancer were
excluded from the study. Polyps sized510mm were assessed in real time by high
definition white light, NBI and WavSTAT version4 optical biopsy forceps.
Standard techniques were used for polypectomy. Histopathological specimens
were read separately by two expert GI pathologists blinded to the results of
the NBI and WavSTAT assessments. The primary outcome measure was the
negative predictive value in distinguishing adenomatous from non-adenomatous
colorectal polyps. The secondary outcome measure was the accuracy of on-site
recommended surveillance intervals.
Results: 156 polyps (146 were 510mm and 10 were 410mm) were found in 70
patients (Males-44, females-27). Average age of the patients was 65 years (range
29–95 years). 16 polyps were not included in the final analysis due to discrepancy
in histological analysis between two pathologists. We failed to retrieve 5 polyps.
26 patients were excluded from the study (No polyps seen in 17 patients, polyps
510mm were not seen in 3 patients, and device failure in 4 patients). A total of
126 polyps510mm were included in final analysis. The diagnostic performance
for WavStat version 4 and endoscopic assessment is detailed in the table.
Wavstat4 had a NPV of 96.8% but lacked specificity. Endoscopic assessment
had a NPV of 91% and was more specific. Since the specificity of WavSTAT was
poor mainly for hyperplastic recto-sigmoid polyps we evaluated an algorithmic
approach where we classified the polyps according to the WavSTAT4 result when
proximal to the recto-sigmoid junction. We classed them according to the endo-
scopic classification only if Wavstat4 prediction was as as an adenomatous polyp
in the recto-sigmoid area. This combined algorithmic approach met the PIVI
thresholds and had a NPV of 95.8% and predicted 100% of surveillance intervals
correctly.
Conclusion: WavSTAT version 4 has a high NPV for characterizing colorectal
polyps less than 10 mm in size but only predicts surveillance intervals correctly in
81.2% of patients.. An algorithmic approach combining Wavstat4 and endo-
scopic assessment had a high NPV with accurate prediction of surveillance
intervals.
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Introduction: Small bowel (SB) assessment is essential for the proper management
of pediatric Crohn’s disease (CD). Magnetic resonance imaging (MRI) is con-
sidered the gold-standard for the evaluation of small bowel (SB). However, MRI
is expensive, it requires a strong compliance and a considerable amount of oral
contrast to adequately distend the intestinal lumen. Small intestine contrast
ultrasonography (SICUS) is non-invasive, low cost and generally well-tolerated
by pediatric patients (pts).
Aims & Methods: We aimed to compare the diagnostic accuracy of SICUS and
MRI in detecting presence, site and extension of SB disease and in assessing
strictures in pediatric CD. Children with suspected CD or relapse of a known
CD were prospectively enrolled. All underwent SICUS, MRI and ileo-colono-
scopy, performed by different operators blinded to other results. The SB was
subdivided into: jejunum, ileum, terminal ileum (TI). The concordance (k)
between the two techniques for presence and site of lesions was calculated
according to Landis and Koch criteria*. For the TI, sensitivity (SE) and speci-
ficity (SP) were also assessed, with ileo-colonoscopy as reference standard. One-
way ANOVA with Kruskal-Wallis post-test was applied to compare the exten-
sion (cm) of disease in the different segments.
Results: 66 pts (median age 13; range 7–18), 23 suspected, 43 known CD were
included. The overall concordance (k) between SICUS and MRI for presence of
SB lesions was 0.94 (ES 0.06; 95%CI 0.8–1). The k for segments was: jejunum
0.67 (ES 0.1, 95%CI 0.4–0.8), ileum 0.91 (ES 0.06, 95% CI 0.76–1), TI 0.91 (ES
0.06; 95%CI 0.8–1). SE and SP (%) of SICUS and MRI for TI lesions were 98,
100 and 93, 92, respectively. There was no difference in the assessment of disease
extension between SICUS and MRI (p ns). The overall k for strictures was 0.62
(ES 0.1, 95% CI 0.4–0.8). SE and SP(%) of SICUS and MRI for TI strictures
were 100, 100 and 92, 87, respectively. MRI provided 7 false positive results, not
detected at SICUS nor confirmed at endoscopy.
Conclusion: The diagnostic performance of SICUS is comparable to that of MRI
in pediatric CD. SICUS is useful in assessing SB strictures, probably with higher
accuracy than MRI. SICUS might represent a first-line tool in pediatric CD, able
to reduce costs and to post-pone or even avoid more invasive and expensive
investigations.
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Introduction: Operative resection in Crohn’s disease is not curative. Indeed, a
majority of CD patients undergoing ileocecal resection have an endoscopic recur-
rence in the neo-terminal ileum as soon as six months after surgery. T cells are
major players in the intestinal immune response. We previously demonstrated the
persistence of T cell clonal expansions over time in the inflamed mucosa of CD
patients (1). The presence of T cell clonal expansions at time of surgery could play
an important role in the post-operative recurrence.
Aims & Methods: The aims of the study were to explore the impact of the pre-
sence of T cell clonal expansions in the inflamed tissue at time of surgery on the
risk of post-operative endoscopic recurrence, and to analyse the correlation
between the persistence of these T cell clones in the neoterminal ileum and
inflammation. The REMIND Post-OPerative study has been performed in 9
centers, collecting data at time of surgery (M0) and of endoscopy (performed
at M6), associated with an extensive bio-banking. Clinical, biological and endo-
scopic parameters were collected at month 6. Endoscopic recurrence was defined
by a Rutgeerts score1. Biopsies of ileal mucosa were collected on surgical speci-
men and by endoscopy six months after surgery. T cell Receptor (TCR) analysis
was performed on DNA extracted from biopsies by next generation sequencing
(Adaptive Biotechnology Inc., Seattle, Washington, USA). The TCR repertoire
was analyzed in biopsies obtained on the surgical specimen and during the con-
trol endoscopy at six months. Sequences, numbers, frequencies and clonality
indexes were assessed; and further analyzed to determine TOP100 clone frequen-
cies and persistent clonal expansions present at both M0 and M6 in each patient.
Results: Fifty-seven patients from the REMIND cohort were analyzed: 33 (58%)
were male; median age at surgery was 38 years old (14). We found that the TCR
repertoire in biopsies from CD patients display a large number of unique TCR
sequences (mean 10000 unique sequences) suggesting a high variety of T cell
specificities. However, measures of diversity of the TCR repertoire showed an
important range of clonality within the cohort (0.001 to 0.5). Importantly, the
frequency of the 100 most represented clones in the tissue at M0 was significantly
increased in patients with endoscopic recurrence (Rutgeerts score1) at M6,
showing that increased clonality at time of surgery was predictive of disease
recurrence. Furthermore, the presence and frequency of persistent clones (present
at M0 and M6) was significantly increased in patients who had an endoscopic
recurrence. High or low proportion of persistent clones could define two sub-
groups of patients with endoscopic recurrence in regard to their TCR repertoire.
Interestingly, expanded clones could be found in different T cell subsets.
Conclusion: T cell clonal expansions in the inflamed tissue at time of surgery and
their persistence in the neoterminal ileum after surgery are both associated with
post-operative endoscopic recurrence in Crohn’s disease.
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Introduction: The gut microbiome is an important modulator of colorectal (CRC)
cancer risk. Here we describe a novel methodology for the targeted analysis of the
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colon cancer microbiome using mass spectrometry imaging in a prospective
cohort of CRC patients.
Aims & Methods: A prospective, multi centre observational study was performed
on patients undergoing elective resections for colorectal cancer at Imperial
Healthcare NHS Trust and the Royal Marsden Hospital. Fresh mucosal tissue
was sampled under aseptic conditions from cancers and adjacent normal tissue
and frozen at –80C. Using 16S rRNA sequencing analysis of corresponding
tissue samples (performed in Mothur and Stamp), target bacteria including
Fusobacterium spp, E.Coli and Bifidobacteria were identified. A chemical data-
base of these bacteria was created using Rapid Evaporative Ionisation Mass
Spectrometry (REIMS) from pure cultures of the target microbes. Desorption
Electrospray Ionisation Imaging Mass Spectrometry (DESI-MSI) was then per-
formed to provide a spatially resolved map of the mucosal microbial lipidome.
Taxon specific data were mapped onto these images using chemical spectra iden-
tified by REIMS. Candidate microbial lipids were validated using cell co-culture
experiments and analysis with REIMS. Multivariate analysis was performed
using Matlab (Mathworks) and R. Both unsupervised Principle Component
Analysis and supervised Linear Disciminant Analysis were performed.
ANOVA was used to perform statistical analysis of single lipid species.
Results: 26 patients with sporadic colorectal cancer were recruited (17 women,
median age 68, range 35–84, median BMI 27 kg/m2). Eight tumours were right
sided, eleven were left sided and seven were rectal. Two patients had neo-adju-
vant chemoradiotherapy. Histology showed six adenomas, one T1, six T2, ten T3
and three T4 cancers. Using DESI-MSI it was possible to geographically identify
distinct anatomical regions based on co-registration of the chemical data with
independently validated HþE stained tissue. Using leave one patient out cross
validation, DESI-MSI was able to diagnose cancer from normal colonic mucosa
with ROC AUC ¼ 97.5. Increased long chain fatty acids were seen in malignant
tissue and increased glycerophospholipids were seen in healthy mucosa (both
p5 0.001). Target spectra just specific to the mucosa were then extracted for
analysis. This revealed 102 lipid species that differentiated colon cancer from
normal adjacent mucosa, including 24 attributable to taxon-specific markers
for Bacteroidetes, Bifidobacteriales and Enterobacteriales. These were positively
validated using cell culture REIMS.
Conclusion: Chemical mapping of the colonic lipidome permits spatially resolved
analysis of the cancer microbiome and its metabolic functions, and this has
diagnostic value. DESI-MSI provides a completely novel methodology for study-
ing microbial-host interactions critical to the aetiology of inflammation and
cancer.
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Introduction: Heterogeneity in IBD patient populations is widely cited as the
main barrier to efficient clinical trials and development of therapies with high
clinical efficacy. We and others hypothesize that phenotypic heterogeneity is a
direct result of molecular heterogeneity in disease-driving molecular pathways.
We present an approach not extensively explored for defining molecular hetero-
geneity in a manner independent of known biology.
Aims & Methods: Whole-genome transcriptomic data was generated for colonic
biopsies from 217 moderately to severely active ulcerative colitis subjects and 21
healthy normal controls. Subjects were scored based on enrichment of 113 co-
expression modules, or lists of correlated genes, derived from colonic biopsies
from both UC and CD biopsies. Scores for each subject and co-expression
module were computed using the gene set variation analysis algorithm. Co-
expression modules were then hierarchically clustered into 4 module clusters
and annotated with pathways using the union of genes within each of the 4
module clusters. Each subject was then reclassified based on the 4 module clusters
by taking the median enrichment score of the modules within each module clus-
ter. IBD subjects and normal controls were then hierarchically clustered into 4
subgroups using the 4 module clusters and assessed for relationship to anti-TNF
response.
Results: The 4 module clusters represented distinct pathway sets which we sum-
marized as inflammation/monocytes, mucosa/pro-regulatory, T cells/metabolism
and mitochondria/metabolism. Patients belonging to the subgroup characterized
by the highest enrichment for the inflammation/monocyte module cluster trended
towards lower response rates to anti-TNF therapy. Conversely, the highest
response rates to anti-TNF therapy were observed in the subgroup characterized
by the lowest enrichment for the inflammation/monocyte module cluster. These
subgroups also contained normal healthy controls. Enrichment values for the
mucosa/pro-regulatory module cluster anti-correlated (r¼0.49) with enrich-
ment values for the inflammation/monocyte module cluster.
Conclusion: We find that there is pronounced molecular heterogeneity in the
pathways present in colonic biopsies from UC patients. We also show that this
heterogeneity may be related to the ability of patients to respond to anti-TNF
therapy. This suggests that molecular stratification may be a key step towards
designing smaller clinical trials and identifying meaningful personalized medicine
approaches for IBD patients.
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PROTEOMIC PROFILING IN NEWLY DIAGNOSED
INFLAMMATORY BOWEL DISEASES: A MULTI-CENTRE COHORT
STUDY
R. Kalla1, A. T. Adams1, J. Lindstrom2, Ibd Character Consortium1,
M.H. Vatn3, J. Jahnsen4, P. Ricanek5, D. Bergemalm6, J.D. So¨derholm7,
M.J. Pierik8, F. Gomollon9, M. D’Amato10, J. Halfvarson11, J. Satsangi1
1Centre For Genomics and Experimental Medicine, University of Edinburgh,
Edinburgh/United Kingdom
2Deparment Of Gastroenterology, University of Oslo, Oslo/Norway
3Inst. Of Clinical Medicine, University of Oslo, Oslo/Norway
4Deparment Of Gastroenterology, Akershus University Hospital, Lorenskog/
Norway
5Department Of Gastroenterology, Oslo University Hospital, Oslo/Norway
6Deparment Of Gastroenterology, O¨rebro University, O¨rebro/Sweden
7University Hospital, Linko¨ping University, Linko¨ping/Sweden
8Dept Of Gastroenterology and Hepatology, Maastrich University Medical Center
Dept. of Gastroenterology, Maastricht/Netherlands
9Servicio De Aparato Digestivo, Hospital Clı´nico Universitario Lozano Blesa,
Zaragoza/Spain
10Unit Of Molecular Genetics Of Digestive Diseases, BioCruces Health Research
Institute, Bilbao/Spain
11Dep. Of Internal Medicine, O¨rebro University Hospital, O¨rebro/Sweden
Contact E-mail Address: rahul.kalla@ed.ac.uk
Introduction: There is an unmet need to gain functional insights into pathways
that are relevant in Inflammatory Bowel Diseases (IBD). By performing tran-
scriptome and proteome profiling in newly diagnosed IBD, we can gain an under-
standing into the molecular mechanisms that may be relevant in disease.
Aims & Methods: Gene expression patterns from whole blood RNA and proteo-
mic profiles from serum were assessed from patients using targeted RNA-seq
(Ion AmpliSeq Transcriptome Human Gene Expression platform) and Olink
multiplex protein panels (Olink Proteomics). Treatment-naı¨ve newly diagnosed
IBD and healthy symptomatic controls were included in the study. Phenotypic
data were captured including demographics and disease classification. Statistical
analysis was performed using R. Differentially expressed transcriptomes were
correlated with serum protein expression to obtain a circulating profile at
diagnosis.
Results: RNA expression profiles were available in 639 patients (351 IBD, 288
controls). A total of 5678 genes were differentially expressed between IBD and
controls. Using hsCRP to adjust for inflammatory status, 1440 remained signifi-
cant. The most differentially expressed genes were CD-177 (Bonferroni corrected
p¼ 2.31036), VBP1 (p¼ 2.901032) and S100 proteins (S100A9,
p¼ 3.31026 and S100A12, p¼ 6.81026). Proteomic profiles were available
in 635 patients (152 CD, 159 UC, 26 IBD-U, 298 non-IBD) Multivariable ana-
lysis identified 59 protein markers that were significantly associated with IBD.
The top significant proteins upregulated in IBD included MMP12 (Holm-
adjusted p¼ 4.11026) and CXCL9 (p¼ 1.71020). Matched serum protein
profiles were available and correlated with RNA expression. 39 proteins
showed significant correlation with gene expression including OSM (rho¼ 0.51,
Holm-adjusted p¼ 1.41040) and S100A12 (rho¼ 0.33, p¼ 3.41014) while
other markers such as CXCL9 show poor correlation (rho¼ 0.16, p¼ 0.04). As
biomarkers, top 2 serum markers were able to discriminate IBD from controls
with a similar area under the receiver operator characteristics curve (AUC) of
0.75 and 0.74 respectively. Individually these markers outperformed hsCRP
(n¼ 619, AUC 0.64, p for comparison¼ 2.7x104 vs. MMP12) and albumin
(AUC 0.66, p¼ 0.004 vs MMP12). 6 proteins differentiated UC from CD includ-
ing MMP12 (p¼ 4.6104). In CD, MMP12 levels were lower in those with
small bowel involvement(Montreal Classification L1, L3 and L4 vs L2;
p¼ 0.009) while in UC, MMP12 levels were significantly higher in extensive
disease (Paris classification E1 and E2 vs. E3, p¼ 5.8x107).
Conclusion: This is the largest integrative multicentre characterisation of the
circulating expression profile studied in IBD at diagnosis. These data identify
key pathways that may be relevant in IBD pathogenesis and demonstrate the
translational potential of these markers in diagnosing and classifying IBD.
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Introduction: Adenoma detection rate (ADR, proportion of patients with at least
one adenoma) is the primary quality indicator of colonoscopy, due to its correla-
tion with the risk of post-colonoscopy interval cancer and mortality [1,2]. Data
from U.S. male veterans [3,4], patients in Taiwan [5] and Europe [6], suggest that
water exchange (WE, infusion of clean water in an airless lumen and removal of
dirty water during insertion), but not water immersion (WI, infusion of water as
adjunct to insufflation and removal of residual water during withdrawal) signifi-
cantly increases ADR in the proximal (cecum-splenic flexure) and right (cecum-
ascending) colon, when compared with standard air insufflation (AI).
Limitations of these studies were their retrospective analysis and/or investigators
unblinded to the insertion method.
Aims & Methods: In a prospective, multi-site randomized controlled trial we
tested the hypothesis that WE, but not WI, significantly increases ADR (primary
outcome measure) compared with AI. The study population was represented by
50–70 years-old asymptomatic subjects, undergoing colonoscopy as primary
screening test or after positive fecal occult blood test. A total of 1224 (672
males) patients were enrolled at three centers and randomly allocated 1:1:1 to
WE, WI and AI. Split-dose bowel preparation was adopted to ensure optimal
pre-procedure cleansing. To overcome the limitation of previous reports of
unblinded colonoscopist performing withdrawal inspection, after reaching the
cecum another investigator blinded to the insertion technique used performed
the withdrawal. To assess adequacy of blinding the withdrawal, the second
endoscopist was asked to guess the insertion technique.
Results: All results are reported in Table 1. Demographics, clinical features,
indications, cecal intubation rates and procedure times were comparable.
Compared with AI (40.4%), WE (49.3%) but not WI (43.4%) achieved signifi-
cantly higher overall ADR (p¼ 0.011 and 0.092, respectively). Compared with AI
(14.2%), WE (19.4%) but not WI (17.2%) achieved significantly higher advanced
ADR (p¼ 0.049 and 0.249, respectively). In the right colon, WE (24%) but not
WI (19.1%) achieved significantly higher ADR than AI (16.9%) (p¼ 0.012 and
0.413, respectively). Even after split-dose preparation, WE was associated with
higher overall and right colon BBPS scores. The impact was most notable in
patients with excellent BBPS, adjusted entire and right colon ADR of WE were
significantly higher than those of WI and AI. Multivariate logistic regression
showed that WE, compared with AI, was an independent predictor of adenoma
detection in the entire colon [OR (95% CI), 1.18 (1.03–1.36)] and in the right
colon [1.24 (1.04–1.47)], respectively. Comparable correct guesses of insertion
method (532%) suggest adequate investigator blinding. Similar withdrawal
times without polypectomy suggested withdrawal technique was comparable.
Equal mean adenoma per positive colonoscopy (MAPþ) suggest ADR was not
negatively impacted by the one-and-done approach. Volumes of water infused
and suctioned suggested that WE, WI and AI methods were correctly used.
Conclusion: The current study shows that in European screening patients, WE
increased adenoma detection by 18% in the entire colon and by 24% in the right
colon. Moreover, compared with the two other methods, WE improves the qual-
ity of colon cleansing. A type II error could account for the absence of statistical
significance between unadjusted ADR in the WE and WI groups, further direct
comparisons between WE and WI are required.
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Table 1 (OP168): Demographics, procedural outcomes, bowel cleanliness and adenoma detection.
Demographics WE N¼ 408 WI N¼ 408 AI N¼ 408
P value
WE vs WI WE vs AI WI vs AI ANOVA
Females, n (%) 184 (45.1) 185 (45.3) 183 (44.9)
Males, n (%) 224 (54.9) 223 (54.7) 225 (55.1) 1y 1y 0.888y 0.990
Age, mean (SD) 61.4 (6.2) 61.0 (6.3) 60.9 (6.2) 0.261z 0.173z 0.822z 0.350
Body Mass Index, mean (SD) 26.4 (4.1) 26.4 (4.4) 26.6 (4.4) 0.751z 0.473z 0.696z 0.775
Indications for colonoscopy, n (%)
Screening FITþ 242 (59.3) 242 (59.3) 222 (54.4) 1y 0.157y 0.157y 0.263
Screening FOBTþ 18 (4.4) 19 (4.7) 19 (4.7) 0.863y 0.863y 1y 0.982
Family history of colorectal cancer 47 (11.5) 47 (11.5) 45 (11.0) 1y 0.823y 0.823y 0.968
Primary colonoscopy 101 (24.8) 100 (24.5) 122 (29.9) 0.920y 0.099y 0.084y 0.143
Procedural outcomes
Cecal intubation rate (final), n (%) 402 (98.5) 400 (98.0) 399 (97.8) 0.590y 0.435y 0.807y 0.734
Cecal intubation time, mean (SD), min 10.1 (5.4) 9.4 (5.7) 9.7 (6.7) 0.050z 0.364z 0.390z 0.188
Withdrawal time without polypectomy, mean (SD), min 9.5 (3.2) 9.5 (3.6) 8.9 (3.1) 0.870z 0.074z 0.128z 0.084
Total procedure time, mean (SD), min 24.8 (11.7) 24.6 (12.0) 23.3 (11.0) 0.842z 0.059z 0.098z 0.128
Withdrawal endoscopists’ correct guesses of insertion method 119 (29.2) 135 (33.1) 116 (28.4) - - - - - - - -
Overall Boston Bowel Preparation Scale (BBPS) score, mean (SD) 7.9 (1.5) 7.4 (1.6) 7.5 (1.7) 50.0005z 50.0005z 0.924z 50.0005
Right colon BBPS score (SD) 2.6 (0.6) 2.4 (0.6) 2.4 (0.7) 50.0005z 50.0005z 0.815z 50.0005
Infused water during insertion, median (range), mL 550 (50–6500) 400 (50–2000) 0 (0–1000) - - - - - - - -
Aspirated water during insertion, median (range), mL 500 (0–6500) 50 (0–1000) 100 (0–900) - - - - - - - -
Adenoma detection
Overall ADR, n (%) 201 (49.3) 177 (43.4) 165 (40.4) 0.395y 0.011y 0.092y 0.036
Overall advanced adenoma detection rate, n (%) 79 (19.4) 70 (17.2) 58 (14.2) 0.4137y 0.049y 0.249y 0.145
Right colon ADR, n (%) 98 (24.0) 78 (19.1) 69 (16.9) 0.089y 0.012y 0.413y 0.034
MAPþ, mean (SD) 1.79 (1.2) 1.98 (1.9) 1.79 (1.3) 0.265z 0.981z 0.245z 0.365
At BBPS 9–8 (entire colon) WE n¼ 275 WI n¼ 227 AI, n¼ 227
Adjusted overall ADR, n (%) 148 (53.8) 94 (41.4) 88 (38.8) 50.0005y 50.0005y 0.566y 0.001
At BBPS 3 (right colon) WE n¼ 243 WI n¼ 186 AI n¼ 190
Adjusted right colon ADR, n (%) 63 (25.9) 32 (17.2) 26 (13.7) 0.0007y 50.0005y 0.346y 0.004
SD, standard deviation; FITþ, positive at fecal immunochemical testing; FOBTþ, fecal occult (guaiac-based) blood testing; Advanced adenomas: adenomas 10mm
in diameter, or high grade dysplasia, or with 20% villous components. yChi-squared; zt test; ANOVA, analysis of variance.
United European Gastroenterology Journal 4(5S) A69
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
OP169 EFFICACY OF ENDOCUFF-ASSISTED COLONOSCOPY IN THE
DETECTION OF COLORECTAL POLYPS
Y. Wada1, Y. Wada1, M. Wada1, Y. Fukuma2, M. Fukuda3, K. Ohtsuka3
1Department Of Endoscopy, Wada Clinic, Wakayama/Japan
2Tranomon Hospital, Tokyo/Japan
3Tokyo Medical and Dental University, Tokyo/Japan
Contact E-mail Address: w-yoshi@mtj.biglobe.ne.jp
Introduction: Colonoscopy is the gold standard for detecting colorectal adenomas
and cancers. Endoscopic surveillance has been shown to be effective for prevent-
ing colorectal cancer. Although the detection of colorectal polyps at an early
stage is important, the endoscopic visualization of early neoplasia can be
difficult.
Aims & Methods: The Endocuff is a new device that can be attached to the tip of
the colonoscope to hold the colonic folds away from the field of view during
withdrawal. The aim of this study was to compare the polyp and adenoma
detection rates between Endocuff-assisted colonoscopy and standard colono-
scopy. This randomized prospective study was conducted at two academic endo-
scopy departments in Japan. The subjects were 446 patients who underwent a
complete colonoscopic examination from April 2015 to September 2015. The
Endocuff group included 239 patients. Cecal intubation rate, insertion time,
withdrawal time, pain score, complications, polyp detection rate, and adenoma
detection rate were assessed.
Results: There were no differences between the groups in cecal intubation rate,
insertion time, withdrawal time, or pain score. Cecal intubation was achieved in
235 patients (98.8%) in the Endocuff group. In four patients, the Endocuff-
assisted examination had to be stopped in the sigmoid colon due to severe ste-
nosis caused by diverticula or cancers. These examinations were completed with a
standard colonoscope. Superficial mucosal erosions occurred in 54 patients
(23.0%) during withdrawal in the Endocuff group but no major complication
occurred. The polyp detection rate in patients increased by 12% (62% vs. 50%,
P¼ 0.013) and the adenoma detection rate increased by 15% (55% vs. 40%,
P¼ 0.001) with the use of Endocuff. The advanced adenoma detection rate
was higher in the Endocuff group but no statistically significant difference was
found (6.1% vs. 3.2%, P¼ 0.17).
Conclusion: Endocuff-assisted colonoscopy enabled a significantly higher polyp
and adenoma detection rate than standard colonoscopy. This attachment
improved important quality measures used for screening colonoscopy.
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Introduction: Optical enhancement (OE) will be introduced at UEGW 2016 as a
novel endoscopic imaging technique that adjusts emitted light to enhance muco-
sal vascular pattern and surface pattern morphology. This study assessed for the
first time the utility of OE to predict colorectal polyp histology.
Aims & Methods: Primary objective was to develop and validate a simple classi-
fication system allowing differentiation of hyperplasic and adenomatous color-
ectal lesions by using OE. In the first phase, the capacity of experienced
endoscopists to predict the histology of colorectal polyps was assessed. In the
second phase, a simplified classification was developed allowing histologic pre-
diction. Thirdly, the validity of the classification was evaluated among inexper-
ienced raters, including medical students, nurses and GI fellows. At least, a pilot
clinical evaluation was performed during real-time colonoscopy.
Results: A simple classification system for differentiating hyperplasic and adeno-
matous colorectal lesions by using OE was developed and validated. Diagnosis
was made in 85% to 90% of polyps with high-confidence. Sensitivity ranged
from 92% to 96% and specificity ranged from 86% to 93%, respectively.
During real-time colonoscopy, diagnosis was made with high-confidence in
90% of polyps with sensitivity of 96%, specificity of 92%, and accuracy of
95%. Positive and negative predictive values were 96% and 93%, respectively.
Conclusion: We developed and validated for the first time a simple and effective
classification system for differentiating hyperplasic and adenomatous colorectal
lesions by using the newly introduced OE-technology during real-time colono-
scopy. These findings need to be evaluated in future prospective, controlled, and
blinded clinical trials.
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Introduction: Endoscopic resection of large non-pedunculated colorectal polyps
(LNPCPs) is challenging, with a significant proportion of them containing malig-
nancy. Diagnostic work-up has the potential to improve clinical outcomes. The
aims of this study were to examine the frequency of LNPCPs in clinical practice,
endoscopic and histopathologic features and predictors for advanced histology.
Aims & Methods: We previously trained all endoscopists (9 faculty and 14 trai-
nees) at Maastricht UMCþ on detection, diagnosis and endoscopic resection of
colorectal neoplasms using a stepwise training program: Phase 1: Training on
detection and diagnosis of colorectal neoplasms, with special attention for non-
polypoid (flat and depressed) colorectal neoplasms using lectures, videos and
individual feedback. Phase 2: Training in endoscopic resection techniques using
videotraining and hands-on training with experienced colonoscopists. Then, we
embarked in a prospective study of all consecutive colonoscopies performed at
our institution from February 2008 to February 2012. Quality indicators (cecal
intubation rate, adenoma and polyp detection and resection rate) were moni-
tored. We recorded patient characteristics (age, gender) and lesion characteris-
tics, i.e. location, size, shape using Paris classification (including photo
documentation) and histopathology. We defined LNPCPs as large (20 mm)
non-pedunculated (i.e. sessile, flat, depressed, combinations) colorectal neo-
plasms (Rutter et al, Gut 2015). We paid special attention to laterally spreading
tumors (LSTs), defined as superficially growing lesions along the mucosa instead
of growing up- or downwards. We conducted a logistic regression analysis to
identify predictors for advanced histopathology, defined as high-grade dysplasia
or early colorectal cancer (pT1).
Results: A total of 7166 neoplasms were identified in 9353 patients (mean age
58.9 years, 46.0% male), of which 205 (2.9%) in 176 (1.9%) patients (mean age
68.3 years, 56.3% male) were LNPCPs. The majority (65.9%) of LNPCPs were
located in the proximal colon. Mean size was 30 mm (20–100mm). Ninety-six
LNPCPs (46.8%) were sessile and 109 (53.2%) LSTs. LNPCPs contained low-
grade dysplasia adenoma (29.8%), high-grade dysplasia adenoma (37.1%), early
colorectal cancer (17.1%), sessile serrated adenoma/polyp (6.6%), hyperplasia
(8.8%), and traditional serrated adenoma (0.5%). Sessile-LNPCPs more often
contained advanced histopathology than LST-LNPCPs (61.5% vs. 34.9%,
p5 0.001). After adjusting for age and gender, distal location (OR 3.1, 95%-
CI 1.6–6.0, p5 0.001), size of lesion (OR 2.7 for LNPCP 40mm compared to
20–29mm, 95% CI 1.1–6.2, p¼ 0.023) and sessile shape (OR 2.3, 95%-CI 1.2–
4.4, p5 0.001) were all independent predictors for advanced histopathology. The
overall referral rate to surgery (n¼ 45) decreased from 30.4% in the first half of
the study period to 16.7%. Delayed bleeding occurred in 6 (5.6%) cases after
endoscopic resection, none requiring surgical intervention. No perforations
occurred.
Conclusion: In this real-life prospective cohort, 1.9% of all patients undergoing a
colonoscopy had a LNPCP. Lesion size, sessile shape and distal location were
independent predictors of advanced histology. Careful case selection which con-
siders both patient-related factors and endoscopic predictors of advanced histol-
ogy is critical to optimize the outcomes of endotherapy for LNPCPs.
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Introduction: Colorectal cancers (CRC) detected shortly after a colonoscopy are
referred to as a post-colonoscopy colorectal cancer (PCCRC), and has been
reported to represent 2–9% of all CRCs, depending on the definition, setting
and methods for estimating its incidence. The delay in detection of the CRC
might imply higher mortality, effect on the quality of life of the diagnosed indi-
viduals, and association with extra costs for health services.
Aims & Methods: The aim of this study was to estimate the loss of health and
health care costs following delay in CRC-diagnosis due to PCCRC in Sweden. A
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recent register study of colonoscopies in Sweden during 2001–2010 revealed that
18,244 individuals were diagnosed with CRC within 0–36 months after a colono-
scopy. A CRC was defined as a PCCRC if it was detected within 6–36 months
after a colonoscopy in which no cancer was detected. A total of 1,473 (8.1%)
PCCRCs were found in the register study and included in this study. A lifelong
mathematical Markov model was employed to calculate the lifelong health effects
and resource usage for PCCRC. The effects were calculated by simulating the
hypothetical lives of the individuals diagnosed with PCCRC if their condition
had instead been diagnosed at the time of colonoscopy. These lives were then
compared with simulated lives of individuals diagnosed with PCCRC, in terms of
life expectancy, quality of life and costs. The simulation model was constructed
by using Swedish registry data, supplemented with data from the published
scientific literature and databases.
Results: Our simulation indicated that if the CRC of the individuals diagnosed
with PCCRC had been diagnosed at the prior colonoscopy, there would have
been a down-staging of the cancer. The proportion of patients at each cancer
stage shifted from 53% in stage I-II, 35% in stage III and 9% in stage IV at the
time of the index colonoscopy, to; 47% in stage I-II, 31% in stage III and 22% in
stage IV, respectively, when diagnosed as a PCCRC. Additionally, based on our
simulations 3% of the PCCRC was expected to be at an adenoma stage at the
time of the colonoscopy and were, thus, theoretically able to prevent. The 1,473
PCCRCs were associated with a loss of 1551 life-years or, expressed differently,
1275 quality-adjusted life-years, compared to being ones detected at colono-
scopy. Additionally, the delay in detection was also associated with higher life-
time costs due to an increased need of health care services related to CRC. The
cumulative cost was estimated to be E1,922, 000 less if the patients had been
diagnosed at the time of the prior colonoscopy. The extra cost per case is E1305.
Conclusion: Our simulation results imply that false negative colonoscopies cause
significant loss of life-years and quality of life in the affected individuals. This,
together with higher costs, motivates further efforts to improve the quality of
colonoscopies.
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Introduction: Several methods for colorectal cancer (CRC) screening are avail-
able; the most often used include colonoscopy, sigmoidoscopy and fecal immu-
nochemical testing (FIT). To date, comparison between these screenings methods
was mainly focused on one-time endoscopic screening to one-time FIT screening.
A fair comparison of diagnostic yield (DY) of FIT would comprise cumulative
DY after multiple rounds of FIT screening. The aim of our study is to compare
the DY of multiple rounds of FIT-screening to one-time screening by sigmoido-
scopy and colonoscopy.
Aims & Methods: Demographic data of 30,007 randomly chosen individuals aged
50–74 were obtained from municipal population registers (June 2006 - August
2010); of these 15,046 were invited for four rounds of FIT, 8,407 for one-time
sigmoidoscopy, and 6,600 for one-time colonoscopy screening. We compared 2
rounds of FIT to one-time sigmoidoscopy and 4 rounds of FIT to one-time
colonoscopy. Cumulative (cum.) participation rate, positivity rate, number of
colonoscopies, and diagnostic yield were calculated for each method. The DY
was calculated relative to eligible invitees and participants. Between-group differ-
ences for participation, number of colonoscopies and DY were evaluated using
multivariable logistic regression analysis adjusted for age and gender.
Results: In total, 28,515 eligible persons (median age 60 years, IQR 55–66; 50%
males) were invited. Cum. participation was significantly higher for FIT (77%)
than for sigmoidoscopy (31%; p5 0.001) and colonoscopy (24%; p5 0.001).
Number of colonoscopies performed relative to eligible invitees was highest for
colonoscopy (24%) compared to FIT (13%; p5 0.001) and sigmoidoscopy (3%;
p5 0.001). For invitees the DY for advanced neoplasia (AN) was significantly
higher after two rounds of FIT compared to one-time sigmoidoscopy (3.1% vs
2.3%; p5 0.001) and after four rounds of FIT compared to one-time colono-
scopy (4.5% vs 2.2%; p5 0.001). For participants, DY for AN was significantly
higher for endoscopic screening; 4.7% for 2 rounds of FIT compared to 7.3% for
sigmoidoscopy (p5 0.001), and 6.1% for 4 rounds of FIT compared to 9.1%
colonoscopy (p5 0.001).
Conclusion: In this population-based CRC screening cohort, we demonstrated
that multiple rounds of FIT screening detects significantly more advanced neo-
plasia per invitee compared to one-time sigmoidoscopy and colonoscopy screen-
ing, and with significantly fewer colonoscopies needed. Colonoscopy detected
more advanced neoplasia per participant. However, due to low participation in
colonoscopy screening, FIT seems most effective in population-based CRC
screening.
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Introduction: Between 2006 and 2010, the UK national audit of adult inflamma-
tory bowel disease admissions revealed a small but non-significant fall in mor-
tality in Crohn’s disease (CD) from 1.3 to 0.8%, an increase in the rate of
prescription of anti-TNF therapy on admission from 3.9 to 8% and a fall in
surgery from 23 to 18%.
Aims & Methods:Hospital Episode Statistics (HES) is an administrative database
of data on all elective and emergency care episodes in hospitals in England. Using
HES, patients aged between 18 and 60 years coded with a first emergency admis-
sion with CD were identified. The influence of demographic factors, comorbidity
and infused anti-TNF therapy on mortality, surgery and emergency readmissions
was examined using multivariate logistic regression.
Results: Between 2004 and 2014, 24,830 patients (55% female, mean age of 35
(IQR 25–44)) were identified. Mortality was 0.22% at 30 days, 0.29% in hospital
and 0.81% within 1 year. During admission, 19.2% of patients underwent sur-
gery (median time to surgery 2 days (IQR 1–6)) and 1.9% received infused anti-
TNF therapy. Surgery during admission rose from 16.1 to 22.9% (OR 1.52 (95%
CI 1.32–1.75), p5 0.001) between 2004 and 2014, and infused anti-TNF therapy
rose from 1.8 to 2.8% between 2006 and 2014. In-hospital and 1-year mortality
fell from 0.51 and 1.03% in 2004 to 0.10 and 0.57% in 2013 (0.18 (95% CI 0.04–
0.77), p¼ 0.021 and 0.46 (0.23–0.91), p¼ 0.026 respectively). Patients aged 35–60
had a higher 30-day (3.99 (1.97–8.05), p5 0.001) and 1-year mortality (4.57
(3.14–6.65), p5 0.001) than those aged 18–34. Increasing comorbidity (15.38
Table 1 (OP172): Logistic regression model adjusted for age and gender to identify predictors for advanced histopathology in LNPCPs. LGD: low-grade dysplasia;
HGD: high-grade dysplasia; early CRC: early colorectal cancer (pT1).
Feature Total (n¼ 205)
Histopathology
Unadjusted OR (95% CI) Adjusted OR* (95% CI)
LGD (n¼ 108) HGD or early CRC (n¼ 97)
Location p5 0.001 p5 0.001
Proximal 135 (65.9%) 87 (64.4%) 48 (35.6%) 1.0 1.0
Distal 70 (34.1%) 21 (30.0%) 49 (70%) 4.2 (2.3–7.9) 3.1 (1.6–6.0)
Size p¼ 0.191 & 0.001 p¼ 0.131 & 0.023
20–29 mm 109 (53.2%) 67 (61.5%) 42 (38.5%) 1.0 1.0
30–39 mm 57 (27.8%) 29 (50.9%) 28 (49.1%) 1.5 (0.8–2.9) 1.7 (0.9–3.5)
40 mm 39 (19.0%) 12 (30.8%) 27 (69.2%) 3.6 (1.6–7.8) 2.7 (1.1–6.2)
Shape p5 0.001 p5 0.001
LST 109 (53.2%) 71 (65.1%) 38 (34.9%) 1.0 1.0
Sessile 96 (46.8%) 37 (38.5%) 59 (61.5%) 3.0 (1.7–5.3) 2.3 (1.2–4.4)
*Logistic regression model adjusted for age and gender
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(7.33–32.23), p5 0.001) and deprivation (3.14 (1.06–9.31), p¼ 0.039) was asso-
ciated with a higher 30-day and 1-year mortality, but not gender. Females were
less likely to have surgery during their admission (0.71 (0.67–0.76), p5 0.001) or
within 1 year (0.82 (0.77–0.97), p5 0.001) and surgery within 1 year was more
common in younger (35–60 years 0.87 (0.81–0.93), p5 0.001) and non-white
patients (1.18 (1.08–1.28), p5 0.001). Anti-TNF therapy during admission was
associated with less surgery immediately (0.39 (0.28–0.54), p5 0.001) and within
1 year (0.55 (0.41–0.73), p5 0.001). Emergency readmissions within 30 days were
associated with male gender (females 0.74 (0.55–0.98), p 0.039), younger age (35–
60 years 0.85 (0.79–0.91), p5 0.001), non-white ethnicity (1.25 (1.13–1.38),
p5 0.001) and not having anti-TNF therapy during admission (0.74 (0.55–
0.98), p0.039).
Conclusion: For patients with a first emergency admission for CD, in-hospital
and 1-year mortality fell considerably over the study period. Surgery and anti-
TNF therapy during admission has increased between 2004 and 2014. Surgery
during admission was associated with men and at 1 year with men, younger age
and non-white ethnicity.
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Introduction: Anti TNF-alpha agents (anti-TNF) are currently the most effec-
tive therapeutics for Crohn’s disease (CD). Some of CD patients under anti-
TNF therapy, however, need surgery because of disease progression. Surgical
resection (‘Reset’) usually leads to the elimination of the intestinal regions with
the most severe activity. However, little is known about whether retreatment with
anti-TNF is effective for patients who underwent ‘Reset’ surgery. The aim of
this study was to evaluate the efficacy of anti-TNF therapy for CD patients who
underwent surgery due to the refractoriness to previous anti-TNF.
Aims & Methods: From July 2005 to November 2015, 65 CD patients underwent
intestinal resection at Okayama University Hospital. Of these, 34 patients
received anti-TNF therapy after surgery: 19 refractory to preoperative anti-
TNF (TNF-refractory group), and 15 anti-TNF naı¨ve (TNF-naı¨ve
group). The efficacy of post-surgical treatment with anti-TNF was compared
according to the status of pre-operative anti-TNF therapy. In addition, clinical
factors predicting relapse in patients with anti-TNF retreatment after precedent
surgery were evaluated. The evaluated factors were clinical backgrounds, dura-
tion of TNF therapy, concomitant medications before and after surgery, labora-
tory data before surgery, and the residual of the affected intestine after surgery,
etc. The relapse was defined as intensification of medical therapy, hospitalization,
or surgery due to worsening of abdominal symptoms, CRP elevation with the
evidence of endoscopic recurrence.
Results: Patients of the TNF-refractory group showed significantly higher rate
of relapse than those of the TNF-naı¨ve group (12/19 (63%) vs. 3/15 (20%),
p 5 0.05). In the evaluation of factors predicting relapse in patients with retreat-
ment of anti-TNF after surgery, only the residual of the affected intestine after
surgery is the significant predictor of relapse (patients with vs. without residual
the affected intestine: 11/12 (92%) vs. 3/7(43%), p 5 0.05).
Conclusion: The ‘Reset’ surgery was not so effective for CD patients refractory to
anti-TNF therapy. In particular, patients with the residual of the affected intes-
tine after surgery had higher risk of relapse despite retreatment with anti-TNF
after surgery. Those patients may need additional treatment besides anti-TNF
therapy or increase in the dosage amount of the anti-TNF agent.
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Introduction: Crohn’s disease (CD) is a chronic illness that interferes with the
daily life of those affected. Surgical treatment is required in about 70% of CD
patients during the course of disease and risk of surgery is among the highest
rated concerns among them. Quality of life is often worsened by intestinal
surgery.
Aims & Methods: The aim of the study is to assess the impact of minimally
invasive surgery on quality of life after surgery for Crohn’s disease terminal
ileitis. From June 2010 to December 2015, one hundred twelve consecutive CD
patients who underwent surgery for Crohn’s disease terminal ileitis were enrolled.
They were interviewed by telephone and responded to the generic Cleveland
Global Quality of Life (CGQL) questionnaire and the Body Image
Questionnarie (BIQ). Their disease activity was defined as Harvey-Bradshaw
Index (HBI). Comparisons and correlations were carried out with non-para-
metric tests. Survival analysis was performed with log rank test.
Results: In our study group 46 patients had minimally invasive surgery for term-
inal ileum CD while 66 had open surgery for the same indication. Twenty seven
patients had a recurrent CD. The total CGQL score and its single items (quality
of health, quality of life and energy levels) were significantly higher (and thus,
better) in the laparoscopy group patients. Similarly, all the BIQ items were sig-
nificantly better in patients who had a minimally invasive surgery compared to
those who had open surgery. At univariate analysis, total CGQL score was
directly correlated with minimally invasive surgery (rho¼ 0.40, p5 0.001) and
inversely correlated with disease activity at the moment of the interview
(rho¼0.44, p¼ 0.001), the use of steroids (rho¼0.20, p¼ 0.02) and recurrent
CD as indication for surgery (rho¼ 0.19, p¼ 0.05). At multivariate analysis, only
minimally invasive surgery and disease activity at the moment of the interview
revealed to be independent predictors of quality of life. Finally, minimally inva-
sive surgery tended to be associate to a less frequently CD recurrence (p¼ 0.08)
Conclusion: Minimally invasive surgery was associated to a better quality of life
and body image perception. This results is probably due in part to the beneficial
effect of minimally invasive surgery on body image but also by the less severe
disease of these patients (less recurrent Cd as indication for surgery or simpler
surgery). Quality of life is essentially predicted by current disease activity and
minimally invasive surgery. Finally, minimally invasive surgery tended to be
associate to a less frequent CD recurrence.
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Introduction: Proctocolectomy or completion proctectomy in inflammatory
bowel disease patients is frequently complicated by disturbed perineal wound
healing and presacral abscess formation. Close rectal dissection (CRD) has
been regarded as an improved surgical technique for benign conditions that
could reduce this complication by leaving the rectal mesentery in situ to minimize
dead space cavity compared to total mesorectal excision (TME).
Aims & Methods: The aim of this study was to compare perineal wound healing
in ulcerative colitis (UC) and Crohn’s disease (CD) patients undergoing TME or
CRD. Since it has been suggested that Crohn’s mesenteric adipose tissue is
involved in CD pathology with reduced regulatory potential of wound healing
macrophages, differences in macrophage populations between UC and CD
patients were assessed. Adult patients undergoing proctocolectomy or comple-
tion proctectomy without reconstruction for UC or CD (2005–2015) were
included. Endpoints were postoperative perineal complications, and healing at
6 and 12 months. Rectal mesentery was cultured and walk-out cells were analysed
by flow cytometry. CD45þ immune cells were identified, with phenotyping of
wound healing macrophages by regulatory markers CD206 and CD14.
Results: Fifty-nine patients (17 UC/42 CD) were included (46.4% male, mean age
45.5 (14.5)). CRD was performed in 8 UC (47.1%) and 32 CD patients
(76.2%). In UC, significantly less perineal complications (17.6% versus 47.6%,
p¼ 0.033) and a higher healing rate at 6 months (87.5% versus 64.3%, p¼ 0.066)
were seen. No significant differences in outcome between the techniques in UC.
Perineal complications occurred less frequently in CD patients who underwent
TME compared to CRD, (20.0% versus 56.3%, p¼ 0.045), with higher healing
rates at 6 months after TME (90.0% versus 53.3%, p¼ 0.052). Perineal healing
rate at 12 months was 87.5% in the TME group versus 65.5% in the CRD group
(p¼ 0.443). Analysis of rectal mesentery showed an enhanced infiltration of
CD45þ immune cells in CD patients with the balance between CD3þ lymphoid
T cells and CD14þ myeloid cells skewed significantly towards the myeloid popu-
lation (UC vs CD median 24% versus 53%, p5 0.01 In addition, macrophages
in CD patients showed significantly less expression of the wound healing marker
CD206, in line with a more pro-inflammatory and less wound healing profile of
CD rectal mesentery. Strikingly, these alterations were maintained in patients
with a defunctioning stoma.
Conclusion: In UC, significantly less perineal complications were seen after proc-
tocolectomy or completion proctectomy, compared to CD with higher healing
rates. 450% of CD patients had perineal complications and impaired healing,
which was seen more frequently after CRD. These findings can probably be
explained by the increased pro-inflammatory myeloid cell population with
decreased wound healing macrophages, irrespective of the presence of a
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defunctioning stoma. These findings suggest that excision of the mesorectum is of
crucial importance in CD.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP178 LONG-TERM FOLLOW-UP AFTER ILEORECTAL
ANASTOMOSIS IN ULCERATIVE COLITIS (UC): A GETAID/
GETAID CHIRURGIE MULTICENTER RETROSPECTIVE COHORT
OF 343 PATIENTS
M. Uzzan1, J. Cosnes2, N. Gault3, A. Amiot4, J. Gornet5, P. Seksik6, S. Nancey7,
D. Laharie8, M. Allez9, M. Nachury10, A.L. Pelletier11, V. Abitbol12,
M. Fumery13, A. Buisson14, R. Altwegg15, Y. Panis3, X. Treton16
1Gastroenteroogy, Hoˆpital Beaujon, APHP, PARIS/France
2Gastroenterology, Hopital St Antoine Gastroenterology GETAID, Paris/France
3Beaujon Hospital, Clichy/France
4Dept. Of Gastroenterology, Henri Mondor Hospital, APHP Dept. of
Gastroenterology, Creteil/France
5Hoˆpital Saint-Louis Gastroente´rologie, Paris Cedex /France
6Saint-antoine Hospital, Gastroenterology & Nutrition Department, Paris Cedex /
France
7Dept. De Gastroenterologie, Hospices de Lyon, Pierre Benite/France
8CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie, Pessac
cedex/France
9Gastroenterology, Hopital Saint-Louis APHP, Universite´ Denis Diderot Paris 7,
Paris/France
10Gastroenterology, Claude Huriez hospital, University of Lille 2, Lille/France
11Bichat Hospital, Paris/France
12Hopital Cochin Gastroente´rologie, Paris Cedex/France
13Amiens University Hospital, Amiens/France
14Dept. Of Gastroenterology, CHU Estaing Clermont-Ferrand, Clermont-ferrand/
France
15Hopital Saint Eloi Hepatologie Gastro enterologie, Montpellier cedex /France
16Hopital Beaujon, Clichy/France
Contact E-mail Address: mathieuuzzan@gmail.com
Introduction: Colectomy is frequently performed in ulcerative colitis (UC)
patients. Although ileal pouch-anal anastomosis is recommended after colect-
omy, ileorectal anastomosis (IRA) is still performed. The main objective of our
study was to determine the cumulative incidence of IRA failure and its prognos-
tic factors.
Aims & Methods: This was a multicenter retrospective cohort study, which
included patients with IRA for UC performed between 1960 and 2014. IRA
failure was defined as secondary proctectomy and/or rectal cancer occurrence.
Uni- and multivariate survival analyses were performed using a Cox-propor-
tional hazards model.
Results: 343 patients from 13 French centers were included. Median follow-up
after IRA was 10.6 years. IRA failure rates were estimated at 27.0% (95CI [22–
32]) and 40.0% (95CI [33–47]) at 10 and 20 years, respectively. Median survival
time without IRA failure was estimated at 26.8 years. Two-thirds of secondary
proctectomies were performed for refractory proctitis, and 20% for rectal neo-
plasia. Univariate analysis identified factors associated with IRA failure: IRA
performed after 2004, a longer duration of disease at the time of IRA and having
received immunomodulative agents prior to IRA. In multivariate analysis, treat-
ment with both immunosuppressant (IS) and anti-TNF before colectomy was
independently associated with IRA failure (HR¼ 2.9, 95CI [1.21–7.10]).
Conversely, colectomy for severe acute colitis was associated with decreased
risk of IRA failure (HR¼ 0.6, 95CI [0.41–0.97]).
Conclusion: Patients with UC have a high risk of IRA failure, particularly when
performed for refractory disease. However, IRA could be discussed after colect-
omy for severe acute colitis, in patients naive to both IS and anti-TNF.
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Introduction: Evidence has been accumulating indicating that the appendix has an
immunomodulatory role in patients with ulcerative colitis (UC) potentially redu-
cing the need for medication and colectomy. However, prospective data are
limited and the therapeutic mechanism is not yet understood. The objective of
this study was to examine the effect of an appendectomy to modulate the disease
course of therapy refractory UC patients.
Aims & Methods: Patients with therapy refractory UC, and referred for procto-
colectomy were invited to undergo laparoscopic appendectomy first. The primary
endpoint was clinical response at 3 months and after 12 months. Secondary
endpoints were remission, improvement in IBDQ score and failure. Results
were measured by the Mayo score (partial clinical 0–9 and endoscopic 0–3)
and IBDQ score (32 to 224). Clinical response was defined as a decrease in the
partial Mayo of 3 points. Remission was defined as an endoscopic Mayo 1
point. Improvement in IBDQ was defined as an increase of 420 points. Failure
was defined as when patients underwent colectomy or prescribed trial medication
(eg. Vedolizumab, Etrolizumab).
Results: In total, 30 patients (57% female) with a median age of 40 (IQR, 33–47)
underwent appendectomy with a mean preoperative total Mayo score of 9 (SD
2). The mean baseline IBDQ was 125 (SD 34). After 3 months, clinical response
was seen in 16 (53%) patients of whom 7 (30%) were in remission (7 patients
refused endoscopy at this time point). Improvement in IBDQ was seen in 14
(47%) patients with a mean of 120 (SD 29) that increased to 168 (SD 29).
After 12 months, 11 patients failed (7 colectomy, 4 trial medication) and 5 did
not yet reach the endpoint. In the remaining 14 patients, 9 (36%) had lasting
clinical response of whom 5 (23%) were in remission (3 patients refused
endoscopy).
Conclusion: Appendectomy was effective in at least 30% of therapy-refractory
UC patients. These early results suggests that UC patients may benefit from
appendectomy and that this effect is maintained for a longer period of time.
However, follow up of at least 2 years is warranted to exclude a possible placebo
effect.
Disclosure of Interest: All authors have declared no conflicts of interest.
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OP180 THE RISK OF CLOSTRIDIUM DIFFICILE INFECTION IN
PATIENTS WITH PERNICIOUS ANAEMIA: A RETROSPECTIVE
COHORT STUDY USING PRIMARY CARE DATABASE
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City Hospital Campus, University Of Nottingham, Nottingham/United Kingdom
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Introduction: Previous studies have shown an association between proton pump
inhibitor use and Clostridium difficile infection1. One suggested mechanism of
this association is the very low stomach acid levels caused by these drugs, since
gastric acidity is an important host defence against ingested pathogens. If acid
suppression is the true cause of Clostridium difficile infection in patients receiving
proton pump inhibitors, then this effect should be manifested in patients with
achlorhydia (no acid production), a condition associated with pernicious anae-
mia. Elucidating this association would provide a clear understating of the acid-
suppression hypothesis underlying the increased risk of infection in patients who
have received gastric acid suppressive therapy.
Aims & Methods: The aim of this study was to determine the risk of Clostridium
difficile infection in patients with pernicious anaemia. We conducted a popula-
tion based cohort study using English linked primary (Clinical Practice Research
Datalink) and secondary (Hospital Episode Statistics) care records (1998–2012).
The exposed group consisted of patients with a diagnosis of pernicious anaemia
who had been treated with vitamin B12 therapy. Each exposed patient was
matched by age (within 5 years), gender and general practice to non-pernicious
anaemia patients, with the follow-up start date of the control being as their
matched exposed patient. Cox regression analysis was used to estimate the
hazard ratio (HR) and 95% confidence interval for the association between
Clostridium difficile infection and pernicious anaemia, adjusted for potential
confounders.
Results: We identified 20,058 patients with pernicious anaemia receiving vitamin
B12 therapy and 196,895 controls. The crude incidence rate of Clostridium diffi-
cile was 3.3/1000 person-years for those with pernicious anaemia while it was 1.7/
1000 person-years for controls. Patients with pernicious anaemia had a greater
risk of Clostridium difficile infection than controls (adjusted HR 1.52, 95% con-
fidence interval 1.33 to 1.73).
Conclusion: Individuals with pernicious anaemia have an increased risk of
Clostridium difficile infection. This study supports severe hypochlorhydria as
the mechanism for the increased Clostridium difficile infection in people who
have received long-term acid suppression medication.
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OP181 CONSISTENT AND REPRODUCIBLE PRODUCTION OF A
MICROBIOTA-BASED DRUG FOR RECURRENT C. DIFFICILE
INFECTION: APPLICATION OF A NOVEL DIAGNOSTIC FOR
DYSBIOSIS
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Introduction: Antibiotics are the first-line treatment for C. difficile infection
(CDI). However, the most commonly prescribed antibiotics for CDI are asso-
ciated with high recurrence rates. Antibiotics have been shown to disrupt the
intestinal microbiota. Restoration of the intestinal microbiota to its pre-disease
state protects against recurrence. There is an unmet need for a standardised,
reproducible microbiota-based therapy for recurrent CDI. RBX2600, a
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microbiota-based drug candidate targeted at recurrent CDI, is sourced from
human-derived microbes from extensively screened donors and manufactured
using standardised, quality controlled processes.
Aims & Methods: To compare the bacterial abundance in the source material for
RBX2660 (DS) with the bacterial abundance in the finished drug product (DP)
used in the Phase 2B PUNCH CD 2 study. A total of 70 DS samples sourced
from 17 unrelated donors (mean age 27; range 18 to 57 years; 94% male) from
August 2014 to February 2016 were compared with 70 matched DP samples
using the GA-map Dysbiosis Test (GA-test), Genetic Analysis AS, Oslo,
Norway. The GA-test uses 54 probes targeting V3 to V7 of the bacterial 16s
rRNA gene to characterise and identify bacteria present. Approximately 300–400
bacteria at different taxonomic levels are covered, providing for an assessment of
the microbial community using multiple variable regions. The GA- test enables
serial assessment of the faecal bacterial abundance profile as well as potentially
clinically relevant alterations in the microbiome over time. These capabilities of
the GA-test were used to assess the production processes for RBX2660. The
differences in bacterial abundance between the DP and DS were calculated
from log10 of the probe values (DP-DS); averaging the differences.
Results: The GA-test found that the bacterial abundance in the RBX2660 DP
was lower than in the DS in 38 of the 54 probes; equal in number in 6 of the
probes; and higher in 10. More specifically, Firmicutes and Actinobacterium
showed reduced signal strength in the DP compared with the DS.
Bacteroidetes showed increased signal strength in the DP compared with the
DS, while Proteobacteria demonstrated equal signal strength in both samples.
The comparative abundance in the DP vs. the DS is shown in Table 1. Accuracy
was as high as 83.4% at cross-validation. Principal component analysis found
that the bacterial profiles in the RBX2660 DP, though lower than in the donor
source material, were largely kept intact during the production process for all 17
donors.
Table 1: Comparative Signal Strength of Bacteria
Bacteria
Signal Strength
in DP vs. DS Mean Difference (95% CIM)
Bacteroidetes
Bacteroides fragilis Increased 0.07 (0.03, 0.11)
Parabacteroides Increased 0.12 (0.07, 0.17)
Alistipes Increased 0.17 (0.11, 0.23)
Firmicutes
Lachnospirae Decreased 0.13 (0.15, 0.11)
Streptococcus Decreased 0.16 (0.20, 0.13
Negativicutes Increased 0.03 (0.01, 0.06)
Clostridia Decreased 0.18 (0.20, 0.16)
Actinobacteria
Bifidobacterium Decreased 0.33 (0.38, 0.28)
DP¼drug product DS¼drug source CIM¼ confidence interval of mean
Conclusion: GA-test analysis confirmed that RBX2660 can be manufactured in a
consistent and reliable manner with the preservation of key bacterial diversity
believed critical for protection from recurrent CDI.
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Introduction: Adherent-invasive E. coli are clearly involved in triggering and
maintaining ileal CD. AIEC bacteria adhere to the enterocytes through high
affinity interaction between their variant type one pili and abnormally expressed
CEACAM6 protein on host cells. We previously reported an original mechanism
of CEACAM6 regulation depending on DNA methylation of transcription
factor HIF-1 binding site (HRE, Hypoxia responsive element) in the promoter
of the gene. We observed that an unmethylated HRE site allows HIF-1 to bind
the promoter and to induce CEACAM6 expression in intestinal epithelial cells
(IEC). Decreasing CEACAM6 expression in CD intestinal cells is one strategy
that could prevent AIEC bacteria colonization of the intestinal mucosa and
subsequent inflammation. This work aims at studying the effect of a methyl-
donor enriched diet (HMD: High Methyl Diet) on the intestinal physiology,
on microbiota composition, on DNA methylation and on genes expression
with a specific focus on CEACAM6.
Aims & Methods: CEABAC10 female mice were fed a HMD (supplemented in
folate, biotin, B12 vitamin, zinc, methionine) for 2 weeks before pregnancy. After
weaning, the colonic epithelial cells from offspring were purified using EDTA.
We analyzed different physiological parameters such as the lipocalin-2 in stools.
E. coli population was quantified using a qPCR approach. DNA methylation
was measured at a global level and on the CEACAM6 promoter using bisulfite-
sequencing. qPCR was used to quantify CEACAM6 mRNA. RNA-seq was also
used to highlight transcriptomic changes in colonic cells in the both conditions
tested.
Results: We observed that mice fed a HMD show a significant decrease in basal
lipocalin-2 level in stools compared to mice receiving a conventional diet suggest-
ing a beneficial effect on global intestinal inflammation. No significant changes
were observed on histological sections following HMD. Microbiota analysis
revealed a 1000-fold decrease in E. coli population in mice fed HMD compared
to mice receiving a conventional diet. As expected, global DNA methylation
analysis revealed a global increase in cytosine methylation in mice fed a HMD
compared to mice fed a conventional diet. Bisulfite sequencing revealed a hyper-
methylation of the CEACAM6 promoter, especially on the HRE sites. This
hypermethylation of the promoter was associated with a significant decrease in
CEACAM6 expression as measured by qPCR and Western-blot. RNA-seq data
confirmed the decrease in CEACAM6 expression and highlighted many mis-
regulated genes following HMD, among them, many genes involved in adaptive
immunity.
Conclusion: This work shows that the addition of a few vitamins and oligo-ele-
ments to the diet could interfere with the DNA-methylation metabolism leading
to changes in genes expression such as a decrease in CEACAM6 and modify
microbiota composition leading to eradication of the E. coli population in the
intestine. A diet-based strategy could help decreasing AIEC colonization in CD
patients by modulating CEACAM6 expression.
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Introduction: The molecular basis of Adherent-invasive Escherichia coli (AIEC)
pathogenicity, a pathotype associated with Crohn’s disease, still needs to be well
resolved. Nowadays the identification of the pathotype is performed with time-
consuming techniques based in phenotypic screening of cultured bacteria; obtain-
ing new molecular tools would therefore be of great significance.
Aims & Methods: Our aim was to identify putative genetic elements involved in
AIEC phenotype to gain insight into the mechanisms of its pathogenicity and to
find molecular targets for its identification. To achieve this objective we per-
formed comparative genomics of three E. coli strain pairs consisting in one
AIEC and one non-AIEC of identical pulsed field gel electrophoresis fingerprint.
Each pair belonged to a distinct phylogroup. This approach was designed in
order to increase the chance of finding sequences AIEC-specific and not strain-
specific. The six strains’ genomes were sequenced de novo by combining paired-
end libraries of HiSeq Illumina and PacBio. Two different approaches for com-
parative genomics were used: i) assembly with Velvet and genome comparison
between pairs with Differences software, ii) SPAdes for assembly and compara-
tive genomics between pairs in relation to a genome of reference (AIEC UM146)
with Mauve. Only non-synonymous Single Nucleotide Polymorphisms (SNPs) in
coding regions were selected. Sanger sequencing was performed to confirm the
presence of SNPs and to evaluate the distribution of the SNPs in a collection of
22 AIEC and 29 non-AIEC isolates. Nucleotides for each SNP were analysed
taking into account AIEC phenotype, adhesion and invasion indices of isolates
by 2 test or ANOVA as required.
Results: Genome sizes of Velvet assemblies for AIEC strains ONT:HNT-D,
O6:H1-B2 and O22:H7-B1 were 4.86, 5.16 and 4.79Mb respectively. When
SPAdes was used, they presented þ95,362bp, þ47,933bp and þ30,178bp respec-
tively. Comparative genomics of the first approach reported 114, 80 and 31
SNPs, whereas the second resulted in 19, 27 and 31 SNPs respectively. Six
SNPs were found with both strategies. From all, 23 SNPs were confirmed by
Sanger and analysed among the study collection. These SNPs were comprised in
14 genes from which 3 were involved in metabolic processes, 2 in stress tolerance
and 3 in adhesion and invasion pathways. Most of the SNPs were strain-specific,
except from one found in a gene putatively implicated in adhesion/invasion, that
was differentially distributed among AIEC and non-AIEC strains (p¼ 0.029).
Interestingly, this SNP plus 3 other SNPs positions located in the same gene
were associated with invasion (p5 0.024) and one of them also with adhesion
(p¼ 0.04).
Conclusion: To conclude, we have detected SNP variations in a single gene that
could be associated with AIEC phenotype. However, further studies with site-
specific mutations are needed to confirm the implication of this gene in the AIEC
pathogenicity and the SNP effects. Our study indicates that there is not an AIEC-
specific genetic marker and widely distributed in all AIEC.
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OP184 ENTEROHEMORRHAGIC ESCHERICHIA COLI TROPISM TO
PEYER’S PATCHES: ROLE OF LONG POLAR FIMBRIAE AND
INHIBITION BY A PROBIOTIC YEAST
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Introduction: Enterohemorrhagic Escherichia coli (EHEC) are food-borne patho-
gens associated with diarrhea, hemorrhagic colitis and life-threatening complica-
tions such as hemolytic-uremic syndrome. EHEC interact with the Follicule-
Associated Epithelium (FAE) of Peyer’s patches of the distal ileum in humans
and translocate across the intestinal epithelium via M cells. Molecular mechan-
isms are still unknown but Long Polar Fimbriae (Lpf), which contribute to
intestinal colonization, may be involved. Currently no specific treatment is avail-
able in EHEC infections and use of antibiotics remains controversial. Probiotic
could be an alternative strategy.
Aims &Methods: The objectives of the study were to investigate the role of Lpf in
EHEC tropism to Peyer’s patches, and to explore the influence of probiotic
yeasts on EHEC interactions with intestinal mucosa. The expression of lpf
genes (encoded by two lpf operons) of EHEC O157:H7 strain EDL933 was
analyzed using in vitro models of the human upper gastrointestinal tract and
large intestine. To investigate the involvement of Lpf in the ability of EDL933 to
target Peyer’s patches, we generated the DlpfA1, DlpfA2, DlpfA1-DlpfA2 iso-
genic mutants and trans-complemented them with lpf genes. Lpf interaction with
M-like cells was investigated using an in vitro model of specialized M cells.
In vivo interactions of EHEC with murine Peyer’s patches were analyzed in
ileal loop assays. Mice were infected with a mixture of two bacterial strains,
and the numbers of Peyer’s patches-interacting bacteria were determined using
a competitive index analysis. To investigate the effect of probiotic yeasts, mice
were given the probiotic for 7 days before ileal loops assays were conducted with
O157:H7 wild type.
Results: Lpf isogenic mutants (i) were not able to interact with ileal biopsies
containing Peyer’s patches compared to the wild type strain in competitive colo-
nization assays and (ii) translocated across M cells at levels significantly lower
than those observed for the wild type strain. Trans-complementation of the
mutants with the cloned lpf genes restored their ability to interact with Peyer’s
patches and M cells, indicating that expression of lpfA1 or/and lpfA2 genes is
required for interactions with Peyer’s patches. Bloodshot Peyer’s patches were
macroscopically observed following EHEC infection of murine ileal loops. We
showed that or pre-treatment with yeasts significantly inhibited O157:H7 inter-
actions with Peyer’s patches and reduced the number of hemorrhagic Peyer’s
patches in murine ileal loops. Since yeast cell surface is rich in mannose, the
role of carbohydrates in EHEC interactions with Peyer’s patches was investi-
gated. Among the carbohydrates tested, only mannose specifically limited the
interactions of EHEC with Peyer’s Patches.
Conclusion: We conclude that Lpf are involved in the interactions of EHEC with
murine Peyer’s patches and are needed for an active translocation across M cell
monolayer. Tropism of EHEC to Peyer’s patches can be limited by probiotic
yeasts and by specific carbohydrates.
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Introduction:Multiple factors have been associated with an acute flare of Crohn’s
disease, including cigarette smoking and non-steroidal anti-inflammatory drug
use. Recently, Clostridium difficile infection (CDI) has been added to this list.
CDI can become chronic or recurrent in 20% of patients. To date, the impact of
CDI on patients’ mortality and other outcomes among patients with Crohn’s
disease has not been investigated.
Aims & Methods: The aim of this study is to explore the impact of past or current
CDI on mortality, morbidity and resource utilization among patients hospita-
lized for Crohn’s disease. This was a retrospective cohort study using the 2012
National inpatient sample, the largest publically available inpatient database in
the United States. The inclusion criteria were: 1- a principal diagnosis of Crohn’s
disease 2- A principal diagnosis of intestinal hemorrhage, obstruction, fistula, or
abdominal abscess with a secondary diagnosis of Crohn’s disease. There were no
exclusion criteria. The primary outcome was in-hospital mortality. The second-
ary outcomes were morbidity as measured by shock, intensive care unit (ICU)
admission, colectomy or intestinal resection rate and resource utilization as mea-
sured by length of hospital stay (LOS), abdominal CT scan, total parenteral
nutrition (TPN) use and total hospitalization charges. Odds ratios and means
were adjusted for the following confounders using multivariate regression ana-
lyses: age, sex, race, median income in the patient’s zip code, Charlson
Comorbidity Index, hospital region, rural location, size and hospital teaching
status.
Results: 74,515 patients with Crohn’s disease were included in the study, 1,465
(2%) of whom had CDI. The mean age was 43 years and 42% of patients were
female. Patients with CDI had higher mortality rate (adjusted odds Ratio
(OR):5.84, 95% confidence interval (CI):1.79–19.07, p5 0.01) compared with
patients without CDI. Looking at morbidity, patients with CDI had similar a
colectomy rate (OR:1.16, CI: 0.75–1.77, p¼ 0.5), ICU admission rate (OR: 2.77,
CI: 0.93–8.29, p¼ 0.07) and shock rate (OR: 3.06, CI: 0.94–9.97, p¼ 0.06) but a
lower intestinal resection rate (OR: 0.26, CI: 0.08–0.82, p¼ 0.02) compared with
patients without CDI. When resource utilization was examined, patients with
CDI had longer LOS (adjusted mean (mean): 2.54 days, CI: 1.78–3.30 days,
p5 0.01), higher TPN use (OR: 2.71, CI: 1.92–3.82, p¼ 0.02), higher total hos-
pitalization charges (mean: $14,250, CI: $8,473–$20,026, p5 0.01) and similar
abdominal CT scan use (OR: 1.41, CI: 0.78–2.59, p¼ 0.25) compared with
patients without CDI.
Conclusion: Current or past CDI is associated with increased mortality among
hospitalized patients with Crohn’s disease. However, patients with CDI have
similar colectomy rates, shock or ICU admission rate compared with patients
without CDI. Finally, CDI has a profound effect on resource utilization with
longer length of stay, increased TPN use and substantially higher total hospita-
lization charges.
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Introduction: Self-expandable metallic stent (SEMS) or transanal drainage tube
(TDT) is endoscopic decompression for malignant colorectal obstruction. SEMS
is said to be superior to TDT at quality of life (QOL) for the patients, but the
comparison between SEMS and TDT for malignant colorectal obstruction was
few reported include the clinical efficiency, safety and prognosis.
Aims & Methods: The aim of this study is to evaluate QOLs, clinical efficiency
and safety between SEMS and TDT for the patients with malignant colorectal
obstruction. We retrospectively analyzed 69 patients who underwent SEMS or
TDT insertion for malignant colorectal obstruction from April 2009 to March
2016 on the basis of single-center experience in Japan. SEMS was inserted for
bridge to surgery (BTS) or palliation, and TDT was inserted for BTS or bridge to
SEMS insertion.
Results: There were 27 patients in SEMS group (male 37.0%, median age
73 17.0years) and 42 patients in TDT group (male 54.8%, median age
65 15.2 years). Technical success rate was 100% of SEMS group and 95.2%
of TDT group (p¼ 0.15). The endoscopic decompression as BTS for primary
colorectal cancer was performed in 57.1% of SEMS group and 85.7% of TDT
group (p¼ 0.02). Among these patients, the duration for surgery after decom-
pression was longer in SEMS group (14.9 7.0 days vs 10.5 6.6 days, p¼ 0.04),
because the rate of temporary discharge was significantly higher in SEMS group
(41.7% vs 0.0%, p5 0.001). No significant difference was shown about the
hospitalization in both group (36.1 23.5 days vs 46.4 36.0 days, p¼ 0.36).
The rate of oral intake (at least soft solids) was significantly higher in SEMS
group (88.9% vs 25.0%, p5 0.001). The Colonic Stent Safe Procedure Research
Group ColoRectal Obstruction Scoring System (CROSS) score before decom-
pression had no significant difference in both group (1.1 0.9 vs 1.2 0.7,
p¼ 0.49), but CROSS score after decompression was significantly improved in
SEMS group (3.7 0.8 vs 2.3 0.5, p5 0.001). The complications after proce-
dure, such as perforation, migration, re-obstruction, had no significant difference
in both group.
Table: Patients characteristics and results
SEMS (n¼ 27) TDT (n¼ 42) p value
Sex (male) 10 (37.0%) 23 (54.8%) N.S.
Age (median, years) 73 17.0 65 15.2 N.S.
-Age4¼ 85years 9 (33.3%) 3 (7.1%) p¼ 0.005
Obstructed location (left side) 23 (85.2%) 38 (90.5%) N.S.
Primary colorectal cancer 21 (77.8%) 28 (70.0%) N.S.
-BTS 12 24 p¼ 0.02
-Bridge to SEMS insertion - 2
-Palliation 7 -
-Emergent surgery 2 1
Metastatic colorectal cancer 6 (22.2%) 12 (30.0%) N.S.
-BTS 0 5
-Bridge to SEMS insertion - 2
-Palliation 5 -
-Emergent surgery 1 1
-Technical Success 27 (100%) 40 (95.2%) N.S.
Complications
-Perforation 2 (7.4%) 6 (14.3%) N.S.
(continued)
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Table Continued
SEMS (n¼ 27) TDT (n¼ 42) p value
-Re-obstruction 5 (18.5%) 1 (2.4%) N.S.
-Migration 2 (7.4%) 2 (4.8%) N.S.
QOLs
-Temporary discharge 5/12 (41.7%) 0/24 (0.0%) p5 0.001
-Duration for surgery (days) 14.9 7.0 10.5 6.6 N.S.
-Hospitalization (days) 36.1 23.5 46.4 36.0 p¼ 0.36
-Oral intake (at least soft solids) 11/12 (88.9%) 6/24 (25.0%) p5 0.001
-CROSS score (before procedure) 1.1 0.9 1.2 0.7 N.S.
-CROSS score (after procedure) 3.7 0.8 2.3 0.5 p5 0.001
Conclusion: SEMS has the equivalent safety, clinical efficiency and is more super-
ior at QOLs for the patients with malignant colorectal obstruction, comparing
TDT.
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Introduction: In January 2012, the National Health Insurance began covering
endoscopic self-expandable metallic stent (SEMS) placement for malignant colo-
nic obstruction, and now this procedure is widely used in Japan. However, the
clinical factors affecting the technical difficulty of SEMS placement are unclear.
Aims & Methods: This study aimed to clarify the clinical factors associated with
the technical difficulty of SEMS placement for malignant colonic obstruction.
We established the Colonic Stent Safe Procedure Research Group to provide
instructions on how to safety perform SEMS placement, and we then conducted
tis prospective, observational, single-arm, multicenter clinical trial between
March 2012 and October 2013 in Japan. Forty-six facilities participated in this
study. An uncovered WallFlex Enteral Colonic Stent (Boston Scientific
Corporation) was placed in each patient. Technically difficult cases of SEMS
placement were defined as those that had a procedure time longer than 45 min
(i.e., 1.5-fold longer than the median procedure time). We evaluated the clinical
data and extracted risk factors associated with the technical difficulty of SEMS
placement by using univariate and multivariate analyses.
Results: A total of 518 consecutive patients were enrolled in this study. Seven
patients were excluded and the remaining 511 patients constituted the per-pro-
tocol cohort. Of these, 289 were men (57%), and the mean age was 70.6 years.
Three hundred eleven patients (61%) underwent stenting as a bridge to surgery,
and 200 (39%) underwent stenting for palliation. Technical success was achieved
in 501 patients (98%). The median (range) procedure time in the cohort with
technical success was 30 min (4–170 min). One hundred thirty-six patients (27%)
were defined as technically difficult cases of SEMS placement. Clinical risk fac-
tors independently associated with the technical difficulty in SEMS placement
were metastasis of peritoneal carcinomatosis (odds ratio [OR], 2.24; 95% con-
fidence interval [CI], 1.26–3.96; p 5 0.01), a Colorectal Obstruction Scoring
System (CROSS) 1score of 0 before SEMS placement (OR, 2.00; 95% CI,
1.18–3.40; p5 0.01), tumor site in the right colon (OR, 3.33; 95% CI, 2.06–
5.42; p5 0.001), stricture length 45 cm (OR, 1.65; 95% CI, 1.01–2.70;
p¼ 0.04), the placement of 41 stent (OR, 5.96; 95% CI, 1.39–29.72; p¼ 0.02),
and a length of46 cm for the first stent (OR, 2.21; 95% CI, 1.38–3.56; p5 0.01).
However, the clinical risk factors independently negatively associated with tech-
nical difficulty were a history of chemotherapy before SEMS placement (OR,
0.47; 95% CI, 0.22–0.98; p¼ 0.04), digestive tract decompression (OR, 0.45; 95%
CI, 0.25–0.81; p5 0.01), and a diameter of 25 mm for the first placed stent (OR,
0.32; 95% CI, 0.12–0.76; p¼ 0.02).
Conclusion: This large study demonstrated the high technical success rate of
SEMS placement for malignant colorectal obstruction. However, clinicians
should perform this procedure very carefully in cases with metastasis of perito-
neal carcinomatosis, severe stenosis with a CROSS score of 0, and/or long stric-
tures treated with a long stent.
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EXPANDABLE METAL STENTS IN COLONIC OBSTRUCTION
T. Bjerke, M. Rasmussen, S. Meisner
Digestive Disease Center, Bispebjerg Hospital, Copenhagen/Denmark
Contact E-mail Address: ta_bjerke@hotmail.com
Introduction: Since 1991, self-expandable metal stents (SEMS) has been used in
the treatment of malignant colonic obstruction (1). In 1997, Bispebjerg Hospital
was the first hospital in Denmark to initiate the use of SEMS in the treatment of
malignant colonic obstruction. This study represents the largest material from a
single centre ever published.
Aims & Methods: This is a prospective registration of all patients who underwent
SEMS at our institution, in the period from January 1st 1997 to October 1st 2014.
No patients were excluded. The indications were predominantly malignant, but a
few were performed at benign indications. All procedures were performed with a
combined endoscopic and fluoroscopic technique. Relevant patient characteris-
tics, the postoperative course, complications and follow-up data, were gathered
by retrospective patient chart review.
Results: In the period, 521 SEMS procedures was performed in 455 patients, 402
of these had colorectal cancer. Mean age was 74 13 years, and 50.3% were
male. The indications for SEMS placement were malignant colonic obstruction in
418 patients, including 158 as bridge to surgery (BTS), 237 as palliation, three
with malignant anastomotic stricture and 20 patients with obstruction due to
external tumor compression. The benign indications in 37 patients were respec-
tively diverticulitis stricture in 15, diverticulitis fistula in two and benign anasto-
motic stricture in 20. Two hundred and seventy-seven patients had manifested
total colonic obstruction and 121 had small bowel dilatation at the time of the
procedure. The placement of the SEMS was 111 in rectum, 221 in sigmoid colon,
52 in descending colon, 30 in splenic flexure, 30 in transverse colon, 6 in hepatic
flexure and 5 in ascending colon. Mean length of stenosis was 4.5 1.9 cm and
mean days of obstruction was 5.2 3.4 days. There was an overall technical
success rate at 90.3% and clinical success rate of 87.7%. Stent procedure related
complications was 4.2%, mainly guidewire perforations, and none of these
patients died within 30 days. A second stent intervention was performed in
5.9% in the BTS group, 11.9% in the palliative group and in 27.3% in the
group of benign indications, external tumor compression and malignant anasto-
motic stricture. Very few patients required additional re-interventions. The over-
all 30-day mortality rate was 13.4%, 5.8% for BTS group and 17% for palliative
group. Follow up time for BTS group was mean 79 70 months and at last
follow up 35.3% (36/102) showed clinical signs of recurrence. 5-year survival
in BTS group was 32.3% and 2.5% in the palliative group.
Conclusion: Our data shows that routine use of SEMS insertion is a safe and
effective technique for colonic decompression in the setting of malignant large
bowel obstruction, as either a palliative measure or as a bridge to subsequent
resection. SEMS for benign conditions is feasible but with less favourable
outcome.
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Introduction: Self-expandable metallic stents are increasingly used in the treat-
ment of obstructive colorectal cancer. Although endoscopic stenting is widely
accepted in a palliative setting, disagreement exists about its role in a curative
setting (1). The main advantage of this approach is the elective, and thereby less
invasive, character of the surgical resection. It offers the opportunity for an
adequate pre-operative assessment of the patient and a good preparation of
the colon (2).
Aims & Methods: This study aims to describe the long-term survival data in a
large patient group, treated with a stent as a bridge to surgery (BTS) for colon
cancer. Ninety-seven patients, who presented in a Belgian secondary hospital
between June 1998 and November 2013 with a large bowel obstruction due to
colon cancer, were included. All patients underwent endoscopic stenting as a BTS
in a potentially curable disease. Procedure-related complications and long-term
follow-up survival data were collected and compared with the colon cancer mor-
tality in Belgium in the same era (3).
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Results: Overall survival in this observational cohort did not differ significantly
from survival in all Belgian colon cancer patients in the same period (p¼ 0.14).
One-, five- and ten-year survival was not statitiscally different in both groups
(95.9% vs 79.0%; 54.7% vs 51.2%; 41.0% vs 35.6% respectively). Additionally,
for tumour stage II, III and IV no statistical differences between both cohorts
were found (p¼ 0.21, p¼ 0.58, p¼ 0.10 respectively). Technical success rate was
94.8%. Seventy patients did not experience any complication. Stent migration
occurred in 9 patients, whereas stent-related micro- and macro perforations were
observed in 14 patients, without influencing survival. Incidence rates of perito-
neal metastases did not differ significantly between patients with and without any
type of perforation (22.2% vs 15.2% respectively, p¼ 0.47). On average, surgery
took place 16.6 days after colonic stenting, ranging from an operation on the
same day as the endoscopic procedure, to an interval of maximal 124 days. In
82.5% of the cases a laparoscopic resection of the tumor was performed. Five
point two per cent of the patients got primarily open surgery. In 5.2% of the
patients a laparoscopic procedure was converted to laparotomy, because of adhe-
sions or peritonitis. Stoma rates were low (5.2%).
Conclusion: These data indicate that stenting before surgery is effective and safe
in the treatment with curative intent of patients with obstructive colon cancer and
reinforce the debate on stenting as a BTS.
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Introduction: Implementation of colorectal cancer (CRC) screening programs
results in an increase in the number of adenoma diagnoses. Some of the advanced
adenomas (AADs) cannot be endoscopically removed and patients may then be
referred for surgery. However these surgical resections have an associated mor-
tality risk and will have a negative impact on the effectiveness of CRC screening.
So far, the size of this impact is unknown. Therefore the objective of this study is
to estimate the size of this perioperative mortality in relation to AAD removal on
the effectiveness of CRC screening.
Aims & Methods: We used the MISCAN-Colon microsimulation model to simu-
late the Dutch population, aged 50 years and older in 2013 and followed them
lifetime. The population was offered biennial FIT (FOB-Gold at a cut-off of 46
mg/g feces) screening between ages 55 and 75. Gradual roll-out was simulated
from 2014 to 2020 according to implementation. To assess the impact of perio-
perative mortality in relation to AAD removal, we simulated a scenario with and
without perioperative mortality within the screening program. In the scenario
with perioperative mortality, we assumed that 3.9% of all AADs diagnosed
during diagnostic colonoscopy need to be surgically removed, based on findings
in Dutch pilot studies. The perioperative mortality rate is estimated at 2.1%,
based on reports of Dutch surgeons. This leads to an overall mortality risk of
0.08% for every AAD diagnosis. The primary outcomes were the size of perio-
perative mortality per year, the number of prevented CRC deaths, life years
gained (LYG), quality adjusted life years (QALYs) and costs. Sensitivity analyses
were performed with a mortality risk of 0.05% and 0.11%.
Results: During the roll out of the Dutch screening program between 2014 and
2020, perioperative mortality caused up to 18 deaths every year. After 2020 the
number of AAD screen detected decreased and thus perioperative mortality
decreased gradually through approximately 11 per year in 2033. Between 2014
and 2033, a total of 251 individuals died from perioperative complications. This
corresponded with a decrease in prevented CRC deaths of 1.5% (22135 without
operation mortality vs 21928 with), a decrease in LYG from screening of 2.5%
and in QALY’s of 1.0%. The impact on costs of the screening program was
negligible. With higher and lower perioperative mortality assumptions, the out-
comes altered proportionally.
Conclusion: Mortality due to surgical AAD resection has a negative impact on
the effectiveness of CRC screening, although the impact is modest. Benefits of
CRC screening as a whole are maintained. However, deaths due to surgical AAD
resection are an order of magnitude larger than deaths due to complications of
colonoscopy. Future studies into the effectiveness of CRC screening should
therefore incorporate the harms of surgical AAD removal.
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Introduction: The recomended age for colonoscopy screening in average risk
population is 50–55 years, but there is no upper age limit. Many patients are
addressed for screening in advanced age. Although the prevalence of neoplastic
lesions increases with age, life expectancy decreases. The aim of or study was to
evaluate the outcomes of screening colonoscopies in population over 70 years of
age.
Aims & Methods: The data from all screening colonoscopies performed in one
non-university gastroenterology center from january 2012 to december 2015 were
recorded to database in MS Excel. The main parts of the database comprise of
epidemiologic data about the patient, data about examination, histologic results
and complications. The data of population aged 70 years and over and under 70
years were compared, the chi-square and Student t test were used to compare
dichotomous and continous variables considering level od significance of .05.
Results: 1677 screening colonoscopies were performed in total, 333 in group 70
years and more, 1344 in group under 70 years. Polyp detection rate (PDR) and
and quality of bowel preparation in both groups were comparable. There were
significantly more neoplasias (ADR), advanced neoplasias (advanced adenoma
and carcinoma) and carcinomas in older group and also adenoma per colono-
scopy rate (APCR) was higher in seniors. Caecal intubation rate was significantly
lower. The numer of colonoscopies after positive FOBT was significantly higher
than primary colonoscopies in seniors. See the table. There were no bleeding
complications or perforations during screening examinations in both groups.
70 years (333) 570 years (1344) p
Men 160 (48%) 706 (53%) 0.139
FOBT/primary col. 213/120 660/684 50.005
PDR 237 (71%) 911 (68%) 0.240
ADR 174 (52%) 616 (46%) 0.037
Advanced ADR 74 (22%) 200 (15%) 0.001
Carcinoma 10 (3%) 17 (1%) 0.024
APCR 1.102 0.875 0.006
Caecal intubation 313 (94%) 1304 (97%) 0.006
Inadequate preparation 24 (7%) 74 (5%) 0.237
Conclusion: Screening colonoscopies in population over 70 years of age in our
study were safe, with higher detection of neoplasias, but with lower completion
rate. There was higher number of colonoscopies after positive FOBT than pri-
mary colonoscopies among seniors.
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Introduction: The EpiCom-cohort is a European prospective population-based
cohort of unselected patients uniformly diagnosed with inflammatory bowel dis-
ease (IBD) in 2010 in 31 Western and Eastern European centres1. Previously, this
cohort has demonstrated differences in the treatment strategy of IBD patients
between Eastern and Western European centre including that significantly more
patients in Western Europe receive biological therapy2. Despite these differences
in treatment no differences regarding disease outcomes including surgery and
hospitalization rates and quality of life between the two regions have been
found. Anaemia is a common systemic complication and/or extra-intestinal man-
ifestation to IBD as well as an indicator of the level of global IBD care and
inflammation control.
Aims & Methods: The aim of the current study was to investigate the occurrence
of anaemia as well as differences between Eastern and Western Europe during the
first year of disease. Incident patients were followed prospectively from the time
of diagnosis. Clinical data on surgery, medical treatment, hospitalization, and
blood samples were captured throughout the follow-up period. Anaemia and its
subtypes were defined according to the World Health Organisation and ECCO
guideline.
Results: A total of 827 patients aged 15 years or older from 29 centres (20
Western, 9 Eastern European) were eligible for analysis of whom 433 (52%)
had ulcerative colitis (UC), 300 (37%) had Crohn’s disease (CD), and 94
(11%) had IBD unclassified (IBDU). The proportion of patients with anaemia
and its subtypes at diagnosis and follow-up is shown in table 1. Overall, anaemia
was more frequent in Eastern than in Western European patients for both CD
and UC. After 1 year of follow-up significantly more patients in Eastern Europe
who were anaemic at diagnosis remained anaemic (23% UC, 24% CD) compared
to Western Europe (8% UC 9% CD), while a similar proportion in both regions
changed from the anaemic state to normal (20% UC and 35% CD in both
regions) during follow-up. More IBD patients receiving biological therapy
during the first year of disease changed status from anaemia at diagnosis to no
anaemia at follow-up (83%) compared to patients not having received biological
therapy (70%), while fewer patients receiving biological therapy remained anae-
mic during follow-up (17% vs 30%). These differences did, however, not reach
statistical significance (p¼ 0.09).
Table 1: Prevalence of anemia at diagnosis and at 1-year follow up.
Ulcerative colitis Crohn’s disease
Eastern Europe Western Europe Eastern Europe Western Europe
Diagnosis
Follow-
up Diagnosis
Follow-
up Diagnosis
Follow-
up Diagnosis
Follow-
up
Anaemia - overall 43% 26% 29% 13% 58% 25% 45% 12%
Iron deficiency 6% 3% 3% 2% 7% 4% 1% 0%
Anaemia of
chronic disease
9% 3% 3% 1% 13% 0% 12% 1%
Mixed anaemia 6% 1% 1% 1% 24% 7% 17% 1%
Other anaemia 6% 4% 4% 2% 2% 0% 6% 2%
Unclassified 14% 16% 16% 6% 13% 15% 10% 9%
Conclusion: In this unselected, population-based inception cohort the frequency
of anaemia was high at the time of diagnosis, especially for CD, but decreased
during the first year of follow-up. More Eastern than Western European patients
remained anaemic after 1 year of follow-up. These geographic differences could
be caused by differences in awareness of anaemia or they might reflect differences
in global care and inflammation control of IBD patients in Europe. Geographic
variations in the use of biological therapy might contribute to the observed
differences in anaemia frequency.
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Introduction: Use of immunosuppressants in IBD is associated with an increased
risk of serious infections that varies considerably according to infection and
immunosuppressant subtypes. This study aimed to determine the incidence rate
and risk factors for serious viral infection (SVI) according to drug exposure and
IBD activity in patients with IBD.
Aims & Methods: Using MICISTA registry, a prospective observational cohort
of IBD patients treated at our tertiary care hospital, we identified between Jan
2005 and Dec 2014 patients who developed SVI as defined by need for hospita-
lization, definite organ damage or disabling sequelae. Cases of CMV colitis with-
out systemic manifestations were excluded. We first estimated incidence rates of
SVI, overall and according to maximal yearly treatment. Additionally, we per-
formed a case-control study (4 controls for 1 case matched for age, gender, IBD
subtype and duration) assessing risk of SVI according to IBD drug use and IBD
clinical activity in the 3 months preceding the SVI (data extracted from individual
health records).
Results: We identified 31 patients with SVI among 2645 patients, followed for a
median period of 6.2 years and a total observational time of 16922 patient-years.
We identified 13 cases of CMV systemic infection (primary infection (n¼ 6),
reactivation (n¼ 7)), 10 cases of EBV infection (primary infection (n¼ 6) includ-
ing 2 haemophagocytic syndromes, reactivation (n¼ 4)), 5 cases of VZV infection
(varicella (n¼ 3), shingles (n¼ 2)) and 3 cases of HSV infection (severe esopha-
gitis, facial nerve paralysis, severe refractory cutaneous manifestation). Most
patients required hospitalization (94%) and received IV anti-viral therapy
(52%), while no death occurred. The incidence rate of SVI in patients with
IBD was 1.83 per 1000 patients-years. Table 1 shows the incidence rate of SVI
according to the maximal treatment received during the year. In the case control
study, risk of SVI was associated with exposure to thiopurine (adjusted odds-
ratio (aOR), 5.1; 95% CI, 1.9–13.4; p¼ 0.001) and methotrexate (aOR, 4.1;
95%CI, 1.0–16.8; p¼ 0.05), and active clinical disease (aOR, 3.2; 95% CI, 1.3–
8.1; p¼ 0.02). Odds-ratios for corticosteroids and anti-TNF did not reach statis-
tical significance (1.1 and 1.2, respectively).
Exposure to
medication
(patients-years)
Incidence rate
for SVI (per 1000
patients-years) P value
95%
Confidence
interval
No treatment or 5ASA 7922 0.50 ref 0.01–1.00
Steroids 1582 0.63 0.68 0–1.87
Immunomodulators 6236 3.2 0.0002 1.80–4.61
Anti-TNF
immunomodulators
5173 1.16 0.31 0.23–2.09
Conclusion: SVI are rare events in patients with IBD who do not receive immu-
nosuppressants. Exposure to thiopurines or methotrexate, and IBD clinical activ-
ity increases substantially the risk. Among 100 patients treated with thiopurines
for 10 years, 3 will develop SVI.
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Introduction: Patients with long-standing colonic inflammatory bowel disease
(IBD) bear an increased colorectal cancer (CRC) risk. Endoscopic surveillance
allows early detection and removal of precancerous lesions such as low-grade
dysplasia (LGD), and may subsequently prevent CRC. However, the long-term
outcome after LGD and the subsequent risk to develop CRC remains uncertain,
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since most available studies are small and cover a relatively short follow-up
period. To this end, we established a nationwide cohort of IBD patients with a
history of LGD to 1) determine the cumulative CRC incidence, and 2) identify
risk factors for developing CRC.
Aims & Methods: Using the Dutch National Pathology Registry (PALGA) we
identified all IBD patients diagnosed with LGD between 1991 and 2005 in the
Netherlands. Subsequently, follow-up data were extracted until 2016. We deter-
mined the cumulative CRC incidence with Kaplan Meier curves censuring
patients at the end of colorectal surveillance or colectomy. A case control
study, comparing IBD patients with LGD who developed CRC (cases) versus
patients who did not develop CRC (controls), was performed to identify risk
factors for developing CRC. Demographic data, including gender, IBD type, age
and duration, and LGD age and recurrence, were extracted from PALGA.
Subsequently univariable and multivariable Cox regression analyses with back-
ward elimination were used to identify independent risk factors.
Results: We identified 1177 IBD patients with colonic LGD with a median
follow-up time of 9.8 years per patient after LGD diagnosis (total follow-up
time: 11741 patient years). 825 (70.1%) patients had ulcerative colitis, 216
(18.4%) Crohn’s disease and 136 (11.6%) indeterminate colitis. Hundred nine
out of 1177 (9.3%) patients underwent colectomy. CRC developed in 86 out of
1177 patients resulting in a cumulative incidence of 2.9%, 5.8%, 11.1%, and
18.7% after respectively 5, 10, 15 and 20 years. Patients with an IBD duration
of more than 5 years before LGD development had a significantly higher cumu-
lative CRC incidence (14.7% after 15 years) compared to those with a shorter
IBD duration (9.4% after 15 years; log rank p¼ 0.001). Furthermore, patients
with recurrent LGD had a higher CRC risk compared to patients with single
LGD (10.5% after 15 years versus 4.5% after 15 years; log rank p¼ 0.026).
Multivariable Cox regression identified both a longer IBD duration (hazard
ratio 2.5, 95% confidence interval 1.5–4.3) and recurrent LGD (hazard ratio
1.9, 95% confidence interval 1.1–3.4) as independent factors associated with
increased CRC risk.
Conclusion:We showed a cumulative CRC risk of 18.7% after 20 years in a large
nationwide cohort of IBD patients with a history of LGD. Both a longer IBD
duration and recurrent LGD were identified as independent risk factors for CRC
development following LGD. These findings may aid in risk stratification follow-
ing a diagnosis of LGD in IBD patients.
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Introduction: In Crohn’s disease (CD) it’s useful to discriminate inflammatory
from fibrotic lesions. MRI-Diffusion Weighted Imaging (DWI) is able to identify
active inflammation in most pathological tissues.
Aims & Methods: We aimed to define the role of DWI in evaluating the risk of
surgery in CD. We performed an observational prospective study including all
consecutive CD patients with active CD undergone MRI. MRI study included:
measurement of bowel wall thickness (BWT), CD extension, enhancement pat-
tern, pre-stenotic dilation, presence of oedema and/or comb-sign, presence of
fistulas/abscesses, T2 and T2 sequences. Furthermore, all patients were studied
by DWI sequences defining: visual analysis of iperintensity and analysis of
Apparent Diffusion Coefficient (ADC) maps. Statistical analysis was performed
dividing all patients in 2 groups (operated vs not operated) using T-student and
X-square test when indicated. To identify the variables associated to surgical risk,
we performed a logistic multiple regression expressing the risk in terms of Odd
Ratio. Finally, the diagnostic accuracy was tested by a ROC curve.
Results: 110 patients were enrolled and 127 bowel segments resulted pathologic at
MRI. 26 patients (23.6%) and 31 segments were resected during the follow-up
period. At all pathological segments, the iperintensity in DWI sequences, the
reduction of ADC max, ADC medium and the presence of fistulas/abscesses
were significantly associated with a subsequent surgical intervention (p5 0.05).
In particular, the presence of CD complication was the variable with the highest
risk of surgery (p¼ 0.008; OR 3.9; 95% CI 1.4–10.7). When excluding the
patients with complications, we reported a significant correlation of DWI iper-
intensity, ADC max and medium with surgical intervention. The reduction of
ADC medium was the variable with the highest risk of surgery (p¼ 0.03; OR 2.0;
95% CI 0.79–0.92). The cut-off value for discriminating patients at risk of sur-
gery was 1.081x10–3 mm2/s (sensibility 55.6%, specificity 70.3%, PPV 33.3%,
NPV 85%).
Conclusion: The presence of fistulas/abscesses remains the variable most asso-
ciated with surgical risk in CD. In not complicated CD, DWI sequences at MRI-
Enterography correlates with the need of surgery. High value of ADC medium
shows high NPV for surgery in CD patients.
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Introduction: Patients with inflammatory bowel disease (IBD) are at increased
risk for developing colorectal neoplasia (CRN). Little is known about risk factors
of first CRN in IBD patients after a surveillance colonoscopy negative for
neoplasia.
Aims & Methods: The aim of our study was to identify predictive factors of first
CRN in IBD patients after a surveillance colonoscopy negative for neoplasia. All
consecutive patients who underwent at least two colonoscopies at Saint-Antoine
Hospital between 01/01/1996 and 01/03/2015 and whose first procedure was a
surveillance colonoscopy were included. A nested case-control study was per-
formed to assess risk factors of CRN in inflamed mucosa. Information on treat-
ments, endoscopic and histologic inflammation was collected. The identified
CRN risk factors were used to build a predictive score that was then tested in
the whole study population.
Results: Among 404 patients who underwent 1236 colonoscopies, 38 patients who
developed CRN in inflamed mucosa and 92 matched controls were included in a
nested case-control study. Independent factors significantly associated with CRN
were primary sclerosing cholangitis (PSC) (Odds ratio (OR), 6.26; CI 95% 1.07–
36.8, p¼ 0.04), presence of neutrophils, crypt abscess or histological ulcerations
(OR, 8.77; CI 95% 1.71–45, p¼ 0.009) and presence of crypt architectural irre-
gularities without neutrophils or ulcerations (OR, 8.09; CI 95% 1.21–54.3,
p¼ 0.03) on more than half of procedures during follow-up, exposure to thio-
purines (OR, 0.18; CI 95% 0.047–0.698, p¼ 0.01) and 5-aminosalicylates (OR,
0.27; CI 95% 0.084–0.876, p¼ 0.03) at the time of neoplasia or last colonoscopy.
We developed a score based on these five items at the time of the surveillance
colonoscopy negative for neoplasia. Among patients with a score of 0, the nega-
tive predictive value in predicting any CRN was 100% in patients with colonos-
copies performed 1 and 3 years after the first surveillance colonoscopy.
Conclusion: In IBD patients undergoing endoscopic surveillance, the risk of first
CRN is increased in case of PSC, persistence of histological acute inflammation
and quiescent disease, and decreased by concurrent treatment with thiopurines
and 5-aminosalicylates. The use of a predictive score derived from these factors
could be considered for making decisions on optimal intervals between two
surveillance colonoscopies.
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Introduction: Quantitative fecal immunochemical tests (FITs) are invariably used
in a qualitative manner using pre-specified cut-offs in colorectal cancer (CRC)
screening. To optimize FIT-based screening programs, it makes sense to explore
if participants with a negative FIT result at first participation and subsequent
participations can be categorized according to fecal Hb (fHb) concentration to
predict risk of developing future colorectal advanced neoplasia (AN).
Aims & Methods: In this population based screening cohort, average-risk subjects
aged 50–74 years, were invited for four rounds of FIT screening (cut-off of 10 mg
Hb/g, corresponding to 50 ng Hb/ml buffer). For this study all subjects with a
negative FIT at first participation were included. Baseline fHb was divided into 3
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categories (0 mg Hb/g, 40–5 mg Hb/g and, 45–10 mg Hb/g) to calculate cumu-
lative incidence of AN. To identify factors associated with AN a Cox propor-
tional hazard regression analysis was performed to calculate hazard ratios (HRs).
Consecutive FIT results were analyzed using logistic regression analyses to cal-
culate relative risks of AN. Risks were visualized by generating heat plots for
men and women.
Results: A total of 13,566 subjects were invited for screening of whom 9,561
(70%) participated at least once. Of those, 7,663 (92%) had a negative FIT at
first screen. Median follow-up was 4.7 years (IQR 2.0–6.1 years). Screenees with
a baseline fHb of more than 5 mg Hb/g had a 23% higher cumulative incidence of
AN than those with a baseline fHb of 0 mg Hb/g (p5 0.001). In multivariate Cox
regression analysis HRs increased from 1.7 (95% CI 1.2–2.2) to 6.0 (95% CI 4.0–
9.0) for a fHb concentration of more than 0 to 5 mg Hb/g and more than 5 up to
10, respectively (p5 0.0001; Table 1). In logistic regression analysis of two con-
secutive negative FIT results, RRs increased with fHb concentration, with up to a
14-fold risk increase for two consecutive FITs with both a fHb concentration of 8
mg Hb/g feces compared to twice a fHb concentration of 0 mgHb/g (p5 0.001).
Table 1: Time-dependent cox-regression analysis of baseline FIT of advanced
neoplasia.
Advanced neoplasia
Univariate Multivariate
HR 95% CI p-value 95%CI p-value
Gender (male) 1.7 1.3–2.3 50.001 1.6 1.2–2.1 50.001
Age (years) 1.1 1.0–1.1 50.001 1.1 1.0–1.1 50.001
Baseline fHb conc.
0 mg Hb/g Ref. 50.001 Ref.
40–5 mg Hb/g 1.8 1.3–2.4 1.7 1.2–2.2 50.001
45–10 mg Hb/g 7.0 4.6–10.5 6.0 4.0–9.0
Socioeconomic status
High Ref. 0.08
Average 1.0 0.7–1.3
Low 0.6 0.4–1.0
Conclusion: Among FIT negative screenees, baseline fHb concentration is an
independent predictor for the risk of future AN. Moreover, fHb concentrations
of two consecutive negative FITs are a strong predictor of the risk of AN with up
to a 14-fold risk increase. These findings suggest a role for fHb in personalized
screening strategies in population-based screening policies. In addition, the use of
fHb of negative FITs may permit alteration of screening intervals. Such strategies
could decrease unnecessary burden for screenee and optimize the use of program
related resources.
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Introduction: To date, there have only been a few large-scale community-based
studies that examined the efficacy of using a fecal immunochemical test (FIT) in
combination with flexible sigmoidoscopy (FS) for colorectal cancer (CRC)
screening. Since 1983, we have been conducting community-based mass screening
for CRC using fecal occult blood testing in combination with FS in Kyushu,
Japan. In 1988, we designed special buses with the necessary equipment to per-
form FS mass screening in order to test as many people as possible. The two-day
FIT method combined with small caliber electronic endoscopes for FS have been
in use since 1992.The aim of this study was to investigate the efficacy of combin-
ing FIT with FS to detect CRC and then analyze the CRC detection rates.
Aims & Methods: A large sample of 1,597,734 subjects that underwent the FIT
procedure to detect CRC and who exhibited a cut-off value of 100 ng/ml were
enrolled in this study from 1992 to 2014. Colorectal cancers that were detected
using FIT in conjunction with follow-up examinations were classified as two-day
FIT-detected cancers. When lesions (i.e. polyps) were found using FS despite a
negative two-day FIT outcome or when CRC was detected using colonoscopy the
cancers were classified as FIT-negative and FS-detected, respectively. Out of the
cases with a negative two-day FIT outcome, 180,779 of them underwent FS.
Results: The positive rate for the negative two-day FIT and FS cases was 8.6%
and 90.9% of them underwent work-up examinations. The work-up examina-
tions resulted in a CRC detection rate of 0.15% (mucosal cancer, 0.12%; invasive
cancer, 0.03%). In first-time negative two-day FIT and FS cases (33,469), the
cancer detection rates were as high as 0.27% (mucosal cancer, 0.22%; invasive
cancer, 0.05%). On the other hand, 7.1% of all the subjects were detected as
positive using only the two-day FIT procedure and 78.0% of them underwent
work-up examinations. This resulted in a detection rate of 0.16% (mucosal
cancer, 0.07%; invasive cancer, 0.09%). Among first-time subjects (417,352),
the cancer detection rate using only the two-day FIT procedure was 0.32%
(mucosal cancer, 0.14%; invasive cancer, 0.17%). The CRC detection rate was
significantly higher in males than in females and the rates increased with age in
both genders. Moreover, the detection rates were significantly higher in males
that were 50 years of age or older. Adverse events included 15 cases of ischemic
colitis that occurred after FS (incidence rate, 0.0082%). There were no cases of
perforation after endoscopy.
Conclusion: Although there are some problems in introducing FS into mass
screening for CRC, (i.e. cost-effectiveness, speed of examinations and lack of
manpower), FS is easier to prepare and it is a shorter and safer procedure
than colonoscopy. The findings suggest that using FIT in combination with FS
is effective for detecting CRC in first-time subjects that are 50 years of age and
older. However, this same procedure provides limited benefit for those who are
below 50 years of age.
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Introduction: Positive fecal immunochemical test (FIT) is associated to colorectal
neoplasia and/or bleeding from non-neoplastic lesions. However, a considerable
proportion of individuals with a positive FIT have a normal colonoscopy.
Aims &Methods:We aimed 1) to identify possible causes of positive-FIT result in
subjects with normal colonoscopy 2) to ascertain the rate of post-colonoscopy
colorectal cancer (CRC) in this cohort. Methods: All individuals from the first
round of the Barcelona’s CRC Screening Program (January 2010–December
2012) with a positive FIT(20 mg/g) and complete negative colonoscopy (i.e.
no neoplastic lesion) were included. Subsequent gastrointestinal events that
implied a medical consultation and/or procedure were recorded at the National
Health Service electronic database. Attribution of causality for positive FIT was
ascertained according to time of presentation of the event: certain (at baseline
colonoscopy), probable (6 months after colonoscopy), possible (6–12 months
after colonoscopy), uncertain (412 months after colonoscopy). Post-colono-
scopy CRC were defined as any invasive CRC detected after colonoscopy until
the end of follow-up (median, 50.6 months [range, 36–69]).
Results: From 2659 individuals who underwent colonoscopy after a positive FIT,
811 (30.5%; age 59.1 0.4 years; 60.7% women) had a negative colonoscopy. In
102 (12.6%) individuals a cause of positive FIT was identified at the colonoscopy
(angiodisplasia, 50; inflammatory lesions, 52). Of those 709 individuals with a
normal colonoscopy, 32 (4.5%) had subsequent gastrointestinal events classified
as probable cause in 2 (gastric adenocarcinoma and Los Angeles’ grade D eso-
phagitis), possible cause in 4 (invasive CRC, small bowel lymphoma, diverticular
hemorrhage, and gastric antral vascular ectasia), and uncertain cause in 26 (2
invasive CRC, 4 advanced adenomas, 2 non-advanced adenomas, 15 inflamma-
tory lesions, and 3 anorectal disorders). Age, sex, FIT levels, comorbidities
(hepatic, renal, coagulopathy) or chronic antiplatelet/anticoagulant/NSAID
treatments were not associated with a higher prevalence of gastrointestinal
events. On the other hand, 3 (0.36%) post-colonoscopy CRC were detected
(age, 56.3 7.5 years; 66% men; TNM stage: 2 were IIIA and 1 was IIIB)
within 11–28 months after screening. There were no significant differences
regarding age, sex and FIT level among subjects with or without post-colono-
scopy CRC.
Conclusion: Most individuals (83%) with a positive FIT and negative colono-
scopy do not have any lesion that may explain this result. Of these, 96% do not
present subsequent gastrointestinal events. Importantly, the rate of post-colono-
scopy CRC in these subjects is very low (0.36%).
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Introduction: Nine out of ten participants in colorectal cancer (CRC) screening
have a negative screening test result. It has been hypothesized that getting a
negative screening test result may reduce incentives to strive for a healthy
lifestyle.
Aims & Methods: The aim of the present study was to investigate potential
differences in changes of health behavior at one-year follow-up between
screen-negative attendees to two different screening modalities and controls
not invited to screening. Participants of both gender, aged 50–74, were invited
to complete a self-reported lifestyle questionnaire (LSQ) on smoking, body
weight, physical activity, alcohol intake and selected dietary items at baseline
and at one-year follow-up. Participants were randomly assigned to five biennial
rounds of fecal immunochemical test (FIT), one round flexible sigmoidoscopy
(FS) or no screening (controls). In total, 1809 and 1327 individuals with a nega-
tive screening test result in the FIT and FS group, respectively, completed the
LSQ, as did 1029 controls. ANCOVA and logistic regression were used to cal-
culate differences in changes of health behavior (and 95% confidence intervals
(CI)) between the arms at follow-up.
Result: Participants with a negative CRC screening test result in the first round of
the FIT arm reduced their alcohol consumption significantly more than controls
(0.29 glass/week, (95%CI; 0.54 to 0.04)) during one-year follow-up. Body
weight decreased more in participant with a negative screening test result in the
FS arm than in the FIT arm during the one-year follow-up (0.31 kg, (95%CI;
0.55 to 0.08)).
Conclusion: The present study does not suggest unfavorable short-term conse-
quences in health behavior after getting a negative CRC screening test result
whether this is from once only FS or first round of FIT screening.
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Introduction: Fecal immunochemical test (FIT)-based colorectal cancer (CRC)
screening aims to detect CRC in an early stage, thereby reducing morbidity and
mortality from this disease. Whereas data on interval CRCs in screening
programs based on guaiac fecal occult blood testing are available in literature,
few data exist on cancers in FIT-screening programs.
Aims & Methods: The aim of our study was to compare patient demographics,
tumor site, stage and survival between patients with screen-detected CRCs (SD-
CRC) and non-screen-detected CRCs (non-SD-CRC). Between 2006 and 2014,
asymptomatic persons aged 50 to 74 were invited to take part in four consecutive
biennial FIT-screening rounds. CRC cases were identified through linkage with
the Netherlands Cancer Registry and were classified into four groups: SD-CRC,
FIT interval cancers (diagnosed between screening rounds after negative FIT),
colonoscopy interval cancers (diagnosed after negative colonoscopy after a posi-
tive FIT) and CRC in non-participants (the latter three representing non-SD-
CRC). Information on gender, age, socioeconomic status (SES), tumor site, stage
and survival were collected and compared between patients in the four CRC
groups using Chi-square-test.
Result: A total of 27,340 people were invited for FIT-screening, of whom 18,752
(68,6%) participated at least once. Median follow-up time was 46,4 months (IQR
18.5–72.4). Among participants, 3,009 (16%) had a positive FIT in one of the 4
screening rounds. In total, 265 patients were diagnosed with CRC: 116 were SD-
CRCs, 27 FIT interval CRCs, 13 colonoscopy interval CRCs and 109 CRCs
detected in non-participants. There were no differences between the groups
regarding age, gender and SES distribution. Screen-detected CRCs, FIT interval
cancers and CRCs in non-participants were mostly located in the distal colon
(70.7%, 63%, 61.5% of cases, respectively), whereas colonoscopy interval CRCs
were mainly located in the proximal colon (69.2%)(p¼ 0.010). Stage distribution
was significantly different between the four groups, with more favorable stages in
patients with SD-CRCs (p5 0.001). Stage distribution in patients with FIT
interval CRC and CRCs in non-participants was similar (p¼ 0.361). Survival-
rates were significantly higher among patients with SD-CRCs and FIT interval
cancers compared to non-participants and patients with colonoscopy interval
CRCs.
Conclusion: In this population-based CRC screening cohort, 0.14% of all parti-
cipants were diagnosed with a FIT interval CRC during follow-up. The patients
with SD-CRCs had the most favorable stages and highest survival rates. Our
results support the effectiveness of FIT-screening programs.
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Introduction: Although the impact of colorectal cancer (CRC) screening on CRC
burden is well studied, the added benefit of surveillance in the context of an
implemented screening programme is unclear.
Aims & Methods: Using the Adenoma and Serrated pathway to Colorectal
CAncer model, we simulated the Dutch faecal immunochemical test (FIT) -
based screening programme and combined this with a colonoscopy surveillance
strategy based on the Dutch guideline. In this strategy, individuals considered at
low risk return to screening after ten years whereas surveillance with a three or
five-year interval is recommended for high- and intermediate-risk individuals,
respectively. Furthermore, we evaluated three strategies in which the surveillance
intervals as recommended in the Dutch guideline were prolonged to a) five years
for all individuals at increased risk, b) five and ten years for respectively high-
and intermediate-risk individuals and c) ten years for all individuals at increased
risk. The comparator strategy was no screening and no surveillance. In addition,
we simulated a screening only strategy without surveillance. Outcomes were CRC
incidence and mortality, number of colonoscopies per detected CRC, life-years
lived and costs per individual in the lifetime of 20,000,000 individuals.
Table (OP202)
Screen-detected cancer FIT interval cancer
Colonoscopy
interval cancer CRC in non-participants p-value
Total CRCs 116 27 13 109
Age diagnosis (%(n))50–
5960–69–470
24.1 (28) 43.1 (50) 32.8 (38) 22.2 (6) 40.7 (11) 37 (10) 7.7 (1) 61.5 (8) 30.8 (4) 19.3 (21) 45 (49) 35.8 (39) p¼ 0.803
Sex (male;%(n)) 62.9 (73) 59.3 (16) 53.8 (7) 63.3 (69) p¼ 0.904
SES (%(n))–Low–Average–
High
11.2 (13) 70.7 (82) 18.1 (21) 7.4 (2) 77.8 (21) 14.8 (4) 15.4 (2) 76.9 (10) 7.7 (1) — p¼ 0.814
Tumor location (%(n))–
Proximal–Distal–
Unknown
29.3 (34) 70.7 (82) 0 (0) 37 (10) 63 (17) 0 (0) 69.2 (9) 23.1 (3) 7.7 (1) 34.9 (38) 61.5 (67) 3.6 (4) p¼ 0.010
Stage–I–II–III–IV–Missing 51.7 (60) 13.8 (16) 31.9 (37)
2.6 (3) 0 (0)
29.6 (8) 22.2 (6) 33.4 (9) 14.8
(4) 0 (0)
38.5(5) 7.7(1) 7.7(1) 38.5(5)
7.7(1)
15.6 (17) 28.5 (31) 33.0 (36)
21.1 (23) 1.8 (2)
p5 0.001
Survival (% (n)) 88 (102) 81.5 (22) 61.5 (8) 59.6 (65) p5 0.001
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Result: FIT screening without a surveillance programme reduced CRC incidence
and mortality with respectively 25.4% and 39.0% compared to a no screening
and no surveillance strategy. CRC incidence and mortality reductions increased
to 28.1% and 40.8% when surveillance based on the Dutch guideline was added
to FIT screening. Prolonging surveillance intervals slightly reduced surveillance
effectiveness (incidence reductions 26.6%–27.2%, mortality reductions 39.6%–
40.8% compared to no screening and no surveillance). In screening, 21 diagnostic
colonoscopies were required to detect one CRC. The burden of surveillance was
considerably higher; in the Dutch guideline strategy, 572 colonoscopies were
required to detect one CRC by surveillance. Prolonging surveillance intervals
decreased this burden to 129–366 colonoscopies per surveillance-detected CRC.
All screening plus surveillance strategies were equally or more effective (0–0.0011
life-years gained) and less costly (E2.45-E8.24) than screening only. The
strategy in which all surveillance intervals were set at five years dominated all
other screening plus surveillance strategies.
Conclusion: Adding surveillance to FIT screening reduces CRC burden and is
cost-effective compared to screening without surveillance. However, the colono-
scopy burden in surveillance is markedly higher than this burden in a screening
programme. Through modelling, we showed that this burden can be substantially
lowered, without substantial loss of effectiveness, if surveillance intervals are
lengthened to five years.
Disclosure of Interest: All authors have declared no conflicts of interest.
TUESDAY, OCTOBER 18, 2016 10:30–12:00
VIRAL HEPATITIS: NATURAL HISTORY AND TREATMENT – ROOM
M_____________________
OP204 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON-FREE
THERAPIES AMELIORATES HCV-INDUCED PORTAL
HYPERTENSION
M. Mandorfer, K. Kozbial, P. Schwabl, C. Freissmuth, R. Schwarzer, R. Stern,
D. Chromy, A. F. Sta¨ttermayer, T. Reiberger, S. Beinhardt, W. Sieghart,
M. Trauner, H. Hofer, A. Ferlitsch, P. Ferenci, M. Peck-Radosavljevic
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Introduction: Portal pressure, assessed by hepatic venous pressure gradient
(HVPG) measurement, drives the development of liver-related complications
and mortality in patients advanced chronic liver disease. Since a decrease in
HVPG translates into a clinically meaningful benefit, it is an acceptable surrogate
endpoint.
Aims & Methods: We aimed to investigate the impact of sustained virologic
response (SVR) to interferon (IFN)-free therapies on portal hypertension in
patients with paired HVPG measurements. One hundred and four patients
with portal hypertension (HVPG 6mmHg) who underwent HVPG and transi-
ent elastography (TE) before IFN-free therapy (baseline [BL]) were retrospec-
tively studied. The effect of SVR on portal pressure was investigated in patients
with SVR who also underwent follow-up (FU)-HVPG and TE after IFN-free
therapy (group A; n¼ 60). To demonstrate the generalizability of our results, we
included a second group (group B; n¼ 40), comprising all patients who achieved
SVR, but did not undergo FU-HVPG measurement. In these patients, only
information on FU-TE was available. Moreover, we also included 4 patients
who did not achieve SVR.
Result: SVR to IFN-free therapies significantly decreased HVPG across all BL-
HVPG strata: 6–9mmHg (BL:7.37 0.28 vs. FU: 5.11 0.38mmHg;
2.26 0.42mmHg; P5 0.001), 10–15mmHg (BL:12.2 0.4 vs.
FU:8.91 0.62mmHg; 3.29 0.59mmHg; P5 0.001) and 16mmHg
(BL:19.4 0.73 vs. FU:17.1 1.21mmHg; 2.3 0.89mmHg; P¼ 0.018). In
the subgroup of patients with BL-HVPG of 6–9mmHg, portal hypertension
resolved in 63%(12/19), while no patient had an increase in HVPG at FU.
Among patients with a BL-HVPG of 10–15mmHg, portal hypertension resolved
in 14%(3/21), 29%(6/21) had a FU-HVPG of 6–9mmHg, while no patient
showed a progression of portal hypertension at FU. Finally, in the subgroup
of patients with a BL-HVPG 16mmHg, 5%(1/20) and 35%(7/20) of patients
had a regression to a FU-HVPG of 6–9mmHg or a FU-HVPG of 10–15mmHg,
respectively. However, portal hypertension did not resolve in any patient and
20%(4/20) of patients showed an increase in HVPG at FU. Patients with Child-
Pugh stage B were less likely to have a HVPG-decrease (HR:0.103; 95%CI:0.02–
0.514; P¼ 0.006), when compared to Child-Pugh A patients. In the subgroup of
patients with a BL-HVPG 10mmHg, the relative change in liver stiffness (per
%; HR:0.972; 95%CI:0.945–0.999; P¼ 0.044) was a predictor of a HVPG-
decrease 10%. The area under the receiver operating characteristic curve for
the diagnosis of FU-HVPG 10mmHg by FU liver stiffness was
0.931(95%CI:0.865–0.997). The liver stiffness values at FU for ruling-in and
ruling-out FU-HVPG 10mmHg were 12.4 (negative predictive value:100%)
and 25.3 kPa (positive predictive value:94%), respectively. Changes in liver stiff-
ness, platelet count, and liver function tests were comparable between patients
with (group A) and without FU-HVPG measurement (group B), providing an
argument for the generalizability of our results. Among the 4 patients without
SVR, one patient underwent FU-HVPG and TE (HVPG increased from 18 to
20mmHg; liver stiffness increased from 45 to 75 kPa), while 3 patients only
underwent FU-TE (16.5 to 14.8 kPa, 72 to 72 kPa and 10.2 to 10.5 kPa).
Conclusion: SVR to IFN-free therapies ameliorates portal hypertension across all
BL-HVPG strata. However, amelioration of portal hypertension was less likely in
patients with more advanced liver dysfunction. TE might be useful for the non-
invasive evaluation of portal hypertension after SVR. In contrast, patients who
did not achieve SVR showed either no significant improvement or even worsen-
ing of liver disease.
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Introduction: Clinical hepatitis may follow virological relapse in chronic hepatitis
B (CHB) patients after discontinuing nucleos(t)ide analogue (NAs), but the inci-
dence and risk predictors remained elusive.
Aims & Methods: Between July 1, 2011 and July 1, 2015, this multicenter study
prospectively enrolled 140 consecutive CHB patients with negative HBeAg and
undetectable viral DNA at the cessation of NAs after a minimum of 3 years on
therapy. In those who experienced virological relapse (viral DNA 42,000 IU/
mL), the incidences of clinical relapse (virological relapse plus ALT480 IU/mL)
and persistent/severe hepatitis (clinical relapse lasting for 3 months or accompa-
nied with jaundice) were estimated by the Kaplan Meier method. Predictors were
explored by the Cox proportional hazard modelling.
Result: Following virological relapse that took place in 94 patients, clinical
relapse and persistent/severe hepatitis occurred in 49 and 34 patients, respec-
tively. The 2-year cumulative incidences were 61.5% (95% CI, 50.1 73.0%)
and 56.2% (95% CI, 42.2 71.2%), respectively. Multivariate-adjusted analyses
revealed clinical relapse was associated with serum concentration of viral DNA
(hazard ratio [HR], 1.26 per log/mL; 95% CI, 1.04 1.53) and alanine amino-
transferase (ALT) at virological relapse (HR, 1.003 per IU/L; 95% CI,
1.0 1.004), as well as ALT at NA cessation (HR, 1.008; 95% CI,
1.002 1.01), whereas persistent/severe hepatitis was associated with viral
DNA (HR, 1.41; 95% CI, 1.16 1.71), ALT (HR, 1.004; 95% CI,
1.001 1.01), and -fetoprotein (HR, 1.13 per ng/ml; 95% CI, 1.02 1.26) at
virological relapse.
Conclusion: Clinical hepatitis frequently occurs following virological relapse in
CHB patients after NA cessation, and may be predicted by serum viral load,
ALT, and -fetoprotein at the viral resurgence.
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OP207 COMBINATION THERAPY WITH DACLATASVIR AND
ASUNAPREVIR IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS
WITH HEPATITIS C VIRUS GENOTYPE 1B IN JAPAN
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Introduction: Combination therapy with daclatasvir (DCV; NS5A inhibitor) and
asunaprevir (ASV; second-generation HCV-NS3/NS4A protease inhibitor) was
approved for patients with HCV genotype 1 in Japan since September 2014.
Now, elderly patients and those with advanced hepatic fibrosis including chronic
liver cancer were administered IFN-free therapy. Our objective was to assess the
efficacy and tolerability of DCV/ASV combination therapy in patients with
hepatic cirrhosis.
Aims &Methods: In total, 153 consecutive patients with HCV 1b initiating DCV/
ASV therapy were enrolled. The cohort comprised 52 patients with compensated
cirrhosis and 101 patients without cirrhosis (67 males and 86 females; median
age, 71 years; 9 patients were 480 years old). NS5A resistance-associated var-
iants (RAV) were examined using direct sequencing. The patients were treated
with 60mg of DCV once daily and 100mg of ASV twice per day for 24 weeks.
Clinical, biological, and virological data, including adverse effects, were recorded
at baseline and during follow-up.
Result: Only 10 (6.5%) patients had L31M or Y93H RAVs. There was no sta-
tistically significant difference in age, sex, IL28B genotypes, HCV viral load at
baseline, ALT level, creatinine level, or NS5A RAVs between patients with and
without cirrhosis. On the other hand, those with cirrhosis showed significantly
lower levels of platelets, white blood cells, and hemoglobin and higher levels of
alpha fetoprotein. The rapid viral response rate (HCV-RNA5 25 IU/ml at week
4) was the same between patients with and without cirrhosis (80% and 84%,
respectively). One of 52 patients with cirrhosis, and two of 101 patients without
cirrhosis who did not have NS5A RAVs at baseline developed viral break-
through. The rate of SVR12 was 94% (49/52) in patients with cirrhosis and
97% (96/99) in patients without cirrhosis. Grade 3/4 complications frequently
occurred in 21% of patients with cirrhosis (p¼ 0.04), of whom two had an
elevated ALT level, two progressed to decompensated cirrhosis without ALT
elevation, one developed interstitial pneumonia, one had severe bronchitis, one
had arterial fibrillation, two had gastrointestinal bleeding, and two developed
edema. Of the patients without cirrhosis (9%), ALT elevation was observed in
five patients, coagulation abnormality developed in two patients, gastrointestinal
bleeding occurred in one, and high fever occurred in one patient. After DCV/
ASV therapy, HCC developed in two cirrhotic patients, and one non-cirrhotic
patient.
Conclusion: DCV/ASV therapy achieved a high anti-HCV effect in patients both
with and without cirrhosis. However, careful management is necessary in patients
with cirrhosis.
Disclosure of Interest: A. Tamori: I have received research funding from Chugai
Pharmaceutical Co., Ltd., MSD K.K., and Bristol-Myers Squibb.
N. Kawada: Dr. Norifumi Kawada has received research funding from MSD
K.K., Chugai Pharmaceutical Co., Ltd. Bristol-Myers Squibb, and a lecturer’s
fee from Janssen Pharmaceutical K.K.
All other authors have declared no conflicts of interest.
OP208 EXPERIENCE IN THE MANAGEMENT OF DECOMPENSATED
HCV CIRRHOTIC PATIENTS WITH LOW DOSE SOFOSBUVIR AND
RIBAVIRIN COMBINED WITH DACLATASVIR
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Contact E-mail Address: amrhanafy@zu.edu.eg
Introduction:With the introduction of oral direct-acting antiviral (DAA) therapy
in the management of chronic active HCV, sustained response rates occurred in
more than 95% of patients with compensated liver disease with improvement in
their survival and the risk of decompensation that necessitates liver transplanta-
tion. The postulated explanation of reduced rates of sustained virological
response in decompensated cirrhosis was explained by extensive portosystemic
collaterals, advanced fibrotic parenchyma which are difficult to be penetrated,
and provide dormant foci for viral reactivation. It was claimed that achieving
SVR will improve MELD and CPT scores with improvement in clinically sig-
nificant portal hypertension and hepatic venous pressure gradient.
Aims & Methods: Evaluation of the efficacy and safety of managing chronic
active HCV in patients with decompensated cirrhosis and if SVR will improve
CTP, MELD scores and quality of life of these patients Forty patients with
decompensated cirrhosis with frequent hepatic encephalopathy or difficult to
treat ascites were included if they had chronic active HCV proved by the posi-
tivity of HCV RNA, elevated transaminases. Patients were excluded if they had
hepatocellular carcinoma, other causes of liver diseases or mixed causes (exces-
sive alcohol consumption, autoimmune liver disease), previous liver transplanta-
tion. The patients were given sofosbuvir 200mg, ribavirin 200mg, and
daclatasvir 60mg for 6 months and evaluated for the development of sustained
virological response (SVR), the occurrence of complications and the effects of
SVR on the rate of development of hepatic encephalopathy, improvement in
ascites control.
Result: Forty patients (31 males, 9 females) presented with chronic active HCV
were enrolled, all showed difficult to treat cirrhotic ascites. 29 patients showed
chronic recurrent episodes of hepatic encephalopathy (62.5%, 2.1 0.6 episodes/
2 months). The mean age was 51.4 6.3 years, albumin 2.3 0.4 gm/dl, total
bilirubin 1.9 0.5mg/dl, Hemoglobin 9.9 0.9 gm/dl, platelet count
83.9 15.4 103 cell/ul, creatinine 1.3 0.2mg/dl, AST 77.4 22.4 IU/dl, ALT
66.5 15.2 IU/dl, AFP 29.8 10.8 ug/dl, MELD score 22.6 2, Child Turcotte
Pugh (CTP) score 9 0.9. After six months of therapy; all the patients were
compliant, with no reported major complications. Mean platelet count was sig-
nificantly increased after treatment (88.6 13.9 103 cell/ul, p¼ 0.000), with
significant improvement in serum albumin (2.7 0.02 gm/dl, p¼ 0.000), total
bilirubin (1.4 0.2mg/dl, p¼ 0.000), AFP (16.3 0.9 ug/dl, p¼ 0.000), CTP
score (8.4 0.5, p¼ 0.002) and MELD score (21.2 1.04, p¼ 0.000). After treat-
ment a significant reduction in the episodes of HE was noted; only 8/29 still
experiencing HE (24 14.312, p¼ 0.0002, 1.4 0.2 episodes/2 months). SVR
was achieved in 36 patients (90%). Ascites became completely controlled in 10
patients (25%) and partially controlled in 23 patients (57.5%) and not changed in
7 patients (17.5%)
Conclusion: Treatment of decompensated cirrhotic patients with a 6-month low
dose DAA had led to SVR in 90% with improvement in CTP, MELD scores and
a significant reduction in hepatic encephalopathy episodes with better control of
ascites.
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Introduction: Patients with HIV/HCV confection show increased fibrosis progres-
sion and are at risk for complications of portal hypertension (PHT). We mea-
sured changes in liver stiffness and portal pressure and evaluated liver histology
after successful interferon (IFN)-free DAA therapy.
Aims & Methods: HIV/HCV patients undergoing IFN-free DAA treatment and
had paired hepatic venous pressure gradient (HVPG) and liver stiffness (LS)
measurements at baseline and three months after end of treatment (SVR12)
were included. LS and HVPG were measured in a fasted, non-sedated state.
Concomitant beta-blocker treatment was stopped for all measurements. Post-
treatment liver biopsies were assessed by METAVIR score.
Result: Of 19 patients (56% male, age: 53.4 6.7 years, 95% concomitant anti-
retroviral therapy), 16 received SOF/DCV, 2 SOF/ RBV, and 1 SOF/LDV. Seven
(37%) patients were treatment experienced and HCV genotype (GT) distribution
was: GT-1a: 12, GT-1b: 2 and GT-3a: 5. All patients had portal hypertension
(HVPG4 5mmHg) and 14 patients (74%) presented with liver cirrhosis
(LS4 12 kPa). DAA treatment resulted in 100% SVR12. LS decreased signifi-
cantly from 23.0 16.5 to 16.9 16.1 kPa (mean change (): 6.1 5.2 kPa;
p5 0.001). Also, HVPG decreased from 10.4 4.0 to 7.6 4.3mmHg (:
2.8 2.4mmHg; p5 0.001). In patients with clinically significant portal hyper-
tension (HVPG 10mmHg, n¼ 9), HVPG decreased from 13.8 3.0 to
10.9 3.8mmHg (: 2.9 2.8mmHg; p¼ 0.015) – resulting in a hemodynamic
response of 10% in 6/9 (66%) patients. In the subgroup of patients with base-
line HVPG5 10mmHg (n¼ 10), a reduction from 7.3 1.3 to 4.6 1.8mmHg
(: 2.7 2.2mmHg; p¼ 0.003) was noted – resulting in cure of PHT
(55mmHg) in 6/10 (60%). Posttreatment liver biopsies were available in 15
patients, of which the majority (66%) did not show any hepatic necroinflamma-
tory activity (METAVIR A0). 8 of 14 (57%) patients with cirrhosis at baseline,
presented a post-treatment histological METAVIR F3. Serum transaminases
were normalized after therapy (AST: 66 34 vs. 33 20, p5 0.001; ALT:
60 37 vs. 24 15, p5 0.001), while hemoglobin, WBC and CD4 cell counts
remained stable.
Conclusion: Virological response to IFN-free DAA therapies decreases LS and
ameliorates portal hypertension. SVR12 seems to abolish histological necroin-
flammatory activity in most HIV/HCV coinfected patients. It remains to be
explored if these improvements result in decreased liver-related mortality in the
setting of HIV/HCV coinfection.
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Introduction: The benefits of narrow band imaging (NBI) for improving the
detection of colorectal polyps remain questionable. The newly available second
generation of NBI using 290 system (290-NBI) privides an at least two folds
brighter image compared with the previous version.
Aims & Methods: The aim of this study was to compare polyp miss rates between
290-NBI and high-resolution white light endoscopy (HR-WLE). Methods: From
June 2015 to September 2015, 102 patients were randomized to undergo either
HD-WLE or 290-NBI colonoscopy. In HD-WLE group, we performed colono-
scopic examination as first inspection with HR-WLE followed by a second
inspection with NBI. In 290-NBI group, colonoscopic examination were per-
formed first inspection with NBI followed by a second inspection with HR-
WLE. The primary outcomes were polyp miss rates.
Result: A total of 127 polyps of 102 patients were detected. In HD-WLE group,
39 polyps were detected during the first inspection. A second inspection with NBI
added 20 polyps, resulting in polyp miss rate of 33.9% with HR-WLE. In the
NBI group, 54 polyps were detected during the first inspection. Subsequent
inspection with HR-WLE added 14 polyps, resulting in polyp miss rate of NBI
of 20.6% (33.9% vs 20.6%, p¼ 0.068). In subgroup analysis, the polyp miss rates
of flat type of HR-WLE and NBI showed significant difference (18.6% vs. 5.9%,
p¼ 0.029).
Conclusion: New generation of NBI (HQ290) may reduce polyp miss rates and be
more effective in reducing polyp miss rates of flat type.
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Introduction: Colorectal cancers are generally recognized to develop from‘‘po-
lyps’’. This ‘‘adenoma-carcinoma sequence’’ theory has been in the mainstream
of development of colorectal cancers. But recently the existence of many
depressed-type cancers has been revealed, which are considered to emerge
directly from normal epithelium, not through the adenomatous stage. This
theory is called ‘‘de novo’’ pathway. Now, it is possible to presume the histology
of colorectal lesions using magnifying endoscopy (pit pattern classification) and
endocytoscopy (EC).We can observe not only the structural atypia but also the
cellular atypia in living colorectal lesions. The aim is to clarify the diagnostic
characteristics of depressed-type colorectal neoplasms, demonstrating the valid-
ity of pit pattern diagnosis and EC classification.
Aims & Methods: A total of 27599 colorectal neoplasms excluding advanced
cancers were resected endoscopically or surgically in our unit from April 2001
to December 2015. Of these, 16075 lesions were low-grade dysplasia, 5241 were
high-grade dysplasia and 1097 were submucosally invasive (T1) carcinomas.
According to the developmental morphology classification, they were divided
into 3 types: depressed, flat and protruded type. We investigated the rate of T1
carcinomas and the characteristics of depressed-type neoplasms concerning pit
pattern and EC classification.
Result: The rate of T1 carcinomas in depressed-type lesions reached to 62.1%,
meanwhile that in flat-type and protruded-type lesions was 3.3% and 2.8%,
respectively. Within less than 5mm in diameter, that was 10.6%, 0% and 0%,
respectively. Most (90.1% and 91.5%) of the flat-type and protruded-type lesions
showed type IIIL or IV pit pattern corresponding to adenomas, whereas 94.6% of
the depressed-type lesions were characterized by type IIIS, VI or VN pit pattern
corresponding to carcinomas. As for endocytoscopy, most of the flat-and pro-
truded-type lesions showed EC2 corresponding to adenomas. In contrast, the
depressed-type lesions were observed as EC3a (38.9%) and EC3b (58.0%) cor-
responding to invasive carcinomas.
Conclusion: This study revealed the diagnostic characteristics of depressed-type
lesions. They show typically type IIIS,VI or VN pit patterns in magnifying endo-
scopy and type EC3a or EC3b in endocytoscopy. These lesions tend to invade the
submucosal layer even when they are small. Therefore, it is important to consider
deeply and examine the developmental morphology of colorectal neoplasms.
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Introduction: Over 50% of the postcolonoscopy colorectal cancers (PCCRCs)
(i.e. CRC diagnosed after a colonoscopy that excluded cancer) originate from
missed precursor lesions, in particular the subtle appearing non-polypoid (flat
and depressed) adenomas and sessile serrated lesions. The biologic pathway of
these lesions is unclear. We hypothesized that PCCRCs and subtle appearing
precursors may share molecular features. In a retrospective, cohort study, we
examined the occurrence of chromosomal instability (CIN), microsatellite
instability (MSI), and CpG island methylator phenotype (CIMP) in PCCRCs
and prevalent CRCs.
Aims & Methods: We identified all PCCRCs diagnosed from 2001 to 2010 in a
large gastroenterology practice from the Netherlands (le Clercq et al, Gut 2014).
PCCRCs were defined as cancers occurring within 5 years after a complete index
colonoscopy, which excluded CRC. We applied a clinical algorithm to assign the
most likely explanation of PCCRC (incomplete colonoscopy/ insufficient bowel
preparation, missed lesion, incompletely resected lesion or new cancer). PCCRCs
attributable to technical factors (insufficient bowel preparation/ incomplete
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colonoscopy or incomplete resection) were excluded. We reviewed clinical and
pathological records. Whole-genome DNA copy number changes and mutation
status of genes commonly affected in CRC (APC, KRAS, BRAF, FBXW7,
PIK3CA, NRAS, SMAD4 and TP53) were examined by shallow whole-
genome sequencing and targeted sequencing, respectively, using Illumina next
generation sequencing platforms. MSI and CIMP status were examined using
the pentaplex marker panel from Promega and the Weisenberger CIMP panel
using methylation-specific PCR, respectively.
Result: In total, 120 PCCRCs and 100 prevalent CRCs were examined.
Regarding clinicopathological features, PCCRCs are more often located proxi-
mally in the colon (p5 0.001), non-polypoid appearing (p¼ 0.001), early stage
tumors (p¼ 0.008), and poorly differentiated (p¼ 0.001) compared to prevalent
CRCs. Regarding DNA copy number alterations, PCCRCs contain less often
17p (p¼ 0.002) and 18q (p¼ 0.003) deletions than prevalent CRCs. Furthermore,
PCCRCs contain less frequently APC (p¼ 0.04), NRAS (p¼ 0.03), and TP53
mutations (p¼ 0.03) than prevalent CRCs. In contrast, MSI (p¼ 0.004), CIMP
(p¼ 0.02) and BRAF mutations (p¼ 0.04) are more frequent in PCCRCs than
prevalent CRCs.
Conclusion: Both CIN and MSI pathways are associated with the occurrence of
PCCRC. PCCRCs contain less often deletions of chromosomes 17p and 18q,
APC, NRAS and TP53 mutations and more often MSI, CIMP and BRAF
mutations than prevalent cancers. Such molecular profiles are similar to those
previously described in non-polypoid (flat and depressed) adenomas and sessile
serrated lesions. Taken together, our results support the hypothesis that non-
polypoid adenomas and sessile serrated lesions are in the origin of PCCRCs.
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Introduction: Three different platforms have been developed to perform deep
enteroscopy; namely, single balloon, double balloon, and spiral enteroscopy.
None of these devices permits routine evaluation of the entire small intestine,
even with a combination of antegrade and retrograde enteroscopy. We report our
early clinical experience with a motorized spiral enteroscope, which may provide
a modality for one-stage complete enteroscopy.
Aims & Methods: We report early experience with a prospective multi-center
efficacy and safety trial. The study was approved by the institutional review
boards of each of the participating centers. Patients referred for evaluation of
small bowel disease at one of the three participating centers requiring antegrade
enteroscopy were offered participation in the study, and then screened for exclu-
sion criteria. If enrolled, informed consent was obtained. Under general
endotracheal anesthesia, the motorized spiral enteroscope (SIF-Y0019,
Olympus, Japan) is inserted through the mouth. The rotational advancement
and withdrawal is controlled by the endoscopist using a foot pedal. The primary
outcome of the study was the depth of insertion of the enteroscope.
Result: Demographics of the study patients are summarized in Table 1. Of the
first 7 completed procedures, we were able to accomplish complete enteroscopy
in 5 (71%) patients. In the other two instances, the distal jejunum and distal
ileum were reached. The average insertion time was 47 minutes [range: 32–61]
with an average total procedure time of 66 minutes [range: 41–94]. A bleeding
event requiring hospitalization occurred within 7 days of one of the procedures
but that was due to the underlying lesion rather than a complication of the
procedure. No other significant adverse events were reported.
Conclusion:We present our initial experience of a safety and efficacy data trial for
the motorized spiral enteroscope. We were able to safely accomplish full entero-
scopy in 71% of cases with a single antegrade deep enteroscopy using the motor-
ized spiral enteroscope. This percent achievement of complete enteroscopy in a
time typically reported for unidirectional deep enteroscopy suggests that this
device is a significant development in design of small bowel enteroscopes. One
patient experienced bleeding requiring hospitalization within 7 days of the pro-
cedure. This was a significant adverse event (SAE) by protocol. However on
further review it was determined that the patient bled from a Meckel’s diverti-
culum, identified during deep enteroscopy. Subsequent surgery was curative.
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Introduction: The Aer-O-Scope Colonoscope System (GI View Ltd., Ramat Gan,
Israel) is a self-propelled, joystick controlled, disposable colonoscope that pro-
vides panoramic (360) endoscopic visualization of the colon and includes two
working channels compatible with standard endoscopic tools [1,2].
Aims & Methods: We aimed to demonstrate the success of the self-propelled Aer-
O-Scope colonoscope in providing endoscopic therapeutic access. Therapeutic
endoscopic access was a priori defined as the ability to reach a pre-defined
target of interest, a pseudo-polyp, within an ex vivo swine colon and deliver
"simulated" endoscopic therapy including: polypectomy with snare or biopsy
forceps, submucosal injection, or thermal coagulation using argon plasma coa-
gulation (APC). This was a prospective cohort study (n¼ 12 ex vivo swine colons
each housed in four different models that simulated variants of a human colon).
Varying sized pseudo-polyps (n¼ 8 in each ex vivo swine colon) were created
using colored thread and were randomly distributed throughout each ex vivo
swine colon. Thus, n¼ 96 pseudopolyps in total were created: 1mm–5mm
(n¼ 77, 80%); 6mm–9mm (n¼ 13, 14%); 10mm (n¼ 6, 6%). Following one
day of Aer-O-Scope training for joystick utilization and endoscopic therapeutic
access, two endoscopists (IMG and SB) performed all the colonoscopies (n¼ 12
colonoscopies per each endoscopist) on three separate procedure dates, in
random order, and blinded to the type of colon model. The study’s primary
endpoint was a success rate of at least 90% in providing simulated endoscopic
therapy and the study’s secondary endpoint was endoscopist-perceived usability
of the Aer-O-Scope for endoscopic therapy. We planned on performing a total of
240 simulated endoscopic therapies (n¼ 192 biopsy forceps, snare polypectomy,
or combination injection/snare polypectomy and n¼ 48 APC applications). This
sample size allowed up to a 10% pseudo-polyp miss rate with a two-sided
Table 1. (OP213)
Subject # Age Sex Indication(s) BMI
ASA
Grade
Insertion
Time (min)
Procedure
Time (min)
Point of
Deepest
Insertion Complications
Final
Diagnosis
1 24 M Abdominal pain; video
capsule findings of
ulcerated mucosa in mid
small bowel
40 III 33 41 Distal Jejunum None None
2 22 M CT scan finding of
intussusception
21 II 32 43 Cecum None None
3 61 F Gastrointestinal bleeding;
video capsule finding of
angioectasia
27 III 61 94 Cecum None None
4 58 F Iron deficiency anemia;
video capsule finding of
angioectasia
23 II 47 70 Distal Ileum None None
5 67 F Iron deficiency anemia 23 II 48 66 Cecum None None
6 33 M Gastrintestinal bleeding 28 III 59 78 Cecum Bleeding Meckel’s diverticulum
7 29 M Suspected crohn’s; video
capsule findings of a
bleeding angioectasia
and a small bowel polyp
28 II 49 72 Cecum None Crohn’s
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statistical precision of 5%. This study protocol was reviewed and approved by an
animal ethics committee.
Result: There were 5 (5.2%) pseudo-polyps dislodged, thus 235 simulated endo-
scopic therapies were able to be attempted. The success rate of the Aer-O-Scope
colonoscope simulated endoscopic therapy was: 234/235¼ 99.6% (95%CI 0.976–
1.00). The overall success rate was 234/240 97.6% (p5 0.001). The below Table
shows the number of successful simulated endoscopic therapies per endoscopic
tool. All endoscopic tools had a success rate 495%. There were only 2 failures,
both during use of a polypectomy snare. Endoscopist-rated subjective usability of
the Aer-O-Scope for simulated endoscopic therapy (easy to perform or only
slightly complicated to perform) was very high (98%–100%) for all endoscopic
tools.
Endoscopic Tool n Therapeutic Successes 95%CI
Snare 140 138 (98.6%) 0.95–1.00
Biopsy Forceps 47 47 (100%) 0.92–1.00
Injection Needle 60 60 (100%) 0.94–1.00
APC 48 48 (100%) 0.93–1.00
Conclusion: In an ex vivo swine colon model, the Aer-O-Scope Colonoscope
System demonstrated the ability to easily provide simulated endoscopic thera-
peutic access using standard endoscopic tools while having very high usability
ratings.
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Introduction: Endoscopic mucosal resection (EMR) has become the standard
technique for resection of large sessile and flat colonic polyps. We aimed to
assess the clinical outcome of colonic EMR of polyps 2 cm and greater in size
at University Hospital of Leicester NHS Trust and to assess changes over a 9-
year period.
Aims & Methods: Data was collected for all sessile colonic polyps 20mm
removed by EMR between 2006 and 2014 by 3 endoscopists (PW, JDC, RJR).
Patient demographics, resection technique, completeness of initial resection,
recurrence rate at first surveillance (SC1), polyp eradication at 2nd surveillance
after at least 1 year (SC2) and complication rates were analysed.
Result: 564 patients were assessed for EMR, among which there were 424 com-
pleted EMRs (BCSP 138, Symptomatic 286) by three operators. Of the 140 not
proceeding to complete EMR, in 65 EMR was not attempted and patients were
referred for surgical resection (cancer 31, technical difficulty 34). In a further 32,
EMR was attempted but abandoned; all were referred for surgery (cancer 18,
benign polyp 14). Finally, 43 had no intervention (13 declined, 22 non-adenoma-
tous or pseudo polyps, 8 moved away). The mean age was 68.7 years (range 25–
93), male 226 (53%), female 198 (47%). Mean polyp size was 33mm (median
30mm). Site of polyp was right colon 27%, transverse colon 5%, left colon 68%
(rectum 58%, sigmoid 4%, descending 6%). Piecemeal EMR was done in 381
(90%), and ‘en bloc’ in 43 (10%). Of those who have undergone surveillance so
far, recurrence was found in 56/284 (19.7%) at initial SC1 (mean 7 month; range
2–36) and was endoscopically treated in 53/56 (94.6%); 3/56 (5.4%) referred for
surgical resection (2 cancer, 1 non lifting). Complete eradication after one year
SC2 (mean 16 months, range 5–51) 211/234 (90.2%) with recurrence in 23 (9.8%)
– but in 22/23 this was endoscopically resected. Overall complication rate 17/424
(4%): immediate perforation 1/424 (0.2%) post-caecal EMR required conserva-
tive medical treatment; post polypectomy pain syndrome 14/424 (3.3%) required
admission for overnight conservative medical treatment. Delayed bleeding 2/424
(0.5%) required endoscopic therapy to achieve haemostasis. There were no pro-
cedure-related deaths. For each 3-year period (2006–8, 2009–11, 2012–14), there
was a consistent reduction in number of polyps not treated endoscopically or
requiring surgery (overall decrease of 15.7%), incomplete EMR referred for
surgical resection (overall decrease of 2.3%) and recurrence rate at first SC1
(overall decrease 16.3%). There were increases in numbers of EMRs performed
annually (overall increase 26%), mean polyp size resected (þ7mm), level 3 & 4
polypectomies (3.7 and 7%) and complete eradication rate at SC1 (16.3%).
Conclusion: This is a large single-centre series of EMR of 424 sessile colonic
polyps 42 cm performed by 3 operators over a 9 year period; almost 20% had
recurrence at initial surveillance, most managed endoscopically, with eradication
rate at 1 year of over 90% (22/23 one year recurrences treated endoscopically).
Examination of time trends over this period showed progressive reduction in
recurrence and a trend for larger, more complex polyps to be resected endosco-
pically, with a corresponding drop in surgical management, demonstrating
improvement in outcome with time.
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Introduction: Neoplasia in Barrett’s can be very subtle and difficult to identify.
Acetic acid chromoendoscopy (AAC) has been demonstrated to highlight neo-
plastic areas allowing for earlier treatment. Although the technique of AAC is
very simple, lesion recognition with acetic acid (AA) remains a challenge and
therefore hampering its widespread usage.
Aims & Methods: We aim to develop a simple and easy to use classification
system for AAC to allow easy identification of Barrett’s neoplasia. Three
expert AAC endoscopists (PB, GLW, OP) formed a working group to identify
AAC component criteria of non-dysplastic and dysplastic Barrett’s using a mod-
ified Delphi Method. Following this, a panel of 7 advanced endoscopists assessed
the performance of each individual criterion by reviewing a bespoke online data-
base of 40 images and 40 videos of non-dysplastic and dysplastic Barrett’s
lesions. Finally, we assessed the diagnostic reproducibility of the validated cri-
teria by asking 13 non-AAC expert endoscopists to complete an assessment tool
of 40 images and 20 videos using this newly developed classification system.
Result: The component criteria identified by the expert AAC endoscopists were
as follows: - Early focal loss of acetowhitening - Present: Indicates presence of
neoplasia - Absent: Indicates the absence of neoplasia - Surface pattern - Normal
(Large uniformly distributed pits): Indicates non-neoplastic Barrett’s - Abnormal
(Compact, irregular or absent pits): Indicates neoplasia A total of 560 observa-
tions were undertaken to validate these criteria. The sensitivity, specificity, nega-
tive predictive value (NPV) and positive predictive value (PPV) is shown in Table
1.
Table 1: Validation results of the classification criteria
Criteria Sensitivity Specificity NPV PPV
Loss of
acetowhitening
96.2%
(93.4–97.9%)
93.8%
(88.9–96.9%)
90.9%
(85.5–94.8%)
97.5%
(95.4–98.8%)
Surface pattern
Normal
Abnormal
77.0%
(69.7–83.3%)
99%
(97.5–99.7%)
99.0%
(97.5–99.7%)
77.0%
(69.7–83.3%)
91.4%
(88.4–93.9%)
96.9%
(92.2–99.1%)
96.9%
(92.2–99.1%)
91.4%
(88.4–93.9%)
When the AAC validated criteria are applied by the 13 endoscopists, the sensi-
tivity, specificity, NPV and PPV of detecting neoplastic Barrett’s are 98.5%,
64.0%, 97.5% and 72.5% respectively.
Conclusion:We have developed and established the validity of a simple classifica-
tion system to identify Barrett’s neoplasia using AAC. When non-AAC trained
endoscopists apply these criteria, the sensitivity and NPV meet the recommended
PIVI threshold.
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Introduction: Endoscopic detection of early neoplasia in Barrett’s esophagus (BE)
is difficult. Volumetric laser endomicroscopy (VLE) is an advanced imaging
system incorporating 2nd generation optical coherence tomography in a bal-
loon-based system, providing a 6-cm long circumferential scan of the esophageal
wall up to 3mm deep, with near-microscopic resolution. Several VLE features of
early BE neoplasia have been determined previously (1,2).
Aims & Methods: Aims of this study were to determine (additional) VLE features
of neoplasia, based on precise VLE-histology correlations ex vivo, and to develop
and validate a VLE prediction score for early BE neoplasia.
A unique database of VLE images from endoscopic resection specimens and
corresponding histology from BE patients þ/- neoplasia was used. Precise
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VLE-histology correlation methodology has been described previously (3). In the
orientation phase, 25 VLE-histology images were evaluated in an unblinded
manner by a GI pathologist, BE endoscopist and VLE researcher. Features
potentially predictive for early BE neoplasia were identified and subsequently
discussed in consensus with 2 VLE experts. In the learning phase, VLE images
corresponding with neoplasia ((high-grade dysplasia (HGD) or early adenocar-
cinoma (EAC); n¼ 10) and non-dysplastic (ND)BE tissue (n¼ 10) were scored by
the 2 VLE experts – blinded to histology – for presence of neoplasia and VLE
features identified in the orientation phase. After a consensus meeting, a predic-
tion score was created based on multivariable logistic regression analysis using
learning phase results. This score was validated by expert scoring of 40 additional
VLE images (20 HGD/EAC; 20 NDBE) using area under receiver operating
characteristic (ROC) curve (AUC) analysis.
Result: Four VLE features potentially predictive for BE neoplasia were identi-
fied: 1) lack of layering; 2) higher surface signal than subsurface signal; 3) pre-
sence of irregular, dilated glands/ducts; 4) homogeneity. In the learning phase,
features 1, 2 and 3 were significantly and independently associated with neopla-
sia. The VLE neoplasia prediction score was developed with: feature 1 (6 points),
2 (6 or 8 points for equal or higher surface signal) and 3 (5 points). ROC curve of
this prediction score showed an AUC of 0.83 (95% CI 0.69–0.96) in the learning
and 0.81 (95% CI 0.71–0.90) in the validation phase. A cut-off value of 8 was
associated with a sensitivity and specificity of 85% and 68% in the learning and
83% and 71% in the validation phase, respectively.
Conclusion: This study, using high-quality ex vivo VLE-histology correlation,
confirms that the VLE features layering, surface signal, and irregular glands/
ducts are independently and significantly associated with early BE neoplasia.
Using these features, we developed and validated a VLE prediction score for
BE neoplasia, with promising accuracy.
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Introduction: Detection of early neoplasia in Barrett’s oesophagus by white-light
endoscopy is challenging due to the inconspicuous nature of dysplasia. Molecular
imaging using fluorescently labelled wheat-germ agglutinin (WGA) is a promis-
ing tool for detecting dysplasia as this topically applied imaging agent shows
lower binding to dysplastic versus non-dysplastic oesophageal glandular
mucosa (1). However in an endoscopy setting, the detection of fluorescence in
the blue/green range is limited by high levels of tissue autofluorescence. This
limitation can be overcome by using near infra-red (NIR) imaging.
Aims & Methods: The aim of this study was to assess in an ex-vivo model the
feasibility of WGA-based NIR imaging for detection of dysplasia in Barrett’s. To
this end, we studied patients with early Barrett’s-related neoplasia undergoing
endoscopic mucosal resection (EMR). Freshly collected EMR specimens were
sprayed with WGA-IR800CW (10mg/mL; 10min, room temperature); washed
with PBS buffer and then imaged with a high-sensitivity NIR camera
(FluobeamTM, Fluoptics). Planar fluorescence images were captured and up to
two punch biopsies (2mm diameter) were collected from each EMR specimen,
under fluorescence guidance. The EMRs were then formalin fixed and paraffin
embedded (FFPE), cut every 2mm and processed for histopathological assess-
ment. Each section was scored by an expert GI pathologist every 1mm to con-
struct a pathology grid, which was manually co-registered with the fluorescence
image. Targeted punch biopsies, taken from areas of interest within the EMR
specimen, were also scored by the pathologist. The mean fluorescence intensity
(MFI) of cells in dysplastic and non-dysplastic areas was compared by the
Wilcoxon matched-pairs signed rank test. The MFI of punch biopsies taken
from dysplastic and non-dysplastic areas was compared by Mann-Whitney
test. The correlation between the fluorescent contrast and spatial extent of dys-
plasia was analysed by linear regression.
Result: Ten patients were recruited at a single centre. We included in the analysis
19 EMR specimens with at least one dysplastic gland and 45 punch biopsies, of
which 16 were dysplastic. In the whole EMR analysis, we found a significantly
lower mean fluorescence intensity (MFI) in dysplastic versus non-dysplastic areas
(P5 0.0001), in accordance with the reported reduced binding of WGA to neo-
plastic Barrett’s epithelium (1). Similarly, the MFI of punch biopsies taken from
dysplastic regions was significant lower compared to that of non-dysplastic areas
(P¼ 0.0002). Finally, we found that the fluorescent contrast between dysplastic
and non-dysplastic areas was higher in EMRs with wider extent of neoplasia (R2
0.58, p¼ 0.0002).
Conclusion: WGA-based NIR imaging is an effective method for differentiating
dysplastic from non-dysplastic Barrett’s mucosa ex vivo, which reduces the
effects of tissue autofluorescence. In-vivo studies are now required to test the
efficacy of this method for detecting dysplasia during endoscopic surveillance.
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Introduction: Radiofrequency ablation (RFA), combined with endoscopic resec-
tion (ER) of visible lesions, can be used as a primary treatment for low-grade
dysplasia (LGD), high-grade dysplasia (HGD) and early adenocarcinoma (EAC)
in Barrett’s esophagus. In prospective multicenter controlled trials, high rates of
complete remission of dysplasia (CR-D) and intestinal metaplasia (CR-IM) has
been reported.
Aims & Methods: The aim of this study is to monitor outcome and efficacy of
RFA in a setting of absence of reimbursement in a multicenter national prospec-
tive registry. Between February 2008 and August 2015, data from 7 centers
performing RFA were collected in the Belgian RFA registry. All procedures
were monitored for indication, treatment before RFA, short/long-term compli-
cations and prospective long-term pathological outcome. Primary endpoint was
CR-D and CR-IM. Secondary endpoints was safety.
Result: 538 RFA procedures were registered in 279 different patients (mean age
65; 84.5% men). In 60% a previous EMR/ESD was performed. Baseline worst
histology prior to RFA (including ER) was: 2% SIM (5), 8% LGIN (22), 52%
HGIN (146), 37% adenocarcinoma (102), 1% unknown (4). At the time of
analysis 44 patients were still under treatment. In an intention to treat analysis
(ITT), 83% (194/235) patients achieved CR-IM and 87% (204/235) CR-D after a
median of 2 RFA sessions. 18 patients discontinued treatment, giving a per
protocol(PP) CR-IM in 89% (194/217) and CR-D in 94% (204/217). 185 and
193 patients with CR-IM respectively CR-D entered follow-up. Recurrence of
disease was limited to IM in 38 patients and recurrent neoplasia occurred in 24
patients: 7 LGD, 17 HGIN/Ca. With a median FU time of 735 days, the ITT and
PP analysis for durability of CR-IM is 63% and 66% respectively. The results of
durability of CR-D with a median FU time of 670 days in an ITT and PP analysis
are 82% and 87% respectively. Immediate complications occurred in 4% of the
procedures in 21 different patients (7.5%): 16 small mucosal lacerations (9 after
sizing), 7 bleedings, no perforations. Late adverse events occurred in 8% of the
procedures in 42 different patients (15%): 19 stenosis (mean 4 dilatations), 7
bleedings, 3 poor healing, 9 prolonged hospitalization for general symptoms, 4
fever without prolonged hospitalization, 2 pneumonia. Comparison of the
Belgian RFA registry with the EURO II trial and with the UK RFA registry
revealed that there was no significant difference for CR-IM, CR-D and compli-
cation rate. Remarkably, there were significantly more rescue treatments
(p5 0.0001) in Belgium before achieving remission in comparison to the UK.
Conclusion: Our data confirm that combined ER- RFA is an efficient treatment
for Barrett’s associated neoplasia. In the absence of reimbursement, more escape
treatments were performed in comparison to published controlled trials. Outside
clinical trials, meticulous follow-up appears to be even more important to detect
and treat early recurrence. We suggest a systematic registration of RFA practice
to monitor long term outcome and efficacy.
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Introduction: Stepwise radical endoscopic resection (SRER) allows for complete
endoscopic resection of Barrett’s esophagus (BE) with early neoplasia. This
approach has been shown very effective in reaching complete eradication of
high-grade dysplasia (HGD) or early cancer (EC) (CE-neo) in 98% and all
intestinal metaplasia (CE-IM) in 85% of patients.
Aims & Methods: The aim of this study was to report the long-term follow-up
(FU) results after successful SRER for BE with early neoplasia. We screened all
patients treated with SRER in two centers between 2001–2014, for BE 5 cm
with HGD/EC, without signs of invasion 4T1sm1, G3/G4 differentiation,
lymph-vascular invasion or irradical deep resection margins in ER specimens.
All patients who had reached endoscopic and histologically confirmed CE-neo
and CE-IM after SRER were included for evaluation of long-term FU. All
information from FU endoscopies and histological outcomes were collected
and entered in a dedicated database. Duration of FU was calculated from last
treatment till last FU endoscopy. Primary outcomes: recurrence of HGD/EC and
recurrence of IM combined with visible BE islands or tongues. Secondary out-
comes: Buried Barrett’s (BB) in neosquamous biopsies, and IM in biopsies
obtained distal to the neo-z-line.
Result: Seventy-three patients were included (64 men, mean age 66 yrs, median
BE C2M3). Worst baseline pathology: HGD, n¼ 50; EC, n¼ 23. Median FU
was 76 months (IQR 55–102) with a median of 6 (IQR 4–8) endoscopies.
Recurrence of HGD/EC was observed in 1 patient (1.4%) after 129 months
FU (T1bN0M0 treated with curative surgery). Recurrence of IM in endoscopi-
cally visible BE was observed in 16 patients (of which 2 had LGD) after a median
FU of 31 months. In all cases the extent of recurrence was limited to small
(51 cm) islands or tongues. Histological recurrence without visible BE was
found in 25 patients: 3 patients had BB in neosquamous biopsies (4% overall,
0.7% per patient year); 24 patients (33%) showed IM in biopsies just distal to a
normal appearing neo-z-line. A finding of IM of the neo-Z-line was reproduced
in 50% of patients and BB in none of the patients. Additional treatment was
performed in 8 patients: esophagectomy for T1b-cancer, ER of small island with
LGD (n¼ 1), APC for small islands (n¼ 5), RFA for LGD in the neo-z-line
(n¼ 1). CE-neo and CE-IM (excluding IM in the neo-z-line) at the last FU
endoscopy (after additional treatment) was seen in 100% and 96% respectively.
Conclusion: This study presents the longest published follow-up data on SRER to
date. The 6-year outcomes show that after successful SRER of BE 5 cm recur-
rence of HGD/EC is rare (1% overall, 0.2% per patient year). Recurrence of
endoscopically visible BE with IM or LGD was found in 22% of patients and
was generally confined to small islands or tongues. Buried glands were rare (0.7%
per patient year) and just as IM of the neo-z-line (33% of cases) of insignificant
importance.
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Introduction: BMP4 is a growth factor with a key role in carcinogenesis and
metastasis. We previously found that BMP4 is aberrantly expressed in Barret’s
esophagus and that together with CDX2 drives the intestinalization of epithelial
metaplasia. Its role in the progression and development towards esophageal
adenocarcinoma remains uncertain. In colorectal cancers that present mutations
in the canonical transcription factor SMAD4, BMP4 induces tumorigenic char-
acteristics in epithelial cells through activation of its SMAD-independent
signaling pathways. SMAD4 mutations or deletions are also found in 10% of
esophageal adenocarcinoma (EAC) patients and are associated to poor prognosis
(1).
Aims & Methods: The aim of this project is to elucidate whether BMP4 is
involved in malignancy in EAC. We have recently developed unique low mole-
cular weight Llama derived antibodies that specifically and effectively target
BMP4 and therefore present less off-target effects, which renders them more
apt for clinical purposes (2–3). These antibodies were used to study the effect
of specific inhibition of BMP4 on both in vitro as well as in vivo models of
Esophageal Adenocarcinoma.
Result: We have found that 70% of EAC tumors express BMP4 at the protein
levels. When the analysis was restricted to SMAD4 negative EAC tumors about
90% of those were BMP4þ. Using an antibody that recognizes the pro-domain
of BMP4, and therefore identifies the cells producing BMP4, we found that
epithelial as well as some stromal cells, produce BMP4. We validated these results
by generating an RNAseq database of 56 EAC biopsies, and confirmed that
approximately 80% of those samples expressed BMP4 at the RNA levels. We
next investigated the correlation of BMP4 expression and found that patients
with high levels of BMP4 expression tend to have a poorer recurrence-free sur-
vival than patients with low BMP4 expression, which suggests a more aggressive
tumor behavior in BMP4 expressing EAC tumors. Inhibition of BMP4 function
in SMAD4 negative EAC cells by the anti-BMP4 antibodies leads to an increase
in chemosensitivity and a decrease in invasive and migratory capabilities in vitro.
Analyses of the signaling pathways showed that inhibition of the BMP4-
mediated non-canonical pathways was responsible for these effects. Next, we
made use of a patient-derived tumor xenograft (PDTX) mouse model of a
SMAD4 negative EAC tumor (4). Preclinical in vivo studies with these mice
confirmed that anti-BMP4 antibodies can effectively reduce tumor growth and
synergistically act with chemotherapy agents.
Conclusion: Our studies support a role of BMP4 as a positive regulator of chemo-
resistance and invasiveness in EAC, and suggest that inhibition of BMP4 with
highly specific antibodies has the potential to ameliorate the malignant behavior
of aggressive SMAD4 negative esophageal cancers.
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Introduction: Upper endoscopy is the most common method for the diagnosis of
upper gastrointestinal tract diseases. Our aim was to determine if pre-medication
with simethicone or N-Acetylcysteine improves mucosal visualization during
upper endoscopy.
Aims & Methods: Randomized double-blinded, placebo controlled trial of 297
patients scheduled for upper endoscopy, pre-medicated 15–30 minutes before
with: A–100mL of water (placebo); B–water plus 100mg simethicone; C–water
plus simethicone plus 600mg N-acetylcysteine. Primary outcome was the quality
of mucosal visualization (score: 1-excellent; 2-adequate; 3-inadequate). Trial
registered in http://clinicaltrials.gov (NCT02357303). Statistical analysis with
X2 and one-way ANOVA with Tukey’s correction.
Result: Visualization scores between groups B and C (versus A) were significantly
better in the oesophagus 1.09 and 1.15 vs. 1.31 (p5 0.05) and stomach 1.26 and
1.30 vs. 1.67 (p5 0.01) and better without significance in the duodenum 1.07 and
1.09 vs. 1.20 (p¼NS). ‘‘Excellent’’ scores versus others provided similar results
(B and C vs. A): oesophagus 91% and 87% vs. 71% (p5 0.001), stomach 76%
and 75% vs. 39% (p5 0.001) and duodenum 85% and 82% vs. 73% (p¼NS).
There were no significant differences in scores between groups B and C or
between gastric scores if previous subtotal gastrectomy (B and C vs. A): 1.45
and 1.68 vs. 1.86 (p¼NS). The rate of reported lesions was higher in group B
(without statistical significance).
Conclusion: Pre-medication with simethicone leads to better mucosal visibility,
might improve diagnostic yield and should be considered standard practice.
Addition of N-acetylcysteine had no benefit over simethicone alone.
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Introduction: Accurate diagnosis of lateral extent of early gastric cancer (EGC) is
important in terms of deciding treatment indication and achieving complete
resection by endoscopy or surgery. Magnifying narrow band imaging (M-NBI)
has been suggested to increase yield of endoscopic diagnosis for determining
extent of EGC.
Aims & Methods: To compare diagnostic ability of M-NBI for determining lat-
eral extent of EGC with that of chromoendoscopy (CE). This study was con-
ducted as a multicenter prospective randomized controlled trial including one
university hospital, one cancer referral center and three general hospitals.
Inclusion criteria were patients with EGC sized 1 cm or over who underwent
endoscopic or surgical treatment. Exclusion criteria were history of gastric resec-
tion and high risk of bleeding for biopsy. After stratification by institution,
tumor location, and histological type, patients were randomly assigned to M-
NBI or CE groups. In each group, tumor extent was firstly evaluated by white
light endoscopy according to difference of mucosal height and color, then oral
margin of the tumor was determined by the assigned method. Diagnostic criteria
of M-NBI were 1) demarcation line and 2) irregular microvessel/microsurface
patterns; and that of CE were 1) abrupt change of mucosal structure of the
surrounding mucosa and 2) irregular structure patterns. Biopsy specimens were
taken from 5-mm-outside and -inside of the oral boundary of the tumor and sent
for histological evaluation. When the outside specimen was non-cancer and the
inside specimen was cancer in histology, it was defined as ‘‘successful delinea-
tion’’. Primary endpoint was difference of proportion of successful delineation
between the two groups. A study protocol was approved by institutional review
board in each institution and written informed consent for study participation
was obtained from all patients.
Result: A total of 382 patients were enrolled and were assigned to the M-NBI
group (n¼ 191) and the CE group (n¼ 191). Eight patients in the M-NBI group
and 12 in the CE group were excluded remaining 183 in the M-NBI and 179 in
the CE group for analysis. Successful delineation rates (95% CI) in the M-NBI
and CE groups were 86% (81–91%) and 84% (78–89%), respectively (p¼ 0.498).
Conclusion: This prospective randomized controlled trial revealed M-NBI and
CE were equally accurate for determining extent of EGC, thus both methods are
adequate to perform in clinical practice (UMIN000014628).
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Introduction: Volumetric laser endomicroscopy (VLE) incorporates 2nd genera-
tion optical coherence tomography technology in a balloon-based system, which
is capable of scanning the esophagus circumferentially over 6 cm, up to a depth of
3mm with near-microscopic resolution. VLE has the potential to improve detec-
tion of early neoplasia in Barrett’s esophagus (BE). However, interpretation of
VLE images is complex due to subtle differences in architecture and gray-scale
color and the large amount of images that needs to be scrutinized by the endos-
copist (a 6-cm VLE scan contains 1200 frames). A recently developed clinical
prediction model of VLE features for BE neoplasia showed a reasonable accu-
racy (AUC of 0.81).
Aims & Methods: The aim of this study was to investigate the feasibility of a
computer algorithm to identify early BE neoplasia on ex vivo VLE images. Sixty
VLE images from a database of high-quality one-to-one VLE-histology correla-
tions were used (30 non-dysplastic (ND)BE and 30 neoplastic images; high-grade
dysplasia and early adenocarcinoma), consisting of VLE scans from endoscopic
resection specimens of Barrett’s patients þ/- neoplasia. VLE images were normal-
ized to a height of 400 pixels in order to obtain a standardized zoom factor.
Previously identified VLE features predictive for BE neoplasia served as clinical
input for the algorithm: 1) higher VLE surface signal than subsurface signal in
tissue, 2) lack of layering. From these VLE features an algorithm feature was
developed analyzing both top layers and surface signal. A signal intensity histo-
gram using 8 intensity categories was calculated over the first 4 layers of 50
pixels, starting at the top of the image. Linear support vector machine was
used to classify the images according to the used VLE texture features. Leave-
one-out cross-validation was employed for validation of the algorithm.
Result: Using the correlated histology as the reference standard, sensitivity, spe-
cificity and accuracy for the algorithm to detect BE neoplasia were 93%, 70%
and 82%, respectively. The performance of the algorithm was good, with an area
under the receiver operating curve (AUC) of 0.91 to detect BE neoplasia in ex
vivo VLE images. Most distinctive features of the algorithm are the top layers
and mid-range intensities of the histogram.
Conclusion: This is the first study in which a computer algorithm for BE neopla-
sia was developed based on VLE images with direct histological correlates. The
algorithm showed good performance to detect BE neoplasia in ex vivo VLE
images (AUC 0.91). Compared to the performance of a recently developed clin-
ical VLE prediction score (AUC 0.81), this study suggests that an automatic
detection algorithm seems to perform at least as good as assessment by VLE
experts in detecting early neoplasia on VLE. Future studies on in vivo VLE scans
are needed to further validate the algorithm.
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Introduction: It has been proposed that high-resolution zoom endoscopes (optical
zoom up to 115 times) could predict gastric pit pattern for gastric pathology.
Recently an image-enhanced endoscopic technology called Optical Enhancement
system (OE SystemTM) was introduced, improving visualization of microvessels.
In addition to this, new high-definition zoom scopes called MagniviewTM are
available allowing an optical zoom up to 136 times with a better evaluation of the
mucosa and superficial vascular aspects.
Aims & Methods: The aim of this study was to evaluate the utility OE SystemTM
plus MagniviewTM in the diagnosis of normal gastric mucosa, Helicobacter pylori
associated gastritis, and gastric atrophy. Methods: Prospective, non-randomized
and double blind study. All of the participants enrolled had functional dyspepsia
according to the Rome III criteria and were tested for Helicobacter Pylori (HP)
using stool antigen test. After this phase two groups were selected, dyspeptic HP
(þ) and dyspeptic HP (-) patients (control group). Finally an upper endoscopy
using OE systemTM plus MagniviewTM scopes was performed and the gastric
body evaluated using a previously described classification of four patterns,
based on the combination of the parameters subepithelial capillary network
(SECN), collecting venules and round pits. Type 1 pattern predicts normal
Table 1. (OP225): Overall accuracy of the four patterns predictions
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI) Accuracy, %
Type Ia 90.00 (55.50–99.75) 79,03 (66.82–88.34) 40.91 (20.70–63.65) 90.00 (89.35–99.95) 80.55
Type II–IIIb 91.43 (76.94–98.20) 78.38 (61.79–90.17) 80.00 (64.35–90.95) 90.62 (74.98–98.02) 84.72
Type IVc 66.67 (9.43–99.16) 88.41 (78.43–94.86) 20.00 (2.52–55.61) 98.39 (91.34–99.96) 87,50
a) Ability to predict normal mucosa. b) Ability to predict Helicobacter pylori infection. c) Ability to predict mucosa atrophy.
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gastric mucosa, types 2 and 3 HP related gastritis and the type 4 gastric atrophy.
(1) Images were photographically recorded and biopsies taken in order to corre-
late the images with the histology
Result: A total of 72 patients were included, 35 in the dyspeptic HP (þ) group
and 37 in the control dyspeptic HP (-) group. The average age was 46.3 (37–58.5)
years old and 69.4% were women. The images were analyzed and classified into
the four patterns after the agreement of three endoscopists. There were 22
(30.6%) patients with type I, 13 (18.1%) with type II, 27 (37.5%) with type III
and 10 (13.9%) with type IV pattern. Almost all patients (90%) with normal
mucosa were Type I. Most type II and III patterns had active chronic gastritis,
which correlates with HP infection. In fact, 32/34 (91.5%) of patients with HP
(þ) were Type II-III. The 66% of patients with atrophy had Type IV pattern. The
Table 1 shows the overall accuracy of the four patterns predictions. Type I
predicts normal mucosa, Type II-III HP infection, and Type IV atrophy with a
sensitivity of 90%, 91% and 66.7% respectively and an accuracy of 80.5%,
84.7% and 87.5% respectively. Finally the intra and inter-observer agreement
was calculated with a kappa value of 0.91 and 0.89 respectively
Conclusion: OE chromoendoscopy plus optical magnification has proved to be
useful in the diagnosis of normal gastric mucosa and HP associated gastritis with
high accuracy, unlike gastric atrophy evaluation
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Introduction: Volumetric laser endomicroscopy (VLE) is an advanced imaging
system that provides a 6-cm long, circumferential scan of the esophageal wall
subsurface layers with near-microscopic resolution. VLE has the potential to
improve the detection of neoplasia during Barrett’s esophagus (BE) surveillance.
A new feature of the VLE system is a laser marking tool that enables direct
marking of suspicious areas during VLE scanning, which subsequently can be
targeted for histological sampling. We herein describe the first in human use of
the VLE laser marking tool in BE patients.
Aims &Methods: The aim is to evaluate visibility and positional accuracy of VLE
laser marks in different esophageal tissue types on white light endoscopy (WLE)
and VLE. BE patients with and without neoplasia were imaged with VLE. In a
learning phase protocol refinements were practiced. In the second phase, visibi-
lity of laser marks (LMs) was assessed by randomly marking 4 quadrants in
squamous, BE and gastric tissue. LMs were automatically placed in offset
mode; 2 LMs 6mm apart horizontally. In the third phase, positional accuracy
of LMs was tested, whereby previously placed electrocoagulation markers
(ECMs) were targeted on VLE and laser marked (2 ECMs per tissue type). In
the final phase, in each patient the most suspicious areas for neoplasia were
identified on VLE, targeted by laser marks and subsequently biopsied.
Result: In total 17 BE patients were included (15 males, median age 67): 11
patients with non-dysplastic (ND)BE, 6 patients with high-grade dysplasia
(HGD) or early esophageal adenocarcinoma (EAC). Median BE length: C2
(IQR 1–9) M4 (IQR 4–11). In total 222 LMs were placed, of which 207 (93%)
were visible upon WLE and 192 (86%) on VLE, see table for visibility per tissue
type. In total in 25/33 of targeted ECMs (76%) the LMs were confirmed to be
positioned accurately. Three ECMs were not accurately targeted due to a system
error and 5 due to difficult visualization on VLE. In the final phase (5 patients),
18 areas identified on VLE as most suspicious were successfully targeted by LMs
(3 areas contained EAC, 3 HGD, 1 LGD and 11 NDBE). Mean VLE procedure
time was 22 minutes (SD 6) – with a mean total endoscopy time of 56 minutes
(SD 17). No adverse events were reported.
Visibility of laser marks in esophageal tissue types
Gastric
mucosa
Barrett’s
mucosa
Squamous
mucosa TOTAL
Upon WLE 49/62 (79%) 96/96 (100%) 62/64 (97%) 207/222 (93%)
Upon VLE 43/62 (69%) 88/96 (92%) 61/64 (95%) 192/222 (86%)
Conclusion: The first in human use of VLE laser marking in 17 BE patients was
found to be feasible and safe. The majority of the LMs was visible upon WLE
and VLE, although appearance on VLE can be subtle. Targeting VLE areas of
interest proved to be highly successful and VLE laser marking may thus improve
the clinical value of VLE in BE surveillance in the future.
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Introduction: Digital subtraction angiography is a method to enhance the contrast
of anatomic structures after opacification with contrast media. Therefore struc-
tures that are not of interest are deleted from the image by subtraction of image
information. A variation of this technique is called Road Map Fluoroscopy
(RMF) where an image at peak opacification is used as the mask for subsequent
subtraction images. With this technique the advancement of guidewires, stents
or catheters can be viewed without additional marking or contrast injection.
In summary, the opacification is only performed once but the information remains
on the image throughout the investigation. In this way anatomic structures such as
length or diameter of stenosis can be measured with high accuracy (1–4). Although
esophageal stent placement has been reported to be safe also without fluoroscopic
guidance most endoscopists prefer to use fluoroscopy during stent deployment
(5–7). Mucosal marking using the injection of lipoidol for stent implantation is
widely used among endoscopists but may no longer be necessary if RMF is used as
guidance of the procedure. The use of RMF has so far not been evaluated for
endoscopic procedures.
Aims &Methods:We aimed to evaluate the usefulness of Road Map Fluoroscopy
to guide endoscopic interventions in the esophagus. Patients with esophageal
strictures were consecutively enrolled in a monocentric observational trial.
After identification of the stenosis, a Road Map (Philips Multidiagnost Eleva,
Philips Healthcare, Netherlands) scan was performed using 20–40ml of water
soluble contrast media that was applied through the working channel of a gas-
troscope (Fujifilm EG530NW or Olympus GIF-Q 180). RMF recording requires
stable fluoroscopy of the region of interest to generate a mask for consecutive
subtraction. Thereafter contrast medium is injected. After RMF application all
further fluoroscopy images contain the information of the subtraction as steady
overlay. Directly after the RMF was finished, the complete fluid was removed
from the esophagus to avoid aspiration. Patients were all investigated in recum-
bent position under sedation with midazolam or propofol. All further interven-
tions and measurements were performed by using the RM images.
Result: 21 investigations were performed in 18 patients (age:71 13 years male:12
female:6). Indications for interventions were: balloon dilatation of benign stric-
tures: n¼ 9 including 1 pneumatic balloon dilatation for the treatment of acha-
lasia, bouginage of benign stricture: n¼ 3 and diagnostic radiography without
intervention: n¼ 1. In addition 8 stents, 5 partially covered and 3 fully covered,
were placed using RMF as a guide for exact determination of stent length and
diameter. Stents were also deployed under RMF guidance (figure). Endoscopic
control revealed desired stent position in all cases. The choice of stent was made
by measurement of the length of the stenosis as well as diameter of healthy
esophagus adjacent to the stricture. Available stents that fitted best to the mea-
sured dimensions were implanted. In all procedures RMF successfully guided the
intervention. The feeling of resistance during bouginage was exactly matching the
location for RMF projection of the stenosis. With the help of RM imaging
dilatation balloons could easily be centered inside the stenosis to avoid slipping
of the balloon. Complications did not occur.
Conclusion: RMF provides the possibility of permanent radiographic illustration of
stenosis or anatomic changes throughout the intervention by using contrast medium
only at the beginning of the intervention. RMF is feasible and safe to guide radi-
ology based interventions in the esophagus. RMF directs the selection of stents
better than endoscopy because all relevant dimensions can be measured exactly.
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Introduction: Common variable immunodeficiency (CVID) is the most common
symptomatic primary immunodeficiency in adults. CVID is a combination of
humoral and cell-mediated deficiency, and the cornerstone of its treatment is
intravenous or subcutaneous immunoglobulin therapy. However, while this
treatment prevents infections, many CVID patients may still develop a broad
spectrum of gastrointestinal disorders including autoimmune and inflammatory
diseases such as atrophic gastritis, small bowel villous atrophy and inflammatory
bowel disease (IBD).
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Aims & Methods: Aim of the study: To investigate in detail the gastrointestinal
phenotype of CVID patients living in southern Finland. Patients and Methods:
Our study cohort consisted of 105 adult CVID patients followed up between
2007–2015 in Helsinki University Hospital´s Adult Immunodefiency Unit and
the respective outpatient clinics of Carea and Eksote. CVID patients were diag-
nosed with the strict vaccine response criteria and lived within these 3 hospital
districts of southern Finland (1.9 million inhabitants). Adult patients of this
cohort were diagnosed from the year 1960 to 2015 when recruitment stopped.
We investigated retrospectively their medical records, laboratory results, endo-
scopy (over 300 endoscopies) ja histology reports and data was collected to an
electronic database designed for the study. Of this patient cohort, 12 patients died
and 11 were lost to follow up.
Result: Upper endoscopy and ileo-colonoscopy were done at least once to 83
(79%) and 77 (73%) patients, respectively. 1. Gastric: Helicobacter pylori was
found in 7 patients, was negative in 74 and unknown in 23 patients. Eradication
was succesful in all Helicobacter-positive patients. Helicobacter-negative chronic
gastritis without marked atrophy, but ranging from mild to severe inflammatory
activity, was found in 11 patients (11%). In addition, atrophic gastritis was found
in 10 patients (10%). 2. Small bowel: All tested patients were seronegative for
coeliac disease. Of patients with increased intra-epithelial lymphocytes and vil-
lous atrophy of duodenum, 2 had complete histological and clinical response to
gluten-free diet and all 4 others were unresponsive but had no enterocyte anti-
bodies. 3 of the patients with refractory duodenal villous atrophy and inflamma-
tion had also inflammatory changes in colon as well. 3. Hepatobiliary: Primary
sclerosing cholangitis or CVID-associated cholangitis was diagnosed in 5
patients. 3. Large Bowel: Inflammatory changes of mucosa ranged from unspe-
cific colitis and microscopic colitis (including lymphocytic colitis and collagen
colitis) to crypt-desctructive and/or graft-versus-host like severe inflammation.
Colonic enteropathy included IBD-like phenotypes: colitis ulcerosa was diag-
nosed in 5 patients (2 colectomies) and one patient had stricturing ileocolonic
Crohn´s disease. Altogether, inflammation of colon was more common than small
bowel enteropathy and it was found in 20 patients (19%). Prior to ileocolono-
scopy, bacterial and parasitic infections were ruled out by standard laboratory
methods including fecal sample screening. Nodular lymphatic hyperplasia was
detected from gastric mucosa to rectum, and ranged from asymptomatic
enhanced ileal nodularity to major changes of the gastric and bowel mucosal
appearance and function. It was relatively common finding and noted in 36
patients (34%). 4. Mortality and gastrointestinal malignancies: 12 patients died
during the follow up and in 3 patients it was directly due to metastatic malig-
nancies of gastrointestinal tract: 2 patients with gastric adenocarcinoma and one
patient with adenocarcinoma of the colon. Small bowel enteropathy had been
found also in other 2 patients that died due to the cardiovascular disease.
Meanwhile, one patient with unspecific inflammatory nodularity of colon even-
tually developed ceacal large B-cell lymphoma which was timely diagnosed, and
treated successfully.
Conclusion: Gastrointestinal and hepatobiliary manifestations are common
among patients with CVID and the risk malignancies are increased.
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Introduction: Bile Acid Diarrhoea (BAD) is an under-recognised cause of chronic
diarrhoea and can be assessed by measuring SeHCAT retention. BAD can relate
to terminal ileal disease or resection (designated as Type 1), be considered as
idiopathic (type 2), or be linked to other underlying conditions (Type 3). Its
prevalence is increased following cholecystectomy, but the clinical profile and
severity of bile acid malabsorption are poorly characterised.
Aims & Methods: A prospective study evaluated SeHCAT usage across the
United Kingdom was undertaken, capturing data from 38 centres and 1,036
patients. Aims were to investigate SeHCAT retention rates according to the
type of BAD suspected, and to evaluate centre-defined abnormal results.
Result: Of the 1,036 patients, 752 had information on suspected BAD type, of
whom 310 had suspected Type 3 BAD (71% female, mean age 49 years). A large
subset were identified as post-cholecystectomy (n¼ 98, 82% female, mean age 52
years) and non post-cholecystectomy (n¼ 212, 67% female, mean age 48 years).
Suspected Type 3 are hereon referred to as BAD Types 3a (all except post-
cholecystectomy) and 3b (post-cholecystectomy only). Patients with suspected
BAM Type 3a had the largest mean retention of 25% (95% CI: 22.3–28.0%,
median¼ 20, while post-cholecystectomy patients (BAD Type 3b) had a mean
retention of 15% (95% CI: 11.7–18.3%, median¼ 9). These compare to mean
retentions of 9% in suspected Type 1 and 21% in Type 2 (1). Centre-defined
abnormal results were higher amongst suspected Type 3b patients (56%) than
Type 3a (30%), with correspondingly higher bile acid sequestrant prescriptions
for Type 3b patients (49%) than Type 3a (25%) at the time of the survey.
Conclusion: Subdivision of BAD Type 3 patients suggest (although not conclu-
sively given the limitations of this survey) that post-cholecystectomy patients
have a physiologically different profile compared to non post-cholecystectomy
Type 3a patients, with more severe bile acid malabsorption. This warrants sepa-
rate analysis in future research.
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Introduction: Amino acid citrulline is a non-essential amino acid which does not
corporate into proteins and small intestine (gut enterocyte) is the main endogen-
ous source of circulating citrulline in blood. Since celiac disease is thought to be a
highly heterogeneous spectrum ranging from classic malabsorptive form to aty-
pical potential or latent form. It is envisaged that citrulline could be an important
metabolomic or proteomic signature to assess silent and potential forms of the
disease, compliance of the disease after institution of gluten free diet and it may
add predictive value for closer surveillance of high risk groups such as first degree
relatives of CD.
Aims & Methods: We aimed to evaluate the baseline and six months follow up
plasma citrulline levels in patients with celiac disease and in their first degree
relatives and to establish a correlation between histopathological findings and the
amino acid levels as a biomarkers for villous atrophy. Materials and Method:
The procedure adopted for measuring plasma citrulline was Tendem Mass
Spectrometery (LC-MS/MS) & RP-HPLC. Disease state was confirmed by his-
topathology findings including Marsh score and HLA typing(DQ2 & DQ8) BY
SSP-PCR
Result: Mean plasma citrulline levels in 54 serology positive subjects was
9.0 SD umol/L whereas the mean citrulline levels in 124 serology negative
subjects (first degree relatives) was 24.3umol/L. This difference was statistically
highly significant with p value of 0.0001. Correlations between biopsy grades of
Subjects with their citrulline levels were established & found to be significant. For
Marsh 3c grade lesions, mean citrulline levels were 5.6SD umol/L. For Marsh
3b, mean citrulline levels were 15.0 SD umol/L with p value 0.006.
Understandably the patients with total villous atrophy had a lower citrulline
levels even if they were asymptomatic. All the patients were on stringent six
month follow up and the mean levels were 12.8SD umol/L. DQ2 heterodimer
were collectively found in 71.63% high risk subjects. A total of 8.69% subjects
found negative for HLA DQ2 heterodimer. HLA type DQ8 was not found in any
of the subject.
Conclusion: Citrulline alone is a very important metabolomic signature of initial
damage of gut enterocytes in celiac disease and also when correlated with Marsh
score. Citrulline estimation on dried blood spots using tandem mass spectrometry
is a minimally invasive and promising test in near future which could be trans-
ported from the remotest place in the country to suggest improvement in gut
enterocyte mass. Plasma citrulline estimation assures detection of potential celiac
disease and may be use for monitoring of compliance and recovery in CD which
is likely to be of immense benefit in the diagnosis of celiac disease and analyzing
citrulline on dried blood spot by a highly sensitive technique of liquid chromato-
graphy mass spectrometry may ease follow up and diagnosis of CD
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Introduction: Intracellular zinc is required for a variety of cell functions. Previous
studies suggest that the intracellular zinc has an essential role in the maintenance
of the intestinal tight junction (TJ) barrier, however, the underlying mechanisms
remain unclear (1, 2). The present study investigated the essential roles of intra-
cellular zinc in the preservation of intestinal TJ integrity and the underlying
molecular mechanisms in human intestinal Caco-2 cells and mouse colons.
Aims &Methods:Depletion of intracellular zinc in Caco-2 cells and mouse colons
was achieved by the application of a cell permeable zinc chelator, N, N,N’,N’-
Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN). Caco-2 cells grown in
Transwell inserts were incubated with TPEN. The TJ barrier function was
assessed by measuring transepithelial electrical resistance (TER) and dextran
flux. The TJ proteins expression and distribution (ZO-1, ZO-2, occludin, JAM-
1, and claudin-1-4) were evaluated by immunoblot, immunofluorescence and
qPCR analyses. To confirm specificity of the TPEN effects, ZnSO4 was supple-
mented to the culture media in the presence of TPEN. The TPEN-induced pro-
teolysis of occluidn was examined by biotinylation of cell surface proteins. To
examine the mechanisms underlying for the zinc depletion-induced occludin pro-
teolysis, selective inhibitors of calpain, proteasomes, autophagy, matrix metallo-
protease and cathepsin were used. The effect of zinc depletion on claudin-3
promoter activity was examined by means of a reporter gene assay. Roles of
transcription factors, sp1 and egr1, for the zinc-mediated claudin-3 promoter
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activity were examined by a mutagenesis technique in the promoter assay and
RNA interference technology. The effects of TPEN on occludin and claudin-3
expression in mouse colons were also examined in combination with the calpain
inhibitor.
Result: Intracellular zinc depletion by TPEN impaired the TJ barrier of intestinal
Caco-2 cells, indicated by decreased TER and increased dextran flux. The TPEN-
induced TJ disruption is associated with downregulation of 2 TJ proteins, occlu-
din and claudin-3. These changes induced by TPEN were completely restored by
supplemental zinc. Biotinylation of cell surface proteins revealed that the zinc
depletion induced the proteolysis of occludin, but not claudin-3. Occludin pro-
teolysis was sensitive to the inhibition of calpain activity, and increased calpain
activity was observed in the zinc-depleted cells. Although qPCR analysis and
promoter reporter assay have demonstrated that the zinc depletion-induced clau-
din-3 downregulation occurred at transcriptional levels, a site-directed mutation
in the egr1 binding site in the claudin-3 promoter sequence induced loss of both
the basal promoter activity and the TPEN-induced decreases. Reduced egr1
expression by a specific siRNA also inhibited the claudin-3 expression and bar-
rier maturation in cells. In mouse colons, the calpain inhibitor restored the
TPEN-induced decrease in occludin, but not claudin-3.
Conclusion: This study shows that intracellular zinc has an essential role in the
maintenance of the intestinal epithelial TJ barrier through regulation of occludin
proteolysis and claudin-3 transcription. Intracellular zinc seems to physiologi-
cally suppress occludin proteolysis by robust calpain activity. Further, zinc
finger-containing egr1 was shown to be critical for the transcriptional regulation
of claudin-3.
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Introduction: Home parenteral nutrition (HPN) is an established treatment for
the management of patients with Type 3 intestinal failure (IF). A Quality of Life
(QOL) assessment tool (HPN-QOL version 1.0) was developed and validated in
2009 specifically for this patient population (1). Little data exist in literature on
the QOL of HPN patients. We incorporated this tool into local clinical practice
to evaluate the QOL of our HPN cohort in Northern and Northeast England.
Aims & Methods: The HPN-QOL was discussed with all patients in clinic and
sent by post with a prepaid return envelope and a letter explaining how informa-
tion will be used. Participation was voluntary. Responses were collected between
February and July 2015. Data were anonymised for analysis and reporting.
Patients scored themselves in 45 questions relating to 10 domains of function and
9 domains of symptoms. 3 further questions asked for a global numerical rating
of QOL. A final question allowed free text comments. Scores were computed if at
least half of the questions in each domain were answered as per the validated
process in HPN-QOL. Raw patient responses were scaled to a score of 0–100 for
each domain. The QOL global numerical ratings had a scale of 60 to 65. Based
on the rating descriptors in the HPN-QOL we interpreted a scaled score of more
than 50 in domains relating to function as good functioning ability. A scaled
score exceeding 50 in symptom domains were interpreted as frequent symptoms
impairing QOL. For the QOL global numerical ratings, a scaled score of 23 or
more was interpreted as good overall QOL.
Patients were grouped according to the following 4 criteria for further analysis:
gender, age (455 and 55), presence of stoma, and aetiology of IF. Within each
group, QOL scaled scores were compared in every domain using the Kruskal-
Wallis test.
Result: 55 responses were received from 67 patients. Two responses were excluded
due to insufficient information to perform any form of analysis. 22 patients
(41.5%) were male and 31 female. Median age was 55 years (range 19–85). 27
patients (50.9%) were 55 years and younger and 26 patients were older than 55
years. The aetiologies of intestinal failure were mesenteric ischaemia, 16 (30.2%);
inflammatory bowel disease (IBD), 15 (28.3%); surgical complications, 8
(15.1%); motility disorder and radiation enteritis, 5 each (18.9% in total); and
malignancy, 4 (7.5%). 37 patients (69.8%) had a stoma and 16 had no stoma.
There was no significant difference between patients with and without a stoma in
all domains except gastrointestinal (GI) symptoms (p¼ 0.01). This is in keeping
with findings by Baxter, et al (1). In gender analysis, males reported better ability
to eat and drink (p¼ 0.027), better perceived support from the MDT (p¼ 0.027),
and better sexual function (p¼ 0.046). However, they also reported more GI
symptoms (p¼ 0.006). In age group analysis, patients over 55 had lower employ-
ment scores (p¼ 0.004) and more GI symptoms (p¼ 0.014). The lower employ-
ment scores may be confounded by advancing age alone. In analysis of aetiology,
patients with motility disorders reported significantly reduced ability to eat and
drink compared to those with other causes of IF except malignancy (p¼ 0.034).
Regardless of gender, age, or presence of stoma, patients generally rated their
ability to travel/holiday, physical function, employment and sexual function
poorly. Fatigue was a major limiting symptom. The global QOL numerical
rating was also poor in all groups.
Conclusion: As part of the holistic clinical care of patients on HPN, their QOL
should be considered. Results of this study show that the majority of our HPN
patients experience problems that impair their QOL. It is not possible to establish
how much this relates to the underlying condition or HPN itself. This is an area
that would benefit from further study.
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Introduction: Current nutritional guidelines recommend the use of enteral over
parenteral nutrition in patients undergoing gastrointestinal surgery. However,
the NJEEN remains controversial in patients undergoing PD.
Aims & Methods: To compare nasojejunal early enteral nutrition (NJEEN) with
total parenteral nutrition (TPN), after pancreaticoduodenectomy (PD), in terms
of postoperative complications. Multicenter, randomized, controlled trial was
conducted between 2011 and 2014. Nine centers in France analyzed 204 patients
undergoing PD to NJEEN (n¼ 103) or TPN (n¼ 101). Primary outcome was the
rate of postoperative complications according to Clavien-Dindo classification.
Successful NJEEN was defined as insertion of a nasojejunal feeding tube, deli-
vering at least 50% of nutritional needs on PoD 5, and no TPN for more than
consecutive 48 hours.
Result: Postoperative complications occurred in 77.5% (IC 95% [68.1–85.1])
patients in the NJEEN group versus 64.4% (IC 95% [54.2–73.6]) in TPN
group (p¼ 0.040). NJEEN was associated with higher frequency of postoperative
pancreatic fistula (POPF) (48.1% vs. 27.7%, p¼ 0.012) and higher severity
(grade B/C 29.4% vs. 13.9%; p¼ 0.007). There was no significant difference in
the incidence of post-pancreatectomy hemorrhage, delayed gastric emptying,
infectious complications, the grade of postoperative complications and the
length of postoperative stay. A successful NJEEN was achieved in 63% patients.
In TPN group, average energy intake was significantly higher (p5 0.001) and
patients had an earlier recovery of oral feeding (p¼ 0.0009).
Conclusion: In patients undergoing PD, NJEEN was associated with increased
overall postoperative complications rate. The frequency and the severity of
POPF were also significantly increased after NJEEN. In term of safety and
feasibility, NJEEN should not be recommended.
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OP234 DIETARY EMULSIFIERS DIRECTLY IMPACT THE HUMAN
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Introduction: We recently demonstrated that, in mice, consumption of dietary
emulsifiers, detergent-like components of many processed foods, results in a
disturbed gut microbiota, including alterations in species composition, elevated
pro-inflammatory potential (i.e. higher levels of bioactive LPS and flagellin) and
microbiota encroachment (1). Such disturbance of the microbiota promotes a
range of chronic inflammatory diseases including metabolic syndrome and coli-
tis. However, the underlying mechanism by which emulsifiers induce such effects,
including whether they act directly upon the microbiota or the host, remains
unclear.
Aims & Methods: Our aim in the current study was to investigate if, and how,
emulsifiers directly impact upon the microbiota in the absence of a host response
The M-SHIME (Mucosal Simulator of the Gastrointestinal Microbial
Ecosystem) model was used to examine the effects of emulsifiers on the micro-
biota in vitro. After a stabilization period of 7 days, this dynamic human gut
model was treated with emulsifiers (Carboxymethylcellulose (CMC) or
Polysorbate-80 (P80), 1%). Microbiota composition, meta-transcriptomic and
pro-inflammatory potential (Flagellin and LPS loads) were analyzed.
Microbiota metagenome was predicted using PICRUSt (Phylogenetic
Investigation of Communities by Reconstruction of Unobserved States).
Human microbiota from the SHIME system was transferred to Germfree reci-
pient mice, with subsequent intestinal inflammation analysis.
Result: Both P80 and CMC treatment increased the pro-inflammatory potential
of human microbiota, as revealed by a dramatic increase in bioactive flagellin
within one day for CMC and 5 days for P80. P80 induced drastic alteration of the
human gut microbiota composition, associated with an increased proportion of
genes involved in bacterial motility. Both P80 and CMC treatment did not sig-
nificantly alter branched or short chain fatty acid compositions, but significantly
increased the proportion of microbiota mRNAs encoding motility related pro-
teins. When transferred to germfree recipient mice, P80 and CMC-treated human
microbiota was sufficient to drive low-grade intestinal inflammation and meta-
bolic syndrome.
Conclusion: Both emulsifiers directly acted upon the microbiota to increase its
pro-inflammatory potential, indicating that at least a portion of the effects of
emulsifiers in vivo results from direct action of these compounds on the micro-
biota. The mechanisms by which P80 and CMC act are distinct, with P80 altering
the composition of the microbiota, favoring species expressing high level of
flagellin, whereas CMC increase the pro-inflammatory potential of the micro-
biota in a composition independent manner, by inducing expression of motility
genes.
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Introduction: Chronic Intestinal Pseudo-Obstruction (CIPO) is a chronic severe
disorder of gastrointestinal (GI) motility leading to clinical features of intestinal
obstruction without mechanical occlusion. The intestinal microbiota is a key
factor determining gut motility. We hypothesized that dysbiosis may be found
in CIPO and that it contributes to clinical features of the disease.
Aims & Methods: 1) To characterize the gut microbiota of patients with CIPO. 2)
To determine whether this microbiota is responsible for clinical features typical
of CIPO using a gnotobiotic mouse model. 3) To evaluate whether faecal micro-
biota transplantation (FMT) improves symptoms of CIPO. The faecal micro-
biota of 3 patients with CIPO (1 female, median age 38.6 11 years) and 3
healthy volunteers (2 females, 39.5 9 years) was analyzed by 16S rRNA
based Illumina sequencing. Stool samples from 1 patient with CIPO and 1
healthy control were used to colonize germ-free NIH Swiss mice (n¼ 15 mice
per donor, mixed gender) by oral gavage. GI transit was determined at 2 weeks
using a validated in vivo videofluoroscopic technique1. Caecum and stomach
size, and maximal bowel diameter, were determined using oral contrast-enhanced
abdominal CT scan. The faecal microbiota of recipient mice was analyzed 48
hours and 2 weeks after colonization by Illumina and inferred metagenomic
profiles were assessed by PICRUSt. The CIPO patient was then treated with
FMT by jejunal infusion from a healthy donor at regular intervals for 20
weeks. GI symptoms, overall health and quality of life were assessed using stan-
dardized questionnaires.
Result: The microbiota of patients with CIPO exhibited marked dysbiosis with
predominance of Proteobacteria species, especially Enterobacteriaceae and
Enterococcaceae. In contrast, healthy volunteers showed a predominance of
Firmicutes and Bacteroidetes. Bacterial richness and diversity were lower in
CIPO patients. The faecal microbiota profiles of gnotobiotic mice resembled
that of human donors. Mice colonized with microbiota from the CIPO patient
had a slower GI transit than mice with healthy control microbiota (mean transit
score 1 2 vs. 12 5, p5 0.001). Furthermore, CIPO microbiota colonized mice
had a larger caecum size (2.39 0.32 cm3 vs. 1.56 0.22 cm3, p5 0.001) and a
higher maximal bowel diameter (3.3 0.2mm vs. 2.9 0.2, p¼ 0.003) compared
to control microbiota colonized mice. Bacterial genes related to bile acid meta-
bolism and disaccharide fermentation were differentially expressed in the faeces
of recipient mice. Importantly, FMT led to a rapid and sustained improvement in
GI symptoms and overall quality of life in our CIPO patient. His microbiota
dramatically changed after FMT and resembled that of the donor.
Conclusion: The faecal microbiota composition and its metabolic activity are
altered in patients with CIPO. This dysbiotic microbiota has the ability to
induce clinical features reminiscent of this disorder in a gnotobiotic mouse
model. Finally, faecal transplantation may be an effective treatment for patients
with CIPO.
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Introduction: Operative resection in Crohn’s disease (CD) is not curative. After
ileocecal resection, endoscopic recurrence is frequently observed on the anasto-
mosis and/or on the neo-terminal ileum.
Aims & Methods: The aim of this study was to analyze the mucosa associated
microbiota at time of surgery and to look for predictors of post-operative endo-
scopic recurrence within the microbiota. This is a prospective study performed in
9 centers of the REMIND group, collecting clinical and biological data at time of
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surgery and of endoscopy (performed at 6 months). Bacterial composition of the
ileal mucosa associated microbiota was analyzed at time of surgery using 16S
(MiSeq, Illumina) sequencing. The obtained sequences (rarefied to 5000 read/
sample) were analyzed using the Qiime pipeline to assess composition, alpha and
beta diversity. Bacterial taxa associated with clinical parameters were identified
using Multivariate association with Linear Models (MaAsLin) taking into
account disease phenotype, clinical parameters and treatments.
Result: 146 patients were included: 73 (50%) were male, median age at surgery
was 32 years (IQR 26–42). Median disease duration was 6 years (IQR 2–12). 44
patients (30%) were active smoker at time of surgery. Thirty patients (21%) had
a previous resection, and 35 patients (24%) had perianal lesions. Indication for
surgery was stricturing disease (n¼ 95), penetrating disease (n¼ 53). At time of
surgery, 67 patients (46%) had received anti-TNF therapy within the last 3
months. After surgery, 31 patients received thiopurines, and 52 patients received
anti-TNF therapy. The microbiota was mainly composed of bacteria from the
Firmicutes (Mean 53%, range 0.3–99%), Proteobacteria (Mean 36%, range 0.5–
99%), Bacteroidetes (Mean 3%, range 0–52%) and Actinobacteria (Mean 6%,
range 0–81%) phyla. As expected, antibiotics treatment within one month before
surgery had a dramatic impact on microbiota composition (Anosim, p5 0.0001)
and diversity (mean observed species: 302 17 vs 236 14, p¼ 0.005). In multi-
variate analysis (MaAsLin), antibiotics treatment was notably associated with an
increase in Enterococcus sp. (q5 0.0001) and with a decrease in Lachnospiraceae
family (q¼ 0.004). Taking into account only the patients who did not received
antibiotics within a month before surgery, we then looked for predictive factors
of endoscopic recurrence. Patients with endoscopic recurrence, defined by a
Rutgeerts score 1 (n¼ 27), had a lower bacterial diversity at time of surgery
compared to patients in endoscopic remission (n¼ 65) (mean observed species:
276 14 vs 365 45, p¼ 0.015).
Conclusion: Ileal mucosa associated microbiota of CD patients at time of surgery
is dominated by bacteria belonging to Firmicutes, Proteobacteria, Bacteroidetes
and Actinobacteria phyla. Antibiotics given during the last month prior to surgery
induce major perturbations of the microbiota. Reduction in bacterial diversity at
time of surgery is predictive of endoscopic recurrence.
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Introduction: Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver
disease leading to strictures in intra- and extrahepatic bile ducts and finally to
cholestasis and secondary biliary cirrhosis (1). The chronic inflammation is asso-
ciated with increased proliferation of biliary epithelial cells and a markedly
increased risk of development of biliary dysplasia and cholangiocarcinoma (2).
The etiopathogenesis of PSC is unknown, but the frequent association with
inflammatory bowel disease, in 62–83% of PSC patients, and increased intestinal
permeability in PSC has suggested a role for microbiota or microbial metabolites
or derivatives, e.g. pathogen-associated molecular patterns, PAMPs) such as
lipopolysaccharide (LPS), lipoteichoic acid, and peptidoglycan in the etiopatho-
genesis of the disease (3–5). It has been proposed that the association between
PSC and IBD can be due to increased enterohepatic circulation of PAMPs
(‘‘leaking gut’’), or abnormal PAMPs (as a result of enteric microbial dysbiosis,
described in IBD). Moreover, 16S ribosomal ribonucleic acid (rRNA) has been
detected in bile and also in cholangiocytes in PSC patients. The microbiota in bile
have also been shown to be modified by genetic factors such as FUT2 (2--L-
fucosyltransferase 2) polymorphism, a gene involved in protein glycosylation.
Aims & Methods: To study the possible role of biliary microbiota in ethiopatho-
genesis, disease progression and risk of dysplasia and cholangiocarcinoma
(CCA). The clinical part of the study was conducted at Helsinki University,
Clinic of Gastroenterology. The patients were recruited from the PSC registry
of the Clinic of Gastroenterology. The indication for ERCP examination was the
documentation of diagnosis of PSC due to: 1) constantly elevated or fluctuating
serum alkaline phosphatase (ALP) levels in conjunction with IBD, or 2) magnetic
resonance cholangiography findings, or 3) liver biopsy suggestive of PSC, or
dysplasia surveillance. During patient’s ERCP and before injecting contrast
media a bile sample was aspirated from extrahepatic bile ducts using balloon
catheter, whenever possible. Brush cytology was routinely performed during
ERC. ERC findings were scored according to the modified Amsterdam score
(mAm score) and the number of ERC examination were recorded in each patient
group. Isolation, amplification and sequencing of the bacterial 16S rRNA gene
were performed. The resulting data was analyzed with negative binomial general-
ized linear models, PERMANOVA, and non-parametric tests.
Result: 1) A very low abundance OTU (‘‘species’’) belonging to the family
Neisseriaceae was reduced in abundance in the early disease group. 2) Increase
in Streptococcus from early disease to long disease progression. Streptococcus
also correlates with increase in ERC severity score and potentially with the
number of ERCP examinations. More robust are the findings regarding overall
community diversity, which decreases in long progression and dysplasia/CCA. 3)
A low abundance Prevotella OTU disappears in patients with dysplasia or CCA.
Streptococcus seems to again increase.
Conclusion: The data in our exploratory study suggests that the etiology of the
disease is not connected with changes in biliary microbiota. However,
Streptococcus seems to be connected with disease progression and risk of dys-
plasia and CCA. It may also be related to the number of ERC examinations and
therefore a role, at least partially, for nosocomial infection cannot be ruled out at
this stage. Overall microbial diversity decreases in long progression and further
more in dysplasia/CCA.
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Introduction: Chromogranins (Cg) and secretogranins (Sg) are acidic gut hor-
mones, which are secreted from the neuroendocrine system and may regulate
immune activation. We have previously shown increased levels of faecal Cg
and Sg in IBS patients (1). However, the consequences and cause of increased
levels of luminal granins in IBS are still undefined.
Aims & Methods: In this study we aimed to quantify faecal granin levels in IBS
patients and evaluate potential relationships between granin levels, microbiota
composition and immune activation. Levels of CgA, CgB, SgII, SgIII and cal-
protectin were analysed with radioimmunoassay and ELISA, respectively, in
faecal samples from IBS patients (n¼ 143) and healthy subjects (n¼ 43).
mRNA expression of interleukin (IL)-8, IL-10, tumour necrosis factor (TNF)
and forkhead box P3 (FOXP3) in mucosal biopsies from the sigmoid colon was
determined with qRT-PCR. Faecal (n¼ 111 subjects) and mucosal-associated
microbiota (n¼ 50 subjects) were analysed by 16S rRNA targeted pyrosequen-
cing. IBS symptom severity and psychological distress were evaluated with the
Gastrointestinal Symptom Rating Scale-IBS (GSRS-IBS) and the Hospital
Anxiety and Depression Scale (HADs), respectively.
Result: IBS patients demonstrated higher levels of faecal CgA (8.1 (3.3–17.4)
pmol/L) compared to healthy subjects (4.7 (2.9–9.0), p5 0.02 pmol/L). The
levels of SgII (0.8 (0.1–3.6) pmol/L) and SgIII (2.0 (0.8–4.8) pmol/L) in IBS
patients were also increased compared to healthy subjects ((0.1 (0.0–0.2),
p5 0.01) respectively (0.7 (0.4–2.4), p5 0.001, pmol/L)). Faecal microbial diver-
sity was negatively correlated with CgA (r¼0.29, p5 0.005), CgB (r¼0.21,
Table (OP237)
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A94 United European Gastroenterology Journal 4(5S)
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
p5 0.05) and SgIII (r¼0.28, p5 0.005). In addition, SgII showed a tendency
to be negatively correlated with faecal microbial Shannon diversity (r¼0.19,
p¼ 0.05). No correlations were found between any of the granins (CgA, CgB,
SgII and SgIII) and mucosal-associated microbiota Shannon diversity or muco-
sal immune activity (i.e. calprotectin or expression of IL-8, IL-10, TNF and
FOXP3). A positive correlation between total GI symptom severity (GSRS-
IBS) and levels of CgB was detected (r¼ 0.22, p5 0.001). General psychological
distress measured with total HAD score was positively correlated to CgA
(r¼ 0.24) and CgB (r¼ 0.34, both p5 0.05).
Conclusion: This study confirms that IBS patients have increased faecal levels of
CgA, SgII and SgIII as compared to healthy subjects. Negative associations were
found between levels of luminal granins and luminal microbiota diversity, but not
with either mucosal immune activity or mucosal-associated microbiota. GI symp-
tom severity and psychological distress were also associated with increased levels
of chromogranins in the lumen.
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Introduction: The microbiota is considered important for development of intest-
inal diseases. In order to create a molecular snapshot of IBD in its early mani-
festation, one part of the IBD-Character project identified faecal microbiota
profiles among the strictly treatment naı¨ve IBD and symptomatic non-IBD
patients, and a healthy control group.
Aims & Methods: Patients where characterized by international criteria including
endoscopy and biopsies. Faecal samples collected during five days prior to diag-
nosis where stored at –80C before examination on GA-mapTM Dysbiosis Test
(1), a 16S rRNA DNA test utilizing DNA probes to recognize gut bacteria
profiles. In total 54 probes have been selected (1) for recognition of dysbiosis.
Result: In total 294 adult patients and healthy individuals were investigated for
microbiota profiling. Table 1 shows the distribution and frequency of dysbiosis in
the diagnose groups, subgroups and healthy controls. Comparing the bacteria
profiles of IBD, non-IBD and control groups, the abundance of Proteobacteria
was increased in IBD and non-IBD as compared to the controls (p5 0.02), while
the abundance of Bifidobacterium and Faecalibacterium prausnitzii was decreased
(p5 0.02 and 50.07, respectively). Concerning the CD and UC subgroups, a
significantly reduced abundance of Firmicutes, Streptococcus and Clostridia was
found in UC patients (p5 0.05 for all) as compared to CD. Looking at the
microbiota profiles of the Montreal classified subgroups of the UC patients, as
compared to the healthy controls in a PLS analysis, the healthy controls (n¼ 48)
and E1 (n¼ 22) patients clustered together, while the combined group of E2
(n¼ 17) and E3 (n¼ 23) patients made a separate cluster. Among 10 bacteria
groups contributing to the clustering we looked into three of the groups in
details; Bifidobacterium and Eubacterium were significantly reduced (p5 0.01),
and Escherichia/Proteobacteria were significantly increased (p5 0.01) in the E2/
E3 group as compared to E1/ healthy controls group. Frequency of high dysbio-
sis among the healthy individuals was higher than observed in other studies (1).
Conclusion: The present results support that alterations in microbial composition
is important in both IBD and symptomatic non-IBD patients. The result demon-
strated: 1) Differences in microbiota profiles between IBD and symptomatic non-
IBD patients and healthy individuals; 2) Equal levels of dysbiosis frequency in
CD and UC, however the bacteria profiles differed; 3) In subgroups of UC,
microbiota profiles were dependent upon the localization of the inflammation.
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Introduction: The intestinal tract is inhabited by a large and diverse community of
bacteria collectively referred as gut microbiota. Mucoid structures coating the
epithelium, largely devoid of bacteria, are central to maintaining intestinal-
microbiota homeostasis. Our recently published work has led to the hypothesis
that, in mice, bacterial encroachment of the epithelium, as a consequence of an
innate immune deficiency or ingestion of substances that alter host-microbiota
interactions, promotes low-grade inflammation that can drive metabolic disease
(1–2).
Aims & Methods: The aim of the current study was to study microbiota localiza-
tion in human subjects with metabolic syndrome. Subjects were enrolled at the
Veteran’s Administration Hospital (Atlanta, GA, USA). A review of the patient
medical record was conducted to determine control and diabetic patients, as
shown by their glycosylated hemoglobin and fasted serum glucose levels.
During the colonoscopy procedure, two mucosal biopsies were taken in the left
colon approximately 40 cm from the anus using a regular forceps. The biopsies
were immediately placed in Carnoy fixative and mucus immunostaining was
paired with fluorescent in situ hybridization in order to analyze bacteria localiza-
tion at the surface of the intestinal mucosa.
Result: We found that bacterial encroachment of the epithelium correlates with
central features of metabolic syndrome in humans. Specifically, confocal micro-
scopic analysis of biopsies from middle-aged persons revealed an inverse correla-
tion between bacterial-epithelial distance and body mass index, fasting blood
glucose, and hemoglobin A1C level. Ethnicity or antibiotic use did not signifi-
cantly correlate with microbiota-epithelial distance.
Conclusion: These observations support the notion that microbiota promotion of
low-grade inflammation may play a causative role in metabolic diseases in
human. Those findings are important advances that will significantly impact
our understanding of the epidemic of metabolic syndrome.
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Table 1. (OP239): Dysbiosis status
Dysbiosis Patients Age [med.] Female IBD CD UC IBDU Non-IBD Healthy control Unknown
No 72 28 (19–68) 43 22 [18%] 7 [16%] 11 [18%] 4 [31%] 21 [17%] 27 [56%] 2 [100%]
Low 96 33 (19–66) 49 33 [28%] 14 [31%] 15 [24%] 4 [31%] 50 [40%] 13 [27%] 0
High 126 32 (18–69) 80 65 [54%] 24 [53%] 36 [58%] 5 [38%] 53 [43%] 8 [17%] 0
Total 294 NA 172 120 45 62 13 124 48 2
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Introduction: Irritable bowel syndrome (IBS) is a common functional gastroin-
testinal disorder, but the relationship between diarrhea-predominant IBS (IBS-
D) and small intestinal bacterial overgrowth (SIBO) is unclear.
Aims & Methods: We aimed to investigate the clinical features and fecal micro-
biota profiles of IBS-D patients with SIBO by hydrogen and methane lactulose
breath test (LBT), and compare them with IBS-D patients without SIBO and
healthy controls. IBS-D patients who met Rome II criteria were divided into IBS-
D with SIBO (IBS-P) and without SIBO (IBS-N) by hydrogen and methane LBT,
while healthy controls with negative LBT (HC) were recruited. All subjects
underwent colonoscopy to exclude organic diseases, and barostat for visceral
hypersensitivity, intestinal permeability test [lactulose (L), mannitol (M) and L/
M in 6-hour urine], systematic inflammation severity (IL-10, IL-12 and IL-10/IL-
12 in supernate of peripheral blood mononuclear cells), fecal short chain fatty
acids(SCFA) evaluation, and fecal microbiota profiles analysis by Illumina
MiSeq high throughput sequencing.
Result: 22 HC and 84 IBS-D patients were enrolled. 35 of patients were with
SIBO (41.67%) and 49 patients were IBS-N. (1) The body mass index of IBS-P
was lower than IBS-N [(21.61 0.57) vs. (23.44 0.54) kg/m2, P5 0.05]. (2) The
IL-12 was higher in IBS-N than IBS-P and HC [2306.24(927.85, 3168.88) vs.
1263.40(482.55, 1965.99)pg/mL, 2306.24(927.85, 3168.88) vs. 1087.04(884.53,
1740.47) pg/mL, P5 0.05, respectively]. (3) The L and M in IBS-P were higher
than that in HC (P4 0.05), with similar L/M. While the L of IBS-N was higher
than that in HC [2.85(1.35, 6.40)vs.1.47(0.97, 2.62) mg/mL, P5 0.05], with higher
M and L/M(P4 0.05). (4) The initial defecation threshold of IBS-P was lower
than HC [16.00(12.00, 20.00) vs. 20.00(18.00, 28.00) mmHg, P5 0.05], while
both thresholds for initial sensory and defecation in IBS-N were lower than
HC [8.00(6.00, 12.00) vs. 12.00(8.00, 14.00) mmHg, 16.00(14.00, 18.00) vs.
20.00(18.00, 28.00) mmHg, P5 0.05]. (5) The fecal SCFA, include acetate, pro-
pionate, butyrate, isobutyrate and isovalerate in IBS-P were higher than that in
HC, while valerate was lower. In IBS-N, the fecal propionate was higher than in
HC [51.90(37.58, 70.82) vs. 35.26(30.48, 42.39) mmol/g, P5 0.05], while the other
SCFA were lower compared with HC. (6) There were significant differences in
Shnnon index and Simpson index between IBS-P and IBS-N [3.57(3.20, 3.70) vs.
3.22(2.75, 3.45), 0.051(0.068, 0.093) vs. 0.094(0.065, 0.140), P5 0.05,
respectively]. (8) The microbiota abundance of IBS-P was different from IBS-
N and HC (table 1). Besides, the fecal microbiota profile of IBS-P was more
similar to HC than IBS-N, according to Pcoa and Hcluster tree-bar.
Conclusion: (1) According to Rome II criteria, approximately 41.67% IBS-D
patients present SIBO, which can be better screened by hydrogen and methane
LBT. (2) SIBO can cause malnutrition and worsen nutritional status. (3)The
intestinal permeability, systemic inflammation and visceral hypersensitivity of
IBS-P are better than IBS-N. (4) Differences are observed in fecal SCFA between
IBS-P and IBS-N. (5) Both IBS-P and IBS-N are different from HC in micro-
biota abundance and community diversity, in which IBS-P is also different from
IBS-N. As a consequence, IBS-P is different from IBS-N in many physiological
parameters and fecal microbiota profile, so IBS-P may be just SIBO which
should be screened before diagnosis of IBS-D according to Rome II criteria.
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Introduction: Fecal microbiota transplantation (FMT) from healthy donors is
considered a highly effective treatment against recurrent Clostridium difficile
infection (rCDI). A single fecal infusion is usually sufficient to resolve symptoms
and eradicate rCDI, but a subgroup of these patients need multiple infusions to
cure the disease. In our previously published randomized controlled trial of FMT
versus vancomycin for rCDI,1 we observed that patients with pseudomembra-
nous colitis (PMC) needed repeat fecal infusions to be cured; further reports
confirmed our findings.2 To date, however, neither PMC nor other factors
have been clearly proven to be associated with the need for multiple FMT.
Table 1. (OP241): The taxa numbers of IBS-P, IBS-N and HC in genus levels [M (Q1, Q3)]
Phylum Genus
Taxa Numbers
IBS-P (n¼ 31) IBS-N (n¼ 39) HC (n¼ 20) P
Actinobacteria Collinsella 95(34, 146)b 21(2, 155) 47(19, 133) 50.05
Bacteroidetes Prevotella_9 726(9, 14813)a 17(1, 9272) 4(1, 5677) NS
Alistipes 434(131, 1064)b 155(13, 467)a 579(70, 849) 50.05
Barnesiella 35(0, 217)b 3(0, 45) 23(0, 142) NS
Butyricimonas 22(4, 80)b 5(0, 15) 9(0, 49) 50.05
Parabacteroides 242(152, 683)b 108(45, 245)a 225(145,538) 50.05
Paraprevotella 6(0, 312)a 1(0, 23) 0(0, 28) 50.05
Odoribacter 35(1, 88)b 5(0, 47) 33(1, 73) NS
Firmicutes Faecalibacterium 3387(1778, 6294)b 2174(449, 4175) 2860(1290, 4699) NS
Pseudobutyrivibrio 3524(1284, 5860)b 1245(269, 3360) 1911(1163, 3133) 50.05
Subdoligranulum 1101(621, 2182)b 544(77, 1666) 1245(316, 1962) NS
Lachnospiraceae_NK4A136 234(82, 672)b 85(22, 468)a 406(169, 1446) 50.05
Eubacterium_coprostanoligenes 197(46, 571)b 90(3, 197) 139(10, 810) NS
Ruminococcus_1 145(35, 523)b 7(1, 111)a 291(4, 436) 50.05
Eubacterium_hallii 313(132, 636)b 118(44, 367) 141(61, 620) NS
ChristensenellaceaeR-7 104(4, 209)b 5(1, 81)a 61(6, 357) 50.05
Enterococcus 7(3, 13) 11(4, 30)a 3(0, 16) NS
Family_XIII 18(2, 28)b 3(0, 16)a 15(4, 31) 50.05
Incertae_Sedis 156(54, 426)b 53(10, 267) 77(15, 515) 50.05
Lachnospiraceae_NC2004 25(7, 60)a 16(2, 37) 13(2, 28) NS
Lachnospiraceae 1020(595, 1971)b 598(289, 1131) 863(409, 2232) 50.05
Romboutsia 86(15, 201)b 156(46, 478) 127(40, 284) NS
Ruminococcaceae 968(337, 1803)b 321(85, 905)a 804(266, 1183) 50.05
Proteobacteria Escherichia_Shigella 49(31, 471)b 338(65, 1458)a 27(9, 216) 50.05
Klebsiella 43(4, 130)b 106(11, 494) 40(1, 172) NS
Raoultella 7(3, 11)a 11(4, 28)a 2(0, 9) 50.05
Sutterella 7(1, 136) 2(0, 57)a 50(4, 163) NS
Indication: IBS-P, IBS with SIBO; IBS-N, IBS without SIBO; HC, health controls; NS, no significance; a, compared with HC, p5 0.05; b, compared with IBS-N,
p5 0.05
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Aims & Methods: Therefore, our aim was to identify predictive factors for the
need for repeated fecal infusions in a series of patients treated with FMT for
rCDI. We identified prospectively and included in the analysis all patients treated
with FMT by colonoscopy for rCDI in our Centre. Demographic, clinical, endo-
scopic, and follow-up data were collected. Repeat fecal infusions were adminis-
tered if the patient recurred or failed to improve after first infusion. Gender, age,
inpatient status, number or CDI recurrences (43), poor/inadequate bowel pre-
paration (according to Ottawa Scale), endoscopic evidence of colonic oedema,
presence of PMC, use of external donors, infusion of frozen material, and infused
grams of faeces were analysed as potential impact factors. Univariate associa-
tions between possible predictors and the need for repeated fecal infusions were
investigated, using t-test for continuous variables and Fisher’s chi-square for
dychotomous variables. Multivariate associations between all candidate predic-
tors and the need for repeated fecal infusions were investigated using logistic
regression analysis. P-values of 50.05 were considered statistically significant.
Result: A total of 54 patients with rCDI (Males¼ 24; mean age¼ 71 years old,
range¼ 29–94) received FMT from healthy donors by colonoscopy. Fifteen
patients received multiple infusions, for a total of 81 procedures. Resolution of
rCDI occurred in 52 of 54 patients (96%); of them, none experienced further
recurrences after FMT. Univariate analysis showed that both poor/inadequate
bowel preparation (p¼ 0.024) and PMC (p5 0.001) were significantly associated
with the need of repeated fecal infusions; also colonic oedema was more common
among patients who needed repeated FMT, albeit nonsignificantly (p¼ 0.083).
On multivariate analysis, both the presence of PMC (OR¼ 2257; 95%
CI¼ 25.17–41000, p¼ 0.014) and poor/inadequate bowel preparation
(OR¼ 64.80; 95% CI¼ 3.43–41000, p¼ 0.021) were identified as significant
predictors of the need of repeated infusions. Additionally, the need for repeated
infusion was more common among patient who experienced a number or CDI
recurrences higher than 3 than among those who did not, although without
reaching statistical significance (OR¼ 26.80; 95% CI¼ 1.69–41000; p¼ 0.054).
The large confidence interval observed for most predictors could be explained
presumably by the relatively low number of cases in our sample. Finally, the
infusion of frozen material was significantly associated with lower need of multi-
ple FMT (OR¼ 0.01; 95% CI¼ 0.0–40.19, p¼ 0.033).
Conclusion: Among patients treated with FMT for rCDI, both PMC and poor/
inadequate bowel preparation appear to be significant predictors of the need for
repeated fecal infusions. Additionally, frozen FMT appears to be significantly
associated with a decreased need of multiple FMT. As the small sample size
represents a limitation of our analysis, our findings, although promising,
should be confirmed by further, larger studies.
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Introduction: Esophageal cancer is the fifth most common cause of cancer-related
death for men and the eighth for women worldwide. Although the effectiveness
of chemotherapy or chemoradiotherapy for the treatment of esophageal cancer
has been reported, esophagectomy remains the standard treatment to cure eso-
phageal cancer. Anastomotic stricture, a major complication after esophagect-
omy, substantially decreases patients’ quality of life, and requires treatment with
multiple sessions of endoscopic balloon dilation (EBD).
Aims & Methods: We conducted a multicenter randomized controlled trial to
evaluate the usefulness of administration of local steroid injections to prevent
the recurrence of anastomotic stricture. Patients were randomized to receive
either triamcinolone or placebo immediately after EBD. The primary endpoint
was the number of dilations required to resolve the stricture. Secondary end-
points were restricture-free survival and adverse events. Restricture-free survival
is defined as the number of days from randomization to performing EBD for any
reason or death from any cause. Patients with a dysphagia symptom score of two
or more after esophagectomy with anastomotic stricture confirmed by endoscopy
were included. Patients and investigators were blinded to the type of agent
injected. The syringe containing triamcinolone or placebo was prepared by nur-
sing staff unconnected to the trial. Patients underwent EBD with a standard
through-the-scope balloon dilator. The balloon was inflated with water, aiming
for a luminal diameter of maximum 15mm for 3min. After EBD, a second
endoscopist who was not involved in the follow-up evaluation of the patients
performed the injections into the mucosal laceration. A total of 50mg of triam-
cinolone acetonide (50mg/5mL; Bristol-Myers Squibb) or an identical volume of
normal saline solution as a placebo was injected per single site using a 25-gauge
needle. Neither the patient nor the treating physician knew which treatment was
given. Esophagogastroduodenoscopy (EGD) was performed on demand when-
ever patients reported dysphagia. In patients without dysphagia, EGD was per-
formed within 3 months after EBD to evaluate the stricture. EBD was performed
when the stricture was confirmed. Stricture was defined as dysphagia to some
solids (dysphagia score 2) and an inability to pass an endoscope of at least 9.2-
mm diameter.
Result: Over a 4-year period, 68 patients met the inclusion criteria and were
screened. Three patients declined to participate. Sixty-five consecutive patients
were therefore recruited to the study and randomized: 33 to receive steroid and 32
to receive placebo. The median number of EBD sessions required to resolve
stricture in the steroid group was 2 (range, 1–7), significantly smaller than the
median of 4 EBD sessions (range, 1–29) required by the control group
(p5 0.001). After 6 months of follow-up, 39% of patients who received steroid
injections remained recurrence-free compared with 19% of those injected with
saline (p5 0.01). There were no adverse events during follow-up.
Conclusion: Steroid injection showed promising results for the prevention of
stricture recurrence in patients who underwent EBD for anastomotic stricture.
Disclosure of Interest: N. Hanaoka: The Japan Foundation for Research and
Promotion of Endoscopy Grant
All other authors have declared no conflicts of interest.
OP244 THE "TUNNEL þ CLIP" METHOD FACILITATES
OESOPHAGEAL ESD PROCEDURES: A PROSPECTIVE,
CONSECUTIVE BI-CENTRIC STUDY
J. Jacques1, R. Legros1, J. Rivory2, D. Sautereau3, T. Ponchon4, M. Pioche2
1Hepato-gastro-enterology, CHU Limoges, Limoges/France
2Gastroenterology And Endoscopy Unit, Digestive Disease Department, H
Pavillon- Edouard Herriot Hospital, Lyon/France
3CHU Limoges Gastroente´rologie, Limoges/France
4Dept. Of Digestive Diseases, Herriot University Hospital Dept. de Hepato-gas-
troenterologie, Lyon/France
Contact E-mail Address: jeremiejacques@gmail.com
Introduction: ESD is the treatment of choice for superficial neoplasms of the
oesophagus due to its oncological efficiency and the morbidity associated with
the surgical alternative. ESD requires a high level of skill and is technically
challenging and time consuming. Therefore, it is often reserved to experts.
Combining the tunnel technique and the clip-line counter-traction may enable
optimisation of oesophageal ESDs.
Aims & Methods: From January 2014 to April 2016 we performed a prospective
bi-centre case series of consecutive "tunnelþ clip" oesophageal ESDs. Four
young operators (fewer than 50 ESDs and fewer than 5 oesophageal ESDs)
performed consecutively the ESD using the tunnelþ clip method: generation of
a classic tunnel beneath the lesion followed by constant counter-traction thanks
to a clip with line dropped at the oral side of the tunnel.
Results: Thirty-three lesions (14 SCC and 19 ADK/HGD complicating Barrett’s
oesophagus) were resected consecutively. En bloc, R0 and curative resection rates
were 100% (33/33), 87.8% (29/33) and 75.8% (25/33), respectively. No perfora-
tion occurred. The mean speed of ESD was 22.3 mm2/min for a mean lesion size
of 61,6mm. The clip provided considerable assistance in performing the proce-
dure. No pathological damage caused by the clipping was reported.
n¼ 33 Mean Min Max
Age (years) 63,9,8 36 85
Male 22 (84.6%)
Procedure duration (min) 131 25 350
Large diameter (mm) 61.6 30 105
Small diameter (mm) 44 20 78
Surface (mm2) 2418 471 6300
Speed (mm2/min) 22,3 7.0 79
Circumference (%) 60.0% 30.0% 100%
Monobloc resection 33 (100%)
R0 resection 29 (87.8%)
Curative resection 25 (75.8%)
Periprocedural bleeding 14 (42.0%)
Perforation 0 (0.0%)
Post-procedural bleeding 2 (6%)
Stenosis 5 (15.1%)
(continued)
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n¼ 33 Mean Min Max
Pathologic analysis
SCC 14 (42.4%)
ADK/DHG 19 (57.6%)
Residual disease (3 months) 0 (0.0%)
Discussion: First study of the strategy "tunnelþ clip". Our en bloc and R0 resec-
tion rates confirmed the usefulness of this technique, despite the relative inex-
perience of the operators. Our resection results were similar to those reported in
large series by international experts, including those in Japan and our absence of
perforation highlighted the safety of this strategy.
Conclusion: The tunnelþ clip method for oesophageal ESD is effective and safe,
in particular for physicians with little experience. This strategy standardizes the
ESD procedure for superficial oesophageal neoplasia and increases of the speed
of dissection. Thus, it will help to widespread oesophageal ESD performed in
Western countries.
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Introduction: BLI is a novel endoscopic imaging technique for enhancement of
subtle mucosal and vascular details. The potential of this novel technology for
in vivo diagnosis of colorectal polyps has yet to be established.
Aims & Methods: Primary study objective was to develop a simple classification
for in vivo differentiation of hyperplasic and adenomatous colorectal lesions by
using the novel BLI technology. Second study endpoint was to validate the
classification among experienced and non-experienced users. In the first phase,
the capacity of experienced endoscopists to predict the histology of colorectal
polyps was assessed. In the second phase, a simplified classification was devel-
oped allowing histologic prediction. Thirdly, the validity of the classification was
evaluated among inexperienced raters, including medical students and GI fel-
lows. At least, a pilot clinical evaluation was performed during real-time
colonoscopy.
Result: A simple classification system for differentiating hyperplasic and adeno-
matous colorectal lesions by using the novel introduced BLI technology was
developed and validated. Diagnosis was made in 80% to 88% of polyps with
high-confidence. Sensitivity and specificity ranged from 93% to 100% and 83%
to 92%, respectively. During real-time colonoscopy, diagnosis was made with
high-confidence in 88% of polyps with sensitivity of 96%, specificity of 92%, and
accuracy of 95%. Positive and negative predictive values were 96% and 92%,
respectively.
Conclusion: This is the first study evaluating the novel BLI technology for in vivo
prediction of colorectal polyps. The proposed classification allowed for adequate
in vivo diagnosis of hyperplastic and adenomatous lesions. Further prospective
multicenter trials should now confirm these preliminary results.
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Introduction: The PIVI initiatives propose that a ‘‘leave in place’’ approach is
acceptable for a diminutive (5 mm), rectosigmoid hyperplastic polyp when
endoscopist’s optical diagnosis provides over 90% negative predictive value
(NPV) for adenomas in high confidence predictions [1]; however, expertise is
required to achieve a high accuracy and some studies conducted in commu-
nity-based hospitals have been disappointing [2]. Recently, we have reported
the usefulness of computer-aided diagnosis (CAD) in supporting endoscopists’
decision making during colonoscopy [3,4]. The present study was aimed to vali-
date the efficacy of the latest CAD model for endocytoscopy (380-fold ultra-
magnifying endoscopy) in management of diminutive, rectosigmoid polyps.
Aims & Methods: The present study was aimed to validate the efficacy of the
latest CAD model for endocytoscopy (380-fold ultra magnifying endoscopy) in
management of diminutive, rectosigmoid polyps. The CAD for endocytoscopy
comprises image acquisition, nuclear segmentation, feature extraction, and clas-
sification into three pathological groups (non-neoplastic, adenoma, and invasive
cancer). The classification algorithm was programmed based on 296 features of
each image (e.g., area, circularity, diameter, and perimeter of nuclei, and over 250
variables calculated by texture analysis of a whole image). We used a support
vector machine to help classify these many features; 6051 endocytoscopic images
were used for machine learning in the process of construction of the model. In
order to validate this CAD model, the pilot study using a test set was undertaken
between August and November 2015. The test set comprised endocytoscopic
images of 65 diminutive, rectosigmoid polyps from the database of Showa
University Northern Yokohama Hospital. Each image was automatically allo-
cated to the CAD, and the predicted pathology was immediately output by the
CAD in 0.2 seconds. The main outcome measure was NPV of the CAD for
adenomatous histology for diminutive, rectosigmoid colon polyps when they
had been diagnosed with high confidence.
Result: Of the 65 diminutive rectosigmoid polyps (mean size, 3.6þ1.0mm), the
CAD diagnosed 55 (19 neoplastic and 36 non-neoplastic) with high confidence.
Details of the diagnostic performance by the CAD for these 55 polyps were
shown in the Table. The CAD correctly predicted neoplastic histology in 18 of
the 20 neoplastic polyps (positive predictive value of 90% [95% CI, 68–99]) and
non-neoplastic histology in 34 of the 35 non-neoplastic polyps (NPV of 97%
[95% CI, 85–100]). This performance of the CAD met the ‘‘leave in situ’’ criteria
proposed by the PIVI initiative.
Table: Details of the diagnostic performance by the CAD
neoplastic in
pathology
non-neoplastic
in pathology
Diagnosis of neoplastic by CAD 18 2
Diagnosis of non-neoplastic by CAD 1 34
Conclusion: The CAD applying endocytoscopy can be a powerful and quick
support tool in management of diminutive, rectosigmoid polyps.
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OP247 IBDOC – FIRST SMARTPHONE BASED CALPROTECTIN HOME
TEST – 18 MONTHS EXPERIENCE
C. Reinhard1, A. Ritz1, M. U¨berschlag1, A. Beyer2, H. Vogelsang2, J. Weber1
1BU¨HLMANN Laboratories AG, Scho¨nenbuch/Switzerland
2AKH Medical University, Vienna/Austria
Contact E-mail Address: cre@buhlmannlabs.ch
Introduction: Inflammatory Bowel Disease (IBD) is a chronic inflammation of
the gut presenting with phases of active inflammation, remission and relapses.
IBD treatment goals are mucosal healing and persistent remission. Calprotectin
measured in patients’ stool samples is a well-established biomarker to measure
the inflammatory activity in the gut. Periodical assessment of calprotectin levels
is important to measure effectiveness of the treatment as well as predicting
relapses. Until now this meant that patients send in their stool sample for labora-
tory analysis, leading to long delays between sample collection, final test result
and potential adaptations of therapies.
Aims &Methods:We have developed a smartphone-based calprotectin home test,
called IBDoc, that allows real-time information about the inflammatory activ-
ities in the gut for both, the patient and the health care provider. The IBDoc
consists of a stool collection and extraction device (CALEX Valve) and an
immunochromatographic calprotectin rapid test, which is measured using a
smartphone App (CalApp) controlling the phone’s camera. Once the test is
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measured the result is instantly sent to a webserver (IBDoc Portal) allowing the
treating physician immediate access to the test result. IBDoc has achieved CE/
IVD mark for self-testing in March 2015 and has since then been in routine use
by patients throughout Europe and overseas. We have gathered data concerning
technical performance of the device in the hands of both professional and lay
users as well as usability aspects for patients.
Result: In a direct method comparison with an existing point-of-care test
(Quantum Blue) and a laboratory based ELISA method (BU¨HLMANN
fCAL ELISA) IBDoc correlated very well with both methods with a mean
bias below 10%. In regard to repeatability and precisions the smartphones as
measuring devices alone showed a coefficient of variability of below 10%, while
the entire method including pre-analytical steps showed a coefficient of variabil-
ity between 16% and 24%. IBDoc displays results as Normal/green (below
100 mg/g mean bias at cut-off, –7.0 to 5.4%), Moderate/amber (100–300 mg/g)
and as High/red (above 300 mg/g, mean bias at cut-off, 1.1–6.5%). No false
positive or false negative results (Normal/green instead of High/red and vice
versa) were observed when lay-users performing the test were compared to pro-
fessional users. There was a 97% within-class agreement observed. Patients
judged the entire IBDoc system as extremely user friendly with a mean of 93
points (out of 100) on a standardized System Usability Scale (SUS) score1,2,3.
Conclusion: IBDoc is the first Calprotectin Home Test available for patients.
IBDoc is well accepted by patients and health care providers and correlates well
to existing calprotectin point-of-care and laboratory based methods and has
proven to be a supportive tool in daily clinical routine.
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Introduction: Telemedicine programmes are of interest for inflammatory bowel
diseases (IBD), but should include adequate monitoring of mucosal inflamma-
tion to prevent long-term complications. Different clinical activity questionnaires
are available, however, none are patient-reported, clear and easy to fill out and
validated against endoscopy. For this reason we previously developed the
Monitor IBD At Home questionnaire (MIAH) (1). The score does not include
laboratory tests or physical examination. The objective of this study was to
investigate whether a combination of the MIAH questionnaire and a calprotectin
home test yields higher diagnostic accuracy.
Aims & Methods: Between September 2015 and April 2016 all consecutive IBD
patients with a scheduled endoscopy in the Maastricht University Medical
Centreþ were eligible for inclusion. Patients with an ileostomy, colostomy, ileoa-
nal pouch anastomosis or ileorectal anastomosis were excluded. Patients were
invited to fill out the 5-item MIAH-UC questionnaire for UC, regarding blood
loss, number of stools, urgency, abdominal pain and general well-being, or the 6-
item MIAH-CD questionnaire for CD, including questions on blood loss, mucus,
number of stools, urgency, fatigue and general well-being. In addition, patients
were asked to collect a stool sample prior to bowel cleansing. Fecal calprotectin
was determined with a calprotectin home test. Mucosal inflammation was
assessed with the simple endoscopic activity score (SES-CD) for Crohn’s disease
(CD) and the Mayo endoscopic subscore (MES) for ulcerative colitis (UC).
Sensitivity, specificity, positive predictive value (PPV) and negative predicted
value (NPV) of the MIAH-UC and MIAH-CD in combination with the calpro-
tectin home test were calculated.
Result: Thirty-two CD patients (50.0% male, mean age 51.4 15.2 years, 43.8%
active disease) and 28 UC patients (50.0% male, mean age 57.3 10.4 years,
39.3% active disease) were included. The combination of the MIAH-CD and
the calprotectin home test showed a sensitivity of 100.0%, a specificity of 61.1%,
a NPV of 100.0% and a PPV of 67.0%. The combination of the MIAH-UC and
the calprotectin home test yielded a sensitivity of 91.7%, a specificity of 68.8%, a
NPV of 91.7% and a PPV of 68.8%.
Conclusion: The MIAH is the first patient-reported questionnaire developed to
predict endoscopic inflammation in IBD patients. A combination of this
questionnaire and a calprotectin home test shows a high sensitivity and thus
excellent diagnostic accuracy for use in telemedicine programmes to screen for
patients who need further assessment of disease activity with biochemical mar-
kers, imaging or endoscopy.
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Introduction: Upper and lower endoscopy with histology together with imaging
of the small bowel is the gold standard for the diagnosis of inflammatory bowel
disease (IBD) in children. Due to high costs and invasive nature of these techni-
ques, accurate selection of patients is mandatory.
Aims & Methods:We aimed to assess the accuracy of non-invasive tests including
fecal calprotectin (FC), blood inflammatory markers (BIM) and bowel ultra-
sound (US) alone or in combination as first level investigations in children
with suspected IBD. Consecutive patients referred to our Unit for a clinical
history compatible with IBD were enrolled during a 3-year period. All underwent
FC (Calprest, Eurospital), C-reactive protein [CRP], erythrocyte sedimentation
rate [ESR] and bowel US as first investigations. Endoscopy with biopsies was the
gold standard for diagnosis. At US pathological findings were: BWT4 3mm,
BW vascularity, loss of stratification, enlarged mesenteric nodes. Multiple logis-
tic analysis with stepwise method considering IBD diagnosis as dependent vari-
able was conducted. Sensitivity (SE), specificity (SP), positive and negative
predictive values (PPV and NPV) of laboratory and US parameters alone or in
combination were analyzed according to the final diagnosis.
Result: 100 patients (58 males, median age 12) were enrolled. The final diagnosis
was IBD in 69 (57 CD, 12 CU) other than IBD in 31. The mean values of CRP,
ESR, FC and BWT were higher in IBD vs non-IBD patients (p5 0.001).
Multiple logistic analysis showed that independent variables predictive of IBD
were: FC (OR 44.8; p5 0.01), BWT (OR 20.4, p5 0.001) and ESR (OR 9;
p5 0.05). The combination of 3 or 2 parameters was more frequent in IBD
patients (p5 0.01). Table 2 shows SE, SP, PPV, NPV of these parameters
alone or in combination.
Parameters SE % SP % PPV % NPV %
FC (ug/g) 94 89 94 89
ESR (mm/h) 75 89 93 65
BWT (mm) 43 mm 94 83 88 57
2 (at least 2 of 3) 96 84 97 92
2 (FCþBWT) 91 100 100 86
3 (FCþBWTþESR) 71 100 100 64
Conclusion: the combination of FC, BIM and bowel US may help to select
children needing further invasive procedures and allow to avoid or delay endo-
scopy in patients with negative initial diagnostic work-up.
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Introduction: Serologic nuclear and anti microbial antibodies have been recog-
nized as predictive markers of disease course and complications in ulcerative
colitis (UC) and Crohn’s disease (CD). The significance of serological markers
from onset of the disease, their ability to predict disease outcome and their
stability over time is not fully explored in IBD patients.
Aims & Methods: To study the prevalence of serological markers in treatment-
naı¨ve pediatric patients with newly diagnosed inflammatory bowel disease and
prospectively evaluate the antibody and titer-variations related to disease sub-
groups, treatments and disease course. We also wanted to compare the value of
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serological markers with the biochemical markers C-reactive protein (CRP),
elevated sedimentation rate (ESR) and fecal calprotectin. Patients aged5 18
years, (n¼ 58) diagnosed with IBD were included between 2005–2007 as a part
of a prospective population based study in South-Eastern Norway (IBSEN- II).
Fecal samples were analyzed for calprotectin (Bu¨hlmann, Basel, Switzerland) and
blood specimens were analyzed for antibodies (Prometheus labs, San Diego),
CRP and ESR at diagnosis and after 1–2 years of treatment. Treatment was
decided at the courtesy of the treating pediatrician. Tumor necrosis factor
(TNF) blocker treatment was regarded as aggressive treatment compared to
treatment with immunomodulators.
Result: Among the UC patients, 13 (72%) were perinuclear anti-neutrophil cyto-
plasmic antibody (pANCA) positive, versus 13 (35%) of the CD patients. None
of the UC patients harbored anti–Saccharomyces cerevisiae (ASCA) antibodies,
whereas 20 (54%) of CD patients were ASCA IgA or IgG positive (p5 0.0001),
18 (49%) were positive for ASCA IgA, 14 (38%) for ASCA IgG, and 12 (33%)
for both. There were no statistically significant differences between CD and UC
patients in the prevalence of antibodies against Pseudomonas fluorescens asso-
ciated sequence (I2) (41% vs. 33%), the outer membrane porin of Escherichia coli
(OmpC) (8% vs. 6%) or flagellin expressed by Clostridial phylum (CBir) (22%
vs. 0%, respectively). The 18 (49%) CD patients who received aggressive therapy
with TNF blockers had higher presence of antibodies against ASCA IgA
(p¼ 0.05) and ASCA IgG (p¼ 0.045) as well as higher titers of ASCA IgG
(p¼ 0.046) compared to the 19 (51%) CD patients who received conventional
treatment. If ASCA antibodies were present at baseline the probability of receiv-
ing infliximab treatment in CD patients was 70%, with OR 8.8 (2.0–37.7),
p¼ 0.004. The presence of pANCA antibodies was less frequent at diagnosis in
TNF blocker treated CD patients compared to conventionally treated CD
patients. The OR of receiving aggressive therapy being pANCA negative was
5.2 (1.11–24.13), p¼ 0.02. CD patients who were given infliximab had signifi-
cantly higher levels of fecal calprotectin, CRP and ESR at diagnosis compared to
conventionally treated CD patients with median values of fecal calprotectin (mg/
kg) 1506 vs. 501 (p¼ 0.01), CRP (mg/l) 28 vs. 7.5 (p¼ 0.02) and ESR (mm/h) of
32 vs. 18 (p¼ 0.01) respectively. Being pANCA negative and/ or ASCA IgA or
ASCA IgG positive was associated with the need for TNF blocker therapy, even
after adjustment for CRP, ESR and fecal calprotectin levels. After treatment
there was no difference in antibody prevalence for ASCA IgA, ASCA IgG, I2,
OmpC or CBir in the CD and UC patients, regardless of treatment modality.
Fewer UC patients, 9 (64%), tested positive for pANCA after treatment, com-
pared to at baseline, 13 (72%), p¼ 0.013. Only one of the 18 UC patients received
TNF blocker treatment.
Conclusion: ASCA and pANCA status was associated with the need for early
aggressive therapy with TNF blockers in our CD patients. We found that being
pANCA negative and/ or ASCA IgA or ASCA IgG positive were more predictive
of needing aggressive treatment than CRP, ESP or fecal calprotectin levels.
ASCA serology was stable, regardless of treatment modality, and might be a
prognostic tool at any time in the disease course.
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Introduction: Fecal Calprotectin (FC), a calcium binding protein in neutrophils,
indirectly reflects intestinal inflammation and is today widely used in the manage-
ment of inflammatory bowel disease (IBD) patients. FC values appears to vary
according to disease type, activity and location. FC seems more sensitive in
assessing disease activity in ulcerative colitis (UC) than in Crohn’s disease
(CD). Several factors may affect FC values. However, few studies have looked
at the intra- and inter-variability of FC in IBD patients.
Aims & Methods:We aimed to assess the robustness of using a single stool punch
for the measurement of FC and prospectively evaluated the intra- and inter-
variability of FC in a cohort of IBD and irritable bowel syndrome (IBS) patients.
72 IBD patients (49 CD and 23 UC) and a control group of 7 IBS patients were
enrolled. Disease location and disease activity were determined using endoscopic
and clinical activity scores (Crohn’s disease activity index and Harvey–Bradshaw
score in CD and Mayo score in UC), as well as C-reactive protein levels. Stool
samples were collected twice (within 1 to 5 days interval) in 62 patients and FC
was measured on both punches (100mg stool per punch) and homogenates (5–8 g
per stool) by fluorometric enzyme immunocapture assay (ELiA Calprotectin,
ThermoFischer). Intra-stool FC variability defined as the variability between 3
punches in the same stool sample and intra-individual FC variability defined as
the variability between 2 stool samples of the same patient a few days apart were
both examined. Intra-stool variability was assessed by measuring the coefficient
of variation (CV) between the 3 punches of a stool sample. Inter-variability of FC
was also measured.
Result: Inter-variability is reported in Figure according to disease type, location
and activity. The highest FC values were found in active UC patients while IBS
and quiescent ileal CD patients had the lowest (p5 0.05). Colonic location just
as active disease seemed to affect FC values, as it has already been described.
Nevertheless, these results were not significant probably due to small sample size.
Concerning intra-stool variability, the average CV between the punches was
32%, showing a wide intra-stool variability. The largest CV were observed for
low FC measurements (550mg/g). However, this resulted in clinical significance
for only 7 IBD patients (9,70%) or 3 IBD patients (4,20%) when using a FC cut-
off of respectively 50mg/g or 250 mg/g. A significant correlation was demon-
strated between FC measurements of 2 stool samples at 1–5 days intervals in
62 patients with correlation coefficient of 0.78 (p5 0.0001). Statistical analysis
(T-test) could not show difference between the 2 stool samples (p4 0,05).
Conclusion: These results suggest that there are variations in FC values within the
same stool but with little clinical significance in IBD patients. Thus, a single stool
punch appears to be reliable for FC measurement. This study confirms that
disease type, location and activity influence the inter-individual FC variability,
while intra-stool and intra-individual FC variability, regardless of disease activ-
ity, remains low.
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Introduction: Inflammatory bowel disease (IBD) is a chronic intestinal inflamma-
tory disorder presenting with phases of active inflammation, remission and
relapse. Fecal calprotectin (fcalpro) measurement has become established for
the monitoring of inflammation activity. Periodical assessment of fcalpro levels
has been demonstrated to be an important non-invasive indicator of treatment
efficacy and predictor of relapse. However, until now, fcalpro determination
required patients to send stool samples in for laboratory analysis, resulting in
a long delay between sample collection and final test results. We developed a
simple home-based calprotectin test system called QuantOnCal to allow patients
to regularly monitor their own inflammatory status by testing fcalpro levels in the
comfort of their own home.
Aims & Methods: QuantOnCal consists of a stool extraction device (IDK
Extract) and an immunochromatographic rapid test performed by an iPhone
App via the phone camera. Results are automatically sent to a webserver
(QuantOnCal website), where they are displayed for monitoring by the consult-
ing physician or IBD nurse. The objective of this study was to validate the
QuantOnCal test system by comparing its quantitative performance with a stan-
dard ELISA-based method. Stool samples from 157 IBD and non-IBD patients
containing various levels of calprotectin (95 IBD: CU/CD/active/remission, 42/
43/48/47; 33 IBS: 23 Chm: 6 Div) were either loaded onto immunochromato-
graphic test cassettes (TCs) or analysed with a commercial ELISA test
(Immundiagnostik, Bensheim, Germany). The QuantOnCal app was installed
on 4 different iPhone models (iPhones 4, 4s, 5c, 6). Agreement between
QuantOnCal testing versus ELISA was assessed by Analyse-it for Microsoft
Excel.
Result: The QuantOnCal system produces a quantitative test result between 25–
2000mg/g fcalpro/g of stool, covering the clinically relevant range of this bio-
marker. The total agreement (TA) was 94.6% with 0% false positive and 0%
false negative rates. The TA for fcalpro between the 4 different iPhone models
was 91.3%.
Conclusion: QuantOnCal is a new, complete and validated test system which
allows the IBD patient to monitor and follow his inflammatory status by mea-
suring the IBD biomarker, faecal calprotectin, using his/her own smartphone.
The performance of the QuantOnCal test system was shown to be comparable to
the professional, ELISA-based method.
Abbreviations IBD, inflammatory bowel disease; Chm, Carbohydrate malab-
sorption; CU, colitis ulcerosa; CD, Crohn´s disease; Div, Diverticulitis; IBS, irri-
table bowel syndrome; TA, total agreement
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Introduction: Abdominal distension is the most bothersome complaint in patients
with functional gut disorders and has no effective treatment. In a previous study
we showed that abdominal distension is produced by diaphragmatic contraction
and descent with protrusion of the anterior abdominal wall, and we developed an
original biofeedback technique based on EMG-guided control of abdomino-
thoracic muscular activity.
Aims & Methods: Our aim was to demonstrate the superiority of biofeedback
versus placebo for the treatment of abdominal distension. We performed a ran-
domized, placebo controlled in a referral center (Clinical Trials Gov Registration
Number 01205100). Forty-eight consecutive patients complaining of episodes of
visible abdominal distension who fulfilled the Rome III criteria for functional
intestinal disorders (47 women, 1 men; 21–74 yr age range) were recruited and
randomly allocated to biofeedback and placebo treatment. Abdomino-thoracic
muscle activity was recorded by EMG during basal conditions (no distension)
and during an episode of distension to prove the abdomino-phrenic origin of
their distension. Each patient underwent three treatment sessions over a 10-day
period. In each session abdomino-thoracic muscle activity was recorded by elec-
tromyography. The patients in the biofeedback group were shown the signal and
instructed to control muscle activity; the patients in the control group were given
and oral placebo. The main outcome was subjective sensation of abdominal
distension scored by a 0–6 graphic rating scale daily for 10 days before and
after treatment
Results: Patients on biofeedback, but not on placebo, effectively learned to
reduce intercostal activity (by 45 3% vs 5 2% on placebo; p5 0.001) and
to increase anterior wall muscle activity (by 101 10% vs 4 2%).
Biofeedback treatment resulted in a 56% 1% reduction of abdominal disten-
sion (from 4.6 0.2 to 2.0 0.2 score after intervention) vs 13 8% on placebo;
p5 0.001 (from 4.7 0.1 to 4.1 0.4 score after intervention).
Conclusion: Abdominal distension can be effectively corrected by biofeedback-
guided control of abdomino-thoracic muscular activity.
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Introduction: Irritable bowel syndrome (IBS) is the most common gastrointestinal
(GI) disorder worldwide. In the lack of cures, different management strategies
have been purposed, including a diet low in FODMAPs (fermentable oligosac-
charides, disaccharides, monosaccharides and polyols). Although being increas-
ingly accepted and recommended as one of the most effective therapies, there is
insufficient high-quality evidence of its efficacy as well as uncertainties regarding
long-term consequences on gut microbiota composition and function.
Aims & Methods: In the present study we aimed to investigate the effect of a low
versus high FODMAP diet on symptoms, gut microbiota, short-chain fatty acids
(SCFAs) and pro-inflammatory cytokine profiles in a randomized, double-
blinded, crossover trial of Norwegian patients with IBS. Twenty patients with
IBS (15 female/5 male, mean age 34.6 y) were instructed to follow a low
FODMAP diet (LFD) throughout a study period of 9 weeks. After 3 weeks
they were randomized and double-blindly assigned to receive a daily supplement
of either high (16 g fructo-oligosaccharides (FOS)) or low (16 g maltodextrin
(¼placebo)) FODMAP for the next 10 days, followed by a 3-week washout
before crossing-over to the alternative supplementation for 10 new days. IBS
Severity Scoring System (IBS-SSS) was used to evaluate symptoms. Blood sam-
ples were collected to analyse serum cytokines (IL-6, IL-8, TNF-), and faeces
samples for gut microbiota (s16r RNA) and SCFAs.
Result: IBS symptoms consistently and significantly improved after 3 weeks of
LFD, with a mean overall reduction of 163.8 points (p5 0.0001). On average, 4
of 5 symptoms were significantly worsened in response to FOS compared with
placebo, with an overall difference of 65.1 points (p¼ 0.014). Serum levels of IL-6
and IL-8, but not TNF-, significantly decreased on the LFD (p¼ 0.001 and
p5 0.0001, respectively). The same did apply to luminal Faecalibacterium praus-
nitzii and Bifidobacterium (p¼ 0.0084 and p¼ 0.0094, respectively). Levels of
total SCFAs and butyric acid were also significantly decreased on the LFD
(p¼ 0.04 and p¼ 0.01, respectively). Ten days of FOS supplementation normal-
ized the level of bacteria, but did not change the levels of cytokines nor SCFAs.
Conclusion: FODMAP content was related to IBS symptoms, cytokine levels and
microbiota composition and function. Our results provide evidence to support
the efficacy of a LFD in reducing functional GI symptoms. Further studies are
warranted to explore the link between FODMAPs, gut microbiota and immune
activation.
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Introduction: The reduction of poorly fermentable carbohydrates collectively
termed FODMAPs (fermentable oligo-, di-, monosaccharides and polyols) is
increasingly being advocated in patients with functional gastrointestinal disor-
ders (FGID). At present, selection criteria or response predictors for dietary
intervention are poorly defined.
Aims & Methods: In this study the predictive associations between clinical char-
acteristics, breath test results and the global outcome measure advocated in
FGID were examined. Clinical characteristics and breath test results from 580
successive patients presenting to our clinic with FGID (Rome III) and fructose or
lactose intolerance, and completing a standardized FODMAP dietary program
were analyzed. Intolerance was defined by a positive symptom index and malab-
sorption by increases in H2 (420 ppm) or CH4 (410 ppm) values during breath
testing. The response to the dietary program was assessed using a standard
adequate global symptom relief question. Predictive associations were assessed
by uni- and multivariate analyses.
Result: Adequate symptom relief was achieved in 81% of the 580 FGID patients,
with similar response rates in patients with fructose (82%) or lactose (79%)
intolerances and across all FGID subtypes (IBS-diarrhea: 80%, IBS-constipa-
tion: 71%, IBS-mixed: 89%, FD: 79%). A positive history of chronic diarrhea or
pruritus predicted adequate symptom relief with the FODMAP diet (univariate
analysis OR (95% CI): 2.96 (1.83–4.79) and 2.50 (1.27–4.92), respectively, both
p5 0.01), while nausea predicted inadequate relief (0.55 (0.34–0.89), p¼ 0.01).
Multivariate analysis confirmed the associations between adequate symptom
relief and a history of diarrhea (positive predictor: 2.74 (1.52–4.94, p¼ 0.001)
and nausea (negative predictor: 0.45 (0.25–0.81), p¼ 0.07). There were no sig-
nificant associations between the H2 or CH4 breath concentrations and the
attainment of adequate relief. A positive dietary response in patients with fruc-
tose intolerance was associated with the development of diarrhea during breath
testing (univariate analysis 1.7 (1.03–2.81, p¼ 0.04). No other significant associa-
tions between symptoms experienced during fructose or lactose breath testing
and dietary outcome were demonstrated.
Conclusion: Adequate global symptom relief with a FODMAP diet is achieved in
a large majority of all FGID patients with fructose or lactose intolerance, and is
predicted by a few clinical and breath-test associated symptoms and not by the
presence of malabsorption. Consequently, a reduction of FODMAPs appears to
modulate multiple physiological processes across the spectrum of FGIDs.
Furthermore, adequate relief likely reflects a complex constellation of psycholo-
gical and physical factors, rather than a reduction in individual symptoms,
explaining the few significant associations with clinical or provoked symptoms.
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Introduction: Tricyclic antidepressants tend to be constipating and, therefore,
may be of most benefit in diarrhea-predominant IBS (IBS-D). The aim of this
study was to compare the effects of low doses of doxepin and nortriptyline on
IBS-D.
Aims & Methods: Seventy-five patients with IBS according to Rome III criteria
were treated for two months. All possible organic diseases responsible for bowel
symptoms were excluded. The patients were randomly assigned to one of three
groups treated with doxepin(10mg), nortriptyline(10mg) or placebo. Subjects
were assessed clinically weekly. The symptoms and adverse effects of the drugs
were recorded in the questionnaire. The primary outcome was the responder rate
for treatment at the end of treatment.
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Result: Abdominal pain and bloating were the most common symptoms before
initiation of treatment, occurring in 62 (82.7%) patients. The frequency of the
symptoms was decreased significantly after treatment in doxepin and nortripty-
line groups compared with pre-treatment. The responder rate was 80%, 52%,
and 36% for doxepin, nortriptyline, and placebo groups, respectively(p¼ 0.007).
The responder rate for doxepin group was superior to nortriptyline and placebo
groups(p¼ 0.037 and p¼ 0.002, respectively) but there was no significant differ-
ence in responder rates of nortriptyline and placebo groups(p¼ 0.254). There
were no significant differences in improvement rates in individual symptoms
between doxepin and nortriptyline groups(all p4 0.05).
Conclusion: Treatment of diarrhea-predominant IBS with low dose of doxepin or
nortriptyline could be effective. Improvement rates of the symptoms are similar
in doxepin and nortriptyline groups but doxepin has a better response rate than
nortriptyline.
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Introduction: Irritable bowel syndrome (IBS) is commonly diagnosed gastroin-
testinal disease worldwide. The pathogenesis of IBS cannot be explained by a
simple mechanism, but alterations in the intestinal microbiome are increasingly a
focus of interest. Traditional treatments of IBS, including psychological thera-
pies, dietary change, probiotics, have had only limited success, underscoring the
need for additional therapeutic options. We hypothesized that fecal microbiota
transplantation (FMT) may be beneficial in managing IBS by restoring the
intestinal homeostasis. The purpose of this study is to prospectively examine
the symptomatic response of FMT in patient with moderate IBS.
Aims & Methods: Patients with IBS who were not responsive to traditional
treatment were enrolled prospectively in this study. Diagnosis of IBS was
based on Rome III Criteria and nonresponsive IBS was defined as failure to
achieve symptomatic relief with traditional therapeutic modalities. The healthy
donors from patient’s family were screened and tested for infectious diseases
before FMT. Patients were questioned with IBS severity score before and 1
month and 3 month after FMT. IBS severity score consist of 5 questions.
Total score is 500. As the score is lower, their general condition is considered
to be better. Study outcomes included the length of symptom-free intervals,
abdominal pain, bloating, flatus, dyspepsia, frequency of bowel movements,
and overall well-being before and after FMT.
Result: A total of 10 patients (mean age of 55 years; 60% male) were identified
and completed the study questionnaire. Mean time from initial diagnosis of IBS
until FMT was 3.6 years. In our study, 80% of the patients experienced resolu-
tion or improvement of symptoms after FMT. There were no long-term side
effects, and none of the participants developed any new diseases. Clinically sig-
nificant improvements in IBS severity scores were observed one month after
FMT (132 100) comparing to baseline (252 121.7) (p¼ 0.027). However,
their symptoms tended to return to their pre-FMT state at 3 month after FMT
(231 110).
Conclusion: This study showed that FMT may be helpful for one month.
However, their effect seemed to decrease over time. FMT may be used as an
adjuvant therapy with standard medication for managing IBS. Further large
prospective population study is needed.
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Introduction: Eluxadoline (ELX), a mixed m-opioid receptor (OR) and -OR
agonist and -OR antagonist that is locally active in the gastrointestinal tract,
is approved for the treatment of irritable bowel syndrome with diarrhoea (IBS-D)
in adults. In two Phase 3 studies, ELX significantly improved symptoms of IBS-
D based on a composite endpoint, defined by simultaneous improvement in stool
consistency and reduction in abdominal pain scores, and the historical ‘adequate
relief’ endpoint. Given the potential long-term use of eluxadoline treatment, it is
important to understand the time course of clinical benefits as experienced by
patients and clinicians, including time to onset and the sustainability over time,
to establish reasonable expectations about the effectiveness of treatment.
Aims & Methods: The efficacy of ELX over longer treatment intervals was eval-
uated in patients who were responders or non-responders for the composite end-
point or adequate relief endpoint over the first month of treatment in the Phase 3
studies. Two double-blind, placebo-controlled, Phase 3 clinical trials (IBS-3001
and IBS-3002) randomised patients meeting Rome III criteria for IBS-D to twice-
daily treatment with ELX (75 or 100mg) or placebo. Patients rated IBS symp-
toms daily, including worst abdominal pain (WAP; 0–10 scale) and stool con-
sistency (Bristol Stool Scale [BSS]). The primary efficacy endpoint was composite
response, based on simultaneous daily improvement of 30% in WAP score vs.
baseline and BSS score 55, with 50% of days demonstrating a response,
evaluated over 12 and 26 weeks. Composite endpoint response rates over
Weeks 1–12 and 1–26 were calculated for patients who were responders and
non-responders over Month 1 (Weeks 1–4) using a pooled analysis of the
intent-to-treat (ITT) population. Comparable analyses for adequate relief were
conducted, for which a responder was defined as reporting a ‘‘yes’’ response to
the question ‘‘Over the past week have you had adequate relief of your IBS
symptoms?’’ for 50% of weeks in the treatment interval.
Result: The pooled ITT analysis set included 2423 patients with IBS-D. Over
Month 1, 12.5% (101/809), 22.8% (184/808), and 24.6% (198/806) of patients
were composite responders in the placebo, ELX 75mg, and ELX 100mg groups,
respectively. Over Month 1, 49.3% (399/809), 59.9% (484/808), and 61.8% (498/
806) of patients were adequate relief responders in the placebo, ELX 75mg, and
ELX 100mg groups, respectively. For both ELX doses, the majority of patients
who were composite or adequate relief responders over Month 1 showed sus-
tained response over Weeks 1–12 and 1–26 (Table). Of the patients who were not
composite or adequate relief responders in Month 1, approximately 13–18%
subsequently achieved response over 6 months of treatment.
Conclusion: Approximately two-thirds of patients who achieved either the com-
posite or adequate relief endpoint over the first month of ELX treatment demon-
strated sustained response over 6 months.
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Table (OP258): Composite response rates over longer treatment intervals in ELX-treated patients who were composite or adequate relief responders over Month 1
Placebo (n¼ 809) ELX 75mg BID (n¼ 808) ELX 100mg BID (n¼ 806)
Patients, n (%) Responder Non-responder Responder Non-responder Responder Non-responder
Composite endpoint: Weeks 1–4 101 (12.5) 708 (87.5) 184 (22.8) 624 (77.2) 198 (24.6) 608 (75.4)
Composite endpoint: Weeks 1–12a 78 (77.2) 23 (22.8) 150 (81.5) 34 (18.5) 154 (77.8) 44 (22.2)
Composite endpoint: Weeks 1–26a 67 (66.3) 34 (33.7) 136 (73.9) 48 (26.1) 140 (70.7) 58 (29.3)
Adequate relief: Weeks 1–4 399 (49.3) 410 (50.7) 484 (59.9) 324 (40.1) 498 (61.8) 308 (38.2)
Adequate relief: Weeks 1–12b 329 (82.5) 70 (17.5) 405 (83.7) 79 (16.3) 419 (84.1) 79 (15.9)
Adequate relief: Weeks 1–26b 278 (69.7) 121 (30.3) 341 (70.5) 143 (29.5) 364 (73.1) 134 (26.9)
BID, twice daily; ELX, eluxadoline
aPercentage calculated based on number of patients who were composite responders over Weeks 1–4
bPercentage calculated based on number of patients who were adequate relief responders over Weeks 1–4
A102 United European Gastroenterology Journal 4(5S)
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
TUESDAY, OCTOBER 18, 2016 14:00–15:30
HOT TOPICS IN PANCREATOLOGY – ROOM N2_____________________
OP259 HUMAN PLURIPOTENT STEM CELL-DERIVED EXOCRINE/
DUCTAL ORGANOIDS GENERATE HUMAN PANCREAS UPON
ORTHOTOPIC TRANSPLANTATION AND ALLOW DISEASE
MODELLING
M. Hohwieler1, A. Illing1, M. Mu¨ller1, Q. Lin2, A. Lechel1, P.C. Hermann1,
J. Rosendahl3, T. Seufferlein1, M. Wagner1, A. Kleger1
1Department Of Internal Medicine 1Ulm University Hospital, Ulm/Germany
2Department Of Cell Biology, Institute for Biomedical Engineering, Aachen/
Germany
3Halle University Hospital, Halle/Germany
Contact E-mail Address: alexander.kleger@uni-ulm.de
Introduction: Exocrine/ductal pancreatic differentiation from human pluripotent
stem cells is a poorly understood process albeit various diseases arise from this
compartment.
Aims & Methods: We designed a straightforward approach to direct human
pluripotent stem cells (PSC) toward pancreatic organoids resembling exocrine
and ductal progeny.
Result: Extensive phenotyping of the organoids not only shows the appropriate
marker profile but also ultra-structural and functional hallmarks of human pan-
creas in the dish. Upon orthotopic transplantation into immunodeficient mice,
these organoids form normal pancreatic ducts and acinar tissue resembling fetal
human pancreas without any evidence of tumour formation or transformation.
Finally, we implemented this unique phenotyping tool as a model for pancreatic
facets of cystic fibrosis (CF) but also other inherited pancreatic disorders. We
provide for the first time evidence that pancreatic commitment occurs generally
unhindered in CF. Importantly, CFTR-activation in mutated pancreatic orga-
noids mirrors the CF-phenotype in a series of functional assays. We also con-
ducted a scalable proof-of concept screen in CF-pancreatic organoids using a set
of CFTR correctors and activators. Finally, we did orthotopic transplantation of
CF-organoids to generate diseased human pancreata in mice and established a
mRNA-mediated gene repair approach in CF-organoids. Similar assays were
applied to another inherited pancreatic disorder.
Conclusion: Thus, our platform provides novel opportunities to model pancreatic
disease and development but also to screen for disease rescuing agents.
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Introduction: The pronounced tumour stroma in pancreatic cancer has recently
been appreciated as physical barrier impeding delivery of therapeutic agents.
Herein, we aim to investigate the delivery of gemcitabine metabolites in primary
pancreas tumours and matched liver metastases and dissect stromal and neoplas-
tic compartments.
Aims & Methods: The cellular and acellular tumour stroma was assessed in
human and mouse primary tumours and matched liver metastases.
Gemcitabine metabolites were analysed in LSL-KrasG12D/þ;LSL-Trp53R172H/þ;
Pdx-1-Cre (KPC) tumours and matched liver metastases, primary tumour cell
lines, cancer associated fibroblasts (CAFs), and pancreatic stellate cells (PSCs) by
liquid chromatography- mass spectrometry/mass spectrometry (LC-MS/MS).
Expression analysis of gemcitabine metabolism pathways was performed
in vitro and in vivo. Viability of CAFs was assessed in vivo following a preclinical
trial in the KPC model.
Result: Fibroblast density and collagen deposition were significantly reduced in
human and murine liver metastases as compared to matched primary tumours.
Gemcitabine (dFdC) and its activate metabolite dFdCTP were significantly
higher in stroma rich tumours compared to stroma poor liver metastases and
normal liver. Mean vessel density did not correlate with gemcitabine delivery at
pharmacodynamically relevant endpoints. In cell culture, significantly increased
concentrations of activated dFdCTP and greatly reduced levels of the inactive
gemcitabine metabolite dFdU were detected in PSCs and CAFs. Importantly,
key metabolite enzymes for gemcitabine inactivation such as deoxycytidylate
deaminase (Dctd), cytidine deaminase (Cda) and hydrolytic cytosolic 5’-nucleo-
tidases (Nt5c1A, Nt5c3) were differentially expressed in PSCs and CAFs.
Moreover, treatment of KPC mice revealed intrinsic resistance of CAFs to
gemcitabine.
Conclusion: Our findings suggest that CAFs sequester gemcitabine and thus may
contribute to the clinical failure of this drug in desmoplastic pancreatic cancer.
Therefore, metabolic engineering of CAFs may constitute a promising new
avenue to enhance the cytotoxic effects of gemcitabine in patients.
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the most common
cancer type of the pancreas. The three PDAC precursor lesions are: (i) pancreatic
intraepithelial neoplasia (PanIN), (ii) mucinous cystic neoplasm (MCN), and (iii)
IPMN. In contrast, serous cystadenomas are strictly benign cystic neoplastic
lesions and rarely require surgery.
Aims & Methods: Frequently, differential diagnosis of neoplastic cysts remains
cumbersome. Thus, non-invasive diagnostic stratification would be welcome.
Such a test should allow both discrimination of (i) IPMN from strictly benign
pancreatic cysts but also (ii) low- from high-grade IPMN.
Result: Little is known about the molecular alterations of IPMN, but GNAS
mutations have been described to promote IPMN formation. A tumor-derived
fraction of cell-free DNA (cfDNA) circulating in the bloodstream represents the
mutational makeup of tumors and could be a tool for non-invasive monitoring.
We demonstrate that cfDNA levels discriminate controls from a cohort of
Fukuoka-negative branch-duct IPMN but also from pancreatic cancer.
Furthermore, GNAS mutations were detected in IPMN patients but were
absent in serous cystadenoma (SCA) and in controls. Moreover, we observed
relevant concordance between tissue and liquid biopsies-based GNAS mutations
in an independent cohort of resected IPMN patients.
Conclusion: These findings establish cfDNA and targeted genotyping as a diag-
nostic tool for IPMN, which may aid differential diagnosis and risk stratification
of cystic pancreatic lesions.
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Introduction: Chronic intestinal pseudo-obstruction (CIPO) is a severe gut dys-
motility mimicking an intestinal sub-occlusion without demonstrable mechanical
causes. Several genes have been identified in familial cases, suggesting a genetic
heterogeneity. We identified a novel mutation in the RAD21 gene in a recessive
form of familial CIPO1. RAD21 is a transcription factor essential for a number
of functions including sister chromatid division during cell replication.
Aims & Methods: This study aimed to identify other mutated genes in a selected
subset of CIPO, i.e. those cases associated with peripheral small fiber neuropathy
(SFN), a condition affecting peripheral neurons including those of the autonomic
system. Whole exome sequencing (WES) was performed on genomic DNA of
n¼ 6 patients (3 trios and 3 sporadic cases) with clinical, radiological and mano-
metric well-defined CIPO. A neurological work-up established SFN in each of
them. Libraries were enriched with the Nimblegen SeqCap EZ v3.0 and
sequenced via paired-end 50 bp reads on HiSeq2500 sequencer. Variants were
annotated with the SeattleSeq137 Annotation Server. Additional 77 patients were
collected for replication study. Target resequencing on selected genes was per-
formed using the TruSeq amplicon panel designed with Design Studio software.
Data analysis and variant calling was performed with the TruSeq Amplicon
application in BaseSpace.
Result: WES analysis was performed considering pathogenic variants present as
autosomal recessive (compound heterozygotes), X-linked or de-novo in the
affected probands, since all the parents were healthy. We identified novel/rare
missense mutations in FAT1 and in CROCC genes, inherited in an autosomal
recessive way (compound heterozygous) in two trios, and a de-novo variant in
B3GAT2 in the affected individual of the other trio analyzed, in combination
with two rare/novel variants in Lipoprotein Related Receptor 2 (LRP2), that
binds APOB which we have previously related to CIPO1. Analysis of these
genes in 77 additional CIPO patients is currently ongoing. All the identified
pathogenic variants were absent in our in-house database of 1,000 Italian
chromosomes.
Conclusion: We identified three novel gene defects in three different CIPO
patients with SFN. FAT1 is an unconventional cadherin, B3GAT2 is a glucur-
onyl transferase implicated in neuronal cellular migration and adhesion, while
CROCC encodes for rootletin, a protein crucial for centrosome cohesion and
separation during the cell cycle. Similarly to RAD21, also rootletin is related to
chromosome structural maintenance suggesting that recessive defects in these
genes may severely impair autonomic, including enteric, neurons. WES imple-
mentation can contribute to decipher complex genetic mechanisms underlying
neurogenic CIPO.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Bonora et al. (2015) Gastroenterology. 148:771–782.
OP263 PROTEASE SIGNALING IN HUMAN SENSORY NEURONS
C. Desormeaux1, T. Bautzova2, C. Rolland3, N. Vergnolle3, N. Cenac3
1Haute Garonne, Digestive Health Research Institute, Toulouse/France
2Digestive Health Research Institute, Toulouse/France
3Haute Garonne, Digestive Health Research Institute, Toulouse/France
Contact E-mail Address: cleo.desormeaux@inserm.fr
Introduction: IBS is a functional bowel disorder characterized by abdominal pain,
associated with constipation and/or diarrhea. Among the mediators studied in
IBS, increased colonic proteolytic activity appears as a common feature in all IBS
sub-groups. Through Protease-Activated Receptors (PARs) activation, proteases
can activate primary afferents and act on visceral pain pathways in rodents, but
the relevance of PAR activation in human sensory neurons still has to be deter-
mined. Thus, the objective of our study was to decipher the PAR pharmacology
in human sensory neurons.
Aims & Methods: Cryo-protected or fresh human thoracic dorsal root ganglia
(DRG) were obtained from the national disease resource interchange (NDRI).
Expression of PAR1, PAR2 and PAR4 was studied on slices of DRG (DRG T12,
n¼ 3) by co-staining immunochemistry with a pan-neuronal marker (pgp9.5) and
PAR antibodies. Calcium signaling responses to PAR agonist peptide (PAR-AP):
PAR1-AP (TFLLR; 1, 10 and 100 mM), PAR2-AP (SLIGRL; 100 mM) and
PAR4-AP (AYPGKF; 100 mM), their irrelevant peptides (PAR-IP; 100 mM) or
proteases: trypsin (1 and 10 U) and thrombin (1 and 10 U) were studied in
cultured human DRG neurons, which were fixed thereafter, to study PAR
expression.
Result: In fixed human DRG, PAR1, PAR2 and PAR4 were expressed in 20, 40
and 40% of human sensory neurons respectively. PAR expression was not mod-
ified after culture. PAR1-AP increased intracellular calcium concentration in a
dose-dependent manner. This increase was inhibited by PAR1 antagonist
(SCH79797, 10 mM). In contrast, PAR2-AP, PAR4-AP and PAR-IP did not
cause calcium mobilization. Thrombin (PAR1 and PAR4 agonist) but not trypsin
(PAR2 and PAR4 agonist) increased calcium flux in human sensory neurons.
PAR1-AP-induced calcium mobilization was significantly reduced by pre-incuba-
tion with PAR4-AP, but not with PAR2-AP or any of the PAR-IP.
Conclusion: Our study demonstrates that PAR1, PAR2 and PAR4 are expressed
in human sensory neurons. In contrast to PAR2 and PAR4, PAR1 activation
induced calcium increase in human sensory neurons. PAR4 activation reduced
PAR1 induced calcium mobilization. Thus, in Human PAR1 and PAR4 seem to
play an important role in neuronal activation and may be relevant in IBS
research.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Vascular catastrophes are an underlying condition for massive
intestinal resection and failure associated with short bowel syndrome (SBS–IF).
Aims & Methods: This post hoc analysis of data reported in patient e-case forms
compared baseline characteristics of patients with SBS–IF due to vascular cata-
strophes (SBS–Vasc) vs patients with nonvascular causes of SBS–IF (SBS–non-
Vasc), including the clinical response to teduglutide (TED). STEPS
(NCT00798967; EudraCT2008-006193-15) was a 24-week, placebo (PBO)–con-
trolled study of TED 0.05mg/kg/day in patients with SBS–IF. Response was
defined as 20% reduction from baseline in weekly parenteral support (PS)
volume at Week 20 that was maintained at Week 24. Vascular catastrophes
were intestinal ischaemia or mesenteric vessel thrombi or emboli. Descriptive
summary statistics are presented with standard deviations (SD) or 95% confi-
dence intervals (CI); this post hoc analysis was not powered for statistical
significance.
Results: The patient characteristics for the SBS–Vasc (n¼ 32) and SBS–non-Vasc
(n¼ 53) groups are detailed in the Table. The reason for the majority of the
intestinal resections was Crohn’s disease (SBS–non-Vasc) or mesenteric vessel
thrombi or emboli (SBS–Vasc), Table. At baseline, more SBS–Vasc patients
were older (55 vs 48 years) and male (53% vs 41%) than SBS–non-Vasc patients.
SBS–Vasc patients had shorter bowel length (55 vs 92 cm), were more likely to
have colon-in-continuity (78% vs 43%), and were less likely to have stoma pre-
sent (19% vs 61%) compared with SBS–non-Vasc patients. SBS–Vasc patients
had lower PS volume at baseline (11.2 vs 14.3 L/week) compared with SBS–non-
Vasc patients. After 24 weeks, 53% (CI, 27%–79%) of SBS–Vasc patients and
70% (CI, 50%–86%) of SBS–non-Vasc patients were responders to TED. In the
PBO groups, 35% (CI, 14%–62%) of SBS–Vasc patients and 27% (CI, 11%–
48%) of SBS–non-Vasc patients met the response criteria. In the TED groups,
reduction in mean PS volume (change and percentage change) took longer in the
SBS–Vasc group (Week 12: 1.9 [CI, 0.3–3.5], 12% [CI, 3%–20%]; Week 24, 3.6
[CI, 1.5–5.7], 25% [CI, 15%–35%]) compared with the SBS–non-Vasc group
(Week 12: 4.0 [CI, 2.0–5.9], 24% [CI, 16%–33%]; Week 24: 5.5 [CI, 3.4–7.6],
36% [CI, 29%–43%]). The overall TED safety profile was generally similar
between the 2 groups. Specifically,415% of SBS–Vasc patients reported abdom-
inal pain, dyspnoea, fatigue, nausea, and peripheral oedema, whereas 15% of
SBS–non-Vasc patients reported nausea, abdominal distension, abdominal pain,
stoma complication, and peripheral oedema.
Conclusion: To our knowledge, this post hoc analysis is the first to compare
baseline characteristics and response to treatment in patients with SBS resulting
from vascular catastrophes and nonvascular diseases. In this group of patients,
SBS-IF patients with vascular catastrophes were more likely to have colon-in-
continuity, less likely to have stoma present, and had less baseline PS volume
than in patients with nonvascular causes of SBS–IF. SBS-IF patients with vas-
cular catastrophes look longer to respond to teduglutide in the observed PS
volume reduction.
Table: Demographic and Baseline Characteristics
SBS–Vasc SBS–Vasc SBS–non-Vasc SBS–non-Vasc
Parameter PBO (n¼ 17) TED (n¼ 15) PBO (n¼ 26) TED (n¼ 27)
Age, y 56.6 (13.8) 52.3 (13.5) 45.2 (15.3) 50.8 (12.0)
Sex, n%
-Male 8 (47) 9 (60) 11 (42) 11 (41)
(continued)
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Table Continued
SBS–Vasc SBS–Vasc SBS–non-Vasc SBS–non-Vasc
-Female 9 (53) 6 (40) 15 (58) 16 (59)
Body weight, kg 66.6 (12.9) 63.9 (11.2) 58.5 (11.5) 62.1 (11.7)
BMI, kg/m2 23.3 (3.4) 22.6 (3.4) 21.5 (2.8) 22.4 (3.1)
SBS history
-Vascular catastrophe cate-
gories, n
–Intestinal ischaemia 4 5
–Mesenteric vessel thrombi
or emboli
13 9 – –
–Unknown vascular cause 0 1
-Nonvascular causes of
SBS-IF, n
–Crohn’s disease 8 10
–Injury 4 4
–Volvulus – – 6 3
–Cancer 2 1
–Other 6 9
-Colon-in-continuity, n (%) 13 (76) 12 (80) 10 (38) 13 (48)
-Stoma presence, n (%) 2 (12) 4 (27) 15 (58) 17 (63)
–Jejunostomy 1 (50) 2 (50) 4 (26) 9 (53)
–Ileostomy 0 1 (25) 9 (60) 5 (29)
–Colostomy 0 1 (25) 1 (7) 3 (18)
–Other 1 (50) 0 1 (7) 0
-Ileo-cecal value presence, n
(%)
9 (53) 4 (27) 5 (19) 6 (22)
–Yes 6 (67) 1 (25) 4 (80) 2 (33)
-Estimated remaining small
bowel length, cm
40.2 (29.9)* 70.9 (57.8) 87.6 (73.6)* 95.8 (67.8)*
PS history
-PS duration at baseline, y 6.1 (6.2) 5.4 (4.7) 5.8 (5.5) 7.2 (7.0)
-PS L/week at baseline 10.2 (5.4) 12.4 (5.5) 15.5 (7.3) 13.3 (8.3)
-PS days per week at
baseline
5.4 (1.8) 5.6 (1.6) 6.3 (1.2) 5.6 (1.8)
Data are expressed as mean (SD) unless otherwise noted.
BMI¼body mass index; PBO¼ placebo; PS¼ parenteral support; SBS-
IF¼ intestinal resection and failure associated with short bowel syndrome;
TED¼ teduglutide.
*SBS–Vasc n¼ 16 PBO; Nonvascular, n¼ 24 PBO, n¼ 24 TED.
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Introduction: There has been an increase in the numbers of small bowel and
multivisceral transplants performed in the UK over the past 10 years. Despite
successful transplants, these patients require close monitoring long-term and
currently there is limited data on their nutritional outcome.
Aims & Methods: Our primary end points are to examine 1) the percentage of
patients who achieved nutritional autonomy (without oral nutritional supple-
ment ONS, enteral nutrition EN, intravenous IV fluid or parenteral nutrition
PN) post-transplant and 2) the change in their weight and body mass index
(BMI) in the immediate and long term. Secondary end points include 1) the
duration on nutritional support post- transplant; 2) change in anthropometry
and 3) difference in nutritional outcome in patients who have colon-containing
graft or received continuity surgery. Data was collected prospectively on all
patients who underwent small bowel or multivisceral transplants at
Addenbrooke’s Hospital, Cambridge, UK. There were 54 patients in total
from January 2006 to April 2015. Patients with survival less than 6 months
post-transplant (n¼ 9) and with incomplete data (n¼ 1) were excluded. This
resulted in 44 eligible patients whose weights, BMI and grip strengths (in non-
dominant hand) were analysed. Grip strengths were performed by one of two
dedicated dietitians.
Result: Patient characteristics: Transplants included 12 isolated small bowel
(SBT), 5 liver and small bowel (LSBT), 12 modified multivisceral (small bowel,
stomach, pancreas-MMVT) and 22 multivisceral (small bowel, stomach, pan-
creas, liver-MVT). 7 patients were re-transplanted. Recently, donor colon has
been included in the graft to help with fluid balance. Mean age at transplant was
43.9 years. Patients were followed up for a median of 30 months, to April 2016 or
death (n¼ 14). Primary outcomes: Out of the 30 long-term survivors, 73.3% (22)
of them are maintained on oral diet alone at the end of follow up. The other 5
patients require ONS, 2 require IV fluids and 1 patient continues on PN. Most
patients (95.5%; 21/22) who achieved nutritional autonomy were previously
dependent on nutritional support (2 ONS; 1 EN; 18 PN) except for one patient
who was listed super-urgently. Of the patients who died, 3 out of 14 were requir-
ing PN. The mean BMI pre-transplant was 21.7 (SD¼ 3.5). Post-operatively, the
majority of patients (86.7%) lost weight (mean 14.3%; range 1–30%) with their
nadir weight occurring at a mean of 10.7 months. 11 lost 20% of their pre-
transplant weight. However more than half (26/44) of the patients weights
improved over time. Compared to the time of assessment, their BMI improved
by 0.9 kg/m2 (SD¼ 4.3) in the first year (median¼ 11 months) and increased
further by 1.4 kg/m2 (SD¼ 4.3) at the end of the follow up. The most recent
mean BMI in 30 survivors were 23.3 kg/m2 (SD¼ 5.2). Further analysis revealed
20 patients have healthy weight (BMI 18.5–25), 4 underweight (BMI5 18.5), 3
overweight (BMI4 25) and 3 obese (BMI4 30). Secondary outcomes: Post-
transplant, PN was given for a median of 22 days (range 2–241) and 39.5 days
(range 11–262) of EN. At the end of the follow up, those who have nutritional
autonomy required a considerably shorter duration of nutritional support post-
transplant compared to those who are nutrition dependent (mean of 65.3 vs 120.7
days). This suggests that the duration on nutritional support post-transplant may
predict nutritional autonomy. Of the patients who have colon (graft or continu-
ity), 64% have nutritional autonomy. However those without functioning colon
are less likely to (47.4%) (P¼ 0.36). Handgrip strength was measured in 31
patients pre and post-transplant. At median of 9 months (range from 2–32),
there was a slight reduction by 6% of expected value which correlates with
their weight loss. 18 patients had further handgrip strength test and they
improved with a mean of 7% at last follow up (median 16 months).
Conclusion: The majority of patients achieved nutritional autonomy post-trans-
plant and a colon-containing graft may be beneficial. It is common for patients to
lose a moderate amount of weight, up to 30% post-operatively. Therefore timely
referral is crucial to allow optimisation of perioperative nutritional status.
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Introduction: Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcera-
tive colitis) is a major underlying condition for massive intestinal resection lead-
ing to intestinal failure associated with short bowel syndrome (SBS–IF).
Aims & Methods: This post hoc subgroup analysis compared response to tedu-
glutide (TED) in patients with SBS–IF due to IBD (SBS–IBD) vs those with
noninflammatory causes of SBS–IF (SBS–non-IBD). STEPS (NCT00798967,
EudraCT2008-006193-15) was a 24-week, phase III, placebo-controlled study
of 0.05mg/kg/day TED in patients with SBS–IF. Patients with CD were in
clinical remission for 12 weeks at baseline. Response was a 20% reduction
from baseline in weekly parenteral support (PS) volume at Week 20 that was
maintained at Week 24. Descriptive summary statistics are presented with 95%
confidence intervals (CIs); this post hoc analysis was not powered for statistical
significance.
Result: The Table details patient characteristics (SBS–IBD, n¼ 19; SBS–non-
IBD, n¼ 67). Patients with SBS–IBD had lower colon-in-continuity, higher
stoma presence, and higher baseline PS volume than those with SBS–non-IBD.
After 24 weeks, 73% (95% CI, 39%–94%) of patients with SBS–IBD and 59%
(95% CI, 41%–76%) with SBS–non-IBD were responders to TED. In the TED
patients, mean PS volume was reduced by 45% (95% CI, 31%–59%) in patients
with SBS–IBD and 29% (95% CI, 22%–35%) in those with SBS–non-IBD. Two
of 9 (22%) patients with SBS–IBD and 6/30 (20%) patients with SBS–non-IBD
achieved a PS reduction of 2 days per week. Overall safety profile was similar in
both groups (SBS–IBD, n¼ 19; SBS–non-IBD, n¼ 66). Among patients receiv-
ing TED, treatment-emergent adverse events (TEAEs) were reported by 100% of
patients with SBS–IBD and 77% of those with SBS–non-IBD. Serious adverse
events among those receiving TED occurred in 27% of patients with SBS–IBD
and 39% of those with SBS–non-IBD. No TEAEs of CD were reported in either
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subgroup. No patients with SBS–IBD and 1/47 (2%) with SBS–non-IBD with a
colon experienced 1 TEAE (TED) of colitis.
Conclusion: In this analysis, the subgroup of patients with inflammatory bowel
disease (SBS–IBD) had evidence of more severe disease based on a higher fre-
quency of stoma presence, higher PS requirements, and lower colon-in-continu-
ity. Despite this, clinical responses to TED were equally strong.
Table: Demographic and Disease History Data
SBS–
IBDPlacebo
(n¼ 8)
SBS–
IBDTED
(n¼ 11)
SBS–Non-
IBDPlacebo
(n¼ 35)
SBS–Non-
IBDTED
(n¼ 32)
Age, mean (SD), y 48 (7) 48 (7) 50 (17) 52 (14)
Women, n (%) 5 (63) 5 (46) 19 (54) 17 (53)
Body mass index, mean
(SD), kg/m2
22.6 (3.6) 23.3 (4.1) 22.2 (3.1) 22.2 (2.8)*
Stoma present, n (%) 7 (88) 11 (100) 10 (29) 10 (32)*
Colon-in-continuity, n (%) 1 (13) 1 (9) 22 (63) 24 (77)*
Estimated small bowel
length, mean (SD), cm
128 (98) 129 (77)y 54 (43)z 73 (56)x
Baseline PS, mean (SD),
L/wk
21.6 (8.1) 15.9 (10.4) 11.5 (5.9) 11.2 (6.4)*
Baseline PS duration, mean
(SD), y
7.2 (7.4) 8.1 (8.0) 5.6 (5.3) 6.1 (5.7)*
*n¼ 31, yn¼ 9, zn¼ 32, xn¼ 30.
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Introduction:Despite a reduction in numbers worldwide, we have seen an increase
in adult Intestinal and Multivisceral transplants in the UK in the past 3 years.
Some recent transplants have been performed ‘superurgently’ for acute wide-
spread splanchnic ischaemia. Longstanding indications include complications
of parenteral nutrition in patients with type 3 Intestinal Failure (IF-associated
liver disease (IFALD), recurrent catheter-related infections and loss of vascular
access), cirrhosis with extensive portomesenteric venous thrombosis precluding
an isolated liver transplant and the need for extensive evisceration due to benign
tumour. Re-transplantation is indicated for loss of previous graft due to rejec-
tion, ischaemia or primary non-function.
Aims & Methods: We describe here the indications and outcomes for Intestinal
and Multivisceral transplant at Addenbrooke’s Hospital, Cambridge, UK Data
was collected prospectively on an internal database of all patients transplanted
from January 2006 to April 2016. All patients considered for an intestine-con-
taining graft require ratification at a national forum (NASIT). Grafts which
include liver or kidney are also discussed at local listing committees. Induction
immunosuppression is with Campath (Alemtuzumab) and maintenance initially
with tacrolimus and steroids. If complications related to tacrolimus occur,
patients are switched to ciclosporin or sirolimus. An antimetabolite is added to
aid steroid withdrawal post discharge.
Result: In the study period, 66 transplants were performed in 61 patients (33
Multivisceral, MVT; 7 Liver/small bowel, LSB; 9 Modified multivisceral,
MMV; 17 small bowel, SB). Grafts can also contain colon and pancreas. 26
patients (39%) received a transplant for complications relating to intestinal fail-
ure (overt IFALD¼ 11, impending IFALD¼ 4, recurrent sepsis¼ 1, loss of vas-
cular access¼ 10). 14 patients (21%) received a multivisceral graft because an
isolated liver transplant was not possible due to extensive portomesenteric venous
thrombosis. An increasing indication is that of ‘acute abdominal catastrophe’ – 9
patients were transplanted for this including 5 with widespread splanchnic ischae-
mia. Less frequent indications included desmoid tumours (4), re-transplant (6),
short bowel and renal failure (2). The median length of hospital stay post trans-
plant is 77 days. 7 patients had a proven episode of acute cellular rejection (ACR)
within 90 days, 12 patients had an episode between 90 days and 1 year and 7 had
ACR after 1 year. The vast majority of episodes were treated with pulsed methyl-
prednisolone (23/26, 88%). Subsequent treatments given were Alemtuzumab
(n¼ 9), Infliximab (n¼ 1), second pulse of steroids (n¼ 6),anti-thymocyte
globulin (ATG, n¼ 4). 3 grafts required removal due to rejection and all 3
patients have been re-transplanted. Within our cohort, there have been 5 cases
of graft versus host disease (GVHD) and 6 cases of post-transplant lymphopro-
liferative disorder (PTLD). Infections continued to be a problem. We have seen
increasing rate of vancomycin resistant enterococcus (VRE) and carbapenem
resistant pseudomonas. Cytomegalovirus is the most common viral infection.
Overall rates are 37.5% but this increases to 91% when seropositive donor is
given to a seronegative recipient. 1 year patient survival for SB recipients is 91%,
for MMV is 89% and for MVT/LSB is 69%. 3 year patient survival for SB
recipients is 81%, for MMV is 89% and for MVT/LSB is 52%.
Conclusion: Transplantation of intestinal-containing grafts is technically challen-
ging and recipients have a higher rate of complications compared to other solid
organ transplants. However, with advances in surgical techniques and increasing
experience of the management of medical complications, survival is improving.
Intestinal or Multivisceral transplant should be considered for certain patients
who have suffered an abdominal catastrophe, are unable to have a liver trans-
plant due to extensive portomesenteric thrombosis, or have complications arising
from intestinal failure. Timely referral to a transplant centre and careful follow-
up is essential to continue improvement in outcomes.
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OP268 EXPRESSION OF DDR2 CORRELATES WITH HIGH
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Introduction: In the previous study, our colleagues identified that discoidin-
domain receptor 2 (DDR2) is a promising driver gene of peritoneal dissemina-
tions in gastric cancer by a comprehensive expression assay. We found DDR2
expression was associated with high frequency of peritoneal dissemination and
poor prognosis in gastric cancer, and also revealed that the DDR2 was upregu-
lated by the loss of DNA methylation and that DDR2 knockdown reduced
peritoneal dissemination in a xenograft. Furthermore, we found dasatinib, an
inhibitor of the DDR2 signaling pathway, suppressed peritoneal dissemination.
In colorectal cancer, peritoneal dissemination is second popular site for color-
ectal cancer metastasis, next to the liver. Its frequency is estimated to be 4–7% of
patients with colorectal cancer at primary surgery, and approximately 4–19% of
patients during follow-up after curative surgery. Peritoneal dissemination is one
of most frequent non-curative clinical factors also in colorectal cancer.
Aims & Methods: In this study, we analyzed correlations of DDR2 expression
with clinicopathological factors in colorectal cancer, especially peritoneal disse-
mination. We selected 63 cases with colorectal cancer who had an operation in
our hospital between 2009 and 2014. Among them, 13 cases had synchronous or
metachronous peritoneal dissemination. We performed immunohistochemical
examinations for 63 primary colorectal cancers and 12 peritoneal dissemination
lesions in 11 cases with anti-DDR2 antibody. We evaluated histological localiza-
tion of DDR2 expressions, divided 63 cases into two groups by the degree of
DDR2 expressions, and compared various clinicopathological factors and overall
survival between these two groups.
Result: In primary lesions, DDR2 was expressed more preferentially in cancer
cells at invasive front of tumors. The group with high DDR2 expression had
significantly more proportion of T4, lymph node metastasis, and peritoneal dis-
semination than the group with low DDR2 expression (p¼ 0.0025, 0.012, and
0.012, respectively), and the prognosis of the former was significantly poorer than
the prognosis of the latter (p¼ 0.0164). In peritoneal dissemination lesions, 11
out of 12 exhibited intense DDR2 expressions.
Conclusion: High DDR2 expression correlates with peritoneal expression and
poor prognosis in colorectal cancer as well as in gastric cancer. DDR2 might
be one of promising driver genes of peritoneal dissemination universally in gas-
trointestinal peritoneal dissemination.
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Introduction: First-degree relatives (FDR) of patients with colorectal cancer
(CRC) have been shown to have a 2- to 3-fold increased risk of developing
CRC compared with the overall population. It is likely that CRC susceptibility
in these individuals results from common variants in low-penetrance genes.
However, very little is known about the relevance of genetic variants in the
development of colorectal preneoplastic lesions according to the family history
of CRC
Aims & Methods: We aimed to evaluate the role of certain single nucleotide
polymorphisms (SNPs) associated with CRC risk in the development of color-
ectal adenomas depending on the family history of CRC. We carried out a case-
control study comprising 750 FDR of patients with non-syndromic CRC (cases),
and 750 sex- aged- and histological lesion- matched individuals with no family
history of CRC (controls). Cases and controls were selected from the Spanish
CRC screening registries in Aragon and The Canary Islands. All subjects under-
went at least one colonoscopy and diagnosis of adenoma was confirmed by
histological study. Genomic DNA from cases and controls was genotyped by
the MassArrayTM(Sequenom) platform for a panel of 99 SNPs previously asso-
ciated with CRC risk. Genetic analysis was performed using the SNPassoc pack-
age implemented in R. To address the issue of adjustment for multiple testing, the
false discovery rate method and Bonferroni’s correction were applied.
Result: Average age of participants was 54.5 9.4 years with a slight predomi-
nance of women (51.7%). In 57% of patients, no preneoplastic lesions were
found. By contrast, 288 patients (144 cases and 144 controls) showed non
advanced adenomas (NAA), and 354 patients (177 cases and 177 controls) had
advanced adenomas (AA). Concerning gene analysis, 2 SNPs (rs10505477 A4G
and rs6983267 G4T) located in the CASC8 gene were associated with the
development of adenomas. Thus, the rs10505477G and the rs6983267T alleles
were significantly associated with a reduced risk of adenomas in patients with no
family history of CRC (controls) (log-additive models, OR: 0.67, 95% CI:0.54–
0.83 and OR: 0.66, 95% CI:0.54–0.84, respectively). However, such a protective
effect was not observed in FDR of patients with CRC (cases). In the stratified
analysis by histological lesion, the rs10505477G and the rs6983267T variants
were significantly associated with a reduced risk of both, NAA and AA in con-
trols, although this effect was stronger on the risk of developing NAA (recessive
models, OR:0.38, 95% CI:0.21–0.67 for rs10505477, and OR: 0.32, 95% CI:
0.17–0. 61 for rs6983267), suggesting their possible implication in early stages
of CRC development. Finally, 2 SNPs (rs10795668G4A and rs11255841T4A)
located in the lncRNA gene LINC00709 were significantly associated with a
reduced risk of NAA in both, FDR of patients with CRC (recessive models,
OR: 0.22, 95% CI: 0.06–0.72 for rs10795668, and OR: 0.08, 95% CI: 0.03–
0.61 for rs11255841) and patients with no family history of CRC (dominant
models, OR: 0.50, 95% CI: 0.34–0.75 for rs10795668, and OR:0.52, 95% CI:
0.35–0.78 for rs11255841), suggesting their possible implication in early stages of
CRC development.
Conclusion: Family history of CRC and some specific variants associated with
CRC risk (rs10505477 and rs6983267 in CASC8 gene and rs10795668 and
rs11255841 in LINC00709 gene) are involved in the development of colorectal
adenomas or specific histological subtypes.
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Introduction: PCI Domain Containing 2 (PCID2) located at 13q34 was identified
to be amplified in colorectal cancer (CRC) by genome sequencing. We evaluated
its amplification, overexpression, biological functions and clinical implication in
CRC.
Aims & Methods: The PCID2 gene amplification status in CRC tissues was
evaluated by Copy Number Assay. The biological effects of PCID2 overexpres-
sion and knockdown were determined by in vitro and in vivo tumorigenicity
assays. The PCID2 interaction partner was identified by immunoprecipitation
followed by mass spectrometry. PCID2 downstream effectors and signaling
pathways were elucidated by promoter luciferase assay and co-immunoprecipita-
tion. The clinical impact of PCID2 overexpression was assessed in three cohorts
of 114 CRC patients from Beijing (cohort I), 46 CRC patients from Hong Kong
(cohort II) and 376 CRC cases from TCGA dataset (cohort III).
Result: Amplification of PCID2 was detected in 32.5% (37/114) of CRC patients
from cohort I and 62.0% (233/376) of CRC patients from cohort III by Copy
Number Assay. The copy number gain was positively correlated with its mRNA
overexpression both in cohort I (r sq¼ 0.327, p5 0.0001) and in cohort III (r
sq¼ 0.619, p5 0.0001). Biological functional investigation of PCID2 revealed
that ectopic expression of PCID2 in colon cancer cell lines (DLD1 and HT29)
significantly increased cell proliferation (p5 0.01 in DLD1 and p5 0.001 in
HT29), G1-S cell cycle transition (p5 0.01 and p5 0.05, respectively), invasion
(p5 0.01 and p5 0.01, respectively) and migration (p5 0.01 and p5 0.05,
respectively) abilities, and suppressed cell apoptosis (p5 0.01 and p5 0.05,
respectively). In addition, PCID2 significantly promoted xenograft tumor
growth as well as lung metastasis in nude mice. On the other hand, knockdown
PCID2 in colon cancer cell lines (HCT116 and SW480) showed opposite effects.
We further revealed that the oncogenic effect of PCID2 was mediated through
degrading its interaction partner promyelocytic leukemia (PML) by ubiquitina-
tion. PML played a tumor suppressive role in CRC. PCID2 induced Wnt signal-
ing pathway and inhibited p53/p21 pathway activity. PCID2 expression level was
evaluated by quantitative PCR in cohort I and cohort II patients. Multivariate
analysis revealed that patients with PCID2 overexpression were significantly
correlated with CRC recurrence (p5 0.05 for cohort I, p5 0.05 for cohort II).
Recurrence curves showed that PCID2 overexpression was a prediction marker
for recurrence of patients with CRC (p¼ 0.004 for cohort I, p¼ 0.03 for cohort
II).
Conclusion: PCID2 plays a pivotal oncogenic role in colorectal carcinogenesis by
degrading its downstream effector PML. PCID2 overexpression is an indepen-
dent recurrence prediction marker for CRC patients.
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Introduction: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal che-
motherapy (HIPEC) is the treatment of choice for colorectal peritoneal carcino-
matosis (PC). Prior to surgery abdominal computed tomography (CT) was
performed to gain insight into the extent of PC and the presence of distant
metastases.
Aims & Methods: Our objective was to evaluate the relation between the com-
pleteness of cytoreduction and the Dutch seven region count evaluated with CT
and during surgery. Patients who underwent abdominal CT-imaging for PC prior
to CRS-HIPEC were eligible. The seven-point region count was assessed with CT
by an experienced radiologist and peroperative evaluation was performed by the
operating surgeon, based on the Dutch region count. The completeness of cytor-
eduction was scored after CRS. Survival analyses were performed.
Result: Two hundred thirty-four patients were included. Patients with incomplete
cytroductive surgery had more often PC in five to seven regions during surgery
(p5 0.001). This result was not found using de CT-related region count
(p¼ 0.06). Regarding disease free survival and overall survival significant differ-
ences were found with medians of 21.9 months (IQR 19.1–24.7) and 44.6 months
(IQR 35.8–53.5) in patients with complete cytoreduction compared to 12.1
months (IQR 9.7–14.6) and 19.0 months (IQR 14.2–23.8) in patients with incom-
plete cytoreductive surgery (p5 0.001 and [p5 0.001).
Conclusion: Patients with four or less involved abdominal regions with PC per-
operative were more likely to have a complete resection. CT assessment of the
region score could not accurately predict a complete resection. Patients with a
complete resection showed better survival than patients with an incomplete
cytoreduction.
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Introduction: Rectal carcinoids are the most common neuroendocrine tumors of
the gastrointestinal tract and their incidence is increasing due to colorectal cancer
screening. Several previous studies have suggested that local excision (endoscopic
or transanal excision) is effective for 10mm lesions but data on long-term
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outcomes are very limited. In addition, management of 11–19mm tumors is not
well defined because of variable estimates of risk of lymph node (LN)/ distant
metastasis.
Aims & Methods: The aims of this study were: 1) to determine the prevalence of
metastasis of resected T1 rectal carcinoid tumors using a large national cancer
database, 2) to identify risk factors for metastasis, 3) evaluate the long-term
survival of patients with T1N0M0 rectal carcinoid tumors after local resection
as compared to radical surgery. The SEER 18 database was used to identify
patients aged 18–80 years with T1 histologically confirmed rectal carcinoids
52 cm in size diagnosed between 1998 and 2012. T1 was defined as tumor
invading lamina propria or submucosa. Prevalence of LN (N1) /distant metas-
tases (M1) at initial diagnosis and risk factors for metastases were analyzed.
Cancer-specific survival (CSS) and overall survival were calculated using
Kaplan-Meier’s estimate and compared with log-rank test.
Result: A total of 788 patients with T1 rectal carcinoids were identified [mean
age: 54.8 (SD 11.3); 49.5% men; 57% white]. Of these, 727 (92.3%) patients had
tumors 510mm in diameter and 61 (7.7%) had tumors 11–19mm. Submucosal
involvement was noted in 54.9%. Overall, 12 patients (1.5%) had N1/M1 at the
time of diagnosis with prevalence of 1.1% in lesions 10mm and 6.6% in lesions
11–19mm in size (p¼ 0.01). Tumor size (OR 6.31; 95%CI 1.8 – 21.5; p¼ 0.003)
and submucosal invasion (p¼ 0.03) were associated with LN/ distant metastasis.
Median follow-up of the entire cohort was 23 months (range 0–172). Survival of
patients with T1 rectal carcinoids without N1/M1 was significantly better than
those with N1/M1 with 5- yr CSS of 100% and 78%, respectively (p5 0.001). Of
559 patients with T1N0M0 rectal carcinoids 510mm in size and follow 46
months, 527 (94.5%) underwent local excision and 32 (5.7%) had radical surgery.
5-yr CSS was 100% and 10-yr CSS was 98% (SE 0.01). For 46 patients with
T1N0M0 rectal carcinoids 11–19mm in size [39 (84.8%) who underwent local
excision and 7 (15.2%) underwent radical surgery], there were no carcinoid
tumor-related deaths after a median follow up of 28 months (range 8–122).
The overall survival of T1N0M0 rectal carcinoids treated by local excision
versus radical surgery were comparable.
Conclusion: Larger T1 rectal carcinoid tumors (11–19mm) are at increased risk of
LN metastases compared those 10mm. Survival is worse with regional or distal
metastatic disease. Hence, thorough evaluation for metastatic disease should be
considered for these lesions. Local therapy is adequate for T1 rectal carcinoids
510mm and 11–19mm N0M0 with excellent long term outcomes.
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Introduction: Non-operative treatment with stringent follow-up (‘watch-and-
wait’) is emerging as an alternative to surgical resection in rectal cancer patients
who show a clinical complete response after chemoradiotherapy. An important
question is how (how frequently and with what modalities) to monitor patients
once surgery is omitted. In addition to clinical examination and endoscopy,
imaging – mainly MRI – plays an important role. Given the novelty of the
‘watch-and-wait’ approach, limited data exists yet on what we can expect to
see on MRI during long-term follow-up after chemoradiotherapy. A pilot
study described various patterns of a complete response during watch-and-wait
in a small group of 19 patients.1
Aims & Methods: Aim of this study was to follow-up on this previous research in
a larger patient cohort. Objectives are to describe the morphology of the rectal
wall in patients with a complete response after chemoradiotherapy and study the
evolution in rectal wall morphology during long-term clinical follow-up in these
patients.
68 patients with a sustained complete response (i.e. no evidence of recurrence on
sequential imaging and endoscopy biopsy examinations) were analysed during
long term follow-up within the scope of a watch-and-wait protocol. Patients
underwent MRI (as well as corresponding clinical examination and endoscopy)
3-monthly in the first year and 6 monthly during the second to fifth year. Two
readers in consensus analysed the rectal wall morphology on the initial post-
chemoradiotherapy MRI scan and studied the evolution in morphology on the
various sequential follow-up MRIs. MRIs were performed at 1.5 T. Routine T2-
weighted sequences in sagittal, trasverse and coronal plane were analysed.
Result:Median follow-up time was 30 months (range 6–98). A total of 512 MRIs
was analysed (median 7, range 3–15/patient). In 7% of patients the rectal wall
completely normalised post-CRT. The other 93% showed a fibrotic remnant
(60% minimal fibrosis limited to the bowel wall; 21% thick/mass-like fibrosis
and 12% irregular/spicular fibrosis). In 94% the rectal wall morphology
remained unchanged during long-term follow-up, in 2% initial fibrosis later
developed into a normalised wall, in 3% the fibrosis slightly thickened (without
evidence of recurrence).
Conclusion: In the majority of patients with a complete response residual fibrosis
is present post-chemoradiotherapy which remains unchanged during long-term
follow-up in almost all patients. A completely normalised wall is observed in
approximately 1 in 10–20 patients. The findings of this study may serve as a
reference and provide teaching for radiologists involved in the clinical follow-
up of patients selected to undergo a watch-and-wait policy.
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Introduction: ElastPQ is a novel point shear wave elastography (PSWE) techni-
que that assesses liver fibrosis by measuring liver stiffness (in kPa) with few
studies published so far. The aim of this study was to determine the accuracy
and the feasibility for the assessment of liver stiffness in a large cohort of patients
undergoing liver biopsy (LB) for various etiologies.
Aims & Methods: Consecutive patients scheduled for LB were studied by using
the iU22 Philips ultrasound system with ElastPQ technique. The correlations
between laboratory findings, liver stiffness and the Metavir score were analyzed
using Spearman correlation and ROC curve analyses were performed to calculate
AUC for F 2, F 3 and F¼ 4.
Result: We enrolled 289 patients (176/113 males/females) who underwent LB for
viral or non-viral chronic hepatitis (HCV 49%; NASH 20%; AIH/PBC 18%;
other 13%). Liver stiffness measurements performed on the right lobe were reli-
able in all cases but eight patients (due to morbid obesity and narrow intercostal
spaces). After univariate and multiple regression analysis PSWE showed a strong
correlation with the fibrosis stage; no significant correlation was found with the
degree of necroinflammation or steatosis. Mean kPa values in the whole cohort
were 3.7 (range 2.3–4.9) for F0, 4.9 (range 2.6–9.6) for F1, 7.6 (2.8–20.7) for F2,
10.2 (6.1–19.9) for F3 and 20.4 (10.9–38.4) for F4 in the right lobe. AUROCs
were 0.92 (0.02), 0.93 (0.02) and 0.96 (0.01), when comparing F0-F1 vs F2-
F4, F0-F2 vs F3-F4 and F0–3 vs F4, respectively. The optimal cut-off values for
different levels of fibrosis were 6.0, 7,7 and 10.9 kPa for F 2, F 3 and F4,
respectively. When analyzing PSWE values according to different etiologies,
AUROCs were 0.89 (0.04), 0.93 (0.29) and 0.96 (0.03) for F 2; 0.88
(0.04), 0.85 (0.03) and 0.95 (0.03) for F 3; 0.90 (0.01), 0.95 (0.01)
and 0.96 (0.01) for F4 in HCV, NASH and AIH/PBC patients, respectively.
Conclusion: To date this is the largest case series evaluating the accuracy of
ElastPQ technique. This novel PSWE system appears to be a very useful tool
for non-invasive evaluation of liver fibrosis not only in patients with viral chronic
hepatitis, but also for patients with different liver diseases. In order to validate
such a non-invasive technique these findings need to be confirmed in larger
studies comparing different elastography devices.
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Introduction: Chronic liver diseases are quite frequent encounterd in daily prac-
tice and are due to chronic viral infections (B or C viruses) and other conditions
such as chronic alcohol abuse (ASH) and NAFLD. In this conditions, the eva-
luation of chronic liver disease’s severity is mandatory, for prognosis, for man-
agement and for decision regarding therapy.
Aims & Methods: The aim of this study was to compare the feasability of two 2D-
Shear Waves Elastography (2D-SWE) methods for the assessment of Liver
Stiffness (LS) and also to compare the methods with a validated one-
Transient Elastography(TE). Our study included 130 consecutive patients with
chronic hepatopathies (HCV–90%, HBV–6%, other–4%), in which Liver
Stiffness (LS) was evaluated in the same session by means of two 2D-SWE
tehniques: 2D-SWE.GE(LOGIQ E9, GE Healthcare) and 2D-SWE.SSI
(Aixplorer ultrasound system, SuperSonic Imagine) and also by an
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elastographic refference method: Transient Elastography (TE)- FibroScan,
EchoSens (M and XL probes). Reliable LS measurements were defined as fol-
lows: for 2D-SWE.GE: the median value of 10 measurements acquired in a
homogenous area and an interquartile range (IQR) 530% (1), for 2D-
SWE.SSI: the median value of 3 measurements acquired in an homogenous
area (2) and for TE- the median value of 10 measurements with a success rate
of 60% and an interquartile range 530% (3). Spearman’s rank correlation
coefficient (r) was used to assess the correlation of LS measurements by means
of 2D-SWE.GE, 2D-SWE.SSI and TE.
Result: Valid measurements were obtained in 94.6% (123/130) for 2D-SWE.GE,
90.7% (118/130) for 2D-SWE.SSI, 89.2% (116/130) for TE (p4 0.05). Reliable
liver stiffness results were obtained in 107 subjects by means of 2D-SWE.SSI, 2D-
SWE.GE and TE. The values ranged from 4.17 to 20.48 kPa for 2D-SWE.GE
and from 3.4 to 82.4 kPa for 2D-SWE.SSI. The mean LS values by 2D-SWE.SSI
were significantly higher than for 2D-SWE.GE: 19 12.3 kPa vs. 12.1 3.7 kPa
(p5 0.0001). There was a significant correlation between 2D-SWE.GE and 2D-
SWE.SSI LS values (r¼ 0.712, p5 0.0001). The correlation between 2D-
SWE.GE and TE was r¼ 0.746, p5 0.0001, and between 2D-SWE.SSI and TE
was r¼ 0.604, p5 0.0001 with no significant differences between them
(p¼ 0.0565). Taking TE as the refference method, both 2D-SWE.SSI and 2D-
SWE.GE had a good value to differentiate between other stages of liver fibrosis
and liver cirrhosis. For 2D-SWE.SSI the best liver stiffness cut-off value to
differentiate between liver cirrhosis and other stages of fibosis was 413.7 kPa
with 88.57 Se, 75.68 Sp, 87.3 positive predictive value (PPV) and 77.8 negative
predictive value (NPV) (AUROC¼ 0.831, p5 0.0001). For a liver stiffness cut-
off value 410.7 kPa, 2D-SWE.GE had 91.43 Se, 78.38 Sp, 88.9 PPV, 82.9 NPV
(AUROC¼ 0.904, p5 0.0001) for differentiating liver cirrhosis. The AUROCs
of 2D-SWE.SSI and 2D-SWE.GE for predicting the presence of liver cirrhosis
were similar (p¼ 0.09).
Conclusion: Both 2D-SWE techniques have a very good feasibility for the non-
invasive liver fibrosis assessment and both have a strong correlation with TE.
Liver stiffness values obtained by 2D-SWE.GE are significantly lower than those
obtained by 2D-SWE.SSI. Both methods have good performance for predicting
liver cirrhosis.
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Introduction: Real-time shear wave elastography (SWE) is a newly developed
method of evaluating liver stiffness, which previously had limited comparability
with other non-invasive fibrosis biomarkers.
Aims & Methods: This study aimed to compare the utility of SWE, magnetic
resonance elastography (MRE), M2BPGi, Fibrosis-4 index (FIB-4), and platelet
count (PLT) for diagnosing liver fibrosis. One hundred thirty-seven patients with
biopsy-proven chronic hepatitis C (73 men and 64 women; mean age, 64.6 10.6
years; mean body mass index, 23.6 5.08 kg/m2) were enrolled. Fibrosis was
staged from liver biopsies according to the MATAVIR score. We compared
the diagnostic performances of SWE (GE Healthcare, USA), MRE (GE
Healthcare, USA), M2BPGi, FIB-4, and PLT. SWE, MRE, and liver biopsy
were performed on the same day, when we also collected blood samples for
M2BPGi, FIB-4, and PLT. Data analysis included Mann-Whitney U test, non-
parametric correlation analysis (Spearman), and the area under the receiver
operating characteristic curve (AUROC).
Result: All patients completed all examinations except MRE, which could not be
performed in 51 patients, primarily due to the presence of metal parts in the
body. Fibrosis severity was F0/F1/F2/F3/F4 in 7/50/33/24/23 patients, respec-
tively. The median SWE (m/s), MRE (kPa), M2BPGi (COI), FIB-4, and PLT
(104/mL) in patients with F0/F1/F2/F3/F4 were 1.37/1.53/1.71/1.95/1.96, 1.97/
2.78/3.43/5.46/6.15, 1.00/1.25/2.20/6.30/6.40, 1.64/2.25/2.94/4.58/6.56, and 20.0/
17.1/14.4/10.6/9.4, respectively. Significant differences were observed between
F1/F2 and F2/F3 in SWE, F0/F1, F1/F2, and F2/F3 in MRE, F1/F2 and F2/
F3 in M2BPGi, F1/F2 and F2/F3 in FIB-4, and F2/F3 in PLT. The AUROCs for
SWE, MRE, M2BPGi, FIB-4, and PLT for detecting considerable fibrosis (F2)
were 0.86 (95% CI, 0.78–0.92; cut-off, 1.75m/s), 0.88 (CI, 0.80–0.95; cut-off,
3.40 kPa), 0.87 (CI, 0.81–0.93; cut-off, 2.2 COI), 0.81 (CI, 0.74–0.88; cut-off,
2.83) and 0.78 (CI, 0.70–0.86; cut-off, 14.5 104/mL), respectively. Similarly,
AUROCs for SWE, MRE, M2BPGi, FIB-4, and PLT for detecting severe fibro-
sis (F3) were 0.93 (95% CI, 0.89–0.98; cut-off, 1.81m/s), 0.92 (CI, 0.86–0.97;
cut-off, 4.21 kPa), 0.89 (CI, 0.83–0.95; cut-off, 2.99 COI), 0.84 (CI, 0.77–0.91;
cut-off, 4.11) and 0.85 (CI, 0.79–0.92; cut-off, 12.6 104/mL), respectively. There
was a strong correlation between SWE and MRE (r¼ 0.77, p5 0.001).
Conclusion: The AUROC for SWE for diagnosing severe fibrosis in patients with
chronic hepatitis C was similar to that for MRE and higher than those for other
fibrosis biomarkers (M2BPGi, FIB-4, and PLT). Compared to MRE, SWE
demonstrated greater utility in its feasibility, with fewer contraindications,
greater ease of performance, and lower cost.
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Introduction: The human Toll like receptors (TLRs) family consists of ten recep-
tors that are critically important for innate immunity. TLRs recognize and
respond to diverse microbial molecules and enable the innate immune system
to discriminate among groups of pathogens and to induce an appropriate cascade
of effector responses. HCV has different effects upon TLR pathway stimulation
in various cellular compartments and in this way is able to both stimulate proin-
flammatorycytokine production leading to liver damage and evade immune
responses to establish viral persistence.
Aims & Methods: The aim of this work is to investigate the association of TLR
SNPs with the outcome of the HCV infection. Four SNPS of TLR2 and TLR4
were genotyped by real time PCR using TaqManallelic discrimination kit (Applied
Biosystems) according to the manufacturer’s protocol. A total 392 families (1176
individuals) were recruited in this study from upper & lower Egypt (east & west
delta), we compared the risk of allele carriage of selected markers in different
groups. These groups included spontaneous virus clearance (SVC) (108 subject),
chronic HCV patients (549), and negative control (519) individuals. The rs
121917864 (C/T) and rs5743708 (G/A) were genotyped for TLR2 while
rs4986791 (C/T) and rs62522600 (G/A) were genotyped for TLR4.
Result: As regard TLR2, The T allele of rs 121917864 (C/T) is significantly higher
in HCV group compared to that control group and spontaneous(SVC) group
({OR 2.960 (95% CI 1.95 to 3.45 P¼ 0.0005) and 2.635 (95%CI 2.14 to 4.15
P¼ 0.0001)} respectively. While A allele of rs5743708 (G/A) is highly significant
associated with HCV group compared to that control group and spontaneous
(SVC) group {OR¼ 2.2071 (95% CI 1.2056 to 4.0404 P¼ 0.007) and 2.1321
(95% CI 1.5528 to 2.9274. P¼ 0.0001)} respectively. On the other hand the
TLR4 genotyping revealed that the carriages of C allele of rs4986791 was sig-
nificantly higher in negative and spontaneous (SVC) group compared to that of
chronic HCV group (OR:0.4843 95% CI :0.388–0.646 and 0.4449 and 95% CI:
0.2917–0.6787) simultaneously indicating that the C allele act as protective allele
against HCV infection and development of chronic HCV. Linkage
Disequilibrium of rs4986791 and rs62522600 SNPs indicating that the carriage
of TA haplotype was significantly higher in chronic HCV compared to that of
negative group (OR¼ 3.8 95% CI: 2.95–4.95). No one of spontaneous group was
carriage for TA haplotype, this revealing the role of TA haplotype as a risk
indicator for HCV infection.
Conclusion: Current study demonstrated that spontaneous clearance of HCV was
associated with The allele C ofrs4986791 of TLR-4 and chronicity of HCV
infection is associated with the risk haplotype (TA) of TLR-4& T allele of
rs121917864 & A allele of rs5743708 of TLR-2.
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Introduction: Fusion imaging technology is reportedly useful for radiofrequency
ablation (RFA), and various types of ultrasound equipment with integral fusion
imaging systems have been developed. Several RFA devices have also become
available in Japan. CelonPOWER (Olympus Surgical Technology), a multipolar
and bipolar RFA device, was approved for use in Japan in 2012. A single pro-
cedure using several applicators simultaneously can ablate an extensive area and
reduce treatment time. A sufficiently wide area of ablation requires the optimal
placement of multiple applicators. The accurate positioning of two applicators
can be quite easily visualized by ultrasonography, whereas precise three-dimen-
sional (3D) positioning of three applicators cannot. The 3D Sim-Navigator
(HITACHI) is a new navigation system that can be used during real-time virtual
sonography (RVS) by simulating the 3D positions of multiple applicators, which
can facilitate their ideal 3D positioning. We evaluated local hepatocellular carci-
noma (HCC) recurrence rates after treatment using a multipolar RF system and
determined the applicability of the 3D Sim-Navigator to the system.
Aims & Methods: We compared the local recurrence rates of 209 HCC treated
using multipolar or monopolar RF systems between January 2013 and October
2015 using propensity-score matching analysis. We evaluated 77 nodules from 63
patients treated using a bipolar RFA system with multiple applicators and com-
pared complete necrosis rates (CNR) generated with or without the 3D Sim-
Navigator.
Results: Propensity-score matching analysis showed that the mean tumor dia-
meter was 24.7 5.9mm, and the cumulative annual local recurrence rates were
0% and 14.9% for the multipolar and monopolar RF systems, respectively
(p¼ 0.228). Thirty-two and 45 nodules with mean diameters of 28.1 11.5 and
22.2 5.7mm (p¼ 0.011) were treated with and without the 3D Sim-Navigator,
respectively, with CNR of 68.8% and 66.6%, respectively, indicating that the two
groups did not significantly differ (p¼ 0.847).
Conclusion: Case matching analysis of local recurrence rates of HCC after RFA
showed that that the multipolar RF system is more effective than the monopolar
RF system against tumors with a diameter 425mm. Although tumor diameter
was significantly larger in the group with, than without the 3D Sim-Navigator,
CNR did not significantly differ between the two groups, because multiple appli-
cators could be placed in ideal 3D positions using the 3D Sim-Navigator.
Therefore, HCC with a tumor diameter 425mm should be ablated using a
multipolar RF system with ideal 3D positioning facilitated by the 3D Sim-
Navigator.
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Introduction: New-onset diabetes mellitus (NODAT) is a common metabolic
complication after liver transplantation (LT). The prevalence of NODAT stays
high and has been reported as 17–36%.1 NODAT contributes to an increased
risk of infections, cardiovascular disease, chronic rejection and renal failure,
which subsequently lead to a reduced life quality and high mortality.2,3 Recent
findings suggest a tight link between ADIPOQ gene polymorphism and glucose
metabolism and diabetes mellitus. Several studies have found that serum adipo-
nectin levels are lower in diabetic patients than healthy people.4 In addition,
reduced pretransplantation serum adiponectin levels are also correlated with
new-onset diabetes mellitus after kidney transplantation.5 From previous studies
we can reasonably infer that adiponectin would be an important protein in the
development of NODAT. However, there have been no report to describe the
association between ADIPOQ gene polymorphism and new-onset diabetes mel-
litus after liver transplantation.
Aims & Methods: In the current study, we aim to investigate whether single
nucleotide polymorphisms of ADIPOQ were correlated with the NODAT and
also to compare the overall survival and graft survival between NODAT group
and non-NODAT. The study included 256 patients who underwent liver trans-
plantation in our center from January 2009 to December 2011. They were divided
into two groups: NODAT group and Non-NODAT group. We screened inde-
pendent risk factors of NODAT with univariate and multivariate analyses. We
further built three NODAT prediction models containing the risk factors and got
optimized model with AUROC curve method. In addition, the association
between metabolic syndrome and NODAT was also examined. Overall survival
and graft survival were determined by the Kaplan-Meier method and tested by
the log-rank statistics.
Result: The incidence rate of NODAT within 6 months post liver transplantation
was 29% (75/181). There were 214 men and 42 women in the study and the
average age was 48.0 9.9 y. Age (54.0 4.1 vs 45.4 6.9, P5 0.001), BMI
(23.1 3.0 vs 22.3 3.0, P5 0.014), blood tacrolimus level at 1 month post
liver transplantation (10.23 3.30 vs 8.76 1.74, P5 0.001), ADIPOQ
rs1501299 (P5 0.007) and rs822396 (P5 0.013) were significantly correlated
with NODAT with univariate analyses. Dominant model and recessive model
confirmed these risk factors further. Three NODAT prediction models were built
containing these risk factors and we finally found the optimized model
(AUROC¼ 0.743). Metabolic syndrome was also associated with NODAT
(21% vs 8%, P5 0.003). The overall survival rate (P5 0.015) and graft survival
rate (P5 0.011) of NODAT were significantly lower than that of Non-NODAT.
Conclusion: This study is the first to provide evidence of the association between
recipient rs1501299 genotype polymorphism and new-onset diabetes mellitus
after liver transplantation on large samples. Our findings demonstrate that reci-
pient rs1501299 is associated with higher risk of NODAT and would be a poten-
tial genetic factor to improve the predictive ability of NODAT. we also confirm
age, BMI, blood tacrolimus level at 1-month after LT are independent risk
factors of NODAT. These findings may be beneficial in helping to estimate the
risk of NODAT development in liver transplantation and thereby in controlling
modifiable risk factors.
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Introduction: Since therapeutic options for patients with inflammatory bowel
disease (IBD) who lose response to anti-TNF therapy are limited, optimal use
of these agents is crucial. Loss of response can be caused by anti-drug antibody
(ADA) formation and subsequent neutralization of the effect of the drug.
Addition of an immunomodulator (IM) to anti-TNF therapy has been proposed
as an approach to reduce antibody formation, increase serum concentrations and
to regain clinical response.
Aims & Methods:We investigated whether addition of an IM to anti-TNF mono-
therapy can lead to a decrease of ADA levels and regained clinical response.
Therefore, we retrospectively collected measurements of infliximab (IFX) and
adalimumab (ADL) serum concentrations together with ADA levels from 602
patients at our IBD centre (September 2005-September 2015). ADA levels were
determined with a drug sensitive assay by Sanquin Biologicals Laboratory. As a
next step, we identified all ADA positive patients with secondary loss of response
to IFX or ADL who received an IM in an attempt to eliminate ADA and to
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regain clinical response. Detailed documentation of disease activity was
registered.
Result: In 98/376 patients ADA directed against IFX and in 61/226 patients
ADA against ADL were detectable. From all 159 ADA positive patients, 17
patients had received an IM, either a thiopurine or MTX, because of secondary
loss of clinical response. Seven patients received MTX, ten a thiopurine (4
azathioprine, 4 mercaptopurine and 2 6-TG). In 7 out of 8 patients treated
with IFX, addition of an IM resulted in an increase of serum drug levels accom-
panied with a decrease of ADA till they were undetectable. The median time for
ADA to IFX to become undetectable was 11 months (IQR 6–28). For patients
treated with ADL, an increase of the serum drug concentrations, together with a
decrease of ADA levels, was reached in 6 out of 7 patients after addition of an
IM. The median time for the ADA levels to be undetectable was also 11 months
(IQR 2–37). All patients receiving MTX responded clinically which resulted in
continuation of the ongoing anti-TNF treatment.
Conclusion: Addition of an IM to IFX or ADL monotherapy in IBD patients
with secondary loss of response due to ADA formation, led to a decrease of ADA
levels and an increase in serum drug concentrations in the majority of the
patients. Patients who regained response due to this strategy could continue
the current anti-TNF treatment and switching to another agent was not
necessary.
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Introduction: Inflammatory Bowel Diseases (IBD) diagnosed after the age of 60
are increasing and seems to have a milder course compared to younger patients.
However, the intestinal surgery rates are similar to those in the young adult
population. Data on post-operative complications (POC) in elderly-onset IBD
are scarce. We reported the incidence and factors associated with POC in general
population.
Aims & Methods: Among 841 elderly-onset population-based EPIMAD Cohort
(1), 139 patients underwent surgery. Among those, 100 had Crohn’s Diseases
(CD) and 39 Ulcerative Colitis (UC). Medical charts for early (within 30 days
of surgery) and late (430 days of surgery) POC (POC) have been reviewed
according to Dindo’s classification (2). Associated factors have been tested by
Cox regression models.
Result: After a median follow-up of 7.3 years [Q1¼ 3-Q3¼ 12], 50 patients (36%)
had at least one POC. No significant difference was observed for POC frequency
between UC and CD. Thirty-two early POC were found in 23 patients (16.5%);
52%were severe (defined by a Dindo’s grade42) and 47% infectious. Among the
37 late complications observed in 33 patients (23.7%), 42 were severe (grade4 2)
and 56% were mechanical (bridle, eventration, anastomotic stricture). The cumu-
lative probability of POC was 7.4% at 6 months (95% CI: 3.9–13.7), 10.9% at 1
year (6.5–18.1), 22.8% at 5 years (16.0–32.0) and 30.5% at 10 years (21.8–41.4). In
multivariate analysis, emergency surgery (HR¼ 4.46 [1.75–11.36]) and acute
severe ulcerative colitis (HR¼ 7.84 [2.15 – 28.52]) were significantly associated
with early POC while recent steroid exposure and co morbidities (Charlson’s
index) were not independently associated with an increased risk. Female gender
(HR¼ 2.10 [1.01 – 4.37]) and time between diagnosis and surgery 43 months
(HR¼ 2.09 [1.01 – 4.31]) were significantly associated with late POC.
Conclusion: In elderly onset IBD patient who underwent surgery, POC were
frequent. The early POC were more severe than the late POC. Emergency surgery
and acute severe ulcerative colitis were significantly associated with early
complications when female gender and delay between diagnosis and surgery
were associated with late POC. These results reinforce the need for specialized
and dedicated management of these at-risk elderly patients.
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Introduction: The most novel treatment used in H. pylori management in Europe
is the single-capsule bismuth quadruple treatment (Pylera), but there is still very
little evidence of its efficacy and safety on routine clinical practice. Pylera is still
non-commercially available in most countries in Europe and, in most of those
available, it has just recently reached pharmacies.
Aims & Methods: We aimed to evaluate the use and outcomes of Pylera in the
European Registry on H. pyloriManagement (Hp-EuReg). Methods: A systema-
tic prospective registry of the clinical practice of European gastroenterologists
regarding H. pylori infection and treatment (31 countries and 280 recruiting
investigators). A local coordinator was selected from each country. Each coor-
dinator selected a representative group of recruiting investigators from its coun-
try. An electronic clinical research file (e-CRF) was created on AEG-REDCap to
systematically register all adult patients infected with H. pylori. Variables
included: Patient’s demographics, previous eradication attempts, prescribed era-
dication treatments, adverse events, and outcomes (cure rates, compliance, follow
up, etc.). Patients with both eradication confirmatory test and with less than one-
year follow-up have been considered ongoing and were excluded from the
analysis.
Result: Up to now, 15,660 patients have been included, and 12,921 have finished
follow up (59% females, 88% Caucasian). Mean age was 55 years. Pylera was
used in 175 patients (1.2% of all treatments registered: 44% in first-line, 27% in
second, 22% in third, and 8% in following rescues). Omeprazole was used in
69% of cases and esomeprazole in 24%. Overall efficacy was 76%
(95%C.I.¼ 66–86%) by ITT and 78% (69–87%) by PP. In first line, efficacy
was 93% (84–100%) both by ITT and PP. Second line efficacy was 68% (51–
85%) by ITT and 74% (58–90%) by PP. Compliance with treatment was 98%.
Adverse events were reported in 14% of cases and did not cause treatment
discontinuation in any patient.
Conclusion: Experience with single-capsule bismuth quadruple therapy (Pylera)
is still limited. Wide confidence intervals do not allow drawing conclusions for
rescue regimens; however, our preliminary data suggests that given its safety
profile, compliance rates and efficacy, it may be an acceptable option as first-
line treatment in Europe.
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Introduction: Addition of bismuth to triple therapy has been proposed as a strat-
egy to improve its efficacy.
Aims & Methods: To evaluate the use and outcomes of a quadruple therapy
containing a proton pump inhibitor, bismuth, clarithromycin and amoxicillin
(BCA) in the European Registry on H. pylori Management (Hp-EuReg).
Methods: A systematic prospective registry of the clinical practice of European
gastroenterologists regarding H. pylori infection and treatment (31 countries and
280 recruiting investigators). A local coordinator was selected from each country.
Each coordinator selected a representative group of recruiting investigators from
its country. An electronic clinical research file (e-CRF) was created on AEG-
REDCap to systematically register all adult patients infected with H. pylori.
Variables included: Patient’s demographics, previous eradication attempts, pre-
scribed eradication treatments, adverse events, and outcomes (cure rates, com-
pliance, follow up, etc.). Patients with both eradication confirmatory test and
with less than one year follow up have been considered ongoing and were
excluded from the analysis.
Result: Up to now, 16,025 patients have been included, and 12,921 have finished
follow up (59% females, 87% Caucasian). Mean age was 55 years. BCA was used
in 248 patients (1.7% of all treatments registered): 92% in first-line. Overall
efficacy was 94% (95%C.I.¼ 91–97%) by ITT and 95% (92–98%) by PP.
First line efficacy was 95% (91–99%) both by ITT and PP. Esomeprazole coad-
juvation (36%) achieved higher eradication rates than other PPIs (98% vs. 94%).
Treatment was prescribed in 10 or 14 days regimens (50% in each). 14-day regi-
men achieved higher eradication rates than 10 day both by ITT (97% vs. 92%;
N.S.) and PP (97% vs. 93%; N.S.) Compliance with treatment was 95%. Adverse
events were reported in 28% of cases and caused treatment discontinuation in 1
patient.
Conclusion: A 14-day regimen combining bismuth salts with standard triple ther-
apy (PPIþ amoxicillinþ clarithromycin) as first-line treatment for H. pylori era-
dication offers near 95% eradication rates.
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Introduction: Currently available methods for small bowel endoscopy are com-
plex to use and time consuming. Novel Motorized Spiral Endoscopy (NMSE)
represents a new technology which offers all advantages of spiral enteroscopy
with a faster and less invasive approach.
Aims & Methods: To prospectively study the efficacy and safety of peroral
NMSE. Primary objective: diagnostic yield of NMSE in patients with suspected
small bowel diseases. Secondary objectives: procedural success, - time, depth of
maximal insertion, therapeutic yield, adverse events. Patients with occult gastro-
intestinal bleeding (OGB) or indeterminate iron-deficiency anemia (IDA) or
positive findings of small bowel imaging examinations were included in a two-
center prospective clinical trial. In total 132 cases will be enrolled to determine
the diagnostic yield. A rate of 28% would be considered as clinically efficacious
under consideration of a two sided non-inferiority margin of 20% in comparison
to conventional enteroscopy. A novel reusable endoscope (Olympus Corp.) with
an integral motor was used for rotating a disposable short spiral overtube
mounted on the insertion tube portion. Rotation of the spiral allows to
‘‘pleat’’ or ‘‘unpleat’’ the bowel either on or off the insertion tube as the spiral
thread rotates in a clockwise or counter-clockwise direction. All procedures were
performed under general anesthesia.
Result: Thirty patients (12 f, 18m; mean age [range]: 62 [20–92] years) with
positive findings of video capsule endoscopy or other small bowel imaging mod-
ality (angiectasias n¼ 18, jejunal/ileal polyps n¼ 3, thickening of wall/stricture
n¼ 3, other n¼ 1) have so far been included in the trial. 27 of 30 patients had
IDA. NMSE could be performed in 29 of the 30 patients with advancement of
the endoscope beyond the ligament of Treitz. In one case further insertion was
not be performed because of a bradycardia which caused discontinuation of the
procedure. Mean insertion time to the jejunum was 6.4 [2–19] min. and to the
deepest point of insertion distal from ligament of Treitz 22.6 [7–52] min. The
mean insertion depth from ligament of Treitz was 393 [0–600] cm.
Panenteroscopy to cecum could be achieved in one patient from the oral route.
The diagnostic yield of NMSE was 83.4% corresponding to no findings in 5
cases, at least one angiectasia in 18 cases, one or more benign polyps in 6 and
other findings in 12 patients. Thirty-two interventions were performed in 22
patients (biopsies n¼ 8, APC n¼ 17, tattooing n¼ 3, clipping n¼ 3, EMR
n¼ 1). Mean withdrawel time without interventions was 14.7 [5–45] min. Mild
mucosal trauma in the esophagus or duodenum was registered in 6 cases. There
were no serious adverse events.
Conclusion: First clinical data of an ongoing large prospective trial demonstrate
that NMSE can be effectively and safely performed for diagnostic and therapeu-
tic enteroscopy. The procedure offers advantages over traditional methods in
terms of procedural duration and ease of use.
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Introduction: Transmural healing (TH) of Crohn’s disease (CD is a new under-
explored and interesting outcome of the concept of deep remission.
Aims & Methods: The aim of this study was to assess the rate of TH evaluated by
bowel sonography (BS) and magnetic resonance enterography (MRE) in CD
patients treated with biologics, directly comparing the two cross-sectional pro-
cedures. We performed a 2-year observational longitudinal prospective study
evaluating steroid-free clinical remission (CR), mucosal healing (MH), and TH
in all patients with CD who would complete a 2-year period of maintenance
treatment with biologics. All patients underwent endoscopy, BS and MRE
before starting biologics and 2 years later. Furthermore, the Crohn’s Disease
Activity Index (CDAI) score was calculated before treatment and 2 years later.
Result: The study included 40 CD patients biologics (38% infliximab and 62%
adalimumab). TH was evident in 10 patients (25%) at BS and in 9 patients (23%)
at MRE (k¼ 0.84; P5 0.01). No significant differences were noted about TH in
relation to the type of biologic used (P¼NS). MH was obtained in 14 subjects
(35%). A good agreement was observed between MH and TH at BS (k¼ 0.63;
P5 0.001) and TH at MRE (k¼ 0.64; P5 0.001). CR was achieved in 24
patients (60%). A poor agreement was found between CR and TH, both at BS
and MRE (k¼ 0.27 and 0.29, respectively; P5 0.01).
Conclusion: TH can be reached in about 25% of CD patients treated with bio-
logic with high agreement between BS and MRE on defining this outcome. After
considering the advantages of BS (high diagnostic accuracy, low costs, high
patient compliance, high availability) and the limitations or MRE (high costs,
low availability), we suggest the use of BS as first cross-sectional procedure in
defining TH in patients with CD.
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Introduction: Some patients with celiac disease (CD), who have followed gluten-
free diet (GFD) and have a normal histological structure of small intestine
mucosa, may still have symptoms of bloating, rumbling and diarrhea. These
symptoms may be associated with changes of the activity of the small intestine
enzymes. Objective: To determine the activity of enzymes (glucoamylase, mal-
tase, sucrase and lactase) in CD patients.
Aims & Methods: Thirteen patients with newly diagnosed CD: 9 women and 4
men, (mean age 38.68 15,75 years) and 30 patients with previously diagnosed
CD: 22 women and 8 men (mean age 41.96 18,46 years) were observed. The
diagnosis of CD was based on clinical presentation, serology, including anti-
gliadin antibodies (AGA) IgA and anti-tissue transglutaminase (anti-tTG) IgA
antibodies and duodenal biopsy. Histological changes of intestinal biopsy were
classified according to the revised Marsh criteria 1999. In 1 group Marsh IIIb
lesions were seen in 23%, Marsh IIIc – in 77%. In 2 group - Marsh IIIa and
Marsh IIIb lesions were seen in 30% respectively, Marsh II - in 13.3%, the
normal structure of small intestine were observed in 26.6%. The enzyme activity
was measured in small intestine mucosa by Dahlquist modified method.
Result: In patients with newly diagnosed CD, the activity of all enzymes was
decreased in 92.3% in the group of patients followed GFD - in 36.5% (p5 0.05).
It was found that the total atrophy (Marsh IIIc) was associated with a reduced
activity of all enzymes in all patients; whereas all patients with Marsh IIIb atrophy
had a decreased activity of lactase, 90% had a decreased activity of glucoamylase
and maltase, and in 81.8% of cases we observed a decreased activity of sucrase. The
recovery of the intestine mucosa showed improvement of activity of all enzymes.
However, even in normal small intestine mucosa the reduction of glucoamylase
activity was observed in 37.5% reduction of maltase activity - in 62.5%, the activity
of sucrase was reduced in 50% and activity of lactase was decreased in 37.5%. The
reduced activity of all enzymeswas found in 37.5%of patients with normal structure
of small intestinemucosa.Aweak correlation between the degree of atrophy and the
activity of sucrase and maltase (rs¼0.513, p¼ 0.005 and rs¼0.406, p¼ 0.029,
respectively) was established. Activity of other enzymes had no significant correla-
tion with the degree of atrophy.
Conclusion: In 37.5% of adult patients with CD who follow GFD and have
a normal structure of mucosa, a decreased activity of intestinal enzymes may
occur, which may be one of the reasons for the persistence of intestinal
symptoms.
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Introduction: 20–30% of coeliac patients on a gluten free diet still have irritable
bowel syndrome (IBS) symptoms. A low FODMAP (fermentable oligo-, di-,
monosaccharides and polyols) diet is effective to reduce symptoms in IBS
patients.
Aims & Methods: We wanted to investigate the benefit from restricting the
FODMAP content of the diet in patients with coeliac disease, who are still
symptomatic on a gluten-free diet. 40 patients with coeliac disease and IBS
symptoms confirmed by the Rome III-criteria and IBS-SSS (Symptom Severity
Scale) were randomized and instructed by dieticians: Group A excluded all wheat
starch and ‘‘traces of gluten’’ from their diet, Group B excluded FODMAPs as
well as gluten. Symptoms on IBS-SSS were recorded at baseline, 3 and 6 weeks,
as well as quality of life (SF-36). Four days prospective dietary intake records at
baseline and 6 weeks, compliance and satisfaction after 6 weeks, and 1 month
later. Dietist Net Free was used for FODMAP calculations. Statistics: paired T-
tests and Wilcoxon’s.
Result: 20 patients were included in each group; A (18F/2M, age 39 15) and B
(15F/5M, age 43 12). 42.5% had constipation, 27.5% diarrhoea and 30% both.
The mean total IBS-SSS score was significantly reduced: Group A from 260 to
204 (p¼ 0.0022), group B from 263 to 145 (p5 0.0001), p¼ 0.0247, group B vs.
A. In group A 10% reached remission, in Group B 25% (p¼ 0.408). All subscales
improved significantly in group B, but only abdominal pain severity in group A.
SF-36 physical health score improved in group B (p¼ 0.0081), but not in group
A. Patients in group B were significantly more satisfied with pain relief
(p¼ 0.0132), but it was also more challenging to follow their diet (p¼ 0.0008).
Conclusion: Patients with coeliac disease and IBS-symptoms had significant
improvement in abdominal symptoms and physical health from a low
FODMAP diet for 6 weeks. A gluten-free diet with reduced FODMAP content
was more effective than a more strict gluten-free diet, and should be offered to
coeliac patients with refractory IBS-symptoms on a gluten-free diet.
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Introduction: Both central and peripheral pathophysiological factors are thought
to contribute to the symptoms of IBS. Psychological symptoms reflect CNS
dysfunction, while abnormal GI sensorimotor function reflects mainly peripheral
dysfunction; both have been associated with symptoms in IBS. These factors may
have additive effects on patient reported outcome (PRO) measures in IBS.
Aims & Methods: Our aim was to study whether these pathophysiological altera-
tions have additive effect on PROs in patients with IBS. To achieve this, we
included 407 patients fulfilling the Rome II or Rome III IBS criteria (74%
females; mean age 36 12 years). The following pathophysiological factors
were measured in all subjects: colonic transit time (radiopaque markers); com-
pliance, allodynia (low pain thresholds) and hyperalgesia (increased pain inten-
sity) (rectal barostat); and anxiety and depression (HAD scale). Abnormal
findings on the physiology assessments were defined based on the 5th and 95th
percentiles in healthy controls, and on the HAD scale by a score 47. The
patients also completed questionnaires to assess IBS symptom severity (IBS-
SSS or GSRS-IBS), and bowel habit (stool diary). To be included in the analysis,
a pathophysiological factor had to be associated with severity of one IBS-
related symptom. As PRO measures we used z-scores of IBS symptom severity
(IBS-SSS or GSRS-IBS total score) and somatic symptom severity (SCL-90
somatization subscale or PHQ-15), and quality of life (IBSQOL).
Result: Allodynia was seen in 40% of patients, hyperalgesia in 17%, accelerated
colonic transit in 18%, delayed transit in 7%, anxiety in 52% and depression in
24% - these factors were associated with severity of at least one IBS symptom.
Rectal compliance (increased in 10% and reduced in 14%) was not associated
with more severe IBS symptoms. At least 3 pathophysiological abnormalities
relevant for symptoms were present in 20% of patients, 2 in 30%, 1 in 31%,
and 18% of patients had none. The number of pathophysiological abnormalities
was not associated with age (p¼ 0.15), gender (p¼ 0.12) or IBS subgroup
(p¼ 0.21). With increasing number of pathophysiological abnormalities, there
was a gradual increase in the severity of IBS symptoms (p5 0.0001) and somatic
Table 1 (OP288): Association between number of pathophysiological alterations and Patient Reported Outcomes (data shown as mean SD)
No abnormality (n¼ 76) 1 abnormality (n¼ 128) 2 abnormalities (n¼ 121) 3 abnormalities (n¼ 82) ANOVA
IBS symptom severity (z score) 0.55 0.94 0.22 1.06 0.11 0.96 0.37 0.86 F¼ 14.0; p5 0.0001
Somatic symptom severity (z score) 0.47 0.80 0.30 0.93 0.17 9.91 0.68 0.98 F¼ 26.7; p5 0.0001
IBSQOL Emotional 60 19 55 24 44 19 37 17 F¼ 20.3;5 0.0001
IBSQOL Mental Health 82 16 76 22 65 20 51 20 F¼ 35.4; p5 0.0001
IBSQOL Sleep 82 16 76 23 69 24 58 24 F¼ 15.3; p5 0.0001
IBSQOL Energy 69 24 58 27 48 24 35 23 F¼ 25.0: p5 0.0001
IBSQOL Physical Functioning 75 20 74 21 68 20 57 26 F¼ 11.8; p5 0.0001
IBSQOL Food 67 20 64 21 59 18 55 20 F¼ 6.3; p5 0.0001
IBSQOL Social Role 71 20 65 23 56 20 51 24 F¼ 13.5; p5 0.0001
IBSQOL Physical Role 64 28 56 31 47 29 40 28 F¼ 10.3; p5 0.0001
IBSQOL Sexual 71 23 70 25 63 25 50 25 F¼ 8.2; p5 0.0001
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symptoms (p5 0.0001), and a gradual reduction of QOL (p5 0.0001) (table 1).
When assessing central (anxiety and depression) and ‘‘peripheral’’/GI pathophy-
siological factors (allodynia, hyperalgesia, accelerated and delayed transit) sepa-
rately, cumulative effects on symptom severity and QOL were also observed.
Conclusion: Visceral hypersensitivity, i.e. allodynia and hyperalgesia, abnormal
colonic transit and psychological factors are all pathophysiological factors that
are associated with GI symptom severity in IBS. These factors have an additive
effect on GI and non-GI symptoms, as well as on quality of life in IBS, and are
therefore relevant treatment targets.
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Introduction: Inspired by the concept of Irritable Bowel Syndrome (IBS) as a
disorder of brain-gut-communication, alterations in central mechanisms are
increasingly acknowledged in IBS pathophysiology. Given high comorbidity
with affective disorders, emotional factors likely play a role in disturbed central
processes in IBS. Dysfunctions particularly in brain regions involved in emotion
processing, including the rostral anterior cingulate cortex (rACC) as a unique
hub of both, affect regulation and anti-nociception, may constitute a central link
between abdominal pain and psychiatric comorbidities. While a growing number
of neuroimaging studies support a crucial role of rACC in altered pain processing
and emotional disturbances in IBS, the biochemical basis of these alterations
remains unknown.
Aims & Methods: We compared IBS patients and healthy controls (HC) regard-
ing concentrations of glutamate (Glu) and -Aminobutyric acid (GABAþ) in
rACC using quantitative magnetic resonance spectroscopy (qMRS). We further
addressed associations with anxiety and depression as the most common psychia-
tric comorbidities in IBS. In a combined MRI and MRS study, GABAþ and Glu
concentrations in 38 female IBS and 19 age-matched female HC were measured
using a Philips Ingenia 3T scanner and a MEGA-PRESS sequence with a
3x3x3cm3 voxel placed in the rACC, localized based on individual T1-weighted
images. Symptoms of anxiety and depression were assessed with the Hospital
Anxiety and Depression Scale (HADS) and correlated with metabolite concen-
trations. Patients were subdivided into a group with (IBSþ) and without (IBS-)
comorbid anxiety based on published HADS cut-offs.
Result: Compared to HC, IBS as a group exhibited significantly increased
GABAþ concentrations within rACC (p5 0.05), while no differences were
observed in concentrations of Glu. Both anxiety (r¼ 0.407; p5 0.01) and depres-
sion (r¼ 0.276; p5 0.05) correlated with GABAþ concentrations. Inclusion of
HADS scores as covariates diminished group differences in GABAþ concentra-
tions in ANCOVA with anxiety, but not with depression. Analyses on IBS sub-
groups revealed a group effect (p5 0.05) with higher GABAþ levels in IBSþ
compared to HC (p5 0.01) and compared to IBS- (p¼ 0.056), whereas differ-
ences between IBS- and HC did not yield significance.
Conclusion: Our findings provide first evidence of dysregulated rACC neuro-
transmission in IBS. This imbalance appears to be driven by increased
GABAþ concentrations in rACC as a crucial structure for anti-nociception
and affect regulation. Abnormal GABAþ levels were most pronounced in
patients with comorbid anxiety, supporting a key role of psychiatric comorbid-
ities in altered brain processes in IBS. Altered inhibitory GABAergic neurotrans-
mission may be fundamental for dysregulations of affective and nociceptive
processing, contributing to functional as well as long-lasting neuroplastic changes
in IBS.
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Introduction: Irritable bowel syndrome (IBS) is a chronic functional intestinal
disorder with a strong female predominance. The pathophysiology is incomple-
tely understood, but an increasing body of evidence demonstrates a role of the
brain-gut-microbiota axis1. Alterations in microbiota have been associated with
onset as well as changes in symptoms of IBS. Prior data suggest that intestinal
barrier function is disturbed in IBS, but to our knowledge the passage of living
bacteria through the colonic mucosa has never been investigated.
Aims & Methods: Aims: To study the paracellular permeability and the passage
of living bacteria, both commensal and pathogenic, through the colonic mucosa
of women with IBS and female healthy controls (HCs). The second aim was to
investigate whether IBS stool consistency subgroups differ in terms of intestinal
barrier function. Methods: Colonic biopsies from 32 women with IBS (mean age
32.6y; 17 with mixed stool pattern IBS-M, 7 with diarrhea IBS-D and 8 with
constipation predominance IBS-C, according to Rome III criteria) and 15 HCs
(mean age 29.7y) were mounted in Ussing chambers2. Mucosal passage of living
Escherichia coli (E.coli) HS and Salmonella typhimurium was investigated. The
paracellular passage was measured by using 51Cr-EDTA.
Result:
Table: Mucosal passage of bacteria (bacteria/chamberx103) and51CrEDTA (cm/
sx106) are shown in median (25%–75% percentile)
IBS HC p
E.coli 627 (563–688) 333 (291–387) 0.0001
Salmonella 880 (689–1104) 315 (194–437) 0.0001
51Cr-EDTA 1.1 (0.7–1.5) 0.9 (0.5–1.1) 50.05
The colonic mucosa of IBS patients had a significantly greater passage both for
living Salmonella typhimurium and E. coli HS compared with HCs (p5 0.0001
and p5 0.0001 respectively). The 51Cr-EDTA passage was also significantly
increased in IBS (p5 0.05). IBS-M, IBS-D and IBS-C did not differ significantly
in terms of mucosal barrier function measures, neither for bacterial nor for
paracellular passage.
Conclusion: The present study demonstrated that passage through the colonic
mucosa of both pathogenic and commensal living bacteria is altered in female
IBS patients. These findings elucidate new aspects of peripheral abnormalities
and support the importance of microbiota as a major factor in the pathophysiol-
ogy of IBS.
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Introduction: Several diseases and disorders are associated with ‘‘leaky gut’’ (or
increased intestinal permeability), such as inflammatory bowel diseases, celiac
disease, food allergy, irritable bowel syndrome, and obesity-metabolic disorders.
Therefore, this topic is an area of growing interest, and a well-established therapy
for preventing or reverting increased intestinal permeability would be valuable.
Since there are no effective medications for ’’leaky gut’’ to date, it would be
important to establish a new therapy which aiming at improvement of intestinal
permeability. Previous studies have reported that non-steroidal anti-inflamma-
tory drugs (NSAIDs) induce small intestinal damage and increased permeability
[1]. Other basic studies have reported that lubiprostone, a chloride channel acti-
vator used for chronic constipation, repairs intestinal mucosal barrier function
and also prevents NSAID-induced small intestinal damage in rodent models [2].
Aims & Methods: Our aim was to verify the effect of lubiprostone on intestinal
permeability in healthy volunteers administrated with diclofenac. We conducted
a prospective, randomized parallel-group trial. Healthy male volunteers, with
documented abstinence from certain drugs (NSAIDs, proton-pump inhibitors,
antibiotics, and probiotics) for at least 3 months prior to the study were enrolled.
The subjects were randomly assigned to either the lubiprostone or control
groups. All participants performed sugar permeability tests on baseline, after
14 days of treatment (day14), and after 28 days of treatment (day28). The
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subjects ingested 400ml of water containing 10 g lactulose and 5 g mannitol, after
an overnight fast. Total urine for the following 4 hours was collected and rapidly
frozen for analysis. Both groups started with oral intake of 75mg diclofenac daily
for 7 days. Thereafter, the lubiprostone group was treated by oral intake of 24mg
lubiprostone daily for 28 days, while the control group did not receive any
medicine after diclofenac. Permeability was expressed as lactulose/mannitol
ratio (LMR), calculated from urinary excretion of the initial administrated
dose of each sugar.
Result: Fourteen subjects for each group with a median age of 23.5 (range, 21–32)
completed the study. The background characteristics including baseline LMR
between the two groups showed no significant difference. Treatment after 28
days of lubiprostone showed significant improvement of LMR (p¼ 0.0497),
while 14 days treatment did not reach statistical significance compared to control
group (p¼ 0.403).
LMR results (analyzed by analysis of covariance: ANCOVA)
LMR control group (n¼ 14) lubiprostone group (n¼ 14) p value
baseline 0.019 (0.016–0.022) 0.021 (0.017–0.025)
day14 0.035 (0.023–0.047) 0.024 (0.019–0.029) 0.403
day28 0.028 (0.023–0.033) 0.017 (0.015–0.019) 0.0497
Conclusion: In our study, 28 days treatment with lubiprostone demonstrated an
improvement of increased intestinal permeability after 1-week administration of
diclofenac in healthy volunteers. This is the first study to demonstrate a signifi-
cant effect of a medication for treatment of increased intestinal permeability, and
suggests a new approach towards several diseases associated to ‘‘leaky gut’’.
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Introduction: Divergent results have been reported regarding the association
between visceral hypersensitivity and GI symptoms in patients with functional
GI disorders (FGIDs). Moreover, it has been proposed that the association
between hypersensitivity and GI symptoms is secondary to psychological factors
and tendency to report symptoms.
Aims & Methods: Our aim was to evaluate the association between visceral
hypersensitivity and GI symptom severity in large cohorts of FGID patients.
To do this, we included 5 cohorts of patients with FGIDs, who had undergone
GI balloon distensions and completed questionnaires to assess GI symptom
severity, somatization, anxiety and depression: 1. Belgian functional dyspepsia
cohort (n¼ 242; 180 females (f); age 39 13 years (mean SD); gastric barostat
(ramp inflation, 2mmHg steps, 2min/step). 2. US IBS cohort (n¼ 243; 203 f; age
34 12 years); colonic barostat (phasic distensions, 30 s duration, 30 s rest;
2mmHg increments); 3. US IBS cohort (n¼ 159; 126 f; age 37 14 years);
rectal barostat (phasic distensions, 30 s duration, 30 s rest; 2mmHg increments);
4. Swedish IBS cohort (n¼ 353; 267 f; age 38 13 years); rectal barostat (phasic
distensions, 30 s duration, 30 s rest; 5mmHg increments); 5. Swedish IBS cohort
(n¼ 147; 102 f; age 34 11 years); rectal barostat (ramp inflation, 4mmHg steps,
1min/step). Subjects were divided into sensitivity tertiles based on pain/discom-
fort thresholds. GI symptom severity (z scores of IBS-SSS, GSRS-IBS or dys-
pepsia symptom severity (DSS)) was compared between sensitivity tertiles in each
cohort and corrected for somatization (RPSQ, PHQ-12 or SCL-90), and anxiety
and depression (HAD or BSI).
Result: The results are summarized in table 1. In all five cohorts GI symptom
severity increased gradually with increasing GI sensitivity, with significant differ-
ences in GI symptom severity between the sensitivity tertiles, and small, but
significant correlations between pain/discomfort thresholds and GI symptom
severity, across all five patient groups (r¼0.20 – 0.29). The differences
between sensitivity tertiles remained significant in all cohorts after correction
for anxiety and depression, and also after correction for somatization (without
GI symptoms) in all of the cohorts (p5 0.05).
Conclusion: A gradual increase in GI symptom severity with increasing GI sensi-
tivity was demonstrated in IBS and functional dyspepsia, which was consistent
across several large patient groups from different countries, different methods to
assess sensitivity, and assessments in different parts of the GI tract. This associa-
tion, although modest, was independent of tendency to report symptoms or
anxiety/depression comorbidity. These findings confirm that visceral hypersensi-
tivity is a contributor to symptom generation in FGIDs.
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Introduction: There is significant comorbidity between the symptoms of IBS and
the urological symptoms of urgency and frequency experienced in overactive
bladder and interstitial cystitis/painful bladder syndromes. Viscero-visceral
cross-talk has also been described in pre-clinical studies, whereby acute colitis
in rodents is associated with altered bladder cystometry and bladder afferent
sensitisation [1,2]. However, it remains to be determined if bladder overactivity
persists following the resolution of colitis, in a model of chronic colonic hyper-
sensitivity (CCH) [3], or if reducing colonic nociception is able to alter bladder
overactivity. Linaclotide, an FDA approved guanylate cyclase-C (GC-C) agonist,
reduces abdominal pain in IBS patients with constipation [3], reverses colonic
mechanical hyper-sensitivity in CCH mice, and reduces noxious signalling to the
spinal cord in mice in vivo. We hypothesized that oral linaclotide administration
may also reduce bladder hypersensitivity.
Aims & Methods: We investigated healthy C57BL/6 J mice and mice with CCH,
28 days after intra-colonic TNBS administration. CCH mice were randomly
assigned to either chronic linaclotide (3 mg/kg/day) or placebo (water)
Table 1 (OP292): Association between visceral hypersensitivity and GI symptom severity in five FGID cohorts
Belgian FD cohort
(n¼ 242)
US IBS cohort
(colon; n¼ 243)
US IBS cohort
(rectum; n¼ 159)
Swedish IBS cohort 1
(n¼ 353)
Swedish IBS cohort 2
(n¼ 147)
z score GI sx severity (mean SD) DSS IBS-SSS IBS-SSS IBS-SSS/GSRS-IBS IBS-SSS
Low sensitivity tertile 0.48 0.99 0.29 0.99 0.34 0.90 0.40 0.98 0.46 0.89
Mid sensitivity tertile 0.07 0.88 0.04 1.00 0.00 1.04 0.11 0.99 0.31 0.83
High sensitivity tertile 0.32 0.99 0.25 0.95 0.28 0.97 0.25 0.95 0.06 1.14
ANOVA F¼ 13.2; p5 0.0001 F¼ 5.9; p¼ 0.003 F¼ 5.1; p¼ 0.007 F¼ 14.0; p5 0.0001 F¼ 8.5; p5 0.0001
ANCOVA (adjusted for somatization) F¼ 9.2; p5 0.001 F¼ 4.9; p¼ 0.008 F¼ 3.1; p¼ 0.046 F¼ 6.3; p¼ 0.002 F¼ 3.9; p¼ 0.02
ANCOVA (adjusted for anx & depr) F¼ 13.3; p5 0.0001 F¼ 5.0; p¼ 0.006 F¼ 4.1; p¼ 0.018 F¼ 10.8; p5 0.0001 F¼ 8.3; p5 0.0001
Correlation sensitivity - GI sx r¼0.27; p5 0.0001 r¼0.20; p5 0.0001 r¼0.27; p¼ 0.001 r¼0.29; p5 0.0001 r¼0.20; p5 0.02
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administration, consisting of a once daily oral gavage for 2 weeks prior to experi-
mentation. In all four groups, whole cell patch clamp recordings from retro-
gradely traced thoracolumbar and lumbosacral bladder dorsal root ganglion
(DRG) neurons determined neuronal excitability, whilst ex-vivo electrophysiolo-
gical recordings determined bladder afferent and contractile sensitivity to ramp
distension as well as muscarinic, purinergic and TRPV1 channel agonists.
Micturition pattern analysis was performed by analysing in-vivo natural voiding
behaviour.
Result: Bladder traced DRG neurons from mice with CCH displayed hyperexcit-
ability with a significant decrease in rheobase (P5 0.01) as well as enhanced
bladder afferent responses to distension (P5 0.001), and exogenous agonists
(P5 0.01), with no changes in muscle compliance or contraction responses. As
a reflection of altered physiological signalling, CCH mice also displayed signifi-
cant changes in voiding frequency (P5 0.01). CCH mice treated with linaclotide
displayed attenuated bladder DRG neuron excitability compared with placebo
treated mice (P 0.001), and attenuated bladder afferent hypersensitivity to dis-
tension (P5 0.001). Linaclotide treatment in the CCH mice also resulted in a
restoration of natural voiding behaviour (P 0.05).
Conclusion: Mice with CCH also display increased bladder afferent excitability
accompanied by abnormal bladder voiding behaviour, an example of viscero-
visceral cross-talk. Chronic oral administration of linaclotide, a gut-restricted
GC-C agonist that inhibits colonic nociceptors, reverses these colitis-induced
changes in bladder function and sensitivity. Agents that improve abdominal
pain may be able to improve urological symptoms through common sensory
innervation pathways.
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Introduction: Several recent referral center studies showed that a significant pro-
portion (3–10%) of children with an early-onset (EO, defined by an age at
diagnosis less than 12 years) inflammatory bowel disease (IBD) present with
an underlying monogenic disorder. Currently, more than sixty disorders of this
type have been identified and their pathophysiological mechanisms are very
heterogeneous. Most of them affecting the intestinal epithelial barrier, are asso-
ciated with defects in phagocytosis or immune deficiency, or are hyper- and auto-
inflammatory diseases. However, they all share the ability to present in the form
of an array of intestinal inflammation with EO.
Aims & Methods: Using a next-generation sequencing (NGS) of the 63 genes
whose abnormalities are responsible for these disorders, and a targeted CGH
array analysis of their chromosomal loci, 91 patients with an initial diagnosis of
EO-IBD between 1988 and 2004 (54% of the whole EO-IBD cohort) issued from
EPIMAD population-based registry were screened; 71 had a Crohn’s disease and
20 an ulcerative colitis.
Result: Analysis isolated 24 patients (26.4%) with very rare or not yet reported
potential pathogenic variants in 17 genes. Seven of them (7/91; 7.6%) had a
genotype compatible with one of the tested disorders: Burton agammaglobuline-
mia, familial diarrhea, familial C2 defect, hyper-IgM syndrome or Omenn syn-
drome. The remaining 17 patients (17/91; 18.7%) were heterozygous carriers of
genes variants involved in autosomal recessive trait. The genotype identified in
these patients was thus probably not likely to be the underlying cause of one of
these disorders. However, one cannot exclude that it may contribute to IBD as
suggested by the unusually high prevalence of these genotypes.
Conclusion: Our study issued from a population-based registry, provides further
evidence to recommend screening for inherited disorders using targeted NGS in
children with an EO-IBD with the potential to enhance optimal selection of
treatment options and adequate counseling of families. This study also indicates
that targeted NGS used in this study may be an adequate and efficient tool for
the reappraisal of the diagnosis in these patients.
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Introduction: The impact of environmental hypoxia on the development of
inflammatory bowel disease (IBD) is controversial, with studies supporting
both a proinflammatory and a protective effect. Hypoxia is known to activate
the autophagy and inflammasome pathways, which are ancient innate immune
mechanisms linked by mutual regulation. In recent years, polymorphisms in gene
loci containing autophagy- and inflammasome proteins have been associated
with an increased risk of IBD. Evidential data suggest that the imbalance in
the mutual regulation of autophagy and NLRP3 inflammasome activation
under hypoxia plays a role in the development of IBD.
Aims & Methods: To study the effects of hypoxia in IBD, healthy volunteers
(n¼ 10), patients with Crohn’s disease (CD, n¼ 11) and patients with ulcerative
colitis (UC, n¼ 9) were subjected to hypoxic conditions resembling an altitude of
4,000m above sea level for 3 h using a hypobaric chamber. Distal colon biopsies
were collected the day before hypoxia, immediately after hypoxia, and one week
after collection of the first biopsy. To further study the effects of hypoxia in
colitis and the role of the NLRP3 inflammasome, wild-type (WT), interleukin
(IL)-10-/-, Nlrp3-/- and IL-10-/- Nlrp3-/- double knockout mice were subjected to
hypoxia (8% O2) for 18 h prior to colon biopsy collection. Mice under normoxic
conditions were used as controls. For the in vitro studies, the human monocytic
cell line THP1 and the intestinal epithelial cell line HT-29 were subjected to
hypoxia (0.2% O2) in the presence and absence of lipopolysaccharide.
Result: Colon biopsies of patients with CD, but not UC showed increased levels
of tumor necrosis factor (TNF) and NLRP3 mRNA expression prior to
hypoxia. Interestingly, hypoxia inhibited the expression of both genes immedi-
ately and one week after hypoxia concomitantly with the induction of the autop-
hagy-associated gene p62. IL-10-/-, but not IL-10-/- Nlrp3-/- mice presented an
increased expression of TNF, IL-6, and inflammasome-associated IL-1b as well
as increased levels of phospho-p65/RelA concomitantly with an accumulation of
the autophagy proteins p62 and LC3, suggesting an autophagy blockage orche-
strated by NLRP3. Interestingly, hypoxic conditions significantly inhibited the
expression of TNF, IL-6 and IL-1b, and restored autophagy in IL-10-/- mice.
THP1 and HT-29 cells subjected to hypoxia showed a decrease in NF-B activa-
tion concomitantly with an increase in autophagy, evidenced by a reduction in
p62 and LC3, and the phosphorylation of mTOR, a major regulator of autop-
hagy. siRNA-mediated silencing of NLRP3 further activated autophagy under
hypoxia.
Conclusion: Our results suggest a protective effect of hypoxia in CD patients and
the IL-10-/- mouse model of colitis. IL-10-/-, but not IL-10-/- NLRP3-/- mice under
presented inhibition of autophagy indicating that NLRP3 is involved in the
blockage of autophagy. Interestingly, hypoxia restored autophagy in IL-10-/-
mice, as well as in THP1 and HT-29 cells concomitantly with a reduction of
inflammatory gene expression and signaling. Hypoxia-induced autophagy was
enhanced in the absence of NLRP3 further supporting a role for NLRP3 in the
regulation of autophagy. Our results confirm a reciprocal regulation between
hypoxia, inflammation, and autophagy, and suggest that hypoxia ameliorates
inflammation through the induction of autophagy via the regulation of NLRP3.
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Introduction: Exploring DNA methylation in Inflammatory Bowel Disease (IBD)
may provide an insight into complex gene-environment interactions, identify
novel targets involved in pathogenesis, and allow development of powerful
new biomarkers. Our study aims to characterize disease-associated methylation
changes in newly diagnosed IBD and to define the contribution of genetic varia-
tion, by discovery of associated quantitative trait loci (meQTL).
Aims & Methods: Genome-wide methylation was measured in 641 DNA samples
from peripheral blood (298 controls, 150 Crohn’s disease (CD), 167 ulcerative
colitis (UC), 26 IBD unclassified (IBDU)) using the Illumina 450k platform with
covariates of age, sex, and differential cell counts, deconvoluted by the
Houseman method; genotyping was performed using Illumina
HumanOmniExpressExome-8 BeadChips. Samples were obtained from new
onset IBD cases in six European centres as part of the European Comission
funded IBD-Character project.
Result: 195 probes exhibited Bonferroni significant IBD-associated methylation
differences, including VMP1/MIR21 (p¼ 3.7 10-20), RPS6KA2 (1.1 1019),
SBNO2 (2.7 1019), and TNFSF10 (1.1 1015); data which provide important
replication and confirmation of methylation differences previously reported in
paediatric CD and adult IBD. Novel findings include PHOSPHO1 (1.3 1015),
MUC4 (5.5 1015), and CDH24 (1.7 1014). 1709 differentially methylated
regions of consecutive FDR significant probes were defined in genes including
VMP1/MIR21, ITGB2, TNF, and at multiple sites throughout the HLA region.
Results were highly similar in CD and UC, with only one probe showing a
significant methylation difference between diagnoses (NAV2, 6.82 108).
Paired genetic and methylation data showed 2327 FDR significant MeQTLs
indicating a genetic influence on key methylation loci such as RPS6KA2
(8.6 1034), and ITGB2 (3.3 1038), and a replication of two SNPs previously
described as correlated to VMP1/MIR21 methylation (rs8078424,
p¼ 4.4 1025, rs10853015, p¼ 7.4 1021). There was an enrichment of
highly significant IBD-associated methylation changes in proximity to IBD
GWAS loci. Previously published two-probe methylation biomarkers derived
from a new onset paediatric CD cohort accurately distinguished IBD from con-
trols in this new onset adult cohort (AUC 0.82).
Conclusion: These data allow methylome profiling in a large multinational cohort
of new onset IBD, identifying novel disease-associated methylation changes and
important unequivocal replication of recent discoveries, together with insight
into the genetic contribution to epigenetic alterations in complex disease, and
the utility of peripheral blood DNA metylation as a biomarker.
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Introduction: Phenotypic expression of colonic inflammation in inflammatory
bowel disease (IBD) in patients with colonic Crohn’s disease (CCD) and ulcera-
tive colitis (UC) can sometimes have a similar appearance and be difficult to
differentiate. MicroRNAs (miRNAs) may offer a method of distinction as dif-
ferential expression of peripheral blood miRNAs has been shown in small studies
of IBD patients and healthy controls.
Aims & Methods: This study aimed to assess peripheral blood mononuclear cell
(PBMC)-derived miRNA signatures in a well-phenotyped cohort of colonic IBD
and to identify differentially expressed miRNAs in patients with CCD and UC.
An IBD cohort with UC and CCD was prospectively accrued. Ileocolonoscopy
was performed and patients with CCD (Montreal Classification L2/L3) or left-
sided UC (Montreal Classification E2/E3) were enrolled. Colonoscopies were
reviewed by IBD endoscopists and scored for presence/absence, severity and
site of inflammation. Pathology reports were reviewed for presence/absence
and severity of inflammation. On the day of endoscopy, C-reactive protein
(CRP) was measured and blood was collected in PAXgene tubes (Qiagen).
Total RNA was extracted from blood using the PAXgene Blood miRNA kit
(Qiagen) and miRNA counts from 798 probes were measured using the
Human v3 miRNA nCounter Platform (NanoString Technologies). Raw
counts were normalized, log2 transformed and batch corrected. Non-parametric
Kruskal-Wallis tests assessed differential miRNA expression across phenotypes.
Raw p-values were corrected for multiple testing by the Benjamini-Hochberg
false discovery rate method. Target prediction and gene ontology biological
process (GO BP) enrichment analyses were performed with miRWalk 2.0.
Receiver operating characteristic (ROC) curves were generated following logistic
regression through 5-fold cross validation repeated 10 times. Area under the
curve (AUC) values for the ROCs were derived in order to evaluate the discri-
minating capacity of the differentially expressed miRNAs in CCD versus UC.
Result: 51 subjects, 32 UC (50% male, 36 yrs mean age), 19 CCD (42% male, 32
yrs mean age) were included in the analysis (see Table 1). There were no signifi-
cant differences in mean CRP or among clinical, endoscopic or histologic disease
activity between the CCD and UC groups suggesting that the degree of inflam-
mation was similar in both groups. Comparing CCD and UC, 5 miRNAs were
differentially expressed: miR-129-5p, miR-603, miR-619-3p, miR-874-3p, miR-
933 (FDRp¼ 0.0214 all probes), all of which were upregulated in CCD vs UC. In
the ROC analysis, the AUC for CCD vs UC for the combined expression of the 5
miRNAs was 0.89 (95% CI: 0.88–0.90). 2 out of 5 miRNAs putatively target the
Autophagy Related 16-Like 1 (ATG16L1) gene, and 4 out of 5 miRNAs had
significant GO BPs on putative target genes in the regulation of autophagy path-
way (FDRp5 0.05).
Conclusion: A PBMC-derived miRNA panel of markers identified here differ-
entiates CCD from UC with similar degrees of inflammation. All of these differ-
entially expressed miRNAs are upregulated in CCD compared to UC, and
Table 1. (OP297)
Feature CCD n¼ 19 UC n¼ 32 P value
Age at testing (meanSD, y) 32.0 14.9 36.0 10.6 0.3
Age at diagnosis (meanSD,y) 25.7 15.5 25.3 10.2 0.9
Disease Duration at testing (meanSD,y) 6.2 4.8 10.5 8.4 0.047
Gender (%,n), male 42 (8) 50 (16) 0.44
Clinically active (%,n) 58 (11) 66 (21) 0.77
Endoscopically active (%,n) 89 (17) 71 (25) 0.45
Histologically active (%,n) 79 (15) 63 (20) 0.35
Treatment (%,n) Biologic Azathioprine ASA Steroid Antibiotic 15.8 (3) 15.8 (3) 15.8 (3) 0 0 7.2 (3) 0 69 (22) 2.3 (1) 0 0.67 0.047 0.0004 1 1
CRP (meanSD, mg/mL) 16.1 21.1 8.7 16.3 0.2
WCC (meanSD,X 109/ L) 6.5 2.0 6.3 1.3 0.7
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several appear to be associated with the autophagy pathway. These findings may
aid individualization of patient care through identification of novel diagnostic
and therapeutic targets.
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Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) are considered to
be driven by both common and distinct underlying mechanisms of pathobiology.
In both diseases there is heterogeneity underscored by the variable clinical
responses obtained to therapeutic interventions. We aimed to identify disease-
driving pathways as well as classify individuals into subpopulations that differ in
their disease pathobiology and response to a specific treatment.
Aims & Methods: Hierarchical clustering on enrichment scores (ES) from gene set
variation analysis (GSVA) was used probing a normal healthy volunteer (NHV),
CD and UC data set of colonic biopsies (GSE16879) with a library of gene set
signatures representative of various immunological and inflammatory processes
as well as specific activated cell types. Patient stratification at baseline (BL) or
after anti-TNF treatment (PT) in either clinical responders (R) or non-responders
(NR) was queried.
Result: Gene set signatures whose ES differed significantly (ES change 0.2,
p 0.05) between comparisons were identified from general linear model ana-
lyses. Comparisons were made at BL in all participants irrespective of clinical
response, in clinical R and in clinical NR respectively compared to NHV. 59% of
the tested signatures were commonly enriched in both CD and UC at BL under-
lining the commonality of both diseases. These signatures included e.g. activated
T cells, monocytes, macrophages or neutrophil signatures as well as poly:IC and
bleomycin signatures, representing acute inflammation and a complex mix of
potential disease-driving biology. Comparing R and NR separately at BL to
NHV, 43% and 70% of signatures were enriched, respectively, indicative of a
higher inflammatory burden in NR. Indeed, specific macrophage, innate lym-
phoid and dexamethasone signatures were uniquely enriched in NR. Hierarchical
clustering of the ES that significantly differed in the comparisons clearly sepa-
rated diseased BL from NHV samples. It also clustered R PT samples with the
NHV while the NR PT samples clustered with the BL diseased samples, with a
better separation observed in CD when compared to UC. Also, clear UC and CD
patient clusters could be observed with increasing ES at BL correlated with NR
to anti-TNF treatment recapitulating the observation of a higher inflammatory
burden in NR.
Conclusion: Our analysis has identified common disease-driving pathways for CD
and UC supporting the notion of a disease continuum rather than two distinct
diseases. However, within that disease continuum, distinct patient groups could
be defined by their overall inflammatory burden correlating with their response
to an anti-TNF therapy. This methodological approach could facilitate better
targeted design of clinical studies to test therapeutics under development, con-
centrating on subsets of patients sharing similar underlying molecular pathology
and therefore increasing the likelihood of clinical response.
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Introduction: A high prevalence of invasive Escherichia coli strains, named AIEC
(adherent-invasive E. coli), has been reported in the intestinal mucosa of Crohn’s
disease (CD) patients. A deregulated microRNA (miRNA) expression profile has
been reported in CD patients’ peripheral blood. Exosomes are small endosomal-
derived vesicles involved in cell-to-cell communication. Exosomes have been
shown to carry miRNAs that can be efficiently transferred to recipient cells.
We recently showed that AIEC-infected human macrophages released exosomes
that trigger a pro-inflammatory response and an increased bacterial intracellular
replication in recipient cells.
Aims & Methods: Here, we investigated whether exosomal miRNAs are involved
in such processes. Exosomes were purified using ExoQuick Exosome
Precipitation kit. miRNA expression levels were analyzed by qRT-PCR.
In vivo infection with AIEC bacteria was performed using ileal loop assays
and exosomes were purified. Purified exosomes were then intravenously injected
in naı¨ve mice (10mg/mouse).
Result: We analyzed the levels of the CD-associated circulating miRNAs
reported in literature in exosomes released from AIEC LF82-infected (Exo-
AIEC) THP-1 macrophages. A significant upregulation of several miRNAs in
Exo-AIEC compared with exosomes released from uninfected (Exo-UI) cells or
cells infected with a non-pathogenic commensal E. coli HS strain was observed
(Exo-HS). To analyze their transfer to recipient cells, naı¨ve THP-1 macrophages
were stimulated with the exosomes, and the levels of miRNAs in recipient cells
were analyzed. The levels of several exosomal miRNAs were increased in THP-1
cells stimulated with Exo-AIEC compared with cells stimulated by Exo-UI or
Exo-HS, suggesting an efficient transfer. In silico analysis showed that the upre-
gulated and transferred miRNAs are involved in inflammatory responses and
autophagy, which is necessary to control AIEC intracellular replication, among
other biological processes. Transfection of antisenses of these miRNAs in THP-1
cells inhibited the Exo-AIEC-triggered increases in pro-inflammatory response
and AIEC intracellular replication in recipient cells, suggesting that these exoso-
mal miRNAs are functional and are involved in the effects of Exo-AIEC in
recipient cells. To confirm the in vitro data, we developed an in vivo model to
analyze the impact of Exo-AIEC on gut colonization by AIEC and AIEC-
induced inflammation. In this model, exosomes were isolated from ileal loops
of genetically susceptible mice infected with AIEC. Purified exosomes were then
intravenously injected in naı¨ve genetically susceptible mice (10mg/mouse), and
AIEC colonization in the gut and AIEC-induced intestinal inflammation were
analyzed.
Conclusion: Our study shows that infection with CD-associated AIEC induces
secretion of exosomes carrying several CD-associated circulating miRNAs by
human THP-1 macrophages. These exosomal miRNAs, when being transferred
into recipient naı¨ve THP-1 macrophages, may be involved in the regulation of
inflammatory and autophagic responses, contributing to host innate defense to
AIEC infection.
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Introduction: Colorectal cancer (CRC) is the third most common in the world of
men, and the second - in women. In Europe remains steady increase in incidence
and mortality according to Globocan 2012 and source EuropaColon. The main
problem after surgery is local recurrences that often develop even after resection
R0. Five-year survival is less than 60% in developed countries [2,3]. Due to this
more and more often there are ideas about intraoperative prevention of local
recurrence. There are a number of studies on intraoperative radiation therapy,
which gives good results for the prevention of CRC recurrence and increase the
five-year survival [4,5]. In fact, we have proposed a method of supporting intrao-
perative chemotherapy with prolonged effect, because most of the local recur-
rence accounts for the second half of the first year after surgery. [2]
Aims & Methods: We aimed to investigate the possibility of using implanting
microreservoirs to improve the results of surgical treatment CRC. To study the
safety and efficacy of this modification surgery. Materials and methods: We have
investigated the number of CRC recurrence for patients without distant metas-
tases, lymph node involvement and no germination of the tumor to other organs
after surgery in a volume R0 for a year after surgery. The study involved 87
patients (54 women and 33 men, mean age 62.4 years þ/ 8.4 years) who were
operated in the Dnipropetrovsk regional proctology centre from February 2014
to February 2015. The control group (42 patients, 17 men and 25 women) per-
formed surgery in standart volume according to giudeline. In the test group (45
patients, 16 males and 29 females) before the anastomosis were formed medicated
microreservoirs with 5-fluorouracil (5FU) supported on polyvinylpyrrolidone
(PVP). In fact, it was a mixture of 30% PVP solution 5ml and 5ml 5FU
(250mg). This mixture was introduced into the muscle layer from the side of
mucosa the 1ml syringe with needle 0,40 10mm27G 1/2 at a distance of 1–
1.5 cm from the edge of the intestine. In one procedure was introduced approxi-
mately 10ml of the drug. The volume of the reservoir was 0.5ml. Next, the
operation was completed in a standard way. As the drug delivery system has
been selected PVP in the concentration of 30% as its safety is confirmed by the
FDA. [8] PVP as a delivery system allows for the gradual release of the drug, due
to 5FU linked ionic bonds with PVP [9], and drug release depends on the rate of
destruction of the carrier polymer. An important advantage is the fact that the
PVP is practically not destroyed at a pH of less than 7 [7], which allows to delay
the release of 5FU, since pH in the stage of inflammation in the tissues is reduced
and consequently the release of the bulk of 5FU will begin after completion of the
inflammation. The 5FU was selected as a drug for the treatment because it does
not require pre-transformation to acting form and is quite effective on condition
achieving sufficient concentration in the tissues.
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Result: In the control group, local recurrence was detected in 12 cases (28.6%).
The following postoperative complications were found: early adhesive intestinal
obstruction in 2 (4.8%) cases of postoperative pneumonia in 1 (2.4%) case.
Within 8 months after surgery 1 patient died of acute coronary syndrome. In
the studied group of local recurrence was detected in 8 cases (17.8%). The fol-
lowing postoperative complications were found: early adhesive intestinal obstruc-
tion in 1 (2.2%) case, even one patient has been adhesive intestinal obstruction in
3 months after the operation, which resulted in the death of the patient on 2 day
after the re-operation due to acute of cardiovascular failure.
Conclusion: 1. Intraoperative implantation of medicated microreservoirs is a safe
and effective procedure for the prevention of early recurrent CRC. 2.
Notwithstanding the low total dose, good effect can be achieved due to the
high concentration of the drug in the tissues. 3. This procedure avoids many
resorptive effects of the chemotherapeutic drug, associated with systemic admin-
istration and high doses required to achieve therapeutic concentrations in tissues.
4. Obviously, it is necessary to continue the monitoring of these patients. 5. It is
possible to consider a combination of other drugs and carrier polymers.
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Introduction: Endoscopic submucosal dissection (ESD) is a minimally invasive
technique, providing en-bloc resection of premalignant and malignant lesions in
early stage gastrointestinal (GI) cancers. Lateral Spreading Tumors (LSTs),
which are endoscopically seen as granular (LST-G) or non granular (LST-NG)
types, are technically difficult to remove as en-bloc with ESD method because of
anatomical features of the colon. In the present study, we present our results of
colorectal ESD procedures in LSTs.
Aims & Methods: Between April 2012- April 2016, a total of 655 colorectal
lesions were referred to our unite for the purpose of removal with advanced
endoscopic techniques (EMR or ESD). Colorectal ESD was performed to 290
lesions. Data was recorded prospectively before and after the procedure. 8 ESD
cases were excluded because the lack of control endoscopy. The results of 282
ESD procedures performed in colon and rectum with diagnosed LST were ana-
lyzed retrospectively.
Result:
Table: Demographic data and colorectal endoscopic submucosal dissection
results [Case (n)¼ 273 Lesion (N)¼ 282]
N¼ 282
Lesion size, mm, mean (SD) (median;
range)
40.44 (26.2)
(33; 14–176)
Tissue size, mm, mean (SD) (median;
range)
49.81 (28.9)
(42; 20–198)
Duration of procedure, min, mean (SD)
(median; range)
79.5 (71.1)
(61.5; 6–540)
Dissection speed, mm2/min, mean (SD)
(median; range)
24.46 (15.41)
(21; 1.74–79.55)
En-Bloc resection rate, N (%) 257 (91.1)
Complete Resection, N (%) 255 (90.4)
Paris Classification, N (%) 1s 1sþ 2a 2a
2aþ 2c
4 (1.4) 142 (50.4) 101 (35.8) 35
(12.4)
Adverse Events, N Delayed bleeding
Perforation
2 9
Localization, N Rectum Sigmoid colon
Descending colon Splenic flexura
Transverse colon Hepatic flexura
Ascending colon Cecum Ileocecal
valve
133 42 16 6 15 25 25 14 6
Pathology, N (%) Carcinoma
Intramucosal Sm1 invasion Sm2
invasion Tubular Adenoma
Tubulovillous Adenoma Villous
Adenoma Serrated Adenoma
124 (44) 99 (35.2) 4 (1.4) 21 (7.4)
28 (9.9) 102 (36.2) 17 (6.0)
11(3.9)
LST LST-G LST-NG 236 46
The 282 colorectal ESD procedures were performed in 273 patients, the demo-
graphic data and results of which are shown in the table. The overall en-bloc and
complete resection rates were 91.1% and 90.4%, respectively. The lesions were
LST-G type in 236 and LST-NG in 46 patients. Histopathology revealed carci-
noma in 124, tubulovillous adenoma in 102, tubular adenoma in 28, villous
adenoma in 17, serrated adenoma in 11 lesions. The rate of carcinoma was
more frequent in LST-NG types than in LST-G type (55,5% vs 37.7%).
Complete resection was not achieved in 9.6% of the patients with positive vertical
border. Perforation occurred in 9 patients which were treated successfully with
endoscopic clip without the need for surgery except for one patient with delayed
perforation. Surgical treatment was performed in all patients with deep submu-
cosal (sm2) invasion, however neoplasia was observed in none of these patients.
Conclusion: Colorectal ESD is a safe and effective method to provide en-bloc and
curative resection of LSTs.
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Introduction: The conventional way for evaluation of rectal cancer angiogenesis
requires a biopsy or a tissue specimen applying specific immunohistochemical or
molecular biological tests. The evaluation of microvessel density is a gold stan-
dard in the assessment of tumour angiogenesis. Doppler ultrasound is an attrac-
tive modality for imaging angiogenesis in vivo which can be repeated without
exposing the patient to any risk.
Aims & Methods: The aim of the current study is to evaluate the preoperative
rectal cancer angiogenic status with Endorectal Power Doppler Ultrasound by
using Doppler Vascularity Index calculated by imaging analysis software and to
compare results with microvessel density in surgical specimens A total of 110
patients (59 males; 51 females, mean age 61.5 years) with rectal cancer were
enrolled in this study. The patients were operated and staged as follows: in
stage I – 20pts (18%), stage II – 29 (26%); stage III – 47 pts (43%); stage IV –
14 pts (13%). Microvessel density was evaluated by using immunohistochemical
staining of surgical specimens with anti-CD-31 antibody. The PDVI of each
tumor was determined using endorectal power Doppler ultrasound with compu-
ter-assisted quantification of colour pixels. The PDVI was defined as the ratio of
the number of the colored pixels within a tumor section to the number of total
pixels in that specific tumor section, and was calculated by using a software.
Result: The mean microvessel density (MVD) was 163 69 microvessels/
mm2(50–328). Median MVD used as the cutoff point divided two groups of
tumours with high (160 vessels/mm2) and low angiogenic activity (4160 ves-
sels/mm2). Mean PDVI was 8.9 6.0% (range: from 0 to 27,3). Median PDVI
(8%) was used as the cutoff divided two groups of tumours with high (8%) and
low PDVI (48%). The MVD and PDVI showed a good positive linear correla-
tion (r¼ 0.438, p¼ 0.002).
Conclusion: Endorectal Power Doppler ultrasonography is a useful noninvasive
method of evaluating the extent of angiogenesis. Tumor angiogenesis assessed by
power Doppler vascular index correlated with histological microvessel density
determination The presented endoultrasound Power Doppler examination is a
reliable and reproducible mean for in vivo preoperative quantitative assessment
of the tumour vascularisation.
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Introduction: Rectal neuroendocrine tumor (NET) less than 10mm in diameter
can be removed by various endoscopic techniques, such as endoscopic mucosal
resection (EMR), modified EMR, and endoscopic submucosal dissection (ESD).
This study aimed to compare efficacy and safety of endocrine submucosal resec-
tion with a ligation device (ESMR-L) or circumferential submucosal incision
prior to EMR (CSI-EMR) versus ESD
Aims & Methods: Fitty-six patients, who underwent endoscopic resection of a
rectal NET less than 10mm in diameter, were enrolled consecutively from March
2013 to June 2015. The patients were classified into three groups according to the
type of endoscopic procedure: ESMR-L group (n¼ 17), CSI-ESD group (n¼ 18),
and ESD group (n¼ 21). We compared treatment outcomes and complications
associated with these methods.
Result: There was no different in tumor diameter between different endoscopic
procedures (ESMR-L, 4.5 1.6mm; CSI-EMR, 5.6 2.0mm; ESD,
5.0 2.2mm, p¼ 0.236). En bloc rsection was achieved in all patients. There
was no lateral margin involvement in all patients. Basal margin involvement
occurred in one patients in the ESD group and two in the CSI-EMR group.
The rates of pathological complete resection were 100% (17 of 17) in the
ESMR-L group, 88.9% (16 of 18) in the CSI-EMR group, and 95.2% (20 of
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21) in the ESD group, respectively (p¼ 0.354). Perforation or delayed bleeding
did not occur. Procedure time of ESMR-L was significantly shorter than those of
the other groups and procedure time increased in order of ESMR-L, CSI-EMR,
and ESD group (4.3 2.0min, 11.2 12.5min, 18.6 3.9min, respectively,
p¼ 0.000)
Conclusion: All endoscopic resection method, including ESMR-L, CSI-EMR,
and ESD were effective and safe for the treatment of rectal NET. compared
with CSI-EMR or ESD, ESMR-L procedure has the advantages of easier and
shorter procedure time. ESMR-L may be considered the treatment of choice for
rectal NET less than 10mm in diameter
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Introduction: The human papilloma virus (HPV) is the leading cause of anal
squamous cell carcinoma. The cytological screening can reduce morbidity and
mortality associated with this cancer, although current recommendations are
based on expert opinion.
Aims & Methods: The authors intend to estimate agreement between anal cyto-
logic examination, histopathology, and anoscopic visual impression. This is a
prospective study of patients receiving anal dysplasia screening between 2010
and 2015, in a proctology consultation of a tertiary referral center. Descriptive
statistics was performed using IBM SPSS Statistics 22 with p5 0.05 deemed to
be statistically significant. Agreement between measures was estimated by
weighted kappa-statistics.
Result: During the period of the study, 141 patients (91% men, mean age 37 14
years, 87% with HIV infection) underwent 175 anal cytology tests: 33% negative
for intraepithelial lesion or malignancy (NILM), 22% atypical squamous cells of
uncertain significance (ASCUS), 33% low-grade squamous intraepithelial lesion
(LSIL), 10% high-grade squamous intraepithelial lesion (HSIL) and 1% carci-
noma in situ (CIS). Concerning anoscopic visual impression, 40% patients had
no lesions (53% NILM, 22% ASCUS, 25% LSIL). In the remaining patients,
excision/biopsy of the identified lesions was performed detecting 40 (23%) high-
grade dysplasia (HGD), 33 (19%) low-grade dysplasia (LGD) and 4 (2%) CIS.
Weighted kappa-agreement between abnormal cytological results and anoscopic
visual impression was moderate (k¼ 0.48). Weighted kappa-agreement between
the presence and degree of dysplasia in anal cytologic tests and concurrent his-
topathology was low (k¼ 0.23 and k¼ 0.20, respectively). Of the 57 NILM cyto-
logic tests, 26% had suspicious lesions in anoscopic visual impression and of
these, 9 (60%) had dysplasia on histopathological exam (4 HGD and 5 LGD).
By other hand, concerning the patients with HGD/CIS on histologic exam, 28
(64%) patients had lower dysplasia grade on cytological exam (6 ASCUS, 18
LSIL and 4 NILM).
Conclusion: The low correlation between anal cytology, histopathology and ano-
scopic visual impression associated with the high number of histological exams
with HGD/CIS with lower dysplastic degree on cytological exam (including
NILM anal cytologies) suggest that anal cytology screening should not be used
as the unique method of anal dysplasia screening. The authors suggest that
anoscopic screening should be offered to all patients.
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Introduction: Current trans-anal surgical (TEMS/TEO) and advanced endoscopic
resection procedures (P-EMR/ESD) have the potential to resect complex rectal
polyps (CRPs). However both approaches have limitations in terms of practi-
cality and safety.
Aims &Methods: Consecutive patients (Jan13/Dec15), referred for the excision of
CRPs, were being considered for proctectomy and/or had failed conventional
endoscopic or trans-anal therapy. The GelPoint Path trans-anal access port
comprises a soft plastic extension, (with a diameter of 3.6 cm) allowing simulta-
neous passage/triangulation of an endoscope and two laparoscopic retractors
and permitting dynamic tissue manipulation to facilitate endoscopic submucosal
dissection/ESD. Supplementary techniques were also used to complete the resec-
tion such as piecemeal endoscopic mucosal resection or ablation/P-EMR or
EMA and trans-anal excision/TAE. The aim of this study was to evaluate the
feasibility, technical success and safety profile of this new hybrid, endo-surgical
Trans-Anal Submucosal Endoscopic Resection- (TASER) approach for CRPs.
Result: Thirty-two TASER procedures were employed in 31 patients (mean age
65years/17 males–14 females) with 31 CRPs (mean size 8 cm/range 5 cm–18 cm).
Complete endoscopic excision in a single session was achieved in 28/31 patients
(93%); in one patient a second TASER session was required for completion
polypectomy, in another deep submucosal invasion was suspected during
TASER-ESD/P-EMR/EMA – patient had an elective laparoscopic anterior
resection (T1,sm3,N0,M0 confirmed) and in a third patient intraperitoneal per-
foration necessitated a de-functioning ileostomy before complete polypectomy
could be undertaken. Mean procedure time was 185min, range 65–480min.
Thirty two TASER sessions were employed using ESD in 12/32, ESDþP-
EMR in 6/32, ESDþP-EMRþEMA in 4/32, ESDþTAE in 3/32, ESD/P-
EMR/TAE in 3/32 and ESDþP-EMRþEMAþTAE in 4/32. Intra-procedural
bleeding was controlled with haemostatic endoscopic devices (coagrasper/clips);
surgical clipping and suturing on 2 occasions. Prophylactic endoscopic clipping
was also applied in 8 cases and suturing on 4 occasions. In 6/10 TASER -TAE
cases there was a need for a full-thickness rectal dissection due to severe sub-
mucosal fibrosis: 4/6 cases were closed with surgical sutures plus endoscopic clips
and in the remaining 2/6 cases only endoscopic clips were deployed. Two epi-
sodes of delayed bleeding were reported among the TASER-ESD/P-EMR and
TASER-ESD sub-cohorts with no transfusion or re-intervention requirement.
All patients were discharged the day after the TASER PROCEDURE apart
from one patient who developed bacteremia post TASER-ESD requiring intra-
venous antibiotics and a 4-night hospital stay and the patient who required a
defunctioning ileostomy, discharged on day 4 post operation. First follow-up
performed at 4–6 months interval in 25/31 patients showed: 21/25 with no recur-
rence (84%) and 4/25 (16%) with a minimal (515mm) polyp recurrence, amen-
able to endoscopic therapy. No rectal stricturing was identified and only one
episode of transient faecal incontinence were reported.
Conclusion: TASER appears to be a safe and efficient endo-surgical approach
providing an optimal platform for the minimally-invasive management of high-
risk, complex rectal polyps.
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Introduction: Endoplasmic reticulum (ER) function and autophagy are necessary
to maintain cellular homeostasis. Genetic variants of inflammatory bowel disease
(IBD) risk genes ATG16L1 or XBP1 are associated with epithelial endoplasmic
reticulum (ER) stress which promotes cell death. While XBP1 plays a beneficial
role in resolving ER stress, ATG16L1 represents an essential component of the
autophagic machinery, a conserved mechanism for protein degradation. Both
processes are strongly connected since impaired autophagy subsequently results
in deregulation of ER function. Interleukin-22 (IL-22) is known to be a protec-
tive cytokine in mucosal regeneration by promoting epithelial proliferation via
STAT3 activation. Therefore, conjugates of IL-22 are in trials as potential drugs
in IBD treatment.
Aims &Methods:Here, we investigate the impact of the IBD risk genes ATG16L1
and XBP1 on regenerative function of IL-22 in intestinal epithelium in mice and
human. Human colon carcinoma HT-29 and Caco2 cells were treated with
recombinant IL-22 and ER stress inductors like Tunicamycin or autophagy
inducers like Rapamycin before they were subjected to wound healing assays,
gene expression analysis and immunoblot analysis. Intestinal organoids derived
from Xbp1 IEC (intestinal epithelial cell-specific deletion) and Atg16l1 IEC
mice were treated with recombinant IL-22 and gene expression analysis using
qRT-PCR, RNA sequencing and transcriptome analysis were performed.
Secreted cytokines in supernatants from cells and organoids were detected with
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ELISA. Atg16l1 IEC and Atg16l1 IEC/Xbp1 IEC mice were treated with
recombinant IL-22 for 6 or 12 days before sacrificing.
Result: IL-22 induces transient self-limiting ER stress in the intestinal epithelium.
While IL-22 improves wound healing in the absence of ER stress, IL-22 leads to
impaired wound closure and increased cell death under ER stress conditions.
This effect is dependent on STAT3 and autophagy as pharmacological STAT3
inhibition or autophagy induction with Rapamycin completely restores IL-22
dependent ER stress induction. On the contrary, impairment of the autophagic
flux by Bafilomycin A provokes inflammatory features as well, which are aggra-
vated by IL-22. Regulation of transient ER stress is dependent on Xbp1 and
Atg16l1 as IL-22 treatment of intestinal organoids derived from Atg16l1 IEC
und Xbp1 IEC mice induces a dramatic increase of inducible ER stress and pro-
inflammatory gene expression. In addition, mRNA transcriptome analysis
reveals differential expression of several IBD related risk genes in Xbp1 IEC
and Atg16l1 IEC organoids in response to IL-22 stimulation. Atg16l1 IEC
mice display defective autophagy in the intestinal epithelium and spontaneous
cell death in intestinal crypts which exacerbates after IL-22 treatment. Finally,
IL-22 aggravates preexisting spontaneous transmural intestinal inflammation in
Atg16l1 IEC/Xbp1 IEC mice. On the flipside, same treatment of wild type
control mice does not affect cell death and inflammation, underlining a genotype
dependency of beneficial and adverse effects of IL-22 application.
Conclusion: These data suggest an unexpected role of the IBD risk genes
ATG16L1 and XBP1 in coordinating regenerative IL-22 function in intestinal
epithelium and may contribute to the development of genotype-based persona-
lized medicine. However, further studies are necessary to decipher the molecular
link between IL-22 signaling and the ER stress/autophagy axis.
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Introduction: Colonic adenomas are premalignant epithelial tumors with gland-
ular origin. Identifying the molecular aberrations in this tissue may help to
understand its malignant potential and could lead to better understanding of
colorectal cancer development. The mammalian HOX clusters encode regulators
of embryonic anterior to posterior specification and are important for the for-
mation of tissues, structures, and organs. Besides having a function in embryol-
ogy, HOX genes have pro-oncogenic activity in various malignant diseases. For
example, HOXA13 overexpression predicts poor outcome for patients with
cancer of the esophagus, stomach, and liver. In a portion of acute myeloid
leukemias (AML), a translocation encoding the NUP98-HOXA9 oncogene
gives overexpression of HOXA9. HOXA9 overexpression is the molecular
factor most strongly correlated with poor prognosis in AML and is also corre-
lated with poor prognosis in ovarian epithelial cancer. HOX gene aberrations are
reported in colorectal cancer, however, it is unclear whether HOX gene aberra-
tions are present at a premalignant stage and could, thus, contribute to cancer
formation.
Aims & Methods: This study firstly aimed to assess the expression of HOXA9 in
colonic adenoma tissue and location matched control tissue. Secondly, it aimed
to evaluate potential effects of increased HOXA9 expression, both in terms of its
influence in anterior to posterior specification and its oncogenic properties. We
collected biopsies from colonic polyps and location matched normal colonic
tissue in patients undergoing colonoscopy. A pathologist classified the colonic
polyp after its resection and we only included tubular adenomas. We used RT-
qPCR to quantify the expression of HOXA9 in relation to UBC, TPT1 and
GAPDH using the efficiency^Ct method. In addition, we transduced Caco2
cells with a lentiviral vector containing HOXA9 and a lentiviral vector without
an insert, enabling inducible expression. Subsequently, we analyzed expression of
genes important in anterior to posterior specification. We determined cell
number and total cell pool with an automatic cell counter and a MTT assay.
Finally, we assessed the expression of genes implicated in oncological transfor-
mation and epithelial to mesenchymal transition.
Result: HOXA9 expression in tubular adenomas of the colon is increased com-
pared to location matched control tissue (p¼ 0.04). HOXA9 overexpression in
Caco2 cells led to a decrease in FGF2 mRNA level (p5 0.001) and an increase in
BMP4 mRNA level (p¼ 0.02). HOXA9 overexpression led to increased cell
numbers when assessed with an automatic cell counter (p¼ 0.004).
Additionally, when assessed with a MTT assay (p5 0.001), HOXA9 overexpres-
sion led to increased total cell pool. The growth factor IGF1 increased signifi-
cantly (p¼ 0.02) as a result of HOXA9 overexpression. Genes important for
epithelial to mesenchymal transition were not found to have significantly
changed.
Conclusion:HOXA9 expression is increased in colonic adenomas. Overexpression
of HOXA9 leads to a decrease in FGF2 and an increase in BMP4, which empha-
sizes that HOXA9 alters anterior to posterior specification. HOXA9 overexpres-
sion leads to growth of the cell pool. A mechanism through which HOXA9 exerts
this effect is the upregulation of IGF1. In conclusion, HOXA9 appears to have
pro-oncogenic activity in the premalignant stage of colorectal cancer.
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Introduction: Genetic deletion of the Toll-interacting protein (Tollip) -an IL-1R
and TLR2/4 regulator- leads to increased acute and chronic colitis in mice (1).
We sought to investigate whether increased susceptibility to inflammation had an
impact on inflammation-driven colorectal carcinogenesis.
Aims &Methods: Colitis-associated cancer (CAC) was induced in 18–20-week old
littermates C57BL/6 mice by azoxymethane (AOM) i.p. injection and 3 cycles of
2.5% oral dextran sodium sulfate (DSS) treatment. Tumor development was
assessed endoscopically, microscopically and histologically. Apoptotic and pro-
liferative index in the colon were determined by Tunel assay and Ki67 immuno-
histochemistry and quantified using the Image J software. Cytokine and gene
expressions were measured by RT-qPCR. SMAD2 phosphorylation was assessed
by Western blot.
Result: Tollip KO mice had significantly lower endoscopic tumor scores than WT
littermates upon AOM-DSS exposure (8.4 7.8 vs 13.4 6.4, p4 0.05).
Likewise, tumor numbers (4.9 3.5 vs 7.1 3.0, p4 0.05) and size were reduced.
Immunohistological studies demonstrated reduced apoptotic index (79.3 75.0
vs 246.8 152.9, p4 0.05) and lower proliferation (21.0 8.5 vs 27.9 7.3, ns) in
Tollip KO tumors when compared to wt controls. RNA analyses showed that
Tollip ablation favors an anti-tumorigenic environment with reduced Bcl-xl
(85.8 50.9 vs 36.2 39.5) and c-myc expression (6.2 4.9 vs 2.1 2.6).
Importantly, Tollip deficiency led to reduced Foxp3 abudance (3.7 2.6 vs
2.1 1.7) in unchallenged colonic as well as in tumoral tissues. In addition,
Tollip deficient tumors harbored reduced TGFbeta expression as well as reduced
SMAD2 phosphorylation suggesting that TGFbeta signaling is dysfunctional in
the absence of Tollip.
Conclusion: Our data show that Tollip partially favors colonic oncogenesis
despite being protective against colitis. Putative mechanisms include reduced
tumor-associated regulatory T cells and aberrant TGFb-induced signals in
Tollip deficient mice.
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Introduction: The patients with ulcerative colitis (UC) are at increased risk of
developing colitis-associated cancer, because long-term inflammation leads to the
development of carcinogenesis. However, the transformation of colonic epithelial
cells during long-term inflammation has not been elucidated. Recently, 3-dimen-
tional (3D) primary organoid culture of colonic epithelial cells in mice has been
established in our group (TMDU method)1.
Aims & Methods: We therefore aimed to assess the effect of long-term inflamma-
tion on the epithelial cells by in vitro model, which might mimic natural history
of UC. Colonic crypts were isolated from 8 week old female mouse and were
cultured by TMDU method. To mimic chronic inflammation, the inflammatory
reagents, the mixture of cytokines and the ligands of toll like receptors, were
added into the medium every other day for 40 weeks. Thereafter, glycogen
synthase kinase 3 (GSK3) inhibitor, CHIR99021 was added into the medium
for 8 weeks with stimulation of inflammatory reagents. To evaluate transforma-
tion into tumor, the organoids were cultured without R-spondin1 and Wnt3a.
The assessment of cell signaling pathways in organoids during long-term inflam-
mation was performed by 3D immunohistochemistry of whole organoid and
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western blot analysis. The gene expression of transformed organoids was assessed
by microarray analysis and quantitative RT-PCR.
Result: The treatment with the inflammatory reagents in mouse colonic orga-
noids showed the time-dependent induction of NF-B target genes. Particularly,
the expression of DUOXA2 gene was gradually increased by the continuous
stimulation with the inflammatory reagents for 40 weeks. 3D immunostaining
analysis showed NF-B p65 was accumulated in nuclei by longer time of the
stimulation, indicating that long-term stimulation might lead to a stronger acti-
vation of NF-B signaling. Interestingly, accumulated NF-B signaling by long-
term stimulation remained active after the removal of all inflammatory reagents,
whereas NF-B signaling induced by short-term stimulation was completely shut
down by the removal of all inflammatory reagents, suggesting that NF-B might
be irreversibly activated by long-term stimulation. Moreover, the organoids
required neither R-spondin1 nor Wnt3a after the treatment with GSK3 inhibitor
for 8 weeks, indicating that the organoids might be transformed like colitis-
associated cancer. Microarray analysis and Gene Set Enrichment Analysis of
transformed organoids showed irreversible Akt signal activation and reduced
expression of Tgfb2, indicating that this transformation might involve the inflam-
matory-rerated carcinogenesis.
Conclusion: Long-term inflammation and nuclear accumulation of b-catenin
leads to irreversible cell transformation, which is wnt independent survival capa-
city of colonic organoids. This in vitro model might mimic the natural history of
epithelial cell transformation during inflammation-related carcinogenesis in UC.
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Introduction: The stability of genomic DNA is under a tightly controlled surveil-
lance. Especially in highly proliferating cells, as e.g. intestinal stem cells, RNA/
DNA hybrids display a menace to DNA integritiy. The ribonuclease RNAseH2b
removes RNA/DNA hybrids and thereby ensures cellular proliferation.
Hypomorphic mutations of the RNAseH2b gene are associated with Aicardi-
Goutie`res syndrome that results in a spontaneous inflammatory phenotype. We
tested the role of RNAseH2b in maintaining proliferation and regeneration in the
intestinal epithelium.
Aims & Methods: We generated RNAseH2bfl/fl and RNAseH2bIEC to study the
role of RNAseH2b in the intestinal epithelium. WB, RT-PCR and IHC were
performed to study the basal phenotype of unchallenged WT and KO mice.
Acute DSS colitis was induced to investigate the impact of RNAseH2b on intest-
inal regeneration. AOM-DSS colitis was induced to study the role of RNAseH2b
on intestinal carcinogenesis. Organoids of RNAseH2bfl/fl and RNAseH2bIEC
were subjected to RNA sequencing.
Result: No macromorphological difference was seen between RNAseH2bfl/fl and
RNAseH2bIEC, with respect to age dependent body weight gain. Histological
characterization reveals spontaneous DNA double strand breaks (DSB) in
epithelial crypts of RNAseH2bIEC, which leads to a restriction of epithelial
stemness, as measured by expression of stem cell markers (Olfm4, Lgr5) and
reduced KI67 staining of intestinal stem cells. When mice were challenged to
acute DSS colitis, RNAseH2bIEC mice reveal a strong phenotype with dramatic
weight loss, increased histological disease activity and impaired intestinal regen-
eration. Interestingly, when mice were challenged to AOM-DSS colitis, mice
again showed increased intestinal inflammation but developed significantly less
tumors. Decreased tumor development was due to DNA induced cellular senes-
cence, as shown by acid ß- galactosidase staining in intestinal crypts in
RNAseH2bIEC but not RNAseH2bfl/flmice.
Conclusion: We show for the first time, that the RNAseH2b plays an essential
role in maintaining intestinal regeneration by protecting genomic DNA of high
proliferating cells from DNA/RNA hybrids induced DNA damage. Knockout of
RNAseH2b leads to loss of epithelial stemness and induction of cellular
senescence.
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Introduction: Intestinal epithelial cells (IECs) are the first to encounter luminal
antigens and play an active role in intestinal immune responses. We recently
reported that the b-glucan receptor Dectin-1 and its major signaling mediator
spleen tyrosin kinase (Syk) are expressed by normal ileal and colonic IECs.
Furthermore, b-glucans, major fungal cell wall glycans, induced chemokine
secretion by IEC lines in a Dectin-1 and Syk dependent manner. Autophagy is
a homeostatic process in the gut and defects in autophagy were associated with
Crohn’s disease (CD) susceptibility. Vague data exist regarding the role of fungi
and their glycans in inducing autophagy.
Aims & Methods: To investigate whether fungi and fungal glycans induce autop-
hagy in IECs. Human IEC lines (HT-29 and SW480) were activated by C. albi-
cans and S. cerevisiae and the b-glucan-rich cell-wall component zymosan.
Autophagy was detected by Western blot (WB) and immunofluorescence (IF)
of microtubule-associated protein 1A/1B-light chain 3 (LC3) or directly visua-
lized in cells stably expressing GFP-LC3. Syk phosphorylation was assessed by
WB and IF. Mucosal samples were obtained from patients undergoing colono-
scopy and active autophagy was assessed by the punctal stain of endogenous LC3
in paraffin embedded sections or in frozen sections by IF.
Result: C. albicans (live, heat-killed [HK] - or UV-inactivated, S. cerevisiae (HK)
and zymosan particles induced autophagy of IEC lines. This was indicated by 1)
Increase in the active (cleaved) form of LC3 (LC3 II) e.g. up to 3.5 fold increase
in LC3 II/actin ratio in response to HKCA vs. no treatment in HT-29 cells; 2)
Appearance of LC3 puncta, indicating autophagosome binding, of endogenous
LC3 as well as GFP-LC3. Comparable levels of autophagy were obtained upon
amino- acid starvation of IECs -e.g. up to 3.7 fold increase in LC3 II/GAPDH
ratio in starved SW480 cells vs. no treatment. Fungal–induced autophagy was
accompanied by Syk phosphorylation and prevented upon Syk inhibition. In ileal
and colonic mucosal samples, active autophagy in IECs was observed as LC3
puncta. Autophagy was further induced ex-vivo by UV-inactivated C. albicans,
zymosan or rapamycin (mTOR inhibitor, autophagy inducer).
Conclusion: Commensal fungi and their cell-wall glycans induce autophagy in
IECs. Syk-dependent autophagy suggests the involvement of antifungal receptors
such as Dectin-1. Fungal-induced autophagy may play a role in mucosal sensing
of luminal microorganisms, and contribute to fungal tolerance. Thus, imbalanced
response to commensal fungi (recognition, autophagy or downstream processes),
may impair homeostasis and contribute to the pathogenesis of CD.
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Introduction: Despite advances in understanding the pathogenesis of acute pan-
creatitis (AP), the mechanisms underlying this disease have not been fully deter-
mined. In the majority of cases, AP is a self-limited process, yet 20% of patients
develop a severe form of AP with pancreatic necrosis, multi-organ involvement,
and high mortality. Heparanase (HPSE), an endoglycosidase which cleaves
heparan sulfate, degrades and remodels the extracellular matrix. HPSE is pre-
ferentially expressed in human tumors, including pancreatic adenocarcinoma.
While the role of HPSE in cancer has been extensively studied, the involvement
of this enzyme in inflammation and in AP in particular remains obscure.
Therefore, this current study examines if HPSE is involved in the pathogenesis
of Cerulein-induced AP in mice.
Aims & Methods: HPSE over-expressing transgenic mice (hpa-TG) and wild-type
(WT) BALB/c mice were intraperitoneally injected with either Cerulein (50mg/
kg, 5 times, at 1 hour apart) or vehicle, with or without low and high doses of
Roneparstat (SST0001, HPSE inhibitor) pretreatment. The animals were sacri-
ficed 24 hours following the development of pancreatitis. The pancreatic response
and the severity of AP were evaluated by pancreatic HPSE activity (determined
by Na235SO4-labeled ECM), pancreatic edema index (determined by organ to
animal weight ratio), tissue inflammatory response (determined by histopatholo-
gical analysis), autophagy response (determined by electron microscopy and
immunohistochemistry staining) and serum pancreatic enzymes (amylase and
lipase) levels.
Result: Cerulein-induced AP in wild type mice was associated with significant
rises in the serum levels of amylase and lipase. These increases were characterized
by an enhancement of HPSE activity, a higher pancreatic edema index, tissue
inflammation and autophagy response. All types of responses to administration
of Cerulein were profoundly exaggerated in hpa-TG mice. In contrast, when
Cerulein was injected to hpa-KO mice, the severity of pancreatic injury was
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attenuated as compared with their wild type controls. Importantly, pretreatment
with Roneparstat significantly reduced, in a dose-related manner, the HSPE
activity, the tissue inflammatory response, autophagy and serum amylase and
lipase levels.
Conclusion: HSPE appears to play an important role in the pathogenesis of AP.
The HSPE inhibitor (Roneparstat) significantly reduced the severity of the AP in
an animal model. This new concept may provide a basis for prophylaxis and
treatment of AP.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Smoking represents an independent risk factor for the development
of chronic pancreatitis (CP). It is well documented that secretion of pancreatic
ductal alkaline fluid (which is regulated mostly by anion exchangers and CFTR)
is diminished in CP.
Aims &Methods: In this study, we would like to understand whether smoking has
any effects on pancreatic ductal fluid and HCO3
- secretion. Guinea pigs were
exposed to cigarette smoke four times a day for 30min for 6 weeks. The expres-
sion of CFTR was analysed by immunohistochemistry. Intra/interlobular pan-
creatic ducts were isolated from guinea pig pancreas. Cigarette smoke extract
(CSE) was prepared by smoking of 15 cigarettes into 10ml distilled water by a
smoking machine. Three different concentraion (20, 40 and 80 mg/ml) were
diluted using the stock solution. Intracellular pH was evaluated by microfluoro-
metry. Basal and forskolin-stimulated fluid secretion was measured by video
microscopy. CFTR currents were detected by whole cell configuration of patch
clamp technique.
Result: Cigarette smoking significantly diminished the expression of CFTR and
the fluid and HCO3
- secretion in guinea pig pancreas. 40mg/ml CSE decreased
HCO3
- secretion via inhibition of Cl-/HCO3
- exchanger activity. CSE dose-
dependently decreased forskolin-stimulated fluid secretion in guinea pig pancrea-
tic ducts and forskolin-stimulated Cl- current of CFTR Cl- channel (20mg/ml by
44.5%, 40 mg/ml by 69.3% and 80 mg/ml by 81.3%).
Conclusion: Cigarette smoking and CSE inhibits pancreatic ductal fluid and
HCO3
- secretion and the activity of CFTR which may play role in the smoke-
induced pancreatic damage. This study was supported by OTKA, MTA and
TA´MOP.
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Introduction: Ghrelin (GHRL), a 28-amino acid polypeptide, that was originally
isolated from the stomach, was shown to protect the pancreas from caerulein-
induced pancreatitis (AP) [1–3].
Aims & Methods: To determine the effects of GHRL on tumor necrosis factor-
alpha (TNF-) concentration in the rats with AP and on the signals for growth
hormone secretagogues receptor type 1a (GHS-R1a) and TNF- in the pancrea-
tic acini. AP was induced by caerulein infusion (25mg/kg s.c.). GHRL (12.5; 25;
50 mg/kg i.p.) was given to the control rats and prior to the start of inflammation
in vivo. Plasma TNF- concentration was measured by ELISA. Pancreatic acini
were isolated from control, GHRL rats and then hyperstimulated by caerulein
(10-8M) in vitro. The gene expressions were determined by RT-PCR and the
protein contents by Western-blot
Result: Administration of GHRL to the control rats failed to affect TNF-
concentration in plasma. AP significantly increased its, but application of
GHRL prior to the inflammation significantly dose-dependently reduced this
pro-inflammatory cytokine. Protein expressions and mRNA signals for GHS-
R1a and TNF- have been detected in the pancreatic acini under basal conditions
and GHRL resulted in a statistically increase of GHS-R1a without changing
signals of TNF-. Caerulein significantly changed the test signals: downregulated
receptor and upregulated cytokine. These adverse effects were reversed by
GHRL.
Conclusion: Caerulein upregulated molecular signals for TNF- and downregu-
lated that for GHS-R1a in the pancreatic acini. This effect could be prevented by
pretreatment of the AP rats with GHRL. Above mechanism could be implicated
in the protective action of this polypeptide in AP.
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Introduction: Diabetes represents one of the major burdens in the 21st century
with approx. 350 million people affected worldwide. Monogenic diabetes such as
juvenile onset insulin-dependent diabetes (JOD) or maturity onset diabetes of the
young (MODY) accounts for approximately 1–2% of diabetes cases and results
from mutations that primarily reduce b-cell function. The identification of the
genetic basis of these diabetes forms has translated into novel avenues of perso-
nalized medicine in the diabetes field, but only few of these genes have been
identified to date.
Aims & Methods: Based on published data, we hypothesize that a proportion of
the genetic contribution to common diabetes (T1D and T2D) may be caused by
rare monogenic variants/mutations missed by the current GWAS strategies tar-
geting common variants. The current project reports on such a novel gene rele-
vant as regulator of human pancreatic islet formation but also as a novel early
onset diabetes gene.
Result: Using stage-specific genome-wide profiling complemented with Chip-Seq
data in differentiating human embryonic stem cells, we show that our gene binds
and activates Nkx2.2, Nkx6.1 and Pdx1, all belonging to the core suite of isle-
togenesis transcription factors. Interestingly, this gene co-occupies the enhancer
and promoter regions of the latter genes together with Foxa2, Pdx1 and Gata6.
Finally, we engineered human embryonic stem cells with previously identified
mutations in JOD patients. Directed differentiation studies of these cells shows
an altered binding pattern of Nkx2.2, Nkx6.1 and Pdx1 finally leading to reduced
amounts of monohormonal b-cells. This reduced target gene binding results from
a limited zinc affinity, due to the mutation, that would be necessary as co-factor
for gene binding.
Conclusion: This platform not only allows personalised drug-testing but also
sheds light on the mechanism how our JOD gene regulates pancreatic develop-
ment and leads to diabetes in case of certain mutations in humans.
Disclosure of Interest: All authors have declared no conflicts of interest.
OP316 LACK OF CFTR RESULTS IN THE IMPAIRED FUNCTION OF
THE PLASMA MEMBRANE CA2þ PUMP THAT CAUSES
INTRACELLULAR CA2þ OVERLOAD AND MITOCHONDRIAL
DAMAGE IN THE PANCREATIC DUCTAL EPITHELIAL CELLS OF
CFTR KNOCK OUT MICE
T. Madacsy1, J. Fanczal1, P. Pallagi1, V. Venglovecz2, Z. Rakonczay3, P. Hegyi4,
J. Male´th1
1First Department Of Medicine, University of Szeged, Szeged/Hungary
2Department Of Pharmacology And Pharmacotherapy, University of Szeged,
Szeged/Hungary
3First Department Of Medicine, University of Szeged 1st Dept. of Medicine,
Szeged/Hungary
4University of Pe´cs, Pe´cs/Hungary
Contact E-mail Address: tamaramadachy@gmail.com
Introduction: The cystic fibrosis transmembrane conductance regulator (CFTR)
has a significant role in pancreatic ductal epithelial secretion and it’s genetic
defects damage the pancreas. The exact mechanism of this pancreatic damage
is only partially known. The toxic cellular Ca2þ overload is a hallmark of acute
pancreatitis and in CFTR-deficient airway epithelial cells the intracellular
Ca2þhomeostasis was disturbed. However the Ca2þ homeostasis of CFTR-defi-
cient pancreatic ductalepithelial cells (PDEC) has never been investigated
Aims & Methods: Our aim was to characterize the Ca2þ homeostasis of CFTR-
deficient PDEC. Pancreatic ducts and acinar cells were isolated from wild type
(WT) and CFTR knockout (KO) mice. Intracellular Ca2þ concentration ([Ca2þ]i)
and changes of the mitochondrial membrane potential was measured.
Result:Maximal [Ca2þ]i release upon carbachol stimulation showed no difference
in WT and CFTR KO PDEC. Notably, the plateau phase of the Ca2þ signal was
significantly higher in CFTR-deficient PDEC, but completely normal in pancrea-
tic acinar cells. Interestingly, the functional inhibition of CFTR with 10mM
CFTR(inh)-172 had no effect on the Ca2þ signals. Next we investigated the
Ca2þefflux in PDEC and found that the Ca2þ extrusion was significantly lower
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in CFTR KO PDEC compared to WT due to the impaired function of the
plasma membrane Ca2þ pump (PMCA). In addition, the sustained elevation of
[Ca2þ]i caused a drop in mitochondrial membrane potential in CFTR KO
PDEC.
Conclusion: Dysfunction of PMCA leads to disturbed Ca2þ homeostasis in
CFTR-deficient PDEC and the consequent cellular Ca2þ overload impairs mito-
chondrial function. These changes might contribute to the pancreatic damage
seen in cystic fibrosis.
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Introduction: Main pancreatic duct (MPD) strictures located in the head of the
pancreas often occur in the course of chronic pancreatitis (CP). Common man-
agement of these strictures is endoscopic placement of a single plastic stent.
Refractory strictures require repeated stent replacement or surgical pancreatico-
jejunostomy. Insertion of multiple plastic stents (MPS) obtained, in a series of 19
patients, symptomatic MPD stricture resolution in 84% of the cases, after 3-year
follow-up (1) The aim of this study was to evaluate the results of the MPS
strategy in a larger series of CP patients.
Aims & Methods: Forty-eight patients (34 men; mean age 44 years, range 5–86)
with severe CP and a symptomatic dominant MPD stricture located in the head
of the pancreas, were evaluated. All the patients experienced pain resolution
following MPD drainage with a single plastic stents. The MPD stricture was
refractory to single plastic stent placement in all cases and patients underwent
insertion of MPS according to the following protocol: balloon dilation of the
stricture if necessary, insertion of the maximum number of plastic stents allowed
by the stricture tightness and pancreatic duct diameter, stents removal after 6
months.
Result: The median number of stents placed through the major or minor papilla
was 3 (range 2–5), 8.5 to 11.5 Fr in diameter and 3 to 7 cm in length. MPS were
removed after a mean time of 6.7 months (range 2–18). Eight patients (16.6%)
had persistence of the MPD stricture after MPS removal and underwent replace-
ment of an increased number of stents; 3/8 patients had a dilation of the stricture
after further multistent placement (overall success 89.5%). Following a mean
followup of 9.5 years (range 0.3–15.5) after MPS removal, 77.1% of patients
were asymptomatic. Symptomatic MPD stricture recurrence was reported in 11
patients (22.9%), after a mean time of 26.4 months (range 5–108) from MPS
removal. No major complications were recorded.
Conclusion: Endoscopic dilation of CP-related dominant MPD strictures seems
possible with the MPS technique. According to this experience on 48 patients,
MPS is highly effective even at long-term follow-up in the majority of patients.
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Introduction: Mortality in patients with chronic pancreatitis (CP) is increased.
Some previous studies suggest that chronic pancreatitis (CP) is an independent
risk factor of cardiovascular disease (CVD). It is well known that malnutrition
secondary to different diseases and conditions increases the risk of CVD too.
Pancreatic exocrine insufficiency (PEI) causes malnutrition in patients with CP,
but if PEI secondary to CP is associated with the risk of CVD and cardiovascular
(CV) events is unknown.
Aims & Methods: Aim of the present study was to assess the risk of CV events in
patients with CP and the impact of PEI and other factors in these patients. A
retrospective analysis of a prospectively collected database of patients with CP,
who were under follow-up in our Pancreas Unit was carried out. Diagnosis of CP
was based on endoscopic ultrasound (EUS), magnetic resonance cholangio-pan-
creatoscopy (MRCP) and pancreatic MRI. PEI was defined as the need of pan-
creatic enzyme replacement therapy due to the presence of maldigestion-related
symptoms and/or abnormal nutritional markers together with an abnormal 13C-
MTG breath test result. Major CV events (stroke, heart attack) and peripheral
arterial disease (claudication, thrombosis) during follow-up were analysed.
Patients with a past history of CV events previous to the diagnosis of CP were
excluded. Data about sex, age at diagnosis of CP, aetiology, alcohol consump-
tion, smoking, PEI and other comorbidities (including diabetes mellitus) were
evaluated. Statistical analysis was done by logistic regression adjusted for con-
founding factors.
Result: 455 patients were finally included (77,8% men), with a median age of 46
years (range 15–88 years). Mean follow-up was 7.8 years. CP was secondary to
alcohol and/or smoking in 301 patients (66.1%). 149 patients (32.7%) had PEI
and 131 (28.8%) had diabetes mellitus. A total of 46 CV events were recorded in
43 patients (9.5%). 22 patients (4.8%) suffered from a mayor CV event and the
remaining 24 patients (5.3%) presented a peripheral arterial disease. CV events
occurred more frequently in patients with PEI (n¼ 28, 18.8%) than in patients
without PEI (n¼ 15, 4.9%) (p5 0.001). In the logistic regression analysis, PEI
(OR 3.76; 95%CI 1.65–8.58), diabetes mellitus (OR 2.55; 95%CI 1.11–5.83) and
smoking (OR 3.90; 95%IC 1.19–12.7) were significantly and independently asso-
ciated with CV events.
Conclusion: Patients with CP are at high risk of CV events. PEI, diabetes mellitus
and smoking are independent risk factors associated with the risk of CV events in
patients with CP.
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Introduction: One of the most serious complications of (ERCP) is acute pancrea-
titis. The reported incidence varies from 1.3% to 24.4% [1]. Measurement of
serum amylase and lipase levels after the procedure may have a possible role
for early recognition of post-ERCP pancreatitis [3]. Asymptomatic elevation in
serum amylase and lipase activities after ERCP is common, occurring in approxi-
mately 25% to 75% of all patients. A rapid test strip has been developed for the
detection of trypsinogen-2 in urine (The urinary trypsinogen-2 dipstick
test—UT2DSTactim pancreatitis) which is based on the immunochromatogra-
phy principle and shows a good sensitivity and specificity in diagnosing acute
pancreatitis [6]. The aim of this study was to evaluate the diagnostic value of
urinary trypsinogen-2 dipstick test for early diagnosis of post-ERCP pancreatitis.
Aims & Methods: After an informed consent by the patients the selected patients
were subjected to: Full clinical assessment (history taking and clinical examina-
tion), laboratory investigations including (complete blood count (CBC), Bilirubin
(total and direct), (ALT), (AST), alkaline phosphatase (ALP), Prothrombin time
and concentration (PT & PC), urea, creatinine, serum amylase, serum lipase,
urinary trypsinogen-2 dipstick test (UT2DST).
Result: Post ERCP UT2DST was negative in 30 patients of the non pancreatitis
group (96.8%) and positive in one of them (3.2%) The test was positive in all
patients with Pancreatitis (100%). The sensitivity of the post ERCP UT2DST
was 100% the Specificity was 97% with PPV 86%, NPV 100% and the P value
was50.01. Comparison between serum lipase and amylase levels post ERCP in
relation to UT2DST test shows that positive UT2DST test was significantly
associated with higher amylase and lipase serum levels after ERCP (post amylase
and post lipase) (P5 0.01).
Conclusion: The urinary trypsinogen-2 dipstick test can be used as an easy and
rapid test for early diagnosis of post-ERCP pancreatitis with high sensitivity and
specificity and can help clinicians to provide intensive care and possible medical
treatment as early as possible.
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Introduction: A pilot study suggests that aggressive intravenous hydration with
lactated Ringer’s solution may reduce the development of post-endoscopic retro-
grade cholangiopancreatography (ERCP) pancreatitis. The present larger multi-
center study aimed to determine what kind of intravenous hydration could
reduce the incidence of post-ERCP pancreatitis.
Aims & Methods: In a prospective randomized multicenter clinical trial, patients
who underwent first-time ERCP were randomly assigned to 3 groups (1:1:1) that
received aggressive hydration with lactated Ringer’s solution (3mL/kg/h during
the procedure, a 20mL/kg bolus after the procedure, and 3mL/kg/h for 8 hours
after the procedure), standard hydration with the same solution (1.5mL/kg/h
during and for 8 hours after the procedure), or aggressive hydration with phy-
siologic saline (3mL/kg/h during the procedure, a 20mL/kg bolus after the pro-
cedure, and 3mL/kg/h for 8 hours after the procedure). The primary end point,
post-ERCP pancreatitis, was defined as hyperamylasemia (level of amylase4 3
times the upper limit of normal) and increased epigastric pain (3 points on
visual analogue scale) persisting for 24 hours after the procedure.
Result: A total of 406 patients were enrolled, and 395 of them completed the
protocols. The three groups had no significant difference in demographic char-
acteristics or other risk factors before ERCP (P4 0.05). The intention-to-treat
post-ERCP pancreatitis rates were 3.0% (4/132) in the aggressive hydration with
lactated Ringer’s solution group and 11.6% (15/129) in the standard hydration
group (P¼ 0.008), whereas the per protocol (PP) post-ERCP pancreatitis rates
were 1.6% (2/128) in the aggressive hydration with lactated Ringer’s solution
group and 11.6% (15/129) in the standard hydration group (P¼ 0.001). No sig-
nificant differences in the intention-to-treat and PP post-ERCP pancreatitis were
found between the aggressive hydration with physiologic saline group (6.7%, 9/
134; 7.0%. 9/128) and standard hydration group (11.6%, 15/129, P¼ 0.167,
P¼ 0.205).
Conclusion: Aggressive hydration with lactated Ringer’s solution is more effective
than standard hydration for prevention of post-ERCP pancreatitis.
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Introduction: Levodopa-carbidopa intestinal gel (LCIG, designated in the US as
carbidopa-levodopa enteral suspension [CLES]) is a long-term treatment option
for advanced Parkinson’s disease (PD) patients and administered via percuta-
neous gastrojejunostomy (PEG-J) from an external pump.
Aims & Methods: The gastrointestinal (GI)-related safety of the LCIG treatment
system (drug/device) has been assessed in advanced PD patients with final safety
data from the GLORIA1 registry. This observational registry of 375 advanced
PD patients treated with LCIG was conducted at 75 centers in 18 countries.
Patients were initially titrated to an optimal dose of LCIG via nasojejunal
(NJ) tube for up to 2 weeks, followed by infusion via PEG-J for 24 months.
Final safety data from patients with advanced PD who had 1 infusion of LCIG
(n¼ 356) were included in this analysis. Adverse drug reactions (ADR), which
are adverse events with a reasonable possibility of causal relationship to the
treatment according to investigators’ judgment, were recorded throughout the
registry. The authors categorized ADRs post hoc as either PEG-J procedure-
related, device-related, or ‘‘other’’ type of GI event.
Result: Of the 375 enrolled patients, 332 (89%) were treated with LCIG via PEG-
J, and 258 (69%) completed the 24 month follow-up. The median [range] dura-
tion of exposure via NJ was 6.0 [1, 53] days (n¼ 307) and via PEG-J was 722 [1,
957] days (n¼ 351). During titration via NJ, there were 3 patients (0.8%) who
had 1 GI related ADR. Within the 24 months of treatment post-PEG-J place-
ment (n¼ 356) 1 GI related ADR was reported in 139 patients (39%), of which
procedure-related ADRs were reported in 35 patients (9.8%), device-related in 93
(26%), other GI events in 63 (18%); the ADRs in all GI categories reported for
4% patients were weight decreased (6.7%), device related infection (5.9%),
device dislocation (4.8%), device issue (4.8%); and the serious ADRs reported
for 2% patients were device dislocation (2.2%) and device issue (2.0%). During
the 28-day follow up period, there were 4 patients (1.1%) who had 1 GI related
ADR. ADRs led to the discontinuation of 10 patients (2.8%) overall, 2 of whom
discontinued due to a procedure-related ADR, 5 due to a device-related ADR,
and 3 due to another type of GI ADR. Of the 29 deaths reported, 23 were deemed
unrelated to treatment, 5 possibly related (to drug/device) and 1 probably related
(to tubing). Of the possibly/probably related deaths, 2 had GI related events; 1
had a small bowel obstruction and died approximately 3 weeks later of unknown
causes, and 1 had a small bowel perforation and peritonitis.
Conclusion:Most GI-related ADRs were related to the device in this registry. The
incidence of GI-related ADRs and discontinuations due to GI-related ADRs
were relatively low, which is supportive of the overall tolerability of LCIG and
consistent with previous studies.2
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Introduction: Endoscopically assisted percutaneous transesophageal gastrotubing
(PTEG) was developed as an alternative route to access the gastrointestinal tract
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for the patients that Percutaneous Endoscopic Gastrostomy was contraindicated.
PTEG by endoscopic assistance may enhance the safety of the procedure and the
new item that may enhance the reliability was developed.
Aims & Methods: The aim of this study is to evaluate the clinical usefulness of
PTEG supported by endoscopy. A rupture-free balloon (RFB) catheter is
inserted into the upper esophagus. Percutaneous balloon puncture with a specia-
lized needle is then performed from the left side of patient’s neck under ultra-
sonographic control. A guide wire is inserted through the needle into the RFB,
followed by a dilator and sheath. A placement tube is then inserted through the
sheath, and the sheath is removed. We started to perform PTEG under endo-
scopy in a total of 119 patients (74 men and 45 women, mean age 71.5 years) in
whom PEG was not feasible. Double Balloons equipped Overtube type RFB
were used instead of primary RFB in seven cases that the puncture needle is
punctured into the overtube trough the balloon. PTEG was performed for nutri-
tion in 65 patients and for decompression in 54.
Result: Satisfactory results were achieved in all 119 patients. Median follow-up
was 64.0 days in patients who received decompression because of the obstruction
due to malignancies and 270.0 days in those who received nutrition. Four of 65
patients for nutrition were able to be free from tube feeding due to PTEG tube
feeding support. There was one patient had tracheal penetration, which was
managed conservatively. Other complications were minor oozing bleeding in
seven patients that did not require blood transfusion, subcutaneous emphysema
in two patients, which were managed conservatively. The complication rate was
13.4%. A stable procedure could performed in all seven cases using the new
overtube, and also there was no complications. No patient required surgical
treatment or died after PTEG.
Conclusion: PTEG is feasible, safe, and useful. PTEG could be an optimal pro-
cedure for long-term nutrition and/or decompression even for the patients who
failed PEG insertion. The use of endoscopy enhances the safety of the procedure
and allows better confirmation of each step involved. New overtube type RFB
will be useful but need more experiences.
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Introduction: A six-food elimination diet (SFED) for eosinophilic esophagitis
(EoE) requires almost a year on a high level of dietary restriction and multiple
endoscopies. A four-food elimination diet (FFED), eliminating the four most
common culprit foods in EoE (animal milk, gluten-containing cereals, egg,
legumes) has been a first step to simplify empiric elimination strategies.
Aims & Methods: To assess the effectiveness of a step-up empiric elimination diet
strategy for EoE. Prospective multicenter study conducted in 12 Spanish hospi-
tals in both children and adults. All patients included fulfilled clinic and histo-
logic criteria for EoE and lack of response to PPI therapy was documented before
inclusion. Initial two-food elimination diet (animal milks and gluten-containing
cereals) was evaluated in all patients, stepping up to a FFED and eventually to a
SFED in non-responders. Response to dietary therapy was defined by symptom
improvement and515 eos/HPF. In responders to empiric diet, each food group
was individually reintroduced for 6 weeks with further histologic reevaluation.
Food triggers were defined as those leading to esophageal inflammation 415
eos/HPF after individual reintroduction.
Result: Presently, 93 patients (25 pediatric) have been included. A two-food
elimination diet achieved EoE remission in 38 patients (40%) unresponsive to
PPI therapy. Remission rates increased to 52% and 65% with a FFED and
SFED, respectively. Individual food reintroduction has been completed in 26/
38 of responders to a two-food elimination diet, of whom 85% had a single food
trigger. The most common food triggers were animal milk (60%), gluten-contain-
ing cereals (25%) and both (15%). Compared to starting with a SFED, this step-
up strategy (2–4–6) allows reducing endoscopic procedures and the diagnostic
process time by 35%.
Conclusion: A two-food elimination diet (animal milk, gluten-containing cereals)
achieves EoE remission in up to 40% of patients unresponsive to PPI therapy.
This diet allows prompt identification of two thirds of responders to empiric
elimination diets, with few food triggers (one food trigger in 85% of responders)
and consequently, good candidates for dietary maintenance therapy. A step-up
empiric diet strategy (2–4–6) might be a cost-effective dietary strategy for pedia-
tric and adult EoE.
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Introduction: An adaptive Th2-type immune response to food antigens is involved
in eosinophilic esophagitis (EoE). Evidences of a potential role for the innate
immunity in EoE has also arisen in parallel to the recognition of changes in
esophageal microbiome in adult and pediatric EoE patients compared to non-
EoE controls. The likely role that microbial pattern recognition receptors (PRRs)
might play in EoE arises as a potential source of research in understanding the
relationship of diet, the esophageal microbiome, and the immune system activa-
tion in EoE, that has not been assessed yet.
Aims & Methods: To gather data about the potential implication of Toll like
receptors (TLRs), the most investigated group of transmembrane PRR in EoE,
we characterized TLR mRNA expression and protein staining in esophageal
mucosal biopsy samples from adults before and after dietary treatment, and
compared with control patients. Esophageal mucosal samples were fixed in for-
malin, embedded in paraffin, and routinely processed for hematoxylin and eosin
staining. Specific antigen retrieval and permeabilization processes were per-
formed before samples were incubated with the primary antibodies anti-TLR1,
TLR2, TLR3, TLR4, TLR6, or TLR9. Incubation with the secondary antibodies
Alexa Fluor 594 goat anti-rabbit IgG or Alexa Fluor 488 goat anti-mouse IgG
Nuclei were counterstained with DAPI. Gene expression for the different TLR
assessed was evaluated in all samples after RNA was isolated with MirVanaTM
Kit. Simultaneous real-time PCRs were performed with TaqMan Low-Density
Arrays. Thermal cycling conditions were 2min at 50C, 10min at 95C, followed
by 40 cycles of denaturation at 95C for 15 s, and annealing and extension at
60C for 1min in an ABI PRISM 7900 HT Sequence Detection System. Relative
changes in mRNA expression were calculated with the cycle threshold (Ct)
method.
Result: A total of 10 EoE patients (8 men) and 10 gender-matched control sub-
jects were included in the analysis. The groups had a mean age of 33.1 (10.1) and
53 (19.9) years, respectively. In the EoE group, peak intraepithelial eosinophil
density was 56.8 (29.9) cells/hpf, which decreased to 3 (4.2) cells/hpf after SFED-
based treatment (p5 0.001). No intraepithelial eosinophils were detected in any
of the esophageal samples from controls. No differences in eosinophil counts
were detected for atopic and non-atopic EoE patients, being 55 (30.4) vs. 61
(34.8) cells/hpf, respectively. Active EoE characterized by significant upregula-
tion of TLR1 (2.7-fold increase), TLR2 (3.7-fold increase) TLR4 (4.6-fold
increase) and TLR9 (3.4-fold-increase) in comparison with the controls
(p5 0.05 for all comparisons). Dietary treatment significantly decreased all the
four TLRs to control group values (p5 0.05) Immunofluorescence staining
demonstrated epithelial-predominant staining in TLR2 and TLR4, and scattered
cell staining for TLR1 and TLR9. TLR expression patters showed differences in
lamina propria and epithelial layers.
Conclusion: EoE is associated with changes in expression levels of several TLRs,
that reverse after effective dietary therapy. Our results points towards an inter-
play of diet, microbiome and innate immune responses in the pathophysiology of
EoE.
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Introduction: Interleukin-13 (IL-13) has been implicated in the pathogenesis of
eosinophilic oesophagitis (EOE). RPC4046 prevents the binding of IL-13 to both
the IL-13R1 and IL-13R2 receptors. This study evaluated the efficacy and
safety of 2 dose levels of RPC4046 compared to placebo (PBO).
Aims & Methods: Subjects were randomized 1:1:1 to receive either RPC4046
180mg [LD] (n¼ 31), RPC4046 360mg [HD] (n¼ 34), or PBO (n¼ 34). An IV
dose on Day 1 was followed by weekly subcutaneous doses. Oesophageal biop-
sies, read by a central blinded pathologist, were obtained at baseline (BL) and
Wk16 to assess change in mean eosinophil count, the primary endpoint.
Secondary endpoints included symptom improvement measured by a Daily
Symptom Diary (DSD), improvement in endoscopic features as measured by
the EOE Endoscopic Reference Score (EREF), and Subject’s Global
Assessment of Disease Severity. Safety was also assessed.
Result: 90 subjects completed the 16Wk double-blind period. Demographic/dis-
ease characteristics were generally comparable between treatment arms. At BL,
mean oesophageal eosinophil counts (cells/hpf) were 92.4 (PBO), 116.6 (LD), and
122.6 (HD). At Wk16, the mean count was significantly reduced from BL for
both RPC4046 dose levels compared to PBO (mean change: PBO –4.4, LD –94.8,
and HD –99.9 [both p5 0.0001 vs PBO]). There was a greater improvement in
dysphagia symptoms as measured by the DSD with HD compared to PBO, but
this did not achieve statistical significance (PBO –6.4, LD –5.3 [p¼ 0.996 vs
PBO], and HD –13.3 [p¼ 0.073 vs PBO]). There were significant improvements
in endoscopic features as determined by the reduction in the total mean EREF
score with both RPC4046 dose levels (mean change: PBO –0.9, LD –4.2, and HD
–4.8 [both p5 0.0004 vs PBO]). There was a significant improvement in Subject’s
Global Assessment of Disease Severity at the HD (PBO 1.5, LD 2.0, HD 2.8
[HD p¼ 0.0107 vs PBO]). The rates of overall adverse events (AEs) were 64.7%
(PBO), 64.5% (LD), and 85.3% (HD). The most frequent AEs were headache
(PBO 14.7%, LD 16.1%, HD 20.6%), upper respiratory infection (PBO 8.8%,
LD 16.1%, HD 14.7%), and arthralgia (PBO 0%, LD 12.9%, HD 5.9%).
Conclusion: RPC4046 demonstrated significant reductions in oesophageal eosi-
nophilic inflammation and improvements in endoscopic features at both dose
levels. Subjects receiving the HD had greater symptom improvement than those
on LD. These phase 2 data support the further study of RPC4046 as a novel
treatment for EOE. (clinicaltrials.gov ID: NCT02098473)
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Introduction: Hypersensitive esophagus (HE) is defined by endoscopy-negative
heartburn with normal esophageal acid exposure time (EAET) but positive symp-
tom association probability (SAP) and symptom index (SI) at reflux monitoring,
and/or heartburn suppression with proton pump inhibitor (PPI) therapy.
Functional heartburn (FH) is distinguished by PPI-refractoriness and negative
SAP/SI. However, diagnostic accuracy of SAP and SI has been recently ques-
tioned leading to consider with caution the diagnosis of FH/HE based on symp-
tom-reflux association analysis only.
Aims & Methods:We aimed to investigate whether impairment of chemical clear-
ance, expressed by post-reflux swallow-induced peristaltic wave (PSPW) index,
and of mucosal integrity, expressed by mean nocturnal baseline impedance
(MNBI), distinguish HE from FH independently from SAP and SI.
Impedance-pH tracings from 303 patients with PPI-dependent (i.e. heartburn
repeatedly abolished by 4-week PPI-therapy and repeatedly recurring after PPI
withdrawal) or PPI-refractory (i.e. 550% of symptom relief after 8-week high-
dosage PPI therapy) heartburn were blindly reviewed, 125 with non-erosive
reflux disease (NERD) defined by abnormal EAET, 108 with HE (normal
EAET, but positive symptom-reflux correlation) and 70 with FH (normal
EAET and negative symptom-reflux correlation). Impedance-pH tracings were
manually analyzed to detect: EAET (abnormal if 3.2% over 24 hours), char-
acteristics of reflux episodes (acid/weakly acidic) and symptom-reflux association
using both SAP (positive if 95%) and SI (positive if 50%). MNBI values were
calculated at 3 cm above the LES, during the overnight rest, for at least 30
minutes after excluding swallows and reflux induced changes. The PSPW index
was calculated by dividing the number of refluxes followed within 30 seconds by
swallow-induced peristaltic waves with the number of total refluxes.
Result: In PPI-dependent patients with HE, PSPW index and MNBI were the
most sensitive impedance parameters; at multivariate analysis, they were inde-
pendent predictors of HE. At receiver operating characteristic analysis, PSPW
index with MNBI efficiently separated HE from FH: the area under the curve
was 0.957. Only 50/108 (46%) patients with HE had concordant SAP/SI positiv-
ity, 48 (96%) of them with abnormal PSPW index and/or MNBI. Abnormal
values for PSPW index and/or MNBI were found in 34/39 (87%) of SAP/SI
negative and in 15/17 (88%) of SAP/SI discordant cases.
Conclusion: HE is characterized by impairment of chemical clearance and of
mucosal integrity. When EAET is normal and SAP/SI afford inconclusive results,
PSPW index and MNBI should be analyzed to objectively distinguish HE from
FH
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Introduction: On-therapy impedance-pH monitoring in proton pump inhibitor
(PPI)-refractory gastroesophageal reflux disease (GERD) yielded conflicting
results. Recently, novel impedance parameters assessing esophageal chemical
clearance and mucosal integrity, namely the post-reflux swallow-induced peri-
staltic wave (PSPW) index and the mean nocturnal baseline impedance (MNBI),
have been shown to increase the diagnostic yield of impedance-pH monitoring in
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investigating PPI-refractory patients studied off-therapy, further improving the
management of these patients.
Aims & Methods: We aimed to investigate whether the impairment of chemical
clearance, expressed by PSPW index, and of mucosal integrity, expressed by
MNBI, are helpful in segregating NERD from FH studied with impedance-pH
monitoring on-PPI therapy. Further, we assessed the value of these novel para-
meters as predictors of PPI-refractory GERD confirmed by 3-year positive sur-
gical outcome. On-therapy impedance-pH tracings from consecutive patients
referred for PPI-refractory heartburn with/without regurgitation (i.e. 550% of
symptom relief or mucosal healing after 8-week high-dosage PPI therapy) were
blindly reviewed. All tracings were manually analyzed to detect: acid exposure
time (AET; abnormal if 3.2% over 24 hours), characteristics of reflux episodes
(acid/weakly acidic) and symptom-reflux association using both symptom asso-
ciation probability (SAP; positive if 95%) and symptom index (SI; positive if
50%). MNBI values were calculated at 3 cm above the LES, during the over-
night rest, for at least 30 minutes after excluding swallows and reflux induced
changes. The PSPW index was calculated by dividing the number of refluxes
followed within 30 seconds by swallow-induced peristaltic waves with the
number of total refluxes. Patients were subdivided into refractory reflux esopha-
gitis (RRE), healed reflux esophagitis (HRE), non-erosive reflux disease (NERD;
defined by abnormal acid exposure time or normal AET but positive symptom-
reflux correlation) and functional heartburn (FH; defined by normal AET and
negative symptom-reflux correlation) according to endoscopy and conventional
impedance-pH variables.
Result: Median PSPW index and MNBI were significantly lower in 39 RRE
(16%; 1145 Ohms) than in 41 HRE (25%; 1741 Ohms) and in 68 NERD
(29%; 2374 Ohms) patients, and in all three GERD subgroups compared to 41
FH cases (67%; 3488 Ohms) (P¼ 0.0001). Comparing NERD to FH, PSPW
index showed an area under curve greater than MNBI at receiver-operating-
characteristic analysis (0.886 vs. 0.677, P¼ 0.005). PSPW index was abnormal
preoperatively in 53/53 patients with positive surgical outcome and resulted
independent predictor of PPI-refractory GERD at multivariate analysis, (odds
ratio 0.6983, P¼ 0.012).
Conclusion: At on-therapy impedance-pH monitoring, impaired chemical clear-
ance and mucosal integrity characterize PPI-refractory typical GERD. PSPW
index and MNBI efficiently distinguish PPI-refractory NERD from FH and
PSPW index appears useful for selecting surgical candidates.
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Introduction: Safety and effectiveness of electrical stimulation of the lower eso-
phageal sphincter (LES-ES) using the EndoStim LES Stimulation System (The
Hague, The Netherlands) was demonstrated in clinical trials. Limited data avail-
able on outcomes in clinical practice.
Aims & Methods: An ongoing, prospective international multicenter web-based
registry is collecting data in patients with disruptive GERD symptoms treated
with LES-ES in clinical practice at baseline and at routine follow-ups for 5-year.
Demographics, adverse events, GERD symptoms recorded in daily diaries,
GERD health related quality of life scores (GERD-HRQL), structured GI symp-
tom questionnaires for extra-esophageal symptoms, use of proton pump inhibi-
tors (PPIs) and physiological data (esophageal pH / manometry) are collected
when available.
Result: Data was available in 50 patients enrolled in eleven sites with 6 months
post-op follow upand from 28 patients with 12 months follow-up. Ninety% (43/
48) patients showed an improvement in their GERD-HRQL score on LES-ES at 6
months and 93% (25/27) showed an improvement at 12 months compared to
baseline. The median (IQR) composite GERD-HRQL score improved from 22
(17–27) preoperatively to 8.0 (4.0–13.3) at 6-month (p5 0.001) and from 20.0
(17–23.5) to 5.0 (2.0–7.0) at 12-months (p5 0.001). At baseline, 44% of patients
(22/50) complained on daily bothersome heartburn symptoms affecting sleep
which decreased to 8% (4/50) at 6 months (p5 0.001) and 0% (0/28) at 12
months (p5 0.001). At baseline, 52% and 15% of subjects reported moderate
or severe regurgitation, respectively which decreased to 22% and 7% at 6 months
(n¼ 27) and 14% and 0% at 12 months (n¼ 14). Data on prior hospitalization
due to GERD was available from 40 patients who with hospitalization data
available for their 6m visit (1m). Annualized hospitalization rates due to
GERD at baseline pre EndoStim was 1.1 days/year (n¼ 40) and 45% (18/40)
reported at least one hospitalization due to GERD which at last follow up
decreased to 0.3 days/year with 83% of patients who were required hospitalization
pre-op reporting no hospitalization post-op. All patients were on long-term PPI at
baseline. Seventy-one% (45/63) patients at 6 month and 75% (27/36) patients at
12 months were completely off PPI. Data on 24 h esophageal pH at 6m showed a
non-statistically significant improvement. Safety data was adjudicated by an inde-
pendent DSMB. Four serious adverse events in three patients were reported. One
myocardial infarction related sudden death at 11 month post-op, not related to
device or procedure was reported. One event of lead erosion into the esophagus
was detected during routine endoscopy. The device was removed during laparo-
scopic fundoplication procedure. Two events of gastroparesis, possibly related to
the device requiring hospitalization were reported in one patient.
Conclusion: Electrical stimulation of the LES is safe and effective in clinical
practice in treating GERD patients with disruptive GERD symptoms despite
PPI. LES stimulation results in significant improvement in GERD outcomes
and reduced healthcare resource utilization. LES-ES should be considered a
viable treatment option for treating GERD patients with disruptive GERD
symptoms despite maximal medical management.
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Introduction: Endoscopic ultrasonography (EUS) and/or magnetic resonance
imaging (MRI) screening of asymptomatic individuals (HRI) at high risk for
PDA to detect for early pancreatic neoplasia can lead to the detection of small
pancreatic cysts in almost 40%1. However, there is limited understanding risk for
neoplastic progression and the natural history of low risk detected lesions after
baseline screening. The long-term clinical outcomes of radiologic surveillance
aiming to detect early PDA and high-grade precursor lesions (IPMN HGD or
PanIN3¼HPCLs) are also not well understood.
Aims & Methods: To determine the incidence of surveillance-detected pancreatic
lesions following baseline screening and calculate the incidence rates of invasive
malignancy and high-grade neoplasia in HRI undergoing long-term surveillance.
We prospectively enrolled HRI in the Cancer of the Pancreas Screening (CAPS)
studies from 1998 to 2014 (n¼ 578) at a tertiary referral academic medical center
with a comprehensive multidisciplinary pancreas screening program. HRI con-
sisted of familial PDA relatives or PDA-associated gene mutation carriers
(BRCA 1/2, PALB2, p16, PRSS1, STK11) who had a 46 months of follow-up
imaging after baseline EUS and MRI. HRI with baseline solid masses or pre-
valent PDA were excluded from the surveillance cohort analyses. Radiological
features of progression (new solid mass, and worrisome features defined by
Sendai International Consensus Guidelines (ICG) for pancreatic mucinous
cysts) were compared to pathologic diagnoses or repeat abdominal imaging
according to clinical surveillance protocol.
Result: 343 HRI were screened and underwent follow-up imaging with EUS and/
or MRI every 6–12 months (depending on baseline findings). 293 (85%) familial
PC relatives and 50 (15%) mutation carriers were studied, mean age 56.4 (range
22–81), 47% male. Mean follow-up time was 5.1 years (range 0.5–15.1). 132/341
HRI (38%) had no pancreatic lesions at baseline and follow-up, 155 (45%) had a
low risk cyst at baseline, and 12 (3.5%) had a solid mass or nodule at baseline. 74
HRI (22%) developed new low risk cysts on follow-up. 54/343 HRI (16%)
developed radiological progression, with detection of a new solid mass
(n¼ 24,7%%), cyst growth 42mm in 6 months (n¼ 11, 3.2%), or 41 ICG
worrisome features (mural nodule n¼ 7, 2%), dilated main pancreatic duct
(MPD) 45mm(n¼ 15,4.4%), abrupt change in MPD caliber (n¼ 1), cyst size
43 cm (n¼ 2). Of these 54 HRI with progression, 38 had surgery and 21 of these
(58%) had PDA, malignant pancreatic neuroendocrine tumor (PanNET), or
HPCLs. The median time to radiological progression from baseline screening
was 3.2 years (IQ range 1.2–6 years), with some HRI progressing at 10.9 years.
In contrast, none of HRI without detected lesions at baseline or follow-up devel-
oped PDA (p¼ .002). During surveillance, 13/343 (3.8%) incident PDA and 8/
343 (2.3%) incident malignant neuroendocrine tumors were detected (all with
radiologic progression). An additional 8/343 (2.3%) HRI had HPCLs. The inci-
dence of PDA was 1/50 (2%) in mutation carriers and 12/293 (4%) in familial PC
relatives. Of the 50 patients with pathological diagnoses (45 surgical resection, 5
biopsy), 27 of 29 (93%) with radiological features of progression had a malig-
nancy (PDA¼ 13 or PanNET tumor¼ 6), or at least one HPCL (n¼ 8). 10 of 13
(77%) of incident PDA were resectable (3 unresectable PDAs were late for sur-
veillance or lost to follow-up). 16/45 (36%) HRI who had surgery had lower-
grade neoplasms (BD-IPMN LGD/IGD, PanIN2, combined IPMN, SCA,
benign neuroendocrine microadenomas). In surgically-treated HRI, the preva-
lence of IPMN HGD in cysts with mural nodules was 5/7 (71%).
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Conclusion: In our 16-year cohort with long-term surveillance, the incidence of
PDA was modestly elevated but majority of detected cancers were asymptomatic
and resectable. Surveillance also detects early stage PanNETs and HPCLs. The
majority of detected proven malignancies had radiologic progression but more
research is needed to improve the selection of patients for surveillance and
surgery.
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Introduction: The recent guideline for intraductal papillary mucinous neoplasms
(IPMNs) focuses on morphological features of the lesion as signs of malignant
transformation, but ignores the background pancreatic parenchyma, including
features of chronic pancreatitis, a risk factor for pancreatic malignancies.
Endoscopic ultrasonography frequently reveals evidence of chronic pancreatitis
(EUS-CP findings) in the background pancreatic parenchyma of patients with
IPMNs. Therefore, we investigated whether background EUS-CP findings were
associated with malignant IPMN.
Aims & Methods: Clinical data for 69 consecutive patients with IPMNs who
underwent preoperative EUS and surgical resection between April 2010 and
October 2014 were collected prospectively. The association of EUS-CP findings
(total number of EUS-CP findings; 0 vs. 1) with invasive IPMN was examined.
The association of EUS-CP findings with pathological changes of the back-
ground pancreatic parenchyma (atrophy/inflammation/fibrosis) was also
examined.
Result: Among patients with EUS-CP findings, invasive intraductal papillary
mucinous carcinoma (IPMC) was significantly more frequent than among
patients without EUS-CP findings (42.5% (17/40) vs. 3.4% (1/29), p¼ 0.0002).
In addition, patients with EUS-CP findings had higher grades of pancreatic
atrophy and inflammation than patients without EUS-CP findings (atrophy:
72.5% (29/40) vs. 34.5% (10/29), p¼ 0.003, inflammation: 45.0% (18/40) vs.
20.7% (6/29), p¼ 0.04).
Conclusion: In IPMN patients, detection of EUS-CP findings in the background
pancreatic parenchyma was associated with a higher prevalence of invasive
IPMC. Accordingly, EUS examination should not only assess the morphological
features of the lesion itself, but also EUS-CP findings in the background
parenchyma.
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Introduction: Diagnosis of solitary pancreatic cyst is clinically challenging due to
the malignant potential of several cyst subtypes. nCLE is emerging as a powerful
technique which enables the observation of the inner wall of pancreatic cysts,
in vivo and in real-time, during an endoscopic ultrasound-guided fine needle
aspiration (EUS-FNA). Three clinical trials evaluated the feasibility, the safety
and highlighted specific criteria for the characterization of pancreatic cystic
lesions. This study aims to prospectively evaluate the diagnostic performance
of nCLE procedure on a larger cohort of patients.
Aims & Methods: 217 patients carrying a single large (42 cm) pancreatic cystic
lesion (PCL) without evidence of communication with the main pancreatic duct
and scheduled for EUS-FNA procedure were included in five centers. nCLE
diagnosis was based on published criteria: ‘‘superficial vascular network’’ for
Serous CystAdenoma (SCA), ‘‘papillae’’ for Intraductal Papillary Mucinous
Neoplasms (IPMN), ‘‘epithelial border’’ for Mucinous Cystic Neoplasms
(MCN), ‘‘dark spots of cell aggregates surrounded by gray areas of fibrosis
and vessels’’ for NeuroEndocrine Neoplasms (NEN) and ‘‘field of bright, gray
or black particles’’ for PseudoCyst (PC). In case of doubt between IPMN and
MCN, Undetermined Mucinous Lesion (UML) was proposed. The absence of
criteria led to inconclusive nCLE diagnosis considered as false-negative. Nine
patients were withdrawn for screen failure (n¼ 6) or procedure failure (n¼ 3).
Among the 208 analyzable patients, final diagnosis was proven in 90 cases by
cytopathological analysis of cystic fluid obtained by FNA (n¼ 59) or by surgical
histopathology (n¼ 31). Statistical analysis of nCLE performance was done for
cysts sufficiently represented.
Result: Among the 217 nCLE procedures, 98.6% were successfully performed.
The pancreatitis rate was 2.3% and no other significant complication occurred.
nCLE was inconclusive in 27 cases. The 90 proven final diagnosis were 32 SCA,
46 Mucinous Lesions (ML) (23 IPMN, 14 MCN and 9 UML), 6 NEN, 2 PC, 1
cystic solid pseudopapillary neoplasm, 1 cystic lymphoma, 1 cystic lymphan-
gioma and 1 congenital pancreatic cyst. These last 6 cysts were underrepresented
and therefore withdrawn from statistical analysis. In the remaining 84 patients,
nCLE was inconclusive in 5 cases. The performances of nCLE were as follows:
SCA ML IPMN MCN NEN
n 32 46 23 14 6
Se (%) 88 87 87 57 100
Sp (%) 98 97 96 97 100
Conclusion: This large prospective study validates the very high sensitivity and
specificity of nCLE for the diagnosis of solitary non communicating PCL which
represents the main diagnostic issue. Being able to precisely discriminate between
benign (SCA) or premalignant lesions (ML, NEN), the nCLE procedure would
significantly improves patient management by avoiding either repeated follow-up
procedures or unnecessary resections due to diagnosis uncertainties. nCLE pro-
cedures should now be included in the guidelines.
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Introduction: Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic
cysts that carry a risk of malignant transformation to pancreatic ductal adeno-
carcinoma (PDAC). Guidelines have been evolving to best identify which criteria
should qualify a patient for resection and which cysts can safely remain under
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surveillance. Our aim was to understand which baseline cyst and patient features
predict disease progression and malignant transformation.
Aims & Methods: Patients with clinically suspected IPMN who did not meet
consensus criteria for resection at diagnosis and were surveyed for at least 12
months or underwent surgery after a minimum surveillance of 3 months were
included. All patients evaluated by radiologic studies or endoscopic ultrasound
between 1998 and 2015 were included. We defined progression as either an
increase in size of the dominant cyst 20% or 2mm or the development of
worrisome features (mural nodule or mass, thick septations, main duct involve-
ment or high grade dysplasia or cancer on cytology or surgical pathology).
Statistical analysis was performed with the Chi square and Fisher exact tests
for categorical variables and Mann-Whitney U test for continuous variables.
All covariates of interest with p5 0.05 in the univariate analysis were included
in the logistic regression model.
Result:
Non-
progressors
(n¼ 248)
Progression
by cyst
size increase
(n¼ 205)
Progression by
development of
worrisome
features
(n¼ 46)
Age at 1st study, mean
(SD)
65.3 (11.3) 66.6 (10.7) 68.5 (10.6)
Male gender, n (%) 95 (38.3%) 80 (39%) 24 (52.2%)
Race
White, n (%) 174 (86.6%) 152 (85.4%) 33 (82.5%)
Black, n (%) 11 (5.5%) 11 (6.2%) 5 (12.5%)
Asian, n (%) 9 (4.5%) 8 (4.5%) 0
Smoker ever, n (%) 100 (43.1%) 86 (44.1%) 22 (51.2%)
EtOH use ever, n (%) 108 (47%) 85 (44.7%) 22 (50%)
CP, n (%) 9 (3.7%) 5 (2.5%) 3 (6.8%)
AP, n (%) 18 (7.5%) 10 (5.1%) 2 (4.5%)
Cancer, n (%) 75 (30.5%) 78 (38.4%) 21 (46.7%) *
Colon, n (%) 3 (1.2%) 4 (2%) 3 (6.7%) *
Breast, n (%) 7 (2.8%) 12 (5.9%) 0
Prostate, n (%) 6 (2.4%) 12 (5.9%) 8 (17.8%) *
Diabetes, n (%) 56 (23%) 45 (22.4%) 20 (44.4%) *
Family hx of PDAC,
n (%)
22 (9.5%) 21 (11%) 2 (4.8%)
Baseline symptoms,
n (%)
71 (28.6%) 60 (29.3%) 14 (30.4%)
Abd pain, n (%) 65 (26.2%) 49 (23.9%) 11 (23.9%)
Weight loss, n (%) 11 (4.4%) 18 (8.8%) 6 (13%) *
Jaundice, n (%) 1 (0.4%) 1 (0.5%) 0
Serum CEA, median
(IQR)
1.6 (1, 3) 1.6 (1, 2.2) 1.1 (.8, 2.3)
Serum CA 19–9,
median (IQR)
13.5 (4.8, 37.3) 17 (8, 46) 14 (10.3, 27.5)
Cyst size, mean (SD),
mm
11.8 (6.0) 11.1 (6.4) 16.9 (6.7) *
Cyst size 0–1 cm, n (%) 100 (40.3%) 94 (45.9%) 7 (15.2%) *
Cyst size 1–2 cm, n (%) 120 (48.4%) 87 (42.4%) 22 (47.8%)
Cyst size 2–3 cm, n (%) 28 (11.3%) 24 (11.7%) 17 (37%) *
Multifocality, n (%) 95 (38.3%) 72 (35.1%) 24 (52.2%)
Location
Head, Uncinate, Neck,
n (%)
93 (37.7%) 79 (38.7%) 17 (37%)
Body, n (%) 93 (37.7%) 72 (35.3%) 15 (32.6%)
Tail, n (%) 61 (24.7%) 53 (26%) 14 (30.4%)
Cytopathology
Benign, n (%) 35 (52.2%) 27 45%) 4 (26.7%)
Non-malignant n (%) 3 (4.5%) 5 (8.3%) 1 (6.7%)
Atypical, n (%) 3 (4.5%) 4 (6.7%) 3 (20%)
Nondiagnostic, n (%) 26 (38.8%) 24 (40%) 7 (46.7%)
Cyst CEA, median
(IQR)
24 (4.1, 104.5) 101 (14, 333) 2555 (13, 5775) *
Cyst CEA =192 ng/mL,
n(%)
8 (19.5%) 13 (37.1%) 11 (68.8%) *
Cyst amylase, median
(IQR)
2749 (261, 124527) 8660 (634, 32905) 1028 (40.5, 4684)
*Statistically significant difference as compared to non-progressors. We identi-
fied 499 patients who met inclusion criteria. Average surveillance time was 47 (þ/
 28.7) months. 251 (50%) patients showed progression: 205 (41%) progressed
by size alone and 46 (9.2%) developed worrisome features. 55 (11%) met resec-
tion criteria and 21 of these went on to surgery; pathology demonstrated 4
invasive carcinoma, 5 IPMN with high-grade dysplasia, 8 IPMN with low-
grade dysplasia, 2 mucinous cystadenoma, 1 serous cystadenoma and 1 neuroen-
docrine tumor. We then compared predictors of progression. In a univariate
analysis, progression to cancer or high-grade dysplasia was associated with
male gender, a history of prostate cancer and diabetes, weight loss and initial
cyst size42 cm. A history of prostate cancer, diabetes, weight loss, elevated cyst
fluid CEA and cyst size 42 cm were associated with development of worrisome
features. In logistic regression analysis, a history of prostate cancer (OR 2.9; 95%
CI 1.7–7.7) and weight loss (OR 2.47; 95% CI 1.18–6.1) were associated with
development of worrisome features (p5 0.05). There were no baseline predictors
of cyst size increase alone. Baseline characteristics such as race, smoking or
alcohol use, a strong family history of PDAC, multifocality and location of
cysts were not associated with increased disease progression.
Conclusion: In the largest multicenter surveillance study of low risk IPMNs to
date, we showed that 41% of suspected IPMNs increased in size only, 9% devel-
oped worrisome features and 2% developed high-grade dysplasia or cancer.
Among baseline characteristics, none were predictive of size increase. A personal
history of prostate cancer and weight loss were the strongest predictors of the
development of worrisome features.
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Introduction: Novel treatment options in locally advanced pancreatic cancer
(LAPC), including FOLFIRINOX and irreversible electroporation (IRE) have
shown promising survival-rates. However, outcomes are heavily influenced by
selection bias as most studies were retrospective and excluded patients who did
not receive FOLFIRIONX or had progressive disease.
Aims & Methods: We aimed to describe outcomes of multimodality treatment
with chemotherapy, surgical exploration and IRE in a prospective consecutive
LAPC-cohort. Patients with histologically proven LAPC (Dutch guideline:
490arterial and/or 4270venous involvement) were prospectively registered
(September 2013–March 2015). After 3 months of chemotherapy
(FOLFIRINOX for WHO physical status 0–1 patients, otherwise gemcitabine),
restaging was performed by assessing RECIST 1.1-response, resectability, and
IRE-eligibility (tumor 5 cm, sufficient vascular patency). All patients with non-
progressive disease, eligible for IRE proceeded to laparotomy, regardless of
resectability. The study was registered with the Dutch trial registry NTR4230.
Result: Of 132 consecutive LAPC-patients, 93 (70%) received chemotherapy (59
(45%) FOLFIRINOX). After 3 months, 59 (45%) had non-progressive disease
and 36 (27%) were IRE-eligible and underwent laparotomy, resulting in 14
(11%) pancreatic resections and 15 (11%) IREs. In 36 patients who underwent
laparotomy, 14 (39%) suffered from Clavien-Dindo grade 3 complications (6/
14 resection, 7/15 IRE, 1/7 palliative exploration). Four patients (11%) died
within 90 days (1/14 resection, 2/15 IRE, 1/7 palliative exploration). Median
overall survival after resection, IRE, in non-progressive disease without resec-
tion/IRE and in all 132 patients was 34, 19, 17 and 11 months respectively.
Conclusion: This is the first prospective study on multimodality treatment, includ-
ing FOLFIRINOX and IRE, in a consecutive LAPC-cohort. An 11% resection-
rate with a median overall survival of 34 months seems highly promising where
no clear survival benefit was seen after IRE. This study highlights the importance
of reporting on unselected LAPC-cohorts.
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Introduction: Due to the centralization of pancreatic cancer treatment, both post-
operative mortality and overall survival are improving. However, a downside of
centralization is the decreasing knowledge on new treatment strategies and clin-
ical trials in non-pancreatic centers.
Aims & Methods: The Dutch Pancreatic Cancer Group (DPCG) aimed to
develop an online expertpanel to facilitate and tailor rapid expert advice for
patients with (locally advanced) pancreatic cancer. In collaboration with Aexist
(The Hague, the Netherlands) we developed the ImageHub system which
allows for secure, online review of CT scans. Next, a nationwide multidisciplinary
expertpanel for pancreatic cancer consisting of surgeons, (interventional) radiol-
ogists and medical oncologists was installed. This study prospectively analyses
the first patients who were referred to the online expertpanel between June 2015
and February 2016.
Result: A total of 59 patients from 7 centers were referred to the expertpanel. All
had locally advanced pancreatic cancer and in 46% (27/59) of the patients this led
to an additional treatment or a change in treatment strategy. A resection with
curative intention was performed in 5 patients (8%) and 21 patients (42%) were
included in a clinical trial, investigating local ablative therapies. In all cases the
expertpanel advice was provided within one week.
Conclusion: The results show that an online expertpanel is feasible and changed
the treatment strategy in almost half of the patients with locally advanced pan-
creatic cancer. Future studies have to determine the impact of an online expert-
panel on the accessibility of new treatment strategies, survival and quality of life.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Linaclotide, a locally acting GC-C agonist, is an FDA-approved
guanylate cyclase-C (GC-C) agonist, for the treatment of Irritable Bowel
Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation
(CIC). Linaclotide reverses colonic mechanical hypersensitivity in chronic colonic
hypersensitive mice, and reduces noxious signaling in vivo to the spinal cord.
Painful Bladder Syndrome/Interstitial Cystitis and Overactive Bladder are
common comorbidities of IBS-C. Chronic oral administration of linaclotide in
a mouse model of bladder overactivity reverses colitis-induced changes in bladder
function and sensitivity via a proposed mechanism involving viscero-visceral
organ cross-talk. We hypothesized that linaclotide may be able to similarly
reduce visceral pain in other chronic pelvic pain conditions, and tested this
hypothesis in a rat model of endometriosis-induced vaginal hyperalgesia.
Aims & Methods: One centimeter segments of the uterine horns of female
Sprague-Dawley rats were surgically removed and 4 pieces of uterine horn
tissue/rat were implanted around the mesenteric arteries adjacent to the cecum
(endometrium side down). Pelvic organ/tissue permeability was measured by
Evans Blue dye plasma extravasation (vascular permeability). The severity of
vaginal hyperalgesia was accessed by viscero-motor responses (VMR) to vaginal
balloon distension. VMR was recorded by electromyography (EMG) using a
wireless telemetry system (telemetric probe was surgically implanted 6 weeks
past the uterine horn tissue implantation). Linaclotide (3 ug/kg/day) was dosed
chronically for 14 days to measure its effects on plasma extravasation, and the
effects of linaclotide (3 ug/kg/day) on vaginal hyperalgesia were measured after
acute (day 1, 2 hours after dosing) and chronic (day 5) dosing, compared to
vehicle. Plasma extravasation and EMG measurements were done 10 weeks
after the first surgical procedure, when rats were in the proestrus stage of their
reproductive cycle. GC-C mRNA expression was determined by qRT-PCR.
Result: Chronic oral dosing of linaclotide (n¼ 12) significantly (P5 0.01)
reduced Evans Blue plasma extravasation in the small intestine compared to
vehicle (n¼ 12). In contrast, linaclotide did not have an effect on plasma extra-
vasation of endometrial cysts and other pelvic organs. Consistent with these
findings, expression of GC-C was restricted to the small intestine, and not
detected in endometrial cysts and other pelvic organs. Both, acute and chronic
oral administration of linaclotide significantly (P5 0.05 (n¼ 14) and P5 0.01
(n¼ 14), respectively) reduced endometriosis-induced vaginal hyperalgesia, com-
pared to vehicle treated animals (n¼ 9).
Conclusion: Oral administration of linaclotide significantly reduced visceral pain
in a rat model of endometriosis-induced vaginal hyperalgesia. These data suggest
that GC-C agonism, beyond its established effect of improving abdominal pain in
IBS-C patients may also be able to alleviate pain in a spectrum of chronic pelvic
pain conditions possibly through common sensory peripheral and central inner-
vation pathways.
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Introduction: Linaclotide, a guanylate cyclase-C (GC-C) agonist, reduces abdom-
inal pain and improves constipation in patients with Irritable Bowel Syndrome
with Constipation (IBS-C). We have shown that linaclotide activates GC-C
expressed on intestinal epithelial cells, resulting in the production and release
of cyclic GMP (cGMP), which accelerates gastrointestinal transit and inhibits
colonic nociceptors. Furthermore distinct alterations in key components of the
GC-C/cGMP signalling pathway across different subtypes of IBS patients from
the Australian population, have been shown. However, it remains to be deter-
mined if these changes extend to 1) other components of this pathway, 2) a
separate U.S. cohort of IBS patients, and 3) patients with chronic idiopathic
constipation (CIC).
Aims & Methods: Female Rome III IBS and CIC patients and healthy controls
ages 18–55 yrs were recruited mainly by community advertisement in the U.S.
Recto-sigmoid mucosal biopsies were taken at 30 cm from the anal verge during
sigmoidoscopy. RNA was extracted from all biopsies and Taqman qRT-PCR
used to assess mRNA expression of 18 different known components of the GC-
C/cGMP signalling pathway. These targets included GC-C (GUCY2C), its endo-
genous ligands (GUCA2A, GUCA2B), PDZ proteins regulating GC-C activity
(PDZD3), cGMP-dependent protein kinases (PRKG2), phosphodiesterases
(PDE3A, PDE3B), components involved in ionic secretion (PDZK1, SLC9A2,
SLC9A3, SLC26A3, CFTR) and transporters of cGMP (ABCC4, ABCC5).
Result: We compared female healthy controls (N¼ 12, mean age 36.4 yrs) with
IBS patients with constipation (N¼ 12, mean age 32.8 yrs), diarrhea (IBS-D;
N¼ 11, mean age 30.2 yrs), mixed bowel habits (IBS-M; N¼ 10, mean age
40.8 yrs), and patients with CIC (N¼ 12, mean age 30.7 yrs). In IBS-C biopsies,
GC-C expression was significantly reduced (2-fold reduction) compared with
biopsies from healthy controls (P5 0.05). However, in these IBS-C biopsies
none of the other GC-C/cGMP pathway components were significantly altered
compared with healthy controls (P4 0.05). In contrast, biopsies from CIC
patients did not display significant alterations in GC-C or the other GC-C/
cGMP pathway components compared with healthy controls (P4 0.05).
Similarly, biopsies from IBS-D and IBS-M patients did not display any signifi-
cant alterations in the GC-C/cGMP pathway components tested (P4 0.05).
Conclusion: In this cohort of female IBS-C patients, GC-C, but not other eval-
uated components of the GC-C cGMP pathway, was significantly reduced. A
lack of GC-C expression in these patients may result in a lack of cGMP produc-
tion, which may reduce intestinal secretion and the anti-nociceptive actions of
cGMP compared with healthy controls. Given these changes were apparent in
IBS-C but not in CIC, IBS-D or IBS-M patients, these changes may help to
explain some aspects of the pathophysiology associated with IBS-C.
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Introduction: Constipation is a prevalent condition with a huge socioeconomic
burden. It is unclear whether patients’ and doctors’ perceptions of the definition
of constipation agree with each other or with formal diagnostic criteria proposed
by expert committees (e.g. Rome III).
Aims & Methods: A cross-sectional survey was undertaken to compare the symp-
toms perceived to be important for the diagnosis of constipation within the adult
general population (with and without constipation), gastrointestinal (GI) specia-
lists (gastroenterologists, colorectal surgeons) and general practitioners (GPs) in
the UK. Symptoms considered important in diagnosing constipation and their
perceived burden, together with 10 case studies based on the Rome III criteria
were investigated. Responses were compared between groups using chi squared
tests.
Result: 2,257 members of the general population (1,623 self-reported constipa-
tion, 934 without), 365 GI specialists and 411 GPs completed the survey. Only a
minority of the general population considered the Rome III symptoms important
for diagnosing constipation (Table 1). Infrequent bowel movements were most
frequently reported as important by GI specialists (65%), compared with less
than half of GPs (41%) and less than a third of the constipated (26%) and non-
constipated (28%) general population (P5 0.001). The symptom most frequently
reported as important for diagnosing constipation by the general population was
straining (40–43%), whereas for GPs it was hard stools (66%).
Table 1: Frequency of symptoms perceived to be important for a diagnosis of
constipation
General Population
Without
constipation
With
constipation
GI
specialists GPs P value
Rome III symptoms
Infrequent bowel
movements
28% 26% 65% 41% 50.001
Hard stool 26% 32% 57% 66% 50.001
Straining 43% 40% 53% 61% 50.001
Sense of incomplete
evacuation
15% 24% 21% 13% 50.001
Manual disimpaction 14% 15% 32% 34% 50.001
Non-Rome III symptoms
Long time on toilet without
stool
42% 29% 33% 23% 50.001
Laxative use 37% 33% 56% 40% 50.001
The symptoms most frequently considered to be bothersome were different for
each of the groups: manual disimpaction for the constipated general population,
bloating for GI specialists and straining for GPs. In the 10 case studies, correct
diagnoses were made by doctors (GPs and GI specialists) on 79–80% of occa-
sions. However, on average, the absence of constipation was correctly identified
by doctors in 85–92% of the six cases without constipation, whereas the presence
of constipation was correctly identified in only 60–70% of the four cases with
constipation.
Conclusion: There are striking differences in the perceived definition and burden
of symptoms of constipation between the general population, GI specialists and
GPs, and variable agreement with the Rome III criteria. These differences have
major implications for patient care, management and satisfaction with treatment.
The findings reinforce the need to re-evaluate current diagnostic criteria for
constipation in clinical practice and to ensure these are communicated widely.
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Introduction: Opioids effectively treat pain but their use is limited by side effects
including opioid-induced constipation (OIC). Naldemedine is an oral, peripher-
ally-acting m-opioid receptor antagonist that is being evaluated for the treatment
of OIC.
Aims & Methods: Two identical Phase-3, double-blind, randomized, placebo-
controlled 12-week studies were conducted. In both studies, subjects 18 to 80
years old, with chronic non-cancer pain and OIC, taking opioids for 3 months
and on a stable regimen for 1 month, not on laxatives, and meeting all other
eligibility criteria were randomized (1:1) to naldemedine 0.2mg taken orally QD
or placebo. The primary objective was to evaluate the efficacy of naldemedine vs.
placebo as assessed by the proportion of responders. A responder was defined as
someone who had 9 positive- response weeks (PRW) out of 12 weeks and 3
PRW out of the last 4 weeks. A PRW was defined as 3 spontaneous bowel
movements (SBMs)/week and 1 SBM/week increase from baseline. The safety
and tolerability of naldemedine was also assessed. Studies were approved by an
IRB prior to randomization of subjects and conducted in accordance with GCP
Guideline (ClinicalTrials.gov identifier NCT01965158 and NCT01993940).
Result: In study 1, 547 subjects were randomized (naldemedine 274; placebo 273)
and in Study 2, 553 subjects were randomized (naldemedine 277; placebo 276). In
both studies, there were a significantly greater proportion of responders with
naldemedine relative to placebo (Study 1: naldemedine 47.6%; placebo 34.6%,
P¼ 0.0020, Study 2: naldemedine 52.5%; placebo 33.6%, P5 0.0001). A signifi-
cantly greater increase in the frequency of SBMs per week from baseline to Week
1 was observed with naldemedine relative to placebo and this difference remained
generally stable between the two groups throughout the 12-week study period.
The naldemedine group also showed a greater increase, relative to the placebo
group, from baseline to the last 2 weeks of the study period in the frequency of
complete SBMs and the frequency of SBMs without straining. Summary mea-
sures of treatment-emergent adverse events (TEAEs) were generally similar
between naldemedine and placebo groups in both studies. The TEAEs reported
for45% of subjects and at a higher frequency in naldemedine relative to placebo
were abdominal pain and diarrhea. In both studies, treatment with naldemedine
was not associated with signs or symptoms of opioid withdrawal, and the analge-
sic effect of opioids was not affected.
Conclusion: Results from two identically designed Phase 3 studies demonstrated a
consistent efficacy and safety profile of naldemedine as a treatment for OIC in
subjects with chronic non-cancer pain. Naldemedine treatment resulted in a sig-
nificantly greater proportion of responders than placebo, with improvement early
on and throughout the 12-week study period. Naldemedine was generally well
tolerated in these two studies.
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Introduction: Fecal incontinence (FI) affects 8% of US adults overall including
15% over age 70. However, less than 1/3 of people with FI have discussed this
problem with their physicians, and most of these report that they were not
screened but volunteered this symptom. This suggests many physicians are not
screening for FI.
Aims & Methods: The goal of this study was to provide preliminary information
on the effectiveness of 3 simple screening interventions for increasing screening
rates in a Geriatric Medicine Clinic (GMC) at the University of North Carolina:
a gastrointestinal (GI) symptom checklist distributed in the clinic waiting room,
screening by the clinic nurse, and screening by the medical provider. The GI
symptom checklist included fecal incontinence [accidental bowel leakage] and 7
other common GI symptoms. Patients checked all they had experienced in the
last month, and gave the checklist to the clinic nurse. To facilitate screening by
nurses and providers, we suggested three screening questions. We also gave
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providers and nurses a modified Fecal Incontinence Severity Inventory (FISI) to
help them decide whether FI was severe enough to warrant referral to a specialist,
and instructions on how to refer to the GI Medicine Clinic.
All patients attending the GMC during 4 two-week periods were considered
subjects. After an initial two-week baseline, all patients were exposed to the
screening methods in the same sequence for two weeks each: GI symptom check-
list, provider screening, and nurse screening. Three types of outcome data were
collected: (1) A limited review of electronic medical records of all patients seen
during these 4 two-week periods was used to identify the number of new FI
diagnoses during these 4 periods. (2) Following the last screening intervention,
all 11 clinic providers rated the effort required by each intervention and indicated
whether they believed the benefit outweighed the burden. (3) Telephone inter-
views were conducted 2–4 weeks after the index clinic visit to determine what
proportion of patients had been screened during their clinic visit. A p-value of
5.10 accepted as significant in this small pilot study.
Result: 1034 unique patients were seen during the 4 two-week periods: 60 had a
diagnosis of FI somewhere in their medical record, and 24 had a diagnosis of FI
at their index visit for this study, including 6 new FI diagnoses. Three of the 6
new diagnoses occurred during the GI checklist intervention and 3 during pro-
vider screening (p5 .10). None occurred during nurse screening. The GI symp-
tom checklist was rated the least burdensome by the 11 providers (p¼ .09). Five
of 11 providers said the benefits of screening outweighed the burden, 4 were
undecided, and 2 rated screening as too burdensome (p¼ .001). Phone interviews
were completed by 88 patients: 33/88 (37.5%) confirmed they were screened by
their doctor or nurse, 55.7% said no, and 6.8% said they did not know or
declined to answer.
Conclusion: Systematically encouraging geriatric medicine providers to screen for
FI significantly increased the number of patients receiving a new diagnosis of FI
compared to baseline, and most geriatricians thought the benefits outweighed the
burden. Distributing a GI symptom checklist in the clinic was rated least burden-
some and was as effective as direct screening by the geriatrician. However, these
interventions to improve screening were only partially effective: 37.5% of
patients remembered being asked about FI at their clinic visit.
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Introduction: Faecal incontinence (FI) is a common and devastating condition
that significantly impacts quality of life. Many individuals suffer in silence and
population surveys report that fewer than 30% of those affected consult a phy-
sician. Little is known about how people prevent or cope with symptoms in the
community.
Aims & Methods: This study aimed to describe the most common coping strate-
gies, the impact of FI severity on ways of coping, whether those under a physi-
cian’s care cope differently and the perceived overall effectiveness of individuals’
coping efforts. A 54-question survey was designed and distributed online
(Qualtrics, UT, USA) to individuals in the US general population in March
2016 who reported symptoms of FI occurring at least twice per month.
Respondents were asked to report coping behaviors using both a pre-defined
list of 15 coping strategies and free-text fields. Symptom severity was defined
by the Fecal Incontinence and Constipation Assessment (FICA) scale as mild if
6, moderate if 7–10 or severe if 11.
Result: A total of 254 complete datasets were received, of which 182 (122F,
median age 41, range 18–86) were retained for analysis after eliminating incon-
sistent responders. The median FICA score was 9 (4–13) with 149 (82%) respon-
dents reporting either moderate or severe symptoms. 103 (57%) had consulted a
physician for FI. The median number of coping strategies used was 3 (range: 1–
13). The most commonly reported strategies were the use of pads (111/182, 61%),
scheduling of bowel movements (88/182, 49%), the use of anti-diarrheal medica-
tion (86/182, 43%) and food avoidance (77/182, 42%). The number of strategies
used was significantly related to FI symptom severity (2.69 for those with mild,
4.17 moderate, and 4.89 severe symptom categories, p5 .001), and consulting
status (3.32 for non-consulters vs. 4.28 for consulters, p¼ .013). Number of
coping strategies was unrelated to sex, age, race/ethnicity, or education. The
coping strategies reported to be most effective were antidiarrheal medications
(48/182, 26% of sample), food avoidance / dietary manipulation (27/182, 14%)
and incontinence pads (21/182, 13%). Individuals who had consulted a physician,
compared to those who had not consulted, were more likely to use antidiarrheal
medication (55% vs. 37%; 2¼ 6. 23, p¼ 0.016) and schedule bowel movements
(56% vs. 38%; 2¼ 6.02, p¼ .017). Only 43/182 (24%) reported that their coping
strategies were ‘‘very’’ or ‘‘completely effective’’ at reducing the impact of
symptoms.
Conclusion: Individuals in the community employ multiple coping strategies to
reduce the impact of FI, but most report poor satisfaction with their effective-
ness. The most commonly used strategy is wearing pads, but the strategy reported
to be the most effective by the largest proportion of subject is taking anti-diar-
rheal medication. Consultation with a physician may reinforce the use of more
positive preventative strategies such as the use of medication and scheduling
bowel movements.
Table 1: Prevalence of Coping Strategies and Impact of Faecal Incontinence
Severity on Coping
Coping Strategy % who use Effect of FI Severity
Wear pads 61
Schedule BM 49
Antidiarrheal drug 43 .029
Avoid food that cause diarrhea 47
Locate all toilets in area 31
Fiber or drugs for constipation 30
Take spare clothes when going out 24
Avoid leaving home if possible 19 .018
Avoid physical activity 19
Avoid eating in restaurants 19 .002
Avoid sex 14 .026
Restrict eating before going out 12 .047
Enema before going out 10
Shop online or have food delivered 06
Discourage visits from friends 04
Average number of coping strategies 3.86 (2.61) 5.001
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Introduction: Endoscopic full-thickness resection (EFTR) of the gastric lesion
using a snaring technique has been applied for gastric subepithelial tumors. We
identified criteria for the use of a novel type of nylon loop device vs. traditional
’Over the scope’-clip (OTSC) for containing artificial submucosal lesions.
Aims & Methods: One hundred and twenty- eight patients with submucosal
tumors in gastric fundus were randomly divided into two groups, study group
with 56 patients and control group with 72 patients, all patients were treated with
endoscopic full-thickness resection. After the resection, novel LeCampTM endo-
loop device and OTSC were used respectively to close the gastric defects in the
study group and control group. The closure success rate, closure time, complica-
tions and the wound-healing rate were compared.
Result: All lesions were removed by using EFTR technique. The closure success
rates of the two groups were both 100%. Of the total of 128 patients, a compar-
ison between the novel endoloop (n¼ 56) and OTSC (n¼ 72) groups demon-
strated no differences in closure time(14.86 4.93min vs. 8.04 5.63min,
p4 0.05) and readmission rate (17.03% vs. 18.2%, p4 0.05). The average
time of removing the stomach tube in the study group was slightly longer (4.
vs. 1 day, p5 0.05), and there was a significant differences in the length of
hospital stay for the study group (4.32 2.45 days vs. 2.1 0.63 days). 24
hours after the operation, X-ray examination showed minor subdiaphragmatic
free air. Due to its low quantities and lack of symptoms, abdominal puncture was
deemed unnecessary. No subcutaneous emphysema, pneumothorax, pneumome-
diastinum were found in 24 hours after the operations. There were no significant
differences in the incidence and severity of complications rate, even though all
patients experienced no postoperative complications such as bleeding, perfora-
tion and abdominal infection in control group. However one case receiving
treatment of endoloop that induced localized peritonitis resulted in serosal
inflammation. The patient was managed conservatively with medical therapy,
such as the administration of intravenous fluids and broad-spectrum parenteral
antibiotics to cover the colonic bacterial flora until the symptoms subsided. All
wounds healed in two month after the operations.
Conclusion: Closure of gastric full-thickness defects with the novel type of endo-
loop device is technically feasible and effective. Both techniques should be
regarded as equally acceptable reconstructive options following endoscopic
full-thickness resection for gastric lesion.
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Introduction: Endoscopic mucosal resection (EMR) and endoscopic submucosal
dissection (ESD) are used for endoscopic treatment of superficial duodenal ade-
noma. They can be combine for the resection of a same lesion (Hybrid
Endoscopic Resection, HER). ESD has higher rates of complications than
EMR, and is technically challenging. We present results on the adverse events
and clinical outcome of ESD/HER compared to EMR in our cohort of patients.
Aims & Methods: In a single tertiary center, we cross-examined our database of
endoscopic procedures to identify patients with duodenal adenoma treated by
ESD, HER and EMR between 2006 and 2016. We included patients with non-
ampullary lesions and familial adenomatous polyposis. Procedure was qualified
as ESD when an endoscopic knife was used. When resection was achieved with
endoscopic knife and resection loop, the procedure was considered as HER. We
divided complications in 3 groups (ASGE and ESGE recommendations): intra-
procedural, early complications (occurring within 15 days) and late complica-
tions (occurring after 15 days). Results were expressed as medians, and compared
with Student’s t-test, Pearson’s chi-squared test.
Results: Thirty-eight patients underwent ESD/HER procedure out of a total of
111 patients. The resection was complete in 38/39 lesions in ESD/HER group,
and 141/149 lesions in EMR group (p¼ 0.182). Histological finding showed 4%
adenocarcinomas, 34% HGD, and 60% LGD. No significant differences were
observed in terms of age, sex, location of lesions or length of hospitalization.
There were significant differences in the procedure time (108min ESD/HER,
79min EMR), intraprocedural complications (46% ESD/HER, 23% EMR)
and early complications (23% ESD/HER, 9% EMR). Intra-procedural compli-
cations occurred in 46% of ESD/HER vs 23% in EMR (p¼ 0.015), including
haemorrhage (ESD/HER 25.6%, EMR 20.1%) and perforation (ESD/HER
20.5%, EMR 3.4%, p¼ 0.07). In ESD/HER, perforations occurred between
2006 and 2010. Early complications (Haemorrhage, perforation, pancreatitis)
occurred in 23% ESD/HER vs 9% in EMR (p¼ 0.001), managed either by
medical or endoscopic treatment. Five cases of perforation occured (4 ESD/
HER, p¼ 0.001) and 2 cases needed surgery. Three cases of late complications
(stenosis) occured in the EMR group. No mortality reported during the study.
Conclusion: There is a higher rate of intraprocedural and early complications in
the ESD/HER group, especially in case of perforation. Those events can be well
managed in a tertiary center, experienced in ESD and HER. Perforation rate
tends to decrease over time, reflecting the experience acquired in our team. This
highlight the importance of a learning process in ESD/HER procedure, which
results in better management of intraprocedural and early complications.
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Introduction: Gastric antral vascular ectasia (GAVE) represents a burden both to
the healthcare system and the patients’ quality of life as the rate of transfusion
dependence due to occult bleeding might be up to 60–70%. Currently, argon
plasma coagulation (APC) is the gold standard treatment, however its efficacy
impairs on the long term. Besides, its efficiency depends on the settings, the size
of the area treated, as well as the individual variations in performance.
Endoscopic band ligation (EBL) has been proven to be a good and a potentially
superior alternative with less variability in the treatment of mucosal and submu-
cosal lesions. Nevertheless, there is still no consensus regarding the end-point of
the treatment (cessation of the endoscopic lesions or resolution of transfusion
need), the optimal treatment choice, and the preferable treatment settings.
Aims & Methods: Our retrospective multicentre study aimed to evaluate and
compare the efficacy of APC and EBL in patients with GAVE both in terms
of required treatment sessions and hospitalization rates, and changes in haemo-
globin levels and transfusion need. Four tertiary endoscopic centres were
involved. Data were collected retrospectively between January 2009 and
December 2014. APC was performed with 30–70W power and 2.4 L/min argon
gas flow settings. In case of EBL, 5–6 ligation bands were applied per treatment
session. The average follow-up period was 18.3 months.
Results: A total of 34 patients with GAVE were treated with either APC or EBL
at one of the four centres involved throughout the study period. 26 patients
presented with diffuse and 8 with linear type of GAVE. Occult gastrointestinal
bleeding occurred in 25, acute bleeding in 15 patients. Both acute and occult
gastrointestinal bleeding was present in 6 cases. 22 patients were treated with
APC and 12 with EBL. Both treatment methods increased haemoglobin levels
and decreased transfusion need significantly (3.01 g/dl and 10.41 blood units in
case of APC, and 2.14 g/dl and 7.78 blood units in case of EBL). The need for
blood transfusions ceased totally in 18 patients after the endoscopic resolution of
the lesions. Significantly less treatment sessions were required in case of EBL
compared to APC (1.50 vs. 5.23, p¼ 0.011), with a longer interval between each
session (4.50 vs. 2.69 months, p¼ 0.480). On the other hand, APC resulted in a
higher increase in haemoglobin levels (3.37 g/dl vs. 2.36 g/dl, p¼ 0.213) and a
higher decrease in the need for blood transfusion (10.41 vs. 7.78 units,
p¼ 0.566), although the differences were not significant. In case of APC, fewer
treatments (4.25) and hospitalizations (2.33) were needed, and higher increase in
haemoglobin level per treatment session (0.76 g/dl) could be observed with the
50W power setting compared to the 30W and 70W setting (number of treat-
ments: 12.5 and 6.13; hospitalizations: 2.5 and 4.63; and increase in haemoglobin
level/treatment session: 0.38 g/dl and 0.46 g/dl), although the small case number
was a severe limiting factor. Generally, more treatment sessions were required for
the endoscopic resolution of GAVE lesions compared to the one needed for the
cessation of the transfusion need (3.45 vs. 3; p¼ 0.037), but the difference was not
significant in case of APC and EBL separately.
Conclusion: Both APC and EBL are effective in the treatment of GAVE.
Although EBL may seem to be superior to APC in terms of the number of
treatment sessions and hospitalizations, no significant difference was found in
the extent to which the two methods influence the haemoglobin level and trans-
fusion need. Optimizing APC setups may also improve the performance and
efficacy. There is a pressing need for further prospective studies with homoge-
nized large case number to establish recommendations about the endoscopic
treatment of GAVE.
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Introduction: Esophageal endoscopic submucosal dissection (ESD) is technically
difficult because of narrow working spaces and ease of perforation due to the
lack of serosa. HybridKnife is a recently developed ESD device that is com-
bined with the high-pressure waterjet ERBEJET 2 system to lift mucosa. We
hypothesized that this waterjet could make submucosal dissection safer and stu-
died this in porcine esophagus.
Aims & Methods: Water pressures of 30–70 bar were tested to determine the
appropriate waterjet ESD with HybridKnife (WJ-ESD) pressure in one pig.
WJ-ESD safety and completion were compared with those of conventional
ESD using DualKnife (C-ESD). Each of 3 virtual esophageal lesions in 2 pigs
were resected alternatively using both methods from the lower to upper esopha-
gus. For WJ-ESD, the submucosa, except for hard fibrous tissues, was dissected
using water pressure alone.
Results: Using 50 bar of water pressure resulted in the best balance between
dissection speed and view-disturbing water backflow. The dissection speeds for
the lower, middle, and upper esophagus were 0.2, 0.9, and 0.2 cm2/min in 50 bar
WJ-ESD and 1.1, 0.5, and 1.0 cm2/min in C-ESD, respectively. Minor bleeding
was frequent in WJ-ESD, but was easily stopped by electrocoagulation with the
same needle. No perforation was observed in either group. Thermal damage of
dissected tissues appeared mild, and the extent of muscle injury was smaller for
WJ-ESD (4, 6, and 8%) compared with C-ESD (14, 16, and 7%).
Conclusion:WJ-ESD spent longer dissection time, but damaged less muscle layer.
It can be combined with electrocautery ESD.
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Introduction: Endoscopic submucosal dissection (ESD) for esophageal cancer has
been widely accepted in last decade; however, it often causes postoperative stric-
ture when over three-quarters of the circumference of the esophagus is dissected,
and lowers quality of life for patients. Although steroid is generally used to
prevent the stricture by expecting anti-inflammatory actions, complications
and side effects are of concern. Mesenchymal stem cells (MSCs) have been
reported to be a valuable cell source in regenerative medicine, and large amounts
of MSCs can be noninvasively isolated from human amnion, which is discarded
after delivery. Moreover, conditioned medium (CM) obtained from MSCs has
been reported to have anti-inflammatory and anti-fibrotic effects in several
animal models. In this study, we evaluated whether CM obtained from amnion
MSC culture could prevent the stricture after large esophageal ESD in pigs.
Aims & Methods: We resected semicircumference of pig’s esophagus by ESD
under general anesthesia. We prepared CM gel by mixing CM with carboxy-
methyl cellulose, and endoscopically applied 20mL of MSC-CM gel onto the
wound bed immediately after ESD, and on day 7 and on day 14 (CM weekly
(CM-W) group, n¼ 3). Standard medium gel was used as a control group (n¼ 3).
We also injected triamcinolone acetonide (80mg) into the remained submucosa
immediately after ESD (steroid group, n¼ 3). In addition, we administered
40mL of CM gel orally from day 1 through day 4 after ESD (CM daily (CM-
D) group, n¼ 3). Finally, we humanely euthanized the pigs on day 21 to measure
the stricture rate and for histological analysis evaluating fiber thickness and
muscle fiber atrophy (masson-trichrome staining), re-epithelialization (p63 and
Ki-67), the number of activated myofibroblasts (a-SMA), capillary density
(CD31), infiltration of macrophages (CD107a) and neutrophils (myeloperoxi-
dase). The experimental protocol was approved by the Animal Care and Use
Committees of Hokkaido University.
Results: Stricture rate in CM-W, CM-D and steroid groups was significantly
lower than control group (56.3 7.1%, 52.3 4.7% and 49.3 4.2% vs
80.0 2.0%, respectively). Histological examination demonstrated that the
number of activated myofibroblasts and fiber thickness were significantly sup-
pressed in CM-W, CM-D and steroid groups as compared with control group
(26.8 8.6, 21.5 4.9 and 20.6 2.3 vs 68.3 5.7 cells/HPF; 832.9 26.1,
987.1 145.1 and 944.3 250.8 vs 1,609 418.2mm, respectively). There were
no differences in re-epithelialization, capillary density, infiltration of macro-
phages and neutrophils among four groups; however, muscle fiber atrophy was
significantly suppressed in CM-W group compared with the control group.
Conclusion: Myofibroblast activation causes fibrosis and contributes to the stric-
ture after ESD, and CM gel prevented the esophageal stricture by suppressing the
myofibroblast activation and fibrosis. Oral administration of CM would be a
promising treatment to prevent post-ESD esophageal stricture, and it is as effec-
tive as steroid treatment.
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Introduction: Gastric cancer is one of the most common malignant tumors in the
gastrointestinal tract. Treatment is based in an accurate staging. Emerging meth-
ods, as EUS or PET-CT, are increasingly being used for this purpose. With the
increasing evolution of those techniques and the expanded clinical experience,
studies comparing the most accurate and efficient methods in this setting are
needed.
Aims & Methods: Our aim was to analyze the results of EUS and PET-CT in
stating and restaging our patients with gastric cancer, comparing both of them
with the histological results. Patients with a confirmed gastric cancer were pro-
spectively enrolled. Only patients who finally received a surgical resection were
included. All patients underwent preoperative TNM staging by means of EUS
and PET-CT within 21 days prior to the surgical treatment. All endoscopic
ultrasounds were performed by two experienced ultrasonographers (E.R-C, J.
M-C). For most of the procedures radial echoendoscope (GF-UM160;
Olympus Europe) reserving curvilinear echoedoscope for FNA, in the rare
cases in which we perform it (UCT-180-OL5; Olympus). Every patient received
propofol sedation guided by the endoscopist and by a trained nurse. A systematic
complete US evaluation was performed in each patient. Statistical analysis was
carried out using the software PAWS Statistics 17.0 (SPSS Inc, Chicago, ILL).
The chi-square and the Kappa tests were used to evaluate the consistency
between the EUS and histopathological staging of gastric cancer. Chi-square
and Fisher exact tests were used to compare EUS and PET-CT as appropriate.
A p-value less than 0.05 was considered statistically significant.
Results: 256 patients (178 men; aged 67.6 12.1 years) with an endoscopic and
pathologic diagnosis of gastric adenocarcinoma were included between January
2011 and December 2014. The overall accuracy of T staging using EUS was 78%
in our series. Regarding restaging, the overall accuracy for of T staging was
80.2%. Considering lymph node involvement, the accuracy of EUS was
76.2%, very similar to what it was observed for PET-CT (72.5%), but with
statistical differences (p¼ 0.02). The accuracy of EUS for preoperative N0, N1,
N2 and N3 staging was 76.2%, 78.6%, 76.2% and 90% respectively. When
studying the performance of both techniques in restaging we found that EUS
had a better performance when considering the main staging differences which
can change patients’ management. In this regard, the accuracy in distinguishing
T1-T2 tumors vs. T3-T4 tumors was 91.3%, better than in the first staging.
Indeed, similar results were found in N staging with an accuracy of 88.3% for
N-positive vs. N-negative distinction. By contrast, PET-CT showed an accuracy
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of 69% for lymph node involvement when restaging, inferior to what was found
for EUS and for the initial staging (p5 0.0001).
TABLE 1.: Accuracy of EUS and PET vs Histology
Sensitivity Specificity PPV NPV Accuracy Kappa
T1 50% 98.5% 75% 95.7% 94.5% 0.57
T2 41.7% 88.5% 41.7% 88.5% 80.8% 0.30
T3 38.5% 86.5% 50% 80% 74% 0.27
T4 77.3% 61% 61% 77.3% 68% 0.37
T4a 76.2% 65.5% 61.5% 75% 70% 0.40
T1-T2/T3-T4 87.3% 50% 84.2% 56.3% 78.1% 0.39
N0 73.9% 78.9% 81% 71.4% 76.2% 0.52
N1 50% 83.3% 33.3% 90.9% 78.6% 0.28
N2 55.6% 81.8% 45.5% 87.1% 76.2% 0.35
N3 97.4% 90.2%
Nþ/N 78.9% 73.9% 71.4% 81% 76.2% 0.52
PET Nþ/N 50% 90.9% 81.8% 69% 72.5% 0.42
RESTAGING
T1–T2/T3–T4 95% 66.7% 95% 66.7% 91.3% 0.62
T2 66.7% 95% 66.7% 95% 91.3% 0.62
T3 50% 76.9% 62.5% 66.7 65.2% 0.28
T4 70% 61.5% 58.3% 72.7% 65.2% 0.31
N0 56.3% 83.3% 82% 58.8% 67.9% 0.38
N1 75% 87% 50% 95.5% 85.7% 0.52
N2 33.3% 76% 14.3% 90.5% 71.4% 0.06
N3 20% 87% 25% 84% 75% 0.08
Nþ/N 83.3% 92.9% 90.9% 86.7% 88.5% 0.77
PET Nþ/N 41.7% 88.2% 71.4% 68.2% 69% 0.32
Conclusion: Our results, obtained from a real clinical practice, showed that the
overall accuracies of EUS and PET-CT for preoperative N staging were 76.2%
and 72.5%, with significant differences between both techniques. The overall
accuracy of EUS for T staging was 78% and 80.2% for restaging. More impor-
tantly, our results show a significant advantage of EUS over PET-CT in resta-
ging, even in our series, in which the vast majority of suspicious lymph nodes
were not sampled. In conclusion, EUS performance in gastric cancer N staging
and restaging is better than PET-CT. Both procedures showed suboptimal
accuracies when considered alone, and more than one single staging method
should be used.
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Introduction: Hepatic progenitor cells (HPCs) are small cells with a relative large
oval nucleus and a scanty cytoplasm situated in the canals of Hering.
Phenotypically, HPCs express both markers of (immature) hepatocytes (e.g. -
fetoprotein) and markers of cholangiocytes (e.g. cytokeratin K7 and K19). The
mechanisms facilitating proliferation and differentiation of human HPCs are still
poorly understood.
Aims &Methods: In this study, we aimed to characterize human HPCs in order to
use them as a potential incessant source of cells for cellular transplantation or to
control their activation and differentiation in vivo in chronic liver diseases.
Therefore we isolated and compared, on both protein and RNA level, HPC-
enriched cell populations from adult human liver tissue using different isolation
methods: side population (SP), TROP-2 and EpCAM-based cell sorting. Fresh
human liver tissue was collected from alcoholic steatohepatitis explant livers, and
HPC-enriched cells were obtained via three different isolation methods. A first
method is the SP which is based on the efflux capacities of the progenitor cells of
the fluorescent DNA binding dye Hoechst-33342. The other methods are based
on the expression of membrane markers EpCAM and TROP-2 in HPCs. Human
livers were dissociated and the cell suspension was analysed and separated by
FACS. The sorted cells and the whole liver extracts were evaluated on both
protein level (immunohistochemical staining) and RNA level (RNA sequencing).
Pathway analysis was performed using KEGG pathways, Ingenuity Pathway
Analysis and Gene Set Enrichment Analysis.
Results: Immunohistochemical evaluation of the isolated fractions indicated the
enrichment of HPCs in the SP, EpCAM-positive and TROP-2-positive cell frac-
tions. Pathway analysis of the RNA sequencing data from the different isolated
HPC fractions shows an enrichment and activation of known HPC pathways like
Wnt/b-catenin and Notch pathways, known for their role in proliferation and
differentiation of HPCs. In addition we identified several novel pathways acti-
vated in human HPC-enriched cells such as the TNF and IL17A pathways.
Mutual comparison of the different isolation methods indicates some slight dif-
ferences between the different HPC populations, e.g. the ErbB signalling path-
way is activated in the TROP-2 positive cells while this is not the case in the
EpCAM-positive or SP cell populations.
Conclusion: Our results indicate that gene signatures of human HPCs are
enriched in pathways already known to be involved in HPC activation in
human and in animal models, but we also identify previously unknown pathways
like TNF, IL17A and ErbB signalling pathways. Comparison of the 3 isolation
methods sheds light on the possible existence of different HPC populations resid-
ing in the human liver. The isolated HPC populations will be used to further
characterize human HPCs and to understand the molecular mechanisms under-
lying their activation and differentiation, with the ultimate goal of using HPCs
for the treatment of liver diseases.
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Introduction: Sortilin, a member of the Vps10 domain receptor family, traffics
newly synthesized proteins from the trans-Golgi network to secretory pathways,
endosomes or to the cell surface. Sortilin trafficked molecules, including acid
sphingomyelinase (aSMase), cathepsins and IL-6, mediate activation of hepatic
stellate cells (HSC), hepatocyte apoptosis, cholangiocyte proliferation and liver
inflammation and fibrosis.
Aims & Methods: We investigated sortilin role in the development of biliary
damage leading to hepatocellular injury and fibrosis, based on its regulation of
aSMase trafficking and on its involvement in IL-6 secretion.Cholestatic injury
was induced in wild type (WT) and Sortilin-/- mice by bile duct ligation (BDL).
Fibrosis was induced both by BDL and by administration of CCl4.Liver inflam-
mation and cholangiocyte activation and proliferation were assessed by qRT-
PCR for inflammatory cytokines and by immunohistochemistry with Ki67
(marker of proliferation) and with Ly6G (neutrophil marker). Liver damage
and hepatocyte apoptosis were determined by serum liver enzymes and by
TUNEL assay. Liver fibrosis was assessed by Sirius Red staining quantitation
and by qRT-PCR for fibrotic markers. ASMase activity was inhibited in vivo by
amitriptyline administration.IL-6 effect was neutralized by administration of an
anti-IL-6 antibody to WT mice after BDL.
Results: Sortilin-/- mice displayed strongly attenuated liver fibrosis following
BDL and CCl4 treatment, accompanied by an attenuated in vitro activation
phenotype of Sortilin-/- HSCs. Reduced Sortilin-/-hepatic aSMase activity was
in line with reduced hepatocyte apoptosis following BDL and CCl4 injury and
reduced susceptibility of hepatocytes from Sortilin-/-mice to bile acid-induced
apoptosis in vitro. The role of aSMase in hepatocyte apoptosis was further
demonstrated using in vivo pharmacological inhibition of aSMase activity after
BDL. Strikingly, Sortilin-/- mice displayed impaired inflammation and ductular
reaction three days after BDL, demonstrated by reduced reactive cholangiocytes,
reduced cholangiocyte proliferation and accompanied by reduced serum IL-6.
Short-term treatment of bile duct-ligated WT mice with a neutralizing antibody
to IL-6 attenuated hepatic inflammation and expression of reactive cholangio-
cyte-derived cytokines and chemokines.
Conclusion: Sortilin mediates cholestatic liver damage and fibrosis via its effects
on aSMase activity and serum IL-6.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Targeting necroptosis, a programmed necrotic cell death pathway
regulated by receptor-interacting protein 3 (RIP3), is being considered as a pro-
mising therapeutic approach for inflammation-driven liver diseases. Still, the role
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of necroptosis in the pathogenesis of cholestatic liver injury has been poorly
explored.
Aims & Methods: We aimed to evaluate the role of necroptosis in patients with
primary biliary cirrhosis (PBC), a cholestatic chronic liver disease, and in mice
after common bile duct ligation (BDL), a classic experimental model of acute
cholestasis and secondary biliary fibrosis. Thioflavin T staining and immunohis-
tochemistry of RIP3 and its target phosphorylated-mixed lineage kinase domain-
like protein (p-MLKL) were performed in liver biopsies of patients with PBC and
healthy controls. C57BL/6N wild-type (WT) or RIP3-deficient (RIP3-/-) mice
were subjected to BDL or sham surgeries for 3 and 14 days, with subsequent
histological and biochemical analysis of hepatic damage. Necroptotic markers
and the functional crosstalk between RIP3, antioxidant response and iron home-
ostasis were investigated in vivo and in vitro.
Results: In PBC patients, expression of RIP3 and p-MLKL was found increased
in hepatocytes surrounded by lymphocytic infiltrates and also in cells morpho-
logically resembling bile duct cells. Moreover, p-MLKL fluorescence co-localized
in cells with increased thioflavin T staining, suggesting necrosome assembly and
necroptosis activation. BDL in mice resulted in progressive bile duct hyperplasia,
multifocal necrosis, fibrosis and inflammation. Concomitantly, necroptosis was
activated as evidenced by increased RIP3 expression and activity and sequestra-
tion of RIP3 and MLKL in the insoluble protein fraction of the liver.
Remarkably, RIP3 deficiency blocked BDL-induced necroinflammation at 3
and 14 days post-BDL. Serum hepatic enzymes, fibrogenic liver gene expression
and oxidative stress decreased in RIP3-/- mice at 3 days after BDL. However, at
14 days, cholestasis aggravated and fibrosis was not ameliorated. RIP3 deficiency
further associated with increased hepatic expression of heme oxygenease-1 (HO-
1) and accumulation of iron in BDL mice. The functional link between HO-1
activity and bile acid toxicity was established in RIP3-deficient primary hepato-
cytes. Finally, TUNEL-positive cells and caspase-3/-7 activity increased 14 days
after BDL in both WT and RIP3-/- mice, while remaining at basal levels at day 3,
indicating that apoptosis is activated at late time-points in the BDL murine
model, reflecting the peak of liver fibrosis.
Conclusion: In conclusion, necroptosis is triggered in PBC patients and mediates
hepatic necroinflammation in BDL-induced cholestasis. Targeting necroptosis
may provide an opportunity to develop novel therapeutic strategies to attenuate
acute cholestatic liver injury. However, therapeutic strategies to inhibit RIP3-
dependent signalling during chronic cholestasis should be undertaken with a
complete understanding of the potential duality of this pathway. (Supported
by HMSP-ICT/0018/2011, SFRH/BD/91119/2012, SFRH/BD/88212/2012 and
SFRH/BD/104160/2014, FCT, Portugal).
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Introduction: Myeloid-derived suppressor cells (MDSCs) comprise a heteroge-
neous population of immature myeloid cells that induces the exhaustion of
anti-tumor immune responses. The accumulation of CD33þHLA-DR- MDSCs
correlates with tumor stage and metastatic burden in various cancers including
hepatocellular carcinoma (HCC) [1]. Cancer cells can secrete a variety of cyto-
kines and chemokines to facilitate the peripheral expansion and tumor infiltra-
tion of MDSCs to maintain tumor microenvironment. However, the cancer cell-
specific signaling cascades that promote MDSC expansion and infiltration
remain poorly understood. We have recently demonstrated that cell cycle-related
kinase (CCRK) acts as a new oncogenic signaling hub in hepatocellular prolif-
eration and transformation [2–4].
Aims & Methods: To investigate whether CCRK regulates tumor microenviron-
ment in hepatocarcinogenesis, we determined the role of CCRK signaling in the
crosstalk between HCC cells and MDSCs. We have used a liver-specific CCRK
transgenic mouse model and HCC orthotopic model in C57/BL6 immunocom-
petent mice. Molecular techniques including co-immunoprecipitation and ChIP
assay were used to investigate the underlying mechanisms.
Results: Transgenic over-expression of CCRK in murine liver led to expansion of
polymorphonuclear MDSCs in circulation. Moreover, co-culture of human per-
ipheral blood mononuclear cells (PBMCs) with CCRK-over-expressing immor-
talized hepatocytes and HCC cells induced the accumulation of
CD33þCD11bþHLA-DR-MDSCs. The CCRK-induced MDSCs possessed
immune suppressive functions by inhibiting T cell proliferation and interferon
gamma expression (IFN-). In contrast, knockdown of CCRK in hepatic cells
reduced the expansion and immune suppression of MDSCs. Using a Hepa1–6
orthotopic HCC model in immune-competent C57BL/6 J mice, we demonstrated
that knockdown of Ccrk significantly decreased hepatic tumorigenicity and the
levels of circulating and tumor-infiltrating MDSCs as well as their T cell sup-
pressive functions. Notably, adoptive transfer of MDSCs rescued the effects of
Ccrk knockdown. In a complementary experiment, we found that MDSC deple-
tion by specific IA8 antibody significantly reduced CCRK-induced tumorigeni-
city. Cytokine profiling analysis revealed that CCRK significantly induced
hepatocellular interferon-6 (IL-6) expression and production, which mediated
MDSC expansion as shown by IL-6 rescue and antibody neutralization experi-
ments. Mechanistic studies demonstrated that CCRK triggered nuclear factor-
kappa B (NF-B) signaling in an enhancer of zeste homolog 2 (EZH2)-dependent
manner. Simultaneously, the phosphorylation of NF-B by CCRK facilitated the
co-occupancy of IL-6 promoter by NF-B-EZH2 complex for transcriptional
activation.
Conclusion: As we also showed elevation of CD33þCD11bþHLA-DR-MDSCs
and concordant over-expression of CCRK/EZH2/NF-B/IL-6 signaling in
human HCCs, our results uncover CCRK to be a critical immune regulator to
promote MDSC functions, thereby providing a new mechanistic link between
aberrant oncogenic signaling and tumor evasion for therapeutic exploitation.
Acknowledgement: This project was supported by the University Grants
Committee through the Collaborative Research Fund C4017-14G and the
Health and Medical Research Fund (03141376).
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Introduction: In chronic liver disease the presence of gut-derived bacterial pro-
ducts and the resultant increase in inflammatory cytokines in the splanchnic and
systemic circulation may contribute to the progression of fibrosis. However, the
composition of the intestinal microbiota and the host-microbe interaction in the
development of liver fibrosis remain largely unknown. We hypothesized that
fibrosis would be attenuated in a gnotobiotic model of limited intestinal coloni-
zation (altered Schaedler flora, ASF) compared to a more complex colonization
with specific pathogen free flora (SPF).
Aims & Methods:We aimed to investigate the development of fibrosis and portal
hypertension in ASF and SPF mice. Liver fibrosis was induced by common bile
duct ligation (BDL) for 14 days or intraperitoneal injection of 20% (dilution in
olive oil) carbon tetrachloride (CCL4) for 10 weeks in ASF or SPF male, C57BL/
6 mice. Hemodynamic measurements were performed after 14 days in BDL or 10
weeks in CCL4 treated mice. Liver histology and collagen deposition were eval-
uated using Sirius red staining for determination of fibrosis degree. To assess
bacterial translocation, mesenteric lymph nodes, spleen and liver were dissected
aseptically and then cultured on Luria Bertani agar and blood agar plates for
aerobic and anaerobic culture respectively.
Result: There were no differences in portal pressure between sham-operated
(controls) ASF or SPF mice. After BDL or CCL4 treatment portal pressure
(PP), portosystemic shunts (PSS) and collagen deposition within the liver
showed a significant increase in both groups. However, the increase in portal
pressure and degree of fibrosis was significantly higher in ASF than SPF mice:
ASF-
sham
ASF-
BDL
SPF-
sham
SPF-
BDL
ASF-
control
ASF-
CCL4
SPF-
control
SPF-
CCL4
PP cmH2O 8.4 11.8** 7.2 9.7* 8.5 12.2** 7.4 10.4*
PSS % 0.29 2.91** 0.38 2.42* 0.6 3.5* 0.5 1.8*
Collagen % 0.1 9.6*** 0.3 5.2*** 1.1 7.6*** 0.8 4.3***
*( p5 0.05 ** p5 0.005 *** p5 0.005) Bacterial translocation was significantly
higher in ASF-BDL than SPF-BDL mice suggesting that bacterial translocation
occurred more frequently in ASF-BDL mice. The increase in the bile infarcts area
was significantly higher in ASF mice (ASF-BDL 13.5% vs. SPF-BDL 4.8%
P¼ 0.026). No significant bacterial translocation was observed in CCL4 treated
mice.
Conclusion: SPF mice presented attenuated fibrosis and portal hypertension com-
pared to ASF mice. Contrary to our hypothesis, these findings suggest that a
more complex intestinal bacterial flora may play a hepato-protective role. Our
results are in line with studies showing that germ free mice are more susceptible
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to liver injury and fibrosis suggesting the beneficial role of intestinal microbiota
in preventing liver injury1, 2.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) pathogenesis and treat-
ment remain unsolved. microRNAs and bile acids were recently suggested to
participate in disease pathogenesis and, as such, constitute potential therapeutic
tools and targets. Moreover, nuclear receptors, namely peroxisome proliferator-
activated receptors (PPARs) and the farnesoid X receptor (FXR) are currently
under scrutiny as modulators of lipid and glucose metabolism in non-alcoholic
steatohepatitis (NASH).
Aims & Methods: We aimed to elucidate the role of the miR-21/PPAR pathway
in liver and muscle tissues of murine NASH models and ascertain the therapeutic
potential of miR-21 abrogation alone or in combination with obeticholic acid
(OCA). Wild-type (WT) and miR-21 KO mice were fed with chow (n¼ 10) or
methionine and choline-deficient (MCD; n¼ 10) diets for 2 and 8 weeks.
Alternatively, mice were fed either chow (n¼ 12) or fast food diet (FF; n¼ 12)
for 25 weeks. Six animals from each group had their diet supplemented with
OCA 10mg/kg/day (Intercept Pharmaceuticals, Inc.). Human liver biopsies
were obtained from morbid obese NAFLD patients (n¼ 28). Liver/muscle sam-
ples were processed for histological analysis and assessment of miR-21, pro-
inflammatory/pro-fibrogenic cytokines, PPAR and metabolic relevant genes,
by qRT-PCR and immunoblotting. A Taqman Array was performed to eval-
uate modulation of lipid regulated genes. ROS levels were analysed through the
use of 2’,7’- dichlorodihydrofluorescein diacetate.
Results: WT mice fed with the MCD diet developed steatohepatitis and fibrosis,
displaying increased levels of apoptosis, necroptosis and serum ALT and AST. In
contrast, miR-21 KO mice displayed a significant decrease in steatosis severity,
liver damage, inflammation and did not develop fibrosis. WT FF-fed mice devel-
oped hepatomegaly, macrovesicular steatosis, inflammatory infiltrates and
increased oxidative stress. miR-21 levels were increased in WT FF-fed mice, in
both liver and muscle, concomitantly with decreased expression of PPAR, a key
miR-21 target. Similar findings were observed in NAFLD patients. Further, WT
FFþOCA-fed mice exhibited decreased steatosis and miR-21 expression, com-
pared with WT FF-fed mice. Importantly, KO FFþOCA-fed mice exhibited
significantly reduced liver inflammation, oxidative stress and steatosis, in parallel
with increased expression of PPAR and its metabolic targets, including CPT-1
and ACOX2. Finally, lipid regulated genes such as ACAT1, ALOX5 and FABP5
were found to be severely deregulated in WT FF-fed mice and reverted to control
levels in KO FFþOCA-fed mice.
Conclusion: In conclusion, activation of PPAR, as a result of miR-21 abroga-
tion, together with FXR activation by OCA, significantly improves metabolic
parameters in NASH, highlighting the therapeutic potential of multi-targeting
therapies for NAFLD. (Supported by PTDC/BIM-MEC/0873/2012, SFRH/BD/
88212/2012, FCT, Portugal).
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Introduction: Presence of the single nucleotide polymorphism (SNP) rs2476601 in
the gene encoding protein tyrosine phosphatase non-receptor type 22 (PTPN22)
results in an altered-function PTPN22 protein product and is associated with
increased risk to develop autoimmune disorders, including type 1 diabetes, rheu-
matoid arthritis, systemic lupus erythematous. However, the same variant
reduces the risk for Crohn’s disease (CD) onset. We have previously shown
that protein and mRNA levels of PTPN22 are reduced in intestinal biopsies
from CD patients, and that loss of PTPN22 results in enhanced inflammatory
cytokine secretion from mononuclear cells treated with interferon-gamma or the
bacterial product muramyl dipeptide.
Aims & Methods: In this study, we addressed how presence of the altered-func-
tion variant in PTPN22 influences the susceptibility to intestinal inflammation in
mouse models of colitis. For this aim, colitis was induced in 10–12 week old
female mice by administration of 2% DSS for 7 days (acute DSS colitis), admin-
istration of four cycles of DSS (1.5% DSS for 7 days, followed by 10 days normal
drinking water each; chronic DSS colitis), or by transferring naı¨ve T cells into
RAG2-/- recipients. PTPN22 deficient (PTPN22-/-) mice, or mice expressing the
IBD-associated variant in PTPN22 (PTPN22-619W mice), and their respective
wild-type (WT) littermates were used for the study.
Result: PTPN22-/- mice suffered from aggravated acute DSS colitis as character-
ized by pronounced weight loss, increased endoscopic and histologic colitis scores
(p5 0.05 each), while PTPN22-619W mice reacted only weak to the DSS treat-
ment when compared to WT littermates (p5 0.05 for weigh development,
p5 0.01 for other parameters). In chronic DSS colitis however, PTPN22-/-
mice suffered from a milder disease course (reduced weight loss [p5 0.05],
decreased histological severity [p5 0.05]) from the third cycle onwards.
PTPN22-619W on the other hand mice tended to show a more pronounced
disease course in the later phase. In the T cell transfer model, PTPN22-/- T
cells induced an enhanced histological pathology (p5 0.05), while weight loss
was not affected when compared to mice receiving WT T cells. In contrast, mice
transfected with PTPN22-619W T cells were protected from disease development
in the first weeks, and later on developed only a mild disease (moderate weight
loss [p5 0.01], reduced shortening of the colon [p5 0.05], low histological dis-
ease scores [p5 0.05]) when compared to mice receiving WT T cells.
Conclusion: Taken together, we here describe for the first time how the IBD-
associated variant in PTPN22 affects colitis development. This helps to explain
why this variant is associated with a reduced risk for CD onset, although it
increases the risk to develop classical autoimmune disorders.
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Introduction: The recognition of intestinal microbiota is in part carried out by
toll-like receptors (TLR), which are responsible for initiating the innate immune
response. Alterations in the intestinal microbiota and its recognition may con-
tribute to the development of intestinal inflammatory pathologies. Otherwise,
hydrogen sulphide (H2S) is an endogenous gaseous signalling molecule and it
potentially plays a relevant role in the intestinal motility. In mammals, two
pyridoxalphosphate-dependent enzymes are responsible for H2S synthesis:
cystathionine b-synthase (CBS) and cystathionine -lyase (CSE).
Aims & Methods: The aim of this study was to investigate the influence of TLR2
on the motor response induced by H2S and the enzymes responsible for H2S
synthesis (CBS and CSE) in mouse colon. Colon strips from male C57/BL10
wild-type (WT) and TLR2-/- mice of 8–12 weeks old were suspended in an
organ bath in the direction of circular smooth muscle. We studied the effect of
NaHS (10 mM–1mM), D,L-propargylglycine (PAG, 10 mm–10mM), an inhibitor
of CSE, and amino-oxyacetic acid (AOAA, 10mm–10mM), an inhibitor of CBS,
on WT and TLR2-/- mice colonic motility. Gene expression (mRNA) of CSE and
CBS were determined by real time-PCR and protein expression of CSE and CBS
were quantified by Western blotting in colon from WT and TLR2-/- mice.
Results: The NaHS, as a source of exogenous H2S, reduced the frequency but not
the amplitude of the spontaneous contractions in colon from WT mice. The
inhibition of CSE or CBS with PAG or AOAA, respectively, increased the fre-
quency but not the amplitude of the spontaneous contractions in colon from WT
mice. The NaHS induced a higher reduction of the frequency of the spontaneous
contractions in TLR2-/- respect to WT mice. The PAG and AOAA did not
modify the spontaneous contractions in colon from TLR2-/- mice. The mRNA
and protein expression of CBS resulted decreased in colon of TLR2-/- compared
with WT mice. The mRNA but not the protein expression of CSE resulted
decreased in TLR2-/- compared with WT mice.
Conclusion: These results suggest that exogenous and endogenous H2S may reg-
ulate the colonic spontaneous contractions in WT mouse, reinforcing the hypoth-
esis that H2S is a gaseous inhibitory mediator of intestinal motility. TLR2
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regulates the expression of CBS and modulates the inhibitory motor response
induced by H2S in mouse colon.
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Introduction: Biologics targeting inflammatory cytokines has reveal a new era in
inflammatory bowel disease treatment. High mobility group protein B1
(HMGB1) acts as an alarmin in early stage and inflammatory cytokine in late
stage during inflammation. Direct blockade of HMGB1 can be protective against
intestinal inflammation.
Aims &Methods: Potential role of anti-HMGB1 neutralizing antibody (HnAb) in
inhibiting intestinal inflammation and the underlying mechanism is investigated
in DSS-induced mice colitis (DSS-C) models. 200mg HnAb was administrated
intraperitoneally to DSS-C at d0, d3 and d6 in HnAb group, whereas 200mg anti-
IgY was used as control in DSS-C (DSS-C group) or normal control (ctrl group).
Colon shortening, disease activity index (DAI), histological score of colitis (HS),
MPO activity and inflammatory cytokines were evaluated to determine the colo-
nic inflammation severity. Mucosa barrier function was assessed by immuno-
fluorescent staining of mucus layer (mucin2) and tight-junction (T-J) protein
detection. mRNA was detected by qPCR. T-J protein, HMGB1, TLR4,
MyD88 was detected by Western blotting and measured by Grey-scale value.
Statistical analysis was performed using one-way ANOVA analysis and the Post
Hoc LSD test or Tamhane’s T2 test.
Results: Treatment with HnAb significantly suppressed colonic inflammation in
DSS-C mice by improving colon shortening (6.2 0.4 cm vs. 5.3 0.5 cm,
p5 0.05), DAI (2.7 0.5 vs. 3.7 0.3, p5 0.05) and HS (6.0 0.1 vs.
9.6 0.7, p5 0.05). Besides, MPO activity (2.6 0.8 vs. 4.8 1.0, p5 0.05)
and TNF- (1.61 0.05 vs. 3.04 0.11, p5 0.05), IFN- (2.14 0.06 vs.
7.87 0.21, p5 0.05) and IL-1b (1.53 0.10 vs. 2.48 0.04, p5 0.05) mRNA
expression was decreased when treated with HnAb as compared to DSS-C group
(mRNA in ctrl group was set to 1). Relatively intact mucus layer was seen in mice
colon of HnAb group as compare to DSS-C group. Significantly higher expres-
sion of tight-junction protein ZO-1 (0.38 0.01 vs. 0.15 0.05, p5 0.0001), clau-
din-5 (0.50 0.09 vs. 0.17 0.07, p5 0.0001) and occludin (0.85 0.09 vs.
0.39 0.01, p5 0.0001) was detected in HnAb mice as compared to mice in
DSS-C group. Interestingly, colonic HMGB1 protein in both nucleus
(0.58 0.02 vs. 0.79 0.03, p5 0.0001) and cytoplasm (0.23 0.01 vs.
0.40 0.03, p5 0.0001) were all decreased when treated with HnAb as compare
to DSS-C, suggesting that primary inhibition of HMGB1 by HnAb blocked
sequential HMGB1 formation and release. Lastly, TLR4 (0.31 0.03 vs.
0.77 0.08, p5 0.0001) and MyD88 (0.30 0.03 vs. 0.78 0.01, p5 0.0001)
protein was significantly reduced in HnAb group than mice in DSS-C group
though MyD88 mRNA was relatively higher in HnAb group than DSS-C
group (0.69 0.04 vs. 0.38 0.01, p5 0.05).
Conclusion: Administration of HnAb ameliorated DSS-C by suppressing inflam-
mation and strengthening mucosa barrier function possibly through inhibition of
HMGB1-TLR4-MyD88 pathway, suggesting a potential interventional target of
HMGB1 in ulcerative colitis treatment.
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Introduction: PETIR (PEptidase-Targeted ImunoRegulation) is a novel therapeu-
tic strategy which takes for the purpose restoration of the immune balance by
limiting the activation of immune cells and induction of endogenous protective
mechanisms, such as TGFb and glucagon-like peptide-2 (GLP-2) through inhibi-
tion of DPP IV-dependent pathways. Experimental data indicate that PETIR
results in suppression of cell proliferation and reduced synthesis of pro-inflam-
matory cytokines without affecting cellular vitality.
Aims & Methods: The objective of this study was to test the anti-inflammatory
activity of a novel DPP IV inhibitor EMDB-1 in the mouse models of colitis. The
inhibitory effect of EMDB-1 on DPP IV was characterized in vitro using the
HPLC system measuring the degradation rate of endomorphin-2 (EM2, natural
DPP IV substrate) in the presence of the test compound. Anti-inflammatory
activity of EMDB-1 was investigated in the model of acute and semi-chronic
colitis induced by trinitrobenzenesulfonic acid (TNBS). Body weight, macro-
scopic score, ulcer score, colon length and thickness, as well as myeloperoxidase
(MPO) activity were recorded. Mesalazine was used as a reference drug.
Results: EMDB-1 is a potent and specific DPP IV inhibitor as shown by signifi-
cantly decreased degradation rate of EM2 by DPP IV (t0.5¼ 1.73 vs. 3.60min in
the absence and the presence of EMDB-1, respectively). The intracolonic (i.c.)
administration of EMDB-1 (0.1, 1 and 3mg/kg, twice daily) attenuated both
acute and semi-chronic TNBS-induced colitis in mice in a dose-dependent
manner, as indicated by significantly reduced macroscopic parameters and
MPO activity. Anti-inflammatory effect of EMDB-1 was not blocked by nalox-
one, thus the opioid receptors are not involved in its mechanism of action.
Conclusion: EMDB-1 is a potent inhibitor of DPP IV in vitro and exhibits sub-
stantial anti-inflammatory activity in the GI tract in vivo. Results of this study
validate the EMDB-1 backbone for further development of peptide DPP IV
inhibitors and suggest their potential use in the treatment of colitis.
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Introduction: Macrophages play a major role in inflammatory bowel disease
(IBD) pathogenesis through an inappropriate response to migration, and an
impaired transition from a pro-inflammatory (classical activated macrophages
(CAMs)) to an anti-inflammatory (alternative activated macrophages (AAMs))
phenotype. While there is growing awareness of a relationship between
Chromogranin (Cg)-A and a susceptibility to inflammatory conditions, the spe-
cific interaction between CgA-derived peptides and macrophage plasticity in IBD
is unknown. Recently, we have shown a linear correlation between CgA and
inflammatory markers in patients with active ulcerative colitis, and colitic
CgA-deficient mice demonstrated a significant decrease of colitis associated to
a modulation of macrophage activation. As Cg-A is a prohormone, herein, we
assessed the functional role of a specific CgA-derived peptides (Chromofungin
(CHR): hCg-A47-66) in the regulation of acute colitis and the functional plasti-
city of murine macrophages.
Aims & Methods: Colitis was induced in C57BL/6 mice (7–8 weeks old) by
administrating dextran sulfate sodium (DSS 5%) in drinking water for 5 days.
Preventive CHR (2.5mg/kg/day) or vehicle treatments started 1 day before
induction of colitis and lasted for a total of 6 days. Disease activity index
(DAI) was evaluated daily and mice were sacrificed on day 5 post-DSS induction
to assess the extent of colitis. At sacrifice macroscopic scores were evaluated,
serum level of C-reactive protein (CRP) was quantified using ELISA, and colonic
interleukin (IL)-1b, IL-6, TNF-, MIP-1, MIP-1b, and ARG-1 were assessed
using ELISA and RT-qPCR. Naı¨ve peritoneal macrophages were isolated from
non-colitic C57BL/6 mice and treated by CHR (200 ng/ml) then exposed for 6 h
to LPS (100 ng/ml) to promote CAMs, or to IL-4/IL-13 (20 ng/ml) to promote
AAMs. CAMs markers (IL-6, IL-1b, TNF-, MIP-1 & MIP-b) and AAMs
markers (ARG-1) were quantified by using ELISA and RT-qPCR.
Results: Preventive treatment with CHR significantly reduced the DAI onset and
severity of colitis associated to rectal bleeding, stool consistency and weight loss.
Macroscopic scores, serum-CRP, colonic IL-1b, IL-6, TNF-, MIP-1, MIP-1b
were significantly decreased, while ARG-1 was significantly increased. In vitro,
CHR-conditioned CAMS expressed significantly less IL-1b, IL-6, TNF-, MIP-
1, MIP-b, but, surprisingly, more ARG-1 when compared to LPS control con-
dition. Moreover, CHR-conditioned AMS expressed significantly more ARG-1
when compared to IL-4/IL-13 control condition.
Conclusion: These findings suggest that CHR can modulate the severity of experi-
mental colitis. CHR treatment can attenuate the severity of experimental colitis
and the inflammatory process via the modulation of the functional plasticity of
murine macrophages and their functions. Targeting CgA-derived peptides may
lead to novel therapeutic strategies in ulcerative colitis.
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Introduction: The adaptive immune system plays a crucial role in the pathogenesis
of inflammatory bowel diseases (IBD). Inflammation in IBD is typically asso-
ciated with a decrease in local pH. The proton-sensing receptor T-cell death
associated gene 8 (TDAG8), also known as G-protein-coupled receptor 65
(GPR65), has been identified as a risk gene for IBD in recent genome wide
association studies.
Aims & Methods: We investigated the role of TDAG8 in T cell-mediated patho-
genesis in intestinal inflammation using a murine adoptive transfer colitis model.
Naı¨ve T-cells (CD4þCD62Lþ), from WT and TDAG8-/- donor mice, were
injected into Rag-/- male mice. Injection of PBS was used in a control group.
The results of colitis were evaluated by weight change, colonoscopy score, spleen
weight, H&E staining, IHC and mRNA expression.
Results: Induction of colitis was observed after 3 weeks by weight loss, diarrhea
and bloody stool. The WT group showed severe weight loss (p¼ 0.013), whereas
the TDAG8-/- group displayed only a minor delay in weight gain. No significant
differences were observed in colon length, spleen weight and colonoscopy score
between PBS and the TDAG8-/- groups. H&E staining of distal and proximal
parts of the colon showed severe infiltration and crypt damage in the WT group.
The TDAG8-/- group displayed significantly less histopathological signs of colitis
in comparison to PBS and WT groups. CD3þ and IL-17A immunoreactive cells
were rarely detected in colonic tissue of TDAG8-/- in comparison to the WT
group. Downregulation of mRNA expression of pro-inflammatory cytokines
(IFN, TNF, IL17A) was observed in the TDAG8-/- group in comparison with
the WT group. No significant differences were observed in mRNA expression
levels of Foxp3, RORgþand IL18.
Conclusion: Our data demonstrate that TDAG8-deficiency in T-cells ameliorates
the development of colitis suggesting an important physiological role of this pH
receptor.
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Introduction: Non-randomized studies suggest that endoscopic mucosal resection
(EMR) is equally effective in removing large rectal adenomas as transanal endo-
scopic microsurgery (TEM). EMR might be more cost-effective and safer. This
trial compares the cost-effectiveness and cost-utility of TEM and EMR for large
rectal adenomas.
Aims & Methods: For this randomised controlled non-inferiority trial, patients
with rectal adenomas 3 cm, without malignant features, from 20 hospitals were
included and randomised (1:1) to EMR or TEM, allowing endoscopic removal of
residual adenoma at 3 months. Unexpected malignancies were excluded post
randomisation. Primary outcomes were recurrence within 24 months and the
number of recurrence-free days alive and out of hospital, analysed by intention
to treat. The trial was designed to demonstrate non-inferiority of EMR with
regards to recurrence rate with an upper limit of 10%. Secondary outcomes
were complications, quality of life, anorectal function and costs. This trial is
registered in the Dutch Trial Registry (NTR1422).
Results: Between Feb 2009 and Sept 2013, 209 patients were randomised to EMR
(n¼ 106) or TEM (n¼ 103). 4 patients withdrew consent. 1 patient had prostate
carcinoma instead of rectal adenoma. The remaining 204 patients (103 EMR, 101
TEM) were treated; 27 (13%) had unexpected cancer and were excluded. One
additional patient withdrew consent. Of the remaining 176 (87 EMR, 89 TEM)
patients, overall recurrence rates were 15% after EMR and 11% after TEM
(relative risk 1.33, 95% confidence interval (CI) 0.77–2.46). However, EMR
was statistically not non-inferior to TEM. The number of recurrence-free days
alive and out of hospital was similar (EMR 609 209, TEM 652 188, p¼ 0.15).
Complications (mostly hemorrhage) occurred in 18% (EMR) vs. 26%
(TEM) (odds ratio (OR) 0.65 (95% CI 0.32–1.33)). Major complications
occurred in 1% (EMR) vs. 8% (TEM) (OR 0.14 (95% CI 0.02–1.13),
p¼ 0.064). Quality adjusted life years were equal in both groups. Although
EMR patients scored more favourable on disease specific quality of life ques-
tionnaires, manometries were similar and continence improved after adenoma
resection regardless of treatment. EMR was approximately E3000 cheaper and
therefore more cost-effective.
Conclusion: Due to unexpected high recurrence rates after both TEM and EMR,
non-inferiority of EMR could not be demonstrated. Taking into account the high
rate of unexpected malignancies, a trend towards more severe complications after
TEM and the cost-effectiveness of EMR, EMR is the recommended technique in
case of similar expertise of TEM and EMR.
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Introduction: Endoscopic submucosal dissection (ESD) has been widely accepted
as an effective treatment for gastrointestinal tumors. However, ESD for early
gastric cancer (EGC) with ulcer scarring is still technically difficult. Non-exposed
endoscopic wall-inversion surgery (NEWS) is an advanced method of endoscopic
full-thickness resection (EFTR) without transluminal communication, applying
ESD technique.
Aims & Methods: The aim of this study is to clarify the short-term outcomes of
NEWS for gastric tumors. Between July 2011 and March 2016, 26 patients (9
females, 17 males; mean age 65.9 years, range 49–85 years) underwent NEWS for
gastric tumors. After marking around a tumor on both the mucosal and serosal
surfaces and submucosal injection of sodium hyaluronate, circumferential sero-
myotomy and sero-muscular suturing were made laparoscopically, followed by
circumferential muco-submucosal incision endoscopically. The resected specimen
was perorally retrieved.
Results: The mean tumor size and resected specimen were 23.3mm (range, 7–
45mm) and 36.1mm (range, 20–66mm), respectively. All lesions were curatively
resected in an en-bloc fashion. The mean operation time was 219.0 minutes
(range, 98–397 minutes), and the median estimated blood loss was 0 g (range,
0–250 g). Patients started oral intake on mean postoperative day 3.1 (range, 2–4),
and the mean length of postoperative hospital stay was 8.2 days (range, 6–14
days). There were no severe postoperative complications. Histopathological
examination of the tumors showed 21 GISTs, 1 schwannoma and 4 early gastric
cancer. No tumor residual or recurrences was confirmed by performing gastro-
scopy and the mean body weight loss was 2.5 kg (range, 3.2–10.9 kg) during a
median follow-up of 11 months (range, 0–37 months).
Conclusion: NEWS is an effective full-thickness resection with minimum possible
margin without contamination and tumor dissemination into the peritoneal
cavity, considering the quality of life of patients. NEWS could be utilized as a
novel treatment option especially for node-negative EGC difficult to resect by
ESD, or EGC with possible lymph node metastasis with a combination of senti-
nel node navigation surgery.
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Introduction: Somatostatin analogues have been proposed as a rescue therapy in
cases of chronic or recurrent obscure gastrointestinal bleeding (GIB) or attribu-
table to gastrointestinal angiodysplasias (GIADs). The long-term results with
lanreotide are still very scarce.
Aims & Methods: Our aim is to determine the medium and long-term benefit of
lanreotide in cases of chronic or recurrent refractory obscure gastrointestinal
bleeding or from gastrointestinal angiodysplasias, in terms of savings of health
resources. This was a retrospective single-center study conducted under conven-
tional clinical practice, following a defined management protocol, between 2003
to 2012. Patients with chronic or recurrent obscure GIB or due to GIADs,
refractory to or not candidates for iron therapy, endoscopic, surgical or angio-
graphic treatments, were included. Cirrhotic patients and those ones with very
severe comorbidity (IV-V of the American Society of Anesthesiologists
Classification-ASA-) were excluded. The diagnostic protocol included upper
and lower endoscopy, abdominal computed tomography, video capsule endo-
scopy and/or single balloon enteroscopy. Lanreotide 60 or 90mg was adminis-
tered monthly, for at least 6 months. During the previous year and 36 months
after starting the drug it was recorded demographics data, comorbidities, chronic
use of antiplatelets and anticoagulants, hemostatic treatments, side effects, hos-
pital admissions related to GIB, number of transfused red cells units, intravenous
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iron doses, and non-diagnostic endoscopies. Differences between data from one
year before and each one of the three years after starting lanreotide were eval-
uated using Wilcoxon test, with significance level of p5 0.05.
Results: Twenty-two patients (median age 76.1 years, range 56–90; 50% male sex)
were included. Before starting treatment 19 were ASA III, 22.7% consumed
antiplatelet and 31.8% anticoagulants drugs. At the end of follow-up only one
patient had stopped the anticoagulant. The bleeding was attributed to GIAD in
77.3% and 22.7% was obscure. The bleeding was overt in 68.2% and occult in
31.8%. Before starting lanreotide 4 patients had received endoscopic treatment
using argon plasma coagulation (APC), 2 hormonal therapy and 1 thalidomide.
Two patients received APC concomitant to lanreotide, and 1 hormonal therapy
after stopping this one without reaching bleeding cessation. The average duration
of treatment with lanreotide was 28.4 months (range 6–36). Mean follow-up was
32.4 months (range 9–36), with the results shown in the table. Five patients did
not complete the follow-up for not related to GIB deaths. No side effects forced
to suspend lanreotide.
Conclusion: The use of lanreotide for al least 6 months in patients with chronic or
recurrent obscure gastrointestinal bleeding or from gastrointestinal angiodyspla-
sias, refractory to or not candidates for other therapies, is safe and is associated
with a decrease in consumption of medical resources within the three years
following its indication.
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Introduction: Cohort studies have shown a beneficial effect of octreotide in
decreasing the rebleeding rates in patients with gastrointestinal angiodysplasias,
however with large variation among individuals. Most studies have a small
sample size and different primary outcomes, such as haemoglobin and rebleed,
which makes it difficult to estimate the true effect on clinical relevant outcomes
such as transfusion dependency and to investigate predictors for good clinical
response.
Aims & Methods: The aim of this individual patient data meta-analysis is to
investigate efficacy of SST on transfusion dependency and identify subgroups
of patients that benefit most from SST. A systematic review was performed to
identify articles reporting the effect of SST in gastrointestinal angiodyplasias. We
collected individual patient data of included articles. Patients with only oral iron
dependency were excluded. The primary outcome was response to SST, defined
as good: 50% reduction of parenteral iron and/or red blood cell (RBC) trans-
fusions; or poor: 550% reduction of parenteral iron and/or RBC transfusions.
We used univariate logistic regression to determine the effects of patient and
disease characteristics on SST. The variable ‘‘study’’ was included in the univari-
ate analysis to correct for study-effect.
Results: We identified 7 studies and obtained individual data from 6 (n¼ 180)
studies. We analyzed data of 159 patients (mean age 70 years, 56% men) with
transfusion dependency due to gastrointestinal angiodysplasia bleeding that were
treated with SST. Fifty percent of patients had angiodysplasias at multiple sites
(small bowel (75%), stomach (45%), and colon (45%)). Endoscopic treatment
prior to SST was started in 48%. Octreotide LAR 20mg was the most frequent
prescribed (81%). Side-effects occurred in 31% (41/131) of the patients, with
gastrointestinal symptoms (19.8%) and erythema / pain at the injection site
(8.4%) the most frequent. In 8 patients (6%) SST was discontinued due to
side-effects. There was a high SST response with 89% of the patients having
450% reduction of their parenteral iron and/or RBC transfusion dependency.
Sex, age, small bowel and stomach localization, the use of anticoagulants, dose,
only parenteral iron dependent and prior endoscopic treatment were not asso-
ciated with treatment response. Angiodysplasia localization in the colon (OR
0.28, 95% CI 0.09–0.88, p¼ 0.03) and at multiple sites (OR 0.37, 95% CI
0.17–0.77, p¼ 0.008) were negatively associated with a good response.
Conclusion: Based on this pooled analysis of data from individual patients with
transfusion dependent angiodysplasia bleeding, SST is effective and safe in the
majority of patients. A decreased SST response is found in patients with angio-
dysplasias located at multiple sites or in the colon.
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Introduction: Endoscopic band ligation (EBL) is the choice for both prophylaxis
and treatment of esophageal varices hemorrhage. Post-EBL ulcer bleeding is a
deemed complication for which risk factors and impact in mortality are not
clearly understood.
Aims &Methods:We aimed at identifying risk factors for variceal post-EBL ulcer
bleeding and determine its impact in short and long-term mortality. We con-
ducted a case control study. Cases: all admissions for post-EBL ulcer bleeding,
in a tertiary gastrointestinal service, from January 2003 to December 2015.
Controls: EBL treated patients without post-therapeutic ulcer bleeding.
Matching was made for Child-Pugh-Turcotte (CPT) score and indication
(bleeding vs elective) in a 1 case for 2 controls ratio. Patient’s demographics,
comorbidities and endoscopic findings were reviewed from medical records.
Endpoints were re-bleeding from post therapeutic ulcer and mortality assessed
at 28, 90, 180 and 360 days post-therapeutic.
Results: A total of 50 post-EBL ulcer bleeding cases and 100 controls were
included. Mean age (57.1 12.0); male:female ratio (4.1:1). Cirrhosis etiologies:
alcoholic (70.7%), HCV (29.3%) and HBV (15.7%). CPT distribution: A
(17,3%) B (46%) and C (36.7%); mean MELD was 14.5 6.1. All patients
underwent EBL and 7.3% also received a sclerosing agent. Mean time to rebleed:
12.6 5.4 days. A higher number of rubber bands (5.8 1.7 vs 5.0 2.1
p¼ 0.003), lower baseline hemoglobin (10.7 1.5 vs 11.5 2.1 g/dL p¼ 0.007),
hemodynamic instability (OR:2.0 p¼ 0.048) portal vein thrombosis (OR:2.8,
p¼ 0.022), HBV cirrhosis (OR:6.2, p¼ 0.007), and endoscopic stigmata of
active or recent bleeding (OR:5.0 p5 0.001) correlated with rebleeding. In multi-
variate logistic regression analysis HBV cirrhosis, multiple concomitant aetiolo-
gies of cirrhosis and endoscopic stigmata of recent bleeding were independently
associated with rebleeding. Post-EBL ulcer bleeding did not significantly
impacted overall short and long term mortality. However CPT class B patients
with post-EBL ulcer bleeding showed a trend for lower survival which was sig-
nificant at 180 days (16% vs 6% log rank p¼ 0.04).
Conclusion:We identified both patient’s and endoscopic features correlating with
post-EBL ulcer bleeding, namely HBV infection related cirrhosis, higher number
of concomitant aetiologies/aggressors, and endoscopic stigmata of recent/active
bleeding. Though overall patient’s short and long-term mortality was not
affected by post-EBL ulcer bleeding, CPT class B patients showed a trend for
Table (OP361)
Comparison in health resources consumption before and after Lanreotide.
Variable Mean SD p value Variable Mean SD p value
Admission days -
Prior yr - 1 yr–2 yr–
3 yr
33.4 9.9 10.0 8.5 24.3 11.6 15.7 14.3 50.01 50.01 50.01 Iron iv doses -
Prior yr–1 yr–2 yr–
3 yr
4.0 2.0 2.5 2.6 6.1 5.9 4.5 5.5 50.01 0.08 0.02
Red cell units -
Prior yr–1 yr–2 yr–
3 yr
11.4 4.5 5.9 6.4 11.6 7.1 10.2 12.6 50.01 0.01 0.04 N.Endoscopies -
Prior yr–1 yr–2 yr–
3 yr
1.6 0.1 0.6 0.7 1.7 0.3 1.1 1.6 50.01 0.01 0.03
SD: Standard deviation. Yr: year
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lower survival. Thus, we hypothesize that CPT class B patients may be a cluster
of patients with low hepatic reserve, to whom post-EBL bleeding may impose an
additional risk for disease progression, that can significantly impact on survival.
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Introduction: Weekend admissions have been associated with higher mortality.
For upper gastrointestinal haemorrhage (UGIH) some studies show significantly
increased mortality1 and delayed endoscopy while the UK UGIH audit reported
no difference2. We studied whether out of hours (OOH) admissions had more co-
morbidity, were less stable and/or had higher mortality.
Aims & Methods: Prospective study over 12 months (from March 2014) from 2
UK and 2 international centres. Admission time, demographics, pulse, BP, lab
results, endoscopy findings, further procedures and 30d mortality were recorded.
3 pre-endoscopy scores (Glasgow Blatchford (GBS), AIMS65 and admission
Rockall scores) and 2 post-endoscopy scores (PNED and full Rockall scores)
were determined. Chi-squared, Fisher’s exact and Kruskal-Wallis tests were used
as appropriate. A two-tailed significance level of 5% was used.
Results: 2118 consecutive patients, 60% male, median age 66 years were seen.
There were no significant differences in mortality, need for endoscopic therapy,
surgery/embolisation or rebleeding in both UK and non-UK centres. There were
no differences in comorbidity, mean ASA 2.3, pulse or BP although weekday
admissions had a lower Hb (110 g/l vs 118 g/l (weeknight) vs 117 g/l (weekend)
p5 0.001 and higher GBS (p5 0.05). No difference in peptic ulcer disease or
varices incidence between periods although more weekday admissions had
normal endoscopy(p¼ 0.002). OOH admissions were less likely to have an endo-
scopy (30% not endoscoped vs 23% for weekday admission p5 0.005). Time to
endoscopy was less for weeknight admissions (13 h vs 17 h for weekend and 20 h
for weekday admissions p¼ 0.0001). 67% weekday, 75% weeknight and 60%
weekend admissions had their endoscopy within 24 hours
Outcome of patients with UGIH and time of presentation
Weekdays:
working time
Weekdays:
overnight Weekends Total
Number 858 603 642 2118
Units blood transfused 1.4 [0–6] 1.3 [0–6] 1.4 [0–6] 1.4 [0–6]
Endoscopic therapy 185 (22) 116 (19) 126 (20) 430 (20)
Surgery/embolisation 4 (0.5) 6 (1.0) 6 (0.9) 16 (0.8)
Rebleeding 49 (5.8) 33 (5.7) 43 (6.9) 126 (6.1)
30 d mortality 61 (7.1) 43 (7.1) 48 (7.5) 153 (7.2)
2118 consecutive patients admitted March 2014-March 2015 from Glasgow
(600), Truro (544), Odense (541) and Singapore (433). Data shown are mean
[95% CI] or number (%).
Conclusion: There is no difference in mortality in patients admitted with UGIH
OOH compared to weekday admissions although weekday admissions had a
lower haemoglobin and higher GBS. There was no evidence of delay in time to
endoscopy with OOH admissions. The severity of UGIH was not related to time
of admission. Similar findings were noted in all four centres.
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Introduction: According to current guidelines a second endoscopic therapy is
generally encouraged for patients with rebleeding secondary to peptic ulcer dis-
ease (PUD). Although risk factors for endoscopic hemostasis failure are well
defined in the setting of the first endoscopic therapy, literature lacks studies
that focused on the risk factors for rebleeding after the second endoscopic
therapy.1
Aims & Methods: To assess risk factors related to the failure of the second
endoscopic therapy in patients with upper gastrointestinal bleeding (UGIB) sec-
ondary to PUD, in order to define high-risk patients that could benefit from
alternative methods like angiography or surgery. Retrospective analysis of all
cases of UGIB secondary to PUD that were submitted to two endoscopic thera-
pies between 2010 and 2014 in a tertiary center. We recorded demographic,
clinical, analytical and endoscopic data. Comorbidities were evaluated according
to the age adjusted charlson comorbidity index (ACCI). The main endpoint was
rebleeding, defined as: objective evidence of UGIB, with hemodynamic instability
and Hb decrease 2g/dL, or need for more than 3 units of blood in the 72-hour
period after the endoscopic treatment.
Results: We identified 56 patients who underwent a second endoscopic therapy.
The mean age was 76 years (males: 63%) and the mean ACCI was 7 (3.1). The
most common location of PUD was duodenal (80.4%) and 26.8% were classified
as having a high-risk location (small gastric curvature / posterior wall of the
bulb); the estimated mean size of PUD was 13.3mm (6.8). The mean number
of blood units transfused was 3 (2.4). Rebleeding occurred in 23% and in-
hospital mortality was 20%. In univariate analysis the female gender
(p¼ 0.041), presence of active non gastrointestinal neoplasia (p¼ 0.021), high-
risk location (p¼ 0.001), large-ulcers (p¼ 0.045), Idiopathic-PUD (p¼ 0.006)
were associated with hemostatic failure. The number of red blood cells (RBC)
units that were transfused was correlated to hemostatic failure (Rs¼ 0.548;
p¼ 0.000). Drug-induced peptic ulcers (presence of anticoagualation or antiag-
gregation agents, non-steroidal anti-inflammatory drugs and no evidence of
Helicobacter pylori infection) were associated with a successful hemostatic treat-
ment (p¼ 0.027). The variables ACCI, presence of hemodynamic instability,
Forrest classification of the PUD in the second endoscopic therapy, gastric or
duodenal location, were not statistically significant different between groups
when evaluated the hemostatic success. In the multivariate analysis, large
ulcers (p¼ 0.014; OR¼ 7.08) and transfusion of 4 blood units (p¼ 0.030;
OR¼ 1.71) were independent risk factors for rebleeding.
Conclusion: In patients with UGIB secondary to PUD that require a second
endoscopic therapy for rebleeding, the need for higher blood transfusion (4)
and large ulcers (420mm) were independent risk factors for hemostasis failure.
Early surgery or angiography should be considered in this group of patients.
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Introduction: Percutaneous endoscopic gastrostomy (PEG) is accepted as the
method that enables enteral feeding in patients with swallowing difficulties.
However, complications and early death are considerably prevalent after PEG.
To decrease the incidence of early mortality after PEG, it is very important to
identify risk factors of this procedure.
Aims & Methods: The aim of our study was to determine factors that could
predict early death within 30 days following PEG. A retrospective analysis of
the records of all patients who underwent PEG at Kure Medical Center and
Chugoku Cancer Center from April 2008 to March 2016 were performed. We
examined clinical and preoperative laboratory data and extracted predictive fac-
tors of early death after PEG by using univariate and multivariate analyses.
Results: A total of 1077 patients [502 female (46.7%) and 575 male (53.3%);
mean age 78 y.o.] were assessed. Predictors of poor survival after PEG included
history of ischemic heart disease (odds ratio [OR] 2.32, 95% confidence interval
[CI] 1.2–4.3, P5 0.01), blood urea nitrogen level 30mg/dl (OR 3.14, 95% CI
1.8–5.5, P5 0.0001), C-reactive protein level 2.6mg/dl (OR 4.04, 95% CI 2.2–
7.3, P5 0.0001), albumin level 2.7mg/dl (OR 4.2, 95% CI 2.1–8.2, P5 0.0001),
and hemoglobin level 11.2 g/dl (OR 4.0, 95% CI 2.0–8.0, P5 0.0001).
Multivariate analysis on predictive factors of early death revealed a significant
correlation between early death and each of the following: history of ischemic
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heart disease (P5 0.01), high blood urea nitrogen (P¼ 0.02) and C-reactive pro-
tein levels (P5 0.01), and anemia (P50.0001).
odds ratio (95% CI) p-Value
History of ischemic heart disease 2.32 (1.2–4.3) 50.01
Blood urea nitrogen level 30mg/dl 3.14 (1.8–5.5) 50.0001
C-reactive protein level 2.6mg/dl 4.04 (2.2–7.3) 50.0001
Albumin level 2.7mg/dl 4.2 (2.1–8.2) 50.0001
Hemoglobin level 11.2 g/dl 4.0 (2.0–8.0) 50.0001
Conclusion: A history of ischemic heart disease and laboratory data, such as high
blood urea nitrogen and C-reactive protein levels and low hemoglobin levels may
be useful predictive clinical factors for early death after PEG. If patients have a
history of ischemic heart disease, high blood urea nitrogen, high C-reactive pro-
tein, or anemia, PEG should be considered carefully.
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Introduction: Colorectal cancer (CRC) with KRAS mutations represents an
unmet clinical need due to the lack of effective therapies. A defining characteristic
of oncogenic KRAS-driven cancers is an altered cellular metabolism, in which
glucose and glutamine metabolism are extensively rewired satisfy their anabolic
needs. In this study, we investigated the metabolic dependencies of KRAS-
mutant CRC, established the role of glutaminolysis in KRAS-mutant CRC
growth and evaluated the synergism between glutaminolysis inhibition and che-
motherapy in this subset of CRC.
Aims & Methods: Metabolic dependencies of KRAS mutant CRC cell lines were
assessed by colony formation and apoptosis assays. Glutamine metabolism in
KRAS mutant CRC cells were traced using stable U13C5-glutamine labeling
and Ultra-high Performance Liquid Chromatography-Mass Spectrometry
(UPLC-MS). Role of glutaminase (GLS1) and the mitochondrial glutamate
transporter (SLC25A22) in mediating glutaminolysis was evaluated. Finally,
the functional effect of glutaminolysis inhibition (via GLS1 or SLC25A22 block-
ade) and its synergy with chemotherapeutic agents were tested.
Results: Deprivation of glucose, glutamine or their combination in six KRAS
mutant CRC (DLD1, HCT116, LOVO, SW480, SW620 and SW1116) and four
KRAS wild type CRC cell lines (CACO-2, COLO205, HT29 and SW48) revealed
that KRAS mutant CRC cells were profoundly sensitive to glutamine depletion
as compared with KRAS wild type CRC cells; whilst exhibiting resistance to
glucose depletion. This indicates that supply of glutamine is obligatory for
KRAS mutant CRC survival. U13C5-glutamine labeling in DLD1 cells and
UPLC-MS revealed that a majority of glutamine was metabolized into gluta-
mate, aspartate and the intermediates of the tricarboxylic acid (TCA) cycle,
indicating that glutamine-derived carbons were channeled to the mitochondria
for the replenishment of TCA cycle (a process known as glutaminolysis). We
further revealed that glutamine was first converted to glutamate by GLS1 at the
outer side of inner mitochondrial membrane, which is coupled to SLC25A22 for
the import of glutamate into the mitochondrial matrix. Consistent with this
model, the silencing of GLS1 or SLC25A22 significantly suppressed cell prolif-
eration in KRAS mutant CRC cells, indicating that their coupled action is indis-
pensable for cell growth. U13C5-glutamine tracing in DLD1 cells with
SLC25A22 knockdown showed an attenuated entry of glutamine-derived car-
bons into the TCA cycle, confirming its involvement in glutaminolysis.
Inhibition of SLC25A22-dependent glutaminolysis triggered metabolic stress,
suppressed ATP production and promoted oxidative stress. Moreover, a combi-
natorial approach utilizing SLC25A22- shRNA plus 5-Fluorouracil synergisti-
cally suppressed KRAS mutant CRC growth in vitro and in subcutaneous
xenograft models.
Conclusion: KRAS mutant CRC cells are addicted to glutamine and the blockade
of glutaminolysis enzymes GLS1 and SLC25A22 suppressed cell survival.
SLC25A22 represents a novel therapeutic target in KRAS mutant CRC and its
synergistic effect with chemotherapy warrants further investigation.
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Introduction: Angiogenesis is a hallmark of cancer development and is considered
as an attractive therapeutic target.
Aims & Methods: In this study, we aimed to unravel the molecular mechanism
underlying tumor angiogenesis in colorectal cancer (CRC). We isolated endothe-
lial and epithelial cells from surgically resected 14 CRC tissues and corresponding
normal colonic tissues using antibodies against endothelial (CD146) and epithe-
lial markers (EpCAM). RNA sequencing (RNA-seq) was carried out in 3 pairs of
normal and tumor endothelial cells. Gene expression was validated by quantita-
tive RT-PCR (RT-qPCR) and immunohistochemistry. Functions of a selected
gene were analyzed by tumor conditioned medium (TCM) experiments, in vitro
tube formation assay, cell cycle analysis, gene expression microarray and xeno-
graft experiments.
Results: Through RNA-seq analysis, we identified a series of 18 genes which were
upregulated in the endothelial cells isolated from CRC tissues. We further vali-
dated the results by qRT-PCR and immunohistochemistry in a larger number of
clinical samples, and identified gene A as a novel candidate of the tumor endothe-
lium-related gene. Expression of gene A was also upregulated in human umbilical
vein endothelial cells (HUVECs) treated with TCM obtained from CRC cell
lines. Knockdown of gene A suppressed in vitro tube formation and induced
G1 cell cycle arrest in HUVECs. Microarray analysis revealed that knockdown
of gene A induced expression changes of approximately 300 genes in HUVECs,
and gene ontology analysis showed that cell cycle-related genes were significantly
enriched in the affected genes. To confirm our findings in vivo, we co-trans-
planted CRC cells with HUVECs into nude mice. We found that knockdown
of gene A in HUVECs resulted in reduced micro vessel formations in the xeno-
graft tissues. Finally, we evaluated the clinical implication of gene A in colorectal
cancer. The Cancer Genome Atlas (TCGA) datasets of primary CRCs (n¼ 411)
revealed that higher expression of gene A is associated with worse overall survi-
val, suggesting that upregulation of gene A in tumor endothelial cells may pro-
mote aggressiveness of CRC.
Conclusion: Our results suggest that gene A may play an important role in the
angiogenesis in colorectal cancer, and that it could be a potential therapeutic
target.
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Introduction: Muscle cramps adversely inFuence the quality of life of patients
with liver cirrhosis. However, despite the obvious association of muscle cramps
with liver disease, there is a paucity of information regarding pathogenesis and
treatment in these patients.
Aims & Methods: This is the first randomized placebo controlled trial of baclofen
in the treatment of muscle cramps in patients with liver cirrhosis. One hundred
patients with liver cirrhosis and suffering from muscle cramps signed informed
consent to participate in this study. They were recruited from Department of
Tropical Medicine-Tanta University hospital. They were randomized to receive
either baclofen or placebo for 3 months. Patients were followed monthly and one
month after withdrawal. Each visit, the clinico-epidemiological data were
recorded, muscle cramp questionnaire was filled, and any drug related side effects
were reported.
Results: In the baclofen group, the frequency of muscle cramps was significantly
decreased after one and three months of treatment (p5 0.005), with a significant
rebound after withdrawal (P5 0.001). Patients receiving baclofen had a signifi-
cant decrease in the severity and duration of muscle cramps (P5 0.001). After
three months of baclofen therapy at dose of 30mg/day, muscle cramps disap-
peared completely in 72%, reduced in 20%, and no change in 8% of patients. No
significant changes in the frequency, severity and duration of muscle cramps were
noted in the placebo group. There were few but non-significant side effects in the
baclofen group when compared to placebo group.
Conclusion: Baclofen was well tolerated, safe, and effective in the treatment of
muscle cramps in Egyptian patients with post-hepatitis C liver cirrhosis.
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Introduction: Spontaneous bacterial peritonitis (SBP) develops in up to 25% of
patients with cirrhosis and its associated with significant short and long-term
morbidity and mortality. With the ambulatorization of medical care, the use of
antibiotics for primary and secondary prophylaxis of SBP, there is some con-
troversial concerning whether the acquisition site of the infection has an effect on
the prognosis of SBP and if the international guidelines for antibiotic therapy
(mainly based on the acquisition site) are still considered to be the best practice.
Aims & Methods: 1) To compare clinical, analytical and microbiological features
between nosocomial and community-acquired SBP; 2) to assess the influence of
the infection acquisition site when evaluated in-hospital mortality and 1 year-
mortality. Retrospective cohort study, conducted in 3 tertiaries centers that eval-
uated all cases of SBP between 2010 and 2014. Medical records and laboratory
data were reviewed. For defining the acquisition site of the infection, we followed
the criteria described by European Center for Disease Prevention and Control
(ECDC). Healthcare-Associated infections and Nosocomial infections were ana-
lyzed as the same variable. Multiresistant bacteria (MDR) was defined according
to the ECDC criteria (resistant to 3 antibiotic families, including beta-lactam
antibiotics).
Results: We identified 222 episodes of SBP, from which 110 were considered as
community-acquired; in-hospital mortality was 28,8% and 1 year-mortality was
56,9%. In 85 episodes we obtained microbiological isolation (MDR¼ 28), with a
predominance of gram negative (53,6%). Community-acquired SBPs were more
frequently caused by gram negative bacteria and Nosocomial-acquired SBPs
were more frequently by gram positive bacteria (p¼ 0,033); SBPs secondary to
MDR-bacteria were more frequent in Nosocomial-acquired group (19,64 vs
6,36%; p¼ 0,003). No statistically significant differences were noticed between
centers when analysed microbiological isolation rate, gram staining of MDR
isolations. There were no statistically significant differences between
Community-acquired SBP and Nosocomial-acquired SBPs for the variables
age, gender, Child-Pugh, MELD, Hb, leukocytes, platelets, CRP, Na, INR,
bilirubin, albumin, ascites fluid characteristics, gastrointestinal bleeding, acute
kidney injury and hemodynamic instability at diagnosis. Nosocomial-acquired
SBPs were associated with longer hospitalizations (17,8 vs 11,7 days; p¼ 0,007).
No statistically significant difference was detected when analyzed in-hospital
mortality (Nosocomial-acquired¼ 29,5 vs Community-acquired¼ 28,2%;
p¼ 0,833). When assessed 1 year-mortality, Nosocomial-acquired SBPs were
associated with a worse prognosis (63,0 vs 51,7%; p¼ 0,025).
Conclusion: Nosocomial-acquired SBPs were associated with higher rates of
MDR-bacteria, longer hospitalization lengths and higher 1 year-mortality.
Clinical and laboratorial features were not significantly different between SBP
according to the infection acquisition site; 6,36% of community-acquired SBPs
were secondary to MDR-bacteria and so in a relevant percentage of our sample,
empiric antibiotic therapy according to the current guidelines would eventually
fail.
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Introduction: Screening colonoscopy only effectively prevents from colorectal
cancer if performed with high quality.
Aims & Methods: Austria implemented a quality assurance program in screening
colonoscopy in 2007. This study provides a report on 8 years of quality assured
screening colonoscopy.
Results: In the investigated time period, 301 endoscopic units provided data of
159,246 screening colonoscopies. 49.1% were female patients. Mean age was 61.1
years. Significant increases over time were found for ADRs, which rose from a
mean of 22.2% (SD 10.7%) in 2007–2008 to 24.2% (11.6%) in 2013–2014, cor-
responding to an average increase of þ1.5% per two-year-period (95% confi-
dence interval [95%CI] þ0.9%, þ2.2%, p5 0.001). Likewise, proximal lesion
detection rates rose from 15.8% (SD 9.8%) to 21.7% (SD 13.3%, þ2.5% per
two-year-period, 95%CI þ1.9%, 3.1%, p5 0.001). Adverse events occurred in
0.3%, 63% thereof were associated with polypectomy. There was a decline in
complication rates of 7.3 per 10,000 endoscopies per two-year-period (95%CI
13.1, 1.5 per 10,000 endoscopies per two-year-period, p¼ 0.013). Sedation
increased the probability of adverse events (0.24% in sedated and 0.16% in
unsedated patients, p¼ 0.025). Notably, all perforations occurred under
sedation.
Conclusion: This study showed a strong improvement in quality of screening
colonoscopies performed within a quality assurance program in Austria between
2007 and 2014. Both overall adenoma detection rate and detection rate of prox-
imal lesions increased strongly in the investigated study period. Interestigly, the
detection rate of advanced adenomas decreased.
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Introduction: Colonoscopy remains the gold standard procedure for screening
and polyp detection, with adenoma detection rate (ADR) being a widely accepted
key performance indicator (KPI). It has long been recognised that even experi-
enced endoscopists incur an appreciable ‘miss-rate’ and a number of novel
devices have been marketed to assist this aspect of practice. The EndoringsTM
device is a simple soft silicone, single-use device consisting of a series of rings
arranged around a central tubular core. As the colonoscope is inserted the rings
fold backward to allow intubation and flare on withdrawal to flatten colonic
folds and aid inspection.
Aims & Methods: This was a single-centre pilot study to determine the effect of
Endorings used in a high-risk cancer screening population (national), when used
by experienced operators with an established ADR already 445%. Prospective
data was collected during screening colonoscopy (performed by two accredited
colonoscopists) when the EndoringsTM device was used and compared the results
to outcomes from the previous few months, for the same two colonoscopists)
when the device was not in use (ie. historical controls).
Results: The ADR without EndoringsTM (n¼ 85) was 49.4% with a per-proce-
dure detection rate (ppr) of 0.97. With the device (n¼ 66), ADR was 66.7%
(p¼ 0.0006) with ppr of 1.625. This represents a 35% increase in ADR and a
68% increase in the number of polyps detected at any given procedure. There
were no significant differences in completion rates, withdrawal time, use of seda-
tion or comfort scores. The device was removed in 5/66 procedures due to inter-
ference with intubation (in the presence of either an angulated sigmoid or
diverticulosis). No complications were recorded.
Conclusion: Use of the EndoringsTM device was associated with a significant
increase in ADR. Qualitatively, the three-ring design was felt to interfere with
normal intubation such that insertion technique had to be modified. An updated
design iteration with two rings in slightly different positions along the central
tube, has been produced and appears to offer a significant advantage in this
regard. Furthermore, the central tube can be pushed further along the distal
end of the colonoscope to allow the terminal ileum to be intubated with the
device in place. The EndoringsTM may offer an advantage in screening colono-
scopy and, in this cohort, further prospective investigation is warranted.
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Introduction: Up to 25% of colonic polyps are missed during colonoscopy. The
Endocuff Vision is a cap with soft flexible arms which attaches to the end of a
colonoscope and improves views during withdrawal. We have performed the first
randomised controlled trial to identify the role of Endocuff Vision in improving
polyp detection.
Aims & Methods: Our aim was to investigate the impact of Endocuff Vision-
assisted colonoscopy on polyp detection, as compared to standard colonoscopy,
in the UK Bowel Cancer Screening Programme (BCSP). This was a single-centre,
parallel group, randomised controlled trial. Ethics approval was obtained (ref:
A144 United European Gastroenterology Journal 4(5S)
 at Kings College London - ISS on November 25, 2016ueg.sagepub.comDownloaded from 
14/SC/0207). Patients attending for BCSP colonoscopy were stratified based on
whether they were attending for index screening colonoscopy or for polyp sur-
veillance. Within each stratum participants were randomised to either Standard
or Endocuff assisted colonoscopy. All procedures were performed by experi-
enced, nationally accredited BSCP endoscopists, who had carried out 45000
colonoscopies and had cecal intubation rates of 490%.
Result: 534 patients were recruited from Sep 2014 to Sep 2015. 3 were excluded
due to new diagnosis of polyposis syndrome, to avoid skewing of results. 531
were included and randomised to the 2 study arms. No significant difference was
seen between the 2 groups for the primary endpoint of number of polyps per
patient. Secondary endpoints: No significant difference was observed between the
2 groups for adenoma detection rate (ADR) or number of adenomas per patient
(Table 1). Endpoints were also evaluated separately for: screening group, surveil-
lance group, and the individual 4 endoscopists. In all these analyses, no signifi-
cant difference was found between the 2 study arms for any of the study
endpoints. No significant adverse events were encountered during the study in
either arm. The cecal intubation time was not prolonged and patients did not
experience any additional discomfort due to the Endocuff Vision.
Table 1: E-CAP results
Standard Endocuff
Patients 265 266
Polyps 470 436
Polyps/patient 1.77 1.64 p¼ 0.441
Adenomas 359 336
Adenomas/patient 1.35 1.26 p¼ 0.536
PDR 185/265¼ 69.8% 187/266¼ 70.3% p¼ 0.925
ADR 167/265¼ 63% 162/266¼ 60.9% p¼ 0.851
Cancer detection rate 15/265¼ 5.7% 14/266¼ 5.3% p¼ 0.851
Conclusion: In the UK, bowel cancer screening is performed by highly experi-
enced endoscopists with special accreditation. Our results suggest that in expert
hands, ADR exceeds 60% even without Endocuff. In such settings, Endocuff
Vision did not improve polyp detection rates (PDR) or ADR. However,
Endocuff did not cause any adverse events, prolong procedure duration or
cause additional discomfort. These data demonstrate the safety and feasibility
of Endocuff. However, no additional gain was demonstrated in expert hands.
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Introduction: Colorectal cancer (CRC) detection is attributed to the early detec-
tion and removal of polyps and adenomas during colonoscopy procedures.
Although colonoscopy is considered to be the ‘‘gold standard’’ for CRC preven-
tion, a significant number of polyps and adenomas go undetected during stan-
dard procedures. This is largely due to polyps that are hidden behind colonic
folds that obscure endoscopic optics and result in interval cancers. The G-EYE
endoscope (Smart Medical Systems Ltd., Ra’anana, Israel) comprises a standard
forward-viewing endoscope with a permanently integrated balloon at the distal
end. Upon withdrawal of the endoscope, the G-EYE balloon is inflated to a
partial pressure allowing for the flattening of haustral folds, centralization of
the endoscope optics, and reduction in bowel slippage, thus providing improved
visualization of the colon anatomy and increased detection of polyps and
adenomas.
Aims & Methods: This prospective, randomized, multicentre study compares the
adenoma detection rate (ADR) of the G-EYE HD colonoscopy with that of
standard HD colonoscopy (SC). Patients (age4 50) referred to colonoscopy
for screening, surveillance, following positive FOBT, or due to change in
bowel habits were randomized to either G-EYE colonoscopy or SC. Detected
polyps were removed and sent for pathology. Polyp and adenoma detection rates
were calculated.
Result: 480 patients were enrolled in the study, of which 238 subjects were ran-
domized to SC and 242 subjects were randomized to G-EYETM colonoscopy.
Baseline parameters and indication for colonoscopy were similar in both groups.
The ADR, adenoma per patient, number of adenomas by size and advanced
adenomas for each group are presented in Table 1. G-EYE colonoscopy
improved ADR by 45.6% when compared to SC. More specifically, the G-
EYE endoscope increased the number of advanced adenomas and large-size
adenomas by 96.9% and 96.2%, respectively. Procedural times were similar in
both groups.
Table 1: Results Summary
SC G-EYE % Increase
ADR 33.8% 49.2% 45.6%
Adenoma per patient 0.57 0.93 63.2%
Diminutive adenomas (2–5mm) 67 105 56.7%
Small adenomas (6–9mm) 19 26 36.8%
Large adenomas (10mm) 26 51 96.2%
Advanced adenomas 32 63 96.9%
Conclusion: Our study shows that the G-EYE endoscope can substantially
improve ADR when compared to SC. In addition to diminutive and small ade-
nomas, the G-EYE endoscope detects a larger number of advanced and large-size
adenomas. Consequently, we conclude that the G-EYE endoscope can signifi-
cantly enhance the quality of CRC screening and thus reduce colonoscopic miss
rates and interval cancer incidents.
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Introduction: Successful colon cleansing enables effective colonoscopy. PEG
based split dosing preparations are traditionally seen as the gold standard in
cleansing, but many still require a high preparation volume intake. NER1006
is the first 1L PEG3350 and ascorbate bowel preparation in phase 3 clinical
development. The low volume of NER1006 is achieved through the use of ascor-
bate in the second dose only.
Aims & Methods: This phase 3, randomised, multicentre, colonoscopist-blinded,
non-inferiority study assessed the efficacy, safety and tolerability of a 2-day
overnight split-dosing regimen of either NER1006 (N2D) or trisulfate solution
(TS) in patients undergoing colonoscopy. Two alternative primary endpoints
were evaluated: overall bowel cleansing success and ‘Excellent plus Good’ cleans-
ing rate in the colon ascendens using the Harefield Cleansing Scale (HCS).
Secondary endpoints included hierarchical evaluation of lesion detection rates
(key), and cleansing assessment using the Boston Bowel Preparation Scale
(BBPS; supportive). Patient tolerability, acceptability and compliance were
assessed using questionnaires. Safety was monitored through adverse events
and clinical laboratory evaluation. The threshold for statistical significance in
this study was P5 0.025. The confidence interval (CI) for the difference between
the groups used a 10% margin to demonstrate non-inferiority vs. TS.
Result: Patients were randomised to receive either N2D (n¼ 310) or TS (n¼ 311).
For N2D and TS, respectively, the mean age (SD) was 57.7 (10.36) and 57.3
(10.56) years. The distribution of males vs. females was 158 (51.0%) vs. 152
(49.0%) for N2D and 169 (54.3%) vs. 142 (45.7%) for TS. High successful
overall bowel cleansing efficacy was achieved in both treatment groups (Table
1). N2D demonstrated non-inferiority (lower CI limit10%) to TS for both
alternative primary endpoints. Numerically, more patients on N2D achieved an
‘Excellent plus Good’ cleansing rate in the colon ascendens compared with TS.
Non-inferiority for N2D in adenoma detection rate in the colon ascendens was
not demonstrated; other key secondary endpoints were not formally tested.
Tolerability and acceptability as assessed by the Bowel Cleansing Impact
Review (BOCLIR) Questionnaire were comparable for N2D and TS (Table 1).
Compliance rates were high in both treatment groups. There were no deaths.
NER1006 was not associated with any serious treatment-emergent adverse events
(TEAEs). The most frequently reported related TEAEs in both treatment groups
were nausea and vomiting.
Conclusion:When administered as a 2-day split dosing regimen, and compared to
trisulfate solution, NER1006 was non-inferior in overall bowel cleansing success
and in achieving an ‘Excellent plus Good’ cleansing rate in the colon ascendens.
Both treatments were well tolerated; most TEAEs were mild or moderate in
severity and reflected the expected safety profile of respective treatments. The
United European Gastroenterology Journal 4(5S) A145
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1L NER1006 showed high efficacy and safety in overnight split-dosing
administration.
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Introduction: Split-dose cleansing regimen for colonoscopy is recommended over
day-before preparation by practice guidelines and it has been shown to increase
the adenoma detection rate. Nevertheless, the compliance with split-dose pre-
scription for early-morning colonoscopy (8–10 am) is poor [1].
Aims & Methods: Present randomized study was aimed at evaluating weather the
addition of oral instructions to a self-explanatory booklet for bowel preparation
increases compliance with split-dose. We prospectively enrolled consecutive 50–
70 yr-old outpatients undergoing screening colonoscopy from 8:00 to 10:00 am.
Exclusion criteria were inability to provide consent and contraindications to the
preparation adopted in the study. All patients received a low-volume prepara-
tion. We designed a dedicated booklet underlying the advantages of split-dose
regimen including: 1. reduction of the risk of missing neoplastic lesions; 2.
improvement of colon cleansing and lower risk of rescheduling the procedure;
3. increase of bowel prep tolerability; 4. reduction in procedure duration. Day-
before preparation was left as an alternative and discouraged, secondary option.
In order to evaluate whether additional oral explanation, aimed at reinforcing the
benefits of split-dose, may further improve compliance, patients were rando-
mized in two groups: group A-only booklet delivered; group B-oral explanation
along with booklet. Patients’ data (demography, education, socioeconomic
status), along with prep-related and procedural data, were collected by a struc-
tured questionnaire on colonoscopy day. Colon cleansing was evaluated by
Boston Bowel Preparation Scale (BBPS). Proportions were compared by chi-
squared test or chi-squared for trend, as appropriate. A logistic regression ana-
lysis was performed to disclose factors associated with compliance to split-dose
prescription. A p-value 50.05 was considered significant for all comparisons.
Results: During the study period (January–April 2016), 286 patients were
enrolled (mean age 59.8 7, males 53.7%), 143 in group A and 143 in group
B; of them 266 have undergone colonoscopy (group A: 130, group B: 136). The
two groups were well balanced as concerns age, gender, education, employment
and marriage status. Split-dose was adopted by 106/130 and by 118/136 patients
in group A and B, respectively (81.5% vs 86.8%, p¼ 0.317). Among patients who
complied with split-dose the quality of bowel cleansing was adequate (BBPS4 2
in each segment of the colon) in 215/224 (96.0%). No significant differences
between group A and B were observed with regards to adherence to preparation
scheme, which were both optimal, (98.1% vs 97.5%, p¼ 0.693) and to the ade-
quacy of bowel prep (BBPS4 2 in each segment) (97.2% vs 94.9%, p¼ 0.785).
No variable was significantly associated with split-dose uptake at logistic regres-
sion analysis.
Conclusion: Present data show an excellent compliance with split-dose prescrip-
tion for early morning colonoscopy in both written only and oral and written
instruction groups, leading to very satisfactory levels of colon cleansing. This
finding underlines that the adoption of a self-explanatory booklet clearly describ-
ing the benefits of split-dose marginalizes the need of additional oral instructions.
This result is relevant in an open-access system, where routine oral education is
unfeasible, and does not support ESGE indications, which recommend both oral
and written explanation by healthcare professionals.
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Introduction: Liver cirrhosis represents the end stage of chronic liver disease,
characterized by high mortality and morbidity (1,2) with relevant health and
social costs (3). Metabolic syndrome represents one of the major risk factors
of liver disease in western countries (4). The real prevalence of this condition is
difficult to assess, since liver disease is silent until clinical decompensation of
cirrhosis occurs.
Aims & Methods: The aim of this study was to estimate the prevalence of occult
liver disease in the Veneto region and to compare the results with the burden of
patient with overt diagnosis in the same geographic area. For the epidemiological
analysis the MilleinRete dataset was used, where medical records of 139,104
subjects were stored by 99 general practitioners in the Veneto region. As indica-
tors, transaminases elevation (42 nv in at least two occasions) for liver disease
and thrombocytopenia (5120,000 m/L) for liver cirrhosis were used. Patients
with thrombocytopenia due to hematologic disorders were excluded.
Prevalence of patients with already diagnosed chronic hepatitis, cirrhosis and
comorbidities was assessed using ICD9-CM-1997 codes.
Result: Among 11.540 patients with elevated transaminases, 35% were already
diagnosed as patients with liver disease of known etiology (viral hepatitis, alcohol
abuse or hepatic steatosis), while in the remaining 65% no liver disease diagnosis
Table 1 (OP375): Efficacy and safety endpoints
NER1006 2-day
split-dosing
Comparator:
trisulfate solution
CI for the
difference [P value]
Abstract legend N2D TS N2D vs. TS
EFFICACY Primary analysis set, n¼ 276 Primary analysis set, n¼ 280
Primary endpoint: Patients with successful
overall bowel cleansing efficacy (HCS) [n]
235 (85.1%) 238 (85.0%) 8.15%* [0.528]
Supportive secondary endpoint: Patients with
successful overall bowel cleansing efficacy
(BBPS) [n]
228 (82.6%) 227 (81.1%) n.a.
Primary endpoint: Excellent plus Good cleans-
ing rate in colon ascendens [n]
99 (35.9%) 82 (29.3%) 1.69%* [0.059]
Key secondary endpoint: Adenoma detection
rate, colon ascendens
14.1% 17.1% 11.36%, 5.28%** [0.863]
Key secondary endpoint: Adenoma detection
rate, overall colon
33.7% 35.0% n.a.
Key secondary endpoint: Polyp detection rate,
colon ascendens
18.5% 23.9% n.a.
Key secondary endpoint: Polyp detection rate,
overall colon
45.7% 48.6% n.a.
Compliance rate (min 75% of both doses taken)
[n]
255 (92.4%) 255 (91.1%) n.a.
BOCLIR score [mean (SD)] 39.9 (17.70) 39.6 (17.51) n.a.
SAFETY Safety set, n¼ 262 Safety set, n¼ 265
All treatment-emergent adverse events [n] 118 67 n.a.
Patients with any related treatment-emergent
adverse event [n]
39 (14.9%) 25 (9.4%) n.a.
*¼ 97.5% 1-sided CI; **¼ 95% 2-sided CI; n.a.¼ not applicable
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was recorded. Sex distribution of these patients was similar to that of the patients
without liver enzymes alteration (M/F:0.91 vs 0.9, respectively), while age was
higher in patients with elevated transaminases [mean age (yrs)¼ 55.5 vs 48.9,
p5 0.0001]. Patients with overt diagnosis of cirrhosis were 0.3% of the overall
population, while thrombocytopenia, as indicator of occult cirrhosis, was
detected in 1.3% of the remaining patients. The epidemiological profile of
these two groups was similar [M/F:1.59; mean age (yrs)¼ 65.6 vs M/F:1.67;
mean age (yrs)¼ 65, p¼ns], but significantly different (p5 0.0001) compared
to the normal population and to subjects with only liver enzyme alterations.
Patients with occult and overt cirrhosis presented a similar prevalence of meta-
bolic syndrome profile (49% and 56% respectively), while these figures were
lower in patients without signs of liver disease (33%, p5 0.0001).
Conclusion: In conclusion, a large proportion of patients with biochemical signs
of chronic hepatitis and cirrhosis are still undiagnosed. Metabolic syndrome
seems to be the major risk factor that characterizes patients with more severe
liver disease.
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Introduction: Hepatic encephalopathy (HE) is a complication of cirrhosis char-
acterized by a broad spectrum of neuropsychiatric manifestations. According to
the clinical symptoms there are two types of HE: covert HE and overt HE
(OHE). In general, the prevalence of OHE is estimated at 10%–14% in cirrhotic
patients and at 10%–50% in patients with transjugular intrahepatic portosyste-
mic shunt (TIPS). In France, the prevalence of OHE was estimated at 25,000
patients (21,000 to 30,000 patients). Yet little is published on the national burden
of hospitalisation of patients with hepatic encephalopathy. The first objective of
this study was to use the retrospective national PMSI data (Programme
Me´dicalise´ des Syste`mes d’Information) to assess the public health burden of
hospitalisations for OHE, documenting its incidence rate but also to analyse
the characteristics of hospitalisations. The second objective was to study the
factors independently associated with length of stay in patients with HE.
Aims & Methods: A retrospective cohort was performed from the national PMSI
database from 2012 and 2013. Given the absence of coding specificity of hepatic
encephalopathy via ICD 10 code "K72 *" Hepatic failure, not elsewhere classi-
fied", an algorithm of patients hospitalised for HE was implemented according to
a medical expertise from the expression of the main symptoms of the disease. A
negative binomial regression model was used to estimate the link between lengths
of stay and HE patient’s characteristics like age, sex, comorbidities (malnutrition,
renal failure, bacterial infection and respiratory diseases), stays in reanimation,
intensive care units and death.
Result: The study collected respectively 13,484 patients on 2012 corresponding to
17,001 hospitalisations and 13,672 patients in 2013 corresponding to 17,491
hospitalisations. The mean age was 63.1 13.8 years in 2013 and 62.7 13.9
years in 2012. Thirty percent of patients were admitted to the intensive care
units. In nearly all hospital stays, the illness was medically managed (87% of
stays in 2013 and 89% in 2012). Nevertheless, there are 12% of surgical stays
(1,664 stays in 2013 and 1,514 stays in 2012). The mean length of HE stay was 15
days (SD 19 days) and the median was 10 days. The length of stay was 48%
longer for patients with malnutrition, and 52% longer in case of a bacterial
infection. The length of stay was 12% and 14% longer for patients with renal
failure and respiratory diseases, respectively. More 40 million euros per year are
spent by Social Security in France for HE hospitalisations with a mean cost per
hospital admission estimated at E5,535 (SD E6,411).
Conclusion: The mean length of stay in patients with HE was high (15 19 days).
The binomial model confirmed the significant longer length of stay induced by
patients with comorbidity such as malnutrition, renal insufficiency, bacterial
infection and respiratory disease. The annual economic burden of HE hospitali-
sations in France amounted to E40 million.
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Introduction: In clinical trials rifaximin- (RFX) has been shown to reduce the
risk of an overt episode of hepatic encephalopathy (HE) and the number of HE-
related hospitalisations, but there are limited data describing its impact on
healthcare resource use in real-world UK practice. This study compared hospital
resource use pre- and post-RFX initiation in UK patients.
Aims & Methods: A retrospective observational study in 11 specialist National
Health Service (NHS) centres of 145 patients prescribed RFX for HE between
July 2008 and May 2014. Local clinical staff reviewed patients’ medical records
for demographics, RFX prescribing and adverse drug reactions (ADRs) to RFX.
Details of inpatient hospitalisations and hospital visits in the 12 months pre- and
post-RFX initiation were extracted from NHS Trust electronic databases. Ethics
reference 14/WS/1017.
Results: Of the 145 patients evaluated, 89 (61%) were male. At RFX initiation,
mean age was 61 years (standard deviation [SD]¼ 11), 119 patients (82%) were
on lactulose. Child-Pugh score was recorded for 67 (46%) patients (10% Class A,
54% B, 36% C). Resource use in the 6/12 months pre- and post-RFX initiation is
shown in Table 1; to avoid nonsurvivor confounding this analysis includes the
114 patients (78%) who were alive at 6 months and 102 (70%) alive at 12 months
post-RFX initiation. 3 patients (2%) had ADRs and 4 (3%) developed C.difficile
infection (none of whom discontinued treatment).
Conclusion: In UK clinical practice, treatment with RFX for HE is well-tolerated
and associated with significant reductions in hospitalisation frequency, bed occu-
pancy (including critical care) and emergency room visits; reductions are
observed within 6 months of treatment initiation and sustained at 12 months.
This is the first study to demonstrate a reduction in critical care bed occupancy
with RFX.
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Table 1 (OP379): All-cause resource use pre- and post-RFX initiation
6 months (n¼ 114) 12 months (n¼ 102)
Mean (SD) n* Pre-RFX Post-RFX P n* Pre-RFX Post-RFX P
Hospitalisations with
overnight stay per patient
101 2.2 (1.9) 1.0 (1.3) 50.001 99 2.7 (2.8) 1.7 (2.0) 0.002
Total bed days 101 2890 1206 - 99 3138 1621 -
Total bed days per inpatient 101 28.6 (31.4) 11.9 (23.2) 50.001 99 31.7 (35.9) 16.4 (29.1) 50.001
Critical care bed days per inpatient 19 7.9 (10.1) 2.0 (5.1) 0.046 18 11.3 (11.8) 2.4 (6.0) 0.017
Emergency room visits per patient 63 1.9 (2.3) 1.0 (1.0) 50.001 65 2.4 (3.4) 1.8 (2.6) 0.099
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Introduction: Previous studies have shown inconsistent results with respect to
hepatitis B (HBV), Hepatitis C (HCV) and pregnancy outcome.
Aims & Methods: The aim of this study was to investigate pregnancy outcome in
women with HBV or HCV. In a nationwide cohort of pregnancies between 1997
and 2011 we investigated the risks of adverse pregnancy outcomes in 3 077 births
to women with HBV and 2 150 births to women with HCV using data from
Swedish healthcare registries. Births to women without HBV (n¼ 1 428 238), and
births without HCV (n¼ 1 429 165) served as population controls. Crude and
adjusted relative risks (RR) were calculated using Poisson regression analysis.
Results:Women with HCV were more likely to smoke (47.62% vs. 8.65%) and to
have alcohol dependence (18.79 vs. 1.07) compared with population controls.
Most women with HBV were born in non-Nordic countries. HCV was associated
with a decreased risk of preeclampsia (aRR: 0.42, 95% CI: 0.25–0.65), an
increased risk of late neonatal death (7–27 days: aRR: 4.47, 95% CI: 1.01–
12.44) and an increased risk of preterm birth (aRR: 1.31, 95% CI: 1.08–1.59).
HBV was associated with an increased risk for preterm birth (aRR: 1.21, 95%
CI: 1.01–1.44).
Conclusion: Both HBV and HCV are risk factors for preterm births, while HCV
seems to be associated with a protective effect against preeclampsia. Future
studies should corroborate these findings.
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Introduction: The renin-angiotensin system (RAS) has well-recognised roles in
cardiovascular and renal homeostasis, but may also regulate inflammation, fibro-
sis and angiogenesis in multiple other organs, including the gastrointestinal tract.
The recently recognised alternative RAS axis comprising angiotensin converting
enzyme 2 (ACE2), the effector peptide angiotensin (Ang) (1–7) and the Mas
receptor, mediate anti-inflammatory and anti-fibrotic effects as opposed to the
classical axis comprising ACE, Ang II and the AT1 receptor. This study aimed to
prospectively characterise the RAS in the circulating and intestinal compart-
ments in patients with inflammatory bowel disease (IBD) and non-IBD controls.
Aims & Methods: Circulating components of the RAS were measured in patients
with Crohn’s disease (CD), ulcerative colitis (UC) and non-IBD controls, and
associations with markers of disease activity evaluated. Terminal ileum, ascend-
ing and sigmoid colon from patients undergoing intestinal resection and colono-
scopy were surveyed for these components by mRNA expression by qRT-PCR,
and immunohistochemical localisation and semi-quantification of particle den-
sity using microscope image processing software. ACE2 activity was measured in
biopsy samples.
Results: 56 patients with CD (mean age 41 [range 21–76] y, 27 females), 45 with
UC (44 [22–82] y, 19 females) and 39 non-IBD controls (46 [22–83] y, 21 females)
were studied. No significant differences in demographic features were noted
across the three groups. Circulating renin (mean 25.4 (95% CI 21.6–29.1) vs
18.6 (13.9–23.3) mIU/L, p¼ 0.026), ACE2:ACE ratio (mean 0.61 (95% CI
0.48–0.75) vs 0.40 (0.32–0.47), p¼ 0.028) and Ang (1–7) (mean 22.8 (20.1–25.4)
vs 14.1 (10.8–17.4) pg/ml, p5 0.001) were higher, and ACE and Ang II similar in
participants with IBD compared with controls. No significant correlations
between circulating RAS components and markers of disease activity (faecal
calprotectin, C-reactive protein, platelet or white cell counts, or albumin) were
noted. Amongst patients undergoing colonoscopy (20 CD, 15 UC, 14 non-IBD
controls) and intestinal resection (5 each with CD, UC and non-IBD), angioten-
sinogen, renin, ACE, ACE2, Ang II, Ang (1–7), AT1R, AT2R and Mas receptor
were identified by qRT-PCR and/or immunohistochemistry in healthy and dis-
eased bowel, with significantly higher gene expression of angiotensinogen (3–4
fold), ACE (30–40 fold) and ACE2 (10 fold) expressed in the terminal ileum than
colon (p5 0.0001 for all). RAS components were consistently localised to the
epithelium; variably in the lamina propria and submucosa, especially microvas-
cular endothelium; and circular muscle myocytes. Expression of mRNA of angio-
tensinogen was two-fold higher in inflamed IBD and non-inflamed IBD or non-
IBD control colonic segments (p5 0.001, Kruskall-Wallis); immunohistochem-
ical staining intensity for ACE2 was higher in the colon in patients with CD
(p¼ 0.002), and that for Ang (1–7) lower (p¼ 0.001) in the colon in patients with
IBD than non-IBD controls. Staining intensity of Mas receptor was higher in
non-inflamed colon in patients with IBD than in inflamed colon or healthy
control tissue (p¼ 0.045, Kruskall-Wallis).
Conclusion: All of the components of the classical and alternative RAS pathways
are present in healthy intestinal tissue suggesting a role in normal physiology,
especially in epithelial cells. Circulating and mucosal components of the alter-
native RAS axis are upregulated in patients with IBD, but mucosal Ang (1–7) is
reduced, suggesting dysregulation and a potential role of the RAS in pathogen-
esis or perpetuation of inflammation in IBD. Novel therapies that increase muco-
sal Ang (1–7) may have a role in IBD.
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Introduction: The anti-4b7 antibody vedolizumab (VDZ), which inhibits gut
homing of lymphocytes via interaction of 4b7 with MAdCAM-1, has greatly
increased therapeutic options in patients with IBD. However, lymphocyte
homing may also occur via other homing molecules like the 4b1 integrin1 and
a considerable portion of patients does not respond to VDZ therapy2. The anti-
b7 antibody etrolizumab3 (ETZ) is currently tested in phase III trials and addi-
tionally blocks the binding of Eb7 to E-Cadherin, which is believed to mediate
epithelial retention of homed lymphocytes4.
Aims & Methods:We aimed to compare lymphocyte trafficking upon blockade of
b7 vs. 4b7 integrin. Hence, 4b7 and Eb7 expression was determined on per-
ipheral blood and lamina propria lymphocyte subsets of UC and CD patients
and healthy donors by flow cytometry or immunofluorescence staining, respec-
tively. The regulation of Eb7 expression upon lymphocyte stimulation and
incubation with cytokines was studied. In in vitro adhesion assays the adhesive
capacities of lymphocytes to MAdCAM-1 and E-Cadherin and the inhibitory
potential of VDZ and the ETZ surrogate antibody FIB504 (ETZs) were tested.
Finally, lymphocytes from UC patients were treated with either of the com-
pounds, fluorescence labelled and injected into the ileocolic artery of immuno-
suppressed mice. Gut homing was assessed by in vivo confocal microscopy and
flow cytometry of lamina propria cells.
Results: AEb7 expression was significantly higher on CD8þ lymphocytes than on
CD4þ lymphocytes both in the peripheral blood and the gut. Among both sub-
sets Eb7 expression was correlated with IL-9 secretion, while CD4þIL9þ cells
expressed less 4b7 than other CD4þ subsets. At the same time, CD8þ cells
exhibited a notably greater potential to increase Eb7 expression upon T cell
receptor stimulation and TGF-b treatment, while butyric and retinoic acid
decreased Eb7 expression on CD8þ cells. ETZs markedly inhibited binding of
CD4þ and CD8þ lymphocytes to rhE-Cadherin and blocked the adhesion of
CD4þ and CD8þlymphocytes to rhMAdCAM-1 to a degree comparable with
VDZ. Fewer lymphocytes bound to a mix of both ligands upon treatment with
ETZs compared with VDZ. In our humanized mouse model the portion of
human CD8þ cells in the murine gut was significantly reduced three hours
after injection when cells were treated with ETZs vs. VDZ. Among CD4þ
cells, the fraction of PU.1þ cells was decreased. The expression of Eb7 on
CD8þ cells from IBD patients treated with VDZ was higher in the maintenance
than in the induction phase of treatment.
Conclusion: VDZ may not equally cover all pathogenetically relevant lymphocyte
subsets leading to insufficient therapeutic response in predisposed patients. ETZ
seems to offer superior reduction of intestinal lymphocyte infiltration especially
concerning CD8þ and Th9 cells.
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Introduction: Dendritic cells (DC) can determine whether the mucosal immune
system mounts an inflammatory or regulatory response to antigen and likely
contributes to the pathogenesis of Crohn’s disease. Vitamin D down-regulates
DC inflammatory responses and could prove beneficial as a treatment adjunct in
Crohn’s. Vitamin D also modulates DC homing marker expression. This study
assessed the effect of high dose parenteral vitamin D treatment on circulating DC
phenotype and function in patients with active luminal Crohn’s disease receiving
anti-TNF therapy.
Aims & Methods: Peripheral blood mononuclear cells were isolated from 14
patients with active luminal Crohn’s disease and suboptimal vitamin D levels
(575 nmol/L) prior to and 6 weeks after starting anti-TNF (infliximab) ther-
apy. Patients with low vitamin D (550 nmol/L) were also given a single high
dose of parenteral vitamin D (300,000 international units 1,25(OH)2vitamin D3).
Flow cytometry was used to identify total DC, (HLA-DRþ cells negative for
markers of other cell lineages (CD3, CD14, CD16, CD19 & CD34)). DC were
further subtyped as myeloid (mDC, CD11cþCD123-) and plasmacytoid (pDC,
CD123þCD11c-). Expression of phenotypic markers (including maturation and
homing markers and pattern recognition receptors) and on-going intracellular
DC cytokine production during 4 hours’ culture were assessed.
Results: Production of TNF by myeloid DC was significantly reduced
(p¼ 0.016) in those patients who received vitamin D alongside anti-TNF ther-
apy, beyond that of those who received anti-TNF therapy alone (mean post-
treatment expression of TNF 24.9% v 39.1% respectively). There was a signifi-
cant correlation between increase in vitamin D level and decrease in TNF
production by myeloid DC (p¼ 0.025; R2¼0.76). An increase of serum
25(OH)vitamin D greater than 20 nmol/L was associated with a decrease in
myeloid DC TNF production. Anti-TNF therapy alone induced a significant
upregulation of the skin homing marker cutaneous lymphocyte antigen (CLA) on
myeloid DC (p¼ 0.0055), an effect which was not seen in patients receiving
adjunctive vitamin D.
Conclusion: High dose parenteral vitamin D, given as an adjunct to anti-TNF
therapy in Crohn’s, promotes down-regulation of circulating myeloid DC pro-
duction of TNF. This may influence the subsequent interaction of DC and T
cells. TNF promotes a TH-17 response characteristic of Crohn’s inflammation;
thus the ability of vitamin D to further block TNF production may promote a
more regulatory T cell response and improve outcomes when used as an adjunct
to anti-TNF therapy. The upregulation of the skin homing marker CLA follow-
ing anti-TNF therapy may explain the high rates of cutaneous side effects to this
drug class. The down-regulation of CLA by vitamin D in this setting may be
clinically useful in those patients suffering cutaneous sequelae of anti-TNF
therapy.
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Introduction: Crohn’s disease is characterised by an exaggerated immune
response to mucosal antigen. Dendritic cells (DC) are the primary antigen
presenting cells and may promote either tolerogenic or inflammatory T cell
responses to mucosal antigens. DC are also capable of imprinting tissue specific
homing markers on T cells which direct T cell migration to sites including the
skin, gut and lymphoid tissue. We characterised homing marker profile and
ongoing cytokine production of circulating DC subsets from patients with
Crohn’s disease and from healthy controls.
Aims &Methods:DC within peripheral blood mononuclear cells from adults with
active luminal Crohn’s disease or from healthy controls were characterised using
flow cytometry. DC were identified as HLA-DRþ and negative for markers of
other cell lineages (CD3, CD14, CD16, CD19, CD34). Myeloid DC (mDC,
CD11cþCD123-) and plasmacytoid DC (pDC, CD11c-CD123þ) were assessed
for phenotype (maturation status, homing markers and pattern recognition
receptors) and on-going cytokine production by surface and intracellular stain-
ing, respectively.
Results: In patients with Crohn’s disease (n¼ 20), a greater proportion of mye-
loid DC expressed a gut-homing profile (CLA-b7þ, p¼ 0.0011) compared to
healthy controls (n¼ 13) where most myeloid DC were not tissue-specific
(CLAþb7þ, p¼ 0.0016). In both Crohn’s and controls, myeloid DC were largely
gut-homing (CLA-b7þ, p¼ 0.001) whilst plasmacytoid DC were strongly skin
(CLAþb7-) and lymph node (CCR7þ) homing (p5 0.0001). Production of pro-
inflammatory cytokines was up-regulated in Crohn’s, with myeloid DC produ-
cing higher levels of TNF and plasmacytoid DC producing higher levels of IL-6
than controls (p¼ 0.0042 and p¼ 0.013 respectively). Expression of maturation
marker CD86 was increased on myeloid DC in Crohn’s but not on plasmacytoid
DC (p¼ 0.027 and p¼ 0.13 respectively). Expression of IFN-, Il-1b, Il-12,
CD40, CD80, TLR2 and TLR4 on DC did not differ between Crohn’s and
controls for either DC subset.
Conclusion: The increased myeloid DC expression of gut homing phenotype
markers and production of TNF in Crohn’s disease compared with controls
highlights the central role that this dendritic cell subset plays in the pathogenesis
of Crohn’s disease. Differences between homing markers on myeloid DC (gut
homing) and plasmacytoid DC (skin homing) suggest that they may have differ-
ent roles in different manifestations of Crohn’s, with myeloid DC being central to
gut inflammation whilst plasmacytoid DC might be involved in cutaneous
Crohn’s disease and the skin sequelae of anti-TNF therapy.
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Introduction: Fructans, such as inulin, are dietary fibers which stimulate gastro-
intestinal function acting as prebiotics. We recently demonstrated the protective
effect of inulin on LPS-induced damage of colonic smooth muscle in an ex vivo
experimental model, which seems to be related to presence of oxidative stress.
Aims & Methods: In the present study, the protective role of inulin against LPS-
induced oxidative stress was evaluated on colonic mucosa using a proteomic
approach. Human colonic mucosa and submucosa, obtained from disease-free
margins of resected segments for cancer, were sealed between two chambers
containing Krebs solution, with the luminal side of the mucosa overlayed with
5ml of Krebs, or 100 mg/mL LPS solution, or 100 mg/mL LPS þ100mg/mL
inulin Fructafit IQ (LPSþ INU). The biological system was kept oxygenated
for 30min at 37C. The solutions on the submucosal side were collected following
mucosal exposure to Krebs in the absence (N-undernatant) or presence of LPS
(LPS-undernatant) or LPSþ inulin (LPSþ INU-undernatant). Undernatants
were tested for the effects on human colonic smooth muscle strips contractility
using an organ bath system. Proteomic analysis (iTRAQ based analysis) was used
to separate and compare the total soluble proteomes from human colonic
mucosa and submucosa treated. Each sample was labelled by one of four
reagents of the iTRAQ 4-plex and then combined into one aliquote. Triplicate
labelling was performed, which showed a high level of reproducibility.
Results: Inulin exposure was able to restore, in human colonic mucosa, the LPS-
dependent alteration of some proteins involved in the host response and in the
intestinal smooth muscle contraction (ZG16, CALM1/MLCK/MYL signaling
pathway) and to reduce the upregulation of two proteins involved in the radi-
cal-mediated oxidative stress induced by LPS (APEX1, CCT7). Moreover the
administration of inulin entails a higher level of some detoxification enzymes
(MT2A, GSTK1, and UGT2B4) with respect to LPS treatment. Following expo-
sure to the LPS-undernatant, a significant decrease in maximal Ach-induced
contraction was observed when compared to the contraction induced in control
muscle strips incubated with the N-undernatant (49 5% vs 10 1% respec-
tively, P5 0.05.) and this was completely prevented by pre-incubation of the
LPS with Inulin (12 2%, P¼ ns versus N-undernatant)
Conclusion: Our data suggest that the exposure of colonic mucosa to inulin is able
to prevent LPS-dependent altered expression of some key proteins which pro-
mote intestinal motility and the host response, reducing the radical-mediated
oxidative stress
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Introduction: Gp96 is an endoplasmic reticulum chaperone for multiple protein
substrates which plays an important role in innate and adaptive immunity. Lack
of this protein in intestinal macrophages (iMACs) of Crohn’s Disease (CD)
patients is correlated with a loss of tolerance against the host gut flora, triggering
a chronic and persistent inflammation. iMACS are crucial for pathogen recogni-
tion at the mucosal surface of the gastrointestinal tract and Toll-like receptors
(TLR), one of the best investigated family of pattern recognition receptors, lead
to the phosphorylation of NFB after their activation. Previous studies of our
group revealed a strong expression of TLR2 and 4 on inflammatory iMACS
leading to a higher susceptibility of CD patients to LPS, in parallel with a specific
loss of gp96.
Aims & Methods: We aim to study the impact of the gp96-knockdown on TLR-
function in the human monocytic cell line MM6 and in a conditional gp96-
LysMcre knock-out mice. MM6 cells were stably transduced with lentiviral
gp96-knockdown vector. The lentiviral vector particles were produced by co-
transfection of HEK293T cells with transfer, packaging and envelope plasmids
using Fugene HD Transfection Kit. After transduction, cells were treated with
LPS (100 ng/ml) for 2 hours. Furthermore, in order to analyze the relevance
in vivo, conditional LysMcre-gp96 knock-out (KO) mice were also generated
after crossing gp96flox-mice with LysMCre mice. Peritoneal macrophages were
isolated from both, wild-type (WT) and KO mice, and treated with LPS (100 ng/
ml) for 2 hours. In transduced MM6 cells and peritoneal macrophages, TLR2
and TLR4 expression was analyzed by flow cytometry and the expression of
NFB, IB-, IL-8, IL-6 and TNF- were analyzed by Western blot, qPCR
and ELISA. Results are expressed as percentage or fold induction SEM. All
experiments were performed with an n 3.
Results: After checking that the efficiency of lentiviral knockdown was more than
90% by Western blot, flow cytometry experiments revealed that the number of
TLR4þ and TLR2þ gp96 shRNA transduced cells were slightly decreased, 81%
and 77% respectively, compared with mock-transduced MM6 cells, 92% and
97% respectively. In line with this, the analysis of the expression of TLR4 and
TLR2 receptors in peritoneal macrophages showed a similar slight decrease in
KO mice (74.4% and 77.0% respectively) compared with WT mice (78.2% and
90.5% respectively). The functionality of TLR4 receptor was also analyzed and
treatment with LPS induced a significant increase in the ratio pIB-/IB- in
gp96 shRNA cells (1.6 fold induction) and in KO peritoneal macrophages
(5 1.5); and in protein expression of pNFB in both gp96 shRNA (1.7) and
in KO peritoneal macrophages (1.5 0.6) compared with non-treated mock-
transduced cells and WT peritoneal macrophages. Furthermore, LPS induced a
significant increase in the mRNA and protein expression of IL-8 (9 fold induc-
tion and 800 pg/ml respectively) in gp96 shRNA compared with mock-trans-
duced cells. These results were strongly reinforced since LPS also induced a
significant increase in the mRNA expression of IL-8 (11.7 2.6), IL-6
(12.3 3.9) and TNF- (7.9 1.9) in KO peritoneal macrophages compared
with non-treated macrophages.
Conclusion: TLR4 receptor is still active and functional even in the absence of
gp96 in macrophages.
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Introduction: Adenocarcinomas at the gastro-oesophageal junction (GOJ) are
currently stratified according to the Siewert classification by location of the
main tumour mass (GOJ1: 1–5 cm proximal to the junction, GOJ2: 1 cm prox-
imal to 2 cm distal to the junction, GOJ3: 2–5 cm distal to the junction). It is
unclear whether this also reflects the molecular phenotype and hence how this
stratification might influence therapy and prognosis in an era of personalised
medicine.
Aims & Methods: The aim of this study was to determine the molecular pheno-
types of GOJ tumours and to relate this to the Siewert classification. The gene
expression profile of 107 treatment naı¨ve gastro-oesophageal adenocarcinomas
was assessed by the Illumina HTv4.0 beadchip array (GOJ1: 35, GOJ2: 31,
GOJ3: 18, true gastric comparators: gastric fundus/proximal body: 6, distal
body: 9, antrum: 8). Only tumours of intestinal Lauren type were included.
Differential gene expression analysis was done using limma in R, unbiased sub-
group assignment was performed applying a model-based algorithm using
MCLUST in R. Gene-set enrichment based pathway analysis was done using
GAGE in R based on KEGG and Gene Ontology terms. Whole genome sequen-
cing data was analysed for a subset of 45 GOJ tumours (50x for tumours and 30x
for matched germline) to assess mutational burden, recurrently mutated genes,
copy number aberrations, and mutational signatures in the identified subgroups.
Results: The Siewert classification did not reveal differential gene expression
apart from the gene REC8, a member of the meiotic recombination proteins,
which was upregulated in GOJ3 compared with GOJ1 (p¼ 0.003). Unbiased
assignment of the gene expression profiles instead revealed three distinct
groups which were not correlated with Siewert type, tumour stage or grade
(p4 0.05). Group 1 showed strong expression of MUC5AC, CTSE, and
CLDN18, and was enriched for pathways involved in cell metabolism and cell
turnover. Group 2 was positive for CDX1, CDX2 and CDH17, and was enriched
for digestive and absorptive processes. Group 3 showed high expression of genes
involved in immune-cell function including CXCL10, IDO1 and HLA-genes, and
was enriched for pathways involved in immune response and cell-cell-commu-
nication. Immunohistochemistry for a subset of the above mentioned genes con-
firmed expression of these genes within the respective subgroups. Comparison of
whole-genome sequencing data showed comparable features across all groups
with the expected recurrent mutations and trinucleotide mutational context.
Survival was significantly different between groups: Group 1 had the worst over-
all survival (group 1: 25.9m, group 2: 45.2m, group 3: 83.5m; p¼ 0.019) and
shorter recurrence-free survival in patients undergoing curative treatment path-
ways (group 1: 24.3m, group 2: 73.5m, group 3: 86.2m; p¼ 0.051).
Conclusion: Adenocarcinomas at the GOJ comprise three distinct molecular phe-
notypes, which are not reflected by the anatomical location. These subgroups
have differences in biological pathways and survival and may thus have implica-
tions for prognosis and targeted therapy.
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Introduction: SRGAP1 (Slit-Robo GTPase-activating protein 1) functions as a
GAP for Rho-family GTPases and downstream of Slit-Robo signaling. However,
the involvement of SRGAP1 activation and functional role in gastric carcinogen-
esis has not been investigated.
Aims & Methods:We aim to investigate the biological functions of SRGAP1 and
comprehensively reveal its regulation by deregulated miRNAs in gastric carcino-
genesis. The mRNA and protein expression of SRGAP1 were examined by qRT-
PCR and Western blot. The biological role of SRGAP1 in GC was demonstrated
by MTT proliferation, monolayer colony formation, cell invasion and migration
assays through siRNA-mediated knockdown. The prediction of miRNAs which
potentially target SRGAP1 was performed by TargetScan (http://www.targets-
can.org/) and miRDB (http://mirdb.org). miR-340 and miR-124 were screened
out for further validation. The regulation of SRGAP1 by miRNAs was con-
firmed by qRT-PCR, Western blot and dual luciferase activity assays by ectopic
expression of miR-340 and miR-124.
Results: SRGAP1 is over-expressed in 9 out of 12 (75.0%) GC cell lines both
from the mRNA and protein level. In clinical samples form TCGA cohort,
SRGAP1 shows gene amplification in 5/258 (1.9%) cases and its mRNA upre-
gulation shows positive correlation with the copy number change. The mutation
rate of SRGAP1 in primary GC is 8/258 (3.1%) Knockdown of SRGAP1 in
MKN28, MGC-803 and SGC-7901 cells exhibited significant anti-oncogenic
effect in vitro. SRGAP1 downregulation suppressed cell proliferation, reduced
monolayer colony formation, and inhibited at least 50% of the cell invasion and
migration ability. Moreover, luciferase activity experiments revealed SRGAP1
knockdown significantly inhibited Wnt/b-catenin pathway, which was further
confirmed by the inactivation of b-catenin and downregulation of CCND1 and
c-Myc. In addition, SRGAP1 was confirmed to be a direct target of miR-340 and
miR-124 in GC. These two miRNAs showed decreased expression compared
with adjacent normal epithelium cells and the downregulation of miR-340 and
miR-124 were associated with poor survival. Enforced overexpression of miR-
340 and miR-124 in GC cells also exerted tumor-suppressive function by inhibit-
ing cell proliferation and inducing G1 phase cell cycle arrest. In 28 paired GC
samples, the expression of SRGAP1 protein showed negative correlation with the
expression of miR-340 and miR-124.
Conclusion: SRGAP1 is over-expressed and plays an oncogenic role in GC
through activating Wnt/b-catenin pathway. Apart from gene amplification and
mutation, the activation of SRGAP1 in GC is partly due to the downregulation
of tumor suppressor miRNAs, miR-340 and miR-124. These findings provided
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clinical implications that targeting SRGAP1 might have therapeutic potential for
GC.
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Introduction: In the previous study we observed that HOXB7 is highly expressed
in gastric cancer and promote migration or invasion, and inhibit apoptosis in
gastric cancer cells.
Aims & Methods: We aimed in this study to demonstrate the roles of HOXB7 in
development of epithelial-mesenchymal transition (EMT) and metastasis in gas-
tric cancer using in vitro and in vivo model. We established HOXB7-expression
stable cell lines (MKN45-B7) and mock cells (MKN45-mock). Western blot was
performed to validate EMT markers and phospho-Akt/PTEN activity. By injec-
tion of stable cell lines, xenograft tumors were produced on the 8-week old male
Balb/C nude mice (nu/nu). 4 weeks after injection, we extracted xenograft
tumors, and implanted fragment of tumors on the stomach of another 8-week
old nude mice. 6 weeks after implantation, mice were sacrificed and their peri-
toneal metastasis, perigastric lymph node and volume of gastric tumor were
compared between both groups.
Results: MKN45-B7 cells frequently showed fibroblast-like mesenchymal pheno-
type, whereas most of MKN45-mock cells showed epithelial phenotype.
Mesenchymal markers (snail, vimentin) were up-regulated and epithelial
marker (E-cardherin) was down-regulated in MKN45-B7 cells, as well as phos-
pho-Akt level was increased and PTEN expression was decreased compared by
MKN45-mock cells. The volume of xenograft tumor was significantly increased
in MKN45-B7 cell-injected mice than MKN-mock cell injected mice. Mean
number of peritoneal metastasis/perigastric lymph node and volume of gastric
tumor were also significantly increased in MKN45-B7 tumor-implanted mice.
When we transiently transfected siAkt on MKN45-B7 cells, snail and vimentin
expression were down-regulated, whereas E-cadherin expression was up-regu-
lated, compared by siControl-transfected MKN45-B7 cells.
Conclusion: Our findings suggest that HOXB7 may play crucial role in inducing
EMT and promoting metastasis in gastric cancer via modulating Akt/PTEN axis.
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Introduction: Relationship of gastric cancer and colon cancer, it is not yet clearly
identified. But usually there is high risk of colorectal cancer known as gastric
cancer patients.
Aims & Methods: The purpose of this study was to discuss the development risk
of colorectal neoplasmand colon cancer in patients with gastric category 4 lesion
(high-grade dysplasia, HGD and early gastric cancer, EGC) who underwent
endoscopic submucosal dissection (ESD) compared to healthy controls. We
also investigated the associated risk factors for colorectal neoplasm and colon
cancer. The study group included a total of 209 patients with gastric category
4 lesion (95 HGD and 114 EGC) that underwent ESD. And 610 healthy controls
were included. All of the patients underwent concurrent screening colonoscopy
between January 2009 and May 2014. High risk colorectal neoplasm was defined
as41 cm, adenoma with villous component, adenoma with HGD, three or more
polyps or adenocarcinoma.
Results: High-risk colorectal neoplasm was found in 50/209 patients (23.9%) in
patient group and 47/610 (7.7%) in controls (p5 0.05). Colon cancer was diag-
nosed in 16/209 patients (7.6%) in patient group and 18/610 (2.9%) in controls
(p5 0.05). The risk factors of high-risk colorectal neoplasm were associated with
age, DM, colon cancer family history, and presence of gastric category 4 lesion.
The risk factors of colon cancer were associated age, and colon cancer family
history, and presence of gastric category 4 lesion.
Conclusion: The incidence of high-risk colorectal neoplasm and colon cancer in
patient group who underwent gastric ESD was higher than that in the control
group. Therefore, patients undergoing ESD with category 4 lesions may need
screening colonoscopy.
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Introduction:More than 50% of patients with esophageal (EC) or gastro-esopha-
geal junction cancer (GEJC) have metastatic disease at the time of diagnosis.
Chemotherapy and targeted therapies are increasingly used for palliative treat-
ment with the intent to control tumor growth, improve quality of life, and pro-
long survival. To date, scientific proof is lacking.
Aims & Methods: Therefore, the aim of this study was to systematically review
and compare the effectiveness of chemotherapy and targeted therapy to best
supportive care (BSC) and, to compare the addition of a cytostatic or targeted
therapeutic to a control arm in patients with EC/GEJC. This abstract is based on
a pre-peer review of a formal Cochrane Review. Upon completion and approval,
the final version is expected to be published in the Cochrane Database of
Systematic Reviews. We searched the Cochrane Central Register of Controlled
Trials, MEDLINE and EMBASE, and searched reference lists of studies. The
search was not restricted to English language publications only. Randomized
controlled trials on palliative chemotherapy and/or targeted therapy, versus
BSC or versus a control arm, in patients with esophageal or gastro-esophageal
junction cancer were included. Two authors independently extracted data.
Results: For the comparison of palliative chemotherapy or targeted therapy
versus BSC, five trials with a total of 751 patients were included in the meta-
analysis for overall survival (OS). This analysis demonstrated a significant benefit
in OS in favor of the group receiving palliative chemotherapy and/or targeted
therapy compared to BSC (hazard ratio (HR) 0.81 (0.71 to 0.92)). A similar trend
was observed for progression free survival (PFS), including two trials and 541
participants, with a HR of 0.58 (95%CI 0.28 to 1.18). For the comparison of
adding a cytostatic and/or targeted agent to a control arm, ten trials, with 1288
patients in total were included for the meta-analysis of OS. This analysis demon-
strated a significant benefit in OS in favor of the arm with an additional cyto-
static or targeted therapeutic with a HR of 0.77 (95% CI 0.70 to 0.85). The
median increased survival time was limited, one month for adding an additional
cytostatic or targeted therapeutic to the control arm. Subanalysis with second
line therapies showed a similar benefit as first line therapies. Ramucirumab was
the only agent, investigated more than once, that significantly improved both OS
and PFS. Palliative chemotherapy and/or targeted therapy increased the fre-
quency of treatment related toxicity of at least grade 3. However, treatment
related deaths did not occur more frequently. Quality of life, for the studies
that reported this outcome, often improved in the arm with an additional agent.
Conclusion: Palliative chemotherapy and/or targeted therapy significantly
increase OS compared to BSC in patients with esophageal or gastroesopha-
geal-junction carcinoma. Additionally, patients who receive multiple chemother-
apeutic or targeted therapeutic agents have an increased OS, PFS and
improvement of quality of life, on the expense of treatment-associated toxicity
of at least grade 3. Based on this meta-analysis, palliative chemotherapy and/or
targeted therapy should be considered standard care for esophageal and gastro-
esophageal junction carcinoma.
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Introduction: Appendectomy has been the standard treatment for acute appendi-
citis for over a century and more than 300 000 appendectomies are performed
annually in the United States1. Although appendectomy is generally well toler-
ated, it is a major surgical intervention and can be associated with postoperative
morbidity. Our APPAC trial2 comparing antibiotic therapy with appendectomy
for treatment of uncomplicated acute appendicitis showed that the majority of
CT-proven uncomplicated acute appendicitis patients were successfully treated
with antibiotics. Most patients randomized to antibiotic treatment did not
require appendectomy during the 1-year follow-up period, and those who
required appendectomy did not experience significant or increased complications.
Aims & Methods: The objective of this study was to compare the treatment costs
of antibiotic therapy and appendectomy for treatment of uncomplicated acute
appendicitis in our Appendicitis Acuta (APPAC) randomized clinical trial. The
APPAC multicenter, open-label, non-inferiority randomized clinical trial was
conducted in Finland from November 2009 until June 2012. A total of 530
adult patients aged 18 to 60 years with CT-scan confirmed uncomplicated
acute appendicitis were enrolled in six Finnish hospitals. Patients were randomly
assigned to early appendectomy (n¼ 273) or antibiotic treatment (n¼ 257). The
cost estimates were based on the cost levels of the final quarter of year 2012. All
costs were recorded, whether generated by the initial visit and subsequent treat-
ment or possible recurrent appendicitis during the one-year follow-up period.
Results: In the operative group, the overall societal costs were 16 times higher
than in the antibiotic group. In both groups productivity losses represented a
slightly higher proportion of overall societal costs than all treatment costs
together, with diagnostics and medicines having a minor role. Patients in the
operative group were prescribed significantly more sick leave days (16.96, SD
8.30) compared with the antibiotic group (9.17, SD 6.89) (p5 0.001). When the
age and sex of the patient as well as the hospital of care were controlled simulta-
neously, the operative treatment option generated significantly more costs in all
models.
Conclusion: To our knowledge, this is the first randomized study comparing
antibiotic therapy and appendectomy in uncomplicated acute appendicitis to
report thorough cost analysis. Avoiding unnecessary appendectomies in our
study resulted in major cost savings. Although 27% of the antibiotic group
patients underwent surgery, the differences in costs both to the service providers
and to the society overall strongly support evaluating antibiotic therapy as the
first alternative for uncomplicated acute appendicitis. Further studies evaluating
the optimal treatment of acute uncomplicated appendicitis are strongly encour-
aged also from an economic standpoint.
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Introduction: Patients with recurrent or persisting complaints following an epi-
sode of diverticulitis are managed with either conservative measures or elective
sigmoidectomy. To date no studies have been done comparing these two treat-
ment modalities. We aimed to determine which treatment is superior in terms of
improving quality of life. (DIRECT trial,NTR1478 (www.trialregister.nl)).
Aims & Methods: An open-label, multicenter, randomized clinical trial was per-
formed in 24 teaching and 2 academic hospitals in the Netherlands (DIRECT
trial). Patients presenting with either recurrent or persistent abdominal com-
plaints after an objectified episode of diverticulitis were included. Patients were
randomly assigned to either conservative treatment, according to current day
practice, or elective (laparoscopic) sigmoidectomy using a stratified digital en-
block randomization system. Primary endpoint was quality of life measured by
the Gastro-intestinal Quality of life Index (GIQLI) after six months.
Results: Between July 1, 2010 and April 1, 2014, 109 patients were randomized
when the data safety and monitoring board prematurely terminated the trial
because off increasing difficulties in recruitment. Fifty-three patients were ran-
domized to resection and 56 to conservative treatment. The GIQLI score was
significantly higher among patients randomized to resection (114.4 (SD 22.3) vs
100.4 (SD 22.7) p¼ 0.0001). Seven (13.2%) patients developed anastomotic
leakage. Among patients treated conservatively, 13 (23.2%) ultimately under-
went elective resection due to ongoing abdominal complaints. There was no
mortality.
Conclusion: Elective sigmoidectomy is superior to conservative managements in
terms of quality of life in patients with recurrent and persisting abdominal com-
plaints after an episode of diverticulitis.
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Introduction: Sessile Serrated Adenomas/Polyps (SSA/P) are responsible for
nearly 20% of colorectal cancer (CRC). Despite the utility of novel image enhan-
cing techniques including narrow band imaging it is difficult to differentiate
hyperplastic (HP) polyps from SSA/Ps. Vast proportion of endoscopists leave
the diminutive and possibly small HP polyps in situ in the recto sigmoid area
(diagnose and disregard approach). Hence there is a possibility of leaving SSA/P
in the recto sigmoid region which could potentially lead to CRC later in life.
Aims & Methods: We aim to estimate the prevalence of SSA/P in recto sigmoid
colon at screening colonoscopy and flexible sigmoidoscopy (FS). Patients aged
455 years underwent a screening colonoscopy (n¼ 500) or a flexible sigmoido-
scopy (n¼ 500) at our institution between August 2014 and April 2015 were
included. Data collected from 500 consecutive patients who underwent a colono-
scopy or a FS. Demographic, procedural and polyp data were retrieved from our
endoscopy database.
Results: 99.6% of (498/500) colonoscopy and 97.6% of flexible sigmoidoscopy
procedures were completed. Screening colonoscopy detected 1006 polyps and FS
detected 249 polyps. Polyp size ranged between 1–80mm (colonoscopy mean size
6mm, SD 7.2mm; FS mean 3.4mm, SD 3.9mm). While colonoscopy detected 43
SSA/Ps (4.3%), FS detected only 6 SSA/Ps (2.4%) which equates to an overall
prevalence of 3.9% (49/1255). Table 1 summarises the SSA/Ps prevalence data
from our cohort. In rectum there were 8 SSA/Ps detected and resected which
equals to a 3.6% of all rectal polyps. All SSA/Ps detected in rectum were less than
10mm in size (range 2–9mm). Prevalence of SSA/Ps in proximal colon was 4.5%.
Site
Total number
of polyps
Number of
SSA/Ps
Prevalence
of SSA/Ps
Rectum 222 08 3.6%
Sigmoid colon 320 13 4%
Descending colon 133 02 1.5%
Splenic flexure 37 00 0%
Transverse colon 217 07 3.2%
Hepatic flexure 37 01 2.7%
Ascending colon 168 09 5.4%
Caecum 114 09 7.9%
Site not specified 07 00 0%
Conclusion: Our cohort showed a slightly higher prevalence of SSA/Ps in rectum
and sigmoid colon. Therefore, it becomes clinically relevant to differentiate SSA/
Ps from HP polyps in recto sigmoid before adapting a diagnose and disregard
approach for small (6–9mm) hyperplastic looking polyps in this location.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Serrated Polyposis Syndrome (SPS) is associated with an increased
risk of colorectal cancer (CRC). Some patients may require colonic surgery but
the literature regarding indication, procedure performed, outcomes and surgical
decision making is sparse. We aimed to address these issues.
Aims & Methods: 434 patients with SPS, were retrospectively enrolled from 7
centers in the Netherlands and 2 in the UK. Data were retrieved from medical
charts, pathology and endoscopy reports and collected in a centralized database.
Data relating to surgical resection and surveillance outcomes were assessed.
Results: A total of 164 (38%) patients underwent colorectal surgery; 114 (70%)
for CRC, 31 (19%) for high polyp burden and 14 (9%) for unresectable polyps.
Surgery for SPS Cancer Twenty seven (25%) SPS cancers were managed with
total colectomy and ileorectal anastomosis (IRA), with the remaining 87 (75%)
patients having a more limited resection. 90% of those undergoing IRA had a
formal diagnosis of SPS at the time of their surgery compared with only 39% of
those undergoing more conservative resections. Fifty eight (50%) patients had a
resection for cancer before a diagnosis of SPS was made. Total polyp burden
(median 40 v 22.5, p5 0.01) and proximal polyp numbers (median 20 v 12,
p5 0.019) were significantly higher in those having more extensive surgery. In
the limited resection group eight (9%) patients developed metachronous
tumours; of these only three have recorded formal post-operative endoscopic
surveillance. None of these patients met SPS criteria at the time of index surgery.
Three had total IRA as management of their second tumour. The median interval
to development of second CRC was 24 months. In the limited resection group
seven (8%) patients required further surgical intervention for endoscopically
unmanageable polyp load. All had IRA as their second procedure. Total polyp
burden (median 40 v 25, p5 0.01), proximal polyp burden (median 25 v 15,
p¼ 0.002) and number of proximal polyps 410mm (median 10 v 2, p¼ 0.005)
were higher in this group compared with those having surgery for CRC alone.
Surgery for High Polyp Burden All 31 patients had a diagnosis of SPS and under-
went IRA. The median total polyp count was 43 (IQR 34–56.5) and median
proximal polyp burden was 31 (IQR 26.8–47.5). Surgery for Unresectable
Polyp Fourteen patients had unresectable polyps and had segmental resections.
None have developed CRC to date. Polyp burden in this group was equivalent to
those having CRC surgery.
Conclusion: 1. Over one-third of SPS patients required colorectal resection. The
vast majority for CRC, of whom only half were known to fulfil criteria for SPS at
the time of their cancer resection. 2. Developing metachronous cancer is uncom-
mon. Segmental resection and close endoscopic surveillance may be appropriate
for at least some of this patient cohort and more extensive surgery reserved for
those whose SPS cancers present concurrently with higher polyp counts. Surgical
decision making should be guided by the endoscopic assessment of the SPS.
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Introduction: Current colonoscopy surveillance recommendations after polyp
removal are arbitrary and resource demanding. We developed a novel risk clas-
sification system for colorectal cancer following adenoma removal.
Aims & Methods: We included all individuals who underwent screening colono-
scopy with adequate bowel cleansing and caecum intubation in the Polish
National Colorectal Cancer Screening Program between January 2000 and
December 2008. They were followed for colorectal cancer incidence and death
through national registries until December 2013. We estimated adjusted hazard
ratios (HR) for individuals with different adenoma characteristics compared to
individuals without adenomas and derived a novel risk classification system.
Results: Among 159,928 individuals (median age 56 years; 37.6% males) with a
median follow-up of 7.1 years we identified 82 colorectal cancers after adenoma
removal (0.31%) and 194 in individuals without adenomas (0.15%). The stron-
gest predictors for colorectal cancer risk were adenoma size 20mm in diameter
(HR 8.70; 95% CI 5.43–13.95, P5 0.001), high-grade dysplasia (HR 4.15; 95%
CI 2.05–8.43, P5 0.001) and 3 adenomas (HR 3.13; 95% CI 1.60–6.12,
P¼ 0.001). In a novel risk classification system using only these three predictors
the number of individuals in the high-risk group was reduced by 56% with no
increased risk of overlooked cancer (absolute risk difference per 10,000 indivi-
duals: 2.2; 95% CI 11.9–16.3).
Conclusion: Limiting surveillance recommendations to patients with adenomas
20mm in diameter or high-grade dysplasia or 3 adenomas significantly
reduces the need of surveillance colonoscopies without increasing the risk for
cancer.
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Introduction: To maximize the usefulness of total colonoscopy (CS) in reducing
deaths from colorectal cancer (CRC), it is essential that cost-effective post-poly-
pectomy CS surveillance programs are implemented. However, this has not been
well examined. European Union and United States guidelines for post-polypect-
omy surveillance recommend risk-stratified programs based on initial CS
results.1,2 Japanese guidelines, however, recommend that post-polypectomy sur-
veillance CS should be performed within 3 years of polypectomy, regardless of
the results of resected polyps.3 Given that different surveillance programs are
recommended in different settings, it is important to determine the most cost-
effective surveillance program.
Aims & Methods: The aim of this study was to determine the most cost-effective
post-polypectomy CS surveillance program by performing a Markov model ana-
lysis using Japanese data. The model was developed by simulating the clinical
course of CRC as a transition from normal epithelium, low-risk adenomatous
polyps sized 1–4mm and 5–9mm, high-risk adenomatous polyps, CRC, and
finally to death from CRC.4 High-risk polyps included intramucosal cancers
and adenomas with a diameter 10mm, with high-grade dysplasia, or with vil-
lous histology (25%). The initial population comprised 100,000 average-risk
individuals aged 40 years. Parameters of transition probabilities, costs, and test
characteristics were determined based on Japanese data.4 Four surveillance
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strategies were evaluated for costs, gained quality-adjusted life-years (QALYs),
and the required number of CS procedures. In strategy 1, post-polypectomy
surveillance CSs were performed 1 year after polypectomy regardless of the
polyp results. In strategy 2, the interval between surveillance CSs and polypect-
omy was 3 years regardless of the polyp results. Strategy 3 was a risk-stratified
one; surveillance CSs were performed 3 years after the resection of high-risk
polyps and 5 years after that of low-risk polyps. In strategies 1, 2 and 3, surveil-
lance CSs were performed 10 years after normal CSs. Strategy 4 was also a risk-
stratified one with more intense use of CS than strategy 3; the interval between
surveillance CSs and the resection of high-risk polyps, low-risk polyps, and no
polyps were 1, 3 and 5 years, respectively. In all strategies, a fecal immunochem-
ical test-based CRC screening program was provided before surveillance, and
uptake rates were set at 60% in the base-case analysis. A probabilistic sensitivity
analysis (PSA) was also performed for all model parameters.
Results: QALYs and costs per person in strategy 1–4 were as follows: strategy 1,
23.004 QALYs and US$1,024.88; strategy 2, 23.000 QALYs and $1,009.02; strat-
egy 3, 23.013 QALYs and $977.40; strategy 4, 23.046 QALYs and $970.31. The
required numbers of CS procedures per person in strategy 1, 2, 3 and 4 were
2.143, 1.664, 1.617 and 2.548, respectively. Risk-stratified strategies (strategies 3
and 4) yielded higher QALYs with lower costs than strategies 1 and 2.
Comparing strategy 3 with strategy 4, yielded QALYs were higher and required
cost was lower in strategy 4. Strategy 4 was most-cost-effective, showing simple
dominance over the other strategies, followed by strategy 3; however, strategy 4
required the most CS procedures. The PSA showed that the probability of strat-
egy 4 being chosen as the most cost-effective at the willingness-to-pay value of
$50,000 was 67.8%.
Conclusion: After polypectomy, risk-stratified CS surveillance programs based on
the polyp results should be recommended owing to higher expected effectiveness
and cost-effectiveness. Furthermore, more intense use of CS procedures in risk-
stratified surveillance can heighten the effectiveness and cost-effectiveness in the
Japanese setting. However, it does require a larger number of CS procedures;
thus, it would be preferable to determine the most appropriate use of CS proce-
dures in risk-stratified surveillance programs depending on the nationwide avail-
ability of CS resources.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Hassan C, et al. Endoscopy. 2013; 45: 842–51.
2. Lieberman DA, et al. Gastroenterology. 2012; 143: 844–57.
3. Tanaka S, et al. J Gastroenterol. 2015; 50: 252–60.
4. Sekiguchi M, et al. Jpn J Clin Oncol. 2016; 46: 116–25.
OP401 NEW NBI MAGNIFYING ENDOSCOPIC CLASSIFICATION FOR
COLORECTAL TUMORS PROPOSED BY THE JAPAN NBI EXPERT
TEAM (JNET)
K. Sumimoto1, S. Tanaka2, Y. Sano3, S. Kudo4, N. Hayashi2, S. Oka2,
M. Iwatate3, S. Saito5, T. Matsuda6, Y. Wada7, T. Fujii8, H. Ikematsu9,
T. Uraoka10, N. Kobayashi11, H. Nakamura12, K. Hotta13, T. Horimatsu14,
N. Sakamoto15, O. Tsuruta16, H. Kawano17, H. Kashida18, Y. Takeuchi19,
H. Machida20, T. Kusaka21, N. Yoshida22, I. Hirata23, T. Terai24, H. Yamano25,
K. Kaneko26, T. Nakajima9, T. Sakamoto6, Y. Yamaguchi27, N. Tamai5,
N. Maruyama23, H. Ishikawa22, Y. Murakami28, S. Yoshida29, Y. Saito30
1Department Of Gastroenterology And Metabolism, Hiroshima University hospital,
Hiroshima/Japan
2Hiroshima University Hospital, Hiroshima/Japan
3Sano Hospital, Kobe/Japan
4Showa University Northern Yokohama Hospital, kanagawa/Japan
5The Jikei University School of Medicine, Tokyo/Japan
6National Cancer Center Hospital, Tokyo/Japan
7Tokyo Medical and Dental University, Tokyo/Japan
8Takahiro Fujii Clinic, Tokyo/Japan
9National Cancer Center Hospital East), Tokyo/Japan
10Dept. Of Gastroenterology, Keio University School of Medicine Res and
Developm. for Minimally, Tokyo/Japan
11Tochigi Cancer Center, Tochigi/Japan
12Department of Gastroenterology, Chofu Surgical Clinic, Tokyo/Japan
13Shizuoka Cancer Center, Shizuoka/Japan
14Kyoto University, Kyoto/Japan
15Juntendo University, Tokyo/Japan
16Kurume University, Fukuoka/Japan
17St. Mary’s Hospital, Tokyo/Japan
18Kinki University, Osaka/Japan
19Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka/Japan
20Machida Gastrointestinal Hospital, Osaka/Japan
21Kyoto Katsura Hospital, Kyoto/Japan
22Kyoto Prefectural University of Medicine, Kyoto/Japan
23Fujita Health University, Aichi/Japan
24Terai Clinic, Tokyo/Japan
25Akita Red Cross Hospital, Akita/Japan
26National Cancer Cener Hospital East, Tokyo/Japan
27Tokura Yamaguchi Clinic, Shizuoka/Japan
28Toho University, Tokyo/Japan
29Aomori Prefectural Central Hospital, Aomori/Japan
30Endoscopy Division, National Cancer Center Hospital Endoscopy Division,
Tokyo/Japan
Contact E-mail Address: sumi102@hiroshima-u.ac.jp
Introduction: There have been many narrow-band imaging (NBI) magnifying
endoscopic classifications advocated (Sano, Hiroshima, Showa, and Jikei classi-
fications) so far in Japan. NBI magnifying endoscopy for qualitative and quan-
titative diagnosis for colorectal lesions is useful, however, some discussion in
Japan has raised issues such as i) the presence of multiple terms for the same
or similar findings, ii) the necessity of including surface patterns in magnifying
endoscopic classifications, and iii) differences in the NBI findings between poly-
poid and superficial lesions. To resolve these issues and unify the classifications,
the Japan NBI Expert Team (JNET) was set up in 2011. The aim of this study is
to scientifically evaluate the NBI scale and determine the NBI findings and
diagnostic criteria used in the unified classification (The JNET classification).
Aims & Methods: The JNET classification, which is a modification of NICE
classification, consists of 4 categories (Types 1, 2A, 2B, and 3) based on vessel
and surface patterns without color. We made a hypothesis that each of them are
correlated with the histopathological findings of hyperplastic polyp/sessile ser-
rated polyp (SSP), low grade intramucosal neoplasia, high grade intramucosal
neoplasia/shallow submucosal invasive cancer, and deep submucosal invasive
cancer, respectively. A web image interpretation study using the modified
Delphi (UMIN000010292: Multicenter study for developing universal NBI mag-
nifying endoscopic classification of colorectal tumors in Japan) was conducted.
25 specialists in magnification evaluated NBI magnifying findings and histology
with 100 NBI still images on the web.
Results: Univariate and multivariate analyses and analysis on diagnosability
from 5 candidate NBI magnifying findings such as 1) loose vessel areas, 2)
interruption of thick vessels, 3) scattered vessels, 4) thick, linearized/meandering
atypical vessels in the tumor, and 5) amorphous areas of surface patterns for
Type 3, and i) variable caliber of vessels, ii) thick vessels iii) irregular distribution
of vessels, iv) vessel meandering, and v) irregular or obscure surface pattern for
type 2B. Among the five candidate NBI findings, three findings such as 1) loose
vessel areas, 2) interruption of thick vessels, and 5) amorphous areas of surface
patterns were identified as the diagnosis of type 3. In addition, three findings such
as I) variable caliber of vessels, III) irregular distribution of vessels, and V)
irregular or obscure surface pattern were selected for the diagnosis of type 2B.
Conclusion: Subclassification of NICE Type 2 (2A & 2B) could be performed
scientifically with NBI magnifying findings without color using web image inter-
pretation study, which could conduct differentiatial diagnosis between low grade
intramucosal neoplasia and high grade intramucosal neoplasia/shallow submu-
cosal invasive cancer.
Disclosure of Interest: All authors have declared no conflicts of interest.
Table (OP401)
JNET Type 1 Type 2A Type 2B Type 3
Vessel pattern Invisible Regular caliber Regular distri-
bution (meshed/spiral
pattern)
Variable caliber Irregular
distribution
Loose vessel areas
Interruption of thick vessels
Surface pattern Regular dark or white spots
Similar to surrounding
normal mucosa
Regular (tubular/branched /
papillary
Irregular or obscure Amorphous areas
Most likely histology Hyperplastic polyp/ Sessile ser-
rated polyp
Low grade intramucosal
neoplasia
High grade intramucosal neo-
plasia/ Shallow submucosal
invasive cancer
Deep submucosal invasive
cancer
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Introduction: Colorectal serrated lesions (SLs) include hyperplastic polyp (HP),
traditional serrated adenoma (TSA) and sessile serrated adenoma/polyp (SSA/P).
Emerging evidences suggest that SSA/Ps are precursor lesions of colorectal can-
cers (CRCs) with BRAF mutation and the CpG island methylator phenotype
(CIMP). We have previously reported that Type II-Open (Type II-O) pit pat-
terns, which is highly specific to SSA/P. However, clinicopathological and mole-
cular features of SLs without Type II-O pits remain unclear.
Aims & Methods: We aimed to identify clinicopathological and molecular fea-
tures of SLs without Type II-O pits. We analyzed the methylation of CIMP
markers (MINT1, 2, 12, 31, p16 and MLH1) and BRAF and KRAS muta-
tion in 448 premalignant and malignant colorectal tumors. By using magnifying
endoscopy, surface microstructures of colorectal lesions were classified into Type
II pit or tumor pit (Type III, IV or V pit) according to the Kudo’s pit pattern
classification system. Type II pit was subcategorized into classical Type-II pit,
Type II-O pit and Type II-Long (Type II-L) pit. CIMP status (CIMP-high, -low
and -negative) was determined by using the five methylation markers.
Results: Endoscopic findings were classified as 41 Type II pit, 8 Type II-L pit, 92
Type II-O pit, 21 Type II plus tumor pit, 22 Type II-L plus tumor pit, 50 Type II-
O plus tumor pit and 214 tumor pit. We identified Type II-L plus tumor pit,
which was specific to TSA with KRAS mutation and CIMP-low (sensitivity,
60%; specificity, 96%). As compared to lesions with only Type II-L pit,
KRAS mutation and CIMP-low were more frequent in lesions with Type II-L
plus tumor pits. Progression of Type II-L pit lesions to TSA was associated with
KRAS mutation and accumulation of moderate DNA methylation. In contrast,
BRAF mutation was frequently observed in colonic tumors with Type II plus
tumor pit. These results suggest that lesions with Type II-L pit and those with
Type II pit appear to develop through distinct tumorigenic pathways, though the
majority of lesions with Type II or Type II-L pit were the same HP.
Conclusion: Our data suggest that Type II-L plus tumor pit is a useful hallmark of
the premalignant stage of CRCs with KRAS mutation and CIMP-low.
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Introduction: ASGE-PIVI guidelines support a ‘‘resect and discard’’ strategy for
diminutive colon polyps, provided that the predictive value of technology allow-
ing for ‘‘optical biopsy’’ depicts at least 90% agreement in assignment of post-
polypectomy surveillance intervals using pathology as standard. In addition, in
order for a technology to be used to guide the decision to leave suspected diminu-
tive rectosigmoid hyperplastic polyps in place (without resection), the technology
should provide 90% negative predictive value for adenomatous histology. Such
standards with optical biopsy might be achievable with experts (although even
that is unclear) but do not cross over into general clinical practice. Several groups
have looked at supporting the process of optical biopsy decision making on
endoscopic assessment of the histology of diminutive colorectal polyps using
traditional machine learning, but to date there are significant limitations in
terms of (1) using still images only, and non-realtime computer support, both
of which are not clinically efficient or effective, and (2) often involving magnifi-
cation endoscopy that is not yet a widespread clinical practice. Deep learning is a
branch of artificial intelligence which is a siginificant advance on traditional
machine learning, and with huge computational power, machines can now recog-
nize objects in real time. We sought to apply novel deep learning techniques to
optical biopsy for colon polyps.
Aims & Methods:We aimed to evaluate deep learning applied to the classification
of colorectal polyps into NICE types 1 and 2, in real-time on unaltered endo-
scopic videos, for the support of clinically efficient optical biopsy. We used 92
videos of small colorectal polyps (510mm) under white light (WL) and narrow-
band imaging (NBI) (38 NICE type 1, 52 NICE type 2), using Olympus 190 series
colonoscopes. ‘‘Optical biopsy’’ was done on all polyps by an expert with495%
accuracy (using pathology as the reference standard) prior to removal and his-
tological confirmation.
We investigated a Deep Learning Artificial Intelligence model with a proprietary
deep convolutional neural network (DCNN) for the computer-assisted NICE
type 1&2 differentiation. We designed a 3-class model representing Types 1, 2,
and unsuitable (frames without statistically representative information–blur,
bubbles, liquid). The model operated at the individual frame level, without
prior segmentation.
For model training purposes, each frame was manually tagged. The final dataset
was split into training and validation sets, without overlap. Finally, the analysis
was performed separately for NBI and WL frames, allowing for reporting of
frame processing time and classification performance.
Results: A total of 33,954 training frames were used, split equally across NBI &
WL, and type 1, type 2, & unsuitable classes. We performed a 5-fold cross-
validation on the tagged frames for quality control. The trained DCNN model
was then used to evaluate the unaltered videos in real-time, with an accuracy for
polyp classification of 90% for NBI, and 83% for WL. The confusion matrix on
whole-video classification of colorectal polyps gives a sensitivity of 93% and
specificity of 85% for NBI. Finally, the processing time of our DCNN model
ran at between 25 and 30 frames per second (fps) using a decent gamer-grade
GPU (NVIDIA Titan-X) on an unaltered video feed of 60 fps, delivering near-
realtime computer support.
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Conclusion: To our knowledge, this is the first application of deep learning to the
optical biopsy challenge for polyp differentiation into NICE types 1&2 using
non-magnification colonoscopy and NBI, specifically in a clinically representa-
tive workflow where computer support is provided in realtime on unaltered
endoscopic video streams. Although the present investigation was carried on a
limited datasets of 92 videos, our deep learning model has shown clinically effi-
cient and relevant performance for optical biopsy, well aligned with PIVI guide-
lines and the performance of experts. Ongoing work will determine if such a
computer support solution could aid in the widespread adoption of a ‘‘resect
and discard’’ strategy, and reduce the economic burden of pathological evalua-
tion of benign diminutive colon polyps.
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Age, mean (SD), y 48 (7) 48 (7) 50 (17) 52 (14)
Women, n (%) 5 (63) 5 (46) 19 (54) 17 (53)
Body mass index, mean (SD),
kg/m2
22.6 (3.6) 23.3 (4.1) 22.2 (3.1) 22.2 (2.8)*
Stoma present, n (%) 7 (88) 11 (100) 10 (29) 10 (32)*
Colon-in-continuity, n (%) 1 (13) 1 (9) 22 (63) 24 (77)*
Estimated small bowel length,
mean (SD), cm
128 (98) 129 (77)y 54 (43)z 73 (56)x
Baseline PS, mean (SD), L/wk 21.6 (8.1) 15.9 (10.4) 11.5 (5.9) 11.2 (6.4)*
Baseline PS duration, mean
(SD), y
7.2 (7.4) 8.1 (8.0) 5.6 (5.3) 6.1 (5.7)*
*n¼ 31, yn¼ 9, zn¼ 32, xn¼ 30.
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